<SEC-DOCUMENT>0001564590-17-023831.txt : 20171114
<SEC-HEADER>0001564590-17-023831.hdr.sgml : 20171114
<ACCEPTANCE-DATETIME>20171114172057
ACCESSION NUMBER:		0001564590-17-023831
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		72
CONFORMED PERIOD OF REPORT:	20170930
FILED AS OF DATE:		20171114
DATE AS OF CHANGE:		20171114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PROTEOSTASIS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001445283
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37695
		FILM NUMBER:		171203037

	BUSINESS ADDRESS:	
		STREET 1:		200 TECHNOLOGY SQUARE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617-225-0096

	MAIL ADDRESS:	
		STREET 1:		200 TECHNOLOGY SQUARE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PROTEOSTASIS THERAPEUTICS INC
		DATE OF NAME CHANGE:	20080916
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>pti-10q_20170930.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
pti-10q_20170930.htm
</title>
</head>
<!-- NG Converter v4.0.8.13 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington,&#160;D.C. 20549</p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form&#160;10-Q</p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-size:12pt;font-family:MS Mincho;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:MS Mincho;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr></table></div>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the quarterly period ended September&#160;30, 2017</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OR</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-size:12pt;font-family:MS Mincho;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:MS Mincho;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr></table></div>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the transition period from <font style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> to <font style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commission file number: 001-37695</p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Proteostasis Therapeutics,&#160;Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter)</p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:540pt;;">
<tr>
<td style="width:270pt;"></td>
<td style="width:270pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">20-8436652</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">200 Technology Square, 4th Floor</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cambridge, Massachusetts 02139</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive office) (Zip Code)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: (617)&#160;225-0096</p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:21.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="bottom"  style="width:53.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:MS Mincho;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="bottom"  style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="bottom"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:MS Mincho;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:21.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:53.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:21.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="bottom"  style="width:53.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9746;</font><font style="font-family:Times New Roman;">&#160;&#160;(Do not check if a smaller reporting company)</font></p></td>
<td valign="bottom"  style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="bottom"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:MS Mincho;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:21.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="bottom"  style="width:53.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9746;</font></p></td>
<td valign="bottom"  style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<font style="font-family:MS Mincho;font-size:10pt;"> </font><font style="font-size:10pt;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9746;</font></font><font style="font-size:10pt;">&#160;&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes<font style="font-size:10pt;">&#160;&#160;</font><font style="font-family:MS Mincho;font-size:10pt;">&#9744;</font><font style="font-size:10pt;">&#160;&#160;&#160;&#160;</font>No<font style="font-size:10pt;">&#160;&#160; </font><font style="font-size:10pt;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9746;</font></font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of November 9, 2017, there were 25,216,088 shares of the registrant&#8217;s Common Stock, $0.001 par value per share, outstanding.</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:6pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FORWARD-LOOKING STATEMENTS</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this Quarterly Report on Form&#160;10-Q are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;aim&#8221;, &#8220;may&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;expects&#8221;, &#8220;intends&#8221;, &#8220;plans&#8221;, &#8220;anticipates&#8221;, &#8220;believes&#8221;, &#8220;estimates&#8221;, &#8220;predicts&#8221;, &#8220;potential&#8221;, &#8220;continue&#8221; or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our estimates regarding our clinical trials, including, without limitation, the timing of the initiation of, completion of, enrollment in, and data from our trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our estimates regarding anticipated filing of INDs for nominated drug candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our estimates regarding expenses, future revenues and capital requirements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to obtain and maintain regulatory approval of PTI-428, PTI-801 and PTI-808, and our combination solutions for any indication, and the labeling under any approval we may obtain;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to obtain and maintain sanctioning or favorable scoring of our clinical trials or protocols from other third parties, such as the Therapeutics Development Network of the Cystic Fibrosis Foundation or the Clinical Trial Network of the European Cystic Fibrosis Society;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">intense competition in the CF market and the ability of our competitors, many of whom have greater resources than we do, to offer different, better or lower cost therapeutic alternatives than our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">anticipated regulatory developments in the United States and foreign countries;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">anticipated developments with respect to, and the commercial availability of, CFTR modulators with which PTI-428 or other of our product candidates is intended to be administered, including Vertex&#8217;s Kalydeco&#174; and Orkambi&#174;;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our plans to develop and commercialize PTI-428, PTI-801, PTI-808 and our combination solutions including expected preclinical and clinical results and timing;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to obtain and maintain intellectual property protection for our proprietary assets;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the size and growth of the potential markets for PTI-428, PTI-801, PTI-808 and our combination solutions, and our ability to serve those markets;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the rate and degree of market acceptance of PTI-428, PTI-801, PTI-808 and our combination solutions for any indication;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to obtain additional financing;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the loss of key scientific or management personnel; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">other forward-looking statements discussed elsewhere in this report.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any forward-looking statements in this Quarterly Report on Form 10-Q reflect our current views with respect to future events and with respect to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those described under Part II, Item&#160;1A. Risk Factors and elsewhere in this Quarterly Report on Form&#160;10-Q. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Quarterly Report on Form 10-Q also contains estimates, projections and other information concerning our industry, the general business environment, and the markets for certain diseases, including estimates regarding the potential size of those markets and the estimated incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events, circumstances or numbers including actual disease prevalence rates and market size, may differ materially from the information reflected in this report. Unless otherwise expressly stated, we obtained this industry, business information, market data, prevalence information and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources, in some cases applying our own assumptions and analysis that may, in the future, not prove to have been accurate. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kalydeco&#174; and Orkambi&#174; are trademarks of Vertex Pharmaceuticals Incorporated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Proteostasis Therapeutics, I</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">nc.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">INDEX</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:6.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:86.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td colspan="5" valign="top"  style="width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;text-transform:uppercase;font-size:10pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a href="#PART_I_FINANCIAL_INFORMATION"><font style="text-decoration:underline;">PART I &#8211; FINANCIAL INFORMATION</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:86.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Condensed Financial Statements (unaudited)</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:86.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#BALANCE_SHEETS"><font style="text-decoration:underline;">Condensed Balance Sheets as of September&#160;30, 2017 and December&#160;31, 2016</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:86.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_OPERATIONS_COMPREHENSIVE_LOSS"><font style="text-decoration:underline;">Condensed Statements of Operations for the Three and Nine Months Ended September&#160;30, 2017 and 2016</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:86.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_COMPREHENSIVE_LOSS"><font style="text-decoration:underline;">Condensed Statements of Comprehensive Loss for the Three and Nine Months Ended September&#160;30, 2017 and 2016</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:86.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_CASH_FLOWS"><font style="text-decoration:underline;">Condensed Statements of Cash Flows for the Nine Months Ended September&#160;30, 2017 and 2016</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:86.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_FINANCIAL_STATEMENTS"><font style="text-decoration:underline;">Notes to Condensed Financial Statements</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:86.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:86.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><font style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:86.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:86.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU"><font style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:86.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:86.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MANAGEMENTS_EVALUATION_OUR_DISCLO"><font style="text-decoration:underline;">Management&#8217;s Evaluation of our Disclosure Controls and Procedures</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:86.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="5" valign="top"  style="width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_II_OR_INFORMATION"><font style="text-decoration:underline;">PART II &#8211; OTHER INFORMATION</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:86.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:86.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_LEGAL_PROCEEDINGS"><font style="text-decoration:underline;">Legal Proceedings</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:86.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><font style="text-decoration:underline;">Risk Factors</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:86.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT"><font style="text-decoration:underline;">Unregistered Sales of Equity Securities and Use of Proceeds</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:86.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_EXHIBITS"><font style="text-decoration:underline;">Exhibits</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:86.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><font style="text-decoration:underline;">Signatures</font></a><font style="font-weight:normal;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><a name="PART_I_FINANCIAL_INFORMATION"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_I_FINANCIAL_INFORMATION"></a>PART&#160;I &#8212; FINANC</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">IAL INFORMATION</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PROTEOSTASIS THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="BALANCE_SHEETS"></a><a name="BALANCE_SHEETS"></a>CONDENSED BALANCE SHEETS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share and per share amounts)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,192</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,613</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,034</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,897</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">294</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,079</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">668</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaids and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,838</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,059</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,437</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90,237</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,582</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">541</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash, net of current portion</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,656</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">294</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,716</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,140</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities and Stockholders&#8217; Equity</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,535</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,855</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,328</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,754</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,204</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">756</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,039</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,754</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue, net of current portion</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">752</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent, net of current portion</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liability</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other liabilities, net of current portion</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,355</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,397</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,684</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $0.001 par value; 5,000,000 shares authorized</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; as of September 30, 2017 and December 31, 2016, respectively; no shares issued</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; and outstanding as of September 30, 2017 and December 31, 2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $0.001 par value; 125,000,000 shares authorized</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; as of September 30, 2017 and December 31, 2016, respectively; 25,112,724 and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; 25,000,734 shares issued and outstanding as of September 30, 2017 and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2016, respectively</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">241,758</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">238,902</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(203,458</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(157,450</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,319</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,456</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,716</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,140</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying unaudited notes are an integral part of these condensed financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PROTEOSTASIS THERAPEUTICS, INC.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="STATEMENTS_OPERATIONS_COMPREHENSIVE_LOSS"></a><a name="STATEMENTS_OPERATIONS_COMPREHENSIVE_LOSS"></a>CONDENSED STATEMENTS OF OPERATIONS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share and per share amounts)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended September&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,551</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,715</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,719</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,324</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,894</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,218</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,372</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,498</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,741</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,266</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,813</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,682</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,635</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,484</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,185</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,180</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,084</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,769</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,466</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,856</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">515</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expense, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(57</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,954</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,771</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,008</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,815</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruing dividends on preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,378</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,954</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,771</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,008</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,193</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stockholders&#8212;basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.56</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.54</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.84</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.75</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average common shares outstanding&#8212;basic and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,093,344</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,073,685</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,051,536</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,672,368</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying unaudited notes are an integral part of these condensed financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PROTEOSTASIS THERAPEUTICS, INC.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="STATEMENTS_COMPREHENSIVE_LOSS"></a><a name="STATEMENTS_COMPREHENSIVE_LOSS"></a>CONDENSED STATEMENTS OF COMPREHENSIVE LOSS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended September&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,954</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,771</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,008</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,815</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive loss:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain (loss) on investments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,934</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,780</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,993</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,824</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying unaudited notes are an integral part of these condensed financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PROTEOSTASIS THERAPEUTICS, INC.</font></p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="STATEMENTS_CASH_FLOWS"></a><a name="STATEMENTS_CASH_FLOWS"></a>CONDENSED STATEMENTS OF CASH FLOWS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,008</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,815</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to cash used in operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">187</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">248</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Premium on short-term investments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(140</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(124</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of premium on short-term investments</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">182</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash rent expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(149</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(134</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,228</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,245</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock issued for consulting services</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">555</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of derivative liability</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(88</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of preferred stock warrant liability</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(82</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gain on disposal of property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(411</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">473</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaids and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,221</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,200</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">514</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">390</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,527</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,849</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,202</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,992</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,557</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,820</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from investing activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,656</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of short-term investments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23,727</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(56,299</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds received from maturities of short-term investments</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,563</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(117</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds received from disposal of property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) investing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,063</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(56,318</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock upon completion of initial public</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; offering, net of commissions and underwriting discounts</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,500</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock upon completion of follow-on public</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; offering, net of commissions and underwriting discounts</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,265</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of stock options</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock pursuant to employee stock purchase plan</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments of initial public offering costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,515</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments of follow-on public offering costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(272</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,122</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(421</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,984</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at beginning of period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,613</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,844</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at end of period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,192</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,828</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of non-cash investing and financing activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of convertible preferred stock into common stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112,292</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock to settle accrued Series A preferred stock dividends</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock for partial payment of accrued bonus</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of preferred stock warrants into common stock warrants</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred offering costs included in accounts payable and accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">524</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts capitalized under build-to-suit lease transaction</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,111</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying unaudited notes are an integral part of these condensed financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PROTEOSTASIS THERAPEUTICS, INC.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="NOTES_TO_FINANCIAL_STATEMENTS"></a><a name="NOTES_TO_FINANCIAL_STATEMENTS"></a>NOTES TO CONDENSED FINANCIAL STATEMENTS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Nature of the Business</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proteostasis Therapeutics, Inc. (the &#8220;Company&#8221;) was incorporated in Delaware on December 13, 2006. The Company is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis (&#8220;CF&#8221;) and other diseases caused by dysfunctional protein processing.&nbsp;&nbsp;The Company focuses on identifying therapies that restore protein function.&nbsp;&nbsp;CF is a disease caused by defects in the cystic fibrosis transmembrane conductance regulator (&#8220;CFTR&#8221;) protein and insufficient CFTR protein function. The Company&#8217;s lead product candidates, PTI-428, PTI-801 and PTI-808&nbsp;&nbsp;are in early clinical development, with plans for double and triple combinations, and the Company&#8217;s other drug candidates are in the preclinical development and discovery phases.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2016, the Company adopted the provisions of Financial Statement Account Standards Board (FASB) Accounting Standard Codification (ASC) Topic 205-40, <font style="font-style:italic;">Presentation of Financial Statements &#8211; Going Concern</font> (ASC 205-40), which requires management to assess the Company&#8217;s ability to continue as a going concern for twelve months after the date of the financial statements are issued. This standard <font style="color:#000000;">requires management to 1) identify and disclose if there are initial conditions indicating substantial doubt about the Company&#8217;s ability to continue as a going concern within twelve months of the issuance date of the financial statements, 2) disclose the principal conditions that gave rise to substantial doubt, 3) disclose management&#8217;s evaluation of the significance of those conditions in relation to the Company&#8217;s ability to meet its obligations and 4) disclose management&#8217;s plans that are intended to mitigate the adverse conditions.&#160;&#160;In accordance with the accounting standard, when considering management&#8217;s plans to mitigate the conditions giving rise to substantial doubt, management can only consider those plans which are probable to be successfully implemented</font>. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred losses from operations since its inception. As of September&#160;30, 2017, the Company had an accumulated deficit of $203.5 million. During the three and nine months ended September&#160;30, 2017, the Company incurred losses of $14.0 million and $46.0 million and during the nine months ended September 30, 2017 the Company used $40.6 million of cash in operations. The Company expects to continue to generate operating losses in the foreseeable future. The Company currently expects that its cash, cash equivalents and short-term investments of $43.2 million will be sufficient to fund its operating expenses and capital requirements, based upon its current operating plan, through the second quarter of 2018. <font style="color:#000000;">As of September 30, 2017, management has further assessed this risk and, in accordance with the requirements of ASC 205-40, determined that there are initial conditions indicating that there is substantial doubt about the Company&#8217;s ability to continue as a going concern within twelve months of the issuance date of these condensed financial statements.&#160;&#160;These indicators are the Company&#8217;s accumulated deficit and the forecasted cash expenditures. </font>Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all, nor is it considered probable under the accounting standards. <font style="color:#000000;">As such, under the requirements of ASC 205-40, management may not consider the potential for future capital raises in its assessment of the Company&#8217;s ability to meet its obligations for the next twelve months. If the Company is unable to obtain funding, the Company would be forced to delay, reduce or eliminate its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability to reduce spending at a level that mitigates the factors described above, is not considered probable, as defined in the accounting standards; as such, under the requirements of ASC 205-40, the full extent to which management may extend the Company&#8217;s funds through these actions may not be considered in management&#8217;s assessment of the Company&#8217;s ability to continue as a going concern for the next twelve months.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thus, in accordance with the requirements of ASC 205-40, management has concluded that substantial doubt exists about the Company&#8217;s ability to continue as a going concern for twelve months from the date these condensed financial statements are issued.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed financial statements have been prepared&#160;assuming that the Company will continue as a going concern, which contemplates continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business<font style="color:#000000;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Summary of Significant Accounting Policies </font></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Unaudited Interim Financial Information</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed balance sheet at December&#160;31, 2016 was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying condensed financial statements as of September&#160;30, 2017 and for the three and nine months ended September&#160;30, 2017 are unaudited. The accompanying unaudited interim financial statements have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the Company&#8217;s&#160;audited financial statements and the notes thereto for the year ended December&#160;31, 2016 included in the Company&#8217;s&#160;Annual Report on Form 10-K filed with the SEC on March&#160;30, 2017. In the opinion of management, all adjustments, consisting only of normal recurring adjustments as necessary, for the fair statement of the Company&#8217;s condensed financial position as of September&#160;30, 2017 and condensed results of its operations and cash flows for the three and nine months ended September&#160;30, 2017 have been made. The results of operations for the three and nine months ended September&#160;30, 2017 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2017. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, the accrual for research and development expenses and the valuation of common stock and the derivative liability. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restricted Cash</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September&#160;30, 2017 and December&#160;31, 2016, restricted cash consisted of a certificate of deposit in the amount of $0.3 million collateralizing a letter of credit issued as a security deposit in connection with the Company&#8217;s lease of its corporate facilities at 200 Technology Square, Cambridge, MA.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 19, 2017, the Company entered into a lease agreement for a new corporate headquarters at 80 Guest Street, Brighton, MA (see Note 11). As of September 30, 2017, restricted cash, net of current portion, consisted of a money market account in the amount of $1.7 million collateralizing a letter of credit issued as a security deposit for this lease agreement.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash Equivalents</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. As of September&#160;30, 2017 and December&#160;31, 2016, the Company&#8217;s cash equivalents consisted of money market funds.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Short-term Investments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments represent holdings of available-for-sale marketable securities in accordance with the Company&#8217;s investment policy and cash management strategy. Short-term investments mature within one-year from the balance sheet date. Investments in marketable securities are recorded at fair value, with any unrealized gains and losses, net of taxes, reported as a component of stockholders&#8217; equity until realized or until a determination is made that an other-than-temporary decline in market value has occurred. The cost of marketable securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investments are reflected as a component of other expense, net.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value Measurements</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Level 2&#8212;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s derivative liability, short-term investments and cash equivalents are carried at fair value determined according to the fair value hierarchy described above (see Note 4). The carrying value of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate their fair value due to the short-term nature of these assets and liabilities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss per Share</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, upon the closing of the IPO, all of the outstanding shares of the Company&#8217;s redeemable convertible preferred stock automatically converted into 9,699,600 shares of the Company&#8217;s common stock. Prior to this conversion, the Company followed the two-class method when computing net loss per share as the Company had issued shares that met the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company&#8217;s redeemable convertible preferred stock contractually entitled the holders of such shares to participate in dividends, but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, the two-class method did not apply for periods in which the Company reported a net loss or a net loss attributable to common stockholders resulting from dividends or accretion related to its redeemable convertible preferred stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net income (loss) per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares, including potential dilutive common shares assuming the dilutive effect of outstanding stock options and unvested restricted common shares, as determined using the treasury stock method. For periods in which the Company has reported net losses, diluted net loss per common share attributable to common stockholders is the same as basic net loss per common share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. For any period in which the Company has reported net income, basic net income per common share attributable to common stockholders is adjusted for certain amounts to calculate diluted net loss per common share attributable to common stockholders, since dilutive common shares are assumed to have been issued if their effect is dilutive and not to have been issued if their effect is anti-dilutive.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a>In May 2014, the <font style="color:#000000;">FASB issued ASU No.&#160;2014-09,&#160;</font><font style="font-style:italic;color:#000000;">Revenue from Contracts with Customers (Topic 606)</font><font style="color:#000000;">&#160;(&#8220;ASU 2014-09&#8221;), which supersedes existing revenue recognition guidance under GAAP. The standard&#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The standard defines a five-step process to achieve this principle, and will require companies to use more judgment and make more estimates than under the current guidance. The Company expects that these judgments and estimates will include identifying performance obligations in the customer contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. In August 2015, the FASB issued ASU 2015-14,&#160;</font><font style="font-style:italic;color:#000000;">Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date</font><font style="color:#000000;">, which delays the effective date of ASU 2014-09 such that the standard is effective for public entities for annual periods beginning after December&#160;15, 2017 and for interim periods within those fiscal years. Early adoption of the standard </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">is permitted for annual periods beginning after December&#160;15, 2016. In April 2016, the FASB issue</font><font style="color:#000000;">d ASU 2016-10,&#160;</font><font style="font-style:italic;color:#000000;">Identifying Performance Obligations and Licensing</font><font style="color:#000000;">. The new standard clarifies two aspects of ASU 2014-09, </font><font style="font-style:italic;color:#000000;">Revenue from Contracts with Customers&#160;</font><font style="font-style:italic;color:#000000;">(Topic 606)</font><font style="color:#000000;">: identifying performance obligations and the licensing implementation guidance. These</font><font style="color:#000000;"> new standards will become effective for the Company on January&#160;1, 2018. The Company only has one contract (see Note 8) within the scope of Topic 606 and intends to use the modified retrospective method for adoption. Since the inception of the contract the</font><font style="color:#000000;"> Company has recognized $8.1 million in revenue. The Company is still assessing the impact that the adoption of these new standards will have on its financial statements and related disclosures.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU No.&#160;2016-02, <font style="font-style:italic;">Leases </font>(&#8220;ASU 2016-02&#8221;)<font style="font-style:italic;">.</font> This guidance will require that lease arrangements longer than 12 months result in an entity recognizing an asset and liability equal to the present value of the lease payments in the statement of financial position. This guidance is effective for annual periods beginning after December&#160;15, 2018, and interim periods therein. This standard requires a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU 2016-02 will have on its financial statements and related disclosures.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016, the FASB issued ASU No.&#160;2016-09,&#160;<font style="font-style:italic;">Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting </font>(&#8220;ASU 2016-09&#8221;)<font style="font-style:italic;">.</font> The new standard involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The new standard was adopted by the Company on January&#160;1, 2017 on a modified retrospective basis. <font style="color:#000000;">As a result, the Company has made an accounting policy election to account for forfeitures as they occur. The adoption of ASU 2016&#8209;09 also requires excess tax benefits and tax deficiencies be recorded in the income statement as opposed to additional paid&#8209;in capital when the awards vest or are settled. This had no material impact on the condensed financial statements as of and for the three and nine months ended September&#160;30, 2017</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2016, the FASB issued ASU 2016-15, <font style="font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</font>. The new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs, settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactions. The new standard also clarifies that an entity should determine each separately identifiable source or use within the cash receipts and cash payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. The new standard will be effective for the Company on January 1, 2018. The Company is currently evaluating the impact that the adoption of this standard will have on its statements of cash flows<font style="color:#000000;">.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2017, the FASB issued ASU 2017-09, <font style="font-style:italic;">Compensation &#8211; Stock Compensation (Topic 719): Scope of Modification Accounting</font>. The new standard provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The new standard will be effective for the Company on January 1, 2018; however, early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company&#8217;s financial position or results of operations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Short Term Investments</font></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s short term investments as of September&#160;30, 2017 and December&#160;31, 2016 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30, 2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Gains</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Losses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S government-sponsored enterprise securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,519</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,516</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,522</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,518</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,041</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,034</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Gains</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Losses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S government-sponsored enterprise securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,384</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,364</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,535</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,533</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,919</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,897</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not have any realized gains or losses on its short-term investments for the three and nine months ended September&#160;30, 2017 and <font style="letter-spacing:-0.1pt;">2016</font>. There were no other-than-temporary impairments recognized for the three and nine months ended September&#160;30, 2017 and <font style="letter-spacing:-0.1pt;">2016</font>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fair Value of Financial Assets and Liabilities</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of September&#160;30, 2017 Using:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,370</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,370</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government-sponsored enterprise securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,516</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,516</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,518</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,518</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,370</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,034</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,404</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liability</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of December&#160;31, 2016 Using:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,440</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,440</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government-sponsored enterprise securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,365</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,365</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,532</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,532</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,440</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,897</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,337</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liability</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the periods ended September&#160;30, 2017 and </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2016, there were no transfers between Level 1, Level 2 and Level 3.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Derivative Liability</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The derivative liability relates to a cash settlement option associated with the change of control provision in our Cystic Fibrosis Foundation Therapeutics, Inc. (&#8220;CFFT&#8221;) agreement, which meets the definition of a derivative. The fair value of the derivative liability is based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of the derivative instrument was determined using the Monte-Carlo simulation analysis. In determining the fair value of the derivative liability, the inputs impacting fair value include the fair value of the Company&#8217;s common stock, expected term of the derivative instrument, expected volatility of the common stock price, risk-free interest rate, expected sales-based milestone payments, discount rate, probability of a change of control event, and the probability that the counterparty would elect to accept the alternative cash payment in lieu of its right to the future sales-based milestone payments.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September&#160;30, 2017 and December&#160;31, 2016, the Company determined the per share common stock price available based on the closing price of its common stock on the NASDAQ Global Market as of September 29, 2017 and December 30, 2016, respectively. The Company determined the expected term of the instrument to be 2.25 years and 2.50 years as of September&#160;30, 2017 and December&#160;31, 2016, respectively. The Company estimated its expected stock volatility to be 80.0% and 81.1% as of September&#160;30, 2017 and December&#160;31, 2016, respectively, based on the historical volatility of publicly traded peer companies for terms matching the expected term of the instrument for each respective period. The risk-free interest rate was determined to be 1.51% and 1.33% as of September&#160;30, 2017 and December&#160;31, 2016, respectively, by reference to the U.S. Treasury yield curve for terms matching the expected term of the instrument for each respective period.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in the values of the derivative liability are summarized below (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Derivative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liability</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value at December 31, 2016</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(88</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value at September&#160;30, 2017</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Prepaids and Other Current Assets</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaids and other current assets consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid clinical, manufacturing and scientific expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,197</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,390</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">218</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">423</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,565</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,838</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.28%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,059</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.28%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Accrued Expenses</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued payroll and related expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,293</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,813</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,086</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,612</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional fees</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">399</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">383</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">520</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,855</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,328</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation</font></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2016 Stock Option and Incentive Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February&#160;3, 2016, the Company&#8217;s stockholders approved the 2016 Stock Option and Incentive Plan (the &#8220;2016 Plan&#8221;), which became effective on February&#160;9, 2016. The 2016 Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock units, restricted stock awards and other stock-based awards. The number of shares initially reserved for issuance under the 2016 Plan is 1,581,839 shares. The number of shares of common stock that may be issued under the 2016 Plan will automatically increase on each January&#160;1, beginning on January&#160;1, 2017, by the lesser of 3% of the shares of the Company&#8217;s common stock outstanding on the immediately preceding December&#160;31 or an amount determined by the Company&#8217;s board of directors or the compensation committee of the board of directors. The shares of common stock underlying any awards that are forfeited, canceled, repurchased or are otherwise terminated by the Company under the 2016 Plan and the 2008 Plan will be added back to the shares of common stock available for issuance under the 2016 Plan.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September&#160;30, 2017, the total number of shares reserved under the 2016 Plan and 2008 Plan was 3,577,930 and the Company had 631,077 shares available for future issuance under the 2016 Plan.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2016 Employee Stock Purchase Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February&#160;3, 2016, the Company&#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the &#8220;2016 ESPP&#8221;), which became effective in connection with the completion of the Company&#8217;s initial public offering. A total of 138,757 shares of common stock were reserved for issuance under this plan. In addition, the number of shares of common stock that may be issued under the 2016 ESPP will automatically increase on each January&#160;1, beginning on January&#160;1, 2017 and ending on January&#160;1, 2026, by the least of (i)&#160;138,757 shares of common stock, (ii)&#160;1% of the Company&#8217;s shares of common stock outstanding on the immediately preceding December&#160;31 and (iii)&#160;an amount determined by the Company&#8217;s board of directors or the compensation committee of the board of directors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the nine months ended September 30, 2017, 10,829 shares of common stock were issued pursuant to the 2016 ESPP. As of September&#160;30, 2017, the total number of shares reserved under the 2016 ESPP was 266,685 shares. The Company recognized less than $0.1 million of stock-based compensation during each of the three and nine month periods ended September&#160;30, 2017. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock Option Grants and Shares to Non-employees</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to 2013, the Company issued options to purchase 203,964 shares of common stock to non-employees, primarily members of the Company&#8217;s scientific advisory board, that vest upon the achievement of specified development and clinical milestones. As of September&#160;30, 2017, options for the purchase of 83,250 shares held by non-employees remained unvested, pending achievement of the specified milestones, and had an aggregate fair value of $0.1 million. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense, including shares issued to a non-employee for consulting services, was classified in the statements of operations as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended September&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">412</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,070</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">351</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">636</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">451</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,713</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,024</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,048</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">570</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,783</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,375</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_Hlk496267259"></a><a name="_AEIOULastRenderedPageBreakAEIOU15"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Collaboration Agreement</font></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Astellas</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk496267151"></a>Under the Collaborative Research, Development, Commercialization and License Agreement (as further amended, the &#8220;Astellas Agreement&#8221;) with Astellas Pharma Inc. (&#8220;Astellas&#8221;), entered into in November 2014, the Company <font style="letter-spacing:-0.1pt;">recognized revenue of $1.6 million and $1.0&#160;million for the three months ended September&#160;30, 2017 and 2016, respectively, and $3.7 million and $2.2 million for the nine months ended September&#160;30, 2017 and 2016, respectively. The Company recognizes revenue from all upfront payments, research funding payments, non-substantive milestone payments and reimbursements of third-party costs under this arrangement, together as a single unit, over the </font>three and a half year research term of the agreement, which commenced in January 2015, with a cumulative catch-up for the elapsed portion of the <font style="letter-spacing:-0.1pt;">services being recognized at the time any non-substantive milestone payment or other consideration is earned. Amounts recorded as deferred revenue under the Astellas Agreement totaled $1.8 million and $3.0 million as of September&#160;30, 2017 and December&#160;31, 2016, respectively.</font> </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Biogen</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the now-terminated collaboration agreement between the Company and Biogen New Ventures, formerly Biogen Idec New Ventures Inc. (&#8220;Biogen&#8221;), the Company recognized revenue of $0.7 million and $2.1 million for the three and nine months ended September&#160;30, 2016. The Company did not have any deferred revenue under the Biogen agreement as of September&#160;30, 2017 and December 31, 2016 and will not recognize any additional revenue under this terminated agreement in the future.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Income Taxes</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not record a federal or state income tax benefit for its losses for the three and nine months ended September&#160;30, 2017 and 2016 due to the conclusion that a full valuation allowance is required against the Company&#8217;s deferred tax assets. &#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Net Loss per Share</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended September&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,954</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,771</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,008</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,815</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruing dividends on preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,378</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stockholders-basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,954</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,771</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,008</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,193</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of common shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; outstanding&#8212;basic</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,093,344</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,073,685</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,051,536</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,672,368</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stockholders&#8212;basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.56</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.54</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.84</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.75</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s potential dilutive securities, which include stock options and a warrant to purchase common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU16"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The</font><font style="color:#000000;"> Company has reported a net loss for all periods presented. Therefore, diluted net loss per </font><font style="color:#000000;">common share is the same as basic net loss per common share. The following potentially dilutive securities outstanding, prior to the use of the treasury stock method or if-converted method, have been excluded from the computation of diluted weighted-averag</font><font style="color:#000000;">e shares outstanding, because such securities had an antidilutive impact due to the losses reported</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,946,853</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,731,823</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant for the purchase of convertible preferred stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; (as converted to common stock)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,800</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,946,853</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,746,623</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="color:#000000;"> warrant for the purchase of common stock was exercised in February 2016. The Company issued 4,349 shares in a net issuance transaction.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Build-to-Suit Lease</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 19, 2017, the Company entered into a lease agreement for its new headquarters, consisting of approximately 30,000 square feet of laboratory and office space located in Brighton, Massachusetts. The lease commencement date will be on the earlier of (i) the first date on which tenant commenced occupancy for the conduct of business in the premises, or (ii)&#160;April 15, 2018, subject to extension for certain delays.&#160;The lease will extend for a lease term from the commencement date and then for ten years starting with the first day of the month following the month in which the commencement date falls, unless terminated earlier.&#160;The Company is entitled to one seven-year option to extend. Annual rent under the lease, exclusive of operating expenses and real estate taxes, will be approximately $1.7 million in the first year, with annual increases of 2.75% each year thereafter. Total expected rental payments through the initial lease term are approximately $18.8 million. The Company will be entitled to an improvement allowance of approximately $4.8 million for certain permitted costs related to the design and construction of Company improvements to the premises. <font style="color:#000000;">The lease contains customary provisions allowing the landlord to terminate the lease if the Company fails to remedy a breach of any of its obligations within specified time periods, or upon bankruptcy or insolvency of the Company</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is not the legal owner of the leased space. However, in accordance with ASC 840, <font style="font-style:italic;">Leases</font>, because of the Company&#8217;s expected level of direct financial and operational involvement in the substantial tenant improvements required, the Company is deemed to be the owner of the leased space, including the building shell, during the construction period. As a result, the Company capitalized approximately $12.1 million as a build-to-suit asset within property, plant and equipment, net and recognized a corresponding build-to-suit facility lease obligation within other liabilities and other non-current liabilities on its balance sheets equal to the estimated replacement cost of its leased portion of the building at the inception of the lease.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, construction costs incurred as part of the build-out and tenant improvements will also be capitalized within property, plant and equipment, net. Rental payments made under the lease will be allocated to interest expense and the build-to-suit facility lease obligation, based on the implicit rate of the build-to-suit facility lease obligation. The build-to-suit facility lease obligation was approximately $12.1 million as of September 30, 2017<font style="color:#000000;">.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU17"></a><a name="ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a><a name="ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Management&#8217;s</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a><a name="ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS"></a> Discussion and Analysis o</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">f Financial Condition and Results of Operation</font></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The following discussion and analysis of our financial condition and the results of operations should be read in conjunction with our financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q (&#8220;Quarterly Report&#8221;) and our audited financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2016 (the &#8220;Annual Report&#8221;) filed with the Securities and Exchange Commission on March&#160;30, 2017. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report,&#160;including information with respect to our plans and strategy for our business, includes forward looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section in our Annual Report and in this Quarterly Report,&#160;our actual results could differ materially from the results described, in or implied by, the forward-looking statements contained in the following discussion and analysis.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis, or CF, and other diseases caused by dysfunctional protein processing.&nbsp;&nbsp;The Company focuses on identifying therapies that restore protein function.&nbsp;&nbsp;CF is a disease caused by defects in the cystic fibrosis transmembrane conductance regulator, or CFTR, protein and insufficient CFTR protein function. Our CF focused pipeline consists of novel CFTR modulators including correctors, potentiators and amplifiers. We have exploited the novel mechanism of action of the amplifiers as a drug screening tool and have identified correctors and potentiators to be developed as part of a combination therapy. We are in clinical development for PTI-428, an amplifier, PTI-801, a corrector, and PTI-808, a potentiator. We are developing and, if approved, intend to commercialize our own therapies, including a double combination of our corrector and potentiator and a triple combination consisting of our corrector, potentiator and amplifier to be indicated for CF patients who have at least one F508del mutation, representing the majority of the patient population.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The approval of CFTR modulator based therapy, consisting of a potentiator and a combination of a potentiator and a corrector, has validated the clinical benefit of a small molecule pharmacological approach to improve CFTR function and has become a standard of care for eligible CF patients. These developments have spurred drug discovery and development initiatives that include a combinational approach of multiple modulators. Several companies are currently developing combined uses of three CFTR modulators whose goal is the restoration of CFTR protein activity in CF patients by using one potentiator and two corrector molecules. Correctors, such as lumacaftor or tezacaftor, are believed to improve protein folding and trafficking to enable abnormally folded CFTR protein to achieve some level of activity without repairing the actual protein mutation. Potentiators, such as ivacaftor, are believed to increase the opening time of the CFTR protein channel resulting in higher ion flow across the cell membrane.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CFTR modulators are compounds that affect the folding, trafficking, function and clearance of CFTR protein and can be classified according to the ways in which they affect CFTR protein. Amplifiers, which include PTI-428, are CFTR modulators designed to selectively increase the amount of the unfolded form of CFTR protein, thereby providing additional substrate for other CFTR modulators, such as correctors and potentiators, to act upon. Using industry-standard <font style="font-style:italic;">in vitro</font> studies, we have demonstrated that co-administration of PTI-428 with these other CFTR modulators significantly improves the <font style="font-style:italic;">in vitro</font> CFTR protein activity achieved by these CFTR modulators alone. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A triple combination regimen that includes PTI-428 with PTI-801, a corrector, and PTI-808, a potentiator, has been shown to restore <font style="font-style:italic;">in vitro</font> CFTR protein activity to approximately 100% of normal, in patient-derived human bronchial epithelial, or HBE, cells homozygous for F508del. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With the recent advent of CFTR modulators, the CF treatment paradigm is shifting from palliative care, which addresses only the symptoms of CF, to disease-modifying agents that target the genetic mutations and protein dysfunction that cause the disease. We are developing and, if approved, intend to commercialize PTI-428 for CF patients with an F508del mutation of the CFTR gene, the most common CFTR gene mutation. In the United States, approximately 86% of all CF patients have an F508del mutation of the CFTR gene, of which approximately 53% are homozygous (having two copies of the F508del mutation), and approximately 47% are heterozygous (having an F508del mutation and one other mutation).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU18"></a>We have analyzed published data by Vertex Pharmaceuticals Incorporated, or Vertex, of its CFTR modulators (the potentiator ivacaftor and the correctors lumacaftor and tezacaftor) and combinations thereof, which showed a strong correlation between the <font style="font-style:italic;">in vitro</font> CFTR protein activity and lung function improvement. We have shown <font style="font-style:italic;">in vitro</font> that PTI-428 increases the amount of available CFTR protein and, when combined with ivacaftor and either lumacaftor or tezacaftor, nearly doubles the CFTR protein activity in the cell compared to a combination of only ivacaftor and either lumacaftor or tezacaftor. In the fourth quarter of 2015, the investigational new drug application, or IND, that we submitted to the U.S. Food and Drug Administration, or FDA, for a Phase 1 clinical trial to evaluate our PTI-428 product candidate became effective. In January 2016, we received Fast Track designation from the FDA for the investigation of PTI-428 for the treatment of CF. We initiated our first Phase 1 clinical trial in CF subjects and healthy volunteers in </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the first half of 2016.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The Phase 1 trial in CF subjects includes single ascending dose, or SAD, and multiple ascending dose, or MAD, cohorts. The Phase 1 trial in healthy volunteers includes SAD and MAD cohorts to assess the safety, pharmacokinetic and exploratory biomarker res</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ults.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We reported preliminary safety and pharmacokinetic (PK) data from MAD cohorts in the PTI-428 Phase 1 clinical trial in CF subjects receiving PTI-428 or placebo for 7 days in addition to Orkambi&#174; as their background, standard of care therapy, as well as a cohort with CF subjects receiving PTI-428 or placebo for 7 days who are not taking CFTR modulator based therapies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have initiated a 28-day Phase 2 clinical trial for PTI-428, which commenced dosing of CF patients to receive PTI-428 or placebo for 28 days in addition to Orkambi&#174; as their background therapy, we have completed enrollment and we expect preliminary data from this cohort in the fourth quarter of 2017. We have also initiated and commenced dosing for a study of patients on Kalydeco&#174; who will be dosed with PTI-428 or placebo for 14 days and currently intend to report preliminary data in the first quarter of 2018.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our IND for the Phase 1 study of PTI-801, a corrector molecule, was submitted to the FDA in the first quarter of 2017 and is now active. In March 2017, we received Fast Track designation from the FDA for the investigation of PTI-801 for the treatment of CF. We have completed dosing of subjects in the key SAD and MAD cohorts of the healthy volunteer portion of this study, to assess the safety and PK of PTI-801, reported initial data on this portion of the study, and are now enrolling and dosing CF subjects on background Orkambi&#174;. We expect initial data from CF subjects on background Orkambi&#174; who have been dosed with PTI-801 or placebo for 14 days in the fourth quarter of 2017. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our IND for the Phase 1 study of PTI-808, a potentiator molecule, was submitted to the FDA in the second quarter of 2017 and is now active. The study protocol includes healthy volunteer cohorts to assess safety and PK, which are underway, and multiple dosing cohorts in CF patients. Under the same study protocol we plan to explore dosing of PTI-808 with our other investigational agents, PTI-428 and PTI-801. We expect initial data from the SAD and MAD cohorts of a 7-day study in healthy volunteers taking PTI-808 in the fourth quarter of 2017.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our combination development program is intended to evaluate the clinical profile of the potential combinations of our drug candidates: PTI-801, PTI-808 and PTI-428. The initiation of the first combination study in CF patients is contingent on the outcome of the ongoing clinical studies with PTI-428 and PTI-801, each as an add-on to Orkambi<font style="font-family:Calibri;">&#174;</font>. We have completed preclinical combination safety and toxicology studies and have initiated a combination safety, tolerability and PK study in healthy volunteers with all three compounds. We expect initial data from a 7-day study in healthy volunteers taking all three compounds in the fourth quarter of 2017. Our CFTR modulators have shown synergy <font style="font-style:italic;">in vitro</font> with other known and investigational CFTR modulators, creating several possible development pathways, including potential add-on therapies to marketed CFTR modulators and proprietary double and triple combinations as shown in Figure 1. Notably, <font style="font-style:italic;">in vitro</font> data in patient cells showed that the combination of PTI-801 and PTI-808 restored CFTR protein activity to levels beyond those observed in cells from healthy carriers. Given the potential therapeutic benefit of multiple combination options and our commitment to next generation modulators, our combination development plan includes a PTI-801 and PTI-808 doublet and a PTI-808, PTI-801, and PTI-428 triplet.&nbsp;&nbsp;This effort enables us to both diversify our combination strategy and understand the value potential of each component within our portfolio.&nbsp;&nbsp;Additionally, co-administration of PTI-801 and PTI-808 is intended to explore the clinical effect of the dual combination based on <font style="font-style:italic;">in vitro</font> assay data we observed which showed superior <font style="font-style:italic;">in vitro </font>CFTR protein activity compared with the agents in the currently approved product Orkambi<sup style="font-size:85%; vertical-align:top">&#174;</sup> or combinations being reviewed for potential marketing authorization in the near future (ivacaftor and tezacaftor). We aim to initiate this dual combination study in CF patients in the fourth quarter of 2017 and initiate a triple combination study in the first half of 2018. These studies are expected to enroll CF patients homozygous for F508del who are not taking Orkambi&#174;.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU19"></a><font style="text-decoration:underline;">Figure 1</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g201711142133156184463.jpg" title="" alt="" style="width:517px;height:281px;"></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We strive to collect endorsement and sanctioning for all our studies in CF patients from key regional advocacy organizations to expedite patient recruitment and trial execution. Our Phase 1/2 study protocol for PTI-428 received approval and favorable ranking from the Clinical Trial Network of the European Cystic Fibrosis Society, or the CTN, a patient advocacy group that reviews protocols for CF trials and provides recommendations to its member sites. The PTI-801 study protocol has been sanctioned and favorably ranked by both the CTN and the Therapeutic Development Network, or TDN, part of the Cystic Fibrosis Foundation Therapeutics. We have submitted the PTI-808 study protocol &#8211; which includes co-administration with PTI-801 and PTI-428 &#8211; to the CTN and TDN for review, and will seek endorsement from both groups upon additional review of clinical data.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we have partnered with a major pharmaceutical company, Astellas Pharma Inc., or Astellas, on our unfolded protein response, or UPR, program. The UPR program is intended to reduce the accumulation of unfolded proteins in the endoplasmic reticulum, or ER, which is observed in many diseases caused by an imbalance in the proteostasis network and characterized by defects in protein folding, trafficking and clearance, including genetic, neurodegenerative and retinal degenerative diseases. In August 2016, we announced the achievement of a preclinical milestone by demonstrating that selective modulation of the UPR pathway is an effective disease-modifying approach in the treatment of multiple diseases with few or no therapies currently available.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception in 2006, we have devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital, acquiring and developing product and technology rights, and conducting research and development activities for our product candidates. We do not have any products approved for sale and have not generated any revenue from product sales. We have funded our operations to date with proceeds from the sale of preferred stock, the issuance of convertible promissory notes, proceeds from our initial public offering in February 2016, our follow-on public offering in September 2016, and, to a lesser extent, payments received in connection with collaboration agreements and a research grant.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have incurred significant operating losses. Our net losses were $14.0 million and $10.8 million for the three months ended September&#160;30, 2017 and 2016, respectively, and $46.0 million and $27.8 million for the nine months ended September&#160;30, 2017 and 2016, respectively. As of September&#160;30, 2017, we had an accumulated deficit of $203.5 million. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. We expect our expenses and capital requirements will increase substantially in connection with our ongoing activities, as we:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">expand clinical trials for PTI-428, PTI-801 and PTI-808;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">explore combination therapies in doublet, triplet and/or quad formats;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seek regulatory approval for our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seek support and approval from our collaboration partners, the </font><font style="Background-color:#FFFFFF;color:#000000;font-family:Times New Roman;">TDN and other interested parties</font><font style="font-family:Times New Roman;">;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">hire personnel to support our product development, manufacturing, commercialization and administrative efforts; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">advance the research and development efforts of our product candidates, including, without limitation, back-up compounds.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU20"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for our product candidates. If we obtain regulatory approval for any of our product candidates, we expect to incur significant expenses related to developing our internal commercialization capability to support product sales, marketing and distribution. I</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n addition, we will continue to incur additional costs associated with operating as a public company.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of public or private equity, debt financings or other capital sources, including potential collaborations with other companies or other strategic transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 31, 2017, we determined to focus our resources on research and clinical development of our CF programs, as well as supporting our collaboration with Astellas. Accordingly, we reduced our headcount dedicated to research from 46% of the total workforce to 34% through the elimination of 13 positions. As a result of this action, which is anticipated to be completed during the fourth quarter, we estimate annualized savings of approximately $3.0 million, with estimated one-time severance and related costs of approximately $0.2 million in the fourth quarter of 2017.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that our cash, cash equivalents and short-term investments as of September&#160;30, 2017 will enable us to fund our operating expenses and capital requirements, based upon our current operating plan, through the second quarter of 2018. See &#8220;<font style="color:#000000;">&#8212;Liquidity and Capital Resources&#8221;</font>.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Components of our Results of Operations</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future. All of our revenue during the three and nine months ended September&#160;30, 2017 was derived from our collaboration agreement with Astellas, while all of our revenue during the three and nine months ended September&#160;30, 2016 was derived from our collaboration agreement with Astellas and our now-terminated collaboration agreement with Biogen New Ventures, formerly Biogen Idec New Ventures Inc. (&#8220;Biogen&#8221;).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Astellas collaboration agreement, entered into in November 2014, we recognized revenue of $1.6 million and $1.0&#160;million for the three months ended September&#160;30, 2017 and 2016, respectively, and $3.7 million and $2.2 million of for the nine months ended September&#160;30, 2017 and 2016. We recognize revenue from all upfront payments, research funding payments, non-substantive milestone payments and reimbursements of third-party costs under this arrangement, together as a single unit, over the three and a half-year research term, which commenced in January 2015, with a cumulative catch-up for the elapsed portion of the research services being recognized at the time any non-substantive milestone payment or other consideration is earned. Amounts recorded as deferred revenue under the Astellas collaboration agreement totaled $1.8 million and $3.0 million as of September&#160;30, 2017 and December&#160;31, 2016, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the now-terminated collaboration agreement we had with Biogen, we recognized revenue of $0.7 million for the three months ended September&#160;30, 2016 and $2.1 million for the nine months ended September&#160;30, 2016. We recognized revenue from all upfront license payments, research funding payments, non-substantive milestone payments and reimbursements of third-party costs under this arrangement, together as a single unit, over the four-year research term, which commenced in December 2013, with a cumulative catch-up for the elapsed portion of the research services being recognized at the time any non-substantive milestone payment or other consideration is earned. We did not have any deferred revenue under the agreement as of September&#160;30, 2017 and December 31, 2016 and we will not recognize any additional revenue under this terminated agreement in the future.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that any future revenue recognized under the Astellas collaboration agreement will fluctuate from quarter to quarter as a result of the uncertain timing of future milestone payments and the uncertain quantity of our research services provided from quarter to quarter. Further, subject to the terms and conditions of our collaboration agreement, our collaborator has certain unilateral rights to discontinue their participation in the research activities and, as a result, future payments to us under the agreement.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU21"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating Expenses</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses, which include costs of research services incurred in connection with our collaboration agreements and research grant, consist primarily of costs incurred in connection with the discovery and development of our product candidates, which include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">employee-related expenses, including salaries, related benefits, travel and stock-based compensation expense for employees engaged in research and development functions;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">expenses incurred in connection with the preclinical and clinical development of our product candidates and under agreements with contract research organizations, or CROs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and supplies; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">payments made under third-party licensing agreements.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expense research and development costs as incurred. We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our direct research and development expenses are tracked on a program-by-program basis and consist primarily of external costs, such as fees paid to consultants, central laboratories, contractors and CROs in connection with our clinical trials and preclinical development activities. We do not allocate employee costs, costs associated with our platform technology and facility expenses, including depreciation or other indirect costs, to specific product development programs because these costs are deployed across multiple product development programs and, as such, are not separately classified. We use internal resources to manage our preclinical development activities and perform data analysis for such activities. These employees work across multiple development programs and, therefore, we do not track their costs by program.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below summarizes our research and development expenses incurred by development program:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended September&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CF</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,484</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,052</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,858</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,999</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UPR</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">529</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">233</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,119</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">877</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unallocated expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,881</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,933</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,395</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,622</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,894</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,218</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,372</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,498</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that our expenses will increase substantially in connection with our ongoing clinical trials and preclinical development activities. At this time, we cannot reasonably estimate the costs for completing the clinical development of PTI-428, PTI-801 or PTI-808 for the treatment of CF or the cost associated with the development of any of our other product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The successful development and commercialization of our product candidates is highly uncertain. This is due to the numerous risks and uncertainties associated with product development and commercialization, including the uncertainty of:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the scope, progress, outcome and costs of our preclinical development activities, clinical trials and other research and development activities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">establishing an appropriate safety profile with IND-enabling studies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">successful patient enrollment in, and the initiation and completion of, clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the cooperation and approval we receive from third parties including clinical investigators, CROs, the TDN and CTN;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the timing, receipt and terms of any marketing approvals from applicable regulatory authorities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">significant and changing government regulation;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU22"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">maintaining a continued acceptable safety profile of the product candidates following approval.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any changes in the outcome of any of these variables, or others identified within this filing, with respect to the development of our product candidates in preclinical and clinical development could mean a significant change in the costs and timing associated with the development of these product candidates. For example, if the FDA or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development of that product candidate.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">General and Administrative Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist primarily of salaries and related costs, including stock-based compensation, for personnel in executive, finance and administrative functions. General and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, consulting, accounting and audit services.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other Income (Expense), Net</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Interest Income<font style="font-style:normal;">. Interest income consists of interest earned on cash equivalents and short-term investments held by us during the three and nine months ended September&#160;30, 2017 and 2016.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Other Income (Expense), Net<font style="font-style:normal;">. Other income (expense), net primarily consists of the amortization of premium on our short-term investments and the gains or losses associated with the changes in the fair values of our derivative liability. The derivative liability relates to a cash settlement option associated with the change of control provision in our CFFT collaboration agreement, which meets the definition of a derivative. Therefore, we have classified this derivative as a liability that we remeasure to fair value at each reporting period, and we record the changes in the derivative liability as a component of other income (expense), net.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies and Significant Judgments and Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our financial statements are prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of our financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our actual results may differ from these estimates under different assumptions or conditions. During the nine months ended September&#160;30, 2017, there were no material changes to our critical accounting policies. Our critical accounting policies are described under the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212; Critical Accounting Policies and Significant Judgments and Estimates&#8221; in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March&#160;30, 2017 and the notes to the financial statements appearing elsewhere in this Quarterly Report on&#160;Form&#160;10-Q.&#160;We believe that of our critical accounting policies, the following accounting policies involve the most judgment and complexity:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">revenue recognition;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">accrued research and development expenses;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">stock-based compensation; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">valuation of derivative liability.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly, we believe the policies set forth above are critical to fully understanding and evaluating our financial condition and results of operations. If actual results or events differ materially from the estimates, judgments and assumptions used by us in applying these policies, our reported financial condition and results of operations could be materially affected.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU23"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comparison of Three Months Ended September&#160;30, 2017 and 2016</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our results of operations for the three months ended September&#160;30, 2017 and 2016 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended September&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Decrease)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research collaboration revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,551</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,715</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(164</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,894</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,218</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,676</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,741</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,266</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(525</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,635</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,484</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,151</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,084</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,769</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,315</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expense, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other expenses, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,954</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,771</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,183</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue was $1.6 million for the three months ended September&#160;30, 2017, compared to $1.7 million for the three months ended September&#160;30, 2016. The decrease of $0.1 million is the result of a reduction of $0.7 million of revenue recognized under the Biogen collaboration that terminated in the fourth quarter of 2016. This decrease was partially offset by an increase of $0.6 million of revenue recognized under the Astellas agreement in the three months ended September&#160;30, 2017, which is primarily a result of payments under the agreement being recognized as revenue over the research term, with a cumulative catch-up for the elapsed portion of the research term<font style="color:#000000;">.</font></p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses were $12.9 million for the three months ended September&#160;30, 2017, compared to $9.2 million for the three months ended September&#160;30, 2016. The increase of $3.7 million was primarily due to an increase of $1.4 million in activities supporting our CF program as we continue to advance our candidates in the clinic. During the three months ended September 30, 2017, costs incurred in connection with the development of PTI-801 and PTI-808 accounted for a combined increase of $5.4 million, or $2.7 million each, largely related to increased manufacturing, preclinical and clinical trial expenses as we transition to Phase 1 clinical trials. The increase was partially offset by a $3.3 million decrease in spending on PTI-428 as compared to the same period last year. Additionally, there was an increase of $1.2 million in personnel-related costs during the three months ended September&#160;30, 2017 as compared to September 30, 2016, including $0.3 million in employee stock-based compensation expense, primarily driven by an overall increase in headcount to support the development of our CF product pipeline. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">General and Administrative Expenses</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses were $2.7 million for the three months ended September&#160;30, 2017, compared to $3.3 million for the three months ended September&#160;30, 2016. The decrease of $0.6 million in general and administrative expenses was primarily due to a decrease of $0.4 million in professional fees and a $0.4 million decrease in facility costs, partially offset by an increase of $0.3 million in personnel-related costs, including $0.2 million of employee stock-based compensation.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Interest Income<font style="font-style:normal;"> </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income was $0.2 million for the three months ended September&#160;30, 2017 as compared to less than $0.1 million for the three months ended September&#160;30, 2016 and consists of interest earned on short-term investments initially purchased in September 2016 with proceeds from our follow-on offering completed in September 2016.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Other Income (Expense), Net<font style="font-style:normal;"> </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expenses were less than $0.1 million for the three months ended September&#160;30, 2017 and 2016. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU24"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comparison of Nine Months Ended September&#160;30, 2017 and 2016</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our results of operations for the nine months ended September&#160;30, 2017 and 2016 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Decrease)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research collaboration revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,719</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,324</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(605</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,372</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,498</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,874</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,813</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,682</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,185</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,180</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,005</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,466</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,856</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,610</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">515</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">459</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(57</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(42</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other expenses, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">458</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">417</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,008</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,815</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,193</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue was $3.7 million for the nine months ended September&#160;30, 2017, compared to $4.3 million for the three months ended September&#160;30, 2016. The decrease of $0.6 million is the result of a reduction of $2.1 million of revenue recognized under the Biogen collaboration that terminated in the fourth quarter of 2016. This decrease was partially offset by an increase of $1.5 million of revenue recognized under the Astellas agreement. Payments under the agreement are recognized as revenue over the research term, with a cumulative catch-up for the elapsed research term being recognized at the time any such payments are earned.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses were $41.4 million for the nine months ended September&#160;30, 2017, compared to $23.5 million for the nine months ended September&#160;30, 2016. The increase of $17.9 million was primarily due to an increase of $10.9 million in activities supporting our CF program, primarily related to the continued advancement of our Phase 1 clinical trials for PTI-801 and PTI-808 which accounted for a combined $11.8 million increase due to manufacturing, preclinical and clinical trial expenses as we prepared and advanced these candidates into their Phase 1 clinical trials during the nine months ended September 30, 2017. Costs incurred on PTI-428 decreased by $1.9 million during the nine months ended September 30, 2017. Additionally, there was an increase of $4.1 million in personnel-related costs, including $0.7 million in employee stock-based compensation expense, primarily driven by an overall increase in headcount to support the development of our CF product pipeline. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">General and Administrative Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses were $8.8 million for the nine months ended September&#160;30, 2017, compared to $8.7 million for the nine months ended September&#160;30, 2016.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Interest Income</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income was $0.5 million for the nine months ended September&#160;30, 2017 as compared to less than $0.1 million of interest income for the nine months ended September&#160;30, 2016. The increase was primarily due to interest earned on short-term investments held during the nine months ended September&#160;30, 2017. Short-term investments were initially purchased with proceeds from our follow-on offering that was completed in September 2016.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Other Income (Expense), Net<font style="font-style:normal;"> </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expenses were less than $0.1 million for the nine months ended September&#160;30, 2017 and 2016. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU25"></a>Since our inception, we have incurred significant operating losses. We have generated limited revenue to date from our collaboration agreements and research grant. We have not yet commercialized any of our product candidates, which are in various phases of preclinical development and clinical trials, and we do not expect to generate revenue from sales of any product for several years, if at </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">all. We have funded our operations to date with proceeds received from our initial public </font><font style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">offering and subsequent follow-on offering, the sale of preferred stock, the issuance of convertible promissory notes and, to a lesser extent, payments received in connection with collaboration agreements and a research grant. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September&#160;30, 2017, we had cash, cash equivalents and short-term investments of $43.2 million. We expect that our cash, cash equivalents and short-term investments as of September&#160;30, 2017 will enable us to fund our operating expenses and capital requirements, based upon our current operating plan, through the second quarter of 2018. <font style="color:#000000;">As of September 30, 2017, we have further assessed this risk and, in accordance with the requirements of ASC 205-40, determined that there are initial conditions indicating that there is substantial doubt about our ability to continue as a going concern within twelve months of the issuance date of these condensed financial statements.&#160;These indicators are our accumulated deficit and the forecasted cash expenditures. </font>Although we have been successful in raising capital in the past, there is no assurance that we will be successful in obtaining such additional financing on terms acceptable to us, if at all, nor is it considered probable under the accounting standards. <font style="color:#000000;">As such, under the requirements of ASC 205-40, our management may not consider the potential for future capital raises in their assessment of our ability to meet its obligations for the next twelve months.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability to reduce spending at a level that mitigates the factors described above, is not considered probable, as defined in the accounting standards; as such, under the requirements of ASC 205-40, the full extent to which we may extend our funds through these actions may not be considered in our management&#8217;s assessment of our ability to continue as a going concern for the next twelve months. In accordance with the requirements of ASC 205-40, management has concluded that it is required to disclose that substantial doubt exists about our ability to continue as a going concern for twelve months from the date these condensed financial statements are issued. While we have plans in place to mitigate these actions, they are not considered probable, as defined in the accounting standards, and a failure to raise the additional funding or to effectively implement cost reductions could harm our business, results of operations and future prospects.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we have been successful in raising capital in the past, there is no assurance that we will be successful in obtaining such additional financing on terms acceptable to us, if at all. &#160;If we are unable to obtain funding, we could be forced to delay, reduce or eliminate some or all of our research and development programs, product portfolio expansion or commercialization efforts, which would adversely affect our business prospects, or we may be unable to continue operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash Flows</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our sources and uses of cash for each of the periods presented (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,557</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,820</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by (used in) investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,063</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(56,318</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,122</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(421</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,984</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Operating Activities.<font style="font-style:normal;"> Net cash used in operating activities was $40.6 million during the nine months ended September&#160;30, 2017, primarily driven by our net loss of $46.0 million, partially offset by changes in our operating assets and liabilities of </font><font style="color:#000000;font-style:normal;">$2.7 million and non-cash charges of $2.8 million. Our net loss was primarily attributed to our research and development activities associated with the advancement of our preclinical studies and clinical trials.</font><font style="color:#000000;font-style:normal;">&#160;</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">During the nine months ended September 30, 2016, operating activities used $27.8 million of cash, primarily resulting from our net loss of $27.8 million. Our net loss was primarily attributed to research and development activities and our general and administrative expenses.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Investing Activities.<font style="font-style:normal;"> During the nine months ended September&#160;30, 2017, net cash provided by investing activities was $40.1 million, primarily consisting of proceeds received from maturities of short-term investments and offset by additional purchases of short-term investments. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the nine months ended September&#160;30, 2016, we used $56.3 million of cash in investing activities primarily as a result of our purchases of short-term investments.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU26"></a><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Financ</font><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ing Activities.</font><font style="font-style:normal;"> During the nine months ended September&#160;30, 2017, net cash provided by financing activities was less than $0.1 million, primarily resulting from the exercise of stock options and the issuance of common stock pursuant to the employee stock pu</font><font style="font-style:normal;">rchase plan.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the nine months ended September&#160;30, 2016, net cash provided by financing activities was $114.1 million, primarily resulting from gross proceeds of $116.8 million from the sale of common stock in connection with our initial and follow-on public offerings, partially offset by payments of $2.8 million of public offering costs.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating Capital Requirements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials of our product candidates in development.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our expenses will also increase as we:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">pursue the clinical development of our most advanced product candidates, including PTI-428, PTI-801 and PTI-808;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seek the support and approval from our collaboration partners, the TDN and other interested parties;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">continue the research and development of our other product candidates and combination therapies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seek to identify and develop additional product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seek marketing approvals for any of our product candidates that successfully complete clinical development;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">develop and expand our sales, marketing and distribution capabilities for our product candidates for which we obtain marketing approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">scale up our manufacturing processes and capabilities to support our ongoing preclinical activities and clinical trials of our product candidates and commercialization of any of our product candidates for which we obtain marketing approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">maintain, expand and protect our intellectual property portfolio;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">expand our operational, financial and management systems and increase personnel, including personnel to support our clinical development, manufacturing and commercialization efforts and our operations as a public company; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">increase our product liability and clinical trial insurance coverage as we initiate our clinical trials and commercialization efforts.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical drugs, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on many factors, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the number and characteristics of the product candidates we pursue;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the scope, progress, results and costs of researching and developing our product candidates, and conducting preclinical studies and clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the timing of, and costs involved in, manufacturing our drug candidates and any drugs we successfully commercialize;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">delays that may be caused by changing regulatory requirements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">cost and timing of hiring new employees to support our continued growth;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the timing, receipt and amount of sales of, or milestone payments related to or royalties on, our current or future product candidates, if any.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU27"></a>Until such time, if ever, as we can generate product revenue sufficient to achieve profitability, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaboration agreements, other third-party funding, strategic alliances, licensing arrangements or marketing and distribution arrangements. To the extent that we raise additional capital through the </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sale of equity or convertible debt securities, ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of a common stockholder. Debt </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> raise additional funds through other third-party funding, collaborations agreements, strategic alliances, licensing arrangements or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue stre</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our p</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">roduct development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based upon our current operating plan, we believe our existing cash, cash equivalents and short-term investments will enable us to fund our operating expenses and capital expenditure requirements through the second quarter of 2018.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contractual Obligations and Commitments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company currently leases office and laboratory space in Cambridge, Massachusetts pursuant to an operating lease that, as amended, expires in May 2018. The Company recorded rent expense of $0.4 million during each of the three months ended September 30, 2017 and 2016 and $1.3 million and $1.2 million during the nine months ended September 30, 2017 and 2016, respectively.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 19, 2017, the Company entered into a lease agreement for its new headquarters, consisting of approximately 30,000 square feet of laboratory and office space located in Brighton, Massachusetts. The lease commencement date will be on the earlier of (i)&#160;the first date on which tenant commenced occupancy for the conduct of business in the premises, or (ii)&#160;April 15, 2018, subject to extension for certain delays.&#160;The lease will extend for a lease term from the commencement date and then for ten years starting with the first day of the month following the month in which the commencement date falls, unless terminated earlier.&#160;The Company is entitled to one seven-year option to extend. Annual rent under the lease, exclusive of operating expenses and real estate taxes, will be approximately $1.7 million in the first year, with annual increases of 2.75% each year thereafter. The Company will be entitled to an improvement allowance of approximately $4.8 million for certain permitted costs related to the design and construction of Company improvements to the premises <font style="color:#000000;">the lease contains customary provisions allowing the landlord to terminate the lease if the Company fails to remedy a breach of any of its obligations within specified time periods, or upon bankruptcy or insolvency of the Company.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our contractual obligations as of September&#160;30, 2017 and the effects that such obligations are expected to have on our liquidity and cash flows in future periods (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less Than</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1 Year</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1&#160;to&#160;3&#160;Years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3&#160;to&#160;5&#160;Years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">More than</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5 Years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease commitments (1)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,670</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,729</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,404</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,594</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,943</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consulting agreement (2)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,470</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">840</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">630</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,140</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,569</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,034</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,594</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,943</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Amounts in the table reflect payments due for our lease of office and laboratory space in Cambridge, Massachusetts under an operating lease agreement that, as amended, expires in May 2018 and our new lease for office and laboratory space in Brighton, MA, which commences in April 2018 and expires approximately March 2028.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In May 2016, we entered into an agreement with Dr. Stelios Papadopoulos to provide consulting and advisory services as and when requested. We will pay a quarterly retainer of $0.2 million to Dr. Papadopoulos over a three-year term for a total of $2.5 million. The quarterly retainer may be settled in cash, common stock of the Company or a combination thereof, at our discretion.</p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Off-Balance Sheet Arrangements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the Securities and Exchange Commission.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160; 3.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU"></a><a name="ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU"></a>Quantitative and Qualitative Disclosures About Market Risks</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Interest Rate Fluctuation Risk</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU28"></a>Our cash, cash equivalents and short-term investments as of September&#160;30, 2017, consisted of money market funds, government-sponsored enterprise securities and U.S. treasury securities. The primary objectives of our investment activities are to preserve principal, provide liquidity and maximize income without significantly increasing risk. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. However, because of the nature </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the instruments in our portfolio, a sudden change in market interest rates </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">would not be expected to have a material impact on our financial condition and/or results of operation.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160; 4.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_4_MANAGEMENTS_EVALUATION_OUR_DISCLO"></a><a name="ITEM_4_MANAGEMENTS_EVALUATION_OUR_DISCLO"></a>Management&#8217;s Evaluation of our Disclosure Controls and Procedures.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities and Exchange Act of 1934 is (1)&#160;recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms and (2)&#160;accumulated and communicated to our management, including our President and Chief Executive Officer, who is our principal executive officer, and our Chief Financial Officer, who is our principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September&#160;30, 2017, our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934). Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and principal financial officer have concluded based upon the evaluation described above that, as of September&#160;30, 2017, our disclosure controls and procedures were effective at the reasonable assurance level.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no changes in our internal control over financial reporting during the three months ended September&#160;30, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU29"></a><a name="PART_II_OR_INFORMATION"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_II_OR_INFORMATION"></a>PART&#160;II &#8212; OTHE</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">R INFORMATION</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160; 1.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_1_LEGAL_PROCEEDINGS"></a><a name="ITEM_1_LEGAL_PROCEEDINGS"></a>Legal Proceedings</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the ordinary course of business, we are from time to time involved in lawsuits, claims, investigations, proceedings, and threats of litigation relating to intellectual property, commercial arrangements, employment and other matters. While the outcome of these proceedings and claims cannot be predicted with certainty, as of September&#160;30, 2017, we were not party to any material pending legal proceedings, and we are not aware of any claims or actions pending or threatened against us that would have a material adverse impact on our financial position, results of operations or cash flows.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160; 1A.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_1A_RISK_FACTORS"></a><a name="ITEM_1A_RISK_FACTORS"></a>Risk Factors</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Investing <font style="Background-color:#FFFFFF;color:#000000;">in our common stock involves a high degree of risk. You should carefully consider the following risks and uncertainties, together with all of the other information in this Quarterly Report on Form 10-Q, or this report, including our financial statements and related notes, before investing in our common stock. Any of the risks we describe below could adversely affect our business, financial condition or results of operations. The market price of our common stock could decline if one or more of these risks or uncertainties actually occur, causing you to lose all or part of your investment. Additional risks that we currently do not know about, or that we currently believe to be immaterial, may also impair our business. Certain statements below are forward-looking statements. See &#8220;Forward-Looking Statements&#8221; in this report.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Relating to Our Business</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have incurred significant losses since our inception. We anticipate that we will continue to incur significant losses for the foreseeable future, and we may never achieve or maintain profitability.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a drug research and development company focused primarily on developing our lead product candidates, PTI-428, PTI-801 and PTI-808 for the treatment of CF, as well as our other product candidates for CF, as part of our potential combination therapies. We have incurred significant net losses in each year since our inception, including net losses of $15.8 million, $25.0 million and $37.2 million for the years ended December 31, 2014, 2015 and 2016, respectively, and $46.0 million for the nine months ended September 30, 2017. As of September 30, 2017, we had an accumulated deficit of $203.5 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have financed our operations primarily through the sale of equity securities and debt financings. We have devoted most of our financial resources to research and development, including our preclinical and clinical development activities. We have not completed the development of any of our product candidates. We expect to continue to incur significant and increasing losses and negative cash flows for the foreseeable future. The size of our losses will depend, in part, on the rate of future expenditures and our ability to generate revenues. In particular, we expect to incur substantial and increased expenses as we:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">continue the clinical development of our lead product candidates, PTI-428, PTI-801 and PTI-808, for the treatment of&#160;CF;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seek to obtain regulatory approvals for PTI-428, PTI-801, and potential combination therapies, and our other product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seek cooperation and support from third parties, including clinical investigators, industry experts, therapeutic development networks of patient advocacy groups and clinical research organizations, as we enroll patients in our clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">conduct our ongoing clinical trials and prepare for additional clinical trials and potential commercialization of PTI-428, PTI-801, and our other product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">scale up contracted manufacturing processes and quantities to conduct our ongoing clinical trials and prepare for additional clinical trials and the commercialization of PTI-428, PTI-801, and our other product candidates for any indications for which we receive regulatory approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">establish outsourcing of the commercial manufacturing of PTI-428, PTI-801, PTI-808 and our other product candidates for any indications for which we may receive regulatory approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">establish an infrastructure for the sales, marketing and distribution of PTI-428, PTI-801 and our other product candidates for any indications for which we may receive regulatory approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">advance our combination therapies, including a potential doublet and triplet candidate, as a treatment for CF into clinical trials;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU30"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">expand our research and development activities and advance the discovery and dev</font><font style="font-family:Times New Roman;">elopment programs for other product candidates, including, without limitation, preclinical laboratory, animal and other testing and reports and the preparation of investigational new drug filings in the U.S., and the equivalent in non-U.S. jurisdictions wh</font><font style="font-family:Times New Roman;">ere we may seek to conduct clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">maintain, expand and protect our intellectual property portfolio;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">continue our research and development efforts and seek to discover additional product candidates, including back-up candidates to existing product candidates; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">add clinical, regulatory, operational, financial and management information systems and personnel, including personnel to support our clinical development and commercialization efforts and operations as a public company.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To become and remain profitable, we must succeed in developing and eventually commercializing products with significant market potential. This will require us to be successful in a range of challenging activities, including discovering product candidates, completing preclinical testing and clinical trials of our product candidates, obtaining and maintaining regulatory approval for these product candidates, and manufacturing, marketing and selling those products. We are only in the preliminary stages of these activities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None of our product candidates has been approved or commercialized. We may never succeed in obtaining regulatory approval for or commercializing any of our product candidates. If our product candidates are not approved or commercialized, if any products that do receive regulatory approvals later show unanticipated properties (for example, unexpected safety issues), or if revenues from any products that do receive regulatory approvals are insufficient, we will not achieve profitability and our business may fail.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, diversify our product offerings or continue our operations. A decline in the value of our company could cause you to lose all or part of your investment.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our ability to generate future revenues from product sales is uncertain and depends upon our ability to successfully develop, obtain regulatory approval for and commercialize our product candidates, as well as the receipt and/or maintenance of regulatory approval of products and product candidates under development by third parties that our product candidates will or may in the future depend on.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to generate revenue and achieve profitability depends on our ability, alone or with collaborators, to successfully complete the development of, obtain the necessary regulatory approvals for, and commercialize, a product candidate or candidates. Our several development programs are currently focused on demonstrating their respective clinical benefit for CF patients. If either PTI-428 or PTI-801 is approved, it may be approved for co-administration with ivacaftor and lumacaftor. We do not anticipate generating revenues from sales of PTI-428, PTI-801 or any product candidate for the foreseeable future, if ever. Our ability to generate future revenues from product sales depends heavily on:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Vertex&#8217;s continued compliance with regulatory requirements, the continued commercial availability of ivacaftor and lumacaftor, the reimbursement of their cost to CF patients by insurers and their overall success in the market;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the successful regulatory approval and commercial launch of CFTR modulators other than ivacaftor and lumacaftor (for example, tezacaftor with ivacaftor) that we desire to test for administration with PTI-428, PTI-801 and/or our other product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtaining favorable results for and advancing the development of PTI-428, PTI-801, PTI-808 and our other product candidates, including successfully enrolling patients in and completing our ongoing clinical trials and initiating and completing additional clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtaining regulatory approval in the United States of PTI-428, PTI-801 and our other product candidates for CF and equivalent foreign regulatory approvals;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">launching and commercializing PTI-428, PTI-801 and our other product candidates, including building a production infrastructure and a sales force, and collaborating with third parties;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">achieving broad market acceptance of PTI-428, PTI-801 and our other product candidates in the medical community and with third-party payors; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">generating and advancing through clinical development, a pipeline of product candidates in addition to PTI-428 and PTI-801, such as PTI-808 (as part of our potential combination therapies), and next-generation CFTR modulators.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU31"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conducting preclinical testing and clinical trials is a time-consuming</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, expensive and uncertain process that takes years to complete, and we may never generate the data necessary to obtain regulatory approval and achieve product sales. Our anticipated development costs would likely increase if we do not obtain favorable resu</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lts or if development of any product candidate is delayed. In particular, if we are required by the U.S. Food and Drug Administration, or FDA, and comparable regulatory authorities in other countries to perform studies or trials in addition to those that w</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e currently expect to undertake, we would likely incur higher costs than we anticipate. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to predict the timing or amount of any increase in our</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> anticipated development costs.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for several years, if at all. Even if one or more of our product candidates is approved for commercial sale, we anticipate incurring significant costs in connection with commercialization. As a result, we cannot assure you that we will be able to generate revenues from sales of any approved product candidates, or that we will achieve or maintain profitability even if we do generate sales.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will require additional capital to fund our operations, including if our operating plan changes. If we fail to obtain additional capital, we would be forced to delay, reduce or eliminate one or more of our product research and development programs, seek corporate partners for the development of our product development programs or relinquish or license on unfavorable terms our rights to technologies or product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a time-consuming, expensive and uncertain process that takes years to complete. We expect our research and development expenses to substantially increase in connection with our ongoing activities, particularly as we advance our clinical programs for PTI-428, PTI-801, PTI-808 and our other product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based upon our current operating plan, we believe that our existing cash, cash equivalents and short-term investments of $43.2 million as of September 30, 2017 will enable us to fund our operating expenses and capital expenditure requirements through the second quarter of 2018. As of September 30, 2017, management has further assessed this risk and, in accordance with the requirements of ASC 205-40, determined that there are initial conditions indicating that there is substantial doubt about our ability to continue as a going concern within twelve months of the issuance date of the financial statements in this Quarterly Report on Form 10-Q. Although we have been successful in raising capital in the past, there is no assurance that we will be successful in obtaining additional financing on terms acceptable to us, if at all, nor is it considered probable under the accounting standards. <font style="color:#000000;">As such, under the requirements of ASC 205-40, management may not consider the potential for future capital raises in their assessment of our ability to meet our obligations for the next twelve months.&nbsp;&nbsp;If we are unable to obtain funding, we would be forced to delay, reduce or eliminate one or more of our research and development programs, product portfolio expansion or commercialization efforts, which would adversely affect our business prospects, or we may be unable to continue operations.&#160;&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thus, in accordance with the requirements of ASC 205-40, management has concluded that it is required to disclose that substantial doubt exists about our ability to continue as a going concern for twelve months from the date the financial statements in this Quarterly Report on Form 10-Q are issued.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, should our operating plan change, we will be required to reassess our operating capital needs and there can be no assurance that we will have the cash resources to fund any changed operating plan or that additional funding will be available on terms acceptable to us, or at all. Changing circumstances including those beyond our control may cause us to consume capital more rapidly than we currently anticipate, and we may need additional funds sooner than planned. For example, our clinical trials may encounter technical, enrollment or other difficulties that could increase our development costs more than we expect, or the FDA may require us or we may choose to perform studies or trials in addition to those that we currently anticipate. We may need to raise additional funds to support our ongoing programs for PTI-428, PTI-801 and PTI-808, and other clinical candidates, through regulatory approval and commercialization, or if we need to obtain regulatory approval for PTI-428 or PTI-801 for administration with drugs other than ivacaftor and lumacaftor.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU32"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securing additional financing may divert our management from our day-to-day activities, which may adversel</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y affect our ability to develop and commercialize our product candidates, including PTI-428, PTI-801 and PTI-808. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. If we </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are unable to raise additional capital when required or on acceptable terms, we may be required to:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">significantly delay, scale back or discontinue the research, development or commercialization of our product candidates, including PTI-428, PTI-801 and PTI-808, and our other research or pre-clinical activities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seek corporate partners for PTI-428, PTI-801, PTI-808 or any of our other product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">relinquish, or license on unfavorable terms, our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we will be prevented from pursuing our development and commercialization efforts, which will have a material adverse effect on our business, operating results and prospects and on our ability to develop our product candidates. In addition, if we are unable to raise capital, we will also need to implement cost reductions, and any failure to effectively do so will harm our business, results of operations and future prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates on terms unfavorable to us.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs primarily through the sale of equity securities, debt financings and government and foundation grants. We may also seek to raise capital through third-party collaborations, strategic alliances and similar arrangements. We currently do not have any committed external source of funds.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to raise additional funds to support our operations, we may sell additional equity or debt securities, enter into collaborations, strategic alliances, or licensing arrangements or other marketing or distribution arrangements. To the extent that we raise additional capital through the sale of equity or debt securities, the ownership interest of existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of common stockholders. For example, our board of directors has the right to issue previously-authorized shares of preferred stock with such preferences without stockholder approval. Debt financing, if available, may involve the right to convert any such debt into equity on favorable conversion terms, which conversion would dilute existing stockholders&#8217; ownership interest. Any such debt financing would also likely include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, and declaring dividends, and will impose limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we raise additional funds through collaborations, strategic alliances, or licensing arrangements or other marketing or distribution arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to expand our operations or otherwise capitalize on our business opportunities, our business, financial condition and results of operations could be materially adversely affected. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts, or grant others rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have a limited operating history, which may make it difficult to evaluate the success of our business to date and to assess our future viability.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were formed and began operations in December 2006. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, acquiring and developing product and technology rights and conducting research and development activities for our product candidates. We are currently in preclinical development for our proposed doublet candidate comprised of PTI-801 and PTI-808 and clinical development for PTI-428, PTI-801 and PTI-808 (the latter of which includes a triple combination of all three of our proprietary compounds). We have not obtained regulatory approval for any of our product candidates. Consequently, any predictions about our future success, performance or viability may not be as accurate as they could be if we had a longer operating history, more experience with clinical development or approved products on the market.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU33"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We might not be able to utilize all or a significant portion of our net operating loss </font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">carryforwards and research and development tax credit carryforwards.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2016, we had federal and state net operating loss carryforwards of $138.7 million and $124.5 million, respectively, which begin to expire in 2026 and 2030, respectively. As of December 31, 2016, we also had federal and state research and development tax credit carryforwards of $4.9 million and $2.6 million, respectively, which begin to expire in 2027 and 2025, respectively. These net operating loss and tax credit carryforwards could expire unused and be unavailable to offset future income tax liabilities. In addition, under Section 382 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income may be limited. We have not determined if we have experienced Section 382 ownership changes in the past and if a portion of our net operating loss and tax credit carryforwards are subject to an annual limitation under Section 382. In addition, we may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. If we determine that an ownership change has occurred and our ability to use our historical net operating loss and tax credit carryforwards is materially limited, it would harm our future operating results by effectively increasing our future tax obligations. We have a full valuation allowance against our net deferred tax assets.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Relating to the Development and Regulatory Approval of Our Product Candidates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We depend substantially on the success of our lead product candidate, PTI-428, which is currently in early clinical development and is a new class of CFTR modulator. We cannot be certain that we will be able to successfully complete the clinical development of, obtain regulatory approval for, or successfully commercialize PTI-428.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have no products on the market, and our most advanced product candidate, PTI-428, is currently in clinical development. We initiated our first Phase 1 clinical trial for PTI-428 in CF patients and another in healthy volunteers in the first half of 2016 and are currently conducting a Phase 2 clinical trial in CF patients. PTI-801 is at an earlier stage, as we have completed dosing of subjects in the key SAD and MAD cohorts of the healthy volunteer portion of this study, to assess the safety and PK of PTI-801, and are now conducting the CF portion of this study. PTI-808, our other product candidate in clinical development, is in a Phase 1 clinical trial in healthy volunteers. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business depends substantially on the successful clinical development, regulatory approval and commercialization of PTI-428, a new class of CFTR modulator known as amplifier, and it will require substantial additional clinical development and regulatory approval efforts before we are permitted to commence its commercialization, if ever. The clinical trials and manufacturing and marketing of PTI-428 and any other product candidates will be subject to extensive and rigorous review and regulation by numerous government authorities in the United States, the European Union and other jurisdictions where we intend to test and, if approved, market our product candidates. Before obtaining regulatory approvals for the commercial sale of any product candidate, we must demonstrate through preclinical testing and clinical trials that the product candidate is safe and effective for use in each target indication, and potentially in specific patient populations, including the pediatric population. This process can take many years and may include post-marketing studies and surveillance, which would require the expenditure of substantial resources beyond the proceeds we have currently raised. Of the large number of drugs in development for approval in the United States and the European Union, only a small percentage successfully complete the FDA or European Medicines Agency, or EMA, regulatory approval processes, as applicable, and are commercialized. Accordingly, even if we are able to obtain the requisite financing to continue to fund our research, development and clinical programs, we cannot assure you that PTI-428 or any of our other product candidates will be successfully developed or commercialized.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We also depend on the success of our product candidate PTI-801, which is currently in early clinical development. We cannot be certain that we will be able to successfully complete the clinical development of, obtain regulatory approval for, or successfully commercialize PTI-801.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For PTI-801, we have completed dosing of subjects in the key SAD and MAD cohorts of the healthy volunteer portion of this study, to assess the safety and PK of PTI-801, and are now conducting the CF portion of this study. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU34"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">depends on the successful clinical development, regulatory approval and commercialization of PTI-801, a class of CFTR modulator known as a corrector, and it will require substantial additional clinical development and regulatory approval efforts before we </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are permitted to commence its commercialization, if ever. The clinical trials and manufacturing and marketing of PTI-801 and any other product candidates will be subject to extensive and rigorous review and regulation by numerous government authorities in </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the United States, the European Union and other jurisdictions where we intend to test and, if approved, market our product candidates. Before obtaining regulatory approvals for the commercial sale of any product candidate, we must demonstrate through precl</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inical testing and clinical trials that the product candidate is safe and effective for use in each target indication, and potentially in specific patient populations, including the pediatric population. This process can take many years and may include pos</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t-marketing studies and surveillance, which would require the expenditure of substantial resources beyond the proceeds we have currently raised. Of the large number of drugs in development for approval in the United States and the European Union, only a sm</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">all percentage successfully complete the FDA or European Medicines Agency, or EMA, regulatory approval processes, as applicable, and are commercialized. Accordingly, even if we are able to obtain the requisite financing to continue to fund our research, de</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">velopment and clinical programs, we cannot assure you that PTI-801 or any of our other product candidates will be successfully developed or commercialized.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for PTI-428, PTI-801, PTI-808 or our other product candidates, our business will be substantially harmed.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are not permitted to market PTI-428, PTI-801, PTI-808 or any of our other product candidates in the United States or the European Union until we receive approval of a New Drug Application, or NDA, from the FDA or a Marketing Authorization Application, or MAA, from the European Commission, respectively. Prior to submitting an NDA to the FDA or an MAA to the EMA for approval of any of our product candidates for a specific indication, we will need to complete preclinical and toxicology studies, as well as Phase&#160;1, Phase 2 and Phase&#160;3 clinical trials.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Successfully initiating and completing our clinical program and obtaining approval of an NDA or an MAA is a complex, lengthy, expensive and uncertain process, and the FDA, the EMA or other comparable foreign regulatory authorities may delay, limit or deny approval of any of our candidates for many reasons, including, among others:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we may not be able to demonstrate that our product candidates are safe and effective to the satisfaction of the FDA or the EMA;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the results of our clinical trials may not meet the level of statistical or clinical significance required by the FDA or the EMA for marketing approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA or the EMA may disagree with the number, design, size, conduct or implementation of our clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA or the EMA may require that we conduct additional clinical trials or cohorts or run cohorts sequentially, all of which could delay our trial completion timelines;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA or the EMA may not approve the formulation, labeling or specifications of PTI-428, PTI-801, PTI-808 or our other product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the clinical research organizations, or CROs, that we retain to conduct our clinical trials may take actions outside of our control that materially adversely impact our clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA or the EMA may find the data from preclinical studies and clinical trials insufficient to demonstrate that PTI-428, PTI-801, PTI-808 and/or our other product candidates&#8217; clinical and other benefits outweigh their safety or other risks, including, without limitation, the potential for drug-drug interaction;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA or the EMA may disagree with our interpretation of data from our preclinical studies and clinical trials, including our characterization of observed toxicities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA or the EMA may not accept data generated at our clinical trial sites;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">if our NDAs or MAAs, if and when submitted, are reviewed by the FDA or the EMA, as applicable, the regulatory agency may have difficulties scheduling the necessary review meetings in a timely manner, may recommend against approval of our application or may recommend that the FDA or the EMA, as applicable, require, as a condition of approval, additional preclinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA may require development of a Risk Evaluation and Mitigation Strategy as a condition of approval or post-approval, and the EMA may grant only conditional approval or impose specific obligations as a condition for marketing authorization, or may require us to conduct post-authorization safety studies;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU35"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">the FDA or the EMA may find deficiencies with or not approve the manufacturing processes or facilities of third-party manufacturers with which we contract; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA or the EMA may change their approval policies or adopt new regulations.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these factors, many of which are beyond our control, could jeopardize our ability to obtain regulatory approval for and successfully market PTI-428, PTI-801, PTI-808 or any of our other product candidates. Any such setback in our pursuit of regulatory approval would have a material adverse effect on our business and prospects.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the United States and the European Union, we intend to market our product candidates, if approved, in other international markets. Such marketing will require separate regulatory approvals in each market and compliance with numerous and varying regulatory requirements. The approval procedures vary from country-to-country and may require additional testing. Moreover, the time required to obtain approval may differ from that required to obtain FDA or EMA approval. In addition, in many countries, a product candidate must be approved for reimbursement before it can be approved for sale in that country. Approval by the FDA or the EMA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA or the EMA. The regulatory approval process in other international markets may include all of the risks associated with obtaining FDA or EMA approval.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our lead product candidate, PTI-428, and our PTI-801 candidate, are designed to be administered with other CF therapies. Developing product candidates for administration with other therapies may lead to unforeseen side effects or failures in our clinical trials that could delay or prevent their regulatory approval or limit the commercial profile of an approved label. Such other therapies could also be removed from or supplanted in the market and result in significant negative consequences.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;letter-spacing:0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are studying our lead product candidate PTI-428, and our PTI-801 candidate, in clinical trials as a combination therapy with therapies that are approved and commercially available to the patients we plan to enroll in such clinical trials. We anticipate that if one or more of our product candidates is approved for marketing, it will be approved to be administered only with other therapies. Our development programs and planned studies carry all the risks inherent in drug development activities, including the risk that they will fail to demonstrate meaningful efficacy or acceptable safety. In addition, our development programs are subject to additional regulatory, commercial, manufacturing and other risks because of the use of other therapies in combination with our product candidates. For example, the other therapies may lead to toxicities that are improperly attributed to our product candidates or the combination of our product candidates with other therapies may result in toxicities that the product candidate or other therapy does not produce when used alone. The other therapies we are using in combination may be removed from the market, or we may not be able to secure adequate quantities of such materials for which we have no guaranteed supply contract, and thus be unavailable for testing or commercial use with any of our approved products. The other therapies we may use in combination with our product candidates may be supplanted in the market by newer, safer and/or more efficacious products or combinations of products. For example, we are testing or intend to test PTI-428 and PTI-801 in clinical trials where we provide our investigational product to CF patients stable on background therapy of ivacaftor and lumacaftor.&nbsp;&nbsp;The manufacturer of this background therapy is conducting testing of ivacaftor and tezacaftor, on its own and together with other modulators as part of triple combinations, any of which, if approved, could supplant the existing therapy. Testing product candidates in combination with other therapies may increase the risk of significant adverse effects or test failures, or impact from drug-drug interactions. The timing, outcome and cost of developing products to be used in combination with other therapies is difficult to predict and dependent on a number of factors that are outside our reasonable control. If we experience safety or toxicity issues in our clinical trials or with any approved products, we may not receive approval to market any products, which could prevent us from ever generating revenues or achieving profitability.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU36"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the data from our existing, ongoing and planned preclinical studies and clinical trials of PTI-428 and PTI-801 each as a combination therapy administered w</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ith ivacaftor and lumacaftor regarding the safety or efficacy of these combinations are not favorable, the FDA and comparable foreign regulatory authorities may not approve either of these combination therapies and we may be forced to delay or terminate th</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e development of either or both of these combination therapies, which would materially harm our business. Further, even if we gain marketing approvals for either of these combination therapies from the FDA and comparable foreign regulatory authorities in a</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> timely manner, we cannot be certain that they will be commercially successful. If the results of the anticipated or actual timing of marketing approvals for these combination therapies, or the market acceptance of these combination therapies, if approved,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> including treatment reimbursement levels agreed to by third-party payors, do not meet the expectations of investors or public market analysts, the market price of our common stock would likely decline.&nbsp;&nbsp;Currently, some jurisdictions outside of the United </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">States do not provide reimbursement for all or some of the standard of care therapies included in our combination therapies. Government and other third-party payors seek to contain costs of health care through legislative and other means. If they fail to p</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rovide coverage and adequate reimbursement rates for these products, it could increase the cost of our trials in such jurisdictions and decrease the possible market for any approved combination therapy that includes these co-administered drugs.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Failures or delays in the commencement, progress or completion of our clinical trials of our product candidates, including PTI-428, PTI-801 and PTI-808, including due to competition from competing trials for CF patients, amended or additional trials or cohorts, lack of sufficient approvals including from the FDA, local regulatory and ethics bodies and those of therapeutic development networks of patient advocacy groups, or trial holds or stoppage due to interim results or safety concerns, could result in increased costs to us and could delay, prevent or limit our ability to generate clinical trial data, advance our product candidates in the clinic, submit an NDA (or foreign equivalent) for any of our product candidates for U.S. or foreign marketing approval, derive revenue and continue our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Successful completion of the clinical trials for PTI-428, PTI-801, PTI-808 and our other candidates is a prerequisite to submitting an NDA to the FDA or a MAA to the EMA and, consequently, the ultimate approval and commercial marketing of PTI-428, PTI-801, PTI-808 and our other candidates in the United States and the European Union. Similar prerequisites apply in other foreign jurisdictions and for all of our product candidates in any jurisdiction. Clinical trials are expensive, difficult to design and implement, can take many years to complete and are uncertain as to outcome. A product candidate can unexpectedly fail at any stage of clinical development. The historical failure rate for product candidates is high due to scientific feasibility, safety, tolerability, toxicology, efficacy, changing standards of medical care and other variables. If the FDA requires us to complete, or we choose to implement, amended or additional studies beyond what we currently expect, or to run additional cohorts or conduct cohorts sequentially, we may be delayed in completing our clinical trials and our expenses will increase. Expansion of our trials into Europe and other ex-U.S. jurisdictions will require IND-equivalent submissions to, and the approval of, local regulatory and ethics bodies, and we cannot assure you we will receive these approvals, or receive them in a timely manner. If therapeutic development networks of CF patient advocacy groups in the United States and/or other jurisdictions such as Europe do not timely sanction or highly rate or score our trials, or prioritize trials of other sponsors over our trials, we may not be able to enroll sufficient patients to conduct our trials at their member sites, or it may take longer to conduct these trials and we may need to look to other jurisdictions where we can more efficiently run our trials.&nbsp;&nbsp;Many CF clinical trial sites place importance on the review, ranking and sanctioning of therapeutic development networks of CF patient advocacy groups. In the U.S., we believe many sites consider sanctioning from the Protocol Review Committee, or PRC, of the Therapeutic Development Network of the U.S.-based Cystic Fibrosis Foundation&#8217;s Therapeutic Branch, or the TDN, when deciding whether and when to participate in a trial or which trials to prioritize. For example, the TDN deferred sanctioning of PTI-428, which we believe has contributed to a delay in our trial. There is also a large number of CF programs in clinical development at this time, including numerous corrector and combination trials from Vertex and other companies with greater resources and experience than us, which we believe has also contributed to a delay in our trials.&nbsp;&nbsp;We face intense competition for eligible CF patients, which has and could continue to hamper our recruitment efforts; this competition is likely to intensify following the recent clinical data announcements from multiple triple combination trials from Vertex. We do not know whether all of our clinical trials will begin or be completed on schedule, if at all, as the commencement and completion of clinical trials can be delayed or prevented for a number of reasons, including, among others:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">delays in reaching or failing to reach agreement on acceptable terms with prospective CROs and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">inadequate quantity or quality of or access to a product candidate or other materials, such as combination therapies for co-administration in our trials that are marketed by other firms, necessary to conduct clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">difficulties obtaining institutional review board, or IRB, or ethics committee approval to conduct a clinical trial at a prospective site or sites;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU37"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">challenges in recruiting and enrolling patients to participate in clinical trials, including the size and nature of the patient population, the proximity of patients to clinical sites (including, without limitation, if U.S. trial sites include interna</font><font style="font-family:Times New Roman;">tional subjects coming to the U.S. on a visa), eligibility criteria for the clinical trial, the nature of the clinical trial protocol (including, without limitation, patient factors such as the time commitment involved in the required number of trial-relat</font><font style="font-family:Times New Roman;">ed visits and procedures and the inability to take certain existing therapies during the trial), risks included in the signed informed consent and any new or amended consents required by each study participant, the availability of approved effective treatm</font><font style="font-family:Times New Roman;">ents for the relevant disease and competition from other clinical trial programs for similar indications;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">unfavorable review of or a decision to defer sanctioning or not sanction one or more of our clinical trials by the TDN, or the CTN, each of which may not sanction our trials for conduct at prospective trial sites, may change or alter any approval it may grant, or may provide a ranking or revised ranking of an amended protocol that adversely impacts recruitment in our clinical trials compared with other investigational new drugs in CF; the TDN deferred sanctioning of PTI-428, and while we remain in discussions with the TDN on its continued review of PTI-428, and the TDN recently approved and favorably ranked our PTI-801 protocol, we cannot assure you that it will ever sanction PTI-428 or any of our other trials, including, without limitation, any combination trials we seek to conduct; the CTN has approved and favorably ranked the protocols for our PTI-428 and PTI-801 trials and we are actively working to expand into Europe with its member sites, subject to regulatory and ethics approvals in local jurisdictions, but we cannot assure you that such expansion will be successful;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">severe or unexpected drug-related side effects experienced by patients in our clinical trials or by individuals using drugs similar to our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">reports from preclinical or clinical testing of other similar therapies that raise safety or efficacy concerns; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">difficulties retaining and/or obtaining data from patients who have enrolled in a clinical trial but may be prone to withdraw due to lack of efficacy, side effects, personal issues, loss of interest, difficulty travelling to the trial site or returning for required check-ins, or other factors, some of which are out of our control.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are an unprecedented number of CF clinical trials ongoing in the United States and in other countries. As a result of this and other factors described above, the activation of clinical trial sites for our ongoing trials, and securing our target subject enrollment for these clinical trials, has been delayed from what we had originally planned. If we are unable to increase our enrollment, we will not have a substantially complete data set for these trials by our target dates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expanded our clinical trial protocols for PTI-428, PTI-801 and PTI-808 to include CF patients. These expansions required protocol amendments to our INDs that are in effect with the FDA, which are subject to FDA comment. We are required to receive IRB approval for these amended protocols but there is no guarantee that IRBs of our existing and prospective clinical trial sites will approve these expansions. Any failure or delay in obtaining necessary permissions from the relevant IRBs to expand our trials may delay their completion and our overall development plan.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials may also be delayed or terminated as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended, placed on clinical hold or terminated by us, the FDA, other regulatory authorities or the IRBs at the sites where the IRBs are overseeing a clinical trial, or a data safety monitoring board, or DSMB, may recommend that the sponsor suspend or terminate a trial, due to a number of factors, including, among others:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">inspection of the clinical trial operations or trial sites by the FDA, the EMA or other regulatory authorities that reveals deficiencies or violations that require us to undertake corrective action, including the imposition of a clinical hold;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">unforeseen safety issues, including any that could be identified in our ongoing toxicology studies, adverse side effects or lack of effectiveness, including as part of ambiguous or negative interim results;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">changes in government regulations or administrative actions;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">problems with clinical supply materials; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">lack of adequate funding to continue the clinical trial.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU38"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Positive results from preclinical</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> or in vitro and in vivo testing of PTI-428, PTI-801, PTI-808, or our other candidates are not necessarily predictive of the results of our ongoing and future clinical trials of these candidates. If we cannot achieve positive results in our clinical trials</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> for PTI-428, PTI-801, PTI-808, or our other candidates, we may be unable to successfully develop, obtain regulatory approval for and commercialize PTI-428, PTI-801, PTI-808, or our other candidates. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Positive results from our preclinical testing of PTI-428, PTI-801, PTI-808 and our other candidates <font style="font-style:italic;">in vitro</font> and <font style="font-style:italic;">in vivo</font> may not necessarily be predictive of the results from our clinical trials in humans. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical trials after achieving positive results in preclinical <font style="font-style:italic;">in vitro</font> and <font style="font-style:italic;">in vivo</font> studies, and we, or the third parties whose drug candidates we expect to be co-administered with PTI-428 and PTI-801, may face similar setbacks. For example, CFTR mRNA levels in target tissues of rats and monkeys exposed to PTI-428 were observed to increase proportionally with exposure to PTI-428. Additionally, preliminary exploratory biomarker nasal CFTR mRNA and protein data from the SAD and MAD cohorts in our Phase 1 clinical trial for PTI-428 in healthy volunteers confirm target engagement. However, later clinical trials may not show that this biomarker is predictive of clinical efficacy or we may not be able to successfully obtain sufficient biomarker data to analyze. Preclinical and clinical data are often susceptible to varying interpretations and analyses, and the FDA or other regulatory agencies may require changes to our protocols or other aspects of our clinical trials or require additional studies. Additionally, many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or EMA approval. If we fail to produce positive results in our clinical trials of PTI-428, the development timeline and regulatory approval and commercialization prospects for our leading product candidate, and, correspondingly, our business and financial prospects, would be materially adversely affected.&nbsp;&nbsp;These risks will also apply to any other of our product candidates, such as PTI-801 and PTI-808, which, if they occur, could also impair our ability to successfully commence, progress or complete studies of our potential combination therapies.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we obtain positive clinical results for PTI-428 or PTI-801 in early-stage clinical trials (including, without limitation, those involving a relatively short duration in a small number of subjects, with the publication of interim, initial, preliminary or final results), those positive results may not be repeated in later-stage clinical trials.&nbsp;&nbsp;These risks will also apply to any other of our product candidates.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before obtaining regulatory approval for the sale of our product candidates, including PTI-428, PTI-801, and any combination therapies, we must conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Successful completion of such clinical trials is a prerequisite to submitting an NDA to the FDA and, consequently, the ultimate approval and commercial marketing of PTI-428 and PTI-801 in the United States. Similar requirements apply in the European Union and other foreign jurisdictions. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and preliminary, initial or interim results of a clinical trial do not necessarily predict final results. Our current CF trials involve relatively short duration in a small number of patients, resulting in limited data sets. From time to time, we may publish or report interim, initial or preliminary data from our clinical trials. Interim, initial or preliminary data from clinical trials that we may conduct may not be indicative of the final results of the trial and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Interim, initial or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the interim, initial or preliminary data. We may also experience delays in analyzing or an inability to analyze samples, including, without limitation, biomarker data, due to insufficient sample size, errors in collection procedures at one or more sites, or other factors. As a result, interim, initial or preliminary data should be viewed with caution until the final data are available<font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Negative or inconclusive results of our clinical trials of PTI-428 or PTI-801, or any other clinical trials we conduct, could mandate repeated or additional clinical studies. We do not know whether our clinical trials of any product candidate will demonstrate adequate efficacy and safety to result in regulatory approval to market such product candidate. Even if early-stage clinical results are favorable, if later-stage clinical trials (including, without limitation, those for longer duration with greater numbers of patients) do not produce favorable results, our ability to obtain regulatory approval for our product candidates, including PTI-428 and PTI-801, may be adversely impacted.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU39"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our product candidates may cause adverse effects or have other properties that could delay or pr</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">event their regulatory approval or limit the scope of any approved label or market acceptance.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in the denial of regulatory approval by the FDA or other comparable foreign regulatory authorities. It is possible that, during the course of the development of PTI-428, PTI-801 or our other product candidates, results of our studies and clinical trials could reveal an unacceptable severity and prevalence of side effects and/or drug-drug interactions. For example, in preclinical testing of PTI-428 we observed reduced platelet counts in the animals we tested following administration at doses in excess of the doses we expect to administer in our clinical trials. As a result of this or any other side effects, our clinical trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development, or deny approval, of our product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims or result in delays in the trials due to requirements to provide new informed consents to patients to disclose new or changed risks or side effects.&nbsp;&nbsp;Even if approved for marketing, our product candidates could face label restrictions based on the above factors or others.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, if one or more of our product candidates receive marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">regulatory authorities may withdraw approvals of such product or impose restrictions on its distribution in a form of a modified Risk Evaluation and Mitigation Strategy;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">regulatory authorities may require additional labeling, such as warnings or contraindications;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we may be required to change the way the product is administered or to conduct additional clinical studies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we could be sued and held liable for harm caused to patients; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our reputation may suffer.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these events could delay or prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we cannot demonstrate an acceptable safety and toxicity profile for our product candidates in our clinical studies, we will not be able to continue our clinical trials or obtain approval for our product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to obtain approval of a product candidate, we must demonstrate safety in various nonclinical and clinical tests. At the time of initiating human clinical trials, we may not have conducted or may not conduct the types of nonclinical testing ultimately required by regulatory authorities, or future nonclinical tests may indicate that our product candidates are not safe for use. Nonclinical testing and clinical testing are both expensive and time-consuming and have uncertain outcomes. For example, results of an earlier laboratory study of PTI-130, a former amplifier candidate, in non-rodent species suggested potential hematologic and reproductive toxicology issues that we believe are specific to the non-rodent species. We cannot predict whether future safety and toxicology studies may produce these same problems or cause other undesirable effects. We also observed certain undesired hematological (including reduced platelet count) side effects in animals dosed at levels of PTI-428 that are higher than those intended for our clinical studies. We plan to complete additional toxicity studies of reproductive toxicity, carcinogenicity and long-term side effects prior to or concurrent with any Phase 3 clinical trials of our product candidates, and we cannot exclude the possible occurrence of these or other side effects in future nonclinical or clinical studies. In addition, success in initial tests does not ensure that later testing will be successful. We may experience numerous unforeseen events during, or as a result of, the testing process, which could delay or prevent our ability to develop or commercialize our product candidates, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our preclinical and nonclinical testing may produce inconclusive or negative safety results, which may require us to conduct additional nonclinical testing or to abandon product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our product candidates may have unfavorable pharmacology or toxicity characteristics or suggest possible drug-drug interaction;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our product candidates may cause undesirable side effects; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA or other regulatory authorities may determine that additional safety testing is required.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any such events would increase our costs and could delay or prevent our ability to commercialize our product candidates, which could adversely impact our business, financial condition and results of operations.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU40"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Combination therapies involve additional complexity and</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> risk that could delay or cause our programs to stall or fail; development of such programs may be more costly, may take longer to achieve regulatory approval and may be associated with unanticipated adverse events.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical development and commercialization of combination therapies, such as our potential doublet and triple combination, and our PTI-428 and PTI-801 candidates being tested in the clinic with patients taking background standard of care therapies, involve additional complexity and risk, including without limitation, those involving pre-clinical studies, drug-drug interactions, dose selection, unanticipated adverse events, clinical design and approvals of regulatory bodies and therapeutic development networks of patient advocacy groups. For example, if we or regulatory bodies identify concerns in pre-clinical combination toxicology studies, we may need to run additional studies before commencing or continuing clinical development. Combination therapy clinical development may also involve more restrictive inclusion criteria based on the profiles of multiple investigational products, which could delay enrollment. We have limited experience developing and commercializing combination therapies and are competing with industry players with greater resources than us. If we are unable to manage the additional complexities and risks of the development and commercialization of combination therapies, our proposed combination program could be delayed, halted or otherwise fail to receive approval.&nbsp;&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PTI-428 is based on a novel technology, which may raise development issues we may not be able to resolve, regulatory issues that could delay or prevent approval, or personnel issues that may keep us from being able to develop our product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidate PTI-428 is based on our novel amplifier technology. We are not aware of other drugs that work in a manner that we believe our amplifier technology does. We cannot assure you that development problems related to our novel technology will not arise in the future that could cause significant delays or that we are not able to resolve.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical development and regulatory approval of novel product candidates such as ours can be more expensive and take longer than other, more well-known or extensively studied pharmaceutical product candidates due to our, investigators&#8217; and regulatory agencies&#8217; lack of experience with them. These factors also apply to patient advocacy groups and sanctioning by their affiliated therapeutic development center arms, such as the TDN. To our knowledge, there are no other amplifiers in clinical development and none have been approved to date. The novelty of our technology may lengthen the clinical development timeline and regulatory review process, require us to conduct additional studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. For example, the FDA could require additional studies or characterization that may be difficult or impossible to perform.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if we are unable to hire and retain the necessary personnel, the rate and success at which we can develop and commercialize product candidates will be limited. Any such events would increase our costs and could delay or prevent our ability to commercialize our product candidates, which could adversely impact our business, financial condition and results of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we meet safety and efficacy endpoints in clinical trials, we cannot predict whether or when we will obtain regulatory approval to commercialize our product candidates and we cannot, therefore, predict the timing of any future revenue from PTI-428, PTI-801, or any of our other product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot commercialize our product candidates, including PTI-428, PTI-801, or combination therapies, until the appropriate regulatory authorities, such as the FDA, have reviewed and approved the product candidate. The regulatory agencies may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval for PTI-428, PTI-801, combination therapies, or our other product candidates at all. Additional delays may result if PTI-428, PTI-801, combination therapies, or any other product candidate is brought before an FDA advisory committee or an analogous foreign body, which could recommend restrictions on approval or recommend non-approval of the product candidate. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency policy during the period of product development, clinical studies and the review process. As a result, we cannot predict when, if at all, we will receive any future revenue from commercialization of any of our product candidates, including PTI-428, PTI-801, and combination therapies. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we obtain regulatory approval for PTI-428, PTI-801 and/or our other product candidates, we will still face extensive regulatory requirements and our products may face future development and regulatory difficulties.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU41"></a>Even if we obtain regulatory approval in the United States, the FDA may still impose significant restrictions on the indicated uses or marketing of our product candidates, including PTI-428 and PTI-801, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance, including Phase 4 clinical trials. For example, the labeling, if approved for our </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product candidates, including PTI-428 and PTI-801, will likely include restrictions on use due to the specific patient population and manner of use in which the drug was evaluated and the safety and efficacy data o</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">btained in those evaluations.&nbsp;&nbsp;</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PTI-428, PTI-801 and our other product candidates will also be subject to additional ongoing FDA requirements governing the labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, record-keeping and reporting of safety and other post-market information. The holder of an approved NDA is obligated to monitor and report adverse events and any failure of a product to meet the specifications described in the NDA. The holder of an approved NDA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, manufacturers of drug products and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current good manufacturing practice, or cGMP, requirements and adherence to commitments made in the NDA. If we, or a regulatory agency, discover previously unknown problems with a product, such as quality issues or adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing facility, including requesting a recall or requiring withdrawal of the product from the market or suspension of manufacturing.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to comply with applicable regulatory requirements following approval of our product candidate, a regulatory agency may:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">issue an untitled or warning letter asserting that we are in violation of the law;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seek an injunction or impose civil or criminal penalties or monetary fines;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">suspend or withdraw regulatory approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">suspend any ongoing clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">refuse to approve a pending NDA or supplements to an NDA submitted by us; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">request a recall and/or seize product.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;letter-spacing:-0.2pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize PTI-428, PTI-801 and our other product candidates and inhibit our ability to generate revenues.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we obtain FDA approval for PTI-428, PTI-801 or any of our other product candidates in the United States, we may never obtain approval for or commercialize PTI-428, PTI-801 or any of our other product candidates outside of the United States, which would limit our ability to realize their full market potential.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and costs for us and require additional preclinical studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our product candidates in those countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of our product candidates will be unrealized.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are not able to obtain orphan product status for PTI-428 or obtain such status for future product candidates for which we seek this status (such as PTI-801), we will not be able to claim the tax credits for our clinical trials of such products provided by this status or potentially take advantage of other benefits of orphan drug status.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU42"></a>Regulatory authorities in some jurisdictions, including the United States and the European Union, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a disease or condition that fewer </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">than 200,000 individuals in the United States have been diagnosed as having at the time of th</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e submission of the request for orphan drug designation. Under Regulation No.&#160;(EC) 141/2000 on Orphan Medicinal Products, a medicinal product may be designated as an orphan medicinal product if, among other things, it is intended for the diagnosis, prevent</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ion or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 people in the European Union when the application is made. Generally, if a product with an orphan drug designation subsequently receives the</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> first marketing approval for the indication for which it has such designation, the product is entitled to a period of market exclusivity. This exclusivity precludes the EMA or the FDA, as applicable, from approving another marketing application for the sa</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">me or, in the European Union, a similar drug for the same indication for that time period, unless, among other things, the later product is clinically superior. The exclusivity period is seven years in the United States and ten years in the European Union </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">following marketing approval. The EU exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation, for example if the drug is sufficiently profitable so that market exclusivity is no longer justified. We</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> did not receive orphan drug designation on our first application for PTI-428, and intend to continue to seek orphan drug designation for PTI-428 once additional data are available.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, orphan drug exclusivity may be lost if the FDA withdraws or revokes the orphan-drug designation as permitted by law, we withdraw the marketing application for the drug, we consent to another&#8217;s marketing application for approval of the same use or indication as the designated orphan drug, or we fail to assure a sufficient quantity of the drug as required by law. Similarly, in the European Union, exclusivity may be lost if we request the removal of the orphan-drug designation or the drug no longer meets any of the criteria that made it eligible for orphan-drug status at the outset. Even after an orphan drug is approved, the same or, in the European Union, a similar drug can subsequently be approved for the same condition if the competent regulatory agency concludes that the later drug is clinically superior to the original orphan drug by providing a significant therapeutic advantage over and above that drug.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;letter-spacing:-0.2pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we do not obtain orphan drug exclusivity or if our competitors obtain orphan drug exclusivity for other rare diseases or conditions we are targeting before we do, we may be delayed in obtaining marketing authorization or we may lose out on the potential benefits of market exclusivity associated with the orphan drug designation. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the NDA application user fee. If we do not obtain orphan designation for PTI-428 or our other product candidates (such as PTI-801), we will lose out on such benefits associated with orphan designation.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of social media platforms presents new risks.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Social media increasingly is being used to communicate about our product candidates and the diseases our therapies are designed to treat. We believe that members of the CF community may be more active on social media as compared to other patient populations. Social media practices in the pharmaceutical and biotechnology industries are evolving, which creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media platforms to comment on the effectiveness of, or adverse experiences with, a drug candidate, which could result in reporting obligations. In addition, there is a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face restrictive regulatory actions or incur other harm to our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Relating to Our Dependence on Third Parties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If third parties on which we depend to conduct our preclinical studies or any ongoing or future clinical trials do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development program could be delayed with materially adverse effects on our business and prospects.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU43"></a>We rely on clinical research organizations, clinical data management organizations and consultants, collectively referred to as CROs, to design, conduct, supervise and monitor preclinical and clinical studies of our product candidates and plan to do the same for our ongoing and future clinical trials for PTI-428, PTI-801, PTI-808, combination therapies and any other clinical trials. We and our CROs are required to comply with various regulations, including Good Clinical Practice, or GCP, requirements, which are enforced by the FDA, and guidelines of the Competent Authorities of the Member States of the European Economic Area, and comparable foreign regulatory authorities to ensure that the health, safety and rights of patients are protected in clinical development and clinical trials, and that trial data integrity is assured. Regulatory authorities ensure compliance with these requirements through periodic inspections of trial sponsors, principal investigators and trial sites, as well as third party contractors. If we or any of our CROs fail to comply with applicable requirements, or the CRO does not perform its contractually required obligations (or makes errors or mistakes), the clinical data, including, without limitation, biomarker data, generated in our clinical trials may not be collected or may be collected but be deemed unreliable, and the FDA, the EMA or other comparable foreign regulatory authorities may require us (or we may choose ourselves) to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with such requirements. In addition, our clinical trials must be conducted with products produced under cGMP requirements, which mandate the methods, facilities and controls used in manufacturing, processing and packaging of a drug product to ensure its safety and identity. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure to comply with these regulations may require us to delay or repeat preclinical and clinical trials, which would delay the regulatory approval process.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our ongoing clinical and preclinical programs. We generally represent a small percentage of these firms&#8217; overall business, which could limit our ability to receive priority allocation of their resources. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also rely on clinical investigators and clinical research organizations, as well as therapeutics development arms of patient advocacy groups, such as the TDN and CTN, to assist in the design and review of our clinical trials, including supporting the enrollment of qualified patients.&nbsp;&nbsp;If these third parties do not approve or sanction our trial design to facilitate enrollment, our ability to conduct clinical trials may be impeded.&nbsp;&nbsp;Because we have relied on third parties, our internal capacity to perform these functions is limited. Outsourcing these functions involves risk that third parties may not perform to our standards, may not produce results in a timely manner or may fail to perform at all. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated or inadvertently be made publicly-available. We currently have a small number of employees, which limits the internal resources we have available to identify and monitor our third-party providers. To the extent we are unable to identify and successfully manage the performance of third-party service providers in the future, our business may be adversely affected. Though we carefully manage our relationships with our CROs, and other third parties, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines, our clinical development programs could be delayed and otherwise adversely affected. In all events, we are responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. The FDA and the EMA require clinical trials to be conducted in accordance with GCP, including for conducting, recording and reporting the results of preclinical studies and clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. Our reliance on third parties that we do not control does not relieve us of these responsibilities and requirements. Any such event could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We rely on third-party manufacturers and suppliers and we intend to rely on third parties to produce preclinical, clinical and commercial supplies of PTI-428, PTI-801, PTI-808 and any future product candidates. These third parties may not perform as contractually required or expected and issues may arise that could delay the commencement or completion of clinical trials.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on third parties to supply the materials and components for our research and development, preclinical and clinical trial supplies. We do not own manufacturing facilities or supply sources for such components and materials. There can be no assurance that our supply of research and development, preclinical and clinical development drugs and other materials will not be limited, interrupted, restricted in certain geographic regions or of satisfactory quality or continue to be available at acceptable prices. Any replacement of these third parties could require significant effort and expertise because there may be a limited number of qualified replacements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU44"></a>The manufacturing process for a product candidate is subject to FDA, EMA and other foreign regulatory authority review. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities to comply with regulatory standards such as cGMP. In the event that any of our suppliers or manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, our regulatory filings may be delayed, our preclinical studies or clinical trials may be delayed or suspended, and we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills or technology to another third party and a feasible alternative may not exist; even if it exists, it may be cost-prohibitive and time-prohibitive to engage in technology transfer to switch vendors for product candidate manufacturing. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third party manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget.&nbsp;&nbsp;Drug formulation is an inherently </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uncertain p</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rocess with numerous steps, some of which may need to be repeated, to ensure quality, accuracy and yield; unexpected variances may occur, which could delay our manufacturing efforts and delay commencement or completion of pre-clinical studies and/or clinic</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">al trials.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to continue to rely on third-party manufacturers if we receive regulatory approval for any product candidate. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third-party manufacturing for product candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully. Our or a third party&#8217;s failure to execute on our manufacturing requirements could adversely affect our business in a number of ways, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">preventing us from initiating or continuing preclinical studies or clinical trials of product candidates under development;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">delaying our submissions of regulatory applications or receipt of regulatory approvals for product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">preventing a collaborator from cooperating with us;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">subjecting our product candidates to additional inspections by regulatory authorities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">requiring us to cease distribution or to recall batches of our product candidates; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">in the event of approval to market and commercialize a product candidate, preventing us from meeting commercial demands for our products.</font></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If a current or future collaborative partner terminates or fails to perform its obligations under an agreement with us, or if research does not produce viable lead candidates or meet specified criteria during the applicable research term, the development and commercialization of the product candidates could be delayed or terminated.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently party to a collaborative arrangement with Astellas. If our collaborative partner does not devote sufficient time and resources to a collaboration arrangement with us, we may not realize the potential commercial benefits of the arrangement, and our results of operations may be materially adversely affected.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Much of the potential revenue from our collaborations consists of contingent payments, such as payments for achieving scientific or regulatory milestones or royalties payable on sales of drugs. The milestone and royalty revenue that we may receive under these collaborations will depend upon our collaborators&#8217; ability to successfully develop, introduce, market and sell new products. Our collaboration partners may fail to develop or effectively commercialize their products using our products or technologies or otherwise discontinue their research activities because they:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">exercise their unilateral right to terminate the collaboration agreement, which, for example, our former collaboration partner, Biogen, did in December 2016, including, without limitation, if research does not produce a viable lead candidate or meet specified criteria during the applicable research term;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">decide not to devote the necessary resources due to internal constraints, such as limited personnel with the requisite expertise, limited cash resources or specialized equipment limitations, or the belief that other drug development programs may have a higher likelihood of obtaining marketing approval or may potentially generate a greater return on investment;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">decide to pursue other technologies or develop other product candidates, either on their own or in collaboration with others, including our competitors, to treat the same diseases targeted by our own collaborative programs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">do not have sufficient resources necessary to carry the product candidate through clinical development, marketing approval and commercialization; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">cannot obtain the necessary marketing approvals.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competition may negatively impact a partner&#8217;s focus on and commitment to our relationship and, as a result, could delay or otherwise negatively affect the commercialization of our products, which would have a material adverse effect on our operating results and financial condition. Terminated collaborations include the risk that the former partner maintains rights to exploit certain co-developed technology, and the risk that, to the extent the program is desired to continue, funding formerly provided by the partner will need to come from alternative sources such as us or a new partner and such funding may not be available on terms acceptable to us, if at all.&nbsp;&nbsp;These factors can cause a delay or abandonment of technology programs and could negatively affect commercialization of our products, which would have a material adverse effect on our operating results and financial condition.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU45"></a>We face a number of challenges in seeking future collaborations. Collaborations are complex and any potential discussions may not result in a definitive agreement for many reasons. For example, whether we reach a definitive agreement for a collaboration will </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of a number of factors, such as the design </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or results of our clinical trials, the potential market for our product candidates, the costs and complexities of manufacturing and delivering our product candidates to patients, the potential of competing products, the existence of uncertainty with respec</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t to ownership or the coverage of our intellectual property, and industry and market conditions generally. If we determine that additional collaborations for our product candidates are necessary and are unable to enter into such collaborations on acceptabl</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e terms, we might elect to delay or scale back the development or commercialization of our product candidates in order to preserve our financial resources or to allow us adequate time to develop the required physical resources and systems and expertise our</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">selves.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner, or at all. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. If a future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Relating to Commercialization of Our Product Candidates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The commercial success of PTI-428, PTI-801 and our other product candidates will depend upon the acceptance of those products, if approved, by the medical community, including physicians, patients and health care payors.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if PTI-428, PTI-801 or our other product candidates are approved for sale, they may not achieve sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. If these product candidates, if approved, do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of any of our product candidates, including PTI-428 and PTI-801, will depend on a number of factors, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">demonstration of safety and efficacy in our clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the relative convenience, ease of administration and acceptance by physicians, patients and health care payors;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the prevalence and severity of any adverse effects;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">limitations or warnings contained in the FDA-approved label for the relevant product candidate;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">availability of alternative treatments;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">pricing and cost-effectiveness;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the effectiveness of our or any future collaborators&#8217; sales and marketing strategies; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to obtain and maintain healthcare payor approval or reimbursement, which may vary from country to country.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our product candidates, including PTI-428 and PTI-801, is approved but does not achieve an adequate level of acceptance by physicians, patients and health care payors, we may not generate sufficient revenue and we may not become or remain profitable.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates if and when they are approved.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have a sales or marketing infrastructure, and we have limited experience in the sales, marketing or distribution of pharmaceutical products. Our commercialization strategy will target key prescribing physicians and advocacy groups, as well as provide patients with support programs, ensure product access and secure reimbursement. Outside of the United States, Canada, Europe and Australia, we may seek a partner to commercialize our products. In the future, we may choose to build a focused sales and marketing infrastructure to market or co-promote our product candidates if and when they are approved, which would be expensive and time-consuming. Alternatively, we may elect to outsource these functions to third parties. Either approach carries significant risks. For example, recruiting and training a sales force is expensive and time-consuming and, if done improperly, could delay a product launch and result in limited sales. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU46"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Factors that may inhibit our efforts to com</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mercialize our product candidates on our own include:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">inability to recruit, manage and retain adequate numbers of effective sales and marketing personnel;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the inability of marketing personnel to develop effective marketing materials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the inability of sales personnel to obtain access to or persuade adequate numbers of physicians to prescribe any future products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also not be successful in entering into additional arrangements with third parties to sell and market our product candidates or doing so on terms that are favorable to us. Even if we do enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenues or the profitability of these product candidates are likely to be lower than if we were to market and sell our products ourselves. In addition, we likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If our competitors develop technologies or product candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize our products may be adversely affected. Competitive products for treatment of CF may reduce or eliminate the commercial opportunity for our product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The clinical and commercial landscape for CF is highly competitive and subject to rapid and significant technological change. New data from clinical-stage products continue to emerge. It is possible that these data may alter the current standard of care, completely precluding us from further developing PTI-428, PTI-801 or our other product candidates for CF. Further, it is possible that we may advance our clinical trials only to find that data from competing products make it impossible for us to complete enrollment in these trials, resulting in our inability to file for marketing approval with regulatory agencies. Even if PTI-428, PTI-801 or our other product candidates are approved for marketing, they may have limited sales due to particularly intense competition in the CF market.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitive therapeutic treatments include those that are currently in development and any new treatments that enter the market. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may try to develop product candidates. Our potential competitors include large pharmaceutical and biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies and research institutions. Examples include Vertex, AbbVie Inc., Galapagos NV, ProQR Therapeutics N.V., F. Hoffmann-LaRoche Ltd., Novartis AG, Gilead Sciences, Inc., Laurent Pharmaceuticals Inc., Pfizer Inc., AstraZeneca, Parion Sciences, Inc., RaNA Therapeutics Inc., Sanofi Genzyme, Bayer AG, Corbus Pharmaceuticals Holdings, Inc., Shire and several other companies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although PTI-428 and PTI-801 are being developed as individual therapies to be administered with ivacaftor and lumacaftor, Vertex or other competitors could develop other drugs or combinations that may obviate the applicability of PTI-428 and PTI-801. Changes in standard of care or use patterns could also make our combination therapy obsolete. For example, Vertex is developing tezacaftor and ivacaftor as a combination therapy on its own and also as part of a triple combination therapy with an additional Vertex corrector. If PTI-428 or PTI-801 is approved for marketing as a combination therapy to be administered with ivacaftor and lumacaftor but use of another therapy becomes more prevalent than ivacaftor and lumacaftor, the availability of ivacaftor and lumacaftor may be limited, sales of PTI-428 or PTI-801 could be negatively impacted and our financial results and stock price would be adversely affected.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our competitors have greater financial, technical, manufacturing, clinical development, marketing, sales and supply resources, technical and human resources or experience than us and significantly greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of product candidates and the commercialization of those products. Accordingly, our competitors may be more successful than we may be in obtaining FDA and other regulatory approvals for therapies and achieving widespread market acceptance. Our competitors&#8217; products may be more effective, or more effectively marketed and sold, than any product candidate we may commercialize and may render our therapies obsolete or non-competitive before we can recover development and commercialization expenses.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU47"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we successfully obtain approval for any product candidate, we will face competition based on many different factors, inclu</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ding the efficacy, safety and tolerability of our products, the ease with which our products can be administered,&nbsp;&nbsp;the extent to which physicians and patients accept combination therapies and, for PTI-428, new classes of modulators, the timing and scope of</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including being mor</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e effective, safer, or less expensive, or could be marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop, or products with which we are approved for use in combination, obsolete or noncom</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">petitive before we recover the expense of developing and commercializing our product candidates. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan. Mergers a</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nd acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a small number of competitors.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also compete with other clinical-stage companies and institutions for clinical trial participants, which could reduce our ability to recruit participants for our clinical trials. For example, actual or perceived risks of our product candidates, such as PTI-428, may negatively affect potential clinical trial participants or patients when deciding whether to participate in our clinical trials, and could result in patients seeking alternative clinical trials or commercial therapies from our competitors. Delay in recruiting clinical trial participants could adversely affect our ability to bring a product to market prior to our competitors. Further, research and discoveries by others may result in breakthroughs that render our product candidates obsolete even before they begin to generate any revenue.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our competitors may obtain patent protection or FDA approval and commercialize products more rapidly than we do, which may impact future sales of any of our product candidates that receive marketing approval. If the FDA approves the commercial sale of any of our product candidates, we will also be competing with respect to marketing capabilities and manufacturing efficiency, areas in which we have limited or no experience. We expect competition among products will be based on product efficacy and safety, the timing and scope of regulatory approvals, availability of supply, marketing and sales capabilities, product price, reimbursement coverage by government and private third-party payors, and patent position. Our profitability and financial position will suffer if we cannot compete effectively in the marketplace, even if our products receive regulatory approval.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Payor approval and reimbursement may not be available for PTI-428, PTI-801 and our other product candidates, or third party therapies taken with our drugs, which could make it difficult or impossible for us to sell our products profitably.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Market acceptance and sales of PTI-428 or PTI-801, or any other product candidates that we develop, will depend in part on the extent to which reimbursement for these products and related third party treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers, health maintenance organizations and pharmacy benefit management organizations, decide which medications they will pay for, at what tier level and establish reimbursement levels. A primary trend in the United States healthcare industry and elsewhere is cost containment. Government authorities and these third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Even if we are successful in gaining reimbursement in one country, that does not mean we will achieve reimbursement at the same levels or at all in any other country. Reimbursement may impact the demand for, or the price of, any product for which we obtain marketing approval. Obtaining reimbursement for our products may be particularly difficult because of the higher prices often associated with products administered under the supervision of a physician. Also, reimbursement amounts may reduce the demand for, or the price of, our products. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize PTI-428, PTI-801, or any other product candidates that we develop. We will also be required to establish systems and programs that assist patients in determining the reimbursement level and in some instances establishing patient economic support programs to alleviate the economic burden of co-pays and/or co-insurance. These patient support programs are complex, costly and require knowledge and expertise that we currently do not possess.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been a number of legislative and regulatory proposals to change the healthcare system in the United States and in some foreign jurisdictions that could affect our ability to sell any future products profitably. These legislative and regulatory changes may negatively impact the reimbursement for any future products, following approval. The availability of generic treatments may also substantially reduce the likelihood of reimbursement for any future products, including PTI-428 and PTI-801. The application of user fees to generic drug products will likely expedite the approval of additional generic drug treatments. We expect to experience pricing pressures in connection with the sale of PTI-428, PTI-801 and any other product candidate that we develop, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU48"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, there may be significant delays in obtaining rei</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mbursement for approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA or regulatory authorities in other countries. Moreover, eligibility for reimbursement does not imply that any product will be </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim payments for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Pa</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">yment rates may vary according to the use of the product and the clinical setting in which it is used, may be based on payments allowed for lower cost products that are already reimbursed, and may be incorporated into existing payments for other services. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net prices for products may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of products from countries where they may be sold at </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any of our product candidates, including PTI-428 and PTI-801, could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The success of our business depends primarily on our ability to identify, develop and commercialize product candidates. Because we have limited financial and managerial resources, we focus on research programs and product candidates for the indications that take advantage of our deep expertise and knowledge and that we believe are the most scientifically and commercially promising. Our resource allocation decisions may cause us to fail to capitalize on viable scientific or commercial products or profitable market opportunities. In addition, we may spend valuable time and managerial and financial resources on research programs and product candidates for specific indications that ultimately do not yield any scientifically or commercially viable products. If we do not accurately evaluate the scientific and commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in situations where it would have been more advantageous for us to retain sole rights to development and commercialization.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Relating to Regulation of Our Industry </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws and health information privacy and security laws. Some of these laws were recently amended, and their interpretation following such amendments remains unclear. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations may be directly, or indirectly through our customers, subject to various federal and state fraud and abuse laws, including, without limitation, the federal anti-kickback statute. These laws may impact, among other things, our proposed sales, marketing and education programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the federal anti-kickback statute which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the federal false claims laws and civil monetary penalties, including civil whistleblower or qui tam actions, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false or fraudulent or from knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) which, among other things, imposes criminal liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or to obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly or willfully falsifying, concealing, or covering up by any trick or device a material fact or making any materially false statement using or making any false or fraudulent document, in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU49"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing re</font><font style="font-family:Times New Roman;">gulations, and as amended by the final HIPAA omnibus rule, Modifications to the HIPAA Privacy, Security, Enforcement, and Breach Notification Rules Under HITECH and the Genetic Information Nondiscrimination Act; Other Modifications to HIPAA, published in J</font><font style="font-family:Times New Roman;">anuary 2013, which imposes certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without appropriate authorization by entities subject</font><font style="font-family:Times New Roman;"> to the rule, such as health plans, clearinghouses and healthcare providers;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the Federal Food, Drug, and Cosmetic Act, or FDCA, which prohibits, among other things, the distribution of adulterated or misbranded drugs or medical devices;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';letter-spacing:-0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';letter-spacing:-0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the federal Physician Payments Sunshine Act, enacted as part of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, collectively referred to herein as the Affordable Care Act, or the ACA, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologicals and medical supplies to report to the Centers for Medicare and Medicaid Services information related to payments and other transfers of value made to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Failure to submit required information may result in civil monetary penalties of up to an aggregate of $150,000 per year (or up to an aggregate of $1 million per year for &#8220;knowing failures&#8221;), for all payments, transfers of value, or ownership or investment interests that are not reported; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">analogous state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by state governmental and non-governmental third-party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; and state laws and regulations that require manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, the ACA, among other things, amends the intent requirement of the federal anti-kickback and criminal health care fraud statutes. A person or entity can now be found guilty of fraud or false claims under ACA without actual knowledge of the statute or specific intent to violate it. In addition, ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the false claims statutes. Possible sanctions for violation of these anti-kickback laws include monetary fines, civil and criminal penalties, exclusion from Medicare, Medicaid and other government programs and forfeiture of amounts collected in violation of such prohibitions. Any violations of these laws, or any action against us for violation of these laws, even if we successfully defend against it, could result in a material adverse effect on our reputation, business, results of operations and financial condition.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, there has been a trend of increased state regulation of payments made to physicians for marketing. Some states, such as California, Massachusetts and Vermont, mandate implementation of corporate compliance programs, along with the tracking and reporting of gifts, compensation, and other remuneration to physicians.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The scope and enforcement of these laws is uncertain and subject to change in the current environment of health care reform, especially in light of the lack of applicable precedent and regulations. Such changes are impossible to predict. It is possible that some of our business activities could be subject to challenge by federal or state regulatory authorities under one or more of these laws. Any such challenge could have a material adverse effect on our reputation, business, results of operations, and financial condition. Any state or federal regulatory review of us, regardless of the outcome, would be costly and time-consuming, and could have a material adverse effect on our business, financial condition and results of operations.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU50"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our emplo</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">yees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, provide accurate information to the FDA, comply with manufacturing standards we have established, comply with federal and state health-care fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a Code of Business Conduct and Ethics but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent misconduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Health care reform measures could adversely affect our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and foreign jurisdictions, there have been a number of legislative and regulatory changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs. The ACA, which includes measures to significantly change the way health care is financed by both governmental and private insurers, was enacted in March 2010. Among the provisions of the ACA of greatest importance to the pharmaceutical and biotechnology industry are the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic products, apportioned among these entities according to their market share in certain government healthcare programs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">new requirements to report certain financial arrangements with physicians and teaching hospitals, including reporting any &#8220;transfer of value&#8221; made or distributed to physicians and teaching hospitals and reporting any ownership interests held by physicians and their immediate family members;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">creation of the Independent Payment Advisory Board which, beginning in 2014, has authority to recommend certain changes to the Medicare program that could result in reduced payments for prescription drugs, which recommendations can have the effect of law even without congressional action; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">establishment of a Center for Medicare Innovation at the Centers for Medicare&#160;&amp; Medicaid Services to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At this time, the full effect that the ACA would have on our business remains unclear. As a result of the 2016 election in the United States, there is great political uncertainty concerning the fate of the ACA and other healthcare laws. Legislation has been drafted to repeal and replace parts of the ACA, but it is uncertain when a bill would be passed and what any replacement law would encompass. We cannot predict any initiatives that may be adopted in the future.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Individual states have become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and marketing cost disclosure and transparency measures, and designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce ultimate demand for our products or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and prospects.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU51"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, given recent feder</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">al and state government initiatives directed at lowering the total cost of healthcare, Congress and state legislatures will likely continue to focus on healthcare reform, the cost of prescription drugs and biologics and the reform of the Medicare and Medic</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">aid programs. While we cannot predict the full outcome of any such legislation, it may result in decreased reimbursement for drugs and biologics, which may further exacerbate industry-wide pressure to reduce prescription drug prices. This could harm our ab</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ility to generate revenues. Increases in importation or re-importation of pharmaceutical products from foreign countries into the United States could put competitive pressure on our ability to profitably price our products, which, in turn, could adversely </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">affect our business, results of operations, financial condition and prospects. We might elect not to seek approval for or market our products in foreign jurisdictions in order to minimize the risk of re-importation, which could also reduce the revenue we g</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enerate from our product sales. It is also possible that other legislative proposals having similar effects will be adopted.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, regulatory authorities&#8217; assessment of the data and results required to demonstrate safety and efficacy can change over time and can be affected by many factors, such as the emergence of new information, including on other products, changing policies and agency funding, staffing and leadership. We cannot be sure whether future changes to the regulatory environment will be favorable or unfavorable to our business prospects. For example, average review times at the FDA for marketing approval applications can be affected by a variety of factors, including budget and funding levels and statutory, regulatory and policy changes.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The Referendum of the United Kingdom&#8217;s Membership of the European Union creates uncertainty and could negatively impact our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 23, 2016, the United Kingdom, or the U.K., held a referendum in which voters approved an exit from the European Union, or the E.U., commonly referred to as &#8220;Brexit.&#8221; As a result of the referendum, it is expected that the British government will begin negotiating the terms of the U.K.&#8217;s withdrawal from the E.U. A withdrawal could, among other outcomes, disrupt the free movement of goods, services and people between the U.K. and the E.U., undermine bilateral cooperation in key policy areas and significantly disrupt trade between the U.K. and the E.U. In addition, Brexit could lead to legal uncertainty and potentially divergent national laws and regulations as the U.K. determines which E.U. laws to replace or replicate. Given the lack of comparable precedent, it is unclear what financial, trade, regulatory and legal implications the withdrawal of the U.K. from the E.U. would have and how such withdrawal would affect us.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The announcement of Brexit caused significant volatility in global stock markets and currency exchange rate fluctuations that resulted in the strengthening of the U.S. dollar against foreign currencies in which we could, if we ever commercialize a product, conduct business. The announcement of Brexit and the withdrawal of the U.K. from the E.U. may also create global economic uncertainty, which may cause third-party payors, including governmental organizations, to closely monitor their costs and reduce their spending budgets. Any of these effects of Brexit, among others, could adversely affect our business, financial condition and operating results, particularly if we receive approval to commercialize a product.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Relating to Protecting Our Intellectual Property</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">It is difficult and expensive to protect our intellectual property rights and we cannot ensure that they will prevent third parties from competing against us. If we are unable to adequately protect our proprietary technology, or obtain and maintain issued patents that are sufficient to protect our product candidates, others could compete against us more directly, which would have a material adverse impact on our business, results of operations, financial condition and prospects.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success will depend, in part, on our ability to obtain and maintain intellectual property rights, both in the United States and other countries, successfully defend this intellectual property against third-party challenges and successfully enforce this intellectual property to prevent third-party infringement. We rely upon a combination of patents, trade secret protection and confidentiality agreements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to protect any of our product candidates and technologies from unauthorized or infringing use by third parties depends in substantial part on our ability to obtain and maintain valid and enforceable patents in both the United States and other countries. Patent matters in the biotechnology and pharmaceutical industries can be highly uncertain and involve complex legal and factual questions. Changes in the patent laws, their implementing regulations or their interpretations may diminish the value of our patent rights.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU52"></a>There can be no assurance that we will discover or develop patentable products or processes or that patents will issue from any pending patent applications owned or licensed by us, or if issued, the breadth of such patent coverage. We currently have no issued patents covering any of our product candidates, including PTI-428, PTI-801 and PTI-808, or our technologies, and many of our patent applications related to our CF program are in the earliest stages, including several provisional patent applications, although we do have two (2) issued patents covering early CFTR modulator compounds not currently in development. We cannot provide any assurances that any of our pending patent applications will lead to issued patents and, if they do, that such patents will include claims </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with a scope sufficient to protect</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> our product candidates or otherwise provide any competitive advantage. Even if issued, we cannot guarantee that claims of issued patents owned or licensed to us are or will be held valid or enforceable by the courts or, even if unchallenged, will provide </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us with exclusivity or commercial value for our product candidates or technology or any significant protection against competitive products or prevent others from designing around our claims. Further, if we encounter delays in regulatory approvals, the per</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iod of time during which we could market our product candidates under patent protection could be reduced. Our patent rights also depend on our compliance with technology and patent licenses upon which our patent rights are based and upon the validity of as</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">signments of patent rights from consultants and other inventors that were, or are, not employed by us.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent positions of biotechnology and pharmaceutical companies, including our patent position, involve complex legal and factual questions, and, therefore, the issuance, scope, validity and enforceability of any patent claims that we may obtain cannot be predicted with certainty. Patents, if issued, may be challenged, deemed unenforceable, invalidated, or circumvented. U.S. patents and patent applications may also be subject to derivation or adversarial proceedings, <font style="font-style:italic;">ex parte</font> reexamination, or <font style="font-style:italic;">inter partes</font> review proceedings, supplemental examination and challenges in district court. Patents may be subjected to opposition, post-grant review, or comparable proceedings lodged in various foreign, both national and regional, patent offices. These proceedings could result in either loss of the patent or denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application. In addition, such proceedings may be costly. Thus, any patents, should they issue, that we may own or exclusively license may not provide any protection against competitors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patent applications are generally maintained in confidence until publication. In the United States, for example, patent applications are maintained in secrecy for up to 18 months after their filing. Similarly, publication of discoveries in scientific or patent literature often lags behind actual discoveries. Consequently, we cannot be certain that we were the first to file patent applications on our product candidates. There is also no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which could be used by a third party to challenge validity of our patents, should they issue, or prevent a patent from issuing from a pending patent application.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, even if patents do successfully issue, third parties may challenge any such patent we own or license through adversarial proceedings in the issuing offices, which could result in the invalidation or unenforceability of some or all of the relevant patent claims. If a third party asserts a substantial new question of patentability against any claim of a U.S. patent we own or license, the U.S. Patent and Trademark Office, or USPTO, may grant a request for reexamination, which may result in a loss of scope of some claims or a loss of the entire patent. The adoption of the Leahy-Smith America Invents Act, or the Leahy-Smith Act, on September&#160;16, 2011, established additional opportunities for third parties to invalidate U.S. patent claims, including <font style="font-style:italic;">inter partes</font> review and post-grant review, on the basis of a lower legal standards than reexamination and additional grounds.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will incur significant ongoing expenses in maintaining our patent portfolio. Should we lack the funds to maintain our patent portfolio or to enforce our rights against infringers, we could be adversely impacted. Moreover, the failure of any patents that may issue to us or our licensors to adequately protect our product candidates or technology could have an adverse impact on our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will not be able to seek and obtain protection for our intellectual property in all jurisdictions throughout the world, and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, prosecuting and defending patents on all of our product candidates throughout the world would be prohibitively expensive. Competitors may manufacture and sell our potential products in those foreign countries where we do not file for and obtain patent protection or where patent protection may be unavailable, not obtainable or ultimately not enforceable. Our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets and, further, may be able to export otherwise infringing products to territories where we have patent protection but where enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The statutory deadlines for pursuing patent protection in individual foreign jurisdictions are based on the priority date of each of our patent applications. For PTI-428, all of the statutory deadlines have passed.&nbsp;&nbsp;For our patent applications related to PTI-801, PTI-808, potentiators and correctors, the relevant statutory deadlines have not yet expired. Thus, for each of these patent families, particularly those that we believe provide coverage for these product candidates, we will need to decide whether and where to pursue protection outside the United States by the relevant deadlines, and we will only have the opportunity to obtain patent protection in those jurisdictions where we file for protection, and prosecute and obtain issued claims.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU53"></a>The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The scope and available coverage thus may vary significantly. Outside of the United States, patents we own or license, if </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">issued, may become subject to patent opposition in the European Patent Of</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fice or similar proceedings, which may result in loss of scope of some claims or loss of the entire patent. Participation in adversarial proceedings is very complex and expensive, and may divert our management&#8217;s attention from our core business and may res</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ult in unfavorable outcomes that could adversely affect our ability to prevent third parties from competing with us.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to biotechnology. This could make it difficult for us to stop the infringement of our patents, if obtained, or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. Patent protection must ultimately be sought on a country-by-country basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries, and we will not have the benefit of patent protection in such countries.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. For example, an April 2014 report from the Office of the United States Trade Representative identified a number of countries, including India and China, where challenges to the procurement and enforcement of patent rights have been reported. Several countries, including India and China, have been listed in the report every year since 1989. If we encounter difficulties in protecting our intellectual property rights in foreign jurisdictions, our business prospects could be substantially harmed.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceedings to enforce our patent rights, if obtained, in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Others may be able to make compounds that are similar to our product candidates but that are not covered by the claims of any patents, should they issue, that we own or have exclusively licensed.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">We or our licensors or strategic collaborators might not have been the first to make the inventions covered by any issued patent or pending patent application that we own or have exclusively licensed.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">We or our licensors or strategic collaborators might not have been the first to file patent applications covering certain of our inventions.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Our pending patent applications may not lead to issued patents.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Patents, should they issue, that we own or that we have exclusively licensed, if any, may not provide us with any competitive advantages, or may be held invalid or unenforceable, as a result of legal challenges by our competitors.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">We may not develop additional proprietary technologies that are patentable.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">The patents of others may have an adverse effect on our business.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should any of these events occur, they could significantly harm our business, results of operations and prospects.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU54"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> applications and the enforcement or defense of our issued patents.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Leahy-Smith Act includes a number of significant changes to United States patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business, our current and pending patent portfolio and future intellectual property strategy. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO, the European Patent Office and other foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign national or international patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of patent rights include, but are not limited to, failure to file non-provisional applications claiming priority to our provisional applications by the statutory deadlines, failure to timely file national and regional stage patent applications based on an international patent application, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications covering our product candidates, our competitors might be able to enter the market, which would have a material adverse effect on our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The patent protection and patent prosecution for some of our product candidates is dependent or may be dependent in the future on third parties.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we normally seek and gain the right to fully prosecute the patents relating to our product candidates, there may be times when platform technology patents or product-specific patents that relate to our product candidates are controlled by our licensors or collaboration partners. In addition, our licensors and/or licensees and/or collaboration partners may have back-up rights to prosecute patent applications in the event that we do not do so or choose not to do so, and our licensees and/or collaboration partners may have the right to assume patent prosecution rights after certain milestones are reached. If any of our licensing partners fails to appropriately prosecute and maintain patent protection for patents covering any of our product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have entered into and may in the future enter into licenses to licensed intellectual property. If we were to lose our rights to licensed intellectual property, we may not be able to continue developing or commercializing a product candidate, if approved, that relied on such licensed intellectual property.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently a party to and may in the future be party to license agreements under which we are or will be granted rights to intellectual property that are important to our business. Certain of our existing license agreements impose, and we expect that future license agreements will impose on us, various diligence obligations, payment of milestones and/or royalties and other obligations, including, without limitation, patent prosecution, research and development and efforts to meet milestones under mutually-agreed development plans. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, the licensor may have the right to terminate the license, in which event we would not be able to continue to use the rights granted under the license, or develop or market products covered by the license. Our business could suffer, for example, if any current or future licenses terminate, if the licensors fail to abide by the terms of the license, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we cannot provide any assurances that third-party patents do not exist that might be enforced against our current product candidates or future products in the absence of such a license. We may fail to obtain any of these licenses on commercially reasonable terms, if at all. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could materially harm our business, and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU55"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Licensing of intellectual property involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the scope of rights granted under the license agreement and other interpretation-related issues;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our right to sublicense patent and other rights to third parties under collaborative development relationships;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If disputes over intellectual property that we license now or in the future prevent or impair our ability to maintain our licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to litigation alleging that we are infringing the intellectual property rights of third parties or litigation or other adversarial proceedings seeking to invalidate our patents or other proprietary rights, and we may need to resort to litigation to protect or enforce our patents or other proprietary rights, all of which will be costly to defend, uncertain in its outcome and may prevent or delay development and commercialization efforts or otherwise harm our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success also will depend, in part, on our refraining from infringing patents or otherwise violating intellectual property owned or controlled by others. Numerous patents and pending applications are owned by third parties in the fields in which we are developing product candidates, both in the United States and elsewhere. It is difficult for industry participants, including us, to identify all third-party patent rights that may be relevant to our product candidates and technologies because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning and scope of patent claims. Moreover, because some patent applications are maintained in secrecy until the patents publish, we cannot be certain that third parties have not filed patent applications that cover our products and technologies. We may fail to identify relevant patents or patent applications or may identify pending patent applications of potential interest but incorrectly predict the likelihood that such patent applications may issue with claims of relevance to our technology. In addition, we may be unaware of one or more issued patents that would be infringed by the manufacture, sale, importation or use of a current or future product candidate, or we may incorrectly conclude that a third-party patent is invalid, unenforceable or not infringed by our activities. Additionally, pending patent applications can, subject to certain limitations, be later amended in a manner that could cover our technologies, our future products or the manufacture or use of our future products. Pharmaceutical companies, biotechnology companies, universities, research institutions and others may have filed patent applications or have received, or may obtain, issued patents in the United States or elsewhere relating to aspects of our technology, including our products, processes for testing, manufacture, formulation or methods of use, including combination therapy. It is uncertain whether the issuance of any third-party patents will require us to alter our product candidates or processes, obtain licenses, or cease certain activities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If patents issued to third parties contain blocking, dominating or conflicting claims we may choose to or, if such claims are ultimately determined to be valid, be required to obtain licenses to these patents or to develop or obtain alternative non-infringing technology and cease practicing those activities, including, potentially, the manufacture or marketing of any products deemed to infringe those patents. If any licenses are required, there can be no assurance that we will be able to obtain any such licenses on commercially favorable terms, if at all, and if these licenses are not obtained, we might be prevented from pursuing the development and commercialization of certain of our potential products entirely or for certain indications. Even if a license can be obtained on acceptable terms, the rights may be non-exclusive, which could give our competitors access to the same technology or intellectual property rights licensed to us. Our failure to obtain a license to any technology that we may require to commercialize our products on favorable terms may have a material adverse impact on our business, financial condition and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU56"></a>We may be exposed to, or threatened with, future litigation by third parties, including our competitors, having patent or other intellectual property rights alleging that our technologies, including our products, processes for manufacture or methods of use, including combination therapy, or other proprietary technologies infringe, either literally or under the doctrine of equivalents, their intellectual property rights. Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful infringement or other intellectual property claim against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our affected products, which may be impossible or require substantial time and monetary expenditure. We cannot </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Parties making successful claims a</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gainst us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. We cannot provide any assurances that third-party patents do not exist which mi</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ght be enforced against our products or product candidates, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties. Any of those</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> occurrences would have a material adverse impact on our business.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or any other patent litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be involved in lawsuits to protect or enforce our intellectual property, which could be time consuming, expensive and unsuccessful, and issued patents covering our product candidates could be found invalid or unenforceable if challenged in court.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors may infringe our patents or the patents of our licensors, assuming patents issue from patent applications we own or license. Litigation, which could result in substantial costs to us (even if determined in our favor), may also be necessary to enforce any patents issued or licensed to us. The cost to us in initiating any litigation or other proceeding relating to patent or other proprietary rights, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s attention. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts and limit our ability to continue our operations. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid, is unenforceable and/or is not infringed, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates or our technology, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the United States and in most European countries, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our products or certain aspects of our platform technology. Such a loss of patent protection could have a material adverse impact on our business. Patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without legally infringing our patents or other intellectual property rights.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. Any of these outcomes would not only have an adverse effect on our patent portfolio but may also have an adverse effect on our business if we are unable to prevent the competitive activities of third parties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or any other patent litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU57"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of our technology and products could be significantly diminished.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on trade secrets to protect technology especially where patent protection is not believed to be appropriate or obtainable or where patents have not issued. We attempt to protect our proprietary technology and processes, in part, with confidentiality agreements and assignment of invention agreements with our employees and confidentiality agreements with our consultants and certain contractors. There can be no assurance that these agreements will not be breached, that we would have adequate remedies for any breach, or that our trade secrets will not otherwise become known or be independently discovered by competitors. We may fail in certain circumstances to obtain the necessary confidentiality agreements, or their scope or term may not be sufficiently broad to protect our interests.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our trade secrets or other intellectual property become known to our competitors, it could result in a material adverse effect on our business, financial condition and results of operations. To the extent that we or our consultants or research collaborators use intellectual property owned by others in work for us, disputes may also arise as to the rights to related or resulting know-how and inventions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We enter into confidentiality and intellectual property assignment agreements with our employees, consultants, outside scientific advisors, and sponsored researchers. These agreements generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, these agreements may not be honored and may not effectively assign intellectual property rights to us. Moreover, we may not obtain these agreements in all circumstances.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets of our employees&#8217; or consultants&#8217; former employers or their clients. These claims may be costly to defend and if we do not successfully do so, we may be required to pay monetary damages and may lose valuable intellectual property rights or personnel.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our employees and consultants were previously or concurrently employed at universities or biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees, consultants or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their employers. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A loss of key research personnel or their work product could compromise our ability to commercialize, or prevent us from commercializing, our product candidates, which could severely harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Relating to Our Business Operations and Industry</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our future success depends on our ability to retain executives and to attract, retain and motivate key personnel in a competitive environment for skilled biotechnology personnel.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the specialized scientific nature of our business and the unique properties of our technology, our success is highly dependent upon our ability to attract and retain qualified scientific and technical personnel, consultants and advisors. We are dependent on the principal members of our scientific and management staff, particularly Ms.&#160;Meenu Chhabra, Ms. Helen Boudreau, and Drs. Po-Shun Lee, Geoffrey Gilmartin, Benito Munoz and Marija Zecevic, who have extensive knowledge of and experience developing our technology. Additionally, we are dependent on our Vice President, Clinical Operations, Ms. Sheila Wilson, to conduct our clinical operations. The loss of any of their services might significantly delay or prevent the achievement of our research, development and business objectives.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU58"></a>We will need to recruit a significant number of additional personnel in order to achieve our operating goals. In order to pursue our product development and marketing and sales plans, we will need to hire additional qualified scientific personnel to perform research and development, and preclinical studies, as well as personnel with expertise in clinical operations, clinical testing, government regulation, compliance, manufacturing, marketing and sales, which may strain our existing managerial, operational, regulatory compliance, financial and other resources. We also rely on consultants and advisors to assist in formulating our research </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and development str</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ategy and adhering to complex regulatory requirements. We face strong competition for qualified individuals from numerous pharmaceutical and biotechnology companies, universities and other research institutions, many of which have greater financial and oth</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">er resources than us. There can be no assurance that we will be able to attract and retain such individuals on acceptable terms, if at all. Additionally, our facilities are located in Massachusetts, which may make attracting and retaining qualified scienti</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fic and technical personnel from outside of Massachusetts difficult. The failure to attract and retain qualified personnel, consultants and advisors could have a material adverse effect on our business, financial condition and results of operations.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">As our product candidates advance through clinical trials we may experience difficulties in managing our growth and expanding our operations, including, without limitation, managing international clinical trials.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have limited experience in drug development. As our product candidates advance through preclinical studies and clinical trials, we will need to expand our development, regulatory and manufacturing capabilities or contract with other organizations to provide these capabilities for us. In the future, we expect to have to manage additional relationships with collaborators or partners, suppliers and other organizations, including, without limitation, international clinical trials. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures. We may not be able to implement improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are exposed to potential product liability or similar claims, and insurance against these claims may not be sufficient to cover our liabilities, or may not be available to us at a reasonable rate in the future or at all.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business exposes us to potential liability risks that are inherent in the testing, manufacturing and marketing of human therapeutic products. Clinical trials involve the testing of product candidates on human subjects or volunteers under a research plan, and carry a risk of liability for personal injury or death to patients due to unforeseen adverse side effects, improper administration of the product candidate, or other factors. Many of these patients are already seriously ill and are therefore particularly vulnerable to further illness or death.&nbsp;&nbsp;Our trials may include third party drugs taken with ours that could injure trial subjects for whose damages we would be liable and, even if we were not, we nevertheless may not be able to show or prove that our product was not a cause of the injury.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We carry clinical trial liability insurance. However, there can be no assurance that we will be able to obtain the amount of insurance necessary to cover potential claims or liabilities. We could be materially and adversely affected if we were required to pay damages or incur defense costs in connection with a claim outside the scope of indemnity or insurance coverage, if the indemnity is not performed or enforced in accordance with its terms, or if our liability exceeds the amount of applicable insurance. In addition, there can be no assurance that insurance, if obtained, will continue to be available on terms acceptable to us. Similar risks would exist upon the commercialization or marketing of any products by us or our collaborators.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regardless of their merit or eventual outcome, product liability claims may result in:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">decreased demand for our product;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">injury to our reputation and significant negative media attention;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">withdrawal of clinical trial volunteers or subjects;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">costs of litigation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">distraction of management; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">substantial monetary awards to plaintiffs.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should any of these events occur, it could have a material adverse effect on our business and financial condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may become involved in securities class action litigation that could divert management&#8217;s attention and adversely affect our business and could subject us to significant liabilities.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU59"></a>The stock markets have from time to time experienced significant price and volume fluctuations that have affected the market prices for the common stock of pharmaceutical and biotechnology companies. These broad market fluctuations as well a broad range of other factors, including the realization of any of the risks described in this &#8220;Risk Factors&#8221; section of this report, may cause the market price of our common stock to decline. In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology and pharmaceutical companies generally experience significant stock price volatility. We may become involved in this type of litigation in </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the future. Litigation often is expensive and diverts management&#8217;s attention and reso</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">urces, which could adversely affect our business. Any adverse determination in any such litigation or any amounts paid to settle any such actual or threatened litigation could require that we make significant payments.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with manufacturing standards we have established, to comply with federal and state healthcare fraud and abuse laws and regulations, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We must comply with environmental laws and regulations, and failure to comply with these laws and regulations could expose us to significant liabilities.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use hazardous chemicals and biological materials in certain aspects of our business and are subject to a variety of U.S. federal, state and local laws and regulations governing the use, generation, manufacture, distribution, storage, handling, treatment and disposal of these materials. Although we believe our safety procedures for handling and disposing of these materials and waste products comply with these laws and regulations, we cannot eliminate the risk of accidental injury or contamination from the use, manufacture, distribution, storage, handling, treatment or disposal of hazardous materials. In the event of contamination or injury, or failure to comply with environmental, occupational health and safety and export control laws and regulations, we could be held liable for any resulting damages and any such liability could exceed our assets and resources, including any available insurance.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Relating to Our Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our stock price will likely continue to be volatile and an active, liquid and orderly trading market may not develop for our common stock. As a result you may not be able to resell your shares at or above your purchase price.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The market price of our common stock may fluctuate substantially as a result of many factors, some of which are beyond our control. These fluctuations could cause you to lose all or part of the value of your investment in our common stock. Factors that could cause fluctuations in the market price of our common stock include the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the development status of our product candidates and when our products receive regulatory approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the results, and the timing of results, of our preclinical studies and clinical trials, including, without limitation, the publication or delay in publication of preliminary, interim or final results, adverse events, side effects, safety or efficacy data or other information;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the support and approval, if any, that we receive from our collaboration partners, the TDN and other interested parties;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">performance of third parties on whom we rely to conduct pre-clinical studies, manage our clinical trials, and manufacture our products, product components and product candidates, including their ability to comply with regulatory requirements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the success of, and fluctuation in, the sales of our product candidates, if approved;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our execution of our sales and marketing, manufacturing and other aspects of our business plan;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">results of operations that vary from those of our competitors and the expectations of securities analysts and investors;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">changes in expectations as to our future financial performance, including financial estimates by securities analysts and investors;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our announcement of significant licensing or collaboration arrangements, or the termination of such arrangements;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU60"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">our announcement of significant contracts, acquisitions, or capital commitments;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">announcements by our competitors of competing products or other initiatives, including, without limitation, those that lead to the development of a new standard of care;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">announcements by third parties of significant claims or proceedings against us;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">regulatory and reimbursement developments in the United States and abroad;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">future sales of our common stock or debt securities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">additions or departures of key personnel; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">general domestic and international economic conditions unrelated to our performance.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the stock market in general has experienced significant price and volume fluctuations that have often been unrelated or disproportionate to operating performance of individual companies. These broad market factors may adversely affect the market price of our common stock, regardless of our operating performance. In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been instituted. A securities class action suit against us could result in significant liabilities and, regardless of the outcome, could result in substantial costs and the diversion of our management&#8217;s attention and resources.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to our initial public offering in February 2016, there was no public market for shares of our common stock. The listing of our common stock on The NASDAQ Global Market does not assure that a meaningful, consistent and liquid trading market exists. Although our common stock is listed on The NASDAQ Global Market, trading volume in our common stock has been limited and an active trading market for our shares may never develop or be sustained. If an active market for our common stock does not develop, you may be unable to sell your shares when you wish to sell them or at a price that you consider attractive or satisfactory. The lack of an active market may also adversely affect our ability to raise capital by selling securities in the future, or impair our ability to license or acquire other product candidates, businesses or technologies using our shares as consideration.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We could be subject to securities class action litigation.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology and pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. If one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, demand for our stock could decrease, which could cause our stock price and trading volume to decline.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our principal stockholders have and will have a controlling influence over our business affairs and may make business decisions with which you disagree and which may adversely affect the value of your investment.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our executive officers, directors and principal stockholders and their affiliates beneficially own or control, directly or indirectly, a majority of the outstanding shares of our common stock. As a result, if some of these persons or entities act together, they will have the ability to exercise significant influence over matters submitted to our stockholders for approval, including the election and removal of directors, amendments to our certificate of incorporation and by-laws and the approval of any business combination. These actions may be taken even if they are opposed by other stockholders. This concentration of ownership may also have the effect of delaying or preventing a change of control of our company or discouraging others from making tender offers for shares of our common stock, which could prevent our stockholders from receiving a premium for their shares. Some of these persons or entities who make up our principal stockholders may have interests different from yours.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU61"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Future sales, or the expectation of future sales, of a substantial number of our common </font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">shares could depress the trading price of our common stock.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or our stockholders sell substantial amounts of shares of our common stock in the public market or if the market anticipates that these sales could occur, the market price of shares of our common stock could decline. These sales may make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem appropriate, or to use equity as consideration for future acquisitions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to our 2016 Stock Option and Incentive Plan, or the 2016 Plan, our board is authorized to grant stock options and other equity-based awards to our employees, directors and consultants. The number of shares available for future grant under the 2016 Plan automatically increases each year by up to 3% of all shares of our capital stock outstanding as of December&#160;31 of the prior calendar year, subject to the ability of our board of directors or compensation committee to take action to reduce the size of the increase in any given year. Currently, we plan to register the increased number of shares available for issuance under the 2016 Plan each year. If our board of directors or compensation committee elects to increase the number of shares available for future grant by the maximum amount each year, our stockholders may experience additional dilution, which could cause our stock price to fall.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">A significant portion of our total outstanding shares may be sold into the market. This could cause the market price of our common stock to drop significantly, even if our business is doing well.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or the market believes that our stockholders intend to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of a significant portion of shares of our common stock, or their transferees, have rights, subject to some conditions, to require us to file one or more registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. If we were to register the resale of these shares, they could be freely sold in the public market. If these additional shares are sold, or if it is believed that they will be sold, in the public market, the trading price of our common stock could decline.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Actual or potential sales of our common stock by our employees, including our executive officers, pursuant to pre-arranged stock trading plans could cause our stock price to fall or prevent it from increasing for numerous reasons, and actual or potential sales by such persons could be viewed negatively by other investors.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with the guidelines specified under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, and our policies regarding stock transactions, our employees and executive officers may adopt stock trading plans pursuant to which they have arranged to sell shares of our common stock from time to time in the future. Generally, sales under such plans by our executive officers and directors require public filings. Actual or potential sales of our common stock by such persons could cause the price of our common stock to fall or prevent it from increasing for numerous reasons. For example, a substantial number of shares of our common stock becoming available (or being perceived to become available) for sale in the public market could cause the market price of our common stock to fall or prevent it from increasing. Also, actual or potential sales by such persons could be viewed negatively by other investors.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have broad discretion in the use of our cash and cash equivalents and may not use them effectively or may use them in a way with respect to which stockholders do not approve.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management will have broad discretion in the use of our cash and could spend it in ways that do not improve our results of operations or enhance the value of shares of our common stock. The failure by our management to utilize our cash effectively could result in financial losses that could have a material adverse effect on our business, cause the market price of shares of our common stock to decline and delay the development of our product candidates. We may invest our cash in a manner that does not produce income or that loses value. If we do not invest our cash in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause the price of shares of our common stock to decline.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU62"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">As an &#8220;emerging growth company,&#8221; we are allowed to postpone the date by which we must comply with certain laws and regulations intended to protect investors and to reduce the amount of information we </font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">provide in our reports filed with the Securities and Exchange Commission, or SEC. This reduced disclosure could make our common stock less attractive to investors.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The JOBS Act is intended to reduce the regulatory burden on &#8220;emerging growth companies.&#8221; As defined in the JOBS Act, a public company whose initial public offering of common equity securities occurred after December&#160;8, 2011 and whose annual gross revenues are less than $1.0&#160;billion will, in general, qualify as an &#8220;emerging growth company&#8221; until the earliest of:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the last day of its fiscal year following the fifth anniversary of the date of its initial public offering of common equity securities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the last day of its fiscal year in which it has annual gross revenue of $1.0 billion or more;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the date on which it has, during the previous three-year period, issued more than $1.0 billion in non-convertible debt; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the date on which it is deemed to be a &#8220;large accelerated filer,&#8221; which will occur at such time as the company (1)&#160;has an aggregate worldwide market value of common equity securities held by non-affiliates of $700.0 million or more as of the last business day of its most recently completed second fiscal quarter, (2)&#160;has been required to file annual and quarterly reports under the Securities Exchange Act of 1934, as amended, or the Exchange Act, for a period of at least 12 months and (3)&#160;has filed at least one annual report pursuant to the Exchange Act.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under this definition, we are an &#8220;emerging growth company&#8221; and could remain an &#8220;emerging growth company&#8221; for more than five years. For so long as we are an &#8220;emerging growth company,&#8221; we will, among other things:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">not be required to comply with the auditor attestation requirements of section 404(b) of Sarbanes-Oxley;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">not be required to hold a nonbinding advisory stockholder vote on executive compensation pursuant to Section&#160;14A(a) of the Exchange Act;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">not be required to seek stockholder approval of any golden parachute payments not previously approved pursuant to Section&#160;14A(b) of the Exchange Act;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">be exempt from any rule adopted by the Public Company Accounting Oversight Board, requiring mandatory audit firm rotation or a supplemental auditor discussion and analysis; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">be subject to reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, Section&#160;107 of the JOBS Act provides that an emerging growth company can use the extended transition period provided in Section&#160;7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. This permits an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other companies. Section&#160;107 of the JOBS Act provides that our decision to opt out of the extended transition period for complying with new or revised accounting standards is irrevocable.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In this report and our other periodic reports we have not included all of the executive compensation related information that would be required if we were not an emerging growth company. We cannot predict whether investors will find our common stock less attractive for relying on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">As a public reporting company, we are and will be subject to rules and regulations established from time to time by the SEC and the Public Company Accounting Oversight Board, or PCAOB, regarding our internal control over financial reporting. We may not complete improvements to our internal control over financial reporting in a timely manner, or these internal controls may not be determined to be effective, which may adversely affect investor confidence in our company and, as a result, the market price of our common stock could decline and you could lose all or part of your investment.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a public reporting company subject to the rules and regulations established from time to time by the SEC and the PCAOB. These rules and regulations require, among other things, that we establish and periodically evaluate procedures with respect to our internal controls over financial reporting. Reporting obligations as a public company are likely to place a considerable strain on our financial and management systems, processes and controls, as well as on our personnel.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU63"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as a public company we are required to document and test our internal controls over financial reporting pursuant to Section&#160;404 of the Sarbanes-Oxley Act</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of 2002, or the Sarbanes-Oxley Act, so that our management can certify as to the effectiveness of our internal controls over financial reporting by the due date for our annual report for the year ending December&#160;31, 2016 and thereafter, which will require</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> us to continue to document and make changes to our internal controls over financial reporting. Likewise, our independent registered public accounting firm will be required to provide an attestation report on the effectiveness of our internal control over </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financial reporting at such time as we cease to be an &#8220;emerging growth company,&#8221; as defined in the JOBS Act, although, as described in the preceding risk factor, we could potentially qualify as an &#8220;emerging growth company&#8221; for more than five years. At such</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> time, our independent registered public accounting firm may issue a report that is adverse in the event it is not satisfied with the level at which our controls are documented, designed or operating.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our senior management is unable to conclude that we have effective internal control over financial reporting, or to certify the effectiveness of such controls, or if our independent registered public accounting firm cannot render an unqualified opinion on management&#8217;s assessment and the effectiveness of our internal control over financial reporting once we cease to be an emerging growth company, or if material weaknesses in our internal controls are identified, we could be subject to regulatory scrutiny and a loss of public confidence, which could have a material adverse effect on our business and our stock price. In addition, if we do not maintain adequate financial and management personnel, processes and controls, we may not be able to manage our business effectively or accurately report our financial performance on a timely basis, which could cause a decline in our common stock price and adversely affect our results of operations and financial condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to the periodic reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably ensure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures as well as internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are and will be met. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating as a public company has significantly increased our costs and requires our management to devote substantial time to compliance efforts.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company, we are incurring and will continue to incur significant legal, accounting, insurance and other expenses that we did not incur as a private company. The Dodd-Frank Act and the Sarbanes-Oxley Act, as well as related rules implemented by the SEC and The NASDAQ Stock Market, have required changes in corporate governance practices of public companies. In addition, rules that the SEC is implementing or is required to implement pursuant to the Dodd-Frank Act are expected to require additional changes. We expect that compliance with these and other similar laws, rules and regulations, including compliance with Section&#160;404 of the Sarbanes-Oxley Act, will substantially increase our expenses, including our legal and accounting costs, and make some activities more time-consuming and costly. We also expect these laws, rules and regulations to make it more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage, which may make it more difficult for us to attract and retain qualified persons to serve on our board of directors or as officers. We expect that we will need to hire additional accounting, finance and other personnel in connection with our efforts to comply with the requirements of being a public company, and our management and other personnel will need to devote a substantial amount of time towards maintaining compliance with these requirements. These requirements will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. Although the JOBS Act may for a limited period of time somewhat lessen the cost of complying with these additional regulatory and other requirements, we nonetheless expect a continued increase in legal, accounting, insurance and certain other expenses in the future, which will negatively impact our business, results of operations and financial condition.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU64"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Anti-takeover provi</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">sions in our charter documents could discourage, delay or prevent a change in control of our company and may affect the trading price of our common stock.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation and amended and restated by-laws and the Delaware General Corporation Law contain provisions that may enable our board of directors to resist a change in control of our company even if a change in control were to be considered favorable by you and other stockholders. These provisions:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">provide that directors can be removed only for cause, and then only by a supermajority stockholder vote;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">establish advance notice requirements for nominating directors and proposing matters to be voted on by stockholders at stockholder meetings;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">require majority stockholder voting to effect certain amendments to our certificate of incorporation and by-laws;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">create a classified board of directors whose members serve staggered three-year terms;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">specify that special meetings of our stockholders can be called only by our board of directors;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">prohibit stockholder action by written consent;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">specify that no stockholder is permitted to cumulate votes at any election of directors;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">expressly authorize our board of directors to modify, alter or repeal our amended and restated by-laws, subject to any limitations set forth therein;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">require supermajority votes of the holders of our common stock to amend specified provisions of our amended and restated certificate of incorporation; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">require supermajority votes of the holders of our common stock to amend our amended and restated by-laws, unless such amendments have been recommended to the stockholders, in which case only a majority vote is necessary.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we are subject to the provisions of Section&#160;203 of the Delaware General Corporation Law. In general, Section&#160;203 prohibits a publicly-held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. A &#8220;business combination&#8221; includes, among other things, a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested stockholder. An &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or did own within three years prior to the determination of interested stockholder status, 15% or more of the corporation&#8217;s voting stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Delaware corporation may &#8220;opt out&#8221; of these provisions with an express provision in its original certificate of incorporation or an express provision in its certificate of incorporation or by-laws resulting from a stockholders&#8217; amendment approved by at least a majority of the outstanding voting shares. We have not opted out of these provisions. As a result, mergers or other takeover or change in control attempts of us may be discouraged or prevented.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We do not expect to pay any dividends on our common stock for the foreseeable future.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently expect to retain all future earnings, if any, for future operations, expansion and repayment of debt and have no current plans to pay any cash dividends to holders of our common stock for the foreseeable future. Any decision to declare and pay dividends in the future will be made at the discretion of our board of directors and will depend on, among other things, our results of operations, financial condition, cash requirements, contractual restrictions and other factors that our board of directors may deem relevant. As a result, you may not receive any return on an investment in our common stock unless you sell our common stock for a price greater than that which you paid for it.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU65"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our by-laws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our </font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or stockholders.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our by-laws provide that the Court of Chancery of the State of Delaware is the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our certificate of incorporation or our by-laws, or any action asserting a claim against us that is governed by the internal affairs doctrine. The choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, other employees or stockholders (including beneficial owners), which may discourage such lawsuits against us and our directors, officers, other employees or stockholders (including beneficial owners). Alternatively, if a court were to find the choice of forum provision contained in our by-laws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160; 2.</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT"></a><a name="ITEM_2_UNREGISTERED_SALES_EQUITY"></a><a name="ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT"></a><a name="ITEM_2_UNREGISTERED_SALES_EQUITY"></a>Unregistered Sales of Equity Securities and Use of Proceeds</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Proceeds from Registered Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February&#160;17, 2016, we closed the sale of 6,250,000 shares of common stock to the public at an initial public offering price of $8.00 per share. The offer and sale of the shares in the IPO were registered under the Securities Act pursuant to a registration statement on Form S-1 (File No.&#160;333-208735), which was filed with the SEC on December&#160;23, 2015 and amended subsequently and declared effective on February&#160;10, 2016. The underwriters of the offering were Leerink Partners and RBC Capital Markets, acting as joint book-running managers for the offering and as representatives of the underwriters. Baird and H.C. Wainwright&#160;&amp; Co. acted as co-managers for the offering. We raised approximately $42.5 million in net proceeds in the IPO after deducting underwriting discounts and commissions of approximately $3.5 million and other offering expenses of $4.0 million. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates. There has been no material change in the planned use of proceeds from our initial public offering as described in our final prospectus filed with the SEC pursuant to Rule 424(b) of the Securities Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160; 3.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Defaults Upon Senior Securities</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160; 4.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a>Mine Safety Disclosures</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160; 5.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_5_OR_INFORMATION"></a><a name="ITEM_5_OR_INFORMATION"></a>Other Information</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160; 6.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU66"></a><a name="ITEM_6_EXHIBITS"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_6_EXHIBITS"></a></font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibits</font></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The exhibits filed as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, which is incorporated herein by reference.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="7" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Description</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File No.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing Date</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;3.1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1445283/000119312516445113/d918922dex32.htm"><font style="text-decoration:underline;">Fifth Amended and Restated Certificate of Incorporation of the Company.</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-208735</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 1, 2016</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;3.2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1445283/000119312516445113/d918922dex34.htm"><font style="text-decoration:underline;">Second Amended and Restated By-laws of the Company.</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-208735</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 1, 2016</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1445283/000119312516445113/d918922dex41.htm"><font style="text-decoration:underline;">Specimen Common Stock Certificate.</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-208735</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 1, 2016</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1445283/000119312516445113/d918922dex42.htm"><font style="text-decoration:underline;">Third Amended and Restated Stockholders&#8217; Agreement of the Company.</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-208735</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 1, 2016</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1445283/000119312515412641/d918922dex43.htm"><font style="text-decoration:underline;">Form of Preferred Stock Warrant.</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-208735</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December&#160;23,&#160;2015</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1445283/000119312517242441/d433246dex101.htm"><font style="Background-color:#FFFFFF;text-decoration:underline;">Employment Agreement between the Company and Helen Boudreau, dated as of July&#160;25, 2017.</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37695</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 31, 2017</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk496109856"></a>&#160;&#160;10.2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="pti-ex102_127.htm"><font style="text-decoration:underline;">Lease Between the Company, as Tenant, and Ice Box, LLC, as Landlord, dated as of September 19, 2017.</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filed herewith</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;31.1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="pti-ex311_7.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer pursuant to Exchange Act rules&#160;13a-14 or 15d-14.</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filed herewith</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;31.2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="pti-ex312_6.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer pursuant to Exchange Act rules&#160;13a-14 or 15d-14.</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filed herewith</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;32.1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="pti-ex321_8.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section&#160;1350.</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furnished herewith</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Instance Document.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filed herewith</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Schema Document.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filed herewith</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Calculation Document.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filed herewith</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Definition Linkbase Document.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filed herewith</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Labels Linkbase Document.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filed herewith</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Presentation Link Document.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filed herewith</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU67"></a><a name="SIGNATURES"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a>SIGNA</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TURES</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:12pt;">
<td valign="middle"  style="width:54.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="middle"  style="width:43.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PROTEOSTASIS THERAPEUTICS,&#160;INC.</p></td>
</tr>
<tr>
<td valign="middle"  style="width:54.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:2.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:39.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:54.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: November 14, 2017</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:2.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:39.84%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Meenu Chhabra&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:54.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:2.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:39.84%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Meenu Chhabra</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:54.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:2.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:39.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
<tr>
<td valign="top"  style="width:54.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: November 14, 2017</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:2.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:39.84%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Helen M. Boudreau&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:54.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:2.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:39.84%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Helen M. Boudreau</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:54.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:2.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:39.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer)</p></td>
</tr>
<tr>
<td valign="middle"  style="width:54.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:2.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:39.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:54.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: November 14, 2017</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:2.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:39.84%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Brett Hagen&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:54.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:2.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:39.84%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brett Hagen</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:54.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:2.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:39.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President of Finance</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>pti-ex102_127.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
pti-ex102_127.htm
</title>
</head>
<!-- NG Converter v4.0.8.13 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Exhibit 10.2</font><font style="font-weight:normal;"> </font></p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:15pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">LEASE</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:15pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">BETWEEN</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:15pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">PROTEOSTASIS THERAPEUTICS, INC., AS TENANT</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:15pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">AND</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:15pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">ICE BOX, LLC, AS LANDLORD</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:15pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">80 <font style="font-family:Times New Roman Bold;font-variant: small-caps;">Guest Street, Brighton, ma</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/81213857.2<font style="margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF CONTENTS</font></p>
<p style="text-align:right;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">PAGE</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 1 BASIC DATA; DEFINITIONS</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">1</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.1</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Basic Data</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">1</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.2</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Additional Definitions</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">4</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.3</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Enumeration of Exhibits</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">7</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 2 PREMISES AND APPURTENANT RIGHTS</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">7</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.1</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Lease of Premises</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">7</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.2</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Appurtenant Rights and Reservations</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">7</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.3</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Parking</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">9</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.4</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Shuttle Service</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">11</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 3 BASIC RENT</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">11</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.1</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Payment</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">.11</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 4 CONDITION OF PREMISES</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">12</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4.1</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Condition of Premises; Initial Improvements</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">12</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 5 USE OF PREMISES</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">12</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.1</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Permitted Use</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">12</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.2</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Installations and Alterations by Tenant</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">.15</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.3</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Extra Hazardous Use</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">18</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.4</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Hazardous Materials</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">.19</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 6 ASSIGNMENT AND SUBLETTING</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">22</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.1</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Prohibition</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">.22</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.2</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Landlord&#8217;s Consent</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">23</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.3</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Acceptance of Rent</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">25</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.4</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Excess Payments</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">26</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.5</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Landlord&#8217;s Recapture Right</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">26</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.6</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Further Requirements</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">26</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 7 RESPONSIBILITY FOR REPAIRS AND CONDITION OF PREMISES; SERVICES TO BE FURNISHED BY LANDLORD</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">27</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.1</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Landlord Repairs</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">.27</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.2</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Tenant Repairs; Compliance with Laws</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">.28</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.3</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Floor Load &#8209; Heavy Machinery</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">.29</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.4</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Utility Services</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">.29</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.5</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Other Services</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">.31</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.6</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Interruption of Service</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">31</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 8 REAL ESTATE TAXES</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">36</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.1</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Payments on Account of Real Estate Taxes</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">.36</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.2</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Abatement</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">37</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 9 BUILDING OPERATING EXPENSES AND LABORATORY OPERATING EXPENSES</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.1</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Definitions</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">38</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.2</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Tenant&#8217;s Payment of Operating Expenses</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">.39</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 10 INDEMNITY AND PUBLIC LIABILITY INSURANCE</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">40</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10.1</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Tenant&#8217;s Indemnity</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">40</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10.2</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Tenant Insurance</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">40</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10.3</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Tenant&#8217;s Risk</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">42</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10.4</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Landlord&#8217;s Insurance</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">43</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10.5</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Waiver of Subrogation</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">43</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 11 FIRE, EMINENT DOMAIN, ETC.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">44</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11.1</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Landlord&#8217;s Right of Termination</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">44</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11.2</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Restoration; Tenant&#8217;s Right of Termination</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">44</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11.3</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Abatement of Rent</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">45</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11.4</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Eminent Domain</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">46</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 12 HOLDING OVER; SURRENDER</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">47</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.1</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Holding Over</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">47</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.2</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Surrender of Premises</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">47</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 13 RIGHTS OF MORTGAGEES; TRANSFER OF TITLE</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">48</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13.1</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Rights of Mortgagees or Ground Lessor</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">.48</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13.2</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Assignment of Rents and Transfer of Title</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">.49</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13.3</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Notice to Mortgagee</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">50</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 14 DEFAULT; REMEDIES</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">50</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14.1</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Tenant&#8217;s Default</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">.50</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14.2</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Landlord&#8217;s Remedies</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">.52</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14.3</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Additional Rent</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">56</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14.4</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Remedying Defaults</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">56</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14.5</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Remedies Cumulative</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">56</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14.6</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Enforcement Costs</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">56</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14.7</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Waiver</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">.56</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14.8</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Security Deposit</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">57</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14.9</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Landlord&#8217;s Default</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">62</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14.10</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Independent Covenants</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">62</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 15 MISCELLANEOUS PROVISIONS</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">62</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.1</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Landlord&#8217;s Rights of Access</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">62</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.2</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Covenant of Quiet Enjoyment</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">63</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.3</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Landlord&#8217;s Liability</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">.63</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.4</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Estoppel Certificate</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">64</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.5</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Brokerage</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">64</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.6</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Rules and Regulations</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">64</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.7</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Financial Statements</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">65</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.8</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-size:12pt;font-family:Times New Roman;"></font><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Substitute Space</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">65</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.9</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Confidentiality</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">65</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.10</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Invalidity of Particular Provisions; Saving Clause</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">65</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.11</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Provisions Binding, Etc</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">66</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.12</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Recording</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">66</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.13</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Notice</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">66</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.14</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Authority</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">67</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.15</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">When Lease Becomes Binding; Entire Agreement; Modification</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">67</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.16</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Paragraph Headings and Interpretation of Sections</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">67</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.17</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Joint and Several Liability; Successors and Assigns</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">67</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.18</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Waiver of Jury Trial</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">68</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.19</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Reservation</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">68</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.20</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Prohibited Persons and Transactions</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">68</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.21</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Time Is of the Essence</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">69</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.22</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Multiple Counterparts; Entire Agreement</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">69</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.23</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-weight:normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Governing Law</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">69</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Exhibit 10.2</font><font style="font-weight:normal;"> </font></p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:15pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-weight:bold;font-size:15pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">L E A S E</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIS LEASE is dated as of September 19, 2017 (the &#8220;<font style="font-weight:bold;">Effective Date</font>&#8221;), between the Landlord and the Tenant named below, and is of space in the Building described below.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">ARTICLE 1</font><font style="text-decoration:underline;"><br />BASIC DATA; DEFINITIONS</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Basic Data</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.<font style="font-weight:normal;">&nbsp;&nbsp;Each reference in this Lease to any of the following terms shall be construed to incorporate the data for that term set forth in this Section:</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Landlord<font style="font-weight:normal;">:&nbsp;&nbsp;ICE BOX, LLC, a Massachusetts limited liability company</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Landlord&#8217;s Notice Address<font style="font-weight:normal;">: c/o NB Development Group, 221 N. Beacon Street, Brighton, MA 02135, Attn: James Halliday</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Landlord&#8217;s Payment Address<font style="font-weight:normal;">: </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.08%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By Wire:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.08%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bank:&#160; </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.08%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ABA#:&#160; </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.08%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Account# :&#160; </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.08%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Account Name:&#160; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.08%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By Mail:</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:14.74%;"><font style="margin-left:36pt;">Ice Box LLC</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.08%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">221 North Beacon Street</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.08%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brighton, MA&#160; 02135</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.08%;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tenant<font style="font-weight:normal;">: PROTEOSTASIS THERAPEUTICS, INC., a Delaware corporation</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tenant&#8217;s Notice Address:<font style="font-weight:normal;margin-left:36pt;">(a)&nbsp;&nbsp;Prior to the Tenant Occupancy Date:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><a name="_cp_text_1_2"></a><font style="margin-left:36pt;">Proteostasis Therapeutics, Inc.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><a name="_cp_text_1_3"></a><font style="margin-left:36pt;">200 Technology Sq.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><a name="_cp_text_1_4"></a><font style="margin-left:36pt;">4th Floor</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><a name="_cp_text_1_5"></a><font style="margin-left:36pt;">Cambridge, MA 02139 </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><a name="_cp_text_1_6"></a><font style="margin-left:36pt;">Attn: </font>Chief Financial Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">With Copies to: </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.08%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_12"></a>Brown Rudnick LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.08%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_13"></a>One Financial Center</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.08%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_14"></a>Boston, MA 02111</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.08%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_15"></a>Attn: Jeffrey A. Huebschmann, Esq.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:30.77%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)&nbsp;&nbsp;After the Tenant Occupancy Date:</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><a name="_cp_text_1_18"></a><font style="margin-left:36pt;">Proteostasis Therapeutics, Inc.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><a name="_cp_text_1_19"></a><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"></font><font style="margin-left:36pt;"></font><font style="margin-left:36pt;"></font><font style="margin-left:36pt;">80 Guest Street</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><a name="_cp_text_1_20"></a><font style="margin-left:36pt;">Brighton, MA 02135 </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><a name="_cp_text_1_21"></a><font style="margin-left:36pt;">Attn: </font>Chief Financial Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Guarantor<font style="font-weight:normal;">: None.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property<font style="font-weight:normal;">:&nbsp;&nbsp;The land located in Brighton, Massachusetts</font><font style="font-style:italic;font-weight:normal;"> </font><font style="font-weight:normal;">together with the buildings and other improvements thereon known as 80 Guest Street, Brighton, Massachusetts 02135 located in the Complex and referred to as &#8220;C3 Parcel&#8221; on the site plan attached hereto as </font><font style="text-decoration:underline;">Exhibit B</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Building<font style="font-weight:normal;">:&nbsp;&nbsp;The multi-story, mixed use building on the Property and containing approximately 246,405 rentable square feet (exclusive of the Rink Building), as the same may be altered, expanded, reduced or otherwise changed by Landlord from time to time.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_24"></a>Premises<font style="font-weight:normal;"><a name="_cp_text_1_24"></a>:&nbsp;&nbsp;Agreed to be 29,836 rentable square feet consisting of the entire fifth (5<sup style="font-size:85%; vertical-align:top">th</sup>) floor of the Building and approximately as shown on the location plan attached hereto as </font><font style="text-decoration:underline;">Exhibit&#160;A</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basic Rent<font style="font-weight:normal;">:&nbsp;&nbsp;The Basic Rent, net of all Additional Rent, is as follows:</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:468.35pt;;">
<tr>
<td style="width:171.35pt;"></td>
<td style="width:90pt;"></td>
<td style="width:112.5pt;"></td>
<td style="width:94.5pt;"></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RENTAL PERIOD</p></td>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RENTAL RATE PER RSF</p></td>
<td valign="bottom"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ANNUAL BASIC RENT</p></td>
<td valign="bottom"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MONTHLY PAYMENT</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First Lease Year</p></td>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$55.50</p></td>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1,655,898.00</p></td>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$137,991.50</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Second Lease Year</p></td>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$57.03</p></td>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1,701,547.08</p></td>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$141,795.59</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third Lease Year </p></td>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$58.60</p></td>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1,748,389.60</p></td>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$145,699.13</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fourth Lease Year</p></td>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$60.21</p></td>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1,796,425.56</p></td>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$149,702.13</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fifth Lease Year</p></td>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$61.87</p></td>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1,845,953.32</p></td>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$153,829.44</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sixth Lease Year</p></td>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$63.57</p></td>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1,896,674.52</p></td>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$158,056.21</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Seventh Lease Year</p></td>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$65.32</p></td>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1,948,887.52</p></td>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$162,407.29</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eighth Lease Year</p></td>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$67.12</p></td>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2,002,592.32</p></td>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$166,882.69</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ninth Lease Year</p></td>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$68.97</p></td>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2,057,788.92</p></td>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$171,482.41</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenth Lease Year</p></td>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$70.87</p></td>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2,114,477.32</p></td>
<td valign="top"  style="padding-left:6pt;padding-Right:6pt; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$176,206.44</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease Year<font style="font-weight:normal;">:&nbsp;&nbsp;Each period of twelve (12) consecutive months, commencing on the Rent Commencement Date and each successive twelve (12) month period, except that if the Rent Commencement Date shall occur on a date other than the first day of a month, then the first Lease Year shall include the period from the Rent Commencement Date to the first day of the following month and the twelve (12) calendar months thereafter.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_28"></a><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>Commencement Date<font style="font-weight:normal;"><a name="_cp_text_1_28"></a>:&nbsp;&nbsp;</font> <font style="font-weight:normal;">The Substantial Completion Date of Landlord&#8217;s Work as provided in </font><font style="text-decoration:underline;">Exhibit C</font><font style="font-weight:normal;">.&nbsp;&nbsp;Notwithstanding the foregoing, if Tenant&#8217;s personnel shall occupy all or any part of the Premises for the conduct of its business prior to the Commencement Date as determined pursuant to the preceding sentence, such date of occupancy shall, for all purposes of </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">this Lease, be the Commencement Date.&nbsp;&nbsp;Promptly upon the occurrence of the Commencement Date, Landlord and Tenant shall execute and deliver a letter designating the Commencement Date substantially in the form attached hereto as </font><font style="text-decoration:underline;">Exhibit&#160;E</font><font style="font-weight:normal;">, but the failure by either party to execute and deliver such a letter shall have no effect on the Commencement Date, as hereinabove determined.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rent Commencement Date<font style="font-weight:normal;">:&nbsp;&nbsp;The earliest date to occur of (i) April 15, 2018 (subject to extension pursuant to Section 7 of </font><font style="text-decoration:underline;">Exhibit C</font><font style="font-weight:normal;"> to this Lease), or (ii) the date Tenant has commenced occupancy of any portion of the Premises for the conduct of business.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tenant&#8217;s Pro Rata Share of the Office Portion<font style="font-weight:normal;">:&nbsp;&nbsp;For purposes of calculating Tenant&#8217;s payments with respect to Taxes and Building Operating Expenses, Tenant&#8217;s Pro Rata Share shall mean the fraction, expressed as a percentage, the numerator of which shall be the rentable square feet in the Premises and the denominator of which shall be total rentable square feet of the Office Portion of the Building.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tenant&#8217;s Laboratory Share<font style="font-weight:normal;">:&nbsp;&nbsp;For purposes of calculating Tenant&#8217;s payments with respect to the Laboratory Operating Expenses associated with the Laboratory Portion of the Premises, Tenant&#8217;s Laboratory Share shall mean the fraction, expressed as a percentage, the numerator of which shall be the rentable square feet of the Premises designed for laboratory use (as determined based on Tenant&#8217;s final as-built interior laboratory construction plans for the Premises approved by Landlord) and the denominator of which shall be total rentable square feet of the Laboratory Portion of the Building.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_37"></a>Letter of Credit<font style="font-weight:normal;"><a name="_cp_text_1_37"></a>:&nbsp;&nbsp;One Million Six Hundred Fifty Five Thousand Eight Hundred Ninety Eight and 00/100 Dollars (</font>$1,655,898.00<font style="font-weight:normal;">) to be held, disposed of and reduced as provided in </font>Section&#160;14.8<font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_40"></a>Term<font style="font-weight:normal;"><a name="_cp_text_1_40"></a>:&nbsp;&nbsp;The period commencing on the Commencement Date and expiring at 12:00 a.m. on the tenth (10<sup style="font-size:85%; vertical-align:top">th</sup>) anniversary of the Rent Commencement Date, except that if the Rent Commencement Date is other than the first day of a calendar month, the expiration of the Term shall be at the close of the last day of the calendar month in which such anniversary falls.&nbsp;&nbsp;The Term shall include any extension thereof that is expressly provided for by this Lease and that is effected strictly in accordance with this Lease; if no extension of the Term is expressly provided for by this Lease, no right to extend the Term shall be implied by this provision.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Initial Commercial General Liability Insurance<font style="font-weight:normal;">:&nbsp;&nbsp;$3,000,000 per occurrence/ $5,000,000 aggregate (combined single limit) for property damage, bodily injury or death.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_42"></a>Permitted Use<font style="font-weight:normal;"><a name="_cp_text_1_42"></a>:&nbsp;&nbsp;The Premises are to be used and occupied by Tenant solely for the purpose of general office and research and development uses, including a biotechnical and Uniform Building Code (&#8220;</font>UBC<font style="font-weight:normal;">&#8221;) &#8220;B&#8221; laboratory use (provided that no laboratory classified as a BSL-3 or BSL-4 or a UBC &#8220;H&#8221; use shall be permitted).&nbsp;&nbsp;The use of the Premises shall be in conformity with all applicable Laws, including any hazardous waste or medical waste rules and regulations promulgated by Landlord or any applicable governmental authority.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><a name="_cp_text_1_47"></a><a name="_cp_text_1_49"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Landlord&#8217;s Contribution</font><font style="font-weight:normal;"><a name="_cp_text_1_47"></a>:&nbsp;&nbsp;An amount equal to $160.00 per </font><font style="font-weight:normal;">rentable </font><font style="font-weight:normal;"><a name="_cp_text_1_49"></a>square foot </font><font style="font-weight:normal;">of the Premises for a total of Four Million Seven Hundred Seventy Three Thousand Seven Hundred Sixty and 00/100 Dollars ($4,773,760.00)</font><font style="font-weight:normal;">.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Office Portion:<font style="font-weight:normal;">&nbsp;&nbsp;That portion of the Building located at and above the ground floor of the Building which is programmed for and serving office uses (i.e. excluding the Parking Garage and the Laboratory Portion and Retail Portion).&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Retail Portion:<font style="font-weight:normal;">&nbsp;&nbsp;The portion of the Building located on the ground floor (i.e. excluding the Parking Garage, the Laboratory Portion and the Office Portion).</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Laboratory Portion<font style="font-weight:normal;">:&nbsp;&nbsp;That portion of floors four (4), five (5) and six (6) of the Building which is leased to tenants for laboratory uses (i.e., excluding the Parking Garage, the Office Portion and the Retail Portion).&nbsp;&nbsp;The Laboratory Portion shall initially be designated as fifty percent (50%) of the floor area on each of floors four (4), five (5) and six (6) of the Building, subject to adjustment based upon final as-built tenant construction plans for those floors in the Building. </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rink Building<font style="font-weight:normal;">:&nbsp;&nbsp;The portion of the connected buildings on the Property that contains the hockey rink and which consists of the ice area, boards, benches and entries thereto.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Parking Garage:<font style="font-weight:normal;">&nbsp;&nbsp;The three-level, podium style parking garage at the Property. </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_53"></a>Complex:<font style="font-weight:normal;"><a name="_cp_text_1_53"></a>&nbsp;&nbsp;The Building, Parking Garage and the adjacent building on the Property referred to as the &#8220;Rink Building,&#8221; and all common areas and other improvements now or hereafter constructed on the Property, as the same may be altered, expanded, reduced or otherwise changed from time to time, subject to the terms and conditions of this Lease.</font> </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Boston Landing Project:&nbsp;&nbsp;<font style="font-weight:normal;">That certain development project known as &#8220;Boston Landing,&#8221; containing the Complex and the additional parcels of land (together with all buildings, structures and other improvements constructed or to be constructed from time to time thereon) shown on the site plan attached hereto as </font><font style="text-decoration:underline;">Exhibit B</font><font style="font-weight:normal;">.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comparable Buildings:<font style="font-weight:normal;"> Shall mean first class, mixed use office and laboratory buildings in the greater Boston area (including, but not limited to, the Boston Landing Project) which have services, systems and facilities comparable to the Building.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_58"></a><a name="_cp_text_1_60"></a>Declaration<font style="font-weight:normal;"><a name="_cp_text_1_58"></a>:&nbsp;&nbsp;That certain Declaration of Covenants, Easements and Restrictions for Boston Landing Boston (Brighton), Massachusetts, dated as of April 14, 2016 and recorded with the Suffolk County Registry of Deeds in Book&#160;55999, Page&#160;85, as the same may be further amended from time to time.<a name="_cp_text_1_60"></a>  Landlord represents and warrants to Tenant that the Declaration is in full force and effect, and Landlord is not in default in the performance of its obligations under the Declaration, and that this Lease shall not be subject to any future amendments which (i) are inconsistent with any of Tenant&#8217;s express rights under this Lease, (ii) which materially adversely affect the use and occupancy of the Premises by Tenant, or (iii) increase any obligations of Tenant as under the Lease (other than to a de minimis extent).</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a><font style="text-decoration:underline;">Additional Definitions</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;When used in Lease, the capitalized terms set forth below shall bear the meanings set forth below.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adequate Assurance<font style="font-weight:normal;">: As defined in </font>Section&#160;14.1<font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adequate Assurance of Future Performance<font style="font-weight:normal;">:&nbsp;&nbsp;As defined in </font>Section&#160;14.1<font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional Rent<font style="font-weight:normal;">:&nbsp;&nbsp;All charges and sums payable by Tenant as set forth in this Lease, other than and in addition to Basic Rent.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Affiliate<font style="font-weight:normal;">:&nbsp;&nbsp;With respect to Landlord or Tenant, as the case may be, a Person or Persons directly or indirectly, through one or more intermediaries, controlling, controlled by or under common control with Landlord or Tenant.&nbsp;&nbsp;The term &#8220;control&#8221; as used in the immediately preceding sentence, means, with respect to a Person that is a corporation, the right to exercise, directly or indirectly, more than fifty percent (50%) of the voting rights attributable to the shares of the controlled corporation and, with respect to a Person that is not a corporation, the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of the controlled Person.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Alterations<font style="font-weight:normal;">:&nbsp;&nbsp;As defined in </font>Section&#160;5.3<font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Bankruptcy Code<font style="font-weight:normal;">:&nbsp;&nbsp;As defined in </font>Section&#160;14.1<font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_67"></a><a name="_cp_text_1_68"></a>Base Building:<font style="font-weight:normal;"><a name="_cp_text_1_67"></a>&nbsp;&nbsp;Shall mean all of the Structural Elements (as hereinafter defined) of the Building, the roof and roof membrane<a name="_cp_text_1_68"></a>, the common building and core facilities of the Building, and the Base Building Systems (as hereinafter defined) serving the Building, but shall not include any Improvements relating to the Premises (whether existing or constructed by Landlord or Tenant), Alterations, the distribution portions of Base Building Systems which exclusively serve the Premises (whether located in the Premises or other areas of the Building), or other fixtures or personal property installed by or on behalf of Tenant or any party claiming by, through or under Tenant.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a>Laboratory Systems<font style="font-weight:normal;">: Shall mean the HVAC system (including outside air handling units, chiller and exhaust fans and risers), laboratory waste water system, the laboratory exhaust facilities and equipment (including the laboratory exhaust energy recovery unit and exhaust riser), boilers, and hot water and chilled water distribution systems (including pumps and risers), electrical panel and facilities, water heaters and risers, fire protection and suppression system for the laboratory areas, water service to the Chemical Storage Room, louvers and mechanical rooms serving the Laboratory Portion, and other common service systems exclusively serving the Laboratory Portion of the Building and whether or not such Laboratory Systems are shared (or capable of being shared) by tenants or other occupants of the Laboratory Portion of the Building.&nbsp;&nbsp;As of the Commencement Date, the Laboratory Systems include, without limitation, the following: (i) ph Neutralization Tank (as hereinafter defined) and ph Neutralization room, (ii) RO/DI, (iii) vacuum equipment and compressed air, (iv) laboratory waste water treatment system, (v) Chemical Storage Room, (vi) laboratory venting equipment and systems (including central exhaust unit supply and exhaust ductwork), (vii) air handling units (for supply air) on floors four (4), five (5) and six (6) of the Building, (viii) laboratory exhaust energy recovery unit, including a new exhaust riser for the Laboratory Portion, (ix) an air chiller to accommodate </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">laboratory loads, (x) two (2) boilers and hot water distribution for on-floor laboratory use, (xi) chilled water distribution for on-floor laboratory and future connections for laboratory floor supplemental cooling for the Laboratory Portion, and (xii) water heaters and risers for non-potable and tempered water loop</font><font style="font-weight:normal;">. </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_75"></a>Base Building Systems:<font style="font-weight:normal;"><a name="_cp_text_2_75"></a>&nbsp;&nbsp;Shall mean the mechanical, gas, electrical, sanitary, heating, air conditioning, ventilating, elevator, plumbing, fire control and suppression, sprinkler/life safety and security systems (to the extent installed by Landlord, exclusive of any security system installed exclusively for Tenant) and other common service systems of the Building, excluding the Laboratory Systems.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Brokers<font style="font-weight:normal;">:&nbsp;&nbsp;Transwestern Consulting Group.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Building Operating Expenses<font style="font-weight:normal;">:&nbsp;&nbsp;As defined in </font>Section&#160;9.1<font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Business Day<font style="font-weight:normal;">:&nbsp;&nbsp;All days except Saturdays, Sundays, New Year&#8217;s Day, Martin Luther King Day, Memorial Day, Presidents Day, Independence Day, Labor Day, Columbus Day, Veteran&#8217;s Day, Thanksgiving Day, Christmas Day (and the following day when any such day occurs on Sunday and the prior day when any such day occurs on a Saturday).</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Facilities<font style="font-weight:normal;">: As defined in </font>Section&#160;2.2<font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Default Interest Rate<font style="font-weight:normal;">: As defined in </font>Section 3.1(a)<font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_76"></a>Emergency:<font style="font-weight:normal;"> Any threat of immediate injury or damage to persons or property or the immediate imposition of a civil or criminal fine or penalty.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Environmental Laws<font style="font-weight:normal;">:&nbsp;&nbsp;Any federal, state and/or local statute, ordinance, bylaw, code, rule and/or regulation now or hereafter enacted, pertaining to any aspect of the environment or human health, including, without limitation, Chapter 21C, Chapter 21D, and Chapter 21E of the General Laws of Massachusetts and the regulations promulgated by the Massachusetts Department of Environmental Protection, the Comprehensive Environmental Response, Compensation and Liability Act of 1980, 42 U.S.C. &#167; 9601 </font><font style="font-style:italic;font-weight:normal;">et seq.,</font><font style="font-weight:normal;"> the Resource Conservation and Recovery Act of 1976, 42 U.S.C. &#167; 6901 </font><font style="font-style:italic;font-weight:normal;">et seq.,</font><font style="font-weight:normal;"> the Toxic Substances Control Act, 15 U.S.C. &#167;2061 </font><font style="font-style:italic;font-weight:normal;">et seq., </font><font style="font-weight:normal;">the Federal Clean Water Act, 33 U.S.C. &#167;1251, and the Federal Clean Air Act, 42 U.S.C. &#167;7401 </font><font style="font-style:italic;font-weight:normal;">et seq</font><font style="font-weight:normal;">. </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expense Charges<font style="font-weight:normal;">: The Additional Rent payable by Tenant pursuant to </font>Article&#160;8<font style="font-weight:normal;"> and </font>Article&#160;9<font style="font-weight:normal;"> of this Lease.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Event of Bankruptcy<font style="font-weight:normal;">:&nbsp;&nbsp;As defined in </font>Section&#160;14.1<font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Event of Default<font style="font-weight:normal;">:&nbsp;&nbsp;As defined in </font>Section&#160;14.1<font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a>Force Majeure<font style="font-weight:normal;">:&nbsp;&nbsp;Collectively and individually, strikes, lockouts or other labor trouble, fire or other casualty, acts of God, governmental preemption of priorities or other controls in connection with a national or other public emergency or shortages of fuel, supplies or labor resulting therefrom, unusually adverse weather conditions, fire or other casualty, acts of </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">terrorism or bioterrorism, civil commotion, or any other cause, whether similar or dissimilar, beyond the reasonable control of the party required to perform an obligation.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holder<font style="font-weight:normal;">: As defined in </font>Section&#160;13.1<font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hazardous Materials<font style="font-weight:normal;">:&nbsp;&nbsp;Shall mean chemicals, contaminants, pollutants, flammables, explosives, materials, wastes or other substances listed, defined, determined or identified as hazardous or toxic under, or regulated by reason of its impact or potential impact on humans, animals and/or the environment under any Environmental Laws or otherwise controlled pursuant to any Environmental Laws, including, without limitation, any &#8220;oil,&#8221; &#8220;hazardous material,&#8221; &#8220;hazardous waste,&#8221; &#8220;hazardous substance&#8221; or &#8220;chemical substance or mixture&#8221;, as the foregoing terms (in quotations) are defined in any Environmental Laws.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Improvements<font style="font-weight:normal;">: As defined in </font>Section 10.2<font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Laboratory Operating Expenses<font style="font-weight:normal;">:&nbsp;&nbsp;As defined in </font>Section&#160;9.1<font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Land<font style="font-weight:normal;">:&nbsp;&nbsp;The land that constitutes a portion of the Property.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Landlord&#8217;s Restoration Work<font style="font-weight:normal;">:&nbsp;&nbsp;As defined in </font>Section&#160;11.2<font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Landlord&#8217;s Work<font style="font-weight:normal;">:&nbsp;&nbsp;As defined in </font><font style="text-decoration:underline;">Exhibit C</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Laws<font style="font-weight:normal;">:&nbsp;&nbsp;All present and future statutes, laws, codes, regulations, ordinances, orders, rules, bylaws, administrative guidelines, requirements, directives and actions of any federal, state or local governmental or quasi-governmental authority, and other legal requirements of whatever kind or nature that are applicable to the Property, Landlord or Tenant, including, without limitation, all Environmental Laws and the Americans With Disabilities Act of 1990 (including the Americans With Disabilities Act Accessibility Guidelines for Buildings and Facilities), and any amendments, modifications or changes to any of the foregoing.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Mortgage<font style="font-weight:normal;">:&nbsp;&nbsp;As defined in </font>Section&#160;13.1<font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Year<font style="font-weight:normal;">:&nbsp;&nbsp;As defined in </font>Section&#160;9.1<font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_80"></a>Original Tenant<font style="font-weight:normal;"><a name="_cp_text_1_80"></a>: the originally named Tenant, Proteostasis Therapeutics, Inc., a Delaware corporation</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Person<font style="font-weight:normal;">:&nbsp;&nbsp;A natural person, a partnership, a joint venture, a corporation, a limited liability company, a trust and any other form of business or legal association or entity.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recapture Date<font style="font-weight:normal;">:&nbsp;&nbsp;As defined in </font>Section&#160;6.4<font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rules and Regulations<font style="font-weight:normal;">:&nbsp;&nbsp;As defined in </font>Section&#160;2.2<font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Specified Restoration Work<font style="font-weight:normal;">:&nbsp;&nbsp;As defined in </font>Section&#160;11.2<font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a><a name="_cp_text_1_83"></a>Structural Elements<font style="font-weight:normal;">:&nbsp;&nbsp;Shall mean the structural (i.e., load bearing) components of the Building, including the roof (including the roof membrane, insulation and decking), and the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;"><a name="_cp_text_1_83"></a>footings, foundations, exterior structural walls, interior structural columns and other load-bearing elements of the Building</font><font style="font-weight:normal;"> (including without limitation floor slabs)</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Substantial Completion Date<font style="font-weight:normal;">:&nbsp;&nbsp;As defined in </font><font style="text-decoration:underline;">Exhibit C</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Successor<font style="font-weight:normal;">:&nbsp;&nbsp;As defined in </font>Section&#160;13.1<font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tangible Net Worth<font style="font-weight:normal;">:&nbsp;&nbsp;Shall mean total assets minus intangible assets (including, without limitation, goodwill, patents and copyrights) and total liabilities, all as calculated in accordance with generally accepted accounting principles.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Taxes<font style="font-weight:normal;">:&nbsp;&nbsp;As defined in </font>Section&#160;8.1<font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tax Year<font style="font-weight:normal;">:&nbsp;&nbsp;As defined in </font>Section&#160;8.1<font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tenant Delay<font style="font-weight:normal;">:&nbsp;&nbsp;As defined in </font><font style="text-decoration:underline;">Exhibit C</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tenant&#8217;s Removable Property<font style="font-weight:normal;">:&nbsp;&nbsp;As defined in </font>Section&#160;5.3<font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tenant&#8217;s Restoration Work<font style="font-weight:normal;">:&nbsp;&nbsp;As defined in </font>Section&#160;11.2<font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Enumeration of Exhibits</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;The following Exhibits are a part of this Lease, are incorporated herein by reference attached hereto, and are to be treated as a part of this Lease for all purposes.&nbsp;&nbsp;Undertakings contained in such Exhibits are agreements on the part of Landlord and Tenant, as the case may be, to perform the obligations stated therein.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;margin-right:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit A - Location Plan of the Premises</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;margin-right:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit B &#8211; Site Plan of Boston Landing Project</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;margin-right:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit C &#8211; Landlord&#8217;s Work Letter</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;margin-right:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit D &#8211; Tenant&#8217;s Work Letter</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;margin-right:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit E - Commencement Date Letter</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;margin-right:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit F &#8211; Building Operating Expenses and Laboratory Operating Expenses</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;margin-right:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit G - Rules and Regulations</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;margin-right:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit H &#8211; Form of Letter of Credit</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;margin-right:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit I &#8211; Tenant&#8217;s Removable Property</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;margin-right:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit J &#8211; HVAC Specifications</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;margin-right:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">ARTICLE 2</font><font style="text-decoration:underline;"><br />PREMISES AND APPURTENANT RIGHTS</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Lease of Premises</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Landlord hereby leases to Tenant and Tenant hereby leases from Landlord the Premises for the Term and upon the terms and conditions hereinafter set forth.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appurtenant Rights and Reservations</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a><a name="_cp_text_1_84"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant shall have, as appurtenant to the Premises, the non</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;exclusive right to use, and permit its invitees to use in common with Landlord and others, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> public or common lobbies, hallways, stairways, elevators and common walkways necessary for access to the Building and the Premises; </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the loading areas, pedestrian sidewalks, landscaped areas, trash enclosures and other areas or facilities, if any, serving the Building and designated by Landlord from time to time for the non</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;exclusive use of tenants and other occupants of the Building, including, without limitation, the podium area of the Building (the </font><font style="font-weight:bold;">&#8220;Common Facilities&#8221;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_84"></a>); and (iii) subject to the terms of this Lease, the Laboratory Systems; but such rights shall always be subject to reasonable rules and regulations from time to time established by Landlord </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and uniformly enforced against all laboratory tenant and occupants of the Building, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pursuant to </font><font style="font-weight:bold;">Section&#160;15.7</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (the </font><font style="font-weight:bold;">&#8220;Rules and Regulations&#8221;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) and to the right of Landlord to designate and change from time to time such areas and facilities so to be used.&nbsp;&nbsp;Subject to applicable Laws and the terms and conditions of the Declaration (including the Boston Landing Rules and Regulations), Tenant shall have, as appurtenant to the Premises, the non</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;exclusive right, in common with Landlord and others entitled thereto, to use, and to permit its invitees to use, the Common Areas and Facilities (as defined in the Declaration) of the Boston Landing Project.&nbsp;&nbsp;Notwithstanding anything in this Lease to the contrary, Landlord shall not during the Term reduce access to, reconfigure, or otherwise modify the Common Facilities in a manner that unreasonably interferes with Tenant&#8217;s use and enjoyment of, and access to, the Premises.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_86"></a><a name="_cp_text_1_88"></a>(b)<font style="margin-left:36pt;"></font><a name="_cp_text_2_86"></a>Excepted and excluded from the Premises and the Common Facilities are the floor slab, demising walls and perimeter walls and exterior windows (except the inner surfaces of each thereof), and any space in the Premises used for shafts, stacks, pipes, conduits, fan rooms, ducts, electric or other utilities, sinks or other Building facilities, but the entry doors (and related glass and finish work) to the Premises are a part thereof.&nbsp;&nbsp;Landlord shall have the right to place in the Premises, but in such manner as to reduce to a minimum interference with Tenant&#8217;s use of the Premises and not to reduce the usable square feet of the Premises (except to a de minimis extent) or otherwise materially adversely affect Tenant&#8217;s use and occupancy of the Premises for the purpose contemplated under this Lease,<a name="_cp_text_1_88"></a> utility lines, equipment, stacks, pipes, conduits, ducts and the like.&nbsp;&nbsp;In the event that Tenant shall install any hung ceilings or walls in the Premises, Tenant shall install and maintain, as Landlord may require, proper access panels therein to afford access to any facilities above the ceiling or within or behind the walls.&nbsp;&nbsp;Tenant shall be entitled to install any such ceilings or walls only in compliance with the other terms and conditions of this Lease.&nbsp;&nbsp;Tenant shall have no right to access and use the fan rooms, janitorial, electrical, telephone and telecommunications closets, conduits, risers, plenum spaces and other service areas of the Building without the prior written consent of Landlord, which consent shall not be unreasonably withheld, conditioned or delayed.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a>(c)<font style="margin-left:36pt;"></font>Tenant may install (i) signs or lettering on or adjacent to the entry doors to the Premises, and (ii) identification signage for Tenant in the elevator lobbies on floors on which the Premises is located, provided such signs conform to sign standards for the Building adopted by Landlord in its reasonable discretion and Tenant has submitted to Landlord a plan or sketch in reasonable detail (showing, without limitation, size, color, location, materials and method of affixation) of the sign to be placed on such entry doors.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except for the foregoing signage, Tenant will not place on the exterior of the Premises (including both interior and exterior surfaces of doors and interior surfaces of windows) or on any part of the Building outside the Premises, any sign, symbol, advertisement or the like visible to public view outside of the Premises.&nbsp;&nbsp;If and only so long as Landlord maintains a tenant directory in the main lobby of the Building, Landlord shall cause Tenant&#8217;s name to be listed on the main lobby tenant directory; provided, however, that any changes or replacements of such lobby listing after the initial installation shall be at Tenant&#8217;s expense. </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_90"></a>(d)<font style="margin-left:36pt;"></font><a name="_cp_text_1_90"></a>The designation or use from time-to-time of portions of the Property or the Complex as Common Facilities, Base Building Systems or Laboratory Systems shall not restrict Landlord&#8217;s use of such areas for buildings, structures and/or for retail or such other purposes in connection with and consistent with the operations of the Property and the Complex as Landlord shall reasonably determine, including, without limitation, the expansion or remodeling of the Building to include one or more additional stores and restaurants, residential or other units (on the present and/or additional levels), Landlord hereby reserving the unrestricted right to build, add to, subtract from, lease, license, relocate and/or otherwise use (temporarily and/or permanently), any buildings, kiosks, other structures, parking areas, roadways or other areas or facilities anywhere upon the Building, the Property or the Complex for retail or such other purposes as Landlord shall reasonably determine, provided Landlord does not in the exercise of such right cause an unreasonable interference under the circumstances with the access to the Premises, the Parking Garage, and/or Tenant&#8217;s use of the Premises and/or the Parking Garage.&nbsp;&nbsp;There shall be a commensurate adjustment in Tenant's Pro Rata Shares set forth in Section 1.1 as a result of any expansion or contraction of the rentable square footage of the Building<font style="font-weight:bold;"> </font>or Laboratory Portion.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Parking </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_C550"></a>(a)<font style="margin-left:36pt;"></font>Beginning on the Commencement Date, Landlord shall provide or shall cause the Parking Garage operator to provide to Tenant monthly parking passes in the Parking Garage at a ratio of&nbsp;&nbsp;2.0 unreserved parking spaces per 1,000 rentable square feet of the Premises (the &#8220;<font style="font-weight:bold;">Tenant&#8217;s Parking Ratio</font><a name="_DV_C550"></a>&#8221;), for the parking of passenger automobiles on a non-exclusive, unassigned, first-come, first-served basis, in the Parking Garage at the Property, which will be provided at no additional rental charge to Tenant.&nbsp;&nbsp;In the event that the rentable square footage of the Premises increases or decreases at any time during the Term, the maximum number of parking passes provided to Tenant hereunder shall be increased or decreased based upon the Tenant&#8217;s Parking Ratio.&nbsp;&nbsp;The parking spaces in the Parking Garage subscribed for by Tenant are referred to herein as &#8220;<font style="font-weight:bold;">Tenant&#8217;s Parking Spaces</font>&#8221;.&nbsp;&nbsp;The Tenant&#8217;s Parking Spaces granted herein are for use by employees of Tenant and other occupants of the Premises, Tenant&#8217;s contractors, agents and invitees, are non-transferable (other than to an assignee or subtenant or other occupant permitted to occupy and use the Premises pursuant to the applicable provisions of this Lease).&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU15"></a>(b)<font style="margin-left:36pt;"></font>Unless otherwise determined by Landlord or the operator of such garage (the &#8220;<font style="font-weight:bold;">Garage Operator</font>&#8221;), the Parking Garage is to be operated on a self-parking </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">basis and Tenant&#8217;s parking shall be on an unreserved basis.&nbsp;&nbsp;Landlord agrees that, in accordance with the Transportation Access Plan Agreement or any LEED certification pursued from time to time by Landlord, the Parking Garage or the Building will provide onsite, secure bicycle storage and shower/changing rooms in the Fitness Facility and, subject to applicable Laws, the Parking Garage will provide priority parking for car/van pools, hybrids, small cars, mopeds and motorbikes.&nbsp;&nbsp;Landlord reserves the right to institute, expand or withdraw a valet or stacked parking system or to institute other reasonable parking controls, rules or regulations, at any time and in its reasonable discretion provided the same are not inconsistent with Tenant&#8217;s rights under this Lease.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>Landlord shall have the absolute right (a) to allocate and assign parking spaces among some or all of the tenants of the Property (and Tenant shall comply with any such parking assignments), including, without limitation, the right to designate a reserved area of the Parking Garage as a valet area for the customers and visitors to the Retail Portion of the Building provided that the same does decrease the number of monthly parking contracts that Tenant is entitled to under this <font style="font-weight:bold;">Section 2.3</font>, (b) to reconfigure the parking area, and/or (c) to modify the ingress to and egress from the Parking Garage as Landlord shall deem appropriate, as long as reasonable access to such area is maintained after such modification is completed.&nbsp;&nbsp;Landlord or the Garage Operator shall have the right to temporarily close all or any portion of the Parking Garage for the purpose of maintaining, repairing, restoring, altering or improving same, provided that Landlord exercises diligent efforts to reopen such areas of the Parking Garage as soon as reasonably possible in light of the nature of repairs or other work being performed in the Parking Garage.&nbsp;&nbsp; </p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_94"></a>(d)<font style="margin-left:36pt;"></font><a name="_cp_text_1_94"></a>Landlord shall have no obligation to monitor the use of such parking facility, nor shall Landlord be responsible for any loss or damage to any vehicle or other property or for any injury to any person.&nbsp;&nbsp;Tenant and its employees shall observe reasonable safety precautions in the use of the Parking Garage and shall at all times abide by all reasonable rules and regulations of uniform applicability to the users of the Parking Garage from time to time established by Landlord or the Garage Operator governing the use thereof.&nbsp;&nbsp; Except to the extent of negligence or willful acts, neither the Landlord nor the Garage Operator assumes any responsibility whatsoever for loss or damage due to fire or theft or otherwise to any automobile or to any personal property therein, however caused, and Tenant agrees, upon written request from the Landlord, from time to time, to notify its officers, employees and agents then using any of the parking privileges provided for herein, of such limitation of liability.&nbsp;&nbsp;Tenant further acknowledges and agrees that a license only is hereby granted, and no bailment is intended or shall be created.&nbsp;&nbsp;Tenant&#8217;s employees having the use of monthly parking passes shall be required to display identification or parking sticker at all times in all vehicles parked in the garage.&nbsp;&nbsp;Any vehicle not displaying such a sticker may be towed away at the vehicle owner&#8217;s expense in accordance with the garage rules and regulations.&nbsp;&nbsp;In addition, Landlord&#8217;s and Tenant&#8217;s use of the garage shall be subject to all Laws and the permits and approvals issued in connection with the development of the Boston Landing Project.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU16"></a><a name="_cp_text_1_97"></a>(e)<font style="margin-left:36pt;"></font>Notwithstanding Tenant&#8217;s parking rights under this Lease, in accordance with the Transportation Access Plan Agreement entered into by Landlord and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_97"></a>the Boston Transportation Department in connection with the development of the Property, Tenant shall exercise reasonable efforts</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to (i) promote and encourage employees of Tenant and other occupants of the Premises to rideshare or carpool, as part of which Tenant shall consider providing subsidized parking rates and other incentives for rideshare or carpool vehicles and participating in the MassRides car sharing program, (ii) promote and encourage employees to use public transportation to commute to the Premises, including providing on-line and on-site or payroll deduction transit pass sales and providing subsidized transit pass rates, (iii) participate in the MBTA Corporate T-Pass Program, and (iv) provide employees with information on bus, subway and commuter rail routes and schedules.&nbsp;&nbsp;Landlord encourages Tenant and all tenants of the Boston Landing Project to reasonably consider offering full-time and part-time employees a subsidy for transit passes and to become members of the local Transportation Management Association.&nbsp;&nbsp;Tenant shall reasonably cooperate with Landlord (at no cost to Tenant) in programs and other activities initiated by Landlord to comply with Landlord&#8217;s obligations under the Transportation Agreements.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Shuttle Service</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Subject to weather and other force majeure delays, Landlord will provide, as part of Building Operating Expenses, shuttle service on Business Days between the Boston Landing Project and Harvard Square and Kenmore Square for the general use of all tenants and occupants of the Boston Landing Project, subject to reasonable modifications from time to time in Landlord&#8217;s reasonable discretion.&nbsp;&nbsp; The hours, frequency and routes of shuttle services shall be subject to reasonable modification by Landlord in Landlord&#8217;s reasonable discretion as demand for use of such shuttle service changes during the Term and subject to any applicable provisions of the Declaration.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">ARTICLE 3</font><font style="text-decoration:underline;"><br />BASIC RENT</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Payment</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_99"></a><a name="_cp_text_2_100"></a><a name="_cp_text_1_101"></a><a name="_AEIOULastRenderedPageBreakAEIOU17"></a>(a)<font style="margin-left:36pt;"></font>Tenant agrees to pay the Basic Rent and Additional Rent to Landlord, or as directed by Landlord, commencing on the Commencement Date, without offset, abatement (except as provided in <font style="font-weight:bold;">Section&#160;11.3</font><a name="_cp_text_1_99"></a>), deduction or demand, except as otherwise expressly provided in this Lease<a name="_cp_text_2_100"></a>.&nbsp;&nbsp;Basic Rent shall be payable in equal monthly installments, in advance, on the first day of each and every calendar month during the Term of this Lease, to Landlord at Landlord&#8217;s Payment Address or at such other place as Landlord shall from time to time designate by notice, in lawful money of the United States. In the event that any installment of Basic Rent or any payment of Additional Rent is not paid when due, Tenant shall pay, in addition to any charges under <font style="font-weight:bold;">Section 14.4</font>, an administrative fee equal to 3% of the overdue payment.&nbsp;&nbsp;In addition to the foregoing, i<a name="_cp_text_1_101"></a>f payment of Rent or other charges due under this Lease are not paid within ten (10) Business Days after the date due, such past due amount shall bear interest from the date due until paid at a rate equal to the lesser of (i) a rate equal to 3% plus the prime rate published from time to time in <font style="text-decoration:underline;">The Wall Street Journal</font> or its successor publication and (ii) the highest rate permitted to be charged by applicable Law (the &#8220;<font style="font-weight:bold;">Default Interest Rate</font>&#8221;).&nbsp;&nbsp;Landlord and Tenant agree that all amounts due from Tenant under or in respect of this Lease, whether labeled Basic Rent, Additional Rent or otherwise, shall be considered as </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rental reserved under this Lease for all purposes, including without limitation regulations promulgated pursuant to the Bankruptcy Code, and including further without limitation Section&#160;502(b) thereof.&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord agrees to waive the administrative fee due hereunder for the first late payment by Tenant under this Lease per calendar year, provided that Landlord receives such payment from Tenant within five (5) Business Days after written notice of such delinquency is given to Tenant (provided that if such payment is not received within the aforesaid five (5) Business Day period, interest on the outstanding amount will accrue as of the original date such payment is due).</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Basic Rent for any partial month shall be pro&#8209;rated on a daily basis, and if the first day on which Tenant must pay Basic Rent shall be other than the first day of a calendar month, the first payment which Tenant shall make to Landlord shall be equal to a proportionate part of the monthly installment of Basic Rent for the partial month from the first day on which Tenant must pay Basic Rent to the last day of the month in which such day occurs, plus the installment of Basic Rent for the succeeding calendar month.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">ARTICLE 4</font><font style="text-decoration:underline;"><br />CONDITION OF PREMISES</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Condition of Premises; Initial Improvements</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_104"></a><a name="_cp_text_1_105"></a><a name="_cp_text_1_108"></a>.&nbsp;&nbsp;Except for the Landlord Work, to be performed by Landlord in accordance with the provisions of <font style="font-weight:bold;text-decoration:underline;">Exhibit C</font><a name="_cp_text_1_104"></a>, the Premises are being leased in their present condition, AS IS, WITHOUT REPRESENTATION OR WARRANTY by Landlord.&nbsp;&nbsp;Except for the Tenant Improvement, Landlord shall have no obligation to perform any alterations or to make any improvements to the Premises to prepare them for Tenant&#8217;s occupancy.&nbsp;&nbsp;Tenant acknowledges that Tenant has inspected the Premises, Laboratory Systems and Common Facilities and has found the same satisfactory, subject to Landlord's obligation to complete Landlord's Work in accordance with all of the terms and conditions of this Lease<a name="_cp_text_1_105"></a>.<a name="_cp_text_1_108"></a>&nbsp;&nbsp;On the Commencement Date Landlord shall deliver exclusive possession of the Premises to Tenant vacant, broom clean and free and clear of all tenants and their personal property.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">ARTICLE 5</font><font style="text-decoration:underline;"><br />USE OF PREMISES</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Permitted Use</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_117"></a><a name="_AEIOULastRenderedPageBreakAEIOU18"></a>(a)<font style="margin-left:36pt;"></font><a name="_cp_text_1_117"></a>Tenant agrees that the Premises shall be used and occupied by Tenant only for the Permitted Use and for no other use without Landlord&#8217;s express written consent.&nbsp;&nbsp;Notwithstanding anything to the contrary contained in this Lease, no more than fifty percent (50%) of the floor area for each floor that is located in the Laboratory Portion may be used or designed for research and development, including a biotechnical and/or laboratory use.&nbsp;&nbsp;This Lease shall at all times be subject and subordinate to the Declaration and the Record Documents (as hereinafter defined) and Tenant agrees that it shall not engage in any action that would result in a violation of the Declaration or any of the Record Documents, as the same may be amended from time to time.&nbsp;&nbsp;For purposes of this </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease, &#8220;</font><font style="font-weight:bold;">Record Documents</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU18"></a>&#8221; shall mean all agreements declarations, covenants, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">restrictions, reservations, liens, conditions, easements, encumbrances and other matters of record and affecting the Property on the date hereof and all agreements declarations, covenants, restrictions, reservations, liens, conditions, easements, encumbrances and other matters hereinafter granted or executed by Landlord, any of Landlord&#8217;s affiliates (or their respective successors or assigns (collectively, the &#8220;</font><font style="font-weight:bold;">Landlord Parties</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), including, without limitation, any amendments to existing Record Documents entered into or obtained by any of the Landlord Parties in connection with the development of the Boston Landing Project, including, without limitation, the Fundamental Approvals (as defined in the Declaration).&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord represents and warrants to Tenant that, as of the date of this Lease, there is no so called &#8220;ground lease,&#8221; &#8220;master lease&#8221; or similar instrument encumbering the Premises.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_138"></a><a name="_cp_text_2_139"></a><a name="_cp_text_1_141"></a>(b)<font style="margin-left:36pt;"></font><a name="_cp_text_1_138"></a>Tenant shall not (a) use or occupy the Building, (b) permit the use or occupancy of the Premises, (c) do anything or bring into or keep in or about the Building, or (d) permit any act or practice to be done or anything to be brought into or kept in or about the Premises or any part thereof that: (i) would violate any of the covenants, agreements, terms, provisions and conditions of this Lease or any applicable Laws; (ii) would constitute a nuisance; or (iii) is inconsistent with the maintenance, operation, or occupancy of the Building as a first<a name="_cp_text_2_139"></a>&#8209;class mixed-use laboratory and office building, or is liable to invalidate any insurance maintained by Landlord on the Building or its contents or the Laboratory Systems or Common Facilities.&nbsp;&nbsp;Tenant shall maintain temperature and humidity in the Premises in accordance with ASHRAE standards at all times.&nbsp;&nbsp;Tenant shall not use any method of HVAC other than that approved in writing by Landlord or present at the Property and serving the Premises as of the Effective <a name="_cp_text_1_141"></a>Date of this Lease.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU19"></a>(c)<font style="margin-left:36pt;"></font>Tenant acknowledges and agrees that the Building is or may become in the future certified under the Green Building Initiative&#8217;s Green Globes TM&nbsp;&nbsp;for Continual Improvement of Existing Buildings (Green Globes TM-CIEB), the U.S. Green Building Council&#8217;s Leadership in Energy and Environmental Design (LEED) rating system, or similar standard pursuant to Landlord&#8217;s sustainable building practices.&nbsp;&nbsp;Landlord&#8217;s sustainability practices may address whole-building operations and maintenance issues including chemical use; indoor air quality; energy efficiency; water efficiency; recycling programs; exterior maintenance programs; and systems upgrades to meet green building energy, water and lighting performance standards.&nbsp;&nbsp;Tenant shall exercise reasonable efforts not to change its manner of use of the Premises or the operation of its business therein in any manner that will cause the Building or any part thereof not to conform with Landlord&#8217;s sustainability practices or the certification of the Building issued pursuant to the U.S. Green Building Council&#8217;s Leadership in Energy and Environmental Design (LEED) rating system or other applicable ratings or standards now or hereafter achieved for the Building, such as, without limitation, the U.S. EPA&#8217;s Energy Star&#174; rating.&nbsp;&nbsp;Tenant agrees to exercise reasonable efforts to use proven energy and carbon reduction measures, including energy efficient bulbs in task lighting; use of lighting controls; daylighting measures to avoid overlighting interior spaces; closing shades on the certain sides of the building to avoid over heating the space; and purchasing ENERGY STAR&#174; qualified equipment, including but not limited to lighting, office equipment, commercial and residential quality kitchen equipment, vending and ice </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU19"></a>machines;&nbsp;&nbsp;purchasing products certified by the U.S. EPA&#8217;s Water Sense&#174; program, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provided, however, other than the cost of any future re-certification of such LEED certification which Landlord shall be entitled to include in Operating Expenses, Tenant shall not be obligated to incur additional expenses, more than di minimis in nature, in order to comply with the provisions of this </font><font style="font-weight:bold;">Section 5.1(c)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_144"></a>(d)<font style="margin-left:36pt;"></font>Landlord reserves the right, at any time during the Term, to submit the Building and/or the Property to the provisions of Chapter 183A of the Massachusetts General Laws to create a condominium (a &#8220;<font style="font-weight:bold;">Condominium Conversion</font>&#8221;).&nbsp;&nbsp;In the event of a Condominium Conversion, this Lease shall remain in full force and effect and be subject and subordinate to the master deed and by-laws and other documents creating the condominium (the &#8220;<font style="font-weight:bold;">Condominium Documents</font><a name="_cp_text_1_144"></a>&#8221;).&nbsp;&nbsp;Following the creation of the Condominium, Landlord and Tenant shall execute a revised Notice of Lease and any other documents to replace the original legal description in such documents with the legal description of the condominium unit in which the Premises is located.&nbsp;&nbsp;Tenant agrees to subordinate this Lease to the Condominium Documents and enter into any instruments reasonably requested by Landlord in connection with the foregoing so long as the same do not diminish or detract from the rights of Tenant or expand or enhance the obligations of Tenant or decrease any obligations of Landlord under this Lease in any material way.&nbsp;&nbsp;As a condition to such subordination, Landlord shall deliver to Tenant a Non-Disturbance Agreement in form reasonably acceptable to Landlord and Tenant from the association or board governing the condominium that Tenant&#8217;s possession of the Premises shall not be disturbed in the event of any termination of the Condominium or any exercise by the association or board of its rights under the Condominium Documents to enforce assessments of unpaid common charges against the unit.&nbsp;&nbsp;If either party reasonably believes that it is necessary to clarify the terms of this Lease as a result of such Condominium Conversion, Landlord and Tenant shall promptly execute an agreement clarifying their respective obligations under this Lease; provided, however, that neither party shall be required to execute any such instrument which would diminish or detract from the rights of such party or expand or enhance the obligations of such party, in either case under this Lease.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_146"></a><a name="_cp_text_1_147"></a><a name="_AEIOULastRenderedPageBreakAEIOU20"></a><a name="_cp_text_1_148"></a>(e)<font style="margin-left:36pt;"></font><font style="font-weight:bold;"> </font><a name="_cp_text_1_147"></a>Tenant shall establish and maintain a chemical safety program administered by a licensed, qualified individual if required by and in accordance with the requirements of the Massachusetts Water Resources Authority (&#8220;<font style="font-weight:bold;">MWRA</font>&#8221;) and any other applicable governmental authority.&nbsp;&nbsp;Tenant shall be solely responsible for all costs incurred in connection with such chemical safety program, and Tenant shall provide Landlord with such documentation as Landlord may reasonably require evidencing Tenant&#8217;s compliance with the requirements of (a) the MWRA and any other applicable governmental authority with respect to such chemical safety program and (b) this Section.&nbsp;&nbsp;Tenant shall be responsible for obtaining and maintaining in full force and effect during the Term (i) all necessary permits required by the MWRA (&#8220;<font style="font-weight:bold;">Tenant&#8217;s</font> <font style="font-weight:bold;">MWRA Permit</font>&#8221;) for Tenant&#8217;s discharge of Industrial Wastewater (as defined by applicable Laws) from the Premises to the sewer system serving the Building, and (ii) a wastewater treatment operator license from the Commonwealth of Massachusetts with respect to Tenant&#8217;s use of the ph Neutralization Tank (as hereinafter defined) in the Building.&nbsp;&nbsp;Tenant shall not introduce anything into the ph Neutralization Tank or the sewer system serving the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU20"></a>Building (x) in violation of the terms of Tenant&#8217;s MWRA Permit, (y) in violation of </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_148"></a>applicable Laws or (z) that would interfere with the proper functioning of the ph Neutralization Tank or the sewer system serving the Building.&nbsp;&nbsp;Landlord agrees to reasonably cooperate with Tenant, at no cost to Landlord, in order to obtain Tenant&#8217;s MWRA Permit and the wastewater treatment operator license.&nbsp;&nbsp;Tenant shall reimburse Landlord within ten (10) Business Days after demand for any </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reasonable out of pocket </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">costs incurred by Landlord pursuant to this Section.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_150"></a>(f)<font style="margin-left:36pt;"></font><font style="font-weight:bold;"> </font>Tenant shall be responsible for the proper use, storage, removal and disposal of all Medical Waste (as hereinafter defined) in accordance with Laws and any additional requirements which Landlord may reasonably establish from time to time by written notice to Tenant.&nbsp;&nbsp;Tenant shall, at its sole cost and expense, engage a reputable, duly licensed and insured contractor for such disposal of Medical Waste, provided,&nbsp;&nbsp;however, Tenant may utilize Tenant&#8217;s own employees for such disposal so long as such employees are properly licensed in Massachusetts to dispose of Medical Waste.&nbsp;&nbsp;Tenant shall not place any Medical Waste in any Common Facilities.&nbsp;&nbsp;&#8220;<font style="font-weight:bold;">Medical Waste</font>&#8221; shall mean collectively, (i) any human or animal tissue, blood, urine or other bodily fluids, materials or biological byproducts, (ii) any medical supplies (including used syringes, gauze and bandages), and (iii) any and all substances and materials defined or referred to as &#8220;a-medical waste,&#8221; &#8220;biological waste,&#8221; &#8220;biohazardous waste,&#8221; &#8220;biohazardous material&#8221; or any other term of similar import under any Environmental Laws.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_152"></a><a name="_cp_text_1_153"></a><a name="_cp_text_1_155"></a><a name="_cp_text_2_156"></a><a name="_cp_text_1_158"></a><a name="_cp_text_1_159"></a>(g)<font style="margin-left:36pt;"></font><a name="_cp_text_1_152"></a>Tenant shall not cause or permit (or conduct any activities that would cause) any release of any odors or fumes of any kind from the Premises that are not common or typical for general office use for the Office Portion of the Premises or common or typical for research and development uses for the Laboratory Portion of the Premises.&nbsp;&nbsp;Tenant shall in compliance with applicable Laws vent all fumes and odors from the Premises (and remove odors from Tenant&#8217;s exhaust stream) as Landlord reasonably <a name="_cp_text_1_153"></a>requires.&nbsp;&nbsp;The placement and configuration of all ventilation exhaust pipes, louvers and other equipment shall be subject to Landlord&#8217;s approval.&nbsp;&nbsp;Tenant shall, at Tenant&#8217;s sole cost and expense, provide odor eliminators and other devices (such as filters, air cleaners, scrubbers and whatever other equipment may in Landlord&#8217;s reasonable <a name="_cp_text_1_155"></a>judgment be necessary or appropriate from time to time) to remove, eliminate and abate any unreasonable <a name="_cp_text_2_156"></a>odors, fumes or other substances in Tenant&#8217;s exhaust stream that, in Landlord&#8217;s reasonable judgment,<a name="_cp_text_1_158"></a> emanate from Tenant&#8217;s Premises and are not common or typical for general office use or for research and development uses, as applicable.&nbsp;&nbsp;Any work Tenant performs under this Section shall constitute Alterations.&nbsp;&nbsp;Tenant&#8217;s responsibility to control <a name="_cp_text_1_159"></a>odors, fumes and exhaust as provided in this <font style="font-weight:bold;">Section 5.1(g)</font> shall continue throughout the Term.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU21"></a><a name="_cp_text_1_160"></a><a name="_cp_text_1_166"></a>(h)<font style="margin-left:36pt;"></font>Tenant acknowledges that it has been advised that the Landlord Parties and/or other Parcel Owners (as defined in the Declaration) intend to construct additional improvements on and continue and complete the full development of the Boston Landing Project pursuant to the Declaration, the Fundamental Approvals and the Other Site Approvals (as such terms are defined in the Declaration) in one or more phases.&nbsp;&nbsp;As a material inducement to Landlord to enter into this Lease, Tenant acknowledges and expressly agrees that the Landlord Parties and/or other third parties shall have the right </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU21"></a>(but without any obligation so to do) at any time during the Term to complete and </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">construct the additional phases of the Boston Landing Project (the &#8220;</font><font style="font-weight:bold;">Project Improvements</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_160"></a>&#8221;) pursuant to the Declaration, the Fundamental Approvals and the Other Site Approvals and the construction of&nbsp;&nbsp;Project Improvements during the Term and while Tenant is in occupancy of the Premises shall not be considered an eviction, actual or constructive, of Tenant from the Premises and shall not entitle Tenant to terminate this Lease or to an abatement of any Basic Rent, Escalation Charges or Additional Rent payable hereunder.&nbsp;&nbsp; Tenant acknowledges and agrees that such ongoing construction may result in noise, dust, vibrations and other disturbances and Tenant has entered into this Lease and agreed to perform the obligations of Tenant hereunder with knowledge of the on-going performance of the Project Improvements.&nbsp;&nbsp;Landlord shall, to the extent any&nbsp;&nbsp;construction activities at the Boston Landing and the performance of the Project Improvements are being performed by </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or on behalf of any of </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_166"></a>the Landlord Parties, implement reasonable construction measures and procedures to mitigate dust and noise to the extent commercially feasible provided that such efforts and measures shall not require any of the Landlord Parties to perform the Project Improvements outside of normal building hours or at material additional cost to any of the Landlord Parties</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc487104340"></a>5.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Tenant Work</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:0pt;"></font>Promptly following the Commencement Date, Tenant shall undertake, at Tenant&#8217;s sole cost and expense, the making of leasehold improvements to and fixturing of the Premises (the &#8220;<font style="font-weight:bold;">Tenant Work&#8221;</font>).&nbsp;&nbsp;All Tenant Work shall be performed in accordance with the terms and conditions of <font style="font-weight:bold;text-decoration:underline;">Exhibit D</font> attached hereto and the terms of this Lease applicable to Alterations.</p>
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:-6pt;"></font>Tenant shall reimburse Landlord within thirty (30) days of receipt of Landlord&#8217;s written invoice, as Additional Rent, for actual out&#8209;of&#8209;pocket, third&#8209;party engineer and architect costs incurred by Landlord in connection with review and approval of the Construction Drawings and Change Orders (as hereinafter defined), provided that the charges of such consultants are commercially reasonable for the services provided to Landlord.&nbsp;&nbsp;Notwithstanding anything to the contrary contained herein, Tenant shall be entitled to apply the Landlord&#8217;s Contribution toward the costs associated with this <font style="font-weight:bold;">Section 5.2(b)</font>; provided, however, such costs will be considered soft costs and shall be subject to and applied toward the twenty percent (20%) cap on soft cost application of the Landlord&#8217;s Contribution set forth in <font style="font-weight:bold;">Section 4(b)</font> of <font style="font-weight:bold;text-decoration:underline;">Exhibit D</font>.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Installations and Alterations by Tenant</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_169"></a><a name="_AEIOULastRenderedPageBreakAEIOU22"></a><a name="_cp_text_1_171"></a><a name="_cp_text_1_172"></a><a name="_cp_text_1_173"></a><a name="_cp_text_1_174"></a><a name="_cp_text_2_175"></a><a name="_cp_text_1_178"></a>(a)<font style="margin-left:36pt;"></font>Tenant shall make no alterations, additions or improvements (collectively, &#8220;<font style="font-weight:bold;">Alterations</font><a name="_cp_text_1_169"></a>&#8221;) in or to the Premises (including any of the Tenant Work, necessary for Tenant&#8217;s initial occupancy of the Premises) or any Base Building Systems or Laboratory Systems serving the Premises without Landlord&#8217;s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed with respect to non&#8209;structural Alterations that do not adversely affect any portion of the Base Building or Laboratory Systems or the Base Building Systems.&nbsp;&nbsp;Notwithstanding the foregoing, Tenant may make Cosmetic Alterations (as hereinafter defined) to the Premises without Landlord&#8217;s consent so long as Landlord is notified in writing at least ten (10) days prior to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU22"></a>commencement of any such Cosmetic Alterations.&nbsp;&nbsp;Landlord may, at the time consent is </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">given, identify in writing any Alterations </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(including any of the Tenant Work, necessary for Tenant&#8217;s initial occupancy of the Premises) </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that adversely affect or alter the Structural Elements as Special Improvements (as hereinafter defined) which, provided Landlord so identifies such alterations, shall be removed by Tenant and the Premises restored at the end of the Term pursuant to </font><font style="font-weight:bold;">Section 5.3(e</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) below.&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any Alterations shall be in accordance with Landlord&#8217;s Rules and Regulations from time to time in effect and with plans and specifications meeting the requirements set forth in such Rules and Regulations and approved in advance by Landlord.&nbsp;&nbsp;All Alterations shall </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> be performed in a good and workmanlike manner using only new and only quality materials and in compliance with all applicable Laws; </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> be made at Tenant&#8217;s sole cost and expense; </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_171"></a> become part of the Premises and the property of Landlord upon the expiration or earlier termination of the Term of this Lease unless Landlord otherwise notifies Tenant </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(at the time consent is given) </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_172"></a>such Alteration must be removed </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at the end of the Term or earlier expiration of this Lease </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as provided in </font><font style="font-weight:bold;">Section 5.3(e)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> below; </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_173"></a> be made by contractors and subcontractors </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reasonably </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approved in advance by Landlord; and </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_174"></a> be coordinated with any work being performed by Landlord in such a manner as not to damage the Building or interfere with the management, maintenance or operation of the Building.&nbsp;&nbsp;At Landlord&#8217;s request, Tenant shall, before its work is started, secure assurances satisfactory to Landlord in its reasonable discretion protecting Landlord against claims arising out of the furnishing of labor and materials for the Alterations.&nbsp;&nbsp;If any Alterations shall involve the removal of fixtures, equipment or other property in the Premises which are not Tenant&#8217;s Removable Property, such fixtures, equipment or property shall be promptly replaced by Tenant at its expense with new fixtures, equipment or property of like utility and of at least equal quality.&nbsp;&nbsp;Tenant shall promptly reimburse Landlord for all reasonable </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">out of pocket </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">costs, including attorneys&#8217;, architects&#8217;, engineers&#8217;, and consultants&#8217; fees, incurred by Landlord in connection with any request from Tenant pursuant to this </font><font style="font-weight:bold;">Section&#160;5.3</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_175"></a>.&nbsp;&nbsp;Tenant acknowledges and agrees that any review or approval by Landlord of any plans and/or specifications with respect to any Alterations is solely for Landlord&#8217;s benefit, and without any representation or warranty whatsoever to Tenant with respect to the adequacy, correctness or efficiency thereof or otherwise.&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_178"></a>Landlord shall have the right to require that Tenant use Landlord&#8217;s designated structural contractor and architect for the Building for the design and performance of any Alterations affecting the Structural Elements and/or that Tenant use Landlord&#8217;s designated fire and life safety contractor and engineer for the Building to perform Tenant&#8217;s connection to the Building&#8217;s fire alarm system or any Alterations that affect the fire alarm or fire/life safety systems in the Building.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes hereof, &#8220;</font><font style="font-weight:bold;">Cosmetic Alterations</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; shall mean painting and other minor cosmetic or decorative alterations to the Premises and other non-structural alterations which other non-structural alterations (1) do not affect any area of the Building outside of the Premises, (2) are not visible from the exterior of the Premises or the Building, (3) do not adversely affect the Building&#8217;s electrical, plumbing, mechanical or fire/life safety systems or any other systems of the Building, and (4) cost less than $100,000 in any Lease Year and do not require the issuance of a building permit.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU23"></a><a name="_cp_text_2_182"></a><a name="_cp_text_5_183"></a><a name="_cp_text_2_184"></a><a name="_cp_text_5_185"></a><a name="_cp_text_2_186"></a>(b)<font style="margin-left:36pt;"></font>Except for Tenant&#8217;s Removable Property (as hereinafter defined), all property of any kind paid for by Landlord, all Alterations, all fixtures and partitions, hardware, built-in machinery, built-in casework and cabinets or other similar additions, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU23"></a>equipment, property or improvements built into the Premises so as to become an integral </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">part of the Premises, including, without limitation, fume hoods which penetrate the roof or plenum area, built-in or walk-in cold rooms, built-in or walk-in warm rooms, deionized water systems, glass washing equipment, autoclaves, chillers, built-in plumbing, electrical and mechanical equipment and systems, and any power generator and transfer switch (collectively, &#8220;</font><font style="font-weight:bold;">Laboratory Reusable</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-weight:bold;">Installations</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), shall be and shall remain the property of Landlord during the Term and following the expiration or earlier termination of the Term, and shall not be removed by Tenant at any time and shall remain in and be surrendered with the Premises as part thereof.&nbsp;&nbsp;&#8220;</font><font style="font-weight:bold;">Tenant&#8217;s Removable Property</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; shall mean any items listed on </font><font style="font-weight:bold;text-decoration:underline;">Exhibit I</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> attached hereto and any items agreed by Landlord in writing to be included on </font><font style="font-weight:bold;text-decoration:underline;">Exhibit I</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_182"></a> in the future, as well as Tenant&#8217;s personal property and all movable business and trade equipment owned or installed by Tenant or any party claiming by, through or under Tenant, not constituting Laboratory Reusable Installations.&nbsp;&nbsp;Tenant&#8217;s Removable Property shall remain the property of Tenant and may be removed by Tenant at any time prior to the expiration or earlier termination of the Term, provided that Tenant, at its expense, shall repair any damage to the Building caused by such removal.&nbsp;&nbsp;Any provision of this Lease to the contrary notwithstanding, Tenant shall be solely responsible for the ordering, delivery and installation of any telephone, telephone switching, telephone and data cabling, and Tenant&#8217;s Removable Property to be installed by or on behalf of Tenant in the Premises</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_5_183"></a> and for the removal of all telephone and data cabling installed in the Building </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_184"></a>by or on behalf of Tenant </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_5_185"></a>or anyone claiming by, through or under Tenant at </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_186"></a>the expiration or earlier termination of </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Term of this Lease.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_189"></a><a name="_cp_text_1_190"></a><a name="_cp_text_1_191"></a><a name="_cp_text_1_192"></a><a name="_cp_text_1_193"></a><a name="_AEIOULastRenderedPageBreakAEIOU24"></a>(c)<font style="margin-left:36pt;"></font><a name="_cp_text_1_189"></a>Notice is hereby given that Landlord shall not be liable for any labor or materials furnished or to be furnished to Tenant upon credit, and that no mechanic&#8217;s or other lien for any such labor or materials shall attach to or affect the reversion or other estate or interest of Landlord in and to the Premises, the Building or the Property.&nbsp;&nbsp;To the maximum extent permitted by law, before such time as any contractor commences to perform work on behalf of Tenant, such contractor (and any subcontractors) shall furnish a written statement acknowledging the provisions set forth in the prior clause.&nbsp;&nbsp;Tenant agrees to pay promptly when due the entire cost of any work done on behalf of Tenant, its agents, employees or independent contractors, and not to cause or permit any liens for labor or materials performed or furnished in connection therewith to attach to all or any part of the Property and within twenty (20) days after receipt of written notice of any such liens <a name="_cp_text_1_190"></a>to discharge or bond over (satisfactory to Landlord) <a name="_cp_text_1_191"></a>any such liens which may so attach.&nbsp;&nbsp;If, notwithstanding the foregoing, any lien is filed against all or any part of the Property for work claimed to have been done for, or materials claimed to have been furnished to, Tenant or its agents, employees or independent contractors, Tenant, at its sole cost and expense, shall, within twenty (20) days after receipt of written notice thereof, <a name="_cp_text_1_192"></a>cause such lien to be dissolved promptly after receipt of notice that such lien has been filed, by the payment thereof or by the filing of a bond sufficient to accomplish the foregoing.&nbsp;&nbsp;If Tenant shall fail to discharge any such lien, Landlord may, at its option, discharge such lien and treat the cost thereof (including attorneys&#8217; fees incurred in connection therewith) as Additional Rent payable upon demand, it being expressly agreed that such discharge by Landlord shall not be deemed to waive or release the Event of Default in not discharging or so bonding over <a name="_cp_text_1_193"></a>such lien within such twenty (20) day period.&nbsp;&nbsp;Tenant shall indemnify and hold Landlord harmless </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU24"></a>from and against any and all expenses, liens, claims, liabilities and damages based on or </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">arising, directly or indirectly, by reason of the making of any alterations, additions or improvements by or on behalf of Tenant to the Premises under this Section, which obligation shall survive the expiration or termination of this Lease.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>In the course of any work being performed by Tenant (including, without limitation, the installation or removal of any Tenant&#8217;s Removable Property), Tenant agrees to use labor compatible with that being employed by Landlord for work in the Building or on the Property or other buildings owned by Landlord or its affiliates (which term, for purposes hereof, shall include, without limitation, entities which control or are under common control with or are controlled by Landlord or, if Landlord is a partnership or limited liability company, by any partner or member of Landlord) and not to employ or permit the use of any labor or otherwise take any action which might result in a labor dispute or disharmony involving personnel providing services in the Building or on the Property pursuant to arrangements made by Landlord.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_194"></a>(e)<font style="margin-left:36pt;"></font>Landlord may, by written notice to Tenant at the time of the approval of any Special Improvement (as hereinafter defined), require Tenant, at Tenant&#8217;s expense, to remove any Special Improvement made to the Premises at the expiration or earlier termination of the Term, and to repair any damage to the Premises and Building caused by such removal and return the affected portion of the Premises to a Building standard tenant improved condition as determined by Landlord.&nbsp;&nbsp;If Tenant fails to complete such removal and/or to repair any damage caused by the removal of any Special Improvements to the Premises designated by Landlord for removal, and return the affected portion of the Premises to a Building standard tenant improved condition as determined by Landlord, then, without limiting Landlord&#8217;s other rights and remedies, at Landlord&#8217;s option, either (A) Tenant shall be deemed to be holding over in the Premises and Rent shall continue to accrue in accordance with the terms of <font style="font-weight:bold;">Article 12</font>, below, until such work shall be completed, or (B) Landlord may do so and may charge the cost thereof to Tenant.&nbsp;&nbsp;For purposes hereof, &#8220;<font style="font-weight:bold;">Special Improvements</font><a name="_cp_text_1_194"></a>&#8221; shall mean any Alterations made by Tenant or any party claiming by, through or under Tenant  that (i) would reasonably be expected to adversely affect any structural or exterior element of the Building, any area or element outside of the Premises or any facility or base building mechanical system serving any area of the Building, or (ii) involve or affect the exterior design, size, height or other exterior dimensions of the Building, or (iii) are inconsistent with the Building standards for Comparable Buildings, or (iv) will require material additional expense to demolish or remove the Premises to normal office/laboratory use on termination of this Lease or increase the Operating Expenses for the Building, and shall expressly include, without limitation, such Alterations as interconnecting/internal staircases, data centers in excess of 2,000 square feet of rentable floor area (either singly or collectively), and non-core restrooms (and any horizontal plumbing lines associated with such restrooms).&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Extra Hazardous Use</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU25"></a>.&nbsp;&nbsp;Tenant covenants and agrees that Tenant will not do or permit anything to be done in or upon the Premises, or bring in anything or keep anything therein, which shall increase the rate of property or liability insurance on the Premises or the Property above the standard rate applicable to Premises being occupied for the Permitted Use.&nbsp;&nbsp;If the premium or rates payable with respect to any policy or policies of insurance carried by or on </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU25"></a>behalf of Landlord with respect to the Property increases as a result of any act or activity on or </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">use of the Premises during the Term by Tenant or Tenant&#8217;s employees, agents, contractors, subtenants, licensee, invitees or anyone claiming by, through or under Tenant (whether or not done knowingly by such a party, but only to the extent resulting from such act or activity as set forth in this </font><font style="font-weight:bold;">Section 5.4</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) or payment by the insurer of any claim arising from any act or neglect of Tenant, its employees, agents, contractors, invitees, subtenants, licensees or anyone claiming by, through or under Tenant, Tenant shall be given written notice and a five (5) business day opportunity to discontinue such use and if Tenant fails to do so, Tenant shall pay such increase, from time to time, within thirty (30) days after written demand therefor by Landlord, as Additional Rent.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Hazardous Materials</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU26"></a><a name="_cp_text_1_199"></a>(a)<font style="margin-left:36pt;"></font>Landlord acknowledges that it is not the intent of this <font style="font-weight:bold;">Section 5.5</font> to prohibit Tenant from using the Premises for the Permitted Use.&nbsp;&nbsp;Tenant may operate its business according to prudent industry practices so long as the use or presence of Hazardous Materials is strictly and properly monitored by Tenant according to all then applicable Environmental Laws.&nbsp;&nbsp;As a material inducement to Landlord to allow Tenant to use Hazardous Materials in connection with its business, Tenant agrees to deliver to Landlord prior to the Commencement Date a list identifying each type of Hazardous Materials to be brought upon, kept, used, stored, handled, treated, generated on, or released or disposed of from, the Premises and setting forth any and all governmental approvals or permits required in connection with the presence, use, storage, handling, treatment, generation, release or disposal of such Hazardous Materials on or from the Premises ("<font style="font-weight:bold;">Hazardous Materials List</font>").&nbsp;&nbsp;Upon request of Landlord, Tenant shall deliver to Landlord an updated Hazardous Materials List within thirty (30) days following Landlord&#8217;s request.&nbsp;&nbsp;Tenant shall deliver to Landlord true and correct copies of the permits, approvals, reports and correspondence, and storage and management plans relating to the use, storage, handling, treatment, generation, release or disposal of Hazardous Materials by Tenant at the Premises.&nbsp;&nbsp; At any time following Tenant's receipt of a request from Landlord, Tenant shall promptly complete a "hazardous materials questionnaire" using the form then-provided by Landlord.&nbsp;&nbsp;At least three (3) months prior to the surrender of the Premises, Tenant shall deliver to Landlord a narrative description of the actions proposed (or required by any governmental authority) to be taken by Tenant in order to surrender the Premises (including any Alterations permitted by Landlord to remain in the Premises, the Improvements and Laboratory Reusable Installations) at the expiration or earlier termination of the Term, free from any residual impact from the Tenant&#8217;s use of Hazardous Materials and otherwise released for unrestricted use and occupancy consistent with Tenant&#8217;s obligations under <font style="font-weight:bold;">Section 5.5(e)</font> below (the "<font style="font-weight:bold;">Surrender Plan</font>").&nbsp;&nbsp;Tenant&#8217;s Surrender Plan shall state that, (a) (i) all laboratory space, including floors, walls, ceilings, counters, piping, supply lines, waste lines and plumbing in or serving the Premises and all exhaust or other ductwork in or serving the Premises, and (ii) any applicable systems shared by laboratory space, including without limitation exhaust or other ductwork, in or serving the Premises have been de-commissioned to the extent required by, and in accordance with, applicable Laws and in accordance with best industry practice; (b) the interior surfaces of the Premises (including floors, walls, ceilings, and counters), piping, supply lines, waste lines and plumbing, and all such </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU26"></a>exhaust or other ductwork in the Premises, may be reused by a subsequent tenant or </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_199"></a>disposed of in compliance with applicable Laws without:&nbsp;&nbsp;(i) incurring special costs on account of uncompleted de-commissioning work; (ii) undertaking special procedures for demolition, disposal, investigation, assessment, cleaning or removal of such Hazardous Materials related to the former laboratory use areas of the Premises; or (iii) giving notice in connection with such Hazardous Materials; and (c) the Premises may be reoccupied for office or laboratory use, or demolished or renovated without:&nbsp;&nbsp;(i) incurring special costs on account of uncompleted de-commissioning work; (ii) undertaking special procedures for disposal, investigation, assessment, cleaning or removal of Hazardous Materials; or (iii) giving notice in connection with Hazardous Materials.&nbsp;&nbsp;Further, for purposes of clauses (b) and (c), &#8220;special costs&#8221; or &#8220;special procedures&#8221; shall mean costs or procedures, as the case may be, that would not be incurred but for the nature of the Hazardous Materials as Hazardous Materials instead of non-Hazardous Materials.&nbsp;&nbsp;The final report shall also include reasonable detail concerning the clean-up measures taken, the clean-up locations, the tests run and the analytic results</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> applicable to the above</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Any handling, treatment, transportation, storage, disposal or use of Hazardous Materials by Tenant in or about the Premises or the Property and Tenant&#8217;s use of the Premises shall comply with all applicable Environmental Laws.&nbsp;&nbsp;Without Landlord&#8217;s prior written consent, Tenant shall not conduct any sampling or investigation of soil or groundwater on the Property to determine the presence of any constituents therein.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_200"></a><a name="_cp_text_1_202"></a>(c)<font style="margin-left:36pt;"></font><a name="_cp_text_1_200"></a>Tenant shall indemnify, defend upon demand with counsel reasonably acceptable to Landlord, and hold Landlord and the Landlord Parties (as hereinafter defined) harmless from and against, any liabilities, losses claims, damages, interest, penalties, fines, reasonable <a name="_cp_text_1_202"></a>attorneys&#8217; and experts&#8217; fees, court costs, remediation costs, and other expenses which result from the use, storage, handling, treatment, transportation, release, threat of release or disposal of Hazardous Materials in or about the Premises or the Property by Tenant or Tenant&#8217;s agents, employees, contractors or invitees.&nbsp;&nbsp;The provisions of this <font style="font-weight:bold;">paragraph&#160;(c)</font> shall survive the expiration or earlier termination of this Lease. </p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_203"></a><a name="_cp_text_4_205"></a>(d)<font style="margin-left:36pt;"></font><a name="_cp_text_2_203"></a>Tenant shall give written notice to Landlord as soon as reasonably practicable of (i) any communication received by Tenant from any governmental authority concerning Hazardous Materials which relates to the Premises or the Property, and (ii)<a name="_cp_text_4_205"></a> any disposal, release or threat of release of Hazardous Materials on, under, from or about the Building or the Property of which Tenant is aware. </p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_206"></a><a name="_AEIOULastRenderedPageBreakAEIOU27"></a><a name="_cp_text_1_207"></a><a name="_cp_text_1_208"></a><a name="_cp_text_1_209"></a><a name="_cp_text_2_210"></a>(e)<font style="margin-left:36pt;"></font><a name="_cp_text_1_206"></a>Upon the expiration of the Term or earlier termination of Tenant&#8217;s right of possession, Tenant shall surrender the Premises to Landlord in the same condition as received, subject to any Alterations or Laboratory Reusable Installations permitted or required by Landlord to remain in the Premises, free of Hazardous Materials (subject to the requirements of <font style="font-weight:bold;">Section 5.5(a)</font>) brought upon, kept, used, stored, handled, treated, generated in, or released or disposed of from, the Premises by any person other than Landlord or any of the Landlord Parties (collectively, &#8220;<font style="font-weight:bold;">Tenant Laboratory Operations</font>&#8221;) and released of all licenses, clearances or other authorization of any kind required to enter </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU27"></a>into and restore the Premises issued by any governmental authority having jurisdiction </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_207"></a>over the use, storage, handling, treatment, generation, release, disposal, removal or remediation of Hazardous Materials, broom clean, ordinary wear and tear and casualty loss and condemnation excepted.&nbsp;&nbsp;Tenant&#8217;s Surrender Plan shall be accompanied by a current listing of (i) all Hazardous Materials licenses and permits held by or on behalf of Tenant or any party claiming by, through or under Tenant with respect to the Premises, and (ii) all Hazardous Materials used, stored, handled, treated, generated, released or disposed of from the Premises, and shall be subject to the review and approval of Landlord&#8217;s environmental consultant.&nbsp;&nbsp;In connection with the review and approval of the Surrender Plan, upon the request of Landlord, Tenant shall deliver to Landlord or its consultant such additional non-proprietary information concerning Tenant Laboratory Operations as Landlord shall </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reasonably </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_208"></a>request.&nbsp;&nbsp;On or before such surrender, Tenant shall deliver to Landlord evidence that the approved Surrender Plan shall have been satisfactorily completed and Landlord shall have the right, subject to reimbursement at Tenant&#8217;s expense as set forth below, to cause Landlord&#8217;s environmental consultant to inspect the Premises and perform such additional procedures as may be deemed reasonably necessary to confirm that the Premises are, as of the effective date of such surrender or early termination of the Lease, free from any residual </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adverse </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_209"></a>impact from Tenant Laboratory Operations.&nbsp;&nbsp;Tenant shall reimburse Landlord, within ten (10) days of demand as Additional Rent, for the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reasonable </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_210"></a>expense incurred by Landlord for Landlord&#8217;s environmental consultant to review and approve the Surrender Plan and to visit the Premises and verify satisfactory completion of the same.&nbsp;&nbsp;Landlord shall have the unrestricted right to deliver such Surrender Plan and any report by Landlord&#8217;s environmental consultant with respect to the surrender of the Premises to third parties</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_213"></a><a name="_cp_text_1_214"></a>(f)<font style="margin-left:36pt;"></font><a name="_cp_text_1_213"></a>Tenant hereby represents and warrants to Landlord that (i) neither Tenant nor any of its legal predecessors has been required by any prior landlord, lender or governmental authority at any time to take remedial action in connection with Hazardous Materials contaminating a property which contamination was permitted by Tenant or <a name="_cp_text_1_214"></a>such predecessor or resulted from Tenant's or such predecessor's action or use of the property in question in violation of Environmental Law, and (ii) Tenant is not subject to any enforcement order issued by any governmental authority in connection with the use, storage, handling, treatment, generation, release or disposal of Hazardous Materials (including, without limitation, any order related to the failure to make a required reporting to any governmental authority).&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU28"></a>(g)<font style="margin-left:36pt;"></font>If Landlord has a reasonable basis to believe that Tenant or any of the Tenant Parties is in violation of any of the terms or conditions of this <font style="font-weight:bold;">Section 5.5</font>, Landlord shall have the right to conduct annual tests of the Premises to determine whether any contamination of the Premises, the Building or the Property has occurred as a result of Tenant's use.&nbsp;&nbsp;In addition, at any time, and from time to time, prior to the expiration or earlier termination of the Term, Landlord shall have the right to conduct appropriate tests of the Premises and the Building to determine if contamination has occurred as a result of Tenant's use of the Premises.&nbsp;&nbsp;In connection with such testing, upon the written request of Landlord, Tenant shall deliver to Landlord or its consultant such non-proprietary information concerning the use of Hazardous Materials in or about the Premises by Tenant or any party claiming by, through or under Tenant.&nbsp;&nbsp;If contamination has occurred for </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which Tenant is liable under this </font><font style="font-weight:bold;">Section 5.5</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU28"></a>, Tenant shall pay all costs to conduct such </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tests.&nbsp;&nbsp;If no such contamination is found, Landlord shall pay the costs of such tests.&nbsp;&nbsp;Tenant shall, at its sole cost and expense, promptly and satisfactorily remediate in accordance with all Environmental Laws any contamination identified by such testing to be in violation of Environmental Laws.&nbsp;&nbsp;Landlord's receipt of or satisfaction with any environmental assessment in no way waives any rights which Landlord may have against Tenant. </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)<font style="margin-left:36pt;"></font>In no event may Tenant install any underground or other storage tanks in or under the Building or at the Property without Landlord&#8217;s prior written consent, which consent may be withheld in Landlord's sole and absolute discretion.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>Tenant's obligations under this <font style="font-weight:bold;">Section 5.5</font> shall survive the expiration or earlier termination of the Lease.&nbsp;&nbsp;Without limitation of Landlord&#8217;s other remedies under this Lease, during any period of time after the expiration or earlier termination of this Lease required by Tenant or Landlord to complete the removal from the Premises of any Hazardous Materials (including, without limitation, the release and termination of any licenses or permits restricting the use of the Premises and the completion of the approved Surrender Plan) or to satisfy Tenant&#8217;s obligations under <font style="font-weight:bold;">Section 5.5(e)</font> above, Tenant shall continue to pay the full Rent in accordance with this Lease for any portion of the Premises not relet by Landlord in Landlord's sole discretion, which Rent shall be prorated daily.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">ARTICLE 6</font><font style="text-decoration:underline;"><br />ASSIGNMENT AND SUBLETTING</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Prohibition</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_239"></a><a name="_cp_text_2_240"></a><a name="_cp_text_1_241"></a><a name="_cp_text_2_242"></a><a name="_cp_field_48_243"></a><a name="_cp_text_2_244"></a><a name="_cp_text_5_245"></a><a name="_cp_text_2_246"></a><a name="_cp_text_5_247"></a><a name="_cp_text_2_248"></a><a name="_cp_field_48_249"></a><a name="_cp_text_2_250"></a><a name="_AEIOULastRenderedPageBreakAEIOU29"></a>(a)<font style="margin-left:36pt;"></font><a name="_cp_text_2_239"></a>Tenant covenants and agrees that neither this Lease nor the term and estate hereby granted, nor any interest herein or therein, will be assigned, mortgaged, pledged, encumbered or otherwise transferred, whether voluntarily, involuntarily, by operation of law <a name="_cp_text_2_240"></a>or otherwise, and that neither the Premises nor any part thereof will be encumbered in any manner by reason of any act or omission on the part of Tenant, or <a name="_cp_text_1_241"></a>used or occupied or permitted to be used or occupied, by anyone other than Tenant, or for any use or purpose other than a Permitted Use, or be sublet (which term, without limitation, shall include granting of concessions, licenses and the like) in whole or in part, or be offered or advertised for assignment or subletting by Tenant or any person acting on behalf of Tenant, without, in each case, the prior written consent of Landlord, which consent shall not be unreasonably withheld, conditioned or delayed, subject to the terms and conditions of <font style="font-weight:bold;">Section 6.2</font> below (all of the foregoing are hereinafter sometimes referred to collectively as &#8220;<font style="font-weight:bold;">Transfers</font>&#8221; and any person to whom any Transfer is made or sought to be made is hereinafter sometimes referred to as a &#8220;<font style="font-weight:bold;">Transferee</font><a name="_cp_text_2_242"></a>&#8221;).<a name="_cp_field_48_243"></a> Without limiting the foregoing, any agreement pursuant to which: <a name="_cp_text_2_244"></a>(x) <a name="_cp_text_5_245"></a>Tenant is relieved from the obligation to pay, or a third party agrees to pay on <a name="_cp_text_2_246"></a>Tenant&#8217;s <a name="_cp_text_5_247"></a>behalf, all or any portion of the Basic Rent or Additional Rent <a name="_cp_text_2_248"></a>under this Lease<a name="_cp_field_48_249"></a>; and/or <a name="_cp_text_2_250"></a>(y) a third party undertakes or is granted by or on behalf of Tenant the right to assign or attempt to assign this Lease or sublet or attempt to sublet all or any portion of the Premises, shall for all purposes hereof </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be deemed to be a Transfer of this Lease and subject to the provisions of this </font><font style="font-weight:bold;">Article 6</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU29"></a>.&nbsp;&nbsp;A </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transfer under this </font><font style="font-weight:bold;">Article 6</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shall also include a sale or other transfer (by one or more transfers) of any of the following:&nbsp;&nbsp;the voting stock, partnership interests, membership or other equity interests in Tenant (or any other mechanism such as the issuance of additional stock or the creation of additional partnership or membership interests) which results in a change of control of Tenant or a sale or other transfer (in one or more transfers) of fifty percent (50%) or more of the assets of Tenant, as if such transfer were an assignment of this Lease.&nbsp;&nbsp;Notwithstanding the foregoing, if equity interests in Tenant at any time are or become traded on a national securities exchange (as defined in the Securities Exchange Act of 1934), the transfer of equity interests in Tenant on a national securities exchange shall not be deemed an assignment within the meaning of this Article; provided, however, that if Tenant is a corporation the outstanding stock of which is listed on a national securities exchange, then any private purchase or buyout of stock shall be deemed a Transfer under this </font><font style="font-weight:bold;">Article 6</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_251"></a><a name="_cp_text_2_252"></a><a name="_cp_text_1_253"></a><a name="_cp_text_2_254"></a><a name="_cp_text_1_256"></a><a name="_cp_text_1_258"></a><a name="_cp_text_1_260"></a><a name="_cp_text_1_262"></a>(b)<font style="margin-left:36pt;"></font><a name="_cp_text_2_251"></a>Notwithstanding the foregoing, Landlord&#8217;s consent shall not be required under <font style="font-weight:bold;">Section 6.1(a),</font> <a name="_cp_text_2_252"></a>and <font style="font-weight:bold;"><a name="_cp_text_1_253"></a>Section <a name="_cp_text_2_254"></a>6.3,</font> <font style="font-weight:bold;">Section 6.4, </font>and<font style="font-weight:bold;"><a name="_cp_text_1_256"></a> Section 6.5  </font><a name="_cp_text_1_258"></a>shall not apply to <a name="_cp_text_1_260"></a>any assignment of this Lease or sublease of all or any portion of the Premises to (x)<a name="_cp_text_1_262"></a> an entity into or with which Tenant is merged or consolidated, or to which all or substantially all of Tenant&#8217;s assets or stock are transferred, or (y) transactions with any entity which controls or is controlled by Tenant or is under common control with Tenant; provided and only on condition that in any such event:</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_264"></a>(i)<font style="margin-left:36pt;"></font>the successor to Tenant has a net worth, computed in accordance with generally accepted accounting principles (&#8220;<font style="font-weight:bold;">GAAP</font><a name="_cp_text_1_264"></a>&#8221;) consistently applied, at least equal to the Tangible Net Worth of Tenant on the date of this Lease,</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font>proof satisfactory to Landlord of the Tangible Net Worth of both the transferee and Tenant shall have been delivered to Landlord at least ten (10) days prior to the effective date of any such transaction, or, if Tenant is prohibited by Law or any restrictions in the agreement facilitating such transaction from disclosing such information prior to the effective date of any such transaction, within ten (10) days following the effective date of any such transaction,</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;"></font>the transfer is for a valid business purpose of Tenant and is not a subterfuge for the provisions of this <font style="font-weight:bold;">Article&#160;6</font>, and</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_266"></a><a name="_cp_text_1_267"></a>(iv)<font style="margin-left:36pt;"></font><a name="_cp_text_1_267"></a>the transferee agrees directly with Landlord, by written instrument in form satisfactory to Landlord in its reasonable discretion, to be bound by all the obligations of Tenant hereunder, including, without limitation, the covenant against further assignment and subletting.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_268"></a><a name="_AEIOULastRenderedPageBreakAEIOU30"></a>Any assignment or sublease under this Section 6.1(b) is referred to herein as a "<font style="font-weight:bold;">Permitted Transfer</font>".&nbsp;&nbsp;<font style="color:#000000;">Except in cases of statutory merger or consolidation or sale of substantially all of the assets or stock of Tenant (and in connection with which </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;"><a name="_AEIOULastRenderedPageBreakAEIOU30"></a>sale Tenant is dissolved and provided the purchaser becomes the named Tenant under </font><font style="color:#000000;">this Lease by operation of law or by written assignment and assumption agreement in form reasonably acceptable to Landlord) in which case the surviving entity in the merger or consolidation or the purchaser of such assets or stock to which this Lease has been assigned shall be </font><font style="text-decoration:underline;color:#000000;">solely</font><font style="color:#000000;"> liable as the Tenant under this Lease, Tenant shall continue to remain fully liable under this Lease, on a joint and several basis with the Permitted Transferee</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Landlord&#8217;s Consent</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_269"></a><a name="_cp_text_1_270"></a><a name="_cp_text_2_271"></a><a name="_cp_text_1_272"></a><a name="_cp_text_2_273"></a><a name="_cp_text_2_275"></a><a name="_cp_text_1_276"></a><a name="_cp_text_2_277"></a><a name="_cp_text_1_278"></a><a name="_cp_text_1_279"></a>(a)<font style="margin-left:36pt;"></font>If Tenant desires Landlord&#8217;s consent to any Transfer, Tenant shall notify Landlord in writing, which notice (the &#8220;<font style="font-weight:bold;">Transfer Notice</font><a name="_cp_text_2_269"></a>&#8221;) shall include (i)&#160;the proposed effective date of the Transfer, which shall not be less than thirty (30)&#160;days nor more than <a name="_cp_text_1_270"></a>one <a name="_cp_text_2_271"></a>hundred <a name="_cp_text_1_272"></a>eighty <a name="_cp_text_2_273"></a>(180<a name="_cp_text_2_275"></a>)&#160;days after the date of delivery of the Transfer Notice, (ii) a description of the portion of the Premises to be transferred, (iii)&#160;all of the terms of the proposed Transfer and the consideration therefor, including the name and address of the proposed Transferee, and an executed copy<a name="_cp_text_1_276"></a>  <a name="_cp_text_2_277"></a>of all documentation <a name="_cp_text_1_278"></a>effectuating <a name="_cp_text_1_279"></a>the proposed Transfer, including all operative documents to evidence such Transfer and all agreements incidental or related to such Transfer, (iv)&#160;current financial statements of the proposed Transferee certified by an officer, partner or owner thereof, business credit and personal references and history of the proposed Transferee and any other information reasonably required by Landlord which will enable Landlord to determine the financial responsibility, character, and reputation of the proposed Transferee, nature of such Transferee&#8217;s business and proposed use of the Premises.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>In the event Landlord does not exercise its options pursuant to <font style="font-weight:bold;">Section&#160;6.5</font> below to recapture the Premises or terminate this Lease in whole or in part, Landlord&#8217;s consent to a proposed Transfer shall not be unreasonably withheld, conditioned or delayed, provided and upon condition that:</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>There shall not be an Event of Default that remains uncured;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font>In Landlord&#8217;s reasonable judgment the proposed Transferee is engaged in a business which is in keeping with the then standards of the Building and Property and the proposed use is limited to the Permitted Use, including being classified by the UBC (as hereinafter defined) as a &#8220;B&#8221; occupancy area for the use and storage of Hazardous Materials;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;"></font>The proposed Transferee is a reputable entity and has sufficient financial worth and stability in light of the responsibilities to be undertaken, based on evidence provided by Tenant (and others) to Landlord, as determined by Landlord in its reasonable discretion;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)<font style="margin-left:36pt;"></font>The proposed Transferee is not then a tenant of Landlord at any part of the Property, provided that Landlord has competing space of similar size available;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_2_290"></a><a name="_cp_text_2_289"></a><a name="_AEIOULastRenderedPageBreakAEIOU31"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The proposed Transferee is not a person or entity with whom Landlord is then, or during the preceding four (4) months has been, actively negotiating to lease space at the Property;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_292"></a><a name="_cp_blt_2_291"></a>(vi)<font style="margin-left:36pt;"></font>The proposed Transferee or any person or entity which, directly or indirectly, controls, is controlled by, or is under common control with, the proposed Transferee is not a direct or indirect competitor, in the footwear or apparel industry, of Landlord or any of Landlord&#8217;s affiliates, including, without limitation, New Balance Athletic Shoe, Inc. or any successor thereto, (a &#8220;<font style="font-weight:bold;">Landlord Competitor</font>&#8221;)</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_294"></a><a name="_cp_blt_2_293"></a>(vii)<font style="margin-left:36pt;"></font>The proposed Transfer shall be in form reasonably satisfactory to Landlord and shall comply with the applicable provisions of this <font style="font-weight:bold;">Article&#160;6</font>;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_296"></a><a name="_cp_blt_2_295"></a>(viii)<font style="margin-left:36pt;"></font>Tenant shall not have advertised or publicized in any way the availability of the Premises at rental rate less than the base rent and additional rent at which Landlord is then offering to lease other space located in the Building without prior notice to and approval by Landlord, which approval shall not be unreasonably withheld, conditioned or delayed;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_2_297"></a><a name="_cp_text_2_298"></a>(ix)<font style="margin-left:36pt;"></font>With respect to a proposed sublease, the&nbsp;&nbsp;proposed sublease involves, in Landlord&#8217;s reasonable judgment, a portion of the Premises which is independently leasable space;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_306"></a><a name="_cp_blt_2_305"></a><a name="_cp_text_1_302"></a>(x)<font style="margin-left:36pt;"></font><a name="_cp_text_1_302"></a>With respect to and after taking into account a proposed sublease, there will not be more than three (3) different entities (including Tenant) occupying the Premises;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_2_307"></a><a name="_cp_text_2_308"></a>(xi)<font style="margin-left:36pt;"></font>Intentionally omitted;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_312"></a><a name="_cp_blt_2_311"></a>(xii)<font style="margin-left:36pt;"></font>The proposed Transfer shall not have (or potentially have) any adverse effect on any real estate investment trust qualification requirements of Landlord or any of its affiliates or otherwise cause Landlord or any of its affiliates to be in violation of any Laws to which Landlord or such affiliate is subject, including, without limitation, the Employment Retirement Security Act of 1974;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_2_313"></a><a name="_cp_text_2_314"></a>(xiii)<font style="margin-left:36pt;"></font>If required in the mortgage documents or ground lease, the holder of any Superior Mortgage and/or Superior Lease, as applicable, consents to such Transfer; and</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_318"></a><a name="_cp_blt_2_317"></a>(xiv)<font style="margin-left:36pt;"></font>Neither the identity nor business of the proposed Transferee would cause Landlord to be in violation of any covenant or restriction contained in another lease then in effect at the Property.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU32"></a>(c)<font style="margin-left:36pt;"></font>As a condition to an assignment or subletting, whether Landlord&#8217;s consent is required or not, Landlord may require a Hazardous Materials List, certified by </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the proposed assignee or sublessee to be true and correct, which the proposed assignee or sublessee intends to use, store, handle, treat, generate in or release or dispose of from the Premises, together with copies of all documents relating to such use, storage, handling, treatment, generation, release or disposal of Hazardous Materials by the proposed assignee or subtenant in the Premises, prior to the proposed assignment or subletting, including, without limitation:&nbsp;&nbsp;permits; approvals; reports and correspondence; and storage and management plans.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Acceptance of Rent</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_323"></a>.&nbsp;&nbsp;If this Lease is assigned, or if the Premises or any part thereof is sublet or occupied by anyone other than Tenant, whether or not in violation of the terms and conditions of the Lease, Landlord may, at any time and from time to time, collect rent and other charges from the Transferee, and apply the net amount collected to the rent and other charges herein reserved, but no such Transfer, collection or modification of any provisions of this Lease shall be deemed a waiver of this covenant, or the acceptance of the Transferee as a tenant or a release of Tenant from the further performance of covenants on the part of Tenant to be performed hereunder. Any consent by Landlord to a particular Transfer or other act for which Landlord&#8217;s consent is required under <font style="font-weight:bold;">paragraph&#160;(a)</font> of <font style="font-weight:bold;">Section&#160;6.1</font> shall not in any way diminish the prohibition stated in <font style="font-weight:bold;">paragraph&#160;(a)</font> of <font style="font-weight:bold;">Section&#160;6.1</font><a name="_cp_text_1_323"></a> as to any further such Transfer or other act or the continuing liability of the Original Tenant.&nbsp;&nbsp;No Transfer hereunder shall relieve Tenant from its obligations hereunder, and Tenant shall remain fully and primarily liable therefor.&nbsp;&nbsp;Landlord may revoke any consent by Landlord to a particular Transfer if the Transfer does not provide that the Transferee agrees to be independently bound, by and upon all of the covenants, agreements, terms, provisions and conditions set forth in this Lease on the part of Tenant to be kept and performed, and as may be applicable to a subtenancy.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Excess Payments</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_324"></a><a name="_cp_text_2_325"></a><a name="_cp_text_2_326"></a><a name="_cp_text_2_327"></a><a name="_cp_text_1_328"></a><a name="_cp_text_2_324"></a>.&nbsp;&nbsp;If Tenant assigns this Lease or sublets the Premises or any portion thereof, Tenant shall pay to Landlord as Additional Rent fifty percent (50%) of the amount, if any, by which (a)<a name="_cp_text_2_325"></a> any and all compensation received by Tenant as a result of such Transfer, net only of reasonable expenses actually incurred by Tenant in connection with such Transfer, including, but not limited to brokerage commissions, legal fees, and in the instance of a sublease, demising and&nbsp;&nbsp;leasehold improvement costs (prorated over the term of the Transfer), as well as any unamortized portion of leasehold improvements paid for directly by Tenant for the Premises, exceeds (b)<a name="_cp_text_2_326"></a>&nbsp;&nbsp;in the case of an assignment, the Basic Rent and Additional Rent under this Lease, and in the case of a subletting, <a name="_cp_text_2_327"></a>the portion of the Basic Rent and Additional Rent allocable to the portion of the Premises subject to such subletting.&nbsp;&nbsp;Notwithstanding the foregoing, Tenant shall not be required to share any rent attributable to the leasing of equipment to a subtenant.&nbsp;&nbsp;Such payments shall be made on the date the corresponding payments under this Lease are due.&nbsp;&nbsp;Notwithstanding the foregoing, the provisions of this Section shall impose no obligation on Landlord to consent to <a name="_cp_text_1_328"></a>an assignment of this Lease or a subletting of all or a portion of the Premises.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Landlord&#8217;s Recapture Right</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU33"></a>.&nbsp;&nbsp;Notwithstanding anything herein to the contrary, in addition to withholding or granting consent with respect to any proposed Transfer, in the event the Transfer request relates to fifty percent (50%) or more of the Premises for the balance of the Term, Landlord shall have the right, to be exercised in writing within thirty (30) days after receipt of a Transfer Notice, to terminate this Lease (in the event of a proposed assignment for the remainder of the Term) or terminate that portion of the Premises to be subleased (in the event </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of a proposed sublease); provided, however, Tenant shall have the right to rescind any request for sublease consent if Landlord exercises its right to recapture in accordance with the terms and conditions of this </font><font style="font-weight:bold;">Section 6.5</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, by providing written notice to Landlord within five (5) Business Days of Tenant&#8217;s receipt of Landlord&#8217;s notice of its intent to recapture such subleased portion of the Premises.&nbsp;&nbsp;In the case of a proposed assignment, this Lease shall terminate as of the date (the &#8220;</font><font style="font-weight:bold;">Recapture Date</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) which is the later of </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> sixty (60) days after receipt of Landlord&#8217;s written notice of such election, and </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the proposed effective date of such Transfer, as if such date were the last day of the Term of this Lease.&nbsp;&nbsp;In either event, if requested by Tenant, Landlord shall provide not less than ninety (90) days from the Recapture Date to allow Tenant to vacate and surrender the Premises, including to comply with the requirements of </font><font style="font-weight:bold;">Section&#160;5.5</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;If Landlord exercises the rights under this </font><font style="font-weight:bold;">Section 6.5</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in connection with a proposed sublease, this Lease shall be deemed amended to eliminate the proposed sublease premises from the Premises as of the Recapture Date, and thereafter all Basic Rent and Expense Charges shall be appropriately prorated to reflect the reduction of the Premises as of the Recapture Date.&nbsp;&nbsp;If Landlord recaptures Tenant&#8217;s sublease space which is less than all of the Premises, as a condition to Landlord&#8217;s recapture, Landlord shall agree, at its cost, to separately demise the recapture space from the balance of the Premises and otherwise adjust all mechanical systems and utilities to provide the same level of service to the retained Premises as had existed prior to Landlord exercising its recapture right.&nbsp;&nbsp;In the event that Landlord exercises its termination right herein, Tenant shall be relieved and discharged from any further obligations under the Lease with respect to that portion of the Premises terminated by Landlord (but not any obligations accruing prior to such termination date) as of the termination date or such later date as Tenant fully vacates and surrenders the recapture space to Landlord in accordance with the terms and conditions of this Lease, including, without limitation, </font><font style="font-weight:bold;">Section 5.5</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of this Lease.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Further Requirements</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_331"></a><a name="_cp_text_1_332"></a><a name="_cp_text_1_331"></a>.&nbsp;&nbsp;Tenant shall reimburse Landlord on demand, as Additional Rent, for any reasonable out&#8209;of<a name="_cp_text_1_332"></a>&#8209;pocket costs (including reasonable attorneys&#8217; fees and expenses), not to exceed $3,000 in each instance, incurred by Landlord in connection with any actual or proposed assignment or sublease or other act described in <font style="font-weight:bold;">paragraph (a)</font> of <font style="font-weight:bold;">Section&#160;6.1</font>, whether or not consummated, including the costs of making investigations as to the acceptability of the proposed assignee or subtenant.&nbsp;&nbsp;Any sublease to which Landlord gives its consent shall not be valid unless and until Tenant and the sublessee execute a consent agreement in form and substance satisfactory to Landlord in its reasonable discretion and a fully executed counterpart of such sublease has been delivered to Landlord.&nbsp;&nbsp;Any sublease shall provide that: (i) the term of the sublease ends no later than one day before the last day of the Term of this Lease; (ii) such sublease is subject and subordinate to this Lease; (iii) Landlord may enforce the provisions of the sublease, including collection of rents; and (iv) in the event of termination of this Lease or reentry or repossession of the Premises by Landlord, Landlord may, at its sole discretion and option, take over all of the right, title and interest of Tenant, as sublessor, under such sublease, and such subtenant shall, at Landlord&#8217;s option, attorn to Landlord, but nevertheless Landlord shall not (A) be liable for any previous act or omission of Tenant under such sublease; (B) be subject to any defense or offset previously accrued in favor of the subtenant against Tenant; or (C) be bound by any previous modification of such sublease made without Landlord&#8217;s written consent or by any previous prepayment of more than one month&#8217;s rent.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU34"></a><font style="text-decoration:none;">ARTICLE 7</font><font style="text-decoration:underline;"><br />RESPONSIBILITY FOR REPAIRS AND CONDITION OF PREMISES; SERVICES TO BE FURNISHED BY LANDLORD </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Landlord Repairs</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_333"></a><a name="_cp_text_1_335"></a><a name="_cp_text_1_337"></a><a name="_cp_text_1_339"></a><a name="_cp_text_1_341"></a><a name="_cp_text_2_342"></a><a name="_cp_text_2_344"></a><a name="_cp_text_1_345"></a><a name="_cp_text_1_346"></a><a name="_cp_text_1_347"></a><a name="_cp_text_2_349"></a><a name="_cp_text_1_351"></a><a name="_cp_text_1_352"></a><a name="_cp_text_1_354"></a><a name="_cp_text_1_355"></a><a name="_cp_text_1_357"></a>(a)<font style="margin-left:36pt;"></font><a name="_cp_text_1_333"></a>Except as otherwise provided in this Lease, Landlord agrees to  maintain, repair and replace so as to <a name="_cp_text_1_335"></a>keep in good working <a name="_cp_text_1_337"></a>order, condition and repair, and in compliance with all applicable Laws, the Structural Elements of the Building, including exterior glass<a name="_cp_text_1_339"></a>, the Base Building and Base Building Systems up to the point of connection with the Premises (but specifically excluding any supplemental heating, ventilation or air conditioning equipment or systems exclusively serving the Premises installed at Tenant&#8217;s request or as a result of Tenant&#8217;s requirements in excess of Building standard design criteria), except that Landlord shall in no event be responsible to Tenant for the repair of interior <a name="_cp_text_1_341"></a>glass in the Premises or <a name="_cp_text_2_342"></a>the doors (or related glass and finish work) leading to the Premises, or subject to <font style="font-weight:bold;">Section 10.5</font>, any condition in the Premises or the Building caused by any act or neglect of Tenant, its invitees or contractors<a name="_cp_text_2_344"></a>.&nbsp;&nbsp;Landlord shall also keep<a name="_cp_text_1_345"></a> and <a name="_cp_text_1_346"></a>maintain <a name="_cp_text_1_347"></a>the Parking Garage and all Common Facilities in a good and clean working <a name="_cp_text_2_349"></a>order, condition and repair, free of snow and accumulation of dirt and rubbish and with reasonable treatment of ice on driveways and pedestrian walkways, and shall keep, <a name="_cp_text_1_351"></a>maintain, and repair <a name="_cp_text_1_352"></a>all landscaped areas on the Property in a neat and orderly condition.&nbsp;&nbsp;Subject to the terms and conditions of this Lease, Landlord shall be responsible for the maintenance, replacement and repair of <a name="_cp_text_1_354"></a>Laboratory Systems only to the portion of the valve or cap for such system on each floor that connects to and exclusively services the Premises; Tenant hereby agreeing that any such portion of such system that extends from the point of such valve or cap connection on each floor to and in the Premises shall not be considered a Laboratory System.&nbsp;&nbsp;<a name="_cp_text_1_355"></a>Landlord shall not be responsible to maintain or make any improvements or repairs to the Building other than as expressly in this <font style="font-weight:bold;">Section&#160;7.1</font><a name="_cp_text_1_357"></a> provided, unless expressly provided otherwise in this Lease.&nbsp;&nbsp;Landlord shall be responsible for the repair and maintenance of any base Building HVAC (as hereinafter defined), subject to such expense being properly includable as an Operating Expense; provided, however, the costs otherwise covered under HVAC warranty or insurance shall not be included as an Operating Expense. </p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_2_358"></a>(b)<font style="margin-left:36pt;"></font>Landlord shall not be liable for any failure to make repairs in the Premises which Landlord has undertaken to make under the provisions of this <font style="font-weight:bold;">Section&#160;7.1</font> or elsewhere in this Lease, unless Tenant has given notice to Landlord of the need to make such repairs (unless Landlord otherwise is known to have actual knowledge of the need for such repairs), and Landlord has failed to commence to make such repairs within a reasonable time after receipt of such notice, or fails to proceed with reasonable diligence to complete such repairs.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU35"></a>(c)<font style="margin-left:0pt;"></font>Except with respect to Tenant&#8217;s obligations under <font style="font-weight:bold;">Section 7.2(b)</font> of this Lease to comply with applicable Laws, Landlord shall, as part of Operating Expenses to the extent permitted pursuant to <font style="font-weight:bold;">Article 9</font> and <font style="font-weight:bold;text-decoration:underline;">Exhibit F</font> of this Lease, maintain the Common Facilities of the Property, the Parking Garage, the Structural Elements of the Building, the Base Building Systems and the Laboratory Systems serving </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Premises and the Building in general in compliance with applicable Laws.&nbsp;&nbsp;Landlord agrees to operate the Building s in a manner consistent with Comparable Buildings.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Tenant Repairs; Compliance with Laws</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_360"></a><a name="_cp_text_2_361"></a><a name="_cp_text_1_362"></a><a name="_cp_text_2_364"></a><a name="_cp_text_1_365"></a>(a)<font style="margin-left:36pt;"></font><a name="_cp_text_1_360"></a>Tenant shall keep and maintain the Premises and the Improvements, Laboratory Reusable Installations, fixtures and appurtenances therein or thereon (including, without limitation, electrical and mechanical or laboratory systems  not considered part of the Base Building Systems or Laboratory Systems or any portion of such systems that have been installed for the exclusive use and benefit of Tenant such as additional HVAC equipment, hot water heaters, electronic, data, phone, and other telecommunications cabling and related equipment, and security or telephone systems for the Premises), neat and clean and in good order, condition and repair, <font style="text-decoration:underline;">excepting only</font><a name="_cp_text_2_361"></a> those repairs for which Landlord is responsible under the terms of this Lease, <a name="_cp_text_1_362"></a>reasonable <a name="_cp_text_2_364"></a>wear and tear, and damage by fire or other casualty or as a consequence of the exercise of the power of eminent domain; and Tenant shall surrender the Premises, at the end of the Term, in such condition.&nbsp;&nbsp;For the avoidance of doubt, Tenant shall be responsible for the Laboratory Systems which serve the Premises from the point of valve or cap connection on each floor to the Premises.&nbsp;&nbsp;Tenant shall be responsible for all Tenant <a name="_cp_text_1_365"></a>specific equipment.&nbsp;&nbsp;Subject to <font style="font-weight:bold;">Section&#160;10.5</font> regarding waiver of subrogation, Tenant shall be responsible for the cost of repairs which may be made necessary by reason of damage to the Building caused by any act or neglect of Tenant, or its employees, contractors or invitees (including any damage by fire or other casualty arising therefrom).&nbsp;&nbsp;Tenant shall be responsible for the installation of any fire suppression or fire rating system that is required for Tenant&#8217;s use, other than the Base Building fire protection system to the extent installed by Landlord pursuant to the Landlord/Tenant Matrix (as hereinafter defined) attached as Schedule 1 to <font style="font-weight:bold;text-decoration:underline;">Exhibit C</font> as shall be provided as part of the Base Building Systems.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_367"></a><a name="_cp_field_48_368"></a><a name="_cp_text_2_371"></a><a name="_cp_text_5_372"></a><a name="_cp_text_2_373"></a><a name="_cp_text_1_374"></a><a name="_cp_text_2_375"></a><a name="_AEIOULastRenderedPageBreakAEIOU36"></a>(b)<font style="margin-left:36pt;"></font>Tenant shall comply with all Laws from time to time in effect and all directions, rules and regulations of governmental agencies having jurisdiction, and the standards recommended by the local Board of Fire Underwriters applicable to the Premises and Tenant&#8217;s use and occupancy thereof and its business and operations therein, and shall, at Tenant&#8217;s expense, obtain all permits, licenses and the like required thereby. Notwithstanding the foregoing, <font style="color:#000000;">Tenant shall not be obligated to make structural repairs or alterations to the Premises in order to comply with any Laws unless the need for such repairs or alterations arises from (i)<a name="_cp_text_2_367"></a> the specific manner and nature of Tenant&#8217;s use or occupancy of the Premises, as distinguished from mere general office<a name="_cp_field_48_368"></a>, research and development uses, including a biotechnical and laboratory use in compliance with the Permitted Use hereunder, (ii) <a name="_cp_text_2_371"></a>any cause or condition created by <a name="_cp_text_5_372"></a>or at the insistance of the Tenant<a name="_cp_text_2_373"></a>, including, without limitation, <a name="_cp_text_1_374"></a>the performance of <a name="_cp_text_2_375"></a>the Tenant Work and/or any other Alterations made by Tenant, or (iii) a breach by Tenant of any provisions of this Lease.&nbsp;&nbsp;Any of the foregoing conditions caused by any employee, agent, contractor, or subtenant of Tenant or any other party claiming by, through, or under Tenant shall be attributable to Tenant for purposes of this Lease.&nbsp;&nbsp;</font>Tenant shall also be responsible for the cost of compliance with all present and future Laws in respect of the Building to the extent arising from any of the causes set forth in <font style="font-weight:bold;">clauses&#160;(i)</font> through <font style="font-weight:bold;">(iv)</font> above of this <font style="font-weight:bold;">Section </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">7.2(b)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, in which event Tenant shall be responsible to perform, at Tenant's sole cost and expense, such repairs or alterations, whether or not such compliance requires work which is structural or non-structural, ordinary or extraordinary, foreseen or unforeseen</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>If repairs are required to be made by Tenant pursuant to the terms hereof, Landlord may demand that Tenant make the same promptly, and if Tenant refuses or neglects to commence and complete such repairs within the applicable time period therefor set forth in <font style="font-weight:bold;">Section 14(a)(ii) </font>of this Lease (except in the case of Emergency, including without limitation, notice of an unsafe condition in the Premises, in which event Landlord may make such repairs immediately and without notice), Landlord may (but shall not be required to do so) make or cause such repairs to be made and the provisions of <font style="font-weight:bold;">Section&#160;14.4</font> shall be applicable to the costs thereof.&nbsp;&nbsp;Landlord shall make a commercially reasonable effort to notify Tenant, which notification may be oral, of Landlord&#8217;s exercise of its rights under this <font style="font-weight:bold;">Section 7.2(c)</font>.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Floor Load &#8209; Heavy Machinery</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Tenant shall not place a load upon any floor in the Premises exceeding the limit such floor was designed to supports or such lower amount as may be proscribed by applicable Law.&nbsp;&nbsp;Landlord reserves the right to prescribe the weight and position of all business machines and mechanical equipment, including safes, which shall be placed so as to distribute the weight. Business machines and mechanical equipment shall be placed and maintained by Tenant at Tenant&#8217;s expense in settings sufficient, in Landlord&#8217;s judgment, to absorb and prevent vibration, noise and annoyance.&nbsp;&nbsp;Tenant shall not move any safe, heavy machinery, heavy equipment, freight, bulky matter or fixtures into or out of the Building without Landlord&#8217;s prior consent, which consent may include a requirement to provide insurance, naming Landlord as an insured, in such amounts as Landlord may deem reasonable.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>If any such safe, machinery, equipment, freight, bulky matter or fixtures requires special handling, Tenant agrees to employ only persons holding a Master Rigger&#8217;s license to do such work, and that all work in connection therewith shall comply with applicable Laws.&nbsp;&nbsp;Any such moving shall be at the sole risk and hazard of Tenant, and Tenant will exonerate, indemnify and save Landlord harmless against and from any liability, loss, injury, claim or suit resulting directly or indirectly from such moving.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Utility Services</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_384"></a><a name="_cp_text_1_386"></a><a name="_cp_text_1_387"></a><a name="_AEIOULastRenderedPageBreakAEIOU37"></a><a name="_cp_text_1_388"></a>(a)<font style="margin-left:36pt;"></font><a name="_cp_text_2_384"></a>Tenant shall pay for all water (including the cost to service, repair and replace reverse osmosis, de-ionized and other treated water), gas, heat, light, power<a name="_cp_text_1_386"></a>, telephone, internet service, cable television, other telecommunications and other utilities supplied to the Premises, together with any fees, surcharges and taxes thereon charged by the applicable utility provider<a name="_cp_text_1_387"></a>.&nbsp;&nbsp;Electricity and gas supplied to the Premises shall each be separately metered, and chilled water and HVAC airflow for the Laboratory Systems shall be separately submetered or check metered.&nbsp;&nbsp;Tenant shall be entitled to use up to fourteen (14) watts per usable square foot of the Laboratory Portion of the Premises and up to six (6) watts per usable square foot of the Office Portion of the Premises of electrical power. &nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_388"></a>Tenant shall be responsible for procuring and paying for separately metered utilities directly to the provider of the utilities.&nbsp;&nbsp;If any utility is not separately metered or submetered to Tenant, Tenant shall pay either Tenant&#8217;s pro rata share, as the case may be, of all charges of such utility jointly metered with other premises, or Tenant&#8217;s Occupied Laboratory Share (as hereinafter defined), as reasonably determined by Landlord, as Additional Rent or, in the alternative, Landlord may, at its option, monitor the usage of such utilities by Tenant and charge Tenant with the cost of purchasing, installing and monitoring such metering equipment, which cost shall be paid by Tenant as Additional Rent</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, unless such separate meters or submeters are installed as part of the Tenant Work, in which event the cost of installation shall be included in the cost of such work</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Landlord may base its bills for utilities on reasonable estimates; provided that Landlord adjusts such billings to reflect the actual cost of providing utilities to the Premises no less than quarterly.&nbsp;&nbsp;To the extent that Tenant uses more than Tenant&#8217;s Laboratory Share of any utilities attributable to the Laboratory Systems or more than Tenant&#8217;s Pro Rata Share of the Office Portion of any utilities attributable to the Building Systems, then Tenant shall pay Landlord for Tenant&#8217;s increased share of such utilities to reflect such excess.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Tenant shall be responsible for the installation of the following check meters (i) the standard flow meter on each floor at the capped connection for non-potable cold water, (ii) the standard flow meter on the supply line and deductive meter on the return line at each floor, located at the capped connection, for non-potable hot water supply and return, (iii) the standard flow meter at each floor, located at the capped connection, for tempered water, (iv) polypropylene purified water meter on the supply line and deductive meter on the return line at each floor, located at the capped connection, for the RO/DI system, (v) mass flow meter at each floor, located at the capped connection, for compressed air, (vi) mass flow meter at each floor, located at the capped connection, for the vacuum system, (vii) chilled water meters on the capped chilled water connections on each floor to meter supplemental chilled water usage, (viii) hot water meters on the capped hot water connections on each floor to meter hot water usage, and (ix) condenser water meters on the capped condenser water connection on each floor to meter condenser water usage (collectively, the &#8220;<font style="font-weight:bold;">Tenant Installed Checkmeters</font>&#8221;).&nbsp;&nbsp;Tenant shall be responsible for the ongoing repair and maintenance of any Tenant Installed Checkmeters.&nbsp;&nbsp;Tenant shall also be responsible for providing bus tap, meter and meter socket at each floor for direct utility metering and an electronic check meter for tenant equipment connected to the Generator.&nbsp;&nbsp;In the event Tenant requires natural gas on any floor within the Premises, Tenant shall be required to request gas service installation from the utility provider and would be billed directly with a separate meter.&nbsp;&nbsp;Notwithstanding anything to the contrary contained herein, in no event shall Tenant be entitled to occupy all or any portion of the Premises until the Tenant Installed Checkmeters have been installed by Tenant and are fully operational.&nbsp;&nbsp;At Tenant&#8217;s election, Tenant shall be entitled to include the installation of the Tenant Installed Checkmeters as part of the Tenant Work pursuant to <font style="font-weight:bold;text-decoration:underline;">Exhibit D</font> but at Tenant&#8217;s sole cost and expense.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_395"></a><a name="_cp_blt_2_394"></a><a name="_cp_blt_1_389"></a><a name="_AEIOULastRenderedPageBreakAEIOU38"></a>(c)<font style="margin-left:36pt;"></font>Notwithstanding anything in this Lease to the contrary, Tenant shall pay the cost of utilities used in the Premises based on the consumption thereof as metered by the applicable Tenant Installed Checkmeters and/or any separate meters or submeters installed by Tenant at the rates for the applicable utility then being charged by </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the applicable public utility (together with all taxes and fees included by the utility provider), without markup or any additional fees or charges added by Landlord.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_391"></a><a name="_cp_text_2_392"></a>(d)<font style="margin-left:36pt;"></font><a name="_cp_text_1_391"></a>In the event any governmental entity promulgates or revises any Law, or issues mandatory controls relating to the use or conservation of energy, water, gas, light or electricity, or the provision of any other utility or service furnished by Landlord in the Building, Landlord may take any appropriate action to comply with such provision of Law or mandatory controls, including the making of alterations to the Building, subject, however, to the terms and conditions of this Lease.&nbsp;&nbsp;Tenant agrees to provide, within 10 Business Days of request by Landlord, such information and documentation as may be needed for compliance with any energy reporting or sustainability requirements as may be adopted from time to time by the City of Boston or any other governmental authority with jurisdiction over the Building, which information shall include, without limitation, usage at or by the Premises of electricity, natural gas, steam, hot or chilled water or other energy.&nbsp;&nbsp;Neither Landlord&#8217;s actions nor its failure to act shall entitle Tenant to any damages, abate or suspend Tenant&#8217;s obligation to pay Basic Rent and Additional Rent or constitute or be construed as a constructive or other eviction of Tenant except as otherwise specifically set forth herein.&nbsp;&nbsp;The parties hereto shall comply with all mandatory energy conservation controls and requirements applicable to the Building that are imposed or instituted by the federal, state, county or municipal governments and are of general applicability to the occupants of the Building, including, without limitation, controls on the permitted range of temperature settings in office/retail buildings, and  <a name="_cp_text_2_392"></a>requirements necessitating curtailment of the volume of energy consumption or the hours of operation of the Building.&nbsp;&nbsp;Any terms or conditions of this Lease that conflict or interfere with compliance with such controls or requirements shall be suspended for the duration of such controls or requirements.&nbsp;&nbsp;Compliance with such controls or requirements shall not be considered an eviction, actual or constructive, of Tenant from the Premises and shall not entitle Tenant to terminate this Lease or to an abatement of any Rent payable hereunder.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Other Services</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU39"></a>(a)<font style="margin-left:36pt;"></font>For the Office Portion of the Premises only, Landlord shall provide Base Building heating, ventilation and air-conditioning (&#8220;<font style="font-weight:bold;">HVAC</font>&#8221;) for heating and cooling as normal seasonal changes may require to provide reasonably comfortable space temperature and ventilation for occupants of the Office Portion of the Premises under normal business operation for general office use during Building Service Hours as defined below and substantially in accordance with the HVAC Specifications for the Office Portion of the Building attached hereto as <font style="font-weight:bold;text-decoration:underline;">Exhibit J</font>.&nbsp;&nbsp;Landlord agrees to carry a separate maintenance contract on the HVAC units and/or systems, which maintenance contract cost shall be included as part of Operating Expenses.&nbsp;&nbsp;If Tenant shall require air conditioning, heating or ventilation outside the hours and days above specified for the office portion of the Premises, Landlord may furnish such service and Tenant shall pay therefor such charges as may from time to time be in effect for the Building upon demand as Additional Rent.&nbsp;&nbsp;In the event Tenant introduces into the Premises personnel or equipment which overloads the capacity of the Building system or in any other way interferes with the system&#8217;s ability to perform adequately its proper functions, supplementary systems may, if </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and as needed, at Landlord&#8217;s option, be provided by Landlord, at Tenant&#8217;s expense.&nbsp;&nbsp;&#8220;</font><font style="font-weight:bold;">Building Service Hours</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; are 8:00 A.M. to 6:00 P.M. on Business Days and, upon at least 24 hours prior written request by Tenant, 8:00 A.M. to 1:00 P.M. on Saturdays, in all events, excluding the holidays set forth in </font><font style="font-weight:bold;">Section 1.1</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of this Lease.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>For the Laboratory Portion of the Premises, Landlord shall provide Base Building HVAC for heating and cooling as normal seasonal changes may require to provide code required ventilation for occupants of the Laboratory Portion of the Premises under normal business operation for general laboratory use and substantially in accordance with the HVAC Specifications attached hereto as <font style="font-weight:bold;text-decoration:underline;">Exhibit J</font> for the Laboratory Portion of the Building.&nbsp;&nbsp; Air will be supplied to the Office Portion of the Premises at 1 cfm per useable square foot of the Office Portion of the Premises and air will be supplied to the Laboratory Portion for the Premises at 1.5 cfm per useable square foot of the Laboratory Portion of the Premises.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>In the event Tenant introduces into the Premises personnel or equipment which overloads the capacity of the applicable Base Building HVAC system or in any other way adversely affects the applicable Base Building HVAC system&#8217;s ability to perform adequately its proper functions, including, without limitation, Tenant&#8217;s design, layout or occupancy level of the Premises in a manner which inhibits the HVAC system&#8217;s ability to perform in accordance with the applicable HVAC specifications attached as exhibits to this Lease, Tenant may be required to install supplementary systems at Tenant&#8217;s sole cost and expense in order to provide comfortable space temperature and ventilation in the applicable portion of the Premises, and Landlord shall not be deemed to be in default of Landlord&#8217;s obligation under this <font style="font-weight:bold;">Section 7.5</font> to provide HVAC service to the Premises in accordance with <font style="font-weight:bold;text-decoration:underline;">Exhibit&#160;J</font>, as applicable to the portion of the Premises at issue (i.e. the Office Portion or Laboratory Portion, as applicable), to the extent resulting from such interference or overloading by Tenant</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_398"></a>(d)<font style="margin-left:36pt;"></font><a name="_cp_text_1_398"></a>For the Laboratory Portion of the Premises, Landlord, as part of Landlord&#8217;s Work, shall install (1) one (1) air handler unit per floor of the Laboratory Portion of the Premises and (2) an additional supplemental chiller system for the tenants of the Laboratory Portion located on the mechanical penthouse roof of the Building.&nbsp;&nbsp;Tenant, at its expense, may install its own heating, ventilation and air conditioning units (&#8220;<font style="font-weight:bold;">Tenant&#8217;s HVAC Units</font>&#8221;) in and serving the Premises, which Tenant&#8217;s HVAC Units must be located within the bounds of the Premises.&nbsp;&nbsp;The Tenant&#8217;s HVAC Units shall be compatible with the Building&#8217;s mechanical system and shall be operated and maintained by Tenant at its expense.&nbsp;&nbsp;Tenant shall furnish and operate and maintain, at its expense, the pumps required to draw and return the condenser water required for Tenant&#8217;s HVAC Units.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU40"></a><a name="_cp_text_1_403"></a>(e)<font style="margin-left:36pt;"></font>Landlord shall provide condenser water of ten (10) tons to the Premises and Tenant shall pay Landlord&#8217;s then standard condenser water charge for the Building for its use of such condenser water.&nbsp;&nbsp;Current charge is $303.00 per annum per ton of condenser water allocated to the Premises subject to increase from time to time during the Term.&nbsp;&nbsp;Tenant shall be responsible for pumping/circulating the supplied condenser water throughout the Premises.&nbsp;&nbsp;Tenant may, at its expense, connect the machinery and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_403"></a>equipment of Tenant&#8217;s HVAC Units to the Building air supply and return systems, condenser water supply and return and steam supply and condensate return lines at such locations, by such means and routing and otherwise in such manner as Landlord shall </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reasonably </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">designate or approve. </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_411"></a>(f)<font style="margin-left:36pt;"></font>Landlord shall provide fresh air units exclusive to each floor within the Laboratory Portion for the supply of air to the Premises.&nbsp;&nbsp;Tenant shall be responsible for Tenant&#8217;s pro rata share based on rentable square footage of the Premises, as the case may be, of all charges of Landlord for operating, repairing and maintaining fresh air units with other premises on the floor.&nbsp;&nbsp;By way of example, in the event Tenant leases a full floor its pro rata share for the fresh air unit on that floor is one hundred percent (100%).</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)<font style="margin-left:36pt;"></font>Landlord shall provide water (at temperatures supplied by the city in which the Property is located) for drinking, lavatory and toilet purposes (&#8220;<font style="font-weight:bold;">Potable Water</font>&#8221;) for the Premises and non-potable hot water for Tenant&#8217;s laboratory use (&#8220;<font style="font-weight:bold;">Non Potable Water</font>&#8221;).&nbsp;&nbsp;Such water shall be made available from the main connection point for such service on the floor on which the Premises is located and the distribution of water (both Potable Water and Non-Potable Water) within the Premises shall be performed by Tenant.&nbsp;&nbsp;If Tenant uses Potable Water for any purpose other than for ordinary lavatory and drinking purposes, Landlord may assess a reasonable charge for the additional water so used, or upon advance written notice to Tenant install a water meter and thereby measure Tenant&#8217;s water consumption for all purposes.&nbsp;&nbsp;In the latter event, Tenant shall pay the cost of the meter and the cost of installation thereof as Additional Rent upon demand and shall keep such meter and installation equipment in good working order and repair.&nbsp;&nbsp;Tenant agrees to pay for water consumed, as shown on such meter (at the rates then charged by the public utility, together with all sewer charges, taxes and fees), together with the sewer charge based on such meter charges, as and when bills are rendered, and in the event Tenant fails timely to make any such payment, Landlord may pay such charges and collect the same from Tenant upon demand as Additional Rent.&nbsp;&nbsp;Notwithstanding anything to the contrary contained in this Section, Tenant shall be responsible for Tenant&#8217;s Laboratory Share of the costs associated with the Non Potable Water.&nbsp;&nbsp;&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)<font style="margin-left:36pt;"></font>Cleaning and janitorial services to the Common Areas.&nbsp;&nbsp;Tenant shall be responsible for all cleaning and janitorial services to the Premises, consistent with such services performed by office and laboratory tenants of Comparable Buildings.&nbsp;&nbsp;Subject to the labor harmony requirements in this Lease and Landlord&#8217;s reasonable approval, Tenant may utilize any qualified cleaning and janitorial contractors to provide these cleaning services to the Premises.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>Access to the Premises and the Parking Garage 24 hours per day, 7 days per week, and 365 days per year, subject to security and safety precautions from time to time in effect, if any, and subject always to restrictions based on emergency conditions.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_422"></a>(j)<font style="margin-left:36pt;"></font><a name="_cp_text_1_422"></a>Passenger elevator service in common with Landlord and other tenants in the Building 24 hours per day, 7 days per week, and 365 days per year.&nbsp;&nbsp;Tenant shall have access, on a non&#8209;exclusive, first&#8209;come, first&#8209;serve basis, to freight elevators serving the Building, at no additional charge during the Building&#8217;s normal freight hours.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU41"></a><a name="_cp_text_1_423"></a><a name="_cp_text_2_424"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(k)</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord may from time to time, but shall not be obligated to, as part of Operating Expenses, provide one or more attendants in or about the common areas of the Building.&nbsp;&nbsp;Tenant expressly acknowledges and agrees that, if provided: </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> such attendants shall not serve as police officers, and will be unarmed, and will not be trained in situations involving potentially physical confrontation; and </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_423"></a> such attendants will be solely an amenity to tenants of the Building for purposes such as assisting visitors and invitees of tenants and others in the Building, monitoring fire control and alarm equipment, and summoning emergency services to the Building as and when needed, and not for the purpose of securing any individual tenant premises or guaranteeing the physical safety of Tenant&#8217;s Premises or of Tenant&#8217;s employees, agents, contractors or invitees.&nbsp;&nbsp;If and to the extent that Tenant desires to provide security for the Premises or for such persons or their property, Tenant shall be responsible for so doing, after having first consulted with Landlord and after obtaining Landlord&#8217;s consent, which shall not be unreasonably withheld</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, conditioned or delayed</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_424"></a>. Landlord expressly disclaims any and all responsibility and/or liability for the physical safety of Tenant&#8217;s property</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and for that of Tenant&#8217;s employees, agents, contractors and invitees, and, without in any way limiting the operation of </font><font style="font-weight:bold;">Article 10</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> hereof, Tenant, for itself and its agents, contractors, invitees and employees, hereby expressly waives any claim, action, cause of action or other right which may accrue or arise as a result of any damage or injury to the person or property of Tenant or any such agent, invitee, contractor or employee</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> except, with respect to personal injury only, if and to the extent caused by Landlord&#8217;s negligence or willful misconduct. Tenant agrees that, as between Landlord and Tenant, it is Tenant&#8217;s responsibility to advise its employees, agents, contractors and invitees as to necessary and appropriate safety precautions.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU42"></a>(l)<font style="margin-left:36pt;"></font>As part of Landlord&#8217;s Work, the Building will be serviced by a common laboratory waste sanitary sewer connection from the pH neutralization room on the third (3<sup style="font-size:85%; vertical-align:top">rd</sup>) floor of the Building to the municipal sewer line in the street adjacent to the Building.&nbsp;&nbsp;Landlord will install, as part of Landlord&#8217;s Work, a separate ph neutralization tank (the &#8220;<font style="font-weight:bold;">ph Neutralization Tank</font>&#8221;) for common use by tenants and occupants of the Laboratory Portion of the Building. Landlord will provide a connection point and tap and Tenant shall be responsible, as part of the Tenant Work, to connect the Premises to the ph Neutralization Tank.&nbsp;&nbsp;Tenant shall have a non-exclusive right to use Tenant&#8217;s Laboratory Share of the ph Neutralization Tank in accordance with applicable Laws in common with other tenants of the Laboratory Portion.&nbsp;&nbsp;Tenant shall reimburse Landlord for all costs, charges and expenses incurred by Landlord from time to time in connection with or arising out of the operation, use, maintenance, repair or refurbishment of the ph Neutralization Tank, including all clean-up costs relating to the ph Neutralization Tank (collectively, &#8220;<font style="font-weight:bold;">Tank Costs</font>&#8221;); provided, however, that if the ph Neutralization Tank is being used by other tenant(s) or occupant(s) of the Laboratory Portion of the Building at any time during the Term, then Tenant shall only be obligated to pay its proportionate share of the Tank Costs, as determined by Landlord in accordance with, as reasonably determined by Landlord, either Tenant&#8217;s Laboratory Share or Tenant&#8217;s Occupied Laboratory Share, if applicable, of the Tank Costs.&nbsp;&nbsp;Notwithstanding the foregoing, in the event the ph Neutralization Tank or the pH neutralization room is damaged or repairs to the ph Neutralization Tank or the pH neutralization room are required solely as a result of the improper use of either the ph Neutralization Tank or the pH neutralization room by </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant, Tenant shall be responsible for one hundred percent (100%) of the cost of any repairs or replacement required as a result of such improper use by Tenant, regardless of whether the ph Neutralization Tank is then being used by other tenant(s) or occupant(s) of the Building.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_429"></a><a name="_cp_text_2_430"></a><a name="_cp_text_1_431"></a><a name="_cp_text_1_432"></a><a name="_cp_text_2_433"></a>(m)<font style="margin-left:36pt;"></font>Landlord has installed a back-up generator at the Property (the &#8220;<font style="font-weight:bold;">Generator</font>&#8221;), with capacity for Tenant to connect its laboratory equipment load of up to four (4) watts per usable square foot of the Laboratory Portion of the Premises (the &#8220;<font style="font-weight:bold;">Tenant&#8217;s Generator Capacity</font><a name="_cp_text_1_429"></a>&#8221;).&nbsp;&nbsp;Tenant shall be entitled to use, at any time during the Term, <a name="_cp_text_2_430"></a>up to Tenant&#8217;s Generator Capacity of power from the Generator (after deducting any power from the Generator required for the Common Facilities) on a non-exclusive basis with other tenants in the Building; provided, however, in no event shall Tenant&#8217;s equipment connected to the Generator exceed four (4) watts per usable square foot of the Laboratory Portion of the Premises.&nbsp;&nbsp;Any back-up power needs of Tenant in excess of Tenant&#8217;s Generator Capacity shall be Tenant&#8217;s responsibility, including Tenant&#8217;s laboratory equipment, and notwithstanding Landlord&#8217;s approval of Tenant&#8217;s Space Plan or Construction Documents in accordance with <font style="font-weight:bold;text-decoration:underline;">Exhibit D</font>.&nbsp;&nbsp;Tenant shall reimburse Landlord for Tenant&#8217;s Laboratory Share of all costs, charges and expenses incurred by Landlord from time to time in connection with or arising out of the operation, use, maintenance, repair or refurbishment of the Generator, including, the costs for fuel, permitting, inspection and testing (collectively, &#8220;<font style="font-weight:bold;">Generator Costs</font><a name="_cp_text_1_431"></a>&#8221;); provided, however, that if the Generator is being used by other tenant(s) or occupant(s) of the Laboratory Portion of the Building at any time during the Term, then Tenant shall only be obligated to pay Tenant&#8217;s Occupied Laboratory Share of the Generator Costs.&nbsp;&nbsp;Landlord expressly disclaims any warranties with regard to the Generator or the installation thereof, including any warranty of merchantability or fitness for a particular purpose.&nbsp;&nbsp;Landlord shall maintain and repair <a name="_cp_text_1_432"></a>the Generator so as to keep same <a name="_cp_text_2_433"></a>in good working condition as part of Generator Costs, but shall not be liable for any failure to make any repairs or to perform any maintenance that is an obligation of Landlord unless such failure shall persist for an unreasonable time after Tenant provides Landlord with written notice of the need for such repairs or maintenance.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_437"></a><a name="_AEIOULastRenderedPageBreakAEIOU43"></a>(n)<font style="margin-left:36pt;"></font>As part of the Laboratory Systems, Tenant shall be allowed to utilize up to Tenant&#8217;s Laboratory Share of space in the chemical storage room within the specified zone in the basement level of the Building (the &#8220;<font style="font-weight:bold;">Chemical Storage Room</font>&#8221;) for chemical storage.&nbsp;&nbsp;The Chemical Storage Room shall be designated by the Uniform Building Code (&#8220;<font style="font-weight:bold;">UBC</font><a name="_cp_text_1_437"></a>&#8221;) as a &#8220;B&#8221; occupancy area for the use and storage of Hazardous Materials.&nbsp;&nbsp;If the use of Hazardous Materials by Tenant requires fire control areas or chemical storage areas in excess of Tenant&#8217;s Laboratory Share, then Tenant shall, at its sole cost and expense and upon Landlord&#8217;s written request, establish and maintain a separate area of the Premises classified by the UBC as a &#8220;B&#8221; occupancy area for the use and storage of Hazardous Materials, or take such other action as is necessary to ensure that its share of the fire control areas or chemical storage areas of the Building is not greater than Tenant&#8217;s Laboratory Share.&nbsp;&nbsp;Notwithstanding anything in this Lease to the contrary, Landlord shall not have and expressly disclaims any liability (unless arising from Landlord's negligence or willful misconduct) related to Tenant&#8217;s or other tenants&#8217; use or disposal of Hazardous Materials within the Chemical Storage Room, it being </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">acknowledged by Tenant that Tenant and other tenants are best suited to evaluate the safety and efficacy of its Hazardous Materials usage and procedures in the Premises and in the Chemical Storage Room.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_444"></a><a name="_cp_text_1_447"></a><a name="_cp_text_1_448"></a>(o)<font style="margin-left:36pt;"></font>Tenant shall indemnify, save, defend (at Landlord&#8217;s option and with counsel reasonably acceptable to Landlord) and hold the Landlord Parties harmless from and against any and all claims, losses, cost, damages any liability or expense of whatever nature (&#8220;<font style="font-weight:bold;">Claims</font><a name="_cp_text_1_444"></a>&#8221;), including (a) diminution in value of the Property or any portion thereof, (b) damages for the loss or restriction on use of rentable or usable space or of any amenity of the Property, and <a name="_cp_text_1_447"></a>(c)&nbsp;&nbsp;and (c<a name="_cp_text_1_448"></a>) sums paid in settlement of Claims that arise during or after the Term as a result of Tenant&#8217;s improper use of any Laboratory Systems, the ph Neutralization Tank, the Chemical Storage Room or Generator.&nbsp;&nbsp;This indemnification by Tenant includes the reasonable costs incurred in connection with any investigation of site conditions or any clean-up, remediation, removal or restoration required by any governmental authority caused by Tenant&#8217;s improper use of the Laboratory Systems, ph Neutralization Tank, the Chemical Storage Room or Generator.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Interruption of Service</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_450"></a><a name="_cp_text_1_451"></a><a name="_cp_text_2_452"></a><a name="_cp_text_1_453"></a><a name="_cp_text_1_454"></a>(a)<font style="margin-left:36pt;"></font><a name="_cp_text_2_450"></a>Landlord reserves the right to <a name="_cp_text_1_451"></a>curtail, suspend, interrupt and/or <a name="_cp_text_2_452"></a>stop the supply of water, sewage, electrical current, cleaning, and other services, <a name="_cp_text_1_453"></a>and to curtail, suspend, interrupt and/or stop use of entrances and/or lobbies serving access to the Building, or other portions of the Property, without thereby incurring any liability to Tenant, when necessary by reason of accident or emergency, or for repairs, alterations, replacements or improvements in the judgment of Landlord reasonably exercised desirable or necessary, or when prevented from supplying such services or use due to any act or neglect of Tenant or Tenant&#8217;s agents employees, contractors or invitees or any person claiming by, through or under Tenant or by Force Majeure, including, but not limited to, strikes, lockouts, difficulty in obtaining materials, accidents, laws or orders, or inability, by exercise of reasonable diligence, to obtain electricity, water, gas, steam, coal, oil or other suitable fuel or power.&nbsp;&nbsp;Except as otherwise set forth in <font style="font-weight:bold;">Section 7.6(b)</font> below, <a name="_cp_text_1_454"></a>no diminution or abatement of rent or other compensation, nor any direct, indirect or consequential damages shall or will be claimed by Tenant as a result of, nor shall this Lease or any of the obligations of Tenant be affected or reduced by reason of, any such interruption, curtailment, suspension or stoppage in the furnishing of the foregoing services or use, irrespective of the cause thereof.&nbsp;&nbsp;Except as otherwise expressly provided in this Lease, the failure or omission on the part of Landlord to furnish any of the foregoing services or use as provided in this paragraph shall not be construed as an eviction of Tenant, actual or constructive, nor entitle Tenant to an abatement of Rent, nor to render the Landlord liable in damages, nor release Tenant from prompt fulfillment of any of its covenants under this Lease.&nbsp;&nbsp;Notwithstanding anything herein to the contrary, in each instance of stoppage, Landlord shall exercise reasonable diligence to eliminate the cause thereof and, except in case of emergency repairs, Landlord will give Tenant reasonable advance notice of any contemplated stoppage and will use reasonable efforts to avoid unnecessary inconvenience to Tenant by reason thereof.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_461"></a><a name="_AEIOULastRenderedPageBreakAEIOU44"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the foregoing, if </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> an interruption or curtailment, suspension or stoppage of an Essential Service (as said term is hereinafter defined) shall occur, except if any of the same is due to any act or neglect of Tenant or Tenant&#8217;s agents employees, contractors or invitees or any person claiming by, through or under Tenant, or is an event which is covered by the provisions of </font><font style="font-weight:bold;">Article&#160;11 </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of this Lease (any such interruption of an Essential Service being hereinafter referred to as a &#8220;</font><font style="font-weight:bold;">Service Interruption</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), and </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> such Service Interruption is within the reasonable control of Landlord to remedy (and Landlord is not impeded by reason of any Force Majeure), and </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as a result of such Service Interruption, the Premises becomes untenantable so that for the Eligibility Period (as hereinafter defined) Tenant is unable to and does not in fact conduct its business in the affected portion of the Premises during the entirety of the Eligibility Period by reason of such untenantability, then there shall be an abatement of one day&#8217;s Basic Rent and Additional Rent (but not any of the Monthly Improvement Costs Payments) for each day during which such Service Interruption continues after the Eligibility Period until such date that the Premises or the affected portion thereof shall be rendered tenantable (or such earlier date, if any, as Tenant shall reoccupy the Premises or the affected portion thereof for the conduct of its business); provided, however, that if any part of the Premises is reasonably useable for Tenant&#8217;s normal business operations or if Tenant conducts all or any part of its operations in any portion of the Premises notwithstanding such Service Interruption, then the amount of each daily abatement of Basic Rent shall only be proportionate to the nature and extent of the interruption of Tenant&#8217;s normal operations or ability to use the Premises.&nbsp;&nbsp;For the purposes hereof, the &#8220;</font><font style="font-weight:bold;">Eligibility Period</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; shall be defined as five (5) consecutive Business Days after Landlord&#8217;s receipt of written notice from Tenant of the condition causing untenantability in the Premises.&nbsp;&nbsp;For purposes hereof, the term &#8220;</font><font style="font-weight:bold;">Essential Services</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; shall mean the following services in accordance with Landlord&#8217;s obligations under this Lease:&nbsp;&nbsp;passenger elevator service, water and sewer/septic service, HVAC, electricity and the Laboratory Systems.&nbsp;&nbsp;The remedies set forth in this </font><font style="font-weight:bold;">Section 7.6(b)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shall be Tenant&#8217;s sole remedy on account of a Service Interruption and this </font><font style="font-weight:bold;">Section 7.6(b)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shall not apply in the event of untenantability caused by fire or other casualty or taking (which shall be subject to the terms and conditions of </font><font style="font-weight:bold;">Article 11</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> below).&nbsp;&nbsp;A Service Interruption will not be deemed to have occurred if Tenant introduces into the Premises personnel or equipment which overloads the capacity of the Building systems or in any other way interferes with any building system&#8217;s ability to perform its proper functions, including, without limitation, Tenant&#8217;s design, layout or occupancy level of the Premises in a manner which inhibits the HVAC system&#8217;s ability to perform properly in the manner designed.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU45"></a>7.7<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Force Majeure</font><font style="font-weight:normal;">.&nbsp;&nbsp;If either party shall be prevented or delayed from punctually performing any obligations or satisfying any condition under this Lease as a result of a Force Majeure event, then the time to perform such obligation to satisfy such condition shall be extended on a day for day basis for the period of the delay caused by such event; provided, however, that the party claiming the benefit of this provision shall, as a condition thereto, give notice to the other party in writing within ten (10) days of the incident specifying with particularity the nature thereof, the reason therefor, the date and time such incident occurred and a reasonable estimate of the period that such incident will delay the fulfillment of obligations contained herein.&nbsp;&nbsp;Failure to give such notice within the specified time shall render such delay invalid in extending the time for performing the obligations hereunder.&nbsp;&nbsp;This </font>Section </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.7 </font><font style="font-weight:normal;">shall not apply to Tenant's obligations under Exhibit C of this Lease nor the inability of either party to pay any sum of money due hereunder or the failure to perform any other obligation due to the lack of money or inability to raise capital or borrow for any purpose.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">ARTICLE 8</font><font style="text-decoration:underline;"><br />INTENTIONALLY OMITTED</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">ARTICLE 9</font><font style="text-decoration:underline;"><br />BUILDING OPERATING EXPENSES AND LABORATORY OPERATING EXPENSES</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Definitions</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_473"></a><a name="_cp_text_1_474"></a><a name="_AEIOULastRenderedPageBreakAEIOU46"></a>.&nbsp;&nbsp;&#8220;<font style="font-weight:bold;">Operating Year</font>&#8221; shall mean each calendar year all or any part of which falls within the Term, &#8220;<font style="font-weight:bold;">Building Operating Expenses</font><a name="_cp_text_1_473"></a>&#8221; shall mean the aggregate  costs and expenses incurred by Landlord with respect to the operation, administration, cleaning, insuring, repair, maintenance and management of the Building and the Building&#8217;s allocable share of costs with respect to the Common Facilities of the Complex, including, without limitation, the costs and expenses set forth in <font style="font-weight:bold;text-decoration:underline;">Exhibit&#160;F</font> attached hereto as Building Operating Expenses (but excluding the Laboratory Operating Expenses), and &#8220;<font style="font-weight:bold;">Laboratory</font> <font style="font-weight:bold;">Operating Expenses</font>&#8221; shall mean the aggregate costs and expenses incurred by Landlord with respect to the operation, administration, cleaning, insuring, repair, maintenance and management of the Laboratory Portion of the Building and the Laboratory Systems, including, without limitation, the costs and expenses set forth in <font style="font-weight:bold;text-decoration:underline;">Exhibit&#160;F</font><a name="_cp_text_1_474"></a> attached hereto as Laboratory Operating Expenses (but excluding the Building Operating Expenses).&nbsp;&nbsp;If during any portion of the Operating Year for which Building Operating Expenses are being computed, less than ninety-five percent (95%) of the Building was occupied by tenants or Landlord was not supplying all tenants with the services being supplied under this Lease, actual Operating Expenses incurred shall be extrapolated reasonably by Landlord on an item by item basis to the estimated Building Operating Expenses that would have been incurred if the Building were at least ninety-five percent (95%) occupied for such Operating Year and such services were being supplied to all tenants, and such extrapolated amount shall, for the purposes hereof, be deemed to be the Building Operating Expenses for such Operating Year. Only those Operating Expenses that are affected by variation in occupancy levels shall be so &#8220;grossed-up&#8221;.&nbsp;&nbsp;In the event that the Laboratory Portion is less than fully occupied, or any tenants or occupants have elected not to use any of the Laboratory Systems during any portion of the Term, Tenant acknowledges that during such time, rather than allocating such expenses based on Tenant&#8217;s Laboratory Share, Landlord may elect to allocate certain Laboratory Operating Expenses and charges to Tenant based on the ratio of the total rentable area of the Premises designed for laboratory use (as determined based on Tenant&#8217;s final as-built interior laboratory construction plans for the Premises approved by Landlord) to the total rentable area of the Laboratory Portion leased to tenants that are using that Laboratory System (&#8220;<font style="font-weight:bold;">Tenant&#8217;s Occupied Laboratory Share</font>&#8221;), as reasonably determined by Landlord.&nbsp;&nbsp;Landlord shall have the right to recalculate the Tenant&#8217;s Occupied Laboratory Share from time to time as occupancy of the Laboratory Portion changes.&nbsp;&nbsp;Except as expressly provided herein, or approved by Landlord, Tenant shall only be entitled to use Tenant&#8217;s Laboratory Share of the Laboratory Systems, regardless of whether Tenant is paying Tenant&#8217;s Occupied Laboratory Share or Pro Rata Share of Laboratory Portion of the costs thereof.&nbsp;&nbsp;If and to the extent the Property includes other buildings as part of a larger project or development, Landlord shall have the right to allocate to each building on the Property, including the Building, an equitable portion of the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">costs and expenses for the Common Facilities of the Property, in accordance with its good faith business judgment, and the allocable portion of such costs and expenses shall be included in Building Operating Expenses hereunder.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord shall have the right, from time to time, to equitably allocate some or all of the Building Operating Expenses for the Building among different portions or occupants of the Building (the &#8220;<font style="font-weight:bold;">Cost Pools</font>&#8221;), in Landlord&#8217;s reasonable discretion.&nbsp;&nbsp;Such Cost Pools may include, but shall not be limited to, the office space tenants of the Building, the laboratory space tenants of the Building and the retail space tenants of the Building and Tenant&#8217;s Pro Rata Share of the Office Portion for any costs included in a Cost Pool shall be calculated on the basis of the ratio of the rentable square footage of the Premises to the rentable square footage of the portions of the Building included in such Cost Pool.&nbsp;&nbsp;If any space in the Building is converted from retail space to office space and/or laboratory space, as applicable, then the rentable area of the space in the Building converted from retail space to office space and/or laboratory space, as applicable, shall be added to the denominator used to calculate Tenant&#8217;s Pro Rata Share of the Office Portion for the remaining portion of that calendar year and subsequent calendar years.&nbsp;&nbsp;Likewise if any space in the Building is converted from office space and/or laboratory space, as applicable, to retail space, then the rentable area of the space in the Building converted from office space and/or laboratory space, as applicable, to retail space shall be deducted from the denominator used to calculate Tenant&#8217;s Pro Rata Share of the Office Portion for the remainder of such calendar year and subsequent calendar years.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Tenant&#8217;s Payment of Operating Expenses</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>From and after the Rent Commencement Date, Tenant shall pay to Landlord, as Additional Rent:</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>an amount equal to (y) the Building Operating Expenses multiplied by (z) Tenant&#8217;s Pro Rata Share of the Office Portion, such amount to be apportioned for any portion of an Operating Year in which the Rent Commencement Date falls or the Term of this Lease ends; and </p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font>an amount equal to (y) the Laboratory Operating Expenses multiplied by (z) Tenant&#8217;s Laboratory Share (or, if applicable per <font style="font-weight:bold;">Section 9.1</font>, Tenant&#8217;s Occupied Laboratory Share), such amount to be apportioned for any portion of an Operating Year in which the Rent Commencement Date falls or the Term of this Lease ends.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU47"></a>(b)<font style="margin-left:36pt;"></font>Estimated payments by Tenant on account of Building Operating Expenses and Laboratory Operating Expenses shall be made on the first day of each and every calendar month during the Term of this Lease, in the fashion herein provided for the payment of Basic Rent.&nbsp;&nbsp;The monthly amount so to be paid to Landlord shall be sufficient to provide Landlord by the end of each Operating Year a sum equal to Tenant&#8217;s required payment, as reasonably estimated by Landlord from time to time during each Operating Year, on account of Building Operating Expenses and Laboratory Operating Expenses for such Operating Year.&nbsp;&nbsp;After the end of each Operating Year, Landlord shall submit to Tenant a reasonably detailed accounting of Building Operating Expenses and Laboratory </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating Expenses for such Operating Year, and Landlord shall certify to the accuracy thereof.&nbsp;&nbsp;If estimated payments theretofore made for such Operating Year by Tenant exceed Tenant&#8217;s required payment on account thereof for such Operating Year according to such statement, Landlord shall credit the amount of overpayment against subsequent obligations of Tenant with respect to Building Operating Expenses and Laboratory Operating Expenses (or promptly refund such overpayment if the Term of this Lease has ended and Tenant has no further obligation to Landlord); but if the required payments on account thereof for such Operating Year are greater than the estimated payments (if any) theretofore made on account thereof for such Operating Year, Tenant shall make payment to Landlord within thirty (30) days after being so advised by Landlord, and the obligation to make such payment for any period within the Term shall survive expiration of the Term.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_484"></a><a name="_cp_text_1_485"></a><a name="_cp_text_1_488"></a><a name="_cp_text_1_490"></a><a name="_cp_text_2_489"></a><a name="_cp_text_1_491"></a><a name="_cp_text_2_492"></a><a name="_cp_text_1_493"></a><a name="_cp_text_1_495"></a><a name="_cp_text_1_497"></a><a name="_cp_text_1_498"></a><a name="_cp_text_1_500"></a><a name="_cp_text_1_502"></a><a name="_cp_text_2_503"></a><a name="_cp_text_2_504"></a><a name="_AEIOULastRenderedPageBreakAEIOU48"></a>(c)<font style="margin-left:36pt;"></font><a name="_cp_text_1_484"></a>Any such accounting by Landlord shall be binding and conclusive upon Tenant unless within one hundred twenty (120) days after Tenant's receipt <a name="_cp_text_1_485"></a>of such accounting from Landlord <a name="_cp_text_1_488"></a>Tenant shall notify Landlord that Tenant intends to undertake an audit of such of Landlord&#8217;s books as are directly relevant to the Building Operating Expenses and Laboratory Operating Expenses accounting for the Operating Year in question, provided and on condition that (i) there is then no uncured Event of Default under this Lease, (ii) Tenant has made all payments of Additional Rent billed or invoiced by Landlord as of the date of the audit, (iii)<a name="_cp_text_1_490"></a> the audit is performed only by Tenant&#8217;s employees, internal accounting department or an independent certified public accounting firm <a name="_cp_text_2_489"></a>or, commercial real estate broker or experienced operating expense review firm such as Cyberlease, all as reasonably approved by Landlord, and provided and on the express condition that such reviewer&#8217;s fee or other compensation is fixed by contract and is in no manner computed or determined based upon the results of the audit, (iv)<a name="_cp_text_1_491"></a> both Tenant and its examiners execute and deliver to Landlord a commercially reasonable <a name="_cp_text_2_492"></a>confidentiality agreement in form and substance reasonably acceptable to Landlord <a name="_cp_text_1_493"></a>whereby such parties expressly agree to maintain the results of such audit in strict confidence (except disclosures to Tenant's officers, employees, attorneys, lenders, investors and/or as required by a court of competent jurisdiction) , and (v)<a name="_cp_text_1_495"></a> such audit is commenced and completed and the results thereof delivered to Landlord within ninety <a name="_cp_text_1_497"></a>(90<a name="_cp_text_1_498"></a>) days following the date Landlord makes its books available to Tenant at Landlord's offices at the <a name="_cp_text_1_500"></a>Boston Landing Project.&nbsp;&nbsp;If Tenant fails to timely deliver a dispute notice to Landlord, or fails to complete its audit and deliver the results thereof to Landlord within the applicable ninety <a name="_cp_text_1_502"></a>(90<a name="_cp_text_2_503"></a>) day period, then, in either of such events, Landlord&#8217;s accounting shall be binding and conclusive upon Tenant for all purposes of this Lease.&nbsp;&nbsp;If it is finally determined by such auditor or mutually agreed by the parties that <a name="_cp_text_2_504"></a>Landlord has overstated the applicable Tenant&#8217;s Pro Rata Share of the Building Operating Expenses or Laboratory Operating Expenses, Landlord shall credit within thirty (30) days following such resolution the amount of such overstatement against the monthly installments of Additional Rent next due under this Lease (or refund within thirty (30) days following such resolution such amount to Tenant if the Term has ended and Tenant has no further obligations to Landlord under this Lease.&nbsp;&nbsp;If it is finally determined by mutual agreement or other legal proceeding that Landlord understated the Additional Rent payable by Tenant, then Landlord may invoice Tenant for any amount by which Tenant&#8217;s payments under this <font style="font-weight:bold;">Section 9.2</font> was understated, which invoice shall be payable by Tenant within thirty (30) days after receipt </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of such invoice.&nbsp;&nbsp;In the event that it is determined by mutual agreement or legal proceeding that Landlord&#8217;s Building Operating Expenses or Laboratory Operating Expenses were overstated by more than five percent (5%), Landlord shall reimburse Tenant for its reasonable out of pocket audit costs (not to exceed $5,000.00).</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">ARTICLE 10</font><font style="text-decoration:underline;"><br />INDEMNITY AND PUBLIC LIABILITY INSURANCE</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Indemnity</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_512"></a><a name="_cp_text_1_513"></a><a name="_cp_text_1_514"></a><a name="_cp_text_1_515"></a><a name="_cp_text_2_516"></a><a name="_cp_text_2_518"></a><a name="_cp_text_2_519"></a><a name="_cp_text_1_520"></a><a name="_cp_text_2_521"></a><a name="_cp_field_48_522"></a><a name="_cp_text_2_523"></a><a name="_cp_field_48_524"></a><a name="_cp_text_2_525"></a><a name="_cp_text_2_527"></a><a name="_cp_text_5_528"></a><a name="_cp_text_2_529"></a><a name="_cp_text_1_533"></a>(a)<font style="margin-left:36pt;"></font>Subject to the waiver of subrogation in <font style="font-weight:bold;">Sections 10.5</font> and <font style="font-weight:bold;">15.3, e</font><a name="_cp_text_1_512"></a>xcept to the extent arising from the negligence or willful misconduct of Landlord or its agents, <a name="_cp_text_1_513"></a>employees or contractors<a name="_cp_text_1_514"></a>, Tenant shall defend with counsel first reasonably approved by Landlord, save harmless, and indemnify Landlord and Landlord&#8217;s managing agent, beneficiaries, partners, members, shareholders, subsidiaries, officers, directors, agents, trustees and employees (&#8220;<font style="font-weight:bold;">Landlord Parties</font><a name="_cp_text_1_515"></a>&#8221;) from and against all, claims losses, cost, damages, any liability or expense of whatever nature arising from injury, loss, accident or damage to any person or property, to the extent <a name="_cp_text_2_516"></a>arising from or claimed to have arisen (a) from any accident, injury or damage whatsoever to any person, or to the property of any person, occurring in the Premises; (b)<a name="_cp_text_2_518"></a> from the omission (where there is a duty to act), fault, willful act<a name="_cp_text_2_519"></a>, negligence or <a name="_cp_text_1_520"></a>other <a name="_cp_text_2_521"></a>misconduct of Tenant or Tenant&#8217;s agents, employees, contractors, licensees <a name="_cp_field_48_522"></a>or invitees, <a name="_cp_text_2_523"></a>(c) <a name="_cp_field_48_524"></a>in connection with Tenant&#8217;s use of the Premises or any business conducted therein or any work done or condition created in the Premises by Tenant, its agent, employees or contractors, or anyone claiming by, through or under Tenant, or <a name="_cp_text_2_525"></a>(d) <a name="_cp_text_2_527"></a>the failure of Tenant to perform and discharge its covenants and <a name="_cp_text_5_528"></a>obligations under this Lease and, in any case, occurring after the Commencement Date (or such earlier date as of which Tenant takes possession of the Premises) until the expiration of the Term of this Lease and thereafter <a name="_cp_text_2_529"></a>so long as Tenant is in occupancy of any part of the Premises<a name="_cp_text_1_533"></a>.&nbsp;&nbsp;This indemnity and hold harmless agreement shall include indemnity against all losses, costs, damages, expenses and liabilities incurred in or in connection with any such claim or any proceeding brought thereon, and the defense thereof, including, without limitation, reasonable attorneys&#8217; fees and costs at both the trial and appellate levels.&nbsp;&nbsp;The provisions of this <font style="font-weight:bold;">Section 10.1(a)</font> shall survive the expiration or earlier termination of this Lease.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU49"></a>(b)<font style="margin-left:36pt;"></font>Subject to the waiver of subrogation in <font style="font-weight:bold;">Sections 10.5</font> and <font style="font-weight:bold;">15.3</font>, except to the extent arising from the negligence or willful misconduct of Tenant or anyone claiming by, through or under Tenant (the &#8220;<font style="font-weight:bold;">Tenant Parties</font>&#8221;), from and against all claims of any third party arising from any accident, injury or damage whatsoever to any person, or to the property of any person, where such accident, damage or injury results or is claimed to have resulted from (i) the gross negligence or willful misconduct of Landlord or Landlord&#8217;s agents, employees or contractors, or (ii) if Landlord exercises its recapture rights pursuant to <font style="font-weight:bold;">Section 6.5</font> of this Lease, any accident, injury or damage whatsoever to any person, or to the property of any person, occurring in the recaptured portion of the Premises after Tenant&#8217;s delivery of possession to Landlord, together with reasonable attorneys&#8217; fees incurred in connection with each such claim or action brought thereon; provided, however, in no event shall this indemnity apply to the extent any such claim </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">arises from the negligence or willful misconduct of Tenant or any of the Tenant Parties.&nbsp;&nbsp;This indemnity and hold harmless agreement shall include indemnity against all losses, costs, damages, expenses and liabilities incurred in or in connection with any such claim or any proceeding brought thereon, and the defense thereof, including, without limitation, reasonable attorneys&#8217; fees and costs at both the trial and appellate levels.&nbsp;&nbsp;The provisions of this </font><font style="font-weight:bold;">Section&#160;10.1(b)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shall survive the expiration or earlier termination of this Lease..</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Tenant Insurance</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU50"></a>(a)<font style="margin-left:36pt;"></font>Tenant agrees to maintain, at Tenant&#8217;s expense, in full force from the date upon which Tenant first enters the Premises for any reason, throughout the Term of this Lease, and thereafter so long as Tenant is in occupancy of any part of the Premises, (a) commercial general liability insurance providing coverage for bodily injury, property damage and personal/advertising injury.&nbsp;&nbsp;Such policy shall include broad form contractual liability, clinical trial liability insurance coverage in at least the amounts of the Initial General Liability Insurance specified in <font style="font-weight:bold;">Section&#160;1.1</font> or such greater amounts as Landlord in its reasonable discretion shall from time to time request, under which Tenant is named as an insured and Landlord,&nbsp;&nbsp;Landlord&#8217;s property manager, any Superior Mortgagee and Superior Lessor, and such other persons as Landlord reasonably may request are named as additional insureds, (b) special form (formerly known as &#8220;all&#8209;risk&#8221;) property insurance on a &#8220;replacement cost&#8221; basis, insuring Tenant&#8217;s Removable Property and any alterations, additions and improvements located from time to time in the Premises, whether made by Tenant pursuant to <font style="font-weight:bold;">Article&#160;5</font> or otherwise existing in the Premises as of the Commencement Date (such alterations, additions and improvements collectively the &#8220;<font style="font-weight:bold;">Improvements</font>&#8221;), (c) workers&#8217; compensation insurance with statutory limits, (d) employer&#8217;s liability insurance with the following limits:&nbsp;&nbsp;bodily injury by disease per person $1,000,000.00; bodily injury by accident policy limit $1,000,000.00; bodily injury by disease policy limit $1,000,000.00, (e) business automobile liability insurance including owned (if any), hired and non&#8209;owned automobiles, in an amount not less than One Million Dollars ($1,000,000) combined single limit per occurrence, (f) business interruption insurance insuring interruption or stoppage of Tenant&#8217;s business at the Premises for a period of not less than twelve (12) months, including leasehold interest coverage insuring Tenant&#8217;s ongoing lease obligations, and (g) umbrella or excess liability insurance with limits of $4,000,000 per occurrence and $4,000,000 aggregate, providing coverage over and above the commercial general liability, employer&#8217;s liability and automobile insurance policies noted above.&nbsp;&nbsp;Pollution Legal Liability insurance is not currently required based on the Hazardous Materials documents that Tenant delivered to Landlord as of the Effective Date.&nbsp;&nbsp;If the Hazardous Materials documents change during the Term and Tenant continues to store, handle, generate or treat Hazardous Materials on or about the Premises or other circumstances change related to Tenant&#8217;s use of Hazardous Materials on or about the Premises, Landlord reserves the right, in Landlord&#8217;s sole discretion, to require Tenant to obtain Pollution Legal Liability insurance.&nbsp;&nbsp;Such coverage shall include bodily injury, sickness, disease, death or mental anguish or shock sustained by any person; property damage including physical injury to or destruction of tangible property including the resulting loss of use thereof, clean-up costs, and the loss of use of tangible property that has not been physically injured or destroyed; and defense costs, charges and expenses incurred in the investigation, adjustment or defense of claims for </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such compensatory damages.&nbsp;&nbsp;Coverage shall apply to both sudden and non-sudden pollution conditions including the discharge, dispersal, release or escape of smoke, vapors, soot, fumes, acids, alkalis, toxic chemicals, liquids or gases, waste materials or other irritants, contaminants or pollutants into or upon land, the atmosphere or any watercourse or body of water.&nbsp;&nbsp;Claims-made coverage is permitted, provided the policy retroactive date is continuously maintained prior to the commencement date of this agreement, and coverage is continuously maintained during all periods in which Tenant occupies the Premises.&nbsp;&nbsp;Coverage shall be maintained with limits of not less than $1,000,000 per incident with a $2,000,000 policy aggregate and for a period of two (2) years thereafter.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Aggregate limits under Tenant&#8217;s commercial general liability and excess/umbrella liability policies set forth in <font style="font-weight:bold;">Section 10.2 (a)</font>&nbsp;&nbsp;shall apply on a &#8220;per location&#8221; basis via endorsement under each policy.&nbsp;&nbsp;Tenant&#8217;s insurance shall include appropriate endorsements providing that the insurance shall be primary to, and not contributory with any insurance carried by Landlord, whose insurance shall be considered excess only.&nbsp;&nbsp;Each policy required hereunder shall be non&#8209;cancelable and non&#8209;amendable with respect to Landlord and Landlord&#8217;s said designees without thirty (30) days&#8217; prior notice, with the exception of cancellation for non-payment of premium which shall be ten (10) day notice.&nbsp;&nbsp;The policies of insurance required to be maintained by Tenant hereunder shall be issued by companies domiciled in the United States and qualified and licensed to conduct business in the state in which the Property is located, and shall be rated A:X or better in the most current issue of A.M Best&#8217;s Key Rating Guide (or any successor thereto).&nbsp;&nbsp;At all times during the Term, such insurance shall be maintained, and Tenant shall cause a current and valid certificate of such policies to be deposited with Landlord.&nbsp;&nbsp;If Tenant fails to have a current and valid certificate of such policies on deposit with Landlord at all times during the Term and such failure is not cured within three (3) Business Days following Tenant&#8217;s receipt of notice thereof from Landlord, Landlord shall have the right, but not the obligation, to obtain such an insurance policy, and Tenant shall be obligated to pay Landlord the amount of the premiums applicable to such insurance within ten (10) days after Tenant&#8217;s receipt of Landlord&#8217;s request for payment thereof.&nbsp;&nbsp;Tenant&#8217;s insurance policies shall not include deductibles in excess of Five Thousand Dollars ($5,000.00). </p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Tenant&#8217;s Risk</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_536"></a><a name="_AEIOULastRenderedPageBreakAEIOU51"></a><a name="_cp_text_2_537"></a><a name="_cp_text_2_536"></a>.&nbsp;&nbsp;Tenant agrees to use and occupy the Premises and to use such other portions of the Property as Tenant is herein given the right to use at Tenant&#8217;s own risk. Landlord shall not be liable to Tenant, its employees, agents, invitees or contractors for any damage, injury, loss, compensation, or claim (including, but not limited to, claims for the interruption of or loss to Tenant&#8217;s business) based on, arising out of or resulting from any cause whatsoever, including, but not limited to, repairs to any portion of the&nbsp;&nbsp;Premises or the Property, any fire, robbery, theft, mysterious disappearance and/or any other crime or casualty, the actions of any other tenants of the Building or of any other person or persons, or any leakage in any part or portion of the Premises or the Building, or from water, rain or snow that may leak into, or flow from any part of the Premises or the Building, or from drains, pipes or plumbing fixtures in the Building, unless due to the gross negligence or willful misconduct of Landlord or Landlord&#8217;s agents, contractors or employees.&nbsp;&nbsp;Any goods, property or personal effects stored or placed in or about the Premises shall be at the sole risk of Tenant, and neither Landlord nor Landlord&#8217;s insurers shall in any manner be held responsible therefor.&nbsp;&nbsp;Landlord shall not be responsible or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_537"></a>liable to Tenant, or to those claiming by, through or under Tenant, for any loss or damage that may be occasioned by or through the acts or omissions of persons occupying adjoining premises or any part of the premises adjacent to or connecting with the Premises or any part of the Property or otherwise.&nbsp;&nbsp;Notwithstanding the foregoing, and to the extent permitted by Law, Landlord shall not be released from liability for any injury, loss, damages or liability to the extent arising from any </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gross </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">negligence or willful misconduct of Landlord, its servants, employees or agents acting within the scope of their authority on or about the Premises; provided, however, that in no event shall Landlord, its servants, employees or agents have any liability to Tenant based on any loss with respect to or interruption in the operation of Tenant&#8217;s business.&nbsp;&nbsp;The provisions of this </font><font style="font-weight:bold;">Section 10.3</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shall be applicable from and after the execution of this Lease and until the end of the Term of this Lease, and during any additional period as Tenant may use or be in occupancy of any part of the Premises or of the Building.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Landlord&#8217;s Insurance</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_538"></a><a name="_cp_text_2_539"></a><a name="_cp_text_2_538"></a>.&nbsp;&nbsp;Landlord shall maintain, as a part of Building Operating Expenses, special form property insurance on the Building in such amounts and subject to such deductibles as Landlord may reasonably determine.&nbsp;&nbsp;Such insurance shall be maintained with an insurance company selected by Landlord or a Superior Mortgagee, and payment for losses thereunder shall be made solely to Landlord subject to the rights of the Superior Mortgagee from time to time.&nbsp;&nbsp;Additionally Landlord may maintain such additional insurance, including, without limitation, earthquake insurance, terrorism insurance, flood insurance, liability insurance and/or rent insurance, as Landlord may in its sole discretion elect.&nbsp;&nbsp;The cost of all such additional insurance shall also be part of the Building Operating Expenses.&nbsp;&nbsp;Any or all of Landlord&#8217;s insurance may be provided by blanket coverage maintained by Landlord or any affiliate of Landlord under its insurance program for its portfolio of properties or by Landlord&#8217;s or any affiliate of Landlord&#8217;s program of self<a name="_cp_text_2_539"></a>&#8209;insurance, and in such event Building Operating Expenses shall include the portion of the reasonable cost of blanket insurance or self-insurance that is allocated to the Building.&nbsp;&nbsp;In no event shall any self-insurance costs or retentions be charged to Tenant, except that Landlord&#8217;s commercially reasonable deductible may be included in Operating Expenses.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Waiver of Subrogation</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_549"></a><a name="_cp_text_1_550"></a><a name="_cp_text_1_551"></a><a name="_cp_text_1_549"></a>&nbsp;&nbsp;Notwithstanding anything herein to the contrary, Landlord and Tenant each hereby waives any and all rights of recovery, claim, action, or cause of action against the other, its agents, employees, licensees, or invitees for any loss or damage to Property, Improvements or personal property (located at the Premises) of such party therein or thereon by reason of fire, the elements, or any other cause which is covered, or would have been covered, by the property <a name="_cp_text_1_550"></a>insurance coverages required to be maintained by Landlord and Tenant, respectively, under this Lease, regardless of cause or origin, including omission of the other party hereto, its agents, employees, licensees, or invitees.  Each party shall look to its respective insurance coverage, and its deductibles and self-insurance or self-insured retentions (which shall be deemed insurance coverage for purposes of this <font style="font-weight:bold;">Section 10.5</font><a name="_cp_text_1_551"></a>), for recovery of any insured property damage.&nbsp;&nbsp;Landlord and Tenant covenant that no insurer shall hold any right of subrogation against either of such parties with respect thereto.&nbsp;&nbsp;The parties hereto agree that any and all such property insurance policies required to be carried by either shall be endorsed with a subrogation clause, substantially as follows:&nbsp;&nbsp;<font style="font-style:italic;">&#8220;This insurance shall not be invalidated should the insured waive, in writing prior to a loss, any and all right of recovery against any party for loss occurring to the Complex described therein,&#8221;</font> and shall provide that such party&#8217;s insurer waives any right of recovery against the other party in connection with any such loss or damage. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU52"></a><font style="text-decoration:none;">ARTICLE 11</font><font style="text-decoration:underline;"><br />FIRE, EMINENT DOMAIN, ETC.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Landlord&#8217;s Right of Termination</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_553"></a><a name="_cp_text_1_556"></a><a name="_cp_text_1_557"></a><a name="_cp_text_2_558"></a><a name="_cp_text_1_559"></a><a name="_cp_text_1_553"></a>.&nbsp;&nbsp;If the Premises or the Building are substantially damaged (the term &#8220;substantially damaged&#8221; meaning damage of such a character that the same cannot, in the ordinary course, reasonably be expected to be repaired within two hundred ten <a name="_cp_text_1_556"></a>(210) days from the time that repair work would commence, as determined in good faith by Landlord's architect) by fire or other casualty (each, a &#8220;<font style="font-weight:bold;">Casualty</font><a name="_cp_text_1_557"></a>&#8221;), then Landlord  <a name="_cp_text_2_558"></a>shall have the right to terminate this Lease by giving notice of <a name="_cp_text_1_559"></a>Landlord&#8217;s election so to do within ninety (90) days after the occurrence of such Casualty provided, however, that Landlord shall only be permitted to terminate this Lease on account of such damage if Landlord terminates the leases of at least 75% of the office tenants in the Building similarly affected by the casualty (where Landlord has a termination right thereunder).&nbsp;&nbsp;If Landlord exercises such termination right, this Lease shall terminate thirty (30) days after the date of such notice with the same force and effect as if such date were the date originally established as the expiration date hereof.&nbsp;&nbsp;In no event shall Landlord have any liability for damages to Tenant for inconvenience, annoyance or interruption of business arising from any Casualty.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Restoration; Tenant&#8217;s Right of Termination</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_560"></a><a name="_cp_text_1_562"></a><a name="_cp_text_2_563"></a><a name="_cp_text_5_564"></a><a name="_cp_text_2_565"></a><a name="_cp_text_2_569"></a><a name="_cp_field_48_570"></a><a name="_cp_text_2_571"></a><a name="_cp_text_5_572"></a><a name="_cp_text_2_573"></a><a name="_cp_text_5_574"></a><a name="_cp_text_2_575"></a><a name="_cp_field_48_576"></a><a name="_cp_text_2_577"></a><a name="_cp_field_48_578"></a><a name="_cp_text_2_579"></a>(a)<font style="margin-left:36pt;"></font><a name="_cp_text_1_560"></a>If the Building or the Premises or any other improvements on or portions of the Complex including, without limitation, the Common Facilities shall be partially or totally damaged or destroyed by a Casualty and if this Lease is not terminated as provided in this <font style="font-weight:bold;">Article&#160;11</font>, then (i)<a name="_cp_text_1_562"></a> Landlord shall repair and restore the same to the condition prior to the Casualty, as applicable, (but excluding Tenant&#8217;s Removable Property and the Improvements) (the &#8220;<font style="font-weight:bold;">Landlord&#8217;s Restoration Work</font>&#8221;) with reasonable dispatch (but Landlord shall not be required to perform the same on an overtime or premium pay basis) after notice to Landlord of the Casualty and the collection of the insurance proceeds attributable to such Casualty, and (ii) Tenant shall repair and restore in accordance with <font style="font-weight:bold;">Section&#160;5.3</font> all of Tenant&#8217;s Removable Property and the Improvements to the condition prior to the Casualty (&#8220;<font style="font-weight:bold;">Tenant&#8217;s Restoration Work</font>&#8221;), with reasonable dispatch after the Casualty,<a name="_cp_text_2_563"></a> following completion of Landlord&#8217;s Restoration Work<a name="_cp_text_5_564"></a>.&nbsp;&nbsp;<a name="_cp_text_2_565"></a>Notwithstanding anything to the contrary contained herein, if in Landlord&#8217;s sole discretion it would be appropriate for safety reasons, health reasons or the efficient operation or restoration of the Building or the Premises for Landlord to perform all or a portion <a name="_cp_text_2_569"></a>of Tenant&#8217;s <a name="_cp_field_48_570"></a>Restoration Work on behalf of Tenant, then <a name="_cp_text_2_571"></a>(x) <a name="_cp_text_5_572"></a>Landlord shall give Tenant a written notice specifying the portion <a name="_cp_text_2_573"></a>of Tenant&#8217;s <a name="_cp_text_5_574"></a>Restoration Work <a name="_cp_text_2_575"></a>to be performed by Landlord (the &#8220;<font style="font-weight:bold;">Specified Restoration Work</font><a name="_cp_field_48_576"></a>&#8221;), <a name="_cp_text_2_577"></a>(y) <a name="_cp_field_48_578"></a>Landlord shall perform the Specified Restoration Work, and <a name="_cp_text_2_579"></a>(z) Tenant shall pay to Landlord within ten (10) days following the giving of Landlord&#8217;s written demand therefor (or Landlord shall retain from the insurance proceeds paid to Landlord in accordance with the last sentence of this <font style="font-weight:bold;">Section 11.2(a)</font>) the cost of such Specified Restoration Work.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU53"></a>(b)<font style="margin-left:36pt;"></font>Landlord shall not carry any insurance on Tenant&#8217;s Removable Property or on the Improvements (including without limitation any of the Tenant Work performed in connection with this Lease other than the Landlord&#8217;s Work) that constitute part of Tenant&#8217;s Restoration Work and shall not be obligated to repair or replace Tenant&#8217;s </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Removable Property or such Improvements (whether or not installed by or at the expense of Landlord).&nbsp;&nbsp;Tenant shall look solely to its insurance for recovery of any damage to or loss of Tenant&#8217;s Removable Property and any Improvements.&nbsp;&nbsp;Tenant shall notify Landlord promptly of any casualty in the Premises.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_2_589"></a><a name="_cp_text_2_582"></a><a name="_cp_text_5_583"></a><a name="_cp_text_5_584"></a><a name="_cp_text_2_585"></a><a name="_cp_text_5_586"></a><a name="_cp_text_2_587"></a><a name="_cp_text_5_588"></a><a name="_cp_text_2_590"></a>(c)<font style="margin-left:36pt;"></font>Within ninety (90) days after the occurrence of any Casualty affecting the Premises or access thereto, Landlord shall deliver to Tenant a written estimate from a reputable contractor, architect or engineer designated by Landlord as to the probable length of time that will be necessary to substantially complete Landlord&#8217;s Restoration Work (&#8220;<font style="font-weight:bold;">Estimated Completion Date</font><a name="_cp_text_5_583"></a>&#8221;).&nbsp;&nbsp;If such time estimate exceeds nine (9) months from the date that repair work would commence, Tenant <a name="_cp_text_5_584"></a>shall have the right to terminate this Lease by giving <a name="_cp_text_2_585"></a>notice to Landlord <a name="_cp_text_5_586"></a>thereof within <a name="_cp_text_2_587"></a>thirty (30) days after receipt of such estimate (time being of the essence with respect to the giving of such notice by Tenant).&nbsp;&nbsp;If Tenant is entitled pursuant to the terms of this <font style="font-weight:bold;">Section 11.2(c)</font><a name="_cp_text_5_588"></a> to <a name="_cp_text_2_590"></a>terminate this Lease and Tenant fails to deliver a termination notice to Landlord within the thirty (30) day period set forth herein, Tenant will be deemed to have waived Tenant&#8217;s rights under this <font style="font-weight:bold;">Section 11.2(c) </font>to terminate the Lease on account of such Casualty.&nbsp;&nbsp;Notwithstanding the foregoing, in the event Landlord fails to complete Landlord&#8217;s Restoration Work within sixty (60) days following the Estimated Completion Date, subject to Force Majeure and any Tenant Delay, Tenant shall have the right to terminate this Lease by giving notice to Landlord thereof within thirty (30) days after Landlord&#8217;s failure to complete the Landlord&#8217;s Restoration Work by the date which is sixty (60) days following the Estimated Completion Date.&nbsp;&nbsp;The provisions of this Section are in lieu of any statutory termination provisions allowable in the event of a Casualty.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_2_591"></a><a name="_cp_text_2_592"></a>(d)<font style="margin-left:36pt;"></font>Except to the extent such damage by fire or other casualty is the result of any act or omission by Tenant, any subtenant or any of their respective partners, directors, officers, servants, employees, agents or contractors, if the Premises or the Building are substantially damaged by fire or other casualty, and this Lease is not otherwise terminated hereunder, and if Landlord&#8217;s Restoration Work shall not be substantially completed within ninety (90) days after the time period set forth in Landlord&#8217;s estimate for substantial completion of Landlord&#8217;s Restoration Work as described in <font style="font-weight:bold;">Section 11.2(c)</font>, Tenant shall have the right to terminate this Lease by delivering at least thirty (30) days prior written notice to Landlord of such election which notice must be delivered within ten (10) Business Days after the expiration of such time period, provided, however, that if Landlord completes such restoration prior to the end of such thirty (30) day notice period, Tenant&#8217;s notice of termination shall be deemed rescinded, and this Lease shall continue in full force and effect.&nbsp;&nbsp;If Tenant is entitled pursuant to the terms of this <font style="font-weight:bold;">paragraph (d)</font> to terminate this Lease and Tenant fails to deliver a termination notice to Landlord within the ten (10) Business Day period set forth herein, Tenant will be deemed to have waived Tenant&#8217;s rights under this <font style="font-weight:bold;">paragraph (d)</font> to terminate the Lease on account of such Casualty.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU54"></a>(e)<font style="margin-left:36pt;"></font>If this Lease is terminated under any of the provisions of this <font style="font-weight:bold;">Article 11</font> as a result of a Casualty, Landlord shall be entitled to retain for its benefit and Tenant shall promptly pay over to Landlord the proceeds of insurance maintained by Tenant on the Improvements after deducting Tenant&#8217;s unamortized cost to initially </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">construct the Improvements above the amount of the Landlord&#8217;s Contribution, with such amortization being done on a straight line basis over the initial Term of this Lease in accordance with GAAP.&nbsp;&nbsp;This </font><font style="font-weight:bold;">Section 11.2</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shall be deemed an express agreement governing any damage or destruction of the Premises by fire or other casualty, and any law providing for a contingency in the absence of an express agreement, now or hereafter in force, shall have no application.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Abatement of Rent</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_594"></a><a name="_cp_text_1_596"></a><a name="_cp_text_1_597"></a><a name="_cp_text_2_598"></a><a name="_cp_text_5_599"></a><a name="_cp_text_2_600"></a><a name="_cp_text_5_601"></a><a name="_cp_text_2_602"></a>(a)<font style="margin-left:36pt;"></font>.&nbsp;&nbsp;If the Premises is damaged by a Casualty, Basic Rent and Expense Charges payable by Tenant shall abate proportionately for the period from the date of such fire or other casualty until the earlier of (a)<a name="_cp_text_1_594"></a> the date that Landlord substantially completes Landlord&#8217;s Restoration Work (provided that if Landlord would have completed Landlord&#8217;s Restoration Work at an earlier date but for Tenant having failed to cooperate with Landlord in effecting such Work or collecting insurance proceeds and such failure continued for more than two (2) Business Days after receipt by Tenant of notice thereof, then the Premises shall be deemed to have been repaired and restored on such earlier date and the abatement shall cease), or (b)<a name="_cp_text_1_596"></a> the date Tenant or other occupant reoccupies any portion of the Premises for the conduct of business <a name="_cp_text_1_597"></a>(in which case the Basic Rent and&nbsp;&nbsp;Expense Charges allocable to such reoccupied  <a name="_cp_text_2_598"></a>portion shall be payable by Tenant from the date of such occupancy).<a name="_cp_text_5_599"></a>&nbsp;&nbsp;Notwithstanding the foregoing, if by reason of any act or omission by Tenant, any subtenant or any of their respective partners, directors, officers, servants, <a name="_cp_text_2_600"></a>employees, agents or contractors<a name="_cp_text_5_601"></a>, Landlord, or any Mortgagee shall be unable to collect all of the insurance proceeds <a name="_cp_text_2_602"></a>(including, without limitation, rent insurance proceeds) applicable to the casualty and such act or omission is not cured within five (5) business days after written notice from Landlord, then, without prejudice to any other remedies which may be available against Tenant, there shall be no abatement of Basic Rent or of Expense Charges.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:6.41%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Eminent Domain</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_605"></a><a name="_cp_text_1_606"></a>(a)<font style="margin-left:36pt;"></font><a name="_cp_text_1_605"></a>If the Premises shall be affected by any exercise of the power of eminent domain, Basic Rent, <a name="_cp_text_1_606"></a>Expense Charges and all other charges payable by Tenant shall be justly and equitably abated and reduced according to the nature and extent of the loss of use thereof suffered by Tenant.&nbsp;&nbsp;In no event shall Landlord have any liability for damages to Tenant for inconvenience, annoyance or interruption of business arising from such exercise of the power of eminent domain.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_608"></a><a name="_cp_text_1_609"></a><a name="_cp_text_1_611"></a>(b)<font style="margin-left:36pt;"></font><a name="_cp_text_1_608"></a>If more than 25% <a name="_cp_text_1_609"></a>of the Building is taken by any exercise of the right of eminent domain, then Landlord or Tenant <a name="_cp_text_1_611"></a>shall have the right to terminate this Lease (even if Landlord&#8217;s entire interest in the Premises may have been divested) by giving notice of its election so to do within ninety (90) days after the occurrence of the effective date of such taking, whereupon this Lease shall terminate thirty (30) days after the date of such notice with the same force and effect as if such date were the date originally established for the expiration of the Term of this Lease.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_621"></a><a name="_cp_blt_2_620"></a><a name="_cp_blt_1_618"></a><a name="_cp_text_1_612"></a><a name="_AEIOULastRenderedPageBreakAEIOU55"></a><a name="_cp_text_4_613"></a><a name="_cp_text_1_614"></a><a name="_cp_text_4_615"></a><a name="_cp_text_1_616"></a><a name="_cp_text_1_619"></a>(c)<font style="margin-left:36pt;"></font>If any part of the Premises is taken and such taking will prevent Tenant from conducting its business in the Premises in a manner reasonably comparable to that conducted immediately before such taking for a period of more than one hundred </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_4_613"></a>eighty (180) days, then Tenant may terminate this Lease as of the date of such taking by giving written </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_614"></a>notice to Landlord </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_4_615"></a>within </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_616"></a>thirty (30) days after </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_619"></a>the taking, and all Basic Rent, Expense Charges and all other charges payable by Tenant under this Lease shall be apportioned as of the date of such taking.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>If this Lease shall not be terminated pursuant to <font style="font-weight:bold;">Section 11.4(b)</font>, Landlord shall thereafter use due diligence to restore the Premises (excluding any Alterations made by Tenant pursuant to <font style="font-weight:bold;">Section&#160;5.3</font>) to proper condition for Tenant&#8217;s use and occupation, provided that Landlord&#8217;s obligation shall be limited to the amount of compensation recoverable by Landlord from the taking authority.&nbsp;&nbsp;If, for any reason, such restoration shall not be substantially completed within six (6) months after the expiration of the ninety (90) day period referred to in <font style="font-weight:bold;">Section 11.4(b)</font> (which six month period may be extended for such periods of time as Landlord is prevented from proceeding with or completing such restoration for any cause beyond Landlord&#8217;s reasonable control, but in no event for more than an additional three (3) months), Tenant shall have the right to terminate this Lease by giving notice to Landlord thereof within thirty (30) days after the expiration of such period (as so extended).&nbsp;&nbsp;Upon the giving of such notice, this Lease shall cease and come to an end thirty (30) days after the giving of such notice, without further liability or obligation on the part of either party unless, within such thirty (30) day period, Landlord substantially completes such restoration.&nbsp;&nbsp;Such right of termination shall be Tenant&#8217;s sole and exclusive remedy at law or in equity for Landlord&#8217;s failure so to complete such restoration.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_624"></a><a name="_cp_blt_2_623"></a>(e)<font style="margin-left:36pt;"></font>Landlord shall have and hereby reserves and excepts, and Tenant hereby grants and assigns to Landlord, all rights to recover for damages to the Property and the leasehold interest hereby created, and to compensation accrued or hereafter to accrue by reason of such taking, and by way of confirming the foregoing, Tenant hereby grants and assigns, and covenants with Landlord to grant and assign to Landlord, all rights to such damages or compensation, and covenants to deliver such further assignments and assurances thereof as Landlord may from time to time request.&nbsp;&nbsp;Nothing contained herein shall be construed to prevent Tenant from prosecuting in any condemnation proceedings a claim for the value of any of Tenant&#8217;s Removable Property installed in the Premises by Tenant at Tenant&#8217;s expense and for relocation expenses, provided that such action shall not affect the amount of compensation otherwise recoverable by Landlord from the taking authority.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">ARTICLE 12</font><font style="text-decoration:underline;"><br />HOLDING OVER; SURRENDER</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Holding Over</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_626"></a><a name="_cp_text_1_628"></a><a name="_cp_text_1_630"></a><a name="_cp_text_1_631"></a><a name="_AEIOULastRenderedPageBreakAEIOU56"></a><a name="_cp_text_1_633"></a><a name="_cp_text_1_635"></a><a name="_cp_text_4_636"></a><a name="_cp_text_1_637"></a>.&nbsp;&nbsp;If Tenant or anyone claiming by, through or under Tenant shall remain in possession of all or any part of the Premises (which shall include Tenant&#8217;s failure to comply with <font style="font-weight:bold;">Section 5.5(e)</font><a name="_cp_text_1_626"></a> of this Lease or a failure by Tenant to remove any Tenant&#8217;s Removable Property or Alterations as required under this Lease) after the expiration or earlier termination of the Term of this Lease, such holding over shall be treated as a daily tenancy at sufferance at a Basic Rent equal to the greater of (i)<a name="_cp_text_1_628"></a> the fair market rental rate for the Premises based upon the most recent comparable transactions for the Building and in transactions for comparable space on the same floor or above in Comparable Buildings, and (ii)<a name="_cp_text_1_630"></a> (y) one <a name="_cp_text_1_631"></a>hundred </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fifty </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU56"></a>percent </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_633"></a>(</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%) of the Basic Rent in effect for the last rental period of the Term </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the first thirty (30) days of Tenant&#8217;s holdover, then (z) two hundred percent (200%) </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the Basic Rent in effect for the last rental period of the Term </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the period following the first thirty (30) days of Tenant&#8217;s holdover, in all events</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_635"></a> plus Expense Charges and other Additional Rent herein provided (prorated on a daily basis).&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_4_636"></a>If any such holding over continues for more </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_637"></a>than thirty (30) days</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, then, in </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">addition to any other liabilities to Landlord accruing therefrom, Tenant shall protect, defend, indemnify and hold Landlord harmless from all loss, costs and damages, direct and/or indirect, sustained by reason of any such holding over, including, without limitation, claims made by and loss of any succeeding tenant arising out of such failure to timely surrender possession in the condition required under this Lease.&nbsp;&nbsp;In all other respects, such holding over shall be on the terms and conditions set forth in this Lease as far as applicable (and excluding any extension, expansion or rights of first offer of tenant) in the Lease.&nbsp;&nbsp;Nothing contained in this </font><font style="font-weight:bold;">Article&#160;12</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shall be construed as a consent by Landlord to any holding over by Tenant, and Landlord shall have the right to immediately terminate such holding over pursuant to applicable Law.&nbsp;&nbsp;The provisions of this </font><font style="font-weight:bold;">Article&#160;12</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shall not be deemed to limit or constitute a waiver of any other rights or remedies of Landlord provided herein or at law.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Surrender of Premises</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_638"></a><a name="_cp_text_1_639"></a><a name="_cp_text_2_640"></a><a name="_cp_text_1_642"></a><a name="_cp_text_1_645"></a><a name="_cp_text_2_648"></a><a name="_cp_text_1_649"></a><a name="_cp_text_2_650"></a><a name="_cp_text_2_638"></a>.&nbsp;&nbsp;Upon the expiration or earlier termination of the Term of this Lease, Tenant shall promptly and peaceably quit and surrender to Landlord the Premises in <a name="_cp_text_1_639"></a>neat and clean <a name="_cp_text_2_640"></a>condition and in good order, condition and repair and consistent with Tenant&#8217;s obligations under this Lease including the Hazardous Materials surrender obligations of <font style="font-weight:bold;">Section 5.5(e)</font><a name="_cp_text_1_642"></a> of this Lease, together with all Alterations which may have been made or installed in, on or to the Premises prior to or during the Term of this Lease (except as otherwise expressly required pursuant to <font style="font-weight:bold;">Section 5.3(e)</font><a name="_cp_text_1_645"></a> above), excepting only ordinary wear and tear, and damage by fire or other casualty for which, under other provisions of this Lease Tenant has no responsibility to repair or restore, or as a consequence of the exercise of the power of eminent domain.&nbsp;&nbsp;Notwithstanding the foregoing, if this Lease has been terminated on account of a Casualty, Tenant will not be obligated to perform the Tenant&#8217;s Restoration Work so long as Tenant has paid the insurance proceeds to Landlord in accordance with <font style="font-weight:bold;">Section 11.2(e)</font><a name="_cp_text_2_648"></a> above.&nbsp;&nbsp;Tenant shall remove all of Tenant&#8217;s Removable Property,<a name="_cp_text_1_649"></a>  <a name="_cp_text_2_650"></a>all signs installed by or on behalf of Tenant in or on the Premises and the Building, all lines and other wiring and cabling installed by Tenant prior to or during the Term.&nbsp;&nbsp;Tenant shall repair any damage to the Premises or the Building caused by such removal and restore the affected area to its condition prior to the installation thereof.&nbsp;&nbsp;Any Tenant&#8217;s Removable Property which shall remain in the Building or on the Premises after the expiration or termination of the Term of this Lease shall be deemed conclusively to have been abandoned, and either may be retained by Landlord as its property or may be disposed of in such manner as Landlord may see fit, at Tenant&#8217;s sole cost and expense.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">ARTICLE 13</font><font style="text-decoration:underline;"><br />RIGHTS OF MORTGAGEES; TRANSFER OF TITLE</font><font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Rights of Mortgagees or Ground Lessor</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU57"></a>(a)<font style="margin-left:36pt;"></font>This Lease, and all rights of Tenant hereunder, are and shall be subject and subordinate to any ground or underlying leases of the Property and to all renewals, extensions, modifications and replacements thereof, and to all mortgages, deeds of trust or similar encumbrances which may now or hereafter affect the Property, whether </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or not such mortgages or other encumbrances shall also cover other lands and/or buildings, and to each and every advance made or hereafter to be made under such mortgages and other encumbrances, and to all renewals, modifications, replacements, extensions and consolidations of such mortgages and other encumbrances.&nbsp;&nbsp;This Section shall be self operative and no further instrument of subordination shall be required.&nbsp;&nbsp;In confirmation of such subordination, Tenant shall promptly execute, acknowledge and deliver any instrument that Landlord, the lessor under any such lease or the holder of any such mortgage or other encumbrance or any of their respective successors in interest may reasonably request to evidence such subordination.&nbsp;&nbsp;Any lease to which this Lease is, at the time referred to, subject and subordinate is herein called &#8220;</font><font style="font-weight:bold;">Superior Lease</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; and the lessor of a Superior Lease or its successor in interest at the time referred to, is herein called &#8220;</font><font style="font-weight:bold;">Superior Lessor</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;; and any mortgage or other encumbrance to which this Lease is, at the time referred to, subject and subordinate, is herein called &#8220;</font><font style="font-weight:bold;">Superior Mortgage</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; and the holder of a Superior Mortgage, or its successor in interest at the time referred to, is herein called &#8220;</font><font style="font-weight:bold;">Superior Mortgagee</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#8221;&nbsp;&nbsp;If any Superior Mortgagee, shall so elect, this Lease and the rights of Tenant hereunder, shall be superior in right to the rights of such holder, with the same force and effect as if this Lease had been executed, delivered and recorded, or a statutory notice hereof recorded, prior to the execution, delivery and recording of any such Superior Mortgage.&nbsp;&nbsp;The election of any such Superior Mortgagee shall become effective upon either notice from such Superior Mortgagee to Tenant in the same fashion as notices from Landlord to Tenant are to be given hereunder or by the recording in the appropriate registry or recorder&#8217;s office of an instrument in which the Superior Mortgagee subordinates its rights under such Superior Mortgage to this Lease.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_652"></a><a name="_AEIOULastRenderedPageBreakAEIOU58"></a><a name="_cp_text_1_653"></a><a name="_cp_text_1_655"></a><a name="_cp_text_1_656"></a>(b)<font style="margin-left:36pt;"></font>If any Superior Lessor or Superior Mortgagee or the nominee or designee of any Superior Lessor or Superior Mortgagee shall succeed to the rights of Landlord under this Lease, whether through possession or foreclosure action or delivery of a new lease or deed, or otherwise, then at the request of such party so succeeding to Landlord&#8217;s rights (herein called &#8220;<font style="font-weight:bold;">Successor Landlord</font>&#8221;), Tenant shall attorn to and recognize such Successor Landlord as Tenant&#8217;s landlord under this Lease and shall promptly execute and deliver any instrument that such Successor Landlord may reasonably request to evidence such attornment.&nbsp;&nbsp;Tenant waives the provisions of any law or regulation, now or hereafter in effect, which terminates or may give or purport to give Tenant any right to terminate or otherwise affect this Lease or the obligations of Tenant hereunder in the event that any such foreclosure, termination or other proceeding is filed, prosecuted or completed.&nbsp;&nbsp;Upon such attornment, this Lease shall continue in full force and effect as a direct lease between the Successor Landlord and Tenant upon all of the terms, conditions and covenants as are set forth in this Lease, except that the Successor Landlord shall not be (i) liable in any way to Tenant for any act or omission, neglect or default on the part of Landlord under this Lease, (ii) responsible for any monies owing by or on deposit with Landlord to the credit of Tenant, (iii) subject to any counterclaim or setoff which theretofore accrued to Tenant against Landlord, (iv)<a name="_cp_text_2_652"></a> bound by any modification of this Lease subsequent to such Superior Lease or Superior Mortgage, or by any previous prepayment of fixed rent for more than one (1) month, which was not approved in writing by the Superior Lessor or the Superior Mortgagee thereto, (v) liable to the Tenant beyond the Successor Landlord&#8217;s interest in the Property and the rents, income, receipts, revenues, issues and profits issuing from such Property, (vi) responsible for the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_653"></a>performance of any work to be done by the Landlord under this Lease to render the Premises ready for occupancy by the Tenant, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_655"></a> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vii)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_656"></a> liable for the payment of any improvement allowance or similar amount owing to Tenant on account of the performance of any alterations or leasehold improvements to the Premises or the Building, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(viii)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> required to remove any person occupying the Premises or any part thereof, except if such person claims by, through or under the Successor Landlord. </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>Landlord shall use commercially reasonable efforts to deliver to Tenant a &#8220;Subordination, Non-Disturbance and Attornment Agreement&#8221; (&#8220;<font style="font-weight:bold;">SNDA</font>&#8221;)<font style="color:#000000;"> in the then customary form of such Superior Mortgagee or Superior Lessor with respect to any future Superior Mortgages and Superior Leases.&nbsp;&nbsp;</font>Landlord shall in no event be required to expend any monies or commence or prosecute litigation or reject financing which is otherwise satisfactory to Landlord in order to deliver such an SNDA.&nbsp;&nbsp;<font style="color:#000000;">Tenant may request customary and reasonable modifications to such SNDA from the Superior Mortgagee and Superior Lessor (as the case may be) except that Landlord&#8217;s obligations under this </font><font style="font-weight:bold;color:#000000;">Section&#160;13.1(c)</font><font style="color:#000000;"> shall be deemed fully satisfied when Landlord delivers an SNDA from its Superior Mortgagee or Superior Lessor, as applicable, on its standard form regardless of the acceptability to such Superior Mortgagee or Superior Lessor of Tenant&#8217;s requested modifications</font>.&nbsp;&nbsp;Notwithstanding anything to the contrary contained in this <font style="font-weight:bold;">Section 13.1</font>, with respect to future Superior Leases, the provisions of <font style="font-weight:bold;">Section 13.1(a)</font> shall be conditioned upon the execution and delivery by and between Tenant and any such Superior Lessor of an SNDA in the then customary form of such Superior Lessor and with such customary and reasonable modifications to such SNDA as may be reasonably acceptable to the Superior Lessor and Tenant.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Assignment of Rents and Transfer of Title</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>With reference to any assignment by Landlord of Landlord&#8217;s interest in this Lease, or the rents payable hereunder, conditional in nature or otherwise, which assignment is made to a Superior Mortgagee on property which includes the Premises, Tenant agrees that the execution thereof by Landlord, and the acceptance thereof by the Superior Mortgagee shall never be treated as an assumption by the Superior Mortgagee of any of the obligations of Landlord hereunder unless the Superior Mortgagee shall, by notice sent to Tenant, specifically otherwise elect and, except as aforesaid, the Superior Mortgagee shall be treated as having assumed Landlord&#8217;s obligations hereunder only upon foreclosure of the Superior Mortgage and the taking of possession of the Premises.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>In no event shall the acquisition of Landlord&#8217;s interest in the Property by a purchaser which, simultaneously therewith, leases Landlord&#8217;s entire interest in the Property back to the seller thereof be treated as an assumption by operation of law or otherwise, of Landlord&#8217;s obligations hereunder, but Tenant shall look solely to such seller&#8209;lessee, and its successors from time to time in title, for performance of Landlord&#8217;s obligations hereunder.&nbsp;&nbsp;In any such event, this Lease shall be subject and subordinate to the lease to such purchaser.&nbsp;&nbsp;For all purposes, such seller&#8209;lessee, and its successors in title, shall be the Landlord hereunder unless and until Landlord&#8217;s position shall have been assumed by such purchaser&#8209;lessor.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU59"></a><a name="_cp_text_1_677"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except as provided in </font><font style="font-weight:bold;">paragraph&#160;(b)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_677"></a> of this Section, in the event of any transfer of title to the Property by Landlord, Landlord shall thereafter be entirely freed and relieved from the performance and observance of all covenants and obligations hereunder</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> arising from and after the date of such transfer, so long as any such transferee assumes in writing (or by operation of law) all of Landlord's obligations under this Lease</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Notice to Mortgagee</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_678"></a><a name="_cp_text_1_680"></a><a name="_cp_text_1_678"></a>.&nbsp;&nbsp;Tenant shall not seek to enforce any remedy it may have for any default on the part of Landlord without first giving any Superior Mortgagee and Superior Lessor (of which Tenant has been provided written notice including their notice addresses), as applicable, written notice by certified mail, return receipt requested, specifying the default in reasonable detail, and affording such Superior Mortgagee and Superior Lessor, as applicable, (i)<a name="_cp_text_1_680"></a> an opportunity to perform Landlord&#8217;s obligations hereunder (but not less than thirty (30) days), or (ii) time to obtain possession of the mortgaged or leased estate and then to cure such default of Landlord, if such default cannot be cured without such Superior Mortgagee or Superior Lessor or taking possession of the mortgaged or leased estate, but not to exceed one hundred eighty (180) days in the aggregate to obtain such possession and cure the Landlord default.&nbsp;&nbsp;The curing of any of Landlord&#8217;s defaults by a Superior Mortgagee or Superior Lessor shall be treated as performance by Landlord.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">ARTICLE 14</font><font style="text-decoration:underline;"><br />DEFAULT; REMEDIES</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Tenant&#8217;s Default</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>If at any time subsequent to the date of this Lease any one or more of the following events (herein referred to as an &#8220;<font style="font-weight:bold;">Event of Default</font>&#8221;) shall occur:</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_688"></a><a name="_cp_text_1_692"></a>(i)<font style="margin-left:36pt;"></font><a name="_cp_text_1_688"></a>Tenant shall fail to pay the Basic Rent, Expense Charges or any other Additional Rent hereunder when due and such failure shall continue for five <a name="_cp_text_1_692"></a>(5) Business Days after written notice to Tenant from Landlord (except that such written notice shall only be required twice (i.e. two separate failures) in any twelve (12) month period, with any subsequent failure to pay such sums  constituting an Event of Default unless paid within five (5) Business Days after the date due without need for an additional written notice); or</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_693"></a><a name="_cp_text_2_694"></a><a name="_AEIOULastRenderedPageBreakAEIOU60"></a>(ii)<font style="margin-left:36pt;"></font><a name="_cp_text_2_693"></a>Tenant shall neglect or fail to perform or observe any other covenant herein contained on Tenant&#8217;s part to be performed or observed and Tenant shall fail to remedy the same within thirty (30) days after notice to Tenant (or such shorter period for completing a cure for such default as may be required by applicable Laws or by virtue of an Emergency) <a name="_cp_text_2_694"></a>specifying such neglect or failure, or if such failure is of such a nature that Tenant cannot reasonably remedy the same within such thirty (30) day period, Tenant shall fail to commence promptly (and in any event within such thirty (30) day period) to remedy the same and thereafter to diligently prosecute such remedy to completion with diligence and continuity (and in any event, within ninety (90) days after the notice described in this <font style="font-weight:bold;">subparagraph (ii)</font>), provided that (x) in no event shall Tenant have such additional period of time that would (A) subject Landlord or any </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Superior Lessor or any Superior Mortgagee to prosecution for a crime or any other fine or charge, or (B) subject the Property, or any part thereof, to any lien or encumbrance which is not removed or bonded within the time period required under this Lease, and (y) such written notice shall only be required twice in any twelve (12) month period, with any of the same subsequent performance default constituting an Event of Default unless cured within the period required under this Lease without need for an additional written notice); or</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;"></font>Tenant&#8217;s leasehold interest in the Premises shall be taken on execution or by other process of law directed against Tenant; or </p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_697"></a><a name="_cp_text_1_699"></a>(iv)<font style="margin-left:36pt;"></font>If Tenant or any guarantor of this Lease shall (i) make an assignment for the benefit of creditors, (ii) acquiesce in a petition in any court in any bankruptcy, reorganization, composition, extension or insolvency proceedings, (iii)&nbsp;&nbsp;seek, consent to or acquiesce in the appointment of any trustee, receiver or liquidator of Tenant or of any guarantor of this Lease or of all or any part of Tenant&#8217;s or such guarantor&#8217;s property, (iv) file a petition seeking an order for relief under the Title 11 of the United States Code, as now or hereafter amended or supplemented (the &#8220;<font style="font-weight:bold;">Bankruptcy Code</font>&#8221;), or by filing any petition under any other present or future federal, state or other statute or law for the same or similar relief, or (v)<a name="_cp_text_1_697"></a> fail to win the dismissal, discontinuation or vacating of any involuntary bankruptcy proceeding filed under the Bankruptcy Code, or under any other present or future federal, state or other statute or law for the same or similar relief, within ninety <a name="_cp_text_1_699"></a>(90) days after such proceeding is initiated; or</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_700"></a>(v)<font style="margin-left:36pt;"></font><a name="_cp_text_2_700"></a>Any lien has been filed against the Property, or any portion thereof, as a result of work performed by or on behalf of Tenant (other than any work performed for Tenant by Landlord or its employees, agents or contractors), and Tenant fails, within 30 days after the lien is filed, either&nbsp;&nbsp;(1) to cause said lien to be removed from the Property, or (2) to furnish a bond sufficient to remove the lien or cause a title insurance endorsement to be issued with respect to such lien, which endorsement shall be satisfactory, in form and substance to Landlord, in Landlord&#8217;s sole and absolute discretion; or</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vi)<font style="margin-left:36pt;"></font>Tenant&#8217;s interest in the Premises shall be transferred without Landlord prior written consent, if so required, in violation of <font style="font-weight:bold;">Article 6</font> hereof, and Tenant shall fail to remedy the same within fifteen (15) days after written notice to Tenant specifying such violation;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">then in any such case Landlord may exercise any of Landlord&#8217;s rights or remedies available under this Lease, at law or in equity.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Landlord&#8217;s Remedies</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU61"></a>(a)<font style="margin-left:36pt;"></font>Upon the occurrence of an Event of Default, Landlord shall have the following remedies, in addition to any and all other rights and remedies available at </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Law or in equity or otherwise provided in this Lease, any one or more of which Landlord may resort to cumulatively, consecutively, or in the alternative:</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>Landlord may continue this Lease in full force and effect, and collect Rent and other charges as and when due, without prejudice to Landlord&#8217;s right to subsequently elect to terminate this Lease on account of such Event of Default;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_704"></a><a name="_cp_text_2_705"></a><a name="_cp_text_1_706"></a>(ii)<font style="margin-left:36pt;"></font><a name="_cp_text_2_704"></a>Landlord may terminate this Lease upon written notice to Tenant to such effect, in which event this Lease (and all of Tenant&#8217;s rights hereunder) shall immediately terminate, but such termination shall not affect those obligations of Tenant which are intended <a name="_cp_text_2_705"></a>by their terms <a name="_cp_text_1_706"></a>to survive the expiration or termination of this Lease, and Tenant shall remain liable for damages as hereinafter set forth in this <font style="font-weight:bold;">Section&#160;14.2</font>.&nbsp;&nbsp;This Lease may also be terminated by a judgment specifically providing for termination;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;"></font>Landlord may terminate Tenant&#8217;s right of possession without terminating this Lease upon written notice to Tenant to such effect, in which event Tenant&#8217;s right of possession of the Premises shall immediately terminate, but this Lease shall continue subject to the effect of this <font style="font-weight:bold;">Section&#160;14.2</font>;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_2_713"></a><a name="_cp_text_2_707"></a><a name="_cp_field_48_708"></a><a name="_cp_text_2_709"></a><a name="_cp_field_48_710"></a><a name="_cp_text_2_711"></a><a name="_cp_field_48_712"></a><a name="_cp_text_2_714"></a>(iv)<font style="margin-left:36pt;"></font>Landlord may, but shall not be obligated to, perform any defaulted obligation of Tenant, and to recover from Tenant, as Additional Rent, the costs incurred by Landlord in performing such obligation.&nbsp;&nbsp;Notwithstanding the foregoing, or any other notice and cure period set forth herein, Landlord may exercise its rights under this <font style="font-weight:bold;">Section 14.2(a)(iv)</font><a name="_cp_field_48_708"></a> without prior notice or upon shorter notice than otherwise required hereunder (and as may be reasonable under the circumstances) in the event of any one or more of the following circumstances is present:&nbsp;&nbsp;<a name="_cp_text_2_709"></a>(i) <a name="_cp_field_48_710"></a>there exists a reasonable risk of prosecution of Landlord unless such obligation is performed sooner than the stated cure period; <a name="_cp_text_2_711"></a>(ii) <a name="_cp_field_48_712"></a>there exists an Emergency arising out of the defaulted obligation; or <a name="_cp_text_2_714"></a>(iii) the Tenant has failed to obtain insurance required by this Lease, or such insurance has been canceled by the insurer without being timely replaced by Tenant, as required herein; and</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_717"></a><a name="_cp_blt_2_716"></a>(v)<font style="margin-left:36pt;"></font>Landlord shall have the right to recover damages from Tenant, as set forth in this <font style="font-weight:bold;">Section&#160;14.2</font>.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_718"></a><a name="_AEIOULastRenderedPageBreakAEIOU62"></a>(b)<font style="margin-left:36pt;"></font>Upon any termination of this Lease or of Tenant&#8217;s right of possession, Landlord, at its sole election,&nbsp;&nbsp;may (i) re<a name="_cp_text_2_718"></a>&#8209;enter the Premises, either by summary proceedings or other lawful proceedings and remove and dispossess Tenant and all other persons and any and all property from the same, as if this Lease had not been made, (ii) remove all property from the Premises and store the same in a public warehouse or elsewhere at Tenant&#8217;s expense, and/or (iii) deem such property to be abandoned, and, in such event, Landlord may dispose of such property at Tenant&#8217;s expense, free from any claim by Tenant or anyone claiming by, through or under Tenant.&nbsp;&nbsp;It shall not constitute a constructive or other termination of this Lease or Tenant&#8217;s right to possession if Landlord (a) exercises its right to repair or maintain the Premises, (b) performs any unperformed </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obligations of Tenant, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> stores or removes Tenant&#8217;s property from the Premises after Tenant&#8217;s dispossession, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> attempts to relet, or, in fact, does relet, the Premises or </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> seeks the appointment of a receiver on Landlord&#8217;s initiative to protect Landlord&#8217;s interest under this Lease.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>If this Lease shall have been terminated as provided in this Article, Tenant shall pay the Basic Rent, Expense Charges, Additional Rent and other sums payable hereunder up to the time of such termination, and thereafter Tenant, until the end of what would have been the Term of this Lease in the absence of such termination, and whether or not the Premises shall have been relet, shall be liable to Landlord for, and shall pay to Landlord, as liquidated current damages:&nbsp;&nbsp;the Basic Rent, Expense Charges, Additional Rent and other sums that would be payable hereunder if such termination had not occurred, less the net proceeds, if any, of any reletting of the Premises, after deducting all actual expenses incurred by Landlord in connection with such reletting, including, without limitation, all repossession costs, brokerage commissions, legal expenses, attorneys&#8217; fees, advertising, expenses of employees, alteration costs and expenses of preparation for such reletting.&nbsp;&nbsp;Tenant shall pay the portion of such current damages to Landlord monthly on the days which the Basic Rent would have been payable hereunder if this Lease had not been terminated.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_735"></a><a name="_cp_text_1_736"></a><a name="_cp_text_1_738"></a><a name="_cp_text_1_740"></a><a name="_cp_text_1_741"></a>(d)<font style="margin-left:36pt;"></font><a name="_cp_text_1_735"></a>At any time after termination of this Lease as provided in this Article, whether or not Landlord shall have collected any such current damages under (c) above, Landlord may elect to receive from Tenant<a name="_cp_text_1_736"></a>, as liquidated final damages and in lieu of all such current damages <a name="_cp_text_1_738"></a>with respect to the recovery of Rent, beyond the date of such demand, an amount equal to the excess, if any, of the then present value <a name="_cp_text_1_740"></a>of the Basic Rent, Expense Charges, Additional Rent and other sums as hereinbefore provided which would be payable hereunder from the date of such demand assuming that, for the purposes of this paragraph, annual payments by Tenant on account of Taxes, Building Operating Expenses and Laboratory Operating Expenses would be the same as the payments required for the immediately preceding Operating or Tax Year plus a three percent (3%) annual increase per year for what would be the then unexpired Term of this Lease if the same remained in effect, over the then fair net rental value (inclusive of all such charges) <a name="_cp_text_1_741"></a>of the Premises for the same period. In the computation of present value, a discount at the then market discount rate as reasonably determined by Landlord shall be employed.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_742"></a><a name="_AEIOULastRenderedPageBreakAEIOU63"></a>(e)<font style="margin-left:36pt;"></font>In case of any Event of Default, re&#8209;entry, expiration and dispossession by summary proceedings or otherwise, Landlord may (i) relet the Premises or any part or parts thereof, either in the name of Landlord or otherwise, for a term or terms which may at Landlord&#8217;s option be equal to or less than or exceed the period which would otherwise have constituted the balance of the Term of this Lease and may grant concessions or free rent to the extent that Landlord considers advisable and necessary to re let the same and (ii)<a name="_cp_text_1_742"></a> make such reasonable alterations, repairs and decorations in the Premises as Landlord considers advisable and necessary for the purpose of reletting the Premises; and the making of such alterations, repairs and decorations shall not operate or be construed to release Tenant from liability hereunder as aforesaid.&nbsp;&nbsp;Tenant, for itself and any and all persons claiming through or under Tenant, including its creditors, upon the termination of this Lease and of the term of this Lease in accordance with the terms </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hereof, or in the event of entry of judgment for the recovery of the possession of the Premises in any action or proceeding, or if Landlord shall enter the Premises by process of law or otherwise, hereby waives any right of redemption provided or permitted by any statute, law or decision now or hereafter in force, and does hereby waive, surrender and give up all rights or privileges which it or they may or might have under and by reason of any present or future law or decision, to redeem the Premises or for a continuation of this Lease for the term of this Lease hereby demised after having been dispossessed or ejected therefrom by process of law, or otherwise.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_743"></a><a name="_cp_text_1_744"></a><a name="_cp_text_2_745"></a><a name="_cp_text_5_746"></a><a name="_cp_text_2_747"></a><a name="_cp_text_1_748"></a><a name="_cp_text_2_749"></a><a name="_AEIOULastRenderedPageBreakAEIOU64"></a>(f)<font style="margin-left:36pt;"></font>In addition to any other remedies under this <font style="font-weight:bold;">Article&#160;14</font><a name="_cp_text_2_743"></a>, Tenant shall immediately become liable to Landlord for all damages proximately <a name="_cp_text_1_744"></a>caused by Tenant&#8217;s breach of its obligations under this Lease, including all actual <a name="_cp_text_2_745"></a>costs Landlord incurs in reletting (or attempting to relet) the Premises or any part thereof, including, without limitation, brokers&#8217; commissions, expenses of cleaning, altering and preparing the Premises for new tenants, legal fees and all other like expenses properly chargeable against the Premises and the rental received therefrom and like costs, provided that nothing set forth in this <font style="font-weight:bold;">Section 14.2(f)</font><a name="_cp_text_5_746"></a> shall be construed to impose upon Landlord any obligation to relet the Premises or <a name="_cp_text_2_747"></a>to mitigate its damages hereunder, except to the extent expressly required under applicable Law or as expressly set forth in this <font style="font-weight:bold;">Section 14.2(f)</font>.&nbsp;&nbsp;If Landlord does elect to relet the Premises (or any portion thereof), such reletting may be for a period shorter or longer than the remaining Term, and upon such terms and conditions as Landlord deems appropriate, in its sole and absolute discretion, and Tenant shall have no interest in any sums collected by Landlord in connection with such reletting except to the extent expressly set forth herein.&nbsp;&nbsp;If the Premises or any part thereof shall be relet in combination with any other space, then proper apportionment on a per-square foot basis shall be made of the rent received from such reletting and of the expenses of such reletting.&nbsp;&nbsp;If Landlord shall succeed in reletting the Premises during the period in which Tenant is paying monthly rent damages as described in <font style="font-weight:bold;">Section&#160;14.2(c)</font><a name="_cp_text_1_748"></a>, Landlord shall credit Tenant with the net rents collected by Landlord from such reletting, after first deducting from the gross rents, as and when collected by Landlord, (A) all actual <a name="_cp_text_2_749"></a>expenses incurred or paid by Landlord in collecting such rents, and (B) any theretofore unrecovered costs associated with the termination of this Lease or Landlord&#8217;s reentry into the Premises, including any theretofore unrecovered expenses of reletting or other damages payable hereunder.&nbsp;&nbsp;If the Premises or any portion thereof be relet by Landlord for the unexpired portion of the Term before presentation of proof of such damages to any court, commission or tribunal, the amount of rent reserved upon such reletting shall, prima facie, constitute the fair and reasonable rental value for the Premises, or part thereof, so relet for the term of the reletting.&nbsp;&nbsp;Landlord shall not be liable in any way whatsoever for its failure or refusal to relet the Premises or, if the Premises or any part are relet, for its failure to collect the rent under such reletting, and no such refusal or failure to relet or failure to collect rent shall release or affect Tenant&#8217;s liability for damages or otherwise under this Lease.  The foregoing notwithstanding, in the event of termination of this Lease or repossession of the Premises after an Event of Default of Tenant, and provided Tenant has cooperated with Landlord in timely surrendering of possession of the Premises as required herein after such termination or repossession, Landlord agrees to use commercially reasonable efforts to mitigate its damages hereunder, provided, however, Landlord&#8217;s obligation to use commercially reasonable efforts to mitigate its damages shall be deemed </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">satisfied by Landlord&#8217;s marketing of the Premises in a manner substantially similar to the manner in which Landlord markets other premises within the Building, and provided further, that Landlord shall not be obligated to show preference for reletting the Premises over any other vacant space in the Building,&nbsp;&nbsp;to lease any space while Landlord is assembling such space as part of a block of space for lease, or to lease the Premises for a rental less than the current fair market rent then prevailing for comparable office space in Comparable Buildings.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)<font style="margin-left:36pt;"></font>If the trustee or the debtor in possession assumes the Lease under applicable bankruptcy law, it may assume and assign its interest in this Lease only if the proposed assignee first provides Landlord with (1) notice of such proposed assignment, setting forth (i) the name and address of the proposed assignee, its proposed use of the Premises, reasonably detailed character and financial references for such person (including its most recent balance sheet and income statements certified by its chief financial officer or, if available, a certified public accountant) and any other information reasonably requested by Landlord, and (ii) all of the terms and conditions of such offer, shall be given to Landlord by Tenant or such trustee no later than twenty (20) days after receipt by Tenant or such trustee of such offer, but in any event no later than ten (10) days prior to the date that Tenant or such trustee shall make application to a court of competent jurisdiction for authority and approval to assume this Lease and enter into such assignment; (2) Adequate Assurance of Future Performance (as hereinafter defined) of all of Tenant&#8217;s obligations under this Lease, and (3) Landlord determines, in the exercise of its reasonable business judgment, that the assignment of this Lease will not breach any other lease, or any mortgage, financing agreement, or other agreement relating to the Property by which Landlord or the Property is then bound (and Landlord shall not be required to obtain consents or waivers from any third party required under any lease, mortgage, financing agreement, or other such agreement by which Landlord is then bound).&nbsp;&nbsp;Landlord shall have the option, to be exercised by notice to Tenant or such trustee given at any time prior to the date the application is filed for court approval of the assumption and assignment of this Lease to the proposed assignee, to accept an assignment of this Lease upon the same terms and conditions and for the same consideration, if any, as the bona fide offer made by such proposed assignee, less any brokerage commissions which may be payable out of the consideration to be paid by such person for the assignment of this Lease.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)<font style="margin-left:36pt;"></font>For purposes only of <font style="font-weight:bold;">paragraph&#160;(g)</font> above, and in addition to any other requirements under the Bankruptcy Code, any future federal bankruptcy law and applicable case law, &#8220;Adequate Assurance of Future Performance&#8221; means at least the satisfaction of the following conditions, which Landlord and Tenant acknowledge to be commercially reasonable:</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>the proposed assignee submitting a current financial statement, audited by a certified public accountant, that allows a net worth and working capital in amounts determined in the reasonable business judgment of Landlord to be sufficient to assure the future performance by the assignee of Tenant&#8217;s obligation under this Lease; and</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU65"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if requested by Landlord in the exercise of its reasonable business judgment, the proposed assignee obtaining a guarantee (in form and substance satisfactory to Landlord) from one or more persons who satisfy Landlord&#8217;s standards of creditworthiness; and</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;"></font>the proposed assignee is of a character and financial worth such as is in keeping with the standards of Landlord in those respects for the Property, the assignee&#8217;s tenancy is of the same quality as other tenants at the Property, and the purposes for which the proposed assignee intends to use the Premises are uses expressly permitted by and not prohibited by this Lease or prohibited by any other lease at the Property.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Additional Rent</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;If Tenant shall fail to pay when due any sums under this Lease designated as an Operating Expense Charge or other Additional Rent, Landlord shall have the same rights and remedies as Landlord has hereunder for failure to pay Basic Rent.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Remedying Defaults</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_753"></a><a name="_cp_text_1_753"></a>.&nbsp;&nbsp;Landlord shall have the right, but shall not be required, to pay such sums or do any act which requires the expenditure of monies which may be necessary or appropriate by reason of the failure or neglect of Tenant to perform any of the provisions of this Lease which failure continues beyond any applicable notice and cure periods, and in the event of the exercise of such right by Landlord, Tenant agrees to pay to Landlord forthwith upon demand all such sums, together with interest thereon at the Default Interest Rate, as Additional Rent.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Remedies Cumulative</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_755"></a><a name="_cp_text_1_755"></a>.&nbsp;&nbsp;The specified remedies to which Landlord may resort hereunder are not intended to be exclusive of any remedies or means of redress to which Landlord may at any time be entitled lawfully, and Landlord may invoke any remedy (including the remedy of specific performance) allowed at law or in equity as if specific remedies were not herein provided for.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Litigation Costs</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;In the event of litigation or other legal proceeding between Landlord and Tenant relating to the provisions of this Lease or Tenant&#8217;s occupancy of the Premises, the losing party shall, upon demand, reimburse the prevailing party for its reasonable costs of prosecuting and/or defending such proceeding (including, without limitation, reasonable attorneys&#8217; fees).</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14.7<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Waiver</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Failure on the part of Landlord or Tenant to complain of any action or non&#8209;action on the part of the other, no matter how long the same may continue, shall never be a waiver by Tenant or Landlord, respectively, of any of the other&#8217;s rights hereunder.&nbsp;&nbsp;Further, no waiver at any time of any of the provisions hereof by Landlord or Tenant shall be construed as a waiver of any of the other provisions hereof, and a waiver at any time of any of the provisions hereof shall not be construed as a waiver at any subsequent time of the same provisions.&nbsp;&nbsp;The consent or approval of Landlord or Tenant to or of any action by the other requiring such consent or approval shall not be construed to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">waive or render unnecessary Landlord&#8217;s or Tenant&#8217;s consent or approval to or of any subsequent similar act by the other.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU66"></a><a name="_cp_text_1_758"></a><a name="_cp_text_1_759"></a>(b)<font style="margin-left:36pt;"></font><a name="_cp_text_1_758"></a>Any waiver by Landlord or Tenant <a name="_cp_text_1_759"></a>of any provisions of this Lease must be in a writing signed by Landlord or Tenant, as applicable.&nbsp;&nbsp;In addition, Landlord&#8217;s acceptance of any payment from Tenant after a termination of this Lease due to an Event of Default by Tenant shall not have the effect of reinstating this Lease, nor estop Landlord from exercising any of the rights and remedies granted to Landlord hereunder arising out of such Event of Default.&nbsp;&nbsp;No payment by Tenant or acceptance by Landlord of a lesser amount than the Basic Rent, Expense Charges, Additional Rent and other sums due hereunder shall be deemed to be other than on account of the total amount due from Tenant to Landlord, to be applied in such order as Landlord deems appropriate.&nbsp;&nbsp;In no event shall any endorsement or statement on any check or accompanying any check or payment be deemed an accord and satisfaction; and Landlord may accept such check or payment without prejudice to Landlord&#8217;s right to recover the balance of such Basic Rent, Expense Charges, Additional Rent or other sum and to pursue any other remedy provided in this Lease.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Security Deposit</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_762"></a><a name="_AEIOULastRenderedPageBreakAEIOU67"></a><a name="_cp_text_5_763"></a><a name="_cp_text_2_764"></a><a name="_cp_text_5_765"></a><a name="_cp_text_2_766"></a><a name="_cp_text_5_767"></a><a name="_cp_text_2_768"></a>(a)<font style="margin-left:36pt;"></font>Simultaneously with the execution of this Lease by Tenant, Tenant shall deliver to Landlord, and Tenant shall maintain in effect at all times during the Initial Term, as security for the full and faithful performance and observance by Tenant of Tenant&#8217;s covenants and obligations under this Lease, an unconditional, irrevocable, absolutely &#8220;clean&#8221; letter of credit in the amount set forth in <font style="font-weight:bold;">Section 1.1</font> hereof and substantially in the form annexed hereto as <font style="font-weight:bold;text-decoration:underline;">Exhibit H</font> or other form reasonably approved by Landlord and otherwise reasonably satisfactory to Landlord and issued by a banking corporation reasonably satisfactory to Landlord and either having its principal place of business or a duly licensed branch or agency in Boston, MA.&nbsp;&nbsp;Such letter of credit shall have an expiration date no earlier than the first anniversary of the date of issuance thereof and shall be automatically renewed from year to year unless terminated by the issuer thereof by notice to Landlord given not less than forty-five (45) days prior to the expiration thereof.&nbsp;&nbsp;Tenant shall, throughout the Initial Term of this Lease, deliver to Landlord, in the event of the termination of any such letter of credit, replacement letters of credit in lieu thereof (each such letter of credit and such extensions or replacements thereof, as the case may be, is hereinafter referred to as a &#8220;<font style="font-weight:bold;">Letter of Credit</font>&#8221;) no later than 30 days prior to the expiration date of the preceding Letter of Credit.&nbsp;&nbsp;The term of each such Letter of Credit shall be not less than one year and shall be automatically renewable from year to year as aforesaid.&nbsp;&nbsp;Notwithstanding the foregoing, if Landlord shall elect, in its sole discretion, to accept a Letter of Credit which is subject to a final expiration date, Tenant shall deliver a replacement of or amendment to such Letter of Credit no later than thirty (30) days prior to such final expiration date, and the final Letter of Credit delivered to Landlord pursuant to this <font style="font-weight:bold;">Section 14.8</font> shall have a final expiration date occurring not earlier than sixty (60) days following the expiration date of this Lease.&nbsp;&nbsp;If Tenant shall fail to obtain any replacement of or amendment to a Letter of Credit within any of the applicable time limits set forth in this <font style="font-weight:bold;">Section 14.8</font>, Tenant shall be in default of its obligations under this <font style="font-weight:bold;">Section 14.8</font> and Landlord shall have the right (but not the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_762"></a>obligation), at its option, to draw down the full amount of the existing Letter of Credit and use, apply and retain the same as security hereunder</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU67"></a>, and notwithstanding such draw by Landlord, Landlord shall have the right (but not the obligation), at its option, to give </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_5_763"></a>written notice to Tenant stating that such failure by Tenant to deliver such replacement of or amendment to the Letter of Credit constitutes a continuing default by Tenant </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_764"></a>of its obligations under this </font><font style="font-weight:bold;">Section 14.8</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_5_765"></a>, and in the event that Tenant shall not have delivered such replacement or amendment to Landlord within fifteen (15) </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_766"></a>Business Days after </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant&#8217;s receipt of such notice, Landlord may give to Tenant a notice of intention to end the term of this Lease at the expiration of five (5) days from the date of the service of such notice of intention, and upon the expiration of said five (5) days unless Tenant shall have delivered such replacement of or amendment to the Letter of Credit during such five (5) day period, this Lease and the term and estate hereby granted, whether or not the Initial Term shall theretofore have commenced, shall terminate with the same effect as if that day was the day herein definitely fixed for the end and expiration of this Lease, but Tenant shall remain liable for damages as provided in this </font><font style="font-weight:bold;">Article 14</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_5_767"></a>.&nbsp;&nbsp;Upon delivery to Landlord of any such replacement of or amendment to the Letter of Credit within the fifteen (15</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_768"></a>) Business Day period </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">described in the preceding sentence, such default shall be deemed cured and Landlord shall return to Tenant the proceeds of the Letter of Credit which had been drawn by Landlord pursuant to the preceding sentence (or any balance thereof to which Tenant is entitled).</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_770"></a><a name="_cp_text_2_771"></a><a name="_cp_text_2_772"></a><a name="_AEIOULastRenderedPageBreakAEIOU68"></a>(b)<font style="margin-left:36pt;"></font><a name="_cp_text_1_770"></a>In the event Tenant defaults in respect of the full and prompt payment and performance of any of the terms, provisions, covenants and conditions of this Lease beyond applicable <a name="_cp_text_2_771"></a>notice (the delivery of which shall not be required for purposes of this <font style="font-weight:bold;">Section 14.8</font> if Landlord is prevented or prohibited from delivering the same under applicable law, including, but not limited to, all applicable bankruptcy and insolvency law) <a name="_cp_text_2_772"></a>and the expiration of any applicable cure periods (except that no notice and cure period shall be required for purposes of this <font style="font-weight:bold;">Section 14.8</font> with respect to any default by Tenant hereunder if, at the time of such default, any of the events set forth in <font style="font-weight:bold;">Section 14.8(b)(iv)</font> shall have occurred with or without the acquiescence of Tenant), including, but not limited to, the payment of Basic Rent and Expense Charges, Landlord may, at its election, (but shall not be obligated to) draw down the entire Letter of Credit or any portion thereof and use, apply or retain the whole or any part of the security represented by the Letter of Credit to the extent required for the payment of: (i) Basic Rent, Expense Charges or any other sum as to which Tenant is in default, (ii) any sum which Landlord may expend or may be required to expend by reason of Tenant&#8217;s default in respect of any of the terms, provisions, covenants, and conditions of this Lease, including but not limited to, any reletting costs or expenses (including, without limitation, any free rent, tenant improvement allowance, leasing commissions, attorneys&#8217; fees, costs and expenses, and other fees, costs and expenses relating to the reletting of all or any portion of the Premises), (iii) any damages or deficiency in the reletting of the Premises, whether such damages or deficiency accrued before or after summary proceedings or other re&#8209;entry by Landlord, or (iv) any damages awarded to Landlord in accordance with the terms and conditions of this <font style="font-weight:bold;">Article 14</font> hereof, it being understood that any use of the whole or any part of the security represented by the Letter of Credit shall not constitute a bar or defense to any of Landlord&#8217;s other remedies under this Lease or any Law, including but not limited to Landlord&#8217;s right to assert a claim against Tenant under 11 U.S.C. &#167;502(b)(6) or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any other provision of Title 11 of the United States Code.&nbsp;&nbsp;To insure that Landlord may utilize the security represented by the Letter of Credit in the manner, for the purpose, and to the extent provided in this </font><font style="font-weight:bold;">Section 14.8</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU68"></a>, each Letter of Credit shall provide that the full </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">amount or any portion thereof may be drawn down by Landlord upon the presentation to the issuing bank (or the advising bank, if applicable) of Landlord&#8217;s draft drawn on the issuing bank without accompanying memoranda or statement of beneficiary.&nbsp;&nbsp;In no event shall the Letter of Credit require Landlord to submit evidence to the issuing (or advising) bank of the truth or accuracy of any such written statement and in no event shall the issuing bank or Tenant have the right to dispute the truth or accuracy of any such statement nor shall the issuing (or advising) bank have the right to review the applicable provisions of the Lease.&nbsp;&nbsp;In no event and under no circumstance shall the draw down on or use of any amounts under the Letter of Credit constitute a basis or defense to the exercise of any other of Landlord&#8217;s rights and remedies under this Lease or under any Law, including, but not limited to, Landlord&#8217;s right to assert a claim against Tenant under 11 U.S.C. &#167;502(b)(6) or any other provision of Title 11 of the United States Code.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>In the event Tenant defaults in respect of any of the terms, provisions, covenants or conditions of this Lease beyond notice (the delivery of which shall not be required for purposes of this <font style="font-weight:bold;">Section&#160;14.8</font> if Landlord is prevented or prohibited from delivering the same under applicable law, including, but not limited to, all applicable bankruptcy and insolvency law) and the expiration of any applicable cure periods (except no notice and cure period shall be required for purposes of this <font style="font-weight:bold;">Section&#160;14.8</font> with respect to any default by Tenant hereunder if, at the time of such default, any of the events set forth in <font style="font-weight:bold;">Section&#160;14.8(b)(iv)</font> shall have occurred with or without the acquiescence of Tenant) and Landlord utilizes all or any part of the security represented by the Letter of Credit but does not terminate this Lease as provided in this <font style="font-weight:bold;">Article 14</font> hereof, Landlord may, in addition to exercising its rights as provided in <font style="font-weight:bold;">paragraph (b)</font> hereof, retain the unapplied and unused balance of the portion of the Letter of Credit drawn down by Landlord (herein called the &#8220;<font style="font-weight:bold;">Cash Security</font>&#8221;) as security for the faithful performance and observance by Tenant thereafter of the terms, provisions, and conditions of this Lease, and may use, apply, or retain the whole or any part of said Cash Security to the extent required for payment of Basic Rent, Additional Rent or any other sum as to which Tenant is in default (beyond applicable notice and cure periods) or for any sum which Landlord may expend or be required to expend by reason of Tenant&#8217;s default in respect of any of the terms, covenants, and conditions of this Lease.&nbsp;&nbsp;In the event Landlord uses, applies or retains any portion or all of the security represented by the Letter of Credit, Tenant shall forthwith restore the amount so used, applied or retained (at Landlord&#8217;s option, either by the deposit with Landlord of cash or the provision of a replacement Letter of Credit) so that at all times the amount of the security represented by the Letter of Credit and the Cash Security (if any) shall be not less than the security required by <font style="font-weight:bold;">Section 1.1</font> hereof, failing which Tenant shall be in default of its obligations under this <font style="font-weight:bold;">Section 14.8</font> and Landlord shall have the same rights and remedies as for the non&#8209;payment of Basic Rent beyond the applicable grace period, unless Tenant shall have restored the Letter of Credit as set forth in this <font style="font-weight:bold;">Section 14.8(c)</font> within five (5) days following Landlord&#8217;s written demand for such restoration. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU69"></a><a name="_cp_text_2_773"></a><a name="_cp_text_2_774"></a><a name="_cp_text_5_775"></a><a name="_cp_text_2_776"></a><a name="_cp_text_5_777"></a><a name="_cp_text_2_778"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to and without limitation of Landlord&#8217;s other rights under this </font><font style="font-weight:bold;">Section 14.8</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU69"></a>, if at any time during the Term of the Lease (as the same may be extended), Landlord reasonably determines that the financial condition of the issuer of the then current Letter of Credit is such that Landlord&#8217;s ability to draw upon the Letter of </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_773"></a>Credit is, or in the future may be, impaired, restricted, refused or otherwise adversely affected, then Tenant shall, within 10 Business Days of Landlord&#8217;s written request to Tenant, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">then Landlord may immediately draw upon the Letter of Credit as provided in </font><font style="font-weight:bold;">Section 14.8</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and use, apply and retain the same as Cash Security hereunder and Landlord shall have the right, by giving Tenant written notice of such requirement, to require that Tenant </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obtain from a new issuer a replacement Letter of Credit, which issuer and replacement Letter of Credit shall both comply in all respects with the requirements of this </font><font style="font-weight:bold;">Section 14.8</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;In the event that Tenant shall not have delivered to Landlord a replacement Letter of Credit complying with all of the requirements of this </font><font style="font-weight:bold;">Section 14.8</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_774"></a> within ten (10) days after Tenant&#8217;s receipt of such notice, Landlord shall have the right (</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_5_775"></a>but not the obligation), at its option, to give written notice to Tenant stating that such failure constitutes a continuing and immediate Default </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_776"></a>of Tenant under this Lease </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_5_777"></a>without any additional notice or cure period applicable thereto, and Landlord shall have the right to exercise all rights and remedies available to Landlord </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_778"></a>under this Lease </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or at Law and in equity with respect to such Default of Tenant.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_780"></a><a name="_cp_text_1_781"></a><a name="_cp_text_2_782"></a><a name="_cp_text_2_784"></a><a name="_cp_text_2_785"></a><a name="_cp_text_1_786"></a><a name="_cp_text_1_787"></a><a name="_cp_text_2_788"></a><a name="_cp_text_5_789"></a><a name="_cp_text_2_790"></a><a name="_cp_text_5_791"></a><a name="_AEIOULastRenderedPageBreakAEIOU70"></a><a name="_cp_text_2_792"></a>(e)<font style="margin-left:36pt;"></font><a name="_cp_text_2_780"></a>If Tenant shall fully and faithfully comply with all of Tenant&#8217;s covenants and obligations under this Lease, the Letter of Credit and the Cash Security (if any) shall be returned to Tenant within <a name="_cp_text_1_781"></a>sixty <a name="_cp_text_2_782"></a>(60<a name="_cp_text_2_784"></a>) days after the date fixed as the end of this Lease and after delivery to Landlord of entire possession of the Premises; provided, however, that in no event shall any such return be construed as an admission by Landlord that Tenant has performed all of its obligations hereunder.&nbsp;&nbsp;In the event of any sale, transfer or leasing of Landlord&#8217;s interest in the Building whether or not in connection with a sale, transfer or leasing of the Land to a vendee, transferee or lessee, Landlord shall have the right to transfer the Letter of Credit and the Cash Security (if any) to the vendee, transferee or lessee or, in the alternative, to require Tenant to deliver a replacement Letter of Credit or appropriate amendment to the Letter of Credit naming the new landlord as beneficiary, and,<a name="_cp_text_2_785"></a> upon <a name="_cp_text_1_786"></a>delivery by Tenant of a replacement Letter of Credit, if applicable, Landlord shall <a name="_cp_text_1_787"></a>return  the existing Letter of Credit to Tenant.&nbsp;&nbsp;Upon such transfer or return of the Letter of Credit and the Cash Security (if any), Landlord shall thereupon be released by Tenant from all liability for the return thereof, and Tenant shall look solely to the new landlord for the return of the same.&nbsp;&nbsp;The provisions of the preceding sentence shall apply to every subsequent sale, transfer or leasing of the Building, and any successor of Landlord may, upon a sale, transfer, leasing or other cessation of the interest of such successors in the Building, whether in whole or in part, transfer the Letter of Credit and the Cash Security (if any) to any vendee, transferee or lessee of the Building (or require Tenant to deliver a replacement Letter of Credit as hereinabove set forth) and shall thereupon be relieved of all liability with respect thereto.&nbsp;&nbsp;If Tenant shall fail to timely deliver a replacement Letter of Credit, as required by Landlord, Tenant shall be in default of its obligations under this <font style="font-weight:bold;">Section 14.8</font><a name="_cp_text_2_788"></a> and Landlord shall have the right (but not the obligation), at its option, to draw down the existing Letter of Credit and retain the proceeds as Cash Security hereunder until a replacement Letter of Credit is delivered, and notwithstanding such draw by Landlord, Landlord shall have the right (but not the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obligation), at its option, to give written notice to Tenant stating that such failure by Tenant to deliver such replacement Letter of Credit constitutes a continuing default by Tenant</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_5_789"></a> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_790"></a>of its obligations under </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">this </font><font style="font-weight:bold;">Section 14.8</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_5_791"></a>, and in the event that Tenant shall not have delivered such replacement to Landlord within fifteen (15) Business Days after </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_792"></a>Tenant&#8217;s </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">receipt of such notice, Landlord may give to Tenant a notice of intention to end the term of this Lease at the expiration of five (5) days from the date of the service of such notice of intention, and upon the expiration of said five (5) days this Lease and the term and estate hereby granted shall terminate in accordance with the provisions of </font><font style="font-weight:bold;">paragraph (a)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of this </font><font style="font-weight:bold;">Section 14.8</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Upon delivery to Landlord of any such replacement Letter of Credit within the fifteen (15) Business Day period described in the preceding sentence, such default shall be deemed cured and Landlord shall return to Tenant the proceeds of the Letter of Credit which had been drawn by Landlord pursuant to the preceding sentence (or any balance thereof to which Tenant is entitled).&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord and Tenant hereby agree that, in connection with the transfer by Landlord or its successors or assigns hereunder of Landlord&#8217;s interest in the Letter of Credit, Tenant shall be solely liable to pay any transfer commission and other costs charged by the issuing bank in connection with any such transfer of the Letter of Credit, as Expense Charges hereunder, upon Landlord&#8217;s demand therefor.&nbsp;&nbsp;Except in connection with a permitted assignment of this Lease, Tenant shall not assign or encumber or attempt to assign or encumber the security represented by the Letter of Credit, and neither Landlord nor its successors or assigns shall be bound by any such assignment, encumbrance, attempted assignment or attempted encumbrance.&nbsp;&nbsp;In any event, in the absence of evidence satisfactory to Landlord of an assignment of the right to receive the security represented by the Letter of Credit, Landlord may return the Letter of Credit to the original Tenant regardless of one or more assignments of this Lease.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:36pt;"></font>Neither the Letter of Credit, any proceeds therefrom or the Cash Security, if any, shall be deemed an advance rent deposit or an advance payment of any other kind, or a measure or limitation of Landlord&#8217;s damages or constitute a bar or defense to any of the Landlord&#8217;s other remedies under this Lease or at law or in equity upon Tenant&#8217;s default.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_793"></a><a name="_cp_text_1_794"></a><a name="_cp_text_1_795"></a><a name="_cp_text_2_796"></a><a name="_cp_text_1_797"></a><a name="_cp_text_1_799"></a>(g)<font style="margin-left:36pt;"></font>Notwithstanding anything to the contrary contained in this <font style="font-weight:bold;">Section 14.8</font>, <font style="color:#000000;"><a name="_cp_text_2_793"></a>provided that there has been no <a name="_cp_text_1_794"></a>monetary Event of <a name="_cp_text_1_795"></a>Default or a material non-monetary Event of Default <a name="_cp_text_2_796"></a>of Tenant at any time prior to the Review Date (as hereinafter defined), the face amount of the Letter of Credit <a name="_cp_text_1_797"></a>may be reduced by Tenant to </font><a name="_cp_text_1_799"></a>$827,949.00 on the earlier to occur of (i) the <font style="color:#000000;">third (3<sup style="font-size:85%; vertical-align:top">rd</sup>) anniversary of the Commencement Date, or (ii) the market capitalization of Tenant meeting or exceeding Two Hundred Million and 00/100 Dollars ($200,000,000) </font>(the earlier to occur of (i) or (ii) being the &#8220;<font style="font-weight:bold;">Review Date</font>&#8221;).<font style="color:#000000;">&nbsp;&nbsp;</font>If Tenant has satisfied the Reduction Condition as of the Reduction Review Date, Landlord shall, at Tenant&#8217;s election and within ten (10) Business Days after Landlord&#8217;s receipt of written request from Tenant, effect the reduction in the Letter of Credit amount required under this Lease by either accepting an amendment to the Letter of Credit which Landlord is then holding (which amendment shall be in form and substance reasonably acceptable to Landlord) or by exchanging the Letter of Credit which Landlord is then holding for a substitute Letter of Credit complying with the requirements of this Lease in the appropriate amount.&nbsp;&nbsp;In no event shall the Letter of Credit have automatic reduction provisions.&nbsp;&nbsp;Tenant shall be deemed to have satisfied the &#8220;<font style="font-weight:bold;">Reduction </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">Condition</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; as of the Review Date if there has been no Event of Default at any time prior to the Review Date.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU71"></a>(h)<font style="margin-left:36pt;"></font>As a material inducement to Landlord to enter into this Lease, Tenant hereby acknowledges and agrees that the Letter of Credit and the proceeds thereof (including, without limitation any Cash Security created by the draw down of all or any portion of the Letter of Credit) and the obligation to make available or pay to Landlord all or a portion thereof in satisfaction of any obligation of Tenant under this Lease, shall be deemed third-party obligations and not the obligation of Tenant hereunder and, accordingly, (A) shall not be subject to any limitation on damages contained in Section 502(b)(6) of Title 11 of the United States Code or any other limitation on damages that may apply under any federal, state or local law, rule or regulation in connection with a bankruptcy, insolvency or other similar proceeding by, against or on behalf of Tenant, (B) shall not diminish or be offset against any amounts that Landlord would be able to claim against Tenant pursuant to 11 U.S.C. &#167;502(b)(6) as if no Letter of Credit existed, and (C) may be relied on by Landlord in the event of an assignment of this Lease that is not expressly permitted in accordance with the terms of this Lease even if such assignment has been authorized and approved by a court exercising jurisdiction in connection with a bankruptcy, insolvency or other similar proceeding by, against or on behalf of Tenant.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Landlord&#8217;s Default</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Subject to the provisions of <font style="font-weight:bold;">Section 14.6(b)</font> below, Landlord shall in no event be in default in the performance of any of Landlord&#8217;s obligations hereunder unless and until Landlord shall have failed to perform such obligations within thirty (30) days, or such additional time as is commercially reasonably required to correct any such default, after written notice by Tenant to Landlord properly specifying wherein Landlord has failed to perform any such obligation.&nbsp;&nbsp;Except as otherwise expressly set forth in this Lease, Tenant shall not assert any right to deduct the cost of repairs or any monetary claim against the Landlord from rent thereafter due and payable, but shall look solely to the Landlord for satisfaction of such claim.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU72"></a>(b)<font style="margin-left:36pt;"></font>If Landlord fails to provide any services, perform any repairs or maintenance, or perform any other obligation expressly required of Landlord under the terms of this Lease (excluding any services, repairs or obligations which Landlord is unable, despite the exercise of reasonable and diligent efforts, to perform due to Force Majeure and Tenant would be similarly affected thereby), which failure materially, adversely affects Tenant&#8217;s ability to occupy or operate its business in any portion of the Premises, and Landlord fails to commence to take corrective action within ten (10) days after written notice from Tenant (or within three (3) Business Days in the event Tenant is unable to conduct business in any portion of the Premises as a result of such failure), or if Landlord timely commences such corrective action but thereafter fails to diligently complete such action, then Tenant, without limiting any other remedies of Tenant, may, after five (5) additional Business Days&#8217; prior written notice given to Landlord, any Mortgagees of Landlord of which Tenant has written notice of, which notice indicates in bold, capitalized text that &#8220;<font style="font-weight:bold;">IF LANDLORD FAILS TO COMMENCE PERFORMANCE WITHIN 5 BUSINESS DAYS&#8217; AFTER RECEIPT, TENANT </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">MAY PROCEED TO EXERCISE TENANT&#8217;S SELF HELP RIGHTS UNDER SECTION 14.9(b) OF THE LEASE,</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU72"></a>&#8221; and if Landlord fails to commence such curative action within such five (5) Business Day period and thereafter diligently pursue such </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">curative action to completion, then Tenant may make such reasonable repairs or perform such services.&nbsp;&nbsp;Landlord shall reimburse Tenant for all out-of-pocket costs reasonably incurred in connection with such repairs or services completed by Tenant hereunder, together with interest thereon at a rate equal to the lesser of </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> a rate equal to 2% plus the prime rate published from time to time in </font><font style="text-decoration:underline;">The Wall Street Journal</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or its successor publication and </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the highest rate permitted to be charged by applicable Law, within fifteen (15) days after submission by Tenant to Landlord of a statement of such costs together with invoices and other reasonable supporting documentation .&nbsp;&nbsp;If Landlord fails to pay such sum to Tenant within thirty (30) days after receipt of invoices and documentation of such expenditures from Tenant, then Tenant may, after five (5) additional Business Days&#8217; prior written notice (an &#8220;</font><font style="font-weight:bold;">Offset Notice</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) given to Landlord which notice indicates in bold, capitalized text that &#8220;</font><font style="font-weight:bold;">THIS IS A TIME SENSITIVE OFFSET NOTICE AND LANDLORD SHALL BE DEEMED TO ACCEPT SUCH OFFSET IF IT FAILS TO RESPOND TO THIS SECOND REQUEST FOR DISBURSEMENT WITHIN FIVE (5) BUSINESS DAYS AFTER RECEIPT,</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; and, if Landlord fails within five (5) Business Days after receipt of such Offset Notice, to either (i) send Tenant written notice which disputes in good faith that the specified payment (or portion thereof) is due from Landlord (a &#8220;</font><font style="font-weight:bold;">Landlord&#8217;s Dispute Notice</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) and setting forth with reasonable particularity Landlord&#8217;s reasons for its claim that Landlord was not in default of its obligations and/or such action did not have to be taken by Tenant pursuant to the terms of the Lease and/or that the charges are unnecessary or excessive (in which case Landlord shall pay the amount it contends would not have been unnecessary or excessive), or (ii) disburse the amount of the payment referenced in the Offset Notice, then Tenant shall have the right to have such unpaid amount, together with interest thereon at the Interest Rate, credited against the next installment(s) of Rent thereafter due under this Lease, up to a maximum monthly offset of twenty-five percent (25%) of the amount of each such payment of monthly Rent.&nbsp;&nbsp;Tenant&#8217;s self-help rights under this </font><font style="font-weight:bold;">Section&#160;14.9(b)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may be exercised only with respect to conditions actually existing within the Premises and, provided and only so long as essential services (including access) to other tenants in the Building are not interrupted or adversely affected, the Building Systems serving the Premises (and in any event not adversely affecting the Building Structure).&nbsp;&nbsp;In the event Landlord delivers a Landlord&#8217;s Dispute Notice to Tenant, Tenant may, but shall not be obligated to, elect to submit Landlord&#8217;s Dispute Notice to arbitration in Boston, Massachusetts for expedited proceedings under the Expedited Procedures of the Commercial Arbitration Rules of the AAA (or its successor).&nbsp;&nbsp;In any case where Tenant elects to utilize such expedited arbitration:&nbsp;&nbsp;(a)&#160;the parties will have no right to object if the arbitrator so appointed was on the list submitted by the AAA and was not objected to in accordance with Expedited Procedure E</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;4 (except that any objection shall be made within four (4) Business Days from the receipt of notice of appointment), (b)&#160;the Notice of Hearing shall be given four (4) Business Days in advance of the hearing, (c)&#160;the first hearing shall be held within five (5) Business Days after the appointment of the arbitrator, and (d)&#160;the losing party in such arbitration shall pay the costs of such arbitration costs charged by the AAA and/or the arbitrator.&nbsp;&nbsp;Judgment upon any award rendered in any </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">arbitration held pursuant to this </font><font style="font-weight:bold;">Section&#160;14.9(b)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may be entered in any court having jurisdiction, and in connection therewith, the arbitrator shall be bound by the provisions of this Lease, and shall not add to, subtract from or otherwise modify such provisions.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU73"></a><font style="text-decoration:underline;">Independent Covenants</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Tenant hereby acknowledges and agrees that the obligations of Tenant hereunder shall be separate and independent covenants and agreements, that the obligations of Tenant hereunder, including, without limitation the obligation to pay Basic Rent, Expense Charges, Additional Rent and other sums due hereunder, shall continue unaffected, unless the requirement to pay or perform the same shall have been terminated or abated pursuant to an express provision of this Lease.&nbsp;&nbsp;Such waiver and acknowledgements by Tenant are a material inducement to Landlord entering into this Lease.&nbsp;&nbsp;To the extent of any conflicts or inconsistencies between the terms and provisions of this <font style="font-weight:bold;">Section&#160;14.10</font> and the terms and provisions of the remainder of this Lease, the terms and provisions of this <font style="font-weight:bold;">Section&#160;14.10</font> shall control.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">ARTICLE 15</font><font style="text-decoration:underline;"><br />MISCELLANEOUS PROVISIONS</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Landlord&#8217;s Rights of Access</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_801"></a><a name="_cp_text_1_803"></a><a name="_cp_text_2_805"></a><a name="_cp_text_5_806"></a><a name="_cp_text_2_807"></a><a name="_cp_text_5_808"></a><a name="_cp_text_2_809"></a><a name="_cp_text_1_810"></a><a name="_cp_text_1_812"></a><a name="_cp_text_1_817"></a>.&nbsp;&nbsp;Upon the terms and conditions of this <font style="font-weight:bold;">Section 15.1</font><a name="_cp_text_1_801"></a>, Landlord and its agents, representatives, contractors and employees shall have the right to enter the Premises upon no less than 48 hours prior notice (except in an emergency, in which event Landlord shall endeavor to give such notice as is reasonably practicable under the circumstances and in all events notice under this <font style="font-weight:bold;">Article&#160;15</font><a name="_cp_text_1_803"></a> may be by telephone to the Chief Financial Officer<a name="_cp_text_2_805"></a> notwithstanding anything to the contrary in this Lease) for the purpose of doing maintenance, making such repairs, alterations or improvements as Landlord shall have the right to make by the provisions of this Lease or otherwise in exercising Landlord&#8217;s rights or fulfilling Landlord&#8217;s obligations under this Lease.&nbsp;&nbsp;Landlord and its agents, representatives, contractors and employees shall have the right to enter the Premises without notice to Tenant for the purpose of performing janitorial and other services which Landlord is obligated to provide<a name="_cp_text_5_806"></a> <a name="_cp_text_2_807"></a>under this Lease or <a name="_cp_text_5_808"></a>for exercising <a name="_cp_text_2_809"></a>any of Landlord&#8217;s rights under <font style="font-weight:bold;"><a name="_cp_text_1_810"></a>Article 14</font> <a name="_cp_text_1_812"></a>of this Lease.&nbsp;&nbsp;Landlord and its invitees shall also have the right on no less than 48 hours prior notice to enter the Premises, for the purpose of inspecting them or exhibiting them to prospective purchasers, prospective or actual Superior Lessors or Superior Mortgagees of the Building and, during the final twelve (12)<a name="_cp_text_1_817"></a> months of the Term, to prospective tenants.&nbsp;&nbsp;For each of the above purposes, Landlord shall at all times have a key with which to unlock all the doors in the Premises, excluding Tenant&#8217;s vaults, safes and special security areas designated in advance by Tenant to Landlord.&nbsp;&nbsp;In an emergency, Landlord shall have the right to use any means that Landlord may deem proper to open the doors in and to the Premises.&nbsp;&nbsp;Any entry into the Premises by Landlord in the manner hereinbefore described shall not be deemed to be a forcible or unlawful entry into, or a detainer of, the Premises, or an actual or constructive eviction of Tenant from any portion of the Premises.&nbsp;&nbsp;No provision of this Lease shall be construed as obligating Landlord to perform any repairs, alterations or decorations except as otherwise expressly agreed to be performed by Landlord in this Lease.&nbsp;&nbsp;In exercising its rights under this <font style="font-weight:bold;">Section 15.1</font>, Landlord shall make a commercially reasonable effort not to unreasonably interfere with Tenant's business operations at the Premises.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU74"></a>Notwithstanding the foregoing, and so long as Tenant makes such representative available at the scheduled time, Tenant shall have the right (except in the case of an emergency) to have a </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU74"></a>representative of Tenant accompany Landlord and its agents, representatives, contractors and employees in exercising its right of access to the Premises; provided, however, Landlord shall </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not be responsible for any obligations under this Lease or applicable Laws to the extent Landlord is not permitted reasonable and timely access by Tenant to the necessary areas of the Premises.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Covenant of Quiet Enjoyment</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_824"></a><a name="_cp_text_2_825"></a><a name="_cp_text_1_824"></a>.&nbsp;&nbsp;Subject to the terms and conditions of this Lease, on payment of the Basic Rent and Expense Charges and other Additional Rent and observing, keeping and performing all of the other terms and conditions of this Lease on Tenant&#8217;s part to be observed, kept and performed, Tenant shall lawfully, peaceably and quietly enjoy the Premises during the term hereof, without hindrance or ejection by any persons lawfully claiming by, through or <a name="_cp_text_2_825"></a>under Landlord to have title to the Premises superior to Tenant.&nbsp;&nbsp;The foregoing covenant of quiet enjoyment is in lieu of any other covenant, express or implied.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Landlord&#8217;s Liability</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Tenant agrees to look solely to Landlord&#8217;s then equity interest in the Property at the time of recovery for recovery of any judgment against Landlord, and agrees that neither Landlord nor any successor of Landlord nor any beneficiary, trustee, member, manager, partner, director, officer, employee or shareholder of Landlord or such successor shall ever be personally liable for any such judgment, or for the payment of any monetary obligation to Tenant.&nbsp;&nbsp;The provision contained in the foregoing sentence is not intended to, and shall not, limit any right that Tenant might otherwise have to obtain injunctive relief against Landlord or any successor of Landlord, or to take any action not involving the personal liability of Landlord or any successor of Landlord to respond in monetary damages from Landlord&#8217;s assets other than Landlord&#8217;s equity interest in the Property.&nbsp;&nbsp;In furtherance of the foregoing, if Landlord fails to perform any provision of this Lease which is Landlord&#8217;s obligation to perform, and as a consequence of such failure, Tenant shall recover a money judgment against Landlord, such judgment shall be satisfied only (i) out of the proceeds of sale received upon levy against the right, title and interest of Landlord in the Building, or (ii) to the extent not encumbered by a secured creditor, out of the rents or other incomes receivable by Landlord from the property of which the Premises are a part.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Except for Tenant&#8217;s liability for damages under <font style="font-weight:bold;">Section 5.5(c)</font> and <font style="font-weight:bold;">Section 12.1</font> of this Lease, in no event shall either Landlord or Tenant ever be liable to the other for any loss of business or any other indirect or consequential damages suffered by that party from whatever cause. Landlord shall look solely to the assets of Tenant to enforce Tenant&#8217;s obligations hereunder and in no event shall any of Tenant&#8217;s partners, former partners, shareholders, directors, officers, principals, clients, employees or agents, directly and indirectly, disclosed or undisclosed, of Tenant ever be personally liable for any judgment against Tenant or for any other liability or obligation of Tenant under this Lease owed to Landlord or any successor of Landlord.&nbsp;&nbsp;The provision contained in the foregoing sentence is not intended to, and shall not, limit any right that Landlord might otherwise have to obtain injunctive relief (or to take any other action against Tenant or any Tenant Parties or their respective successors in interest not involving the personal liability of Tenant or any Tenant Parties and which is not otherwise inconsistent with the recourse limitations set forth in the prior sentence).</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU75"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Where provision is made in this Lease for Landlord&#8217;s consent, and Tenant shall request such consent, and Landlord shall fail or refuse to give such consent, Tenant shall not be entitled to any damages for any withholding by Landlord of its consent, it being intended that Tenant&#8217;s sole remedy shall be an action for specific performance or injunction, and that such remedy shall be available only in those cases where Landlord has expressly agreed in writing not to unreasonably withhold its consent.&nbsp;&nbsp;Furthermore, whenever Tenant requests Landlord&#8217;s consent or approval (whether or not provided for herein), Tenant shall pay to Landlord, on demand, as Additional Rent, any reasonable expenses incurred by Landlord (including without limitation reasonable attorneys&#8217; fees and costs, if any) in connection therewith.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>Any repairs or restoration required or permitted to be made by Landlord under this Lease may be made during normal business hours, and Landlord shall have no liability for damages to Tenant for inconvenience, annoyance or interruption of business arising therefrom.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Estoppel Certificate</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_854"></a><a name="_cp_text_1_855"></a><a name="_cp_text_2_856"></a><a name="_cp_text_2_854"></a>.&nbsp;&nbsp;Landlord and Tenant shall, at any time and from time to time, upon not less than <a name="_cp_text_1_855"></a>ten <a name="_cp_text_2_856"></a>(10) Business Days&nbsp;&nbsp;prior written request from the other, execute, acknowledge and deliver to the requesting party an estoppel certificate, containing a certification as to: (i) whether the Term has commenced, setting forth the Commencement Date and the expiration date; (ii) that this Lease is unmodified and in full force and effect (or, if there have been modifications, that this Lease is in full force and effect, as modified, and stating the modification(s)); (iii) the dates to which the Basic Rent, Additional Rent and all other amounts to be paid by Tenant hereunder have been paid in advance, if at all; (iv) whether to the actual knowledge of the signer there are any uncured defaults, and, if defaults are claimed, stating the facts giving rise thereto; and (v) such other factual statements as may be reasonably requested by either party. </p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Brokerage</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Tenant warrants and represents that Tenant has dealt with no broker in connection with the consummation of this Lease other than the Brokers specified in <font style="font-weight:bold;">Section 1.1</font>, and, in the event of any brokerage claims against Landlord predicated upon prior dealings with Tenant, Tenant agrees to defend the same and indemnify Landlord against any such claim (except any claim by Brokers).&nbsp;&nbsp;Landlord warrants and represents that Landlord has dealt with no broker in connection with the consummation of this Lease other than Brokers, and, in the event of any brokerage claims against Tenant predicated upon prior dealings with Landlord, Landlord agrees to defend the same and indemnify Tenant against any such claim.&nbsp;&nbsp;Landlord shall be responsible to pay the commission or fee due to Brokers as and to the extent provided in a separate written agreement.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Rules and Regulations</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU76"></a>.&nbsp;&nbsp;Tenant, its employees, representatives, agents, subtenants, licensees, contractors, and invitees shall abide by the Rules and Regulations from time to time established by Landlord and the Boston Landing Rules and Regulations (as defined in the Declaration), it being agreed that (i) Landlord shall have the right from time to time during the Term to make reasonable changes in and additions to the Rules and Regulations as Landlord deems necessary for the management, safety, care, cleanliness, conservation and sustainability of the Building and the Property and for the preservation of good order therein and (ii) BLOC (as defined in the Declaration shall have the right from time to time during the Term to make </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reasonable changes in and additions to the Boston Landing Rules and Regulations as BLOC deems necessary for the management, safety, care, cleanliness, conservation and sustainability of the Boston Landing Project and for the preservation of good order therein.&nbsp;&nbsp;The Rules and Regulations shall be generally applicable to all tenants of the Building of similar nature to the Tenant named herein.&nbsp;&nbsp;Landlord agrees that any such Rules and Regulations will be uniformly enforced, provided, however, Landlord may waive any one or more of the Rules and Regulations for the benefit of any particular tenant if Landlord reasonably deems such waiver appropriate, but no such waiver shall be construed as a waiver of such Rules and Regulations in favor of any other tenant, nor prevent Landlord from enforcing such Rules and Regulations against any or all tenants of the Building.&nbsp;&nbsp;Landlord shall not have any obligation to enforce the Rules and Regulations or the terms of any other lease against any other Tenant and Landlord shall not be liable to Tenant for violation thereof by any other tenant, its employees, representatives, agents, contractors, visitors, subtenants, licensees or invitees.&nbsp;&nbsp;In the event that there shall be a conflict between such Rules and Regulations and the provisions of this Lease, the provisions of this Lease shall control.&nbsp;&nbsp;The Rules and Regulations currently in effect are set forth in </font><font style="font-weight:bold;text-decoration:underline;">Exhibit G</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> attached hereto and made a part hereof.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Financial Statements</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_859"></a><a name="_cp_text_1_860"></a><a name="_cp_text_2_861"></a><a name="_cp_text_2_863"></a><a name="_cp_text_2_859"></a>.&nbsp;&nbsp;Tenant shall deliver to Landlord, within <a name="_cp_text_1_860"></a>ten <a name="_cp_text_2_861"></a>(10<a name="_cp_text_2_863"></a>) Business Days after Landlord&#8217;s reasonable request for the same, Tenant&#8217;s most recently completed financial statements (audited if available) prepared and certified by an independent certified public accountant or certified by an officer of Tenant as being true and correct in all material respects.&nbsp;&nbsp;Landlord and its affiliates and investors shall keep such financial statements confidential, provided that Landlord shall be permitted to deliver such financial statements to a lender, purchaser or lessor or a prospective lender, purchaser or lessor in connection with (i) a sale or financing of the Building or the Property or any interest in any deed of trust encumbering the Building or the Property, or (ii) a sale of all or substantially all of the interests in Landlord or (iii) any other recapitalization of the equity interests in Landlord, so long as Landlord first advises the recipient of the confidential nature of such statements.&nbsp;&nbsp;Notwithstanding the foregoing, if and only so long as Tenant&#8217;s stock is publicly traded on a national exchange (or publicly listed in an equivalent manner, such as on NASDAQ) that requires its financial statements to be publicly disclosed, Tenant shall have no obligation to deliver any financial statements to Landlord.&nbsp;&nbsp;Any such financial statements may be relied upon by any actual or potential lessor, purchaser, or mortgagee of the Property.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Substitute Space</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Intentionally omitted.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Confidentiality</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:22.12%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU77"></a>(a)<font style="margin-left:36pt;"></font>Tenant agrees that this Lease and the terms contained herein will be treated as strictly confidential and except as required by Law (or except with the written consent of Landlord) Tenant shall not disclose the same to any third party except for Tenant&#8217;s partners, lenders, accountants, auditors, brokers and attorneys who have been advised of the confidentiality provisions contained herein and agree to be bound by the same. In the event Tenant is required by Law to provide this Lease or disclose any of its terms, Tenant shall give Landlord prompt written notice of such requirement prior to making disclosure so that Landlord may seek an appropriate protective order. If failing the entry of a protective order Tenant is compelled to make disclosure, Tenant shall only disclose portions of the Lease which Tenant is </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">required to disclose and will exercise reasonable efforts to obtain assurance that confidential treatment will be accorded to the information so disclosed.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Landlord will not, and will use reasonable efforts to cause Landlord&#8217;s agents not to, reveal to any person, association or company, any confidential information provided to Landlord by Tenant concerning the business or finances of Tenant.&nbsp;&nbsp;For purposes of this <font style="font-weight:bold;">Section 15.9(b)</font>, confidential information shall not include information that (i) is or becomes generally available to the public other than as a result of a disclosure by Landlord or any Landlord agent, or (ii) was available to Landlord on a non-confidential basis prior to its disclosure to Landlord by Tenant or its representatives).&nbsp;&nbsp;Notwithstanding the foregoing, Landlord may disclose such financial information as may be provided by Tenant to Landlord to actual or prospective lenders or purchasers of the Property and/or actual or prospective investors in Landlord or any of its affiliates and to Landlord&#8217;s consultants, attorneys, insurers, auditors and accountants, so long as any person or entity to whom Landlord discloses such information agrees to keep such information confidential and may disclose any information to the extent required by any Law or order of any public authority or court.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Invalidity of Particular Provisions; Saving Clause</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;If any term or provision of this Lease, or the application thereof to any person or circumstance shall, to any extent, be invalid or unenforceable, the remainder of this Lease, or the application of such term or provision to persons or circumstances other than those as to which it is held invalid or unenforceable, shall not be affected thereby, and each term and provision of this Lease shall be valid and be enforced to the fullest extent permitted by law.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Provisions Binding, Etc.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Except as herein otherwise provided, the terms hereof shall be binding upon and shall inure to the benefit of the successors and assigns, respectively, of Landlord and Tenant (except in the case of Tenant, only such successors and assigns as may be permitted hereunder) and, if Tenant shall be an individual, upon and to his heirs, executors, administrators, successors and permitted assigns.&nbsp;&nbsp;Each term and each provision of this Lease to be performed by Tenant shall be construed to be both a covenant and a condition.&nbsp;&nbsp;Any reference in this Lease to successors and assigns of Tenant shall not be construed to constitute a consent to assignment by Tenant.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Recording</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Tenant agrees not to record this Lease, but, if the Term of this Lease (including any extended term) is seven (7) years or longer, each party hereto agrees, on the request of the other, to execute a notice of lease in recordable form and complying with applicable Law and shall contain no information other than what is statutorily required to record a notice of lease.&nbsp;&nbsp;In no event shall such document set forth the rent or other charges payable by Tenant under this Lease; and any such document shall expressly state that it is executed pursuant to the provisions contained in this Lease, and is not intended to vary the terms and conditions of this Lease.&nbsp;&nbsp;At any time following Landlord&#8217;s request, Tenant shall execute and deliver to Landlord within ten (10) days after such request a release of any document recorded in the real property records for the location of the Property evidencing this Lease or notice of termination of this Lease in recordable form, which shall be held in escrow by Landlord until the expiration or earlier termination of the Term.&nbsp;&nbsp;The obligations of Tenant under this Section shall survive the expiration or any earlier termination of the Term.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU78"></a><font style="text-decoration:underline;">Notice</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Whenever, by the terms of this Lease, notice shall or may be given either to Landlord or to Tenant (excluding notices pursuant to <font style="font-weight:bold;">Section&#160;15.1</font> which may be oral or by email), such notice shall be in writing and shall be sent by hand, registered or certified mail, or overnight or other commercial courier, postage or delivery charges, as the case may be, prepaid as follows:</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If intended for Landlord, addressed to Landlord at the address set forth in <font style="font-weight:bold;">Article 1</font> of this Lease (or to such other address or addresses as may from time to time hereafter be designated by Landlord by like notice).</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If intended for Tenant, addressed to Tenant at the address set forth in Article I of this Lease except that from and after the Commencement Date the address of Tenant shall be the Premises (or to such other address or addresses as may from time to time hereafter be designated by Tenant by like notice).</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except as otherwise provided herein, all such notices shall be effective when received; provided, that (i) if receipt is refused, notice shall be effective upon the first occasion that such receipt is refused, (ii) if the notice is unable to be delivered due to a change of address of which no notice was given, notice shall be effective upon the date such delivery was attempted, (iii) if the notice address is a post office box number, notice shall be effective the day after such notice is sent as provided hereinabove or (iv) if the notice is to a foreign address, notice shall be effective two (2) days after such notice is sent as provided hereinabove.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_868"></a><a name="_cp_text_1_868"></a>Any notice given by an attorney on behalf of Landlord or by Landlord&#8217;s managing agent shall be considered as given by Landlord and shall be fully effective.&nbsp;&nbsp;Any notice given by an attorney on behalf of Tenant shall be considered as given by Tenant and shall be fully effective.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Authority</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_870"></a><a name="_cp_field_48_871"></a><a name="_cp_text_2_872"></a>(a)<font style="margin-left:36pt;"></font>Tenant hereby represents and warrants to Landlord that (i)<a name="_cp_text_1_870"></a> Tenant is duly organized and validly existing in good standing under the laws of the State of Delaware and authorized to conduct business in the Commonwealth of Massachusetts, and possesses all licenses and authorizations necessary to carry on its business, (ii) Tenant has full power and authority to carry on its business, enter into this Lease and consummate the transaction contemplated by this Lease, (iii) the individual executing and delivering this Lease on Tenant&#8217;s behalf has been duly authorized to do so, (iv) this Lease has been duly executed and delivered by Tenant, (v) this Lease constitutes a valid, legal, binding and enforceable obligation of Tenant (subject to bankruptcy, insolvency or creditor rights laws generally, and principles of equity generally), (vi)<a name="_cp_field_48_871"></a> the execution, delivery and performance of this Lease by Tenant will not cause or constitute a default under, or conflict with, the organizational documents of Tenant or any agreement to which Tenant is a party, <a name="_cp_text_2_872"></a>(vii) the execution, delivery and performance of this Lease by Tenant will not violate any applicable Law, and (viii) all consents, approvals, authorizations, orders or filings of or with any court or governmental agency or body, if any, required on the part of Tenant for the execution, delivery and performance of this Lease have been obtained or made.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU79"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord hereby represents and warrants to Tenant that </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Landlord is duly organized under the laws of Massachusetts and validly existing and in good standing under the laws of, the Commonwealth of Massachusetts, and possesses all licenses and authorizations necessary to carry on its business, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Landlord has full power and authority to carry on its business, enter into this Lease and consummate the transaction contemplated by this Lease, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the individual executing and delivering this Lease on Landlord&#8217;s behalf has been duly authorized to do so, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> this Lease has been duly executed and delivered by Landlord, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> this Lease constitutes a valid, legal, binding and enforceable obligation of Landlord (subject to bankruptcy, insolvency or creditor rights laws generally, and principles of equity generally), </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vi)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the execution, delivery and performance of this Lease by Landlord will not cause or constitute a default under, or conflict with, the organizational documents of Landlord or any agreement to which Landlord is a party, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vii)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the execution, delivery and performance of this Lease by Landlord will not violate any applicable Law, and </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(viii)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> all consents, approvals, authorizations, orders or filings of or with any court or governmental agency or body, if any, required on the part of Landlord for the execution, delivery and performance of this Lease have been obtained or made.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">When Lease Becomes Binding; Entire Agreement; Modification</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;The submission of this document for examination and negotiation does not constitute an offer to lease, or a reservation of, or option for, the Premises, and this document shall become effective and binding only upon the execution and delivery hereof by both Landlord and Tenant.&nbsp;&nbsp;This Lease is the entire agreement between Landlord and Tenant, and this Lease expressly supersedes any negotiations, considerations, representations and understandings and proposals or other written documents relating hereto.&nbsp;&nbsp;This Lease may be modified or altered only by written agreement between Landlord and Tenant, and no act or omission of any employee or agent of Landlord shall alter, change or modify any of the provisions hereof.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Paragraph Headings and Interpretation of Sections</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;The paragraph headings throughout this instrument are for convenience and reference only, and the words contained therein shall in no way be held to explain, modify, amplify or aid in the interpretation, construction or meaning of the provisions of this Lease.&nbsp;&nbsp;The provisions of this Lease shall be construed as a whole, according to their common meaning (except where a precise legal interpretation is clearly evidenced), and not for or against either party.&nbsp;&nbsp;Use in this Lease of the words &#8220;including,&#8221; &#8220;such as&#8221; or words of similar import, when followed by any general term, statement or matter, shall not be construed to limit such term, statement or matter to the specified item(s), whether or not language of non&#8209;limitation, such as &#8220;without limitation&#8221; or &#8220;including, but not limited to,&#8221; or words of similar import, are used with reference thereto, but rather shall be deemed to refer to all other terms or matters that could fall within a reasonably broad scope of such term, statement or matter.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Joint and Several Liability; Successors and Assigns</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_873"></a><a name="_cp_text_1_874"></a><a name="_cp_text_1_873"></a>.&nbsp;&nbsp;If there shall be more than one person or entity which constitute the &#8220;Tenant&#8221; or "Landlord" <a name="_cp_text_1_874"></a>hereunder, the obligations of Tenant of Landlord, as applicable, hereunder shall be joint and several for all such persons and entities.&nbsp;&nbsp;The covenants and conditions herein contained, subject to the provisions as to assignment, shall inure to and bind the heirs, successors, executors, administrators and assigns of the parties hereto.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU80"></a><font style="text-decoration:underline;">Waiver of Jury Trial</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;IN ANY ACTION OR PROCEEDING ARISING HEREFROM, LANDLORD AND TENANT HEREBY CONSENT TO (I) THE JURISDICTION OF ANY COMPETENT COURT WITHIN THE STATE WHERE THE BUILDING IS LOCATED, (II) SERVICE OF PROCESS BY ANY MEANS AUTHORIZED BY THE LAW OF THE STATE WHERE THE BUILDING IS LOCATED, AND (III) IN THE INTEREST OF SAVING TIME AND EXPENSE, TRIAL WITHOUT A JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM BROUGHT BY EITHER OF THE PARTIES HERETO AGAINST THE OTHER OR THEIR SUCCESSORS IN RESPECT OF ANY MATTER ARISING OUT OF OR IN CONNECTION WITH THIS LEASE, THE RELATIONSHIP OF LANDLORD AND TENANT, TENANT&#8217;S USE OR OCCUPANCY OF THE PREMISES, AND/OR ANY CLAIM FOR INJURY OR DAMAGE, OR ANY EMERGENCY OR STATUTORY REMEDY.&nbsp;&nbsp;IN THE EVENT LANDLORD COMMENCES ANY SUMMARY PROCEEDINGS OR ACTION FOR NONPAYMENT OF BASE RENT OR ADDITIONAL RENT, TENANT SHALL NOT INTERPOSE ANY COUNTERCLAIM OF ANY NATURE OR DESCRIPTION (UNLESS SUCH COUNTERCLAIM SHALL BE MANDATORY) IN ANY SUCH PROCEEDING OR ACTION, BUT SHALL BE RELEGATED TO AN INDEPENDENT ACTION AT LAW.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Reservation</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_875"></a><a name="_cp_text_1_875"></a>.&nbsp;&nbsp;Except as otherwise expressly set forth in this Lease, nothing set forth in this Lease shall be deemed or construed to restrict Landlord from making any repairs, renovations, replacements, improvements and modifications to, or to reconfigure, any of the parking areas, Base Building Systems, Laboratory Systems or Common Facilities serving the Property, and Landlord expressly reserves the right to make any such repairs, renovations, replacements, improvements and modifications or reconfigurations to such areas and other facilities of the Building, Base Building Systems, Laboratory Systems, and Common Facilities as Landlord may deem appropriate, including the addition or deletion of temporary or permanent improvements therein, or the conversion of areas now dedicated for the non- exclusive common use of tenants (including Tenant) to the exclusive use of one or more tenants or licensees within the Building.&nbsp;&nbsp;In connection with the foregoing, Landlord may temporarily close or cover entrances, doors, windows, corridors, or other facilities without liability to Tenant; however, in doing so, Landlord shall use commercially reasonable efforts to not unreasonably interfere with or disturb Tenant&#8217;s use and occupancy of the Premises.&nbsp;&nbsp;Notwithstanding anything in this Lease to the contrary, Landlord shall not during the Term reduce access to, reconfigure, or otherwise modify the Common Facilities in a manner that unreasonably interferes with Tenant&#8217;s use and enjoyment of, and access to, the Premises.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Prohibited Persons and Transactions</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Tenant represents and warrants that neither Tenant nor any of its affiliates, nor any of their respective partners, members, and none of their respective employees, officers, directors, representatives or agents is, nor will they become, a person or entity with whom U.S. persons or entities are restricted from doing business under regulations of the Office of Foreign Asset Control (&#8220;<font style="font-weight:bold;">OFAC</font>&#8220;) of the Department of the Treasury (including those named on OFAC&#8217;s Specially Designated and Blocked Persons List) or under any statute, executive order (including the September 24, 2001, Executive Order Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit, or Support Terrorism), or other governmental action and is not and will not Transfer this Lease to, contract with or otherwise engage in any dealings or transactions or be otherwise associated with such persons or entities.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU81"></a><font style="text-decoration:underline;">Time Is of the Essence</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Time is of the essence of each provision of this Lease.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Multiple Counterparts; Entire Agreement</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;This Lease may be executed in multiple counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same document.&nbsp;&nbsp;This Lease constitutes the entire agreement between the parties hereto, Landlord&#8217;s managing agent and their respective affiliates with respect to the subject matter hereof and thereof and supersedes all prior dealings between them with respect to such subject matter, and there are no verbal or collateral understandings, agreements, representations or warranties not expressly set forth in this Lease. No subsequent alteration, amendment, change or addition to this Lease shall be binding upon Landlord or Tenant, unless reduced to writing and signed by the party or parties to be charged therewith.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Governing Law</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;This Lease shall be governed by the laws of the state in which the Property is located, without regard to application of any conflict of law principles.</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">ARTICLE 16</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">EXTENSION OF TERM</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_881"></a><a name="_AEIOULastRenderedPageBreakAEIOU82"></a><a name="_cp_text_2_882"></a><a name="_cp_text_5_883"></a><a name="_cp_text_2_884"></a><a name="_cp_text_5_885"></a><a name="_cp_text_2_886"></a>16.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Options to Extend</font><font style="font-weight:normal;"><a name="_cp_text_2_881"></a>.&nbsp;&nbsp;Provided that, both at the time of exercise or at the commencement of the Extended Term (as hereinafter defined), (i) this Lease is in full force and effect, and (ii) no Event of Default shall have occurred and be continuing (either at the time of exercise or at the commencement of the Extended Term), and (iii) Tenant is in occupancy of not less than 75% of the Premises and Tenant shall not have assigned this Lease or sublet more than 25% of the Premises (other than a transfer permitted without Landlord&#8217;s consent pursuant to </font>Section 6.1(b)<font style="font-weight:normal;">) (any of which conditions described in clauses (i), (ii), and (iii) may be waived by Landlord at any time in Landlord&#8217;s sole discretion), Tenant shall have the option to extend the Term of this Lease for up to one (1) extended term (the &#8220;</font>Extended Term<font style="font-weight:normal;">&#8221;) of seven (7) years by giving written notice to Landlord (an &#8220;</font>Extension Notice<font style="font-weight:normal;">&#8221;) not later than twelve (12) months prior to the expiration date of the Term.&nbsp;&nbsp;The effective giving of such notice of extension by Tenant shall automatically extend the Term of this Lease for the Extended Term, and no instrument of renewal or extension need be executed.&nbsp;&nbsp;In the event that Tenant fails timely to give such notice to Landlord, this Lease shall automatically terminate at the end of the Term, and Tenant shall have no further option to extend the Term of this Lease.&nbsp;&nbsp;The Extended Term shall commence on the day immediately succeeding the expiration date of the original Term, and shall end on the day immediately preceding the seventh (7<sup style="font-size:85%; vertical-align:top">th</sup>) anniversary of such Extended Term.&nbsp;&nbsp;The Extended Term shall be on all the terms and conditions of this Lease, except:&nbsp;&nbsp;(x) Tenant shall have no further option to extend the Term, (y) the Basic Rent for the Extended Term shall be one-hundred percent (100%) of the Fair Market Rental Value of the Premises as of the commencement of the Extended Term, taking into account all then relevant factors and determined pursuant to </font>Section 16.2<font style="font-weight:normal;"> below, and (z) Landlord shall not be required to furnish any materials or perform any work to prepare the Premises for Tenant&#8217;s occupancy during the Extended Term and Landlord shall not be required to provide or pay any work allowance or reimburse Tenant for any alterations made or to be made by Tenant, or to grant Tenant any rent concession with respect to the Extended Term.&nbsp;&nbsp;The termination of this Lease during the initial Term shall terminate and render void any option or right on Tenant&#8217;s part to extend this Lease for any Extended Term, and nothing contained in this </font>Section 16.1<font style="font-weight:normal;"> shall prevent Landlord from exercising any right granted to or reserved by Landlord in this Lease to </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;"><a name="_cp_text_2_882"></a>terminate this Lease.&nbsp;&nbsp;</font><font style="font-weight:normal;">Tenant&#8217;s right under this </font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Article 16</font><font style="font-weight:normal;"><a name="_cp_text_5_883"></a> shall be personal to the Original Tenant under this Lease and shall not apply in favor of or be exercisable by any assignee of this Lease (other than a permitted transferee pursuant to </font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_884"></a>Section 6.1(b) </font><font style="font-weight:normal;"><a name="_cp_text_5_885"></a>of this Lease), nor any sublessee </font><font style="font-weight:normal;"><a name="_cp_text_2_886"></a>of all or any portion of the Premises</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU83"></a>16.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Determination of Fair Market Rental Value</font><font style="font-weight:normal;">.&nbsp;&nbsp;Provided Tenant has timely delivered an Extension Notice hereunder to extend the Term of this Lease pursuant to </font>Section 16.1 <font style="font-weight:normal;">above and the conditions for Tenant&#8217;s exercise have been satisfied, Landlord shall provide Tenant, at least nine (9) months prior to the then expiration of the Term of this Lease, with Landlord&#8217;s good faith estimate of the Fair Market Rental Value of the Premises for the Extended Term.&nbsp;&nbsp;If Tenant disagrees with Landlord&#8217;s estimate of the Fair Market Rental Value as set forth in Landlord&#8217;s notice referred to above, Tenant shall notify Landlord within ten (10) Business Days after its receipt of Landlord&#8217;s notice setting forth Tenant&#8217;s estimate of the Fair Market Rental Value of the Premises and the parties agree to act in good faith to attempt to reach agreement on the Fair Market Rental Value of the Premises for the Extended Term.&nbsp;&nbsp;If Tenant fails to notify Landlord that Tenant disagrees with Landlord&#8217;s estimate and setting forth Tenant&#8217;s Fair Market Rental Value estimate within such ten (10) Business Day period then Tenant will be deemed to have accepted Landlord&#8217;s estimate of the Fair Market Rental Value for the Premises during the Extended Term.&nbsp;&nbsp;If Tenant has timely given its dispute notice and the parties are unable to reach agreement thereon within thirty (30) days after the delivery of such notice by Tenant, then either party may submit the determination of the Fair Market Rental Value of the Premises to arbitration by giving notice to the other party naming the initiating party&#8217;s arbitrator within ten (10) Business Days after the expiration of such thirty (30) day period.&nbsp;&nbsp;Within fifteen (15) days after receiving a notice of initiation of arbitration, the responding party shall appoint its own arbitrator by notifying the initiating party of the responding party&#8217;s arbitrator.&nbsp;&nbsp;If the second arbitrator shall not have been so appointed within such fifteen (15) day period, the initiating party shall deliver written notice of such failure to the responding party and the responding party shall have a period of ten (10) days after receipt of such notice to appoint its arbitrator and deliver written notice thereof to the initiating party.&nbsp;&nbsp;If the responding party fails to notify the initiating party of its designated arbitrator within the foregoing additional ten (10) day period, then the second arbitrator shall be chosen in the same manner as described below with respect to the selection of the third arbitrator.&nbsp;&nbsp;Upon the selection (or appointment, as the case may be) of the second arbitrator, the two arbitrators thus appointed shall, within fifteen (15) days after the responding party&#8217;s notice of appointment of the second arbitrator, appoint a third arbitrator.&nbsp;&nbsp;If the two initial arbitrators are unable timely to agree on the third arbitrator, then either may, on behalf of both, request such appointment by the Boston office of the American Arbitration Association, or its successor, or, on its failure, refusal or inability to act, by a court of competent jurisdiction.&nbsp;&nbsp;The Fair Market Rental Value of the Premises for the Extended Term shall be determined by the method commonly known as &#8220;baseball arbitration&#8221;, whereby Landlord&#8217;s selected arbitrator and Tenant&#8217;s selected arbitrator shall each set forth its respective determination of the Fair Market Rental Value of the Premises, and the third arbitrator must select one or the other (it being understood that the third arbitrator shall be expressly prohibited from selecting a compromise figure).&nbsp;&nbsp;Landlord&#8217;s selected arbitrator and Tenant&#8217;s selected arbitrator shall deliver their determinations of the Fair Market Rental Value of the Premises to the third arbitrator within five (5) Business Days of the appointment of the third arbitrator and the third arbitrator shall render his or her decision within ten (10) days after receipt of both of the other two determinations of the Fair Market Rental </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">Value of the Premises.&nbsp;&nbsp;The third arbitrator&#8217;s decision shall be binding on both Landlord and Tenant.&nbsp;&nbsp;All arbitrators shall be commercial real estate brokers who are independent from the parties and who have had at least ten (10) years&#8217; experience in Comparable Buildings.&nbsp;&nbsp;Each party shall pay the fees of its own arbitrator, and the fees of the third arbitrator shall be shared equally by the parties.&nbsp;&nbsp;In the event Tenant initiates the aforesaid arbitration process and as of the commencement of the Extended Term the amount of the Basic Rent for the Extended Term has not been determined, Tenant shall pay the amount determined by Landlord for the Premises and when the determination has actually been made, an appropriate retroactive adjustment shall be made as of the commencement of the Extended Term if necessary.&nbsp;&nbsp;In the event that such determination shall result in an overpayment by Tenant of any Basic Rent, such overpayment shall be paid by Landlord to Tenant promptly after such determination has been made, and if such determination shall result in an underpayment by Tenant of any Basic Rent, Tenant shall pay any such amounts to Landlord promptly following such determination.&nbsp;&nbsp;As used in this Lease, the term &#8220;Fair Market Rental Value&#8221; shall mean the fixed annual rent and additional rent that owners of Comparable Buildings have agreed to accept, and nonaffiliated tenants of Comparable Buildings have agreed to pay in current arms-length, nonequity transactions for comparable space, for a term comparable to the Extended Term and taking into account all other then relevant factors.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">ARTICLE 17</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">RIGHT OF FIRST OFFER</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Right of First Offer.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_890"></a><a name="_cp_text_2_891"></a><a name="_cp_text_1_892"></a><a name="_cp_text_2_893"></a><a name="_cp_text_1_894"></a><a name="_cp_text_1_895"></a><a name="_cp_text_2_896"></a><a name="_AEIOULastRenderedPageBreakAEIOU84"></a>(a)<font style="margin-left:36pt;"></font>Subject to the terms and conditions of this <font style="font-weight:bold;">Article 17</font><a name="_cp_text_1_890"></a> and the rights of any Superior Occupants (as defined in Section 17.1(e)) and provided the ROFO Conditions (as hereinafter defined) are satisfied, Landlord shall give Tenant written notice (&#8220;<font style="font-weight:bold;">Landlord&#8217;s Offer Notice</font><a name="_cp_text_2_891"></a>&#8221;), at the time that Landlord determines, in its sole judgment, that any Available ROFO Space (as hereinafter defined) will become available for lease to <a name="_cp_text_1_892"></a>an unrelated <a name="_cp_text_2_893"></a>third party and after (1) the Superior Occupants have declined or failed to exercise their rights to lease such space, and (2) the expiration or termination of the lease with the then tenant of such space and the failure of such tenant in such space to exercise any extension or renewal rights granted to such <a name="_cp_text_1_894"></a>party (any such party described in clause (2) of this <font style="font-weight:bold;">Section 17.1</font> being an &#8220;<font style="font-weight:bold;">Existing Tenant</font>&#8221;), and Tenant will have the right to lease the offered Available ROFO Space pursuant to the terms and conditions of this <font style="font-weight:bold;">Section 17.1</font>.&nbsp;&nbsp;For purposes hereof, &#8220;<font style="font-weight:bold;">Available ROFO Space</font><a name="_cp_text_1_895"></a>&#8221; shall mean any leasable space  on the fourth (4<sup style="font-size:85%; vertical-align:top">th</sup>) and sixth (6<sup style="font-size:85%; vertical-align:top">th</sup><a name="_cp_text_2_896"></a>) floors of the Building, after (i) all Superior Occupants have declined or failed to exercise their rights to lease such space, (ii) the expiration or termination of the lease or occupancy agreement (whether or not such tenant or occupant occupies such space pursuant to a written agreement) with the then tenant or occupant of such space and the failure of such tenant or occupant in such space to exercise any extension or renewal rights granted to such party, and (iii) the failure of Landlord to grant any tenant or occupant of the space the right to renew or continue its term of occupancy whether or not such rights are expressly granted by a lease or other written instrument and whether or not such right to renew or continue its term of occupancy is subsequently memorialized in a lease or written instrument (any such party described in </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clauses (ii) and (iii) being an &#8220;</font><font style="font-weight:bold;">Existing Tenant</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;).&nbsp;&nbsp; Tenant acknowledges and agrees that the Available ROFO Space is currently available for lease and the term &#8220;Initial Available ROFO Space Lease Up&#8221; shall refer to the initial leases (and any extensions or renewals thereof) entered into by Landlord with third party tenants for all or any portion of the Available ROFO Space&nbsp;&nbsp;(any such tenant or occupant of leases entered into as part of the Initial Available ROFO Space Lease-Up being a Superior Occupant for purposes of this </font><font style="font-weight:bold;">Article 17</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> with respect to the Available ROFO Space leased to such tenant or occupant).&nbsp;&nbsp;The parties agree that the provisions of this </font><font style="font-weight:bold;">Article 17</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shall not apply to any Available ROFO Space until after the applicable Available ROFO Space has been leased by Landlord as part of the Initial Available ROFO Space Lease Up, and the tenants of the initial available ROFO Space Lease Up shall be deemed &#8220;Superior Occupants&#8221; for the purposes of this Lease.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Landlord&#8217;s Offer Notice shall specify the rentable square footage and location of the Available ROFO Space (together with a floor plan of such space), the Basic Rent for the Available ROFO Space (which shall be Landlord&#8217;s estimate of the Offer Space Fair Market Rental (as defined in <font style="font-weight:bold;">Section 17.2</font>) of the Available ROFO Space), the date that Landlord estimates the Available ROFO Space will be delivered to Tenant (the &#8220;<font style="font-weight:bold;">Anticipated ROFO Commencement Date</font>&#8221;), the term of the Lease with respect to the Available ROFO Space (which term shall be coterminous with the remaining Term of this Lease subject to <font style="font-weight:bold;">Section 17.1(d)</font> below), and all other material terms and conditions which will apply to the Available ROFO Space.&nbsp;&nbsp;Tenant shall have an option exercisable by written notice to Landlord within fifteen (15) Business Days after the date of Landlord&#8217;s Offer Notice, time being of the absolute essence, that (x) Tenant elects to lease all (but not less than all) of the Available ROFO Space identified in Landlord&#8217;s Offer Notice on the terms set forth in Landlord&#8217;s Offer Notice, (y) Tenant elects to lease the Available ROFO Space, but that Tenant disputes Landlord&#8217;s determination of Offer Space Fair Market Rental set forth in Landlord&#8217;s Offer Notice, or (z) Tenant rejects Landlord&#8217;s Offer Notice.&nbsp;&nbsp;If Tenant rejects Landlord&#8217;s Offer Notice or if Tenant fails to timely notify Landlord of Tenant&#8217;s election, time being of the absolute essence, Tenant shall be deemed to have given notice that Tenant rejects Landlord&#8217;s Offer Notice and, in either case, Landlord shall thereafter be entitled to lease such Available ROFO Space to any third party on such terms and conditions and for such rent as Landlord determines in its sole discretion and Tenant will have no further right to lease the Available ROFO Space unless such space again becomes &#8220;Available ROFO Space&#8221; after Landlord leases the offered space to a third party after Tenant&#8217;s rejection or deemed rejection of Landlord&#8217;s Offer Notice.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU85"></a>(c)<font style="margin-left:36pt;"></font>If Tenant timely delivers a Tenant Exercise Notice electing to lease the Available ROFO Space, then, on the date on which Landlord delivers vacant possession of such Available ROFO Space to Tenant (the &#8220;<font style="font-weight:bold;">Offer Space Commencement Date</font>&#8221;), the Available ROFO Space shall become part of the Premises, upon all of the terms and conditions set forth in this Lease, except that (i) the Basic Rent for the Available ROFO Space shall be the Offer Space Fair Market Rental (as hereinafter defined) for such Available ROFO Space as of the Offer Space Commencement Date, determined in the manner set forth in <font style="font-weight:bold;">Section 17.2</font> below (unless Tenant has accepted or deemed to have accepted Landlord&#8217;s determination of the Offer Space Fair Market Rental set forth in </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord&#8217;s Offer Notice), (ii) except as set forth in Landlord&#8217;s Offer Notice, Landlord shall not be required to perform any leasehold improvements, alterations or any other work, pay any Landlord&#8217;s contribution or grant any work allowance or any other amount, grant any rent concessions, or render any services to make the Building or the Available ROFO Space ready for Tenant&#8217;s use or occupancy, and Tenant shall accept the Available ROFO Space in its &#8220;as is&#8221; condition on the Offer Space Commencement Date, except that Landlord shall deliver the Available ROFO Space to Tenant vacant and broom clean, and (iii) subject to </font><font style="font-weight:bold;">Section 17.1(d)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> below, Tenant&#8217;s lease of the Available ROFO Space shall be co-terminous with the Term of this Lease for the Premises (including being subject to </font><font style="font-weight:bold;">Article 16</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of this Lease).</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_898"></a><a name="_cp_text_1_899"></a><a name="_cp_text_2_900"></a><a name="_cp_text_2_904"></a><a name="_cp_text_1_905"></a>(d)<font style="margin-left:36pt;"></font><a name="_cp_text_2_898"></a>If the Available ROFO Space shall be available for delivery to Tenant at any time during the last <a name="_cp_text_1_899"></a>thirty-six <a name="_cp_text_2_900"></a>(36) months of either the original Term or the Extended Term, as the case may be, then:&nbsp;&nbsp;(i) if Tenant then has a right to extend the Term pursuant to <font style="font-weight:bold;">Section 16.1</font> which has not either lapsed unexercised or been irrevocably waived, then Tenant shall have no right to lease such Available ROFO Space unless Tenant irrevocably and unconditionally exercises Tenant&#8217;s extension option prior to, or simultaneously with, the giving of Tenant&#8217;s extension option exercise notice (notwithstanding any limitation as to the time of exercise set forth in <font style="font-weight:bold;">Section 16.1</font>), in which event the term as to the Available ROFO Space shall be co-terminous with the Term as so extended; or (ii) if Tenant has no further right to extend the Term (i.e., because Tenant&#8217;s right to extend the Term of the Lease pursuant to <font style="font-weight:bold;">Section 16.1</font> has been irrevocably waived by Tenant or has lapsed unexercised), then Landlord shall have no obligation to offer to Tenant and Tenant shall have no right to lease the Available ROFO Space under this <font style="font-weight:bold;">Section 16.1</font>.&nbsp;&nbsp;Notwithstanding Tenant&#8217;s exercise of its extension option in accordance with the foregoing clause (i), the Fair Market Rental Value for the original Premises (as it may have been previously expanded) for such Extended Term shall be determined at the same time and in the same manner such Fair Market Rental Value would have been determined if Tenant had exercised the extension option within the time periods for such exercise set forth in <font style="font-weight:bold;"><a name="_cp_text_2_904"></a>Section <a name="_cp_text_1_905"></a>16.1</font> of this Lease.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_907"></a><a name="_cp_text_2_908"></a><a name="_cp_text_2_909"></a><a name="_cp_text_1_910"></a><a name="_AEIOULastRenderedPageBreakAEIOU86"></a>(e)<font style="margin-left:36pt;"></font>The term &#8220;<font style="font-weight:bold;">Superior Occupants</font>&#8221; for purposes of this <font style="font-weight:bold;">Section 17.1</font><a name="_cp_text_1_907"></a> shall mean and refer to (i) the  <a name="_cp_text_2_908"></a>tenants of the initial ROFO Space Lease Up, (ii) the Existing Tenant from time to time of any <a name="_cp_text_2_909"></a>Available ROFO Space (or any affiliate of such tenant or occupant), including any extension or renewal rights granted by Landlord at any time whether prior to or subsequent to the date hereof to the Existing Tenants of any space and regardless of whether the existing or future leases for such space expressly provide the Existing Tenants thereunder with any such right to renew or extend; and (iv) any person or entity to whom Landlord may have granted prior to the date of this Lease any written option, right of first offer, right of second offer, right of first refusal, expansion right or other right to lease or occupy any space that would otherwise have been Available ROFO Space.&nbsp;&nbsp;Landlord shall have the right to negotiate with and to lease any Available ROFO Space at any time to the Superior Occupant(s) or to extend or renew the lease or occupancy of any Superior Occupant(s) (whether or not such rights are expressly set forth in the Superior Occupant lease or occupancy agreement) before Landlord will have any obligation to offer the applicable Available ROFO Space to Tenant pursuant to this <font style="font-weight:bold;">Section 17.1</font><a name="_cp_text_1_910"></a>.&nbsp;&nbsp;In addition, Tenant acknowledges and agrees that any space in the Building </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that intends to convert to common area or building amenity space shall not be considered available to lease or subject to Tenant&#8217;s rights under this </font><font style="font-weight:bold;">Section 17.1</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:36pt;"></font>Except with respect to the co-terminous Term of the Lease for any Available ROFO Space and the original Premises, nothing contained in this <font style="font-weight:bold;">Article 17</font> shall be construed to require Landlord to offer Available ROFO Space at business terms identical to or consistent with the terms for the initial Premises under this Lease.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_2_911"></a><a name="_cp_text_2_912"></a>(g)<font style="margin-left:36pt;"></font>The rights created by this <font style="font-weight:bold;">Section 17.1</font> shall be personal to the Original Tenant under this Lease and shall not apply in favor of or be exercisable by any assignee of this Lease (other than an assignee or successor that is permitted without Landlord&#8217;s consent pursuant to <font style="font-weight:bold;">Section 6.1(b)</font> of this Lease), nor any sublessee of all or any portion of the Premises.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_920"></a><a name="_cp_blt_2_919"></a><a name="_cp_text_1_914"></a><a name="_cp_text_2_915"></a><a name="_cp_text_2_916"></a><a name="_cp_text_1_917"></a><a name="_cp_text_2_918"></a>(h)<font style="margin-left:36pt;"></font>The &#8220;<font style="font-weight:bold;">ROFO Conditions</font><a name="_cp_text_1_914"></a>&#8221; shall mean the following conditions are satisfied in full both as of the date of Landlord&#8217;s Offer Notice, and on the commencement date of this Lease as to the applicable Offer Space (as hereinafter defined):&nbsp;&nbsp;(1) this Lease is in full force and effect,  <a name="_cp_text_2_915"></a>(2) no Event of Default of Tenant shall have occurred and be continuing and there shall not have been more than two monetary or material non-monetary Event of Defaults of Tenant under this Lease (even if subsequently cured by Tenant), and (3) the Original Tenant shall be in occupancy of the entire Premises and Tenant has not assigned this Lease or sublet any portion of the Premises, exclusive of transfers permitted without consent pursuant to <font style="font-weight:bold;">Section 6.1(b)</font> <a name="_cp_text_2_916"></a>(provided that the foregoing requirements of <font style="font-weight:bold;"><a name="_cp_text_1_917"></a>clauses <a name="_cp_text_2_918"></a>(2)</font> and <font style="font-weight:bold;">(3)</font> of this sentence may be waived by Landlord in its sole discretion, at any time).</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.28%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Determination of Offer Space Fair Market Rental.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU87"></a>(a)<font style="margin-left:36pt;"></font>The Basic Rent with respect to any Available ROFO Space leased by Tenant pursuant to this <font style="font-weight:bold;">Section 17.1</font> (individually or collectively for purposes of this <font style="font-weight:bold;">Section 17.2</font>, the &#8220;<font style="font-weight:bold;">Offer Space</font>&#8221;) shall be the Offer Space Fair Market Rental for such Offer Space and which shall be determined as of the date estimated by Landlord in Landlord&#8217;s Offer Notice as the Anticipated ROFO Commencement Date for such Offer Space.&nbsp;&nbsp;If Tenant timely so elects to lease the Available ROFO Space pursuant to <font style="font-weight:bold;">Section 17.1</font>, but disputes Landlord&#8217;s determination of the Offer Space Fair Market Rental for the Available ROFO Space, and the parties do not agree on the Offer Space Fair Market Rental within thirty days (30) after delivery of such notice from Tenant, then either party may initiate the arbitration procedure set forth in <font style="font-weight:bold;">Section 16.2</font> above to determine the Offer Space Fair Market Rental by giving notice to the other within an additional thirty (30) days after the end of such thirty (30) day period, provided, however, for purposes of any arbitration procedure, references in <font style="font-weight:bold;">Section 16.2</font> to &#8220;Premises&#8221; shall be deemed to refer instead to the applicable Offer Space and references to &#8220;Fair Market Rental Value&#8221; shall be deemed to refer instead to the Offer Space Fair Market Rental defined in this Section 17.2 for the remainder of the Term of this Lease.&nbsp;&nbsp;If neither party timely submits the dispute for arbitration within such ten (10) Business Day period, Landlord&#8217;s determination in the Landlord&#8217;s Offer Notice shall be binding on the parties.&nbsp;&nbsp;Upon determination of the Offer Space Fair Market Rental of the applicable Offer Space, or if </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant has accepted (or is deemed to have accepted) Landlord&#8217;s determination in the Landlord&#8217;s Offer Notice, Landlord and Tenant shall, within thirty (30) days, execute an amendment to this Lease incorporating the applicable Offer Space into the Premises upon the terms contained in Landlord&#8217;s Offer Notice, and otherwise on substantially the same terms and conditions as contained in this Lease, provided, however, failure of the parties to execute such an amendment shall have no effect on the effectiveness of the expansion of the Premises to include the applicable Offer Space and the economic terms associated therewith as set forth above.&nbsp;&nbsp;If either party submits the determination of the Offer Space Fair Market Rental Value to arbitration&nbsp;&nbsp;and as of the commencement date of this Lease for such Offer Space the amount of the Offer Space Fair Market Rental Value has not been determined, Tenant shall pay the amount set forth in Landlord&#8217;s determination in the Landlord&#8217;s Offer Notice as the Basic Rent for the Offer Space and when the determination has actually been made, an appropriate retroactive adjustment shall be made as of the commencement date for such Offer Space if necessary.&nbsp;&nbsp;In the event that such determination shall result in an overpayment by Tenant of any Basic Rent, such overpayment shall be paid or, at Tenant&#8217;s election, credited by Landlord to Tenant promptly after such determination has been made, and if such determination shall result in an underpayment by Tenant of any Basic Rent, Tenant shall pay any such amounts to Landlord within thirty (30) days following such determination.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:6.73%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_923"></a>(b)<font style="margin-left:36pt;"></font>For purposes of this <font style="font-weight:bold;">Article 17</font>, the &#8220;<font style="font-weight:bold;">Offer Space Fair Market Rental</font><a name="_cp_text_1_923"></a>&#8221; of the applicable Offer Space means the fixed annual rent and additional rent that owners of Comparable Buildings&nbsp;&nbsp;have agreed to accept, and nonaffiliated tenants of Comparable Buildings have agreed to pay in current arms-length, nonequity transactions for comparable expansion space for comparable office and laboratory use, for a term comparable to the remaining Term of this Lease following the Anticipated ROFO Commencement Date and taking into account all other relevant factors, including that Landlord shall be entitled to laboratory rental rates for fifty percent (50%) of each floor now or hereafter designated for the Laboratory Portion even in the event Tenant shall not be using the same for laboratory purposes.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Signatures commence on following page]</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU88"></a><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[Signature page of lease]</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF,<font style="font-weight:normal;"> Landlord and Tenant have caused this Lease to be duly executed by persons hereunto duly authorized, as of the date first set forth above.</font></p>
<p style="margin-bottom:18pt;margin-top:12pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LANDLORD:</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ICE BOX, LLC, a Massachusetts limited liability company </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: ICE BOX MANAGER, LLC, a Massachusetts limited liability company, its Manager<br /><br />By:/Jim Halliday<font style="margin-left:36pt;"></font></p>
<p style="margin-bottom:18pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: James M. Halliday<br />Title: Vice President</p>
<p style="margin-bottom:18pt;margin-top:12pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TENANT:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PROTEOSTASIS THERAPEUTICS, INC.<font style="font-style:italic;"><br /><br /></font>By:/s/ Meenu Chhabra<font style="margin-left:36pt;"></font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Meenu Chhabra<font style="margin-left:36pt;"></font><br />Title:&nbsp;&nbsp;President and CEO<font style="margin-left:36pt;"></font><br />Tenant&#8217;s Federal Taxpayer<br />Identification Number:<font style="margin-left:36pt;"></font><br /></p>
<p style="text-align:center;margin-top:12pt; clear:both;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU89"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT A</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />Location Plan of Premises</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g201711142133435995631.jpg" title="" alt="" style="width:623px;height:401px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU90"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT B</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />Site Plan of the Boston Landing Project</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g201711142133436175632.jpg" title="" alt="" style="width:622px;height:402px;"></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B-1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU91"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT C</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord&#8217;s Work</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc15451055"></a><a name="_Toc9777819"></a><a name="_Toc9681047"></a><a name="_Toc9681002"></a><a name="_Toc9415850"></a><a name="_Toc9415792"></a><a name="_Toc9402510"></a><a name="_Toc9333840"></a><a name="_Toc9333800"></a><a name="_Toc9313562"></a><a name="_Toc8618321"></a><a name="_Toc293559234"></a><a name="_Toc292454033"></a><a name="_Toc289976795"></a><a name="_Toc289973372"></a><a name="_Toc289868365"></a><a name="_Toc15451061"></a><a name="_Toc9777825"></a><a name="_Toc9681052"></a><a name="_Toc9681007"></a><a name="_Toc9415855"></a><a name="_Toc9415797"></a>1.<font style="margin-left:72pt;"></font><font style="font-weight:bold;">Construction of Landlord&#8217;s Work</font><a name="_Toc293559234"></a><a name="_Toc292454033"></a><a name="_Toc289976795"></a><a name="_Toc289973372"></a><a name="_Toc289868365"></a><a name="_Toc15451061"></a><a name="_Toc9777825"></a><a name="_Toc9681052"></a><a name="_Toc9681007"></a><a name="_Toc9415855"></a><a name="_Toc9415797"></a>.&nbsp;&nbsp;Subject to the provisions of this <font style="font-weight:bold;text-decoration:underline;">Exhibit C</font>, Landlord, at Landlord&#8217;s sole cost and expense, shall cause John Moriarty &amp; Associates, or such other general contractor acceptable to Landlord (&#8220;<font style="font-weight:bold;">General Contractor</font>&#8221;) to perform the laboratory conversion of the Building and the shell delivery condition of the Premises (&#8220;<font style="font-weight:bold;">Landlord&#8217;s Work</font>&#8221;) substantially in accordance the Landlord/Tenant Matrix (&#8220;<font style="font-weight:bold;">Landlord/Tenant Matrix</font>&#8221;) attached hereto as <font style="font-weight:bold;text-decoration:underline;">Schedule 1</font> and those construction documents listed on <font style="font-weight:bold;text-decoration:underline;">Schedule 2</font> attached hereto.&nbsp;&nbsp;The Landlord&#8217;s Work shall not include the elements shown on <font style="font-weight:bold;text-decoration:underline;">Exhibit D</font> or any attachments thereto, which elements shall be performed by Tenant, at Tenant&#8217;s expense, as part of the Tenant Work.&nbsp;&nbsp;Landlord shall have the right to make changes to Landlord&#8217;s Work (the &#8220;<font style="font-weight:bold;">Landlord Permitted Changes</font>&#8221;)&nbsp;&nbsp;that do not (i)&#160;materially reduce the quality of materials shown in the Landlord&#8217;s Work, or (ii)&#160;materially and adversely affect the design, costs to install, or performance of the Tenant Work (but only to the extent Tenant has already submitted Tenant&#8217;s Construction Drawings (as hereinafter defined) pursuant to <font style="font-weight:bold;text-decoration:underline;">Exhibit D</font> for the Tenant Work to Landlord) or Tenant&#8217;s use thereof for the Permitted Use.&nbsp;&nbsp;Landlord shall give Tenant reasonable advance written notice of any such changes to the Landlord&#8217;s Work that affect the Premises prior to implementing such changes, indicating whether or not such change is a Landlord Permitted Change or not, and if such change is not a Landlord Permitted Change, the change shall be subject to prior written approval by Tenant, which approval shall not be unreasonably withheld, conditioned or delayed.&nbsp;&nbsp;Failure by Tenant to disapprove any submission of proposed changes to the Landlord&#8217;s Work within five (5) Business Days after submission shall constitute approval thereof.&nbsp;&nbsp;Any disapproval shall be accompanied by a specific statement of the reasons therefor.&nbsp;&nbsp;Landlord shall be responsible for obtaining all building permits and other governmental approvals required to construct the Landlord&#8217;s Work and for causing the General Contractor to construct the Landlord&#8217;s Work as described on and substantially in accordance with the Landlord/Tenant Matrix, in compliance with all of the terms and conditions of this <font style="font-weight:bold;text-decoration:underline;">Exhibit C</font> and the Lease,&nbsp;&nbsp;in a good and workmanlike manner and with all applicable Laws.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU92"></a>2.<font style="margin-left:72pt;"></font><font style="font-weight:bold;">Substantial Completion</font>.&nbsp;&nbsp;The Landlord&#8217;s Work shall be deemed &#8220;<font style="font-weight:bold;">Substantially Complete</font>&#8221;<font style="font-weight:bold;"> </font>as of the date (the &#8220;<font style="font-weight:bold;">Substantial Completion Date</font>&#8221;) that (i) the Landlord&#8217;s Work is completed except for minor, punch list-type items of work and adjustment of equipment and fixtures (&#8220;<font style="font-weight:bold;">Punch List Items</font>&#8221;) that can be completed after Tenant commences the performance of the Tenant Work or after its occupancy of the Premises without, in the aggregate, causing material interference with the performance of the Tenant Work or Tenant&#8217;s use or occupancy of the Premises, (ii) all governmental inspections for occupancy of the base building have been successfully completed and a temporary certificate of occupancy has been authorized for issuance by the applicable governmental authority to the extent required by law, and (iii) Landlord&#8217;s architect has issued a Certificate of Substantial Completion relating thereto, provided, however, if the Landlord&#8217;s Work is delayed by any Tenant Delay, then the Substantial Completion Date shall be the date upon which the aforesaid conditions would have been satisfied but for such Tenant Delay.&nbsp;&nbsp;In the event Landlord has a qualified third party commission the Base Building Systems Landlord shall provide Tenant with a copy of such commissioning report.&nbsp;&nbsp;Landlord shall complete, as soon as conditions practically permit and within thirty (30) days following the Substantial Completion Date all Punch List Item, subject to delays resulting from </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C-1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord&#8217;s Force Majeure and delays due to the failure of Tenant to permit timely access to the Premises</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;">Landlord&#8217;s Force Majeure</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; shall mean any prevention, delay or stoppage due to governmental regulation, strikes, lockouts or other labor difficulties, acts of God, acts of war, terrorist acts, civil commotions, unusual scarcity of or inability to obtain labor or materials, casualty or other causes reasonably beyond Landlord's control and excluding normal weather related events typical for the applicable season of the year; provided, however, that in no event shall the financial inability of Landlord or Landlord&#8217;s contractors constitute a cause beyond Landlord&#8217;s reasonable control.&nbsp;&nbsp;Landlord will exercise reasonable efforts to Substantially Complete the Landlord&#8217;s Work by February 15, 2018 (the &#8220;</font><font style="font-weight:bold;">Estimated Commencement Date</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU93"></a>3.<font style="margin-left:72pt;"></font><font style="font-weight:bold;">Early Access.</font>&nbsp;&nbsp;Provided and on the express condition that Tenant uses John Moriarty &amp; Associates as the general contractor to perform the Tenant Work, Landlord will permit Tenant and Tenant&#8217;s contractors to access the Premises from and after September 15, 2017 in order to commence the performance of the Tenant Work so long as, in Landlord&#8217;s reasonable determination, such access and work can be performed without interference with or delay in the timely performance of any remaining Landlord&#8217;s Work.&nbsp;&nbsp;If Tenant does not use John Moriarty &amp; Associates as the general contractor for the Tenant Work, Tenant will have no right to access the Premises for the performance of the Tenant Work until the Substantial Completion Date, provided, however, upon the request of Tenant, Landlord shall grant Tenant reasonable access to the Premises following completion of Landlord&#8217;s demolition work to the Premises to allow Tenant to perform Customary Pre-Construction Activities (as hereinafter defined), provided such access, in Landlord&#8217;s reasonable discretion, is coordinated with and will not interfere with the timely performance of Landlord&#8217;s Work.&nbsp;&nbsp;Any early access by Tenant prior to the substantial completion of the Landlord&#8217;s Work shall be subject to reasonable rules and regulations as may be established by Landlord from time to time, including, without limitation, hours of access and that the performance of Landlord&#8217;s Work shall have priority over any activities that Tenant is conducting or shall propose to conduct during the period prior to the Substantial Completion of Landlord&#8217;s Work.&nbsp;&nbsp;Any interference by Tenant, its employees, agents, invitees or contractors that causes an actual delay in the performance of the Landlord&#8217;s Work as a result of Tenant&#8217;s early access to the Premises shall constitute a Tenant Delay under this Lease.&nbsp;&nbsp;&#8220;Customary Pre-Construction Activities&#8221; shall mean such architectural and engineering activities that are generally performed in preparation for the construction of first class office space in the financial district of Boston, Massachusetts and which do not involve the performance of work which physically alters in any way any portion of the Premises or the Building and which do not affect or interfere with the operation of any Building systems.&nbsp;&nbsp;Examples of Customary Pre-Construction Activities are the taking or preparation of measurements, surveys, elevations, sketches and layouts.&nbsp;&nbsp;Any such access to the Premises by Tenant and Tenant&#8217;s employees, agents, contractors, subcontractors material suppliers and laborers prior to the Substantial Completion Date shall be (i) at Tenant&#8217;s sole risk and expense, (ii) coordinated with the timely performance of the Landlord&#8217;s Work and not interfere with or delay in any material respect the performance of the Landlord&#8217;s Work, and (iii) subject to such reasonable access rules as Landlord may impose based upon the status of completion of Landlord&#8217;s Work and the remaining Landlord&#8217;s Work to be performed in the Premises, (iv) subject to and upon all of the same terms and conditions of this Lease except for the obligation to pay Rent, (v) conditioned upon Tenant&#8217;s complying with and performing, and causing its employees, agents, contractors, subcontractors, material suppliers and laborers to comply with and perform, all of Tenant&#8217;s insurance and indemnity obligations and other obligations governing the conduct of Tenant at the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C-2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property under the Lease (provided that no Basic Rent, or Additional Rent shall accrue or be payable during such time), and (vi) to the fullest extent permitted by applicable Laws, the installation or placement of any&nbsp;&nbsp;furniture, equipment, construction materials and supplies and other property in the Premises shall be at the sole risk and hazard of Tenant and Landlord shall not be liable for any theft, loss, injury or damage to any such property therein and Tenant shall be solely responsible for the security of any such Tenant&#8217;s property, materials and supplies.&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc293559238"></a><a name="_Toc292454036"></a><a name="_Toc289976798"></a><a name="_Toc289973378"></a><a name="_Toc289868368"></a><a name="_Toc9681011"></a><a name="_Toc9402520"></a><a name="_Toc9333810"></a><a name="_Toc9313583"></a><a name="_Toc9333850"></a><a name="_Toc8618342"></a><a name="_Toc15451063"></a><a name="_Toc9777828"></a><a name="_Toc9681056"></a><a name="_Toc9415859"></a><a name="_Toc9415801"></a><a name="_Toc8618345"></a><a name="_Toc9313586"></a><a name="_Toc9333812"></a><a name="_Toc9333852"></a><a name="_Toc9402521"></a><a name="_Toc9415802"></a><a name="_Toc9415860"></a><a name="_Toc9681012"></a><a name="_Toc9681057"></a><a name="_Toc15700764"></a><a name="_Toc15470462"></a><a name="_Toc15470049"></a><a name="_Toc15451064"></a><a name="_Toc9777829"></a>4.<font style="margin-left:72pt;"></font><font style="font-weight:bold;"><a name="_Toc15700764"></a><a name="_Toc15470462"></a><a name="_Toc15470049"></a><a name="_Toc15451064"></a><a name="_Toc9777829"></a>Tenant Delays</font>.&nbsp;&nbsp;As used in this Work Letter, &#8220;<font style="font-weight:bold;">Tenant Delay</font>&#8221; shall mean any actual delay in the design, commencement, progress or substantial completion of any elements of the Landlord&#8217;s Work&nbsp;&nbsp;attributable to the following (i) the default of Tenant, or Tenant&#8217;s agents, employees or contractors under the Lease, including this <font style="font-weight:bold;text-decoration:underline;">Exhibit C</font>, or (ii) the failure of Tenant or Tenant&#8217;s Construction Representative (as defined in <font style="font-weight:bold;text-decoration:underline;">Exhibit D</font>) to make any requested written submission, or to respond to any written request to Tenant from Landlord, or to take any other required action, within the time periods for such submission, response, or action as set forth in the Lease and/or this <font style="font-weight:bold;text-decoration:underline;">Exhibit C</font>; or (iii) Tenant Change Orders made by Tenant in accordance with <font style="font-weight:bold;text-decoration:underline;">Exhibit D</font>; or (iv) any delays resulting from Tenant or any of Tenant&#8217;s contractors not complying with the rules and regulations for the performance of the Tenant Work in the Building of which Tenant is given written notice; or (v) any other delays caused by the acts or, where there is a duty of Tenant to act under the Lease or <font style="font-weight:bold;text-decoration:underline;">Exhibit C </font>or<font style="font-weight:bold;text-decoration:underline;"> Exhibit D</font>, omissions by Tenant, Tenant&#8217;s contractors, architects, engineers or anyone else engaged by, through or under Tenant in connection with the preparation of the Premises for Tenant&#8217;s occupancy, including, without limitation, utility companies and other entities furnishing communications, data processing or other service, equipment or furniture.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant agrees that no Tenant Delay shall delay commencement of the Term or the obligation to pay Basic Rent or Additional Rent and the Commencement Date will be the date the Commencement Date would have occurred but for Tenant Delay.&nbsp;&nbsp;Tenant shall reimburse Landlord for the amount, if any, by which the cost of Landlord&#8217;s Work is increased as the direct result of any Tenant Delay within thirty (30) days of billing therefor, and shall be considered to be Additional Rent.&nbsp;&nbsp;Landlord agrees to provide Tenant with written notice advising Tenant that such Tenant Delay is occurring and setting forth Landlord&#8217;s good faith estimate as to the likely length of such Tenant Delay within a reasonable period of time after Landlord becomes aware of such Tenant Delay, provided, however, that Landlord will not have any obligation to deliver any Tenant Delay notice to Tenant with respect to any Tenant Delay that Landlord has previously disclosed in writing to Tenant or Tenant is otherwise aware of, such as, by way of example only, the Tenant Delay that Landlord disclosed in writing to Tenant in connection with Landlord&#8217;s review and approval of a Tenant Change Order.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Warranty Period. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU94"></a>Landlord warrants to Tenant that the materials and equipment furnished in the performance of the Landlord&#8217;s Work will be of good quality and the Landlord&#8217;s Work will be free from defects not inherent in the quality described in the applicable plans and specifications therefor.&nbsp;&nbsp;Any portion of the Landlord&#8217;s Work not conforming to the foregoing requirements will be considered defective and will be repaired or replaced by Landlord at Landlord&#8217;s expense so long as Landlord receives notice of such defect prior to the expiration of the Warranty Period (as hereinafter defined).&nbsp;&nbsp;The foregoing warranty shall not apply to the extent of damage or defect caused by (1) the negligent acts or omissions or the willful misconduct of Tenant or any of Tenant&#8217;s agents, employees or contractors, (2) improper </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C-3</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">operation by Tenant or anyone claiming by, through or under Tenant, or (3) normal wear and tear and normal usage.&nbsp;&nbsp;The foregoing warranty with respect to each component of the Landlord&#8217;s Work shall commence on the Substantial Completion Date and shall expire on the date which is one (1) year after the Substantial Completion Date (the &#8220;</font><font style="font-weight:bold;">Warranty Period</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), and Tenant shall be required to deliver notice to Landlord of any defects prior to the expiration of the Warranty Period in order to permit Landlord to take action to enforce Landlord&#8217;s warranty rights with respect to the Landlord&#8217;s Work.&nbsp;&nbsp;Landlord agrees that it shall correct any portion of the Landlord&#8217;s Work which during the Warranty Period is found not to be in accordance with the warranties set forth in this Section 5.&nbsp;&nbsp;Landlord shall use commercially reasonable efforts to enforce warranties from its general contractors, subcontractors, vendors and others on Tenant&#8217;s behalf.&nbsp;&nbsp;Except for Punch List Items and except to the extent to which Tenant shall have given Landlord notice of defective items or any other items as to which Landlord has not performed Landlord&#8217;s construction obligations under this </font><font style="font-weight:bold;text-decoration:underline;">Exhibit C</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> within the Warranty Period, subject to Landlord&#8217;s obligations with respect to claims submitted by Tenant to Landlord prior to the expiration of the Warranty Period, Tenant shall be deemed conclusively to have approved Landlord&#8217;s construction following Tenant&#8217;s taking possession of the Premises for the normal conduct of its business and shall have no claim that Landlord has failed to perform any of Landlord&#8217;s obligations under this Lease or </font><font style="font-weight:bold;text-decoration:underline;">Exhibit C</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> with respect to Landlord&#8217;s Work.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Remedy for Late Delivery</font>.&nbsp;&nbsp;If the Substantial Completion Date of the Landlord&#8217;s Work has not occurred by the Estimated Commencement Date, subject to a day for day postponement of such Estimated Commencement Date on account of delays in the substantial completion of the Landlord&#8217;s Work resulting from any Tenant Delay, then the April 15, 2018 date set forth in clause (i) of the definition of the Rent Commencement Date in <font style="font-weight:bold;">Section 1.1</font> of this Lease, shall be postponed one (1) day for each day the Substantial Completion Date is delayed beyond the Estimated Commencement Date (as so extended).&nbsp;&nbsp;If the Substantial Completion Date of the Landlord&#8217;s Work has not occurred by March 15, 2018 (the &#8220;<font style="font-weight:bold;">Outside Date</font>&#8221;), subject to a day for day postponement of such Estimated Commencement Date on account of delays in the substantial completion of the Landlord&#8217;s Work resulting from any Landlord&#8217;s Force Majeure delay and/or any Tenant Delay, and such failure of the Landlord&#8217;s Work by the Outside Date results in an actual delay of the Substantial Completion of the Tenant Work (as hereinafter defined) then Tenant shall have the right to receive a credit against the Basic Rent payable under the Lease equal to one (1)&#160;day&#8217;s Basic Rent for each calendar day following the Outside Date (as so extended) and ending on the Substantial Completion Date.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU95"></a><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C-4</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SCHEDULE 1</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />Landlord/Tenant Matrix</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g201711142133436845633.jpg" title="" alt="" style="width:623px;height:804px;"></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C-5</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g201711142133437095634.jpg" title="" alt="" style="width:623px;height:804px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C-6</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU96"></a><img src="g201711142133437335635.jpg" title="" alt="" style="width:623px;height:804px;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C-7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU97"></a><img src="g201711142133437595636.jpg" title="" alt="" style="width:623px;height:804px;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C-8</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g201711142133437865637.jpg" title="" alt="" style="width:623px;height:804px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C-9</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU98"></a><img src="g201711142133438185638.jpg" title="" alt="" style="width:623px;height:804px;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C-10</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU99"></a><img src="g201711142133438435639.jpg" title="" alt="" style="width:623px;height:804px;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C-11</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU100"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SCHEDULE 2</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />List of Construction Documents for Landlord&#8217;s Work</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g201711142133438715640.jpg" title="" alt="" style="width:623px;height:804px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C-1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU101"></a><img src="g201711142133438995641.jpg" title="" alt="" style="width:623px;height:804px;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C-2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU102"></a><img src="g201711142133439275642.jpg" title="" alt="" style="width:623px;height:804px;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C-3</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU103"></a><img src="g201711142133439555643.jpg" title="" alt="" style="width:623px;height:804px;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C-4</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU104"></a><img src="g201711142133439835644.jpg" title="" alt="" style="width:623px;height:804px;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C-5</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU105"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT D</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />Tenant Work</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">DEFINED TERMS</font>.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized terms not defined herein shall have the same meaning&nbsp;&nbsp;ascribed to such terms within the Lease (including all other Exhibits to the Lease). In addition, the following terms shall have the following meanings:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;text-decoration:underline;">Building Permit Date</font><font style="font-weight:bold;">&#8221;</font> shall mean the date upon which a building permit for the Tenant Work is first issued or issuable by the applicable governmental authority to Tenant (and/or any contractor, architect or permit expediter processing such building permit on Tenant&#8217;s behalf), whether or not Tenant (or such contractor, architect or permit expediter) actually obtains the issuance of such permit on such date.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;text-decoration:underline;">Change Order</font><font style="font-weight:bold;">&#8221;</font> shall have the meaning set forth in Section 3 of this <font style="font-weight:bold;text-decoration:underline;">Exhibit&#160;D</font> below.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;text-decoration:underline;">Construction Documents</font>&#8221; shall mean the construction drawings for the Tenant Work, as approved (and/or deemed approved) by Landlord and Tenant, as the same may be modified (i) by Change Orders, and/or (ii) to meet the requirements of a reviewing governmental authority and comply with all applicable laws, codes, rules and regulations as part of the process of obtaining the issuance of building permits or other approvals for the Tenant Work, provided any material modifications to the approved Construction Documents required by a reviewing governmental authority for the issuance of a building or other permit required to perform the Tenant Work shall be subject to Landlord&#8217;s approval in accordance with the standards set forth in Section 5.3 of the Lease.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="text-decoration:underline;">Landlord&#8217;s Contribution</font>&#8221;<font style="font-weight:normal;"> shall mean an amount equal to $160.00 per rentable square foot of the Premises for a total of Four Million Seven Hundred Seventy Three Thousand Seven Hundred Sixty and 00/100 Dollars ($4,773,760.00). </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Partial Lien Release</font>&#8221;<font style="font-weight:normal;"> means a&nbsp;&nbsp;partial release of liens to be provided at the time of each payment of a portion of Landlord&#8217;s Contribution, other than the final payment of the Landlord's Contribution, and relating to payment for the portion of work for which the prior Landlord's Contribution was applied.&nbsp;&nbsp;Partial Lien Releases shall (i) be executed and delivered by Tenant&#8217;s Contractor and any and all subcontractors and/or materialmen supplying labor and/or materials in connection with the Tenant Work performed under the Tenant's Contractor's construction contract with Tenant, and (ii) be in form and substance reasonably satisfactory to Landlord</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">"<font style="text-decoration:underline;">Final Lien Release</font>"<font style="font-weight:normal;"> means the final release of liens to be provided at the time of final completion of the Tenant Work, and in all events prior to Landlord making final payment of any unfunded portion of Landlord&#8217;s Contribution relating to the applicable portion of the work in question.&nbsp;&nbsp;Final Lien Releases shall (i) be executed and delivered by Tenant&#8217;s Contractor and any and all subcontractors and/or materialmen supplying labor and/or materials in connection with the Tenant Work performed under the Tenant's Contractor's construction contract with Tenant, and (ii) be in form and substance reasonably satisfactory to Landlord.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D-1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU106"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;</font><font style="font-weight:bold;text-decoration:underline;">Space Plan</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; shall mean that certain Space Plan entitled Proteostasis Therapeutics, Inc. Floor 5 80 Guest Street, Brighton, Massachusetts Preliminary Layout (Job #17158.11) dated August 10, 2017, prepared by R.E. Dinneen Architects &amp; Planners, Inc. and relating to the Premises.</font><font style="font-style:italic;"> </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;text-decoration:underline;">Substantial Completion of the Tenant Work</font>&#8221; and phrases of a similar nature shall mean that the Tenant Work shall have been completed substantially in accordance with the Construction Documents, other than&nbsp;&nbsp;(A) items that require an unusually long lead time for procurement and/or installation, and (B) &#8220;punch list&#8221; items and other minor defects which will not unreasonably interfere with Tenant&#8217;s ability to lawfully occupy and use the Premises or prevent the issuance of an final inspection approvals and an occupancy permit or its equivalent.&nbsp;&nbsp;Tenant shall be responsible for obtaining all governmental inspection and other approvals with regard to the Tenant Work and/or which are necessary to permit Tenant to install its furniture, fixtures and equipment in, and to occupy and use, the Premises lawfully for the Permitted Use.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Tenant&#8217;s Contractor</font>&#8221;<font style="font-weight:normal;"> means the general contractor selected by Tenant to perform the Tenant Work, which general contractor shall be subject to Landlord&#8217;s prior approval, which shall not be unreasonably withheld, conditioned or delayed.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;text-decoration:underline;">Tenant&#8217;s Construction Representative</font>&#8221; shall mean Brett Hagan and Michael McDonell, or any other representative appointed by Tenant of which Landlord is notified.&nbsp;&nbsp;Tenant&#8217;s Construction Representative shall have the power to bind Tenant with respect to all matters arising under this <font style="font-weight:bold;text-decoration:underline;">Exhibit&#160;D</font>.&nbsp;&nbsp;In addition, Tenant agrees that written notices or transmittals given by Landlord to Tenant&#8217;s Construction Representative pursuant to this <font style="font-weight:bold;text-decoration:underline;">Exhibit&#160;D</font> shall be deemed duly delivered to Tenant for all purposes of the Lease (effective as of the earlier to occur of actual receipt or refusal of such delivery by Tenant&#8217;s Construction Representative).</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;text-decoration:underline;">Tenant Work</font>&#8221; shall mean all improvements, alterations, installations and work shown on the Construction Documents, except as otherwise set forth in this <font style="font-weight:bold;text-decoration:underline;">Exhibit&#160;D</font>.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">PREPARATION OF PLANS AND SPECIFICATIONS</font>.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;">Promptly following the date of this Lease, Tenant shall cause construction drawings for the Tenant Work (&#8220;</font><font style="font-weight:bold;text-decoration:underline;">Construction Drawings</font>&#8221;) consistent with the Space Plan to be completed and submitted to Landlord for review and approval.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU107"></a>(b)<font style="margin-left:36pt;">Within ten (10) Business Days after receipt of any Construction Drawings, Landlord shall return such Construction Drawings to Tenant with its objections, suggested modifications and/or approval (which suggested objections and suggested modifications are herein referred to as &#8220;</font><font style="font-weight:bold;text-decoration:underline;">Landlord Modifications</font>&#8221;).&nbsp;&nbsp;Unless Tenant has an objection to any Landlord Modifications, said Construction Drawings shall thereafter be revised by Tenant to reflect the applicable changes. If, upon receipt of any Landlord Modifications, Tenant wishes to take exception thereto, Tenant may do so within ten (10) Business Days after Tenant&#8217;s receipt of such Landlord Modifications.&nbsp;&nbsp;In such event, Tenant shall confer with Landlord prior to the expiration of such ten (10) Business Day period to resolve all matters with which Tenant was not in agreement.&nbsp;&nbsp;Landlord and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D-2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant, in good faith, agree to resolve outstanding issues within such ten (10) Business Days, and Tenant thereafter will as soon as reasonably practicable revise the Construction Drawings to reflect such final agreement.&nbsp;&nbsp;After the first submission and resubmission, Landlord and Tenant agree (i) to restrict further objections or disputes to matters which have not previously been agreed upon or accepted by the other party, (ii) to deliver revised submissions or objections within ten (10) days following receipt, and (iii) to confer regularly in a good faith effort to resolve all matters in dispute expeditiously.&nbsp;&nbsp;The parties shall, in all events, attempt to reach final agreement on the Construction Drawings as soon as possible. Each party agrees that its failure to respond to a submission or resubmission within the above- referenced time frames shall constitute such party&#8217;s acceptance of the submission or resubmission in question, or, to the extent applicable, a delay caused by the delinquent party.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;">Promptly upon final approval of the Construction Documents, Tenant shall submit an application for, and diligently pursue issuance of, a building permit (and any other approvals required) for the Tenant Work.&nbsp;&nbsp;Landlord, at no cost, shall reasonably assist Tenant in the procurement of its building permit including signing any typical permit processing documents.&nbsp;&nbsp;Tenant shall provide Landlord with copies of all written comments, responses, approvals, disapprovals and/or other correspondence received from all&nbsp;&nbsp;applicable governmental authorities in connection with such application, and shall otherwise keep Landlord informed regarding the processing of Tenant&#8217;s building permit application.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">PERFORMANCE OF TENANT WORK</font>.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;">Promptly after the issuance of a building permit for the Tenant Work, Tenant shall commence and perform the Tenant Work, in order to achieve Substantial Completion of the Tenant Work.&nbsp;&nbsp;Except as provided herein, no deviation from the Construction Documents shall be made by Tenant (other than field changes, substitution of material and other minor changes) except by written change order approved by Landlord (&#8220;</font><font style="font-weight:bold;text-decoration:underline;">Change Order</font>&#8221;), which approval shall not be unreasonably withheld, conditioned or delayed subject to the terms of Landlord&#8217;s construction and other building rules and regulations.&nbsp;&nbsp;Tenant shall be responsible for the payment of any and all costs to complete the Tenant Work except to the extent Tenant is entitled to receive Landlord&#8217;s Contribution and the Space Planning Allowance under this <font style="font-weight:bold;text-decoration:underline;">Exhibit&#160;D</font>.&nbsp;&nbsp;All Tenant Work shall be performed by Tenant&#8217;s Contractor and subcontractors; and those subcontractors whose cost of work exceeds $5,000.00 shall have been approved by Landlord, which approval will not be unreasonably withheld, conditioned or delayed.&nbsp;&nbsp;All subcontractors performing the Tenant Work shall be financially sound and able to complete the portion of the Tenant Work for which they are responsible in a prompt and timely fashion.&nbsp;&nbsp;In the performance of the Tenant Work by Tenant or Tenant&#8217;s Contractor, Tenant shall comply with, and shall cause Tenant&#8217;s Contractor and all subcontractors to comply with, the provisions of this <font style="font-weight:bold;text-decoration:underline;">Exhibit&#160;D</font>.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU108"></a>(b)<font style="margin-left:36pt;">The performance of the Tenant Work by Tenant or under Tenant&#8217;s supervision shall be governed (in addition to the provisions of this </font><font style="font-weight:bold;text-decoration:underline;">Exhibit&#160;D</font>) by all covenants, agreements, rules and regulations set forth in the Lease with regard to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D-3</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alterations, as if such provisions were fully restated herein and expressly made applicable to the performance of the Tenant Work.&nbsp;&nbsp;Without limitation, Tenant will enter into one or more construction contracts for the performance of the Tenant Work with the Tenant&#8217;s Contractor, and will deliver a true, correct and complete copy of such construction contract(s) to Landlord promptly after execution.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;">The Tenant Work under this </font><font style="font-weight:bold;text-decoration:underline;">Exhibit&#160;D</font> may not commence nor may Tenant permit Tenant&#8217;s Contractor or any other contractors and/or subcontractors to commence any work until all required contractors (including Tenant&#8217;s Contractor) and subcontractor insurance has been obtained, and, if Landlord requests, until such contractor and subcontractor certificates of such insurance have been delivered to Landlord.&nbsp;&nbsp;Such insurance policies shall name the Landlord, Landlord&#8217;s property manager and Landlord&#8217;s mortgagee(s) as additional insureds and such other parties as may be reasonably requested by Landlord as additional insureds.&nbsp;&nbsp;Such certificates of insurance shall provide that no material change or cancellation of such insurance coverage shall be undertaken without thirty (30) days&#8217; prior written notice to Landlord of the insurer will not include such a provision in the certificates, then Tenant shall provide such notice to Landlord.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;">Landlord will, upon reasonable prior notice to Tenant, have the right to inspect the performance of the Tenant Work by Tenant&#8217;s Contractor and any subcontractor(s), and Tenant agrees to cooperate with Landlord to facilitate such inspections, including notifying Landlord prior to any and all government inspections of the Tenant Work so that Landlord&#8217;s construction manager can be present for such inspections.&nbsp;&nbsp;Landlord shall not unreasonably interfere with the performance of the Tenant Work during the course of any inspections by Landlord pursuant to this subparagraph but Landlord shall have no liability to Tenant in connection with such inspections except to the extent of the negligence or willful misconduct of Landlord or any Landlord Parties and subject to the waiver of claims and subrogation set forth in Section 10.5 of this Lease</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;">Tenant and its contractor performing the Tenant Work shall provide copies of warranties for the Tenant Work and the materials and equipment which are incorporated into the Building and Premises in connection therewith, as well as provide to Landlord all operating and maintenance manuals for all equipment and materials incorporated into the Building and/or Premises as part of the Tenant Work.&nbsp;&nbsp;Tenant shall enforce all such warranties to the extent repairs and/or maintenance is required to be performed by Landlord under this Lease on warranted items covered by such warranties.&nbsp;&nbsp;Without limitation, all aspects of the Tenant Work shall be warranted to be free from defects in design and workmanship for a period of not less than one (1) year from Substantial Completion of the Tenant Work.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU109"></a>(f)<font style="margin-left:36pt;">Except as expressly permitted under Section 3 of </font><font style="font-weight:bold;text-decoration:underline;">Exhibit </font>C attached hereto, Tenant shall have no right to enter the Premises prior to the Substantial Completion Date.&nbsp;&nbsp;However, in the event Landlord consents in its discretion to any such entry, such entry shall be subject to all of the terms and conditions of the Lease, except for the obligation to pay Rent (which will not be applicable until the Rent </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D-4</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commencement Date, as provided in the Lease).&nbsp;&nbsp;Tenant shall bear the full risk of loss for any materials, equipment or other property which are brought into the Building or the Premises as part of the Tenant Work (which shall be stored or installed in the Premises at Tenant&#8217;s sole risk).&nbsp;&nbsp;Notwithstanding the Substantial Completion Date, Tenant shall not occupy or conduct business in or from the Premises until the Tenant Work is Substantially Complete and Tenant has obtained a temporary or final certificate of occupancy and similar approvals from applicable governmental authorities for the lawful use and occupancy of the Premises for the Permitted Use.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)<font style="margin-left:36pt;">Upon Substantial Completion of the Tenant Work, Tenant shall deliver to Landlord a written notice (the &#8220;</font><font style="font-weight:bold;">Completion Notice</font>&#8221;) certifying that the Tenant Work is Substantially Complete.&nbsp;&nbsp;Within five (5) days after Tenant delivers the Completion Notice, Tenant and a representative of Landlord shall jointly inspect the Premises with Tenant&#8217;s architect and Tenant&#8217;s Contractor.&nbsp;&nbsp;If, as a result of the aforementioned joint inspection, either Landlord or Tenant discovers minor deviations or variations from the Construction Documents of a nature commonly found on a &#8220;punch list&#8221; (as that term is used in the construction industry), Tenant shall promptly notify Tenant&#8217;s Contractor of such deviations; provided, however, that in the event of a dispute, Landlord (or Landlord&#8217;s Representative) and Tenant (or Tenant&#8217;s Contractor) shall negotiate in good faith, using their reasonable discretion, to determine which items constitute punch list items.&nbsp;&nbsp;The existence of such punch list items shall not affect the obligation of Tenant to pay Rent, additional rent or any other charges due under this Lease.&nbsp;&nbsp;Tenant&#8217;s construction contract for the Tenant Work will require that Tenant&#8217;s Contractor cause all such punch list items to be remedied as soon as is practicable after the date of such joint inspection, and Tenant will use all reasonable and diligent efforts to enforce such obligation.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)<font style="margin-left:36pt;">All Tenant Work shall be performed using contractors and subcontractors which will not create or increase the likelihood of any labor disputes, disharmony, strikes or any other forms of protest at the Property.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">PAYMENT OF COSTS; TENANT&#8217;S CONTRIBUTION; LANDLORD&#8217;S CONTRIBUTION</font>.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;">Tenant shall complete the Tenant Work on a lien-free basis.&nbsp;&nbsp;Without limiting Landlord&#8217;s rights and remedies due to an Event of Default by Tenant due to its violation of this covenant, if a lien is filed or attaches to the Premises, the Building or the Property as a result of the Tenant Work, Landlord shall have the right (but not the obligation) to pay such costs to remove such lien, and to deduct from Landlord&#8217;s Contribution, or bill Tenant for, any amount so paid by Landlord.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU110"></a>(b)<font style="margin-left:36pt;">In consideration of Tenant&#8217;s fulfillment of all of its obligations under this </font><font style="font-weight:bold;text-decoration:underline;">Exhibit D</font> and the performance of all of its financial and other obligations under this Lease and subject to the terms of this <font style="font-weight:bold;text-decoration:underline;">Exhibit D</font>, Landlord agrees to fund Landlord&#8217;s Contribution (subject to the limitations set forth below) towards the total costs (the "<font style="font-weight:bold;">Total TI Costs</font>&#8221;) incurred by Tenant to perform the Tenant Work in or to the Premises, subject to the Landlord Funding Conditions (as hereinafter defined).&nbsp;&nbsp;Notwithstanding </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D-5</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any provision of this Section 4(b) to the contrary, Tenant shall have the right to apply up to twenty percent (20%) of the Landlord&#8217;s Contribution to soft costs associated with the Tenant Work including, but not limited to, architect&#8217;s and engineer&#8217;s fees and data and telecom cabling, but not for Tenant&#8217;s furniture, fixtures and equipment or moving costs.&nbsp;&nbsp;Tenant acknowledges and agrees that Landlord&#8217;s total financial obligation with respect to the design, permitting, purchase, construction, and installation of the Tenant Work or any other improvements to the Premises shall be limited solely to Landlord&#8217;s Contribution and Landlord shall have absolutely no obligation to make any payment of the Landlord&#8217;s Contribution until the requirements set forth in Section 4 (c) of this </font><font style="font-weight:bold;text-decoration:underline;">Exhibit D</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> have been satisfied.&nbsp;&nbsp;Tenant shall be solely responsible for any and all Total TI Costs, except to the extent Landlord is obligated to disburse any portion of Landlord&#8217;s Contribution.&nbsp;&nbsp;The amount of Total TI Costs in excess of Landlord&#8217;s Contribution shall be paid by Tenant and is herein referred to as the &#8220;</font><font style="font-weight:bold;">Tenant Contribution</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#8221;&nbsp;&nbsp;From and after September 15, 2017, the Landlord&#8217;s Contribution solely with respect to the Tenant's Work to be performed under Tenant's construction contract with Tenant's Contractor will be payable on a percentage of completion basis, not more than once during each calendar month, and any amount so funded will be paid to Tenant&#8217;s Contractor (or reimbursed to Tenant if Tenant has already paid Tenant&#8217;s Contractor and provided evidence of such payment and a partial lien waiver therefor to Landlord) within thirty (30) days following Landlord&#8217;s receipt of all of the following items:</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;">a payment request (a &#8220;</font><font style="font-weight:bold;">Funding Request</font>&#8221;), seeking that percentage of Landlord&#8217;s Contribution (less the applicable holdback amount specified below) which corresponds to the percentage of completion of the Tenant Work performed in or to the Premises which has been achieved as of the date of such payment request:</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (ii)<font style="margin-left:36pt;">a certificate of Tenant&#8217;s architect to Landlord and any other party reasonably designated by Landlord (such as Landlord&#8217;s mortgagee, if any) specifying the percentage of completion of the Tenant Work performed in or to the Premises in accordance with the Construction Documents which Tenant has achieved as of the date of such certificate, which shall in no event be less than the sum of (A) the percentage of Landlord&#8217;s Contribution which Tenant is then seeking to have disbursed (exclusive of any holdback amount hereinafter provided in this </font><font style="font-weight:bold;text-decoration:underline;">Exhibit&#160;D</font>), <font style="font-style:italic;">plus</font> (B) the percentage of Landlord&#8217;s Contribution (exclusive of any holdback amount previously impounded) which has previously been disbursed to Tenant in connection with any and all prior payment requests made by Tenant for the Premises (and in any payment request seeking final payment, such certificate shall include a certification by the Tenant&#8217;s architect that the Tenant Work for the Premises has been Substantially Completed in accordance with the Construction Documents, and that all punch list items noted by the parties have also been fully completed);</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU111"></a>(iii)<font style="margin-left:36pt;">a copy of the temporary or final certificate of use and occupancy (or its equivalent) issued to Tenant by the applicable governmental authority with respect to the Premises (final payment of Landlord&#8217;s Contribution only).&nbsp;&nbsp;If the temporary certificate of use and occupancy is provided, Tenant shall provide the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D-6</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">final certificate of use and occupancy as soon as it is issued by the applicable governmental authority;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)<font style="margin-left:36pt;">a copy of complete as-built plans and specifications for the Tenant Work to the Premises (final payment of Landlord&#8217;s Contribution only);</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)<font style="margin-left:36pt;">evidence that Tenant has funded the Tenant Contribution prior to any payment request (and each prior payment request made by Tenant), as defined in and determined pursuant to Section 4(c), below; and</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vi)<font style="margin-left:36pt;">Partial Lien Release for the Tenant Work with respect to which payment is being requested, other than the final payment, and a Final Lien Release for the final payment of the Landlord's Contribution.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon receipt and approval of all such items and subject to Landlord&#8217;s right to dispute the amount properly due pursuant to this <font style="font-weight:bold;text-decoration:underline;">Exhibit&#160;D</font> in connection with a Funding Request, Landlord shall, within thirty (30) days following receipt of the Funding Request, disburse the amount requested to be funded to Tenant.&nbsp;&nbsp;If Tenant fails to pay any portion of the Tenant Contribution as and when required, Landlord shall have the right to withhold any further funding of Landlord&#8217;s Contribution pending Tenant&#8217;s delivery of evidence reasonably satisfactory to Landlord that Tenant has made such Tenant Contribution and any such withholding by Landlord shall not be deemed a delay by Landlord or otherwise postpone Tenant&#8217;s obligation to pay Rent under this Lease.&nbsp;&nbsp;In addition, excluding any portion of a Funding Request relating solely to soft costs, Landlord shall have the right to hold back five percent (5%) of the amount of requested from any Funding Request until such time as, in addition to Tenant&#8217;s satisfaction of the requirements otherwise applicable to a final payment under clauses (i) &#8211; (vi) above of this Section 4(b), Landlord has received a certificate from Tenant&#8217;s architect that all punch list items have been corrected or completed; provided, however, such hold back shall not be in addition to the retainage under Tenant&#8217;s construction contract for the Tenant&#8217;s Work and in the event Tenant submits a Funding Request that reflects at least a five percent (5%) retainage under Tenant&#8217;s construction contract for the Tenant&#8217;s Work then Landlord will not withhold such additional five percent (5%) hold back and will retain a five percent (5%) hold back only from the final Funding Request in accordance with this <font style="font-weight:bold;">Section 4(b)</font>.&nbsp;&nbsp;Subject to the twenty percent (20%) cap set forth in this <font style="font-weight:bold;">Section 4(b)</font>, from and after September 15, 2017, the Landlord&#8217;s Contribution allocable to soft costs applicable to Tenant's Work hereunder shall be paid by Landlord to Tenant within thirty (30) days after Landlord's receipt of a reasonably detailed invoice therefor. </p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU112"></a>(c)<font style="margin-left:36pt;"></font>In addition to the Landlord&#8217;s Contribution, Landlord agrees to provide Tenant with a space planning allowance (the &#8220;<font style="font-weight:bold;">Space Planning Allowance</font>&#8221;) in an amount not to exceed $2,983.60 to be applied toward the cost of the preparation of a preliminary space plan or fit plan for the Premises to be prepared by Tenant&#8217;s architect.&nbsp;&nbsp;The Space Planning Allowance shall be paid to Tenant within ten (10) Business Days </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D-7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">after the later of the date this Lease is executed and delivered by the parties and the date Landlord receives a copy of a paid invoice therefore from Tenant. </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;">Notwithstanding anything in this Lease, including this </font><font style="font-weight:bold;text-decoration:underline;">Exhibit D</font> to the contrary, Landlord&#8217;s obligation to make any payment of the Landlord&#8217;s Contribution or the Space Planning Allowance is conditioned upon there being no uncured Event of Default under this Lease.&nbsp;&nbsp; </p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Without limiting Tenant&#8217;s obligations to complete all of the Tenant Work to the Premises in accordance with the terms hereof, Tenant acknowledges and agrees that Landlord shall have no obligation to pay or fund the final installment of Landlord&#8217;s Contribution if the Tenant Work to the Premises is not substantially complete and conditions (i) through (vi) above are not satisfied within twelve (12) months following the Rent Commencement Date of this Lease.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;text-transform:uppercase;">Additional Provisions Regarding the Tenant Work</font>.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With regard to the performance of the Tenant Work pursuant to this <font style="font-weight:bold;text-decoration:underline;">Exhibit&#160;D</font>, the following provisions shall apply:</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Insurance Requirements During Construction</font>.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;">Tenant shall secure, pay for, and maintain, or cause its contractors and subcontractors to secure, pay for, and maintain, during the continuance of construction and fixturing work within the Premises, all of the insurance policies required in the amounts as set forth herein, together with such insurance as may from time to time be required by city, county, state or federal laws, codes, regulations or authorities.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;">The Tenant Work under this </font><font style="font-weight:bold;text-decoration:underline;">Exhibit&#160;D</font> may not commence nor may Tenant permit its contractors and/or subcontractors to commence any work until all required insurance has been obtained, and, if Landlord requests, until Tenant&#8217;s, or its contractors and subcontractors, certificates of such insurance have been delivered to Landlord.&nbsp;&nbsp;Tenant&#8217;s or its contractors and subcontractors insurance policies shall name the Landlord, Landlord&#8217;s property manager, and Landlord&#8217;s mortgagee(s) as additional insureds and such other parties as may be reasonably requested by Landlord as additional insureds.&nbsp;&nbsp;Such certificates of insurance shall provide that no change or cancellation of such insurance coverage shall be undertaken without thirty (30) days&#8217; prior written notice to Landlord; provided, however, in the event such insurer is unable to provide such notice, Tenant shall be obligated to provide such notice to Landlord.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;">Landlord shall have the right to require Tenant, and Tenant shall have the duty, to stop work in the Premises immediately if any of the insurance coverage Tenant or its contractors and subcontractors are required to carry herein lapses during the course of such work, in which event the Tenant Work may not be resumed until the required insurance is obtained and satisfactory evidence of same is provided to Landlord.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D-8</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU113"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)</font><font style="margin-left:36pt;">In the event Tenant employs a contractor or subcontractor to perform all or part of the Tenant Work, Tenant shall carry, or cause Tenant&#8217;s Contractors to carry, General Contractor&#8217;s and Subcontractor&#8217;s Required Minimum Coverages and Limits of Liability as follows (the insurance required under this </font><font style="font-weight:bold;text-decoration:underline;">Exhibit&#160;D</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shall be in addition to any and all insurance required to be procured by Tenant pursuant to the terms of the Lease):</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:23.08%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(A)<font style="margin-left:36pt;">Worker&#8217;s Compensation, as required by state law, and Employer&#8217;s Liability Insurance with a limit of not less than $1,000,000 (or more if required by the law of the State) and any insurance required by any Employee Benefit Act or similar statute applicable where the work is to be performed, as will protect the contractor and subcontractors from any and all liability under the aforementioned act(s) or similar statute.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:23.08%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(B)<font style="margin-left:36pt;">Comprehensive General Liability Insurance (including Contractor&#8217;s Protective Liability) in an amount not less than $2,000,000 per occurrence whether involving personal injury liability (or death resulting therefrom) or property damage liability or a combination thereof (combined single limit coverage) with a minimum aggregate limit of $2,000,000.&nbsp;&nbsp;Such insurance shall insure Tenant&#8217;s general contractor against any and all claims for personal injury, death, and damage to the property of others arising from its operations under its contract, whether such operations are performed by Tenant&#8217;s contractors, subcontractors, or sub-subcontractors, or by anyone directly or indirectly employed by any of them.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:23.08%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(C)<font style="margin-left:36pt;">Comprehensive Automotive Liability Insurance, for the ownership, maintenance, or operation of any automotive equipment, whether owned, leased, or otherwise held, including employer&#8217;s non-ownership and hired car liability endorsements, in an amount not less than $2,000,000 per occurrence and $2,000,000 aggregate, combined single limit bodily injury and property damage liability.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:23.08%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(D)<font style="margin-left:36pt;">Builder&#8217;s risk insurance in such amount as is commensurate with the scope and Total TI Cost of such work.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Minimize Disturbances During Construction</font>.&nbsp;&nbsp;In the performance of the Tenant Work, Tenant shall cause its contractor(s) to use reasonable and diligent efforts not to unreasonably interfere with ongoing operations in the Building and the Property.&nbsp;&nbsp;Without limiting the foregoing, Tenant agrees to cause its contractor to use reasonable and diligent efforts to minimize excess noise, and to limit its construction activities to the portion of the Premises being constructed and those portions of the Common Areas (if any) in which Tenant is permitted to stage materials and perform the Tenant Work in accordance with the Construction Documents.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU114"></a>(c)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Utilities During Construction</font>.&nbsp;&nbsp;Tenant shall be responsible for all utility costs associated with the performance of the Tenant Work and shall either supply its own </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D-9</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">electricity and other utilities, or shall reimburse Landlord for all utility costs associated with such work.&nbsp;&nbsp;Tenant shall keep all construction areas reasonably clean and free of trash and debris, and shall police the activities of its contractors, subcontractors and their respective employees with regard to keeping the Building and the Property clean.&nbsp;&nbsp;Tenant shall also use reasonable and diligent efforts to minimize any disturbance to the other tenants and occupants of the Building and Property in the course of such construction activities. Tenant agrees to follow (or cause its contractors and subcontractors to follow) all reasonable directions given to Tenant or its contractors or subcontractors by Landlord&#8217;s Construction Representative and to otherwise comply with any reasonable rules and regulations established by Landlord from time to time with regard to Tenant&#8217;s construction activities within the Building. Tenant&#8217;s construction contract shall indemnify Tenant and Landlord from damages, losses, and expenses associated with the acts and omissions of Tenant&#8217;s Contractor, its agents, employees, and subcontractors.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Violations with respect to the Tenant Work</font>.&nbsp;&nbsp;In the event (i) of any material violation of this <font style="font-weight:bold;text-decoration:underline;">Exhibit&#160;D</font>, or (ii) the construction of any improvements in the Premises which are not within the scope of the Construction Documents (or other Landlord-approved plans), Landlord shall have the right to cause Tenant and Tenant&#8217;s contractor to stop the Tenant Work and to remove any such improvements which have been constructed in violation of the Construction Documents (or other Landlord-approved plans) or this <font style="font-weight:bold;text-decoration:underline;">Exhibit&#160;D</font> at Tenant&#8217;s expense, and to seek any and all appropriate legal and equitable relief in order to enforce the provisions of this <font style="font-weight:bold;text-decoration:underline;">Exhibit&#160;D</font>.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;">Without limiting the generality or applicability of this </font><font style="font-weight:bold;text-decoration:underline;">Exhibit&#160;D</font> or the Lease, Tenant agrees that the following provisions shall apply to the performance of the Tenant Work:</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;">In performing any plumbing work which is contemplated under the Construction Documents (or other Landlord-approved plans if required by the terms of the Lease) which may require removal of floor slab in corridors or areas which are within the common areas of the Building, Tenant agrees: (A) to conduct such work expeditiously and in a manner which is calculated to minimize, to the fullest extent practicable, any inconvenience to Landlord&#8217;s building personnel, and other Building tenants, occupants and invitees who use such common corridors; (B) upon completion of the plumbing work, to restore the finishes within such common corridors to their original condition; and (C) if materials necessary to match such finishes, upon restoration, to the finish of the portions of the corridor which were not removed or affected by such work or alterations, are not available, Tenant shall be responsible to restore the entire corridor to a uniform finish acceptable to Landlord in Landlord&#8217;s sole but reasonable discretion, consistent with the quality of the existing finish.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU115"></a>(ii)<font style="margin-left:36pt;">In performing any portions of the Tenant Work which involve construction work which affects the exterior portions of the Building, the Property or Common Areas, Tenant agrees that it shall, at Tenant&#8217;s sole expense, restore all areas of the Building&#8217;s or Property&#8217;s exterior and/or Common Areas, including without limitation all adjacent planting areas, sidewalks and parking areas, </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D-10</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">affected by the performance of such work or alterations to their original condition upon the completion of such portions of the Tenant Work.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;">Tenant shall, as part of the Tenant Work, protect and restore all work areas of the Building and Property (including without limitation, any portions of the Common Areas of the Property) required for access to the Premises, or otherwise utilized or affected in performing the Tenant Work, including, but not limited to, the Building roof, common corridor floors, walls, and ceilings, floor penetrations and chase wall penetrations. Tenant shall use only qualified roofing contractors for penetrations and reflashing of affected roof areas (if any), which roofing contractors shall be subject to Landlord&#8217;s approval, and Tenant and such contractor shall warrant to Landlord the integrity of any such roof or exterior penetrations that are performed as part of the Tenant Work, and that the same are free from leakage and are otherwise properly waterproof.&nbsp;&nbsp;Tenant shall further ensure (and warrant to Landlord) that all floor penetrations that are performed as part of the Tenant Work are properly fire-stopped, in accordance with applicable building and fire codes and prudent construction practices.&nbsp;&nbsp;Landlord&#8217;s construction manager and/or representatives shall be advised at the time Tenant commences any portion of the Tenant Work involving the exterior of the Building, the Property, the Building roof, the common corridors, and all floor to floor penetrations, and all such work shall be subject to the inspection and approval of Landlord (and in the case of work involving the exterior of the Building, shall be supervised by Landlord&#8217;s construction manager and/or other representatives).&nbsp;&nbsp;In regard to the foregoing right of inspection and approval, Tenant and its contractor shall, upon reasonable prior notice, permit such construction manager and/or representatives free access to all affected areas of the Premises and Building necessary for Landlord to conduct such inspections and/or supervision</font><font style="font-size:10pt;">.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt; clear:both;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D-11</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU116"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT E</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />Commencement Date Letter</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">___________________, 20__</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">[Name of Contact]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">[Name of Tenant]</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">[Address of Tenant]</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RE:</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">[<font style="font-style:italic;">Name of Tenant]<br />[Premises Rentable Area and Floor]<br />[Address of Building]</font></p></td></tr></table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dear <font style="font-style:italic;">[Name of Contact]:</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reference is made to that certain Lease, dated as of _________________, 20__, between<font style="font-style:italic;"> [Landlord]</font>, as Landlord and<font style="font-style:italic;"> [Tenant]</font> as Tenant, with respect to Premises on the ______floor of the above-referenced building.&nbsp;&nbsp;In accordance with Section&#160;[____] of the Lease, this is to confirm that the Commencement Date of the Term of the Lease occurred on ______________, and that the Term of the Lease shall expire on ________________.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the foregoing is in accordance with your understanding, kindly execute the enclosed duplicate of this letter, and return the same to us.</p>
<p style="margin-bottom:30pt;margin-top:12pt;margin-left:53.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very truly yours,</p>
<p style="margin-bottom:30pt;margin-top:12pt;margin-left:53.85%;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">[Landlord]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:53.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="margin-left:36pt;"></font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:57.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:<font style="margin-left:36pt;"></font><br />Title:<font style="margin-left:36pt;"></font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accepted and Agreed:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">[Tenant]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:<font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:<font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:<font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E-1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU117"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT F</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />Building Operating Expenses and Laboratory Operating Expenses</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Building Operating Expenses shall include the following expenses, without limitation, and reasonably and equitably allocated to the Office Portion of the Building&#8217;s cost pool:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_text_1_925"></a><a name="_cp_text_2_926"></a><a name="_cp_text_1_927"></a><a name="_cp_text_1_925"></a> All  <a name="_cp_text_2_926"></a>expenses incurred by Landlord or Landlord&#8217;s agents which shall be directly related to employment of personnel,<a name="_cp_text_1_927"></a>  including amounts incurred for wages, salaries for services, payroll, social security, unemployment and similar taxes, workmen&#8217;s compensation insurance, disability benefits, pensions, hospitalization, retirement plans and group insurance, uniforms and working clothes and the cleaning thereof, and expenses imposed on Landlord or Landlord&#8217;s agents pursuant to any collective bargaining agreement for the services of employees of Landlord or Landlord&#8217;s agents in connection with the operation, repair, maintenance, cleaning, management and protection of the Property, including, without limitation, day and night supervisors, manager, accountants, bookkeepers, janitors, carpenters, engineers, mechanics, electricians and plumbers and personnel engaged in supervision of any of the persons mentioned above; provided that, if any such employee is also employed on other property of Landlord, such compensation shall be suitably prorated among the Property and such other properties.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_text_2_928"></a><a name="_cp_text_2_928"></a>The cost of services, utilities, materials and supplies furnished or used in the operation, repair, maintenance, cleaning, management and protection of the Property.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The cost of replacements for tools and other similar equipment used in the repair, maintenance, cleaning and protection of the Property, provided that, in the case of any such equipment used jointly on other property of Landlord, such costs shall be suitably prorated among the Property and such other properties.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Where the Property is managed by Landlord or an affiliate of Landlord, management fees at reasonable rates for self managed buildings consistent with the class of building and the services rendered, which management fees shall not exceed three percent (3%) of Gross Receivable Rents for the Building (&#8220;<font style="font-weight:bold;">Gross Receivable Rents for the Building</font>&#8221; for the purposes hereof being defined as annual Basic Rent, Building Operating Expenses, with the exception of the aforesaid management fee, Laboratory Operating Expenses, and Taxes for the Building for the relevant year), whether or not actually paid, or where managed by other than Landlord or an affiliate thereof, the amounts accrued for management, together with, in either case, amounts accrued for legal and other professional fees relating to the Property, but excluding such fees and commissions paid in connection with services rendered for securing or renewing leases and for matters not related to the normal administration and operation of the Property.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_text_1_931"></a><a name="_AEIOULastRenderedPageBreakAEIOU118"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercially reasonable premiums and deductibles incurred for insurance against damage or loss to the Property from such hazards as Landlord shall determine, including, but not by way of limitation, insurance covering loss of rent attributable to any such hazards, and public liability insurance</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_text_1_933"></a><a name="_cp_text_1_934"></a>Replacements to the roof or other structural elements or other capital expenditures or improvements but only to the extent (i) Landlord, during the Term, installs or replaces any equipment or other item in or to the Building which Landlord anticipates in good faith will effect an energy savings or will make the Building or any part thereof more energy efficient or for the purpose of reducing Operating Expenses, or (ii) which are required due to changes in applicable Laws or as a result of new Laws not in effect as of the Effective Date of the Lease (collectively, the &#8220;<font style="font-weight:bold;">Permitted Capital Expenditures</font><a name="_cp_text_1_933"></a>&#8221;), provided, however, that only the annual charge<a name="_cp_text_1_934"></a>&#8209;off of such Permitted Capital Expenditure shall be included in each Operating Year's Operating Expenses (or a prorata amount thereof for any partial Operating Year).&nbsp;&nbsp;Annual charge&#8209;off shall be determined by dividing the original Permitted Capital Expenditure plus an interest factor, reasonably determined by Landlord, as being the interest rate then being charged for long&#8209;term mortgages by institutional lenders on like properties within the locality in which the Property is located, by the number of years of useful life of the Permitted Capital Expenditure; and the useful life shall be determined reasonably by Landlord in accordance with GAAP and practices in effect at the time of making such expenditure.&nbsp;&nbsp;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_text_1_935"></a><a name="_cp_text_1_935"></a>Cost of operation of the Building and the other areas of the Complex as more specifically provided in the Lease, including those incurred in discharging the obligations under Article 7 of the Lease; provided, however, there shall be excluded from the Building Operating Expenses the expenses that solely relate to and benefit only the Retail Portion of the Building or the Laboratory Portion of the Building and/or do not serve or benefit the Office Portion of the Building in any manner. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_text_1_937"></a><a name="_cp_text_1_937"></a>The Building&#8217;s share (as reasonably determined by Landlord) of expenses related to the operation of the open areas, public areas and amenities, plazas, common areas, facilities and other non-leasable areas of the Complex and Complex&#8217;s Percentage Share (as defined in the Declaration) of the CAM Charges for the Boston Landing Project allocated to the Complex under the Declaration, including the Complex&#8217;s share of all costs incurred to operate the shuttle service for the Boston Landing Project and like amenities for use of tenants of the Building either alone or in common with tenants of other buildings in the Complex or the Boston Landing Project (excluding the costs to construct and initially fixture or furnish any such amenities), provided that there shall be no duplication in any such expense charged to Tenant as Operating Expenses hereunder.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_text_1_939"></a><a name="_cp_text_1_941"></a><a name="_AEIOULastRenderedPageBreakAEIOU119"></a><a name="_cp_text_1_943"></a><a name="_cp_text_1_944"></a><a name="_cp_text_1_939"></a>The costs to operate, repair and maintain Base <a name="_cp_text_1_941"></a>Building Systems and Common Facilities in the Building (including, without limitation, utility and other costs to maintain, repair and operate Base Building Systems , if any, serving the Building, </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_943"></a>including, without limitation, the general costs to operate, repair and maintain the Building (including, without limitation, insurance costs for the Building); provided, however, (1) in no event shall Landlord be entitled to pass through greater than one hundred percent (100%) of those costs for the operation, repair and maintenance of </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Base </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_944"></a>Building Systems and </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facilities due to the same being allocated to both the Office Portion, Retail Portion or Laboratory Portion of the Building, and (2) there shall be excluded from the Building Operating Expenses the expenses that solely relate to and benefit only the Retail Portion of the Building or the Laboratory Portion of the Building and do not serve or benefit the Office Portion of the Building in any manner.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Costs for electricity, water and sewer use charges, gas and other utilities supplied to the Property and not paid for directly by tenants.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Taxes (as hereinafter defined).&nbsp;&nbsp;&#8220;<font style="font-weight:bold;">Taxes</font>&#8221; shall mean (i) all ad valorem real property taxes, assessments (including betterment, special or otherwise), levies, fees and all other government levies, exactions and charges of every kind and nature, general and special, ordinary and extraordinary, foreseen and unforeseen, which are, at any time prior to or during the Term, imposed or levied upon or assessed against the Property or any portion thereof or against any Basic Rent, Additional Rent or other rent of any kind or nature payable to Landlord by anyone on account of the ownership, leasing or operation of the Property, or which arise on account of or in respect of the ownership, development, leasing, operation or use of the Property or any portion thereof; (ii) all gross receipts taxes or similar taxes imposed or levied upon, assessed against or measured by any Basic Rent, Additional Rent or other rent of any&nbsp;&nbsp;kind or nature or other sum payable to Landlord by anyone on account of the ownership, development, leasing, operation, or use of the Property or any portion thereof; (iii) all value added, use and similar taxes at any time levied, assessed or payable on account of the ownership, development, leasing, operation, or use of the Property or any portion thereof; (iv) the Building&#8217;s pro rata share of the Taxes allocated to the Complex under the Declaration, and (v) reasonable expenses of any proceeding for abatement of any of the foregoing items included in Taxes, but the amount of special taxes or special assessments included in Taxes shall be limited to the amount of the installment (plus any interest, other than late charges and penalty interest, payable thereon) of such special tax or special assessment required to be paid during the year in respect of which such Taxes are being determined. There shall be excluded from Taxes all income, estate, succession, gift, franchise, inheritance and transfer taxes of Landlord (or any affiliate thereof); provided, however, that if at any time during the Term, the present system of ad valorem taxation of real property shall be changed so that a gross receipts capital levy, franchise, income, profits, sales, rental, use and occupancy, or other new or additional tax or charge shall in whole or in part be substituted for, or added to, such ad valorem tax and levied against, or be payable by, Landlord with respect to the Property or any portion thereof, such tax or charge shall be included in the term &#8220;<font style="font-weight:bold;">Taxes</font>&#8221; for the purposes of this Article.&nbsp;&nbsp;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_AEIOULastRenderedPageBreakAEIOU120"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Betterment assessments, provided the same are apportioned equally over the longest period permitted by law, and to the extent, if any, not included in Taxes.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_text_1_947"></a><a name="_cp_text_1_947"></a>Amounts paid to independent contractors for services, materials and supplies furnished for the operation, repair, maintenance, cleaning and protection of the Property not in excess of market rates for Comparable Buildings.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Except to the extent covered by warranty or an insurance claim, any convector units, filters or heat pump repairs and replacements.</p></td></tr></table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_949"></a><a name="_cp_text_1_949"></a>Laboratory Operating Expenses shall include the following, without limitation and without duplication of any other Operating Expenses or Taxes charged to Tenant under this Lease:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.65%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:6.73%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_text_1_950"></a><a name="_cp_text_2_951"></a><a name="_cp_text_1_952"></a><a name="_cp_text_1_950"></a>All costs of any kind paid or incurred by Landlord in connection with the operation or maintenance of the Laboratory Systems and the provision of services that exclusively serve the Laboratory Portion of the Building, which shall include, without limitation, costs of repairs and replacements to Laboratory Systems; costs of utilities furnished to the Laboratory Systems and any Common Facilities exclusively serving the Laboratory Systems; sewer fees; HVAC; maintenance or replacement of equipment utilized for operation and maintenance of the Laboratory Systems; license, permit and inspection fees; sales, use&nbsp;&nbsp;and excise taxes on goods and services purchased by Landlord in connection with the operation, maintenance or repair of the Laboratory Systems; other expenses incurred in connection with the operation, maintenance or repair of the Laboratory Systems; accounting, legal and other professional fees and expenses incurred in connection with the Laboratory Systems; Permitted Capital Expenditures  <a name="_cp_text_2_951"></a>related to the Laboratory Systems; costs of complying with applicable Laws (except to the extent such costs are incurred to remedy non-compliance as of the Commencement Date with applicable Laws);<a name="_cp_text_1_952"></a>  costs to keep the Laboratory Systems in compliance with, or costs or fees otherwise required under or incurred pursuant to any covenants, conditions or restrictions associated with the Property or Complex, including insurance premiums attributable to Laboratory Systems, and premiums for commercial general liability, property casualty, earthquake, terrorism and environmental coverages; portions of insured losses to Laboratory Systems paid by Landlord as part of the deductible portion of a loss pursuant to the terms of insurance policies; service contracts; costs of services of independent contractors retained to do work of a nature referenced above; and costs of compensation (including employment taxes and fringe benefits) of all persons who perform regular and recurring duties connected with the day-to-day operation and maintenance of Laboratory Systems. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.65%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:6.73%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Any taxes or assessments in lieu thereof imposed separately on any Laboratory Systems or reasonably determined by Landlord to be attributable to any Laboratory Systems and not other portions of the Property or Complex.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.65%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:6.73%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_AEIOULastRenderedPageBreakAEIOU121"></a>Cost of operation of the Building and the other areas of the Complex as more specifically provided in the Lease, including those incurred in discharging the </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.65%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:6.73%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obligations under Article 7 of the Lease; provided, however, there shall be excluded from the Laboratory Operating Expenses the expenses that solely relate to and benefit only the Retail Portion of the Building or the Office Portion of the Building and do not serve or benefit the Laboratory Portion of the Building in any manner.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If Landlord shall receive any tax refund or reimbursement of Taxes or sum in lieu thereof with respect to any Tax Year all or any portion of which falls within the Term, then out of any balance remaining thereof after deducting Landlord&#8217;s expenses in obtaining such refund, Landlord shall, provided there does not then exist an Event of Default, credit an amount equal to such refund or reimbursement or sum in lieu thereof (exclusive of any interest, and apportioned if such refund is for a Tax Year a portion of which falls outside the Term,) multiplied by Tenant&#8217;s Pro Rata Share against the monthly installments of Additional Rent next due under this Lease (or refund such amount to Tenant if the Term has ended and Tenant has no further obligations to Landlord).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding anything to the contrary set forth in the Lease, Building Operating Expenses and Laboratory Operating Expenses shall not include the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Any cost or expense to the extent to which Landlord is paid or reimbursed (other than as a payment for Operating Expenses), including work or services performed for any tenant (including Tenant) or the cost of any item for which Landlord has been paid or reimbursed by insurance, warranties, service contracts, condemnation proceeds or otherwise;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The cost of any work or services performed for any other property other than the Building or Complex;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Leasing commissions, attorneys&#8217; fees, space planning costs, and other costs and expenses incurred in connection with lease, sublease and/or assignment negotiations and transactions with present or prospective tenants or other occupants of the Building;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_text_1_957"></a><a name="_cp_text_1_957"></a>Costs associated with the operation of the business of the entity which constitutes Landlord, Landlord's management company or any affiliate of Landlord as the same are distinguished from the costs of operation of the Building;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Taxes;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vi)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Costs (including permit, license, and inspection fees) incurred in renovating, improving, decorating, painting or redecorating vacant leasable space or space for tenants, the cost of tenant improvements, build out allowances, moving expenses, assumption of rent under existing leases and other concessions incurred in connection with leasing space in the Building or in the Complex;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vii)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_AEIOULastRenderedPageBreakAEIOU122"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization on the Building, except as expressly permitted elsewhere in the Lease;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(viii)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Overhead and profit and other costs paid to subsidiaries or affiliates of Landlord for services or materials on or to the Property or for supplies or other materials (exclusive of the management fee set forth in Item&#160;#4 above), to the extent that the costs of the service, supplies or materials exceed the competitive costs of the services, supplies or materials were they not provided by a subsidiary or affiliate;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ix)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_text_1_958"></a><a name="_cp_text_1_958"></a>Interest on debt or amortization payments on mortgages or deeds of trust or any other debt for borrowed money and any other costs and expenses incurred in connection with the financing and/or refinancing of the Building, Property and/or Complex;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(x)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_text_2_959"></a><a name="_cp_text_1_960"></a><a name="_cp_text_2_961"></a><a name="_cp_text_2_962"></a><a name="_cp_text_2_963"></a><a name="_cp_text_2_959"></a>Items and services which Tenant <a name="_cp_text_1_960"></a>is <a name="_cp_text_2_961"></a>not entitled to <a name="_cp_text_2_962"></a>receive under this Lease but which <a name="_cp_text_2_963"></a>Landlord provides selectively to one or more tenants of the Building other than Tenant or for which Landlord is separately reimbursed;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(xi)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_text_1_964"></a><a name="_cp_text_1_965"></a><a name="_cp_text_1_967"></a><a name="_cp_text_1_964"></a>Costs incurred, in excess of the commercially reasonable deductible, in connection with repairs or other work needed to the Building and/or the Complex <a name="_cp_text_1_965"></a>because of fire, windstorm, or other casualty or cause required to be <a name="_cp_text_1_967"></a>insured against by Landlord under this Lease or the exercise of eminent domain; provided, however, in no event shall any self-insurance retentions be charged to Tenant, other than the aforementioned commercially reasonable deductible; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(xii)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_text_1_969"></a><a name="_cp_text_1_969"></a>Any costs, fines or penalties incurred because Landlord violated any Law;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(xiii)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Capital expenditures other than Permitted Capital Expenditures; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(xiv)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Legal, auditing, consulting and professional fees and other costs, (other than those legal, auditing, consulting and professional fees and other costs incurred in connection with the normal and routine maintenance and operation of the Building), including, without limitation, those: (i) paid or incurred in connection with financings, refinancings or sales of any Landlord's interest in the Building or the Complex, (ii) relating to specific disputes with tenants, and (iii) relating to any special reporting required by securities laws;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(xv)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Costs incurred in performing work or furnishing services for any tenant (including Tenant), whether at such tenant's or Landlord's expense, to the extent that such work or services is in excess of any work or service that Landlord is obligated to furnish to Tenant (e.g., if Landlord agrees to provide extra cleaning to another tenant, the cost thereof would be excluded since Landlord is not obligated to furnish extra cleaning to Tenant);</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(xvi)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The cost of repairs or replacements incurred by reason of fire or other casualty or condemnation other than costs not in excess of a reasonable deductible on any insurance maintained by Landlord;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(xvii)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_AEIOULastRenderedPageBreakAEIOU123"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance premiums to the extent any tenant requires Landlord to purchase additional insurance because of such tenant's use of the Building;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(xviii)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Any advertising, promotional or marketing expenses for the Building, the Complex and the Boston Landing Project including any merchant&#8217;s association except for expenses passed through under the Declaration;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(xix)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The cost of any service or materials (exclusive of the management fee) provided by any party related to Landlord, to the extent such costs exceed the reasonable cost for such service or materials absent such relationship in buildings similar to the Building in the vicinity of the Building;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(xx)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Payments for rented equipment, the cost of which equipment would constitute a capital expenditure if the equipment were purchased to the extent that such payments exceed the amount which could have been included in Operating Expenses had Landlord purchased such equipment rather than leasing such equipment;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(xxi)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Penalties, damages, and interest for late payment or violations of any obligations of Landlord, including, without limitation, taxes, insurance, equipment leases and other past due amounts;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(xxii)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Contributions to charitable organizations;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(xxiii)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Costs incurred in removing the property of former tenants or other occupants of the Building;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(xxiv)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The cost of testing, remediation or removal of Hazardous Materials in the Building, the Complex or the Boston Landing Project required by Environmental Laws;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(xxv)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The cost of acquiring, installing, moving or restoring objects of art;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(xxvi)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Wages, salaries, or other compensation paid to any executive employees above the grade of senior property or regional property manager at the Complex;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(xxvii)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"> The net (i.e. net of the reasonable costs of collection) amount recovered by Landlord under any warranty or service agreement from any contractor or service provider shall be credited against Operating Expenses;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(xxviii)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Cost or expenses due to the willful misconduct or negligence of Landlord or any of the Landlord Parties;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(xxix)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Bad debt expenses; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(xxx)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Ground lease payments, if any (except to the extent payment is for Taxes); </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(xxxi)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_AEIOULastRenderedPageBreakAEIOU124"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs to finance or refinance debt, create and/or file condominium maps or documents or sell the Building or the Complex; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(xxxii)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Costs related to the Rink Building; or </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(xxxiii)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Reserves.</p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU125"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT G</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />Rules and Regulations of Building</font></p>
<p style="margin-top:12pt;margin-bottom:12pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following regulations are generally applicable:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The public sidewalks, entrances, passages, courts, elevators, vestibules, stairways, corridors or halls shall not be obstructed or encumbered by Tenant (except as necessary for deliveries) or used for any purpose other than ingress and egress to and from the Premises.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">No awnings, curtains, blinds, shades, screens or other projections shall be attached to or hung in, or used in connection with, any window of the Premises or any outside wall of the Building.&nbsp;&nbsp;Such awnings, curtains. blinds, shades, screens or other projections must be of a quality, type, design and color, and attached in the manner, approved by Landlord.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">No show cases or other articles shall be put in front of or affixed to any part of the exterior of the Building, nor, if the Building is occupied by more than one tenant, displayed through interior windows into the common areas of the Building, nor placed in the halls, corridors or vestibules.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The water and wash closets and other plumbing fixtures shall not be used for any purposes other than those for which they were designed and constructed, and no sweepings, rubbish, rags, acids or like substances shall be deposited therein.&nbsp;&nbsp;All damages resulting from any misuse of the fixtures shall be borne by the Tenant.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Tenant shall not use the Premises or any part thereof or permit the Premises or any part thereof to be used as a public employment bureau or for the sale of property of any kind at auction.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Tenant must, upon the termination of its tenancy, return to the Landlord all locks, cylinders and keys to offices and toilet rooms of the Premises.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Landlord reserves the right to exclude from the Building after business hours and at all hours on days other than Business Days all persons connected with or calling upon the Tenant who do not present a pass to the Building signed by the Tenant or who are not escorted in the Building by an employee of Tenant.&nbsp;&nbsp;Tenant shall be responsible for all persons for whom it issues any such pass and shall be liable to the Landlord for all wrongful acts of such persons. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The requirements of Tenant will be attended to only upon application at the Building Management Office.&nbsp;&nbsp;Employees of Landlord shall not perform any work or do anything outside of their regular duties, unless under special instructions from the office of the Landlord.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">G-1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_AEIOULastRenderedPageBreakAEIOU126"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There shall not be used in any space in the Building, or in the public halls of the Building, either by Tenant or its agent, contractors, employees or others, in the delivery or receipt of merchandise, any hand trucks, except those equipped with rubber tires and side guards.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_text_1_1001"></a><a name="_cp_text_1_1001"></a>No bicycles, vehicles or animals (except service animals) of any kind shall be brought into or kept in or about the Premises.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">No tenant shall make, or permit to be made, any unseemly or disturbing noises or disturb or interfere with occupants of this or any neighboring building or premises or those having business with them whether by use of any musical instrument, radio, talking machine, unmusical noise, whistling, singing, or in any other way.&nbsp;&nbsp;No tenant shall throw anything out of the doors, windows or skylights or down the passageways.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The Premises shall not be used for lodging or sleeping or for any immoral or illegal purpose.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">No smoking shall be permitted in the Premises or the Building.&nbsp;&nbsp;Smoking shall only be permitted in smoking areas outside of the Building which have been designated by the Landlord.&nbsp;&nbsp;Tenant shall comply with all applicable &#8220;No Smoking&#8221; and if Tenant is required by Law to adopt a written smoking policy, a copy of said policy shall be on file in the property manager&#8217;s office in the Building.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_blt_2_1003"></a><a name="_cp_text_2_1004"></a>Landlord shall have the right, exercisable without notice and without liability to any tenant, to change the name and street address of the Building.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_blt_1_1006"></a><a name="_cp_blt_2_1005"></a>Tenant shall not use the name of the Building for any purpose other than Tenant&#8217;s business address; Tenant shall not use the name of the Building for Tenant&#8217;s business address after Tenant vacates the Premises; nor shall Tenant use any picture or likeness of the Building in any circulars, notices, advertisements or correspondence.&nbsp;&nbsp;Tenant shall not represent itself as being associated with any company or corporation by which the Building may be known.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_blt_2_1007"></a><a name="_cp_text_2_1008"></a>No article which is explosive or dangerous is allowed in the Building.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_blt_1_1010"></a><a name="_cp_blt_2_1009"></a>Room&#8209;to&#8209;room canvassing to solicit business from other tenants of the Building is not permitted.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_blt_2_1011"></a><a name="_cp_text_2_1012"></a>Tenant shall not waste electricity, water or air-conditioning and shall cooperate fully with Landlord to assure the most effective and efficient operation of the Building&#8217;s heating and air-conditioning systems.&nbsp;&nbsp;Tenant shall participate in any recycling programs undertaken by Landlord or required by applicable Laws.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">G-2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_blt_2_1013"></a><a name="_AEIOULastRenderedPageBreakAEIOU127"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No locks or similar devices shall be attached to any door except by Landlord and Landlord shall have the right to retain a key to all such locks.&nbsp;&nbsp;Tenant may not install any locks without Landlord&#8217;s prior approval, which approval shall not be unreasonably withheld.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_blt_1_1015"></a><a name="_cp_blt_2_1014"></a>To the extent permitted by law, Tenant shall not cause or permit picketing or other activity which would interfere with the business of Landlord or any other tenant or occupant of the Building, or distribution of written materials involving its employees in or about the Building, except in those locations and subject to time and other limitations as to which Landlord may give prior written consent.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_blt_1_1018"></a><a name="_cp_blt_2_1017"></a>Tenant shall not cook, otherwise prepare or sell any food or beverages in or from the Premises or use the Premises for housing accommodations or lodging or sleeping purposes except that Underwriters&#8217; Laboratory&#8209;approved equipment and microwave ovens may be used in the Premises for heating food and brewing coffee, tea and similar beverages for Tenant&#8217;s employees and visitors provided such use is in compliance with applicable Laws and does not disturb other tenants in the Building with odor, refuse or pests.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_blt_1_1020"></a><a name="_cp_blt_2_1019"></a>All office equipment of any electrical or mechanical nature shall be placed by Tenant in the Premises in settings approved by Landlord to absorb or prevent any vibration, noise or annoyance.&nbsp;&nbsp;Tenant shall not permit the use of any apparatus for sound production or transmission in such manner that the sound so transmitted or produced shall be audible or vibrations therefrom shall be detectable beyond the Premises; nor permit objectionable odors or vapors to emanate from the Premises.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_blt_1_1023"></a><a name="_cp_blt_2_1022"></a>Tenant shall not construct or place partitions, furniture or other obstructions that interfere with Landlord&#8217;s free access to mechanical installations located in the Building, including air-cooling, fan, ventilating and machine rooms and mechanical and electrical closets, the proper functioning of the Base Building Systems or the moving of Landlord&#8217;s equipment to and from the enclosures containing said installations.&nbsp;&nbsp;Neither Tenant nor any contractor, invitee or licensee of Tenant shall at any time enter said enclosures or tamper with, adjust, or otherwise affect in any manner such mechanical installations</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_blt_1_1026"></a><a name="_cp_blt_2_1025"></a><a name="_cp_text_1_1024"></a><a name="_cp_text_1_1024"></a>No floor covering shall be affixed to any floor in the Premises by means of glue or other adhesive without Landlord&#8217;s prior written consent not to be unreasonably withheld, conditioned or delayed.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_blt_1_1028"></a><a name="_cp_blt_2_1027"></a>Tenant shall comply with all safety, fire protection and evacuation procedures and regulations established by Landlord or any governmental agency.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">G-3</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_blt_1_1030"></a><a name="_cp_blt_2_1029"></a><a name="_AEIOULastRenderedPageBreakAEIOU128"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant shall cause all freight to be delivered to or removed from the Building and the Premises in accordance with the requirements established by Landlord therefor.&nbsp;&nbsp;Deliveries shall be made during Building Service Hours and are subject to local municipal noise ordinances.&nbsp;&nbsp; No deliveries shall be made that impede or interfere with other tenants in or the operation of the Property or Complex.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_blt_1_1032"></a><a name="_cp_blt_2_1031"></a>Tenant shall comply with all orders, requirements and conditions now or hereafter imposed by applicable Laws or Landlord (&#8220;<font style="font-weight:bold;">Waste Regulations</font>&#8221;) regarding the collection, sorting, separation and recycling of waste products, garbage, refuse and trash generated by Tenant (collectively, &#8220;<font style="font-weight:bold;">Waste Products</font>&#8221;), including (without limitation) the separation of Waste Products into receptacles reasonably approved by Landlord and the removal of such receptacles in accordance with any collection schedules prescribed by Waste Regulations.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_blt_1_1035"></a><a name="_cp_blt_2_1034"></a><a name="_cp_text_1_1033"></a><a name="_cp_text_1_1033"></a>Tenant shall store all of its trash, garbage and Hazardous Materials in receptacles within its Premises or in receptacles designated by Landlord outside of the Premises, including a dumpster at the loading dock for the disposal of trash and garbage other than Hazardous Materials, which dumpster shall be supplied by Landlord  subject to Force Majeure (the &#8220;<font style="font-weight:bold;">Dumpster</font>&#8221;).&nbsp;&nbsp;Tenant shall not place in any such receptacle any material that cannot be disposed of in the ordinary and customary manner of trash or garbage disposal.&nbsp;&nbsp;Any Hazardous Materials transported through outside of the Premises shall be held in secondary containment devices.&nbsp;&nbsp;With the exception of items placed in the Dumpster, Tenant shall be responsible, at its sole cost and expense, for Tenant&#8217;s removal of its trash, garbage and Hazardous Materials.&nbsp;&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_blt_1_1037"></a><a name="_cp_blt_2_1036"></a>The rules and regulations set forth in Attachment I to this Exhibit, which is by this reference made a part hereof, are applicable to any Alterations being undertaken by or for Tenant in the Premises pursuant to <font style="font-weight:bold;">Section 5.3</font> of the Lease.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU129"></a><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">G-4</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attachment I to Exhibit G</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></font><font style="text-decoration:underline;">Rules and Regulations for Tenant Alterations</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">General</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">All Alterations made by Tenant in, to or about the Premises shall be made in accordance with the requirements of this Exhibit and by union contractors or mechanics approved by Landlord.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Tenant shall, prior to the commencement of any work, submit for Landlord&#8217;s written approval, complete plans for the Alterations, with full details and specifications for all of the Alterations, in compliance with Section D below.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Alterations must comply with the Building Code applicable to the Property and the requirements, rules and regulations and any other governmental agencies having jurisdiction.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">No work shall be permitted to commence before Tenant obtains and furnishes to Landlord copies of all necessary licenses and permits from all governmental authorities having jurisdiction.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">All demolition, removals or other categories of work that may inconvenience other tenants or disturb Building operations, must be scheduled and performed before 7:00 a.m. or after 6:00 p.m. and Tenant shall provide the Building manager with at least 48 hours&#8217; notice prior to proceeding with such work.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">All inquiries, submissions, approvals and all other matters shall be <br />processed through Landlord&#8217;s property manager.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">All work, if performed by a contractor or subcontractor, shall be subject to reasonable supervision and inspection by Landlord&#8217;s representative.&nbsp;&nbsp;Such supervision and inspection shall be at Tenant&#8217;s sole expense and Tenant shall pay Landlord&#8217;s reasonable charges for such supervision and inspection as Additional Rent within thirty (30) days after receiving Landlord&#8217;s invoice therefor.&nbsp;&nbsp;</p></td></tr></table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Prior to Commencement of Work</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Tenant shall submit to the property manager a request to perform the work.&nbsp;&nbsp;The request shall include the following enclosures:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_text_2_1040"></a><a name="_cp_text_1_1041"></a><a name="_cp_text_1_1042"></a><a name="_cp_text_2_1040"></a>A list of Tenant&#8217;s <a name="_cp_text_1_1041"></a>contractors and/or subcontractors <a name="_cp_text_1_1042"></a>for Landlord&#8217;s approval, which approval shall not be unreasonably withheld conditioned or delayed.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Four complete sets of plans and specifications properly stamped by a registered architect or professional engineer and meeting the requirements in Section D below.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">A properly executed building permit application form.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">G-5</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_AEIOULastRenderedPageBreakAEIOU130"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Four executed copies of the Insurance Requirements Agreement in the form attached to this Exhibit as Attachment II and made a part hereof from Tenant&#8217;s contractor and, if requested by Landlord, from the contractor&#8217;s subcontractors.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Contractor&#8217;s and subcontractor&#8217;s insurance certificates, including an indemnity in accordance with the Insurance Requirements Agreement.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Landlord will return the following to Tenant:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Two sets of plans approved or a disapproved with specific comments as to the reasons therefor (such approval or comments shall not constitute a waiver of approval of governmental authorities).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Two fully executed copies of the Insurance Requirements Agreement.</p></td></tr></table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;">Landlord&#8217;s approval of the plans, drawings, specifications or other submissions in respect of any Alterations shall create no liability or responsibility on the part of Landlord for their completeness, design sufficiency or compliance with requirements of any applicable laws, rules or regulations of any governmental or quasi</font>&#8209;governmental agency, board or authority.&nbsp;&nbsp;Any plan or design approval rights reserved to or exercised by Landlord hereunder are for the sole and exclusive benefit of Landlord to ensure compatibility of such work with Building systems and Building standards, and such approval does not constitute any representation or warranty whatsoever as to the adequacy, correctness, efficiency or compliance with applicable Law of such plan or design or the work shown thereon and Landlord is expressly not reviewing Tenant&#8217;s plans for such purposes.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Tenant shall obtain a building permit from the Building Department and necessary permits from other governmental agencies.&nbsp;&nbsp;Tenant shall be responsible for keeping current all permits.&nbsp;&nbsp;Tenant shall submit copies of all approved plans and permits to Landlord and shall post the original permit on the Premises prior to the commencement of any work.&nbsp;&nbsp;</p></td></tr></table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Requirements and Procedures</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">All structural and floor loading requirements shall be subject to the prior approval of Landlord&#8217;s structural engineer, such approval to be granted or withheld in accordance with <font style="font-weight:bold;">Section 5.3</font> of the Lease.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_cp_text_1_1045"></a><a name="_cp_text_1_1045"></a>All mechanical (HVAC, plumbing and sprinkler) and electrical requirements shall be subject to the approval of Landlord&#8217;s mechanical and electrical engineers, such approval to be granted or withheld in accordance with <font style="font-weight:bold;">Section 5.3</font> of the Lease, and all mechanical and electrical work shall be performed by contractors who are engaged by Landlord in constructing, operating or maintaining the Building.&nbsp;&nbsp;When necessary, Landlord will require engineering and shop drawings, which drawings must be approved by Landlord before work is started, such approval to be granted or withheld in accordance with <font style="font-weight:bold;">Section 5.3</font> of the Lease.&nbsp;&nbsp;Drawings are to be prepared by Tenant and all approvals shall be obtained by Tenant.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">G-6</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_AEIOULastRenderedPageBreakAEIOU131"></a><a name="_cp_text_1_1047"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1047"></a>Elevator service for construction work shall be charged to Tenant at standard Building rates which will include the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reasonable </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cost of operators and supervisory staff.&nbsp;&nbsp;Prior arrangements for elevator use shall be made at least 48 hours in advance with Building manager by Tenant.&nbsp;&nbsp;No material or equipment shall be carried under or on top of elevators.&nbsp;&nbsp;If an operating engineer or master mechanic is required by any union regulations, such engineer or master mechanic shall be paid for by Tenant.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">If shutdown of risers and mains for electrical, HVAC, sprinkler and plumbing work is required, such work shall be supervised by Landlord&#8217;s representative and shall be performed only at times approved by Landlord.&nbsp;&nbsp;No work will be performed in Building mechanical equipment rooms without Landlord&#8217;s approval and under Landlord&#8217;s supervision.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Tenant&#8217;s contractor shall:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">have a superintendent or foreman on the Premises at all times;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">police the job at all times, continually keeping the Premises orderly;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">maintain cleanliness and protection of all areas, including elevators and lobbies.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">protect the front and top of all peripheral HVAC units and thoroughly clean them at the completion of work;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">block off supply and return grills, diffusers and ducts to keep dust from entering into the Building air conditioning system; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vi)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">avoid disturbance of other tenants.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">If Tenant&#8217;s contractor is negligent in any of its responsibilities, Tenant shall be charged for corrective work.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">All equipment and installations must be equal to the standards generally in effect with respect to the remainder of the Building.&nbsp;&nbsp;Any deviation from such standards will be permitted only if indicated or specified on the plans and specifications and approved by Landlord, such approval to be granted or withheld in accordance with <font style="font-weight:bold;">Section 5.3</font> of the Lease.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">A properly executed air balancing report signed by a professional engineer shall be submitted to Landlord upon the completion of all HVAC work.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Upon completion of the Alterations, Tenant shall submit to Landlord a permanent certificate of occupancy and final approval by the other governmental agencies having jurisdiction.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Tenant shall submit to Landlord a final &#8220;as&#8209;built&#8221; set of drawings in Auto&#8209;CAD format and one set of blueprints showing all items of the Alterations in full detail.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">G-7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_AEIOULastRenderedPageBreakAEIOU132"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional and differing provisions in the Lease, if any, will be applicable and will take precedence.</font></p></td></tr></table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Standards for Plans and Specifications</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Whenever Tenant shall be required by the terms of the Lease (including this Exhibit) to submit plans to Landlord in connection with any Alterations, such plans shall include at least the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Floor plan indicating location of partitions and doors (details required of partition and door types).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Location of standard electrical convenience outlets and telephone outlets.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Location and details of special electrical outlets; e.g., photocopiers, etc.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Reflected ceiling plan showing layout of standard ceiling and lighting fixtures. Partitions to be shown lightly with switches located indicating fixtures to be controlled.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Locations and details of special ceiling conditions, lighting fixtures, speakers, etc.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Location and specifications of floor covering, paint or paneling with paint colors referenced to standard color system.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Finish schedule plan indicating wall covering, paint, or paneling with paint colors referenced to standard color system.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Details and specifications of special millwork, glass partitions, rolling doors and grilles, blackboards, shelves, etc.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Hardware schedule indicating door number keyed to plan, size, hardware required including butts, latchsets or locksets, closures, stops, and any special items such as thresholds, soundproofing, etc. Keying schedule is required.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Verified dimensions of all built&#8209;in equipment (file cabinets, lockers, plan files, etc.)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Location and weights of storage files.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Location of any special soundproofing requirements.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Location and details of special floor areas exceeding 50 pounds of live load per square foot.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">All structural, mechanical, plumbing and electrical drawings, to be prepared by the base building consulting engineers, necessary to complete the Premises in accordance with Tenant&#8217;s Plans.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">G-8</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_AEIOULastRenderedPageBreakAEIOU133"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All drawings to be uniform size (30&#8221; x 46&#8221;) and shall incorporate the standard project electrical and plumbing symbols and be at a scale of 1/8&#8221; = 1&#8217; or larger.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.<font style="margin-left:0pt;">All drawings shall be submitted in hard</font>&#8209;copy paper form (together with a PDF scanned copy of all paper drawings) and on disk in Auto&#8209;CAD Version 2000.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">All drawings shall be stamped by an architect (or, where applicable, an engineer) licensed in the jurisdiction in which the Property is located and without limiting the foregoing, shall be sufficient in all respects for submission to applicable authorization in connection with a building permit application.</p></td></tr></table></div>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU134"></a><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">G-9</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attachment II to Exhibit G</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></font><font style="text-decoration:underline;">Contractor&#8217;s Insurance Requirements</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Building:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Premises:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The undersigned contractor or subcontractor (&#8220;<font style="font-weight:bold;">Contractor</font>&#8221;) has been hired by the tenant named above (hereinafter called &#8220;<font style="font-weight:bold;">Tenant</font>&#8221;) of the Building named above (or by Tenant&#8217;s contractor) to perform certain work (&#8220;<font style="font-weight:bold;">Work</font>&#8221;) for Tenant in the Premises identified above.&nbsp;&nbsp;Contractor and Tenant have requested the landlord named above (&#8220;<font style="font-weight:bold;">Landlord</font>&#8221;) to grant Contractor access to the Building and its facilities in connection with the performance of the Work, and Landlord agrees to grant such access to Contractor upon and subject to the following terms and conditions:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Contractor agrees to indemnify and save harmless Landlord and its respective officers, employees and agents and their affiliates, subsidiaries and partners, and each of them, from and with respect to any claims, demands, suits, liabilities, losses and expenses, including reasonable attorneys&#8217; fees, arising out of or in connection with the Work (and/or imposed by law upon any or all of them) because of personal injuries, bodily injury (including death at any time resulting therefrom) and loss of or damage to property, including consequential damages, whether such injuries to person or property are claimed to be due to negligence of the Contractor, Tenant, Landlord or any other party entitled to be indemnified as aforesaid except to the extent specifically prohibited by law (and any such prohibition shall not void this Agreement but shall be applied only to the minimum extent required by law).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Contractor shall provide and maintain at its own expense, until completion of the Work, the following insurance:</p></td></tr></table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;">&#8220;Builder&#8217;s All Risk&#8221; insurance in an amount at least equal to 100% of the replacement value of such Alterations.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;">Workmen&#8217;s Compensation and Employers Liability Insurance covering each and every workman employed in, about or upon the Work, as provided for in and in the amounts required by each and every statute applicable to Workmen&#8217;s Compensation and Employers&#8217; Liability Insurance.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;">Commercial General Liability Insurance including coverages for Protective and Contractual Liability (to specifically include coverage for the indemnification clause of this Agreement) for not less than the following limits:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Personal Injury:<font style="margin-left:36pt;">$5,000,000 per person</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:46.15%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$10,000,000 per occurrence</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property Damage:<font style="margin-left:36pt;">$3,000,000 per occurrence</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">G-10</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:30.77%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU135"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3,000,000 general aggregate </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;">Commercial Automobile Liability Insurance (covering all owned, non</font>&#8209;owned and/or hired motor vehicles to be used in connection with the Work) for not less than the following limits:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:30.77%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bodily Injury:</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">$3,000,000 per person</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:46.15%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5,000,000 per occurrence</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:30.77%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property Damage:</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">$1,000,000 per occurrence</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:46.15%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3,000,000 general aggregate</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;margin-right:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractor shall furnish a certificate from its insurance carrier or carriers to the Building office before commencing the Work, showing that it has complied with the above requirements regarding insurance and providing that the insurer will give Landlord ten (10) days&#8217; prior written notice of the cancellation of any of the foregoing policies.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Contractor shall require all of its subcontractors engaged in the Work to provide the following insurance:</p></td></tr></table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;">Workmen&#8217;s Compensation and Employers Liability Insurance covering each and every workman employed in, about or upon the Work, as provided for in and in the amounts required by each and every statute applicable to Workmen&#8217;s Compensation and Employers&#8217; Liability Insurance.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;">Commercial General Liability Insurance including Protective and Contractual Liability coverages with limits of liability at least equal to the limits stated in paragraph 2(c).</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;">Commercial Automobile Liability Insurance (covering all owned, non</font>&#8209;owned and/or hired motor vehicles to be used in connection with the Work) with limits of liability at least equal to the limits stated in paragraph 2(d).</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the request of Landlord, Contractor shall require all of its subcontractors engaged in the Work to execute an Insurance Requirements agreement in the same form as this Agreement.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreed to and executed this day of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 20&nbsp;&nbsp;.</p>
<p style="margin-bottom:30pt;margin-top:12pt;margin-left:53.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractor:</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:53.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="margin-left:36pt;"></font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:53.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="margin-left:36pt;"></font></p>
<p style="text-align:center;margin-top:12pt; clear:both;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">G-11</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU136"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT H</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Letter of Credit</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IRREVOCABLE TRANSFERABLE STANDBY LETTER OF CREDIT NUMBER</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISSUING BANK:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">______________________________</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PLACE AND DATE OF ISSUE:<font style="margin-left:36pt;">PLACE AND DATE OF EXPIRY:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">_________________<font style="margin-left:36pt;">AT OUR COUNTERS</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BENEFICIARY:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">______________________</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">______________________</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ATTN:&nbsp;&nbsp;_______________</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">APPLICANT:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">______________________</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">______________________</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UP TO AN AGGREGATE AMOUNT THEREOF:&nbsp;&nbsp;USD</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PARTIAL DRAWINGS:&nbsp;&nbsp;PERMITTED</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CREDIT AVAILABLE WITH:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">______________________</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">______________________</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ATTN:&nbsp;&nbsp;_______________</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AGAINST PRESENTATION OF DOCUMENTS AS DETAILED HEREIN</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DRAFTS:&nbsp;&nbsp;AT SIGHT</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DRAWN ON:&nbsp;&nbsp;__________________________</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WE HEREBY ESTABLISH OUR IRREVOCABLE STANDBY LETTER OF CREDIT NO. ______ IN YOUR FAVOR FOR THE ACCOUNT OF _______________ AVAILABLE FOR DRAWINGS FOR UP TO AN AGGREGATE AMOUNT OF USD</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIS LETTER OF CREDIT IS AVAILABLE BY PAYMENT UPON YOUR (OR YOUR TRANSFEREE&#8217;S) DRAFT(S) IN THE FORM OF ANNEX&#160;A HERETO, DRAWN AT SIGHT ON US AND PURPORTEDLY SIGNED BY AN AUTHORIZED REPRESENTATIVE OF YOU (OR YOUR TRANSFEREE).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS PRESENTED UNDER THIS LETTER OF CREDIT MAY BE SUBMITTED EITHER IN PERSON, BY RECOGNIZED OVERNIGHT DELIVERY SERVICE, OR UNITED STATES POSTAL SERVICE TO ___________________________________________ (UNLESS SENT BY FACSIMILE AS DESCRIBED BELOW)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">H-1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU137"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DRAFTS PRESENTED WITH OUR ____________ OFFICE, AS LISTED HEREABOVE, SHALL BE PAYABLE IN IMMEDIATELY AVAILABLE FUNDS, WITH PAYMENT TO TAKE PLACE PRIOR TO THE END OF THE NEXT BANKING DAY IN MASSACHUSETTS FOLLOWING THE SUBMISSION DATE.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PRESENTATION WILL ALSO BE DEEMED MADE UPON OR RECEIPT OF YOUR TELECOPIER TRANSMISSION TO US AT FAC NO. (XXX) XXX-XXXX OF A FACSIMILE OF THE APPROPRIATE SIGHT DRAFT AND DRAWINGS CERTIFICATE PROPERLY COMPLETED AND SIGNED, TOGETHER WITH:&nbsp;&nbsp;(I) YOUR STATEMENT THAT YOU HAVE SENT TO US BY NATIONALLY RECOGNIZED OVERNIGHT COURIER (FREIGHT PREPAID), FOR RECEIPT TO OUR OFFICE LOCATED AT ____________________________ ON THE FOLLOWING BUSINESS DAY, THE SIGNED ORIGINALS OF SUCH DOCUMENTS AND (II) YOUR TELEPHONE ADVICE TO US AT (XXX) XXX-XXXX (OR SUCH OTHER NUMBER AS WE SHALL SPECIFY TO YOU IN WRITING) OF YOUR SENDING OF THE ABOVE&#8209;DESCRIBED TELECOPIER TRANSMISSION.&nbsp;&nbsp;IN THE EVENT OF ANY DISCREPANCY ON SUCH ORIGINALS, THE DOCUMENTS SENT BY TELECOPIER TRANSMISSION UPON WHICH PAYMENT WAS MADE, SHALL BE CONSIDERED AS VALID.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DRAFTS SO PRESENTED VIA TELECOPIER TRANSMISSION (&#8220;FAX&#8221;) SHALL BE PAYABLE IN IMMEDIATELY AVAILABLE FUNDS ON THE SAME BUSINESS DAY OF SUCH SUBMISSION PROVIDED THAT SUCH SUBMISSION IS MADE PRIOR TO 12:00 NOON ON ANY BUSINESS DAY, AND IF SUCH SUBMISSION IS MADE BETWEEN NOON AND 5:00 P.M. ON ANY BUSINESS DAY PAYMENT SHALL BE NO LATER THAN THE NEXT BUSINESS DAY FOLLOWING SUCH SUBMISSION.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIS LETTER OF CREDIT EXPIRES AT OUR CLOSE OF BUSINESS ON THE EXPIRATION DATE AS STATED ABOVE, OR ANY AUTOMATICALLY EXTENDED EXPIRATION DATE AS HEREINAFTER SET FORTH.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DRAFTS MUST BE ACCOMPANIED BY:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THE ORIGINAL OF THIS LETTER OF CREDIT AND AMENDMENTS THERETO, IF ANY.&nbsp;&nbsp;IN THE EVENT OF A PARTIAL DRAWING WE WILL ENDORSE THE AMOUNT ON THE CREDIT AND RETURN THE ORIGINAL TO YOU VIA OVERNIGHT COURIER SERVICE.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A STATEMENT (SUCH STATEMENT, THE &#8220;DRAWING CERTIFICATE&#8221;) PURPORTEDLY SIGNED BY AN AUTHORIZED REPRESENTATIVE OF YOU (OR YOUR TRANSFEREE), IN THE FORM OF ANNEX&#160;B&#8209;1 OR B&#8209;2 HERETO, AS APPROPRIATE.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MULTIPLE AND PARTIAL DRAWS ARE PERMITTED.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU138"></a>THIS LETTER OF CREDIT SHALL INITIALLY EXPIRE ON ___________________, BUT SUCH EXPIRATION DATE SHALL BE AUTOMATICALLY EXTENDED FOR SUCCESSIVE PERIODS OF ONE (1) YEAR ON THE PRESENT EXPIRATION DATE AND EACH SUCCESSIVE EXPIRATION DATE UNLESS AT LEAST NINETY (90) DAYS BEFORE THE THEN CURRENT EXPIRATION DATE WE NOTIFY YOU (OR YOUR TRANSFEREE) IN WRITING BY OVERNIGHT COURIER (NATIONALLY RECOGNIZED AND PROVIDING EVIDENCE OF DELIVERY) OR CERTIFIED/REGISTERED MAIL, RETURN RECEIPT REQUESTED THAT THIS LETTER OF CREDIT WILL NOT BE EXTENDED BEYOND THE THEN CURRENT EXPIRATION DATE.&nbsp;&nbsp;IN THE EVENT YOU (OR YOUR TRANSFEREE) ARE SO NOTIFIED, ANY UNUSED PORTION OF THE LETTER OF CREDIT SHALL BE AVAILABLE UPON PRESENTATION, PRIOR </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">H-2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TO THE THEN CURRENT EXPIRATION DATE, OF A SIGHT DRAFT AND A DRAWING CERTIFICATE, IN THE FORM OF ANNEX&#160;B</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;2 HERETO, PURPORTEDLY SIGNED BY AN AUTHORIZED REPRESENTATIVE OF YOU (OR YOUR TRANSFEREE).</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WE HEREBY ENGAGE WITH YOU TO HONOR DRAFTS DRAWN UNDER AND IN COMPLIANCE WITH THE TERMS OF THIS IRREVOCABLE STANDBY LETTER OF CREDIT UPON PRESENTATION TO US AS LISTED ABOVE.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXCEPT AS EXPRESSLY STATED HEREIN, THIS UNDERTAKING IS NOT SUBJECT TO CONDITION OR QUALIFICATION.&nbsp;&nbsp;OUR OBLIGATION UNDER THIS LETTER OF CREDIT IS OUR INDIVIDUAL OBLIGATION, AND IS IN NO WAY CONTINGENT UPON REIMBURSEMENT WITH RESPECT THERETO.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIS LETTER OF CREDIT SETS FORTH ALL OF THE TERMS AND CONDITIONS OF OUR OBLIGATION TO YOU AND SHALL NOT BE AMENDED OR MODIFIED EXCEPT BY WRITTEN INSTRUMENT DULY EXECUTED BY YOU AND US.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIS LETTER OF CREDIT MAY BE TRANSFERRED, ONE OR MORE TIMES, IN ITS ENTIRETY BUT NOT IN PART, BY YOU OR ANY TRANSFEREE OF THIS LETTER OF CREDIT (A &#8220;TRANSFEREE&#8221;) AND ANY TRANSFEREE SHALL SUCCEED TO ALL OF THE RIGHTS HEREUNDER OF SUCH TRANSFEREE&#8217;S TRANSFEROR; PROVIDED, HOWEVER, THAT NO TRANSFER SHALL BE EFFECTIVE UNLESS (A) THE TRANSFEROR SHALL FIRST HAVE SUBMITTED TO US AN INSTRUCTION IN THE FORM OF THE SPECIMEN ATTACHED HERETO AS ANNEX&#160;C (THE &#8220;TRANSFER INSTRUCTIONS&#8221;) AND (B) NOTICE OF SUCH TRANSFER HAS BEEN ENDORSED HEREON BY US.&nbsp;&nbsp;UPON SUBMISSION TO US OF THE TRANSFER INSTRUCTIONS, WE WILL ENDORSE A NOTICE OF TRANSFER ON THIS LETTER OF CREDIT.&nbsp;&nbsp;THE LAST TRANSFEREE HEREOF, FROM TIME TO TIME, SHALL BE THE &#8220;TRANSFEREE&#8221; REFERENCED IN THE TEXT OF OTHER PARAGRAPHS OF THIS LETTER OF CREDIT.&nbsp;&nbsp;OUR TRANSFER FEE IN EFFECT WILL BE PAID BY THE APPLICANT, BUT SUCH PAYMENT SHALL NOT BE A CONDITION TO TRANSFER.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXCEPT AS OTHERWISE EXPRESSLY STATED HEREIN THIS LETTER OF CREDIT IS SUBJECT TO THE INTERNATIONAL STANDBY PRACTICES (ISP98) INTERNATIONAL CHAMBER OF COMMERCE PUBLICATION NO.&#160;590 AND, TO THE EXTENT NOT INCONSISTENT THEREWITH, THE LAW OF THE STATE OF MASSACHUSETTS, INCLUDING THE MASSACHUSETTS UNIFORM COMMERCIAL CODE.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PLEASE ADDRESS ANY INQUIRIES OR CORRESPONDENCE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ATTN:&nbsp;&nbsp;_______________., QUOTING OUR REF. NO.:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ATTN:&nbsp;&nbsp;________________ TEL.: (XXX) XXX-XXXX&nbsp;&nbsp;SWIFT: XXXXX</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;"></font><font style="text-decoration:underline;margin-left:252pt;"></font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;margin-left:36pt;"></font>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">AUTHORIZED SIGNATURE<font style="margin-left:252pt;"></font><font style="margin-left:36pt;">AUTHORIZED SIGNATURE</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">H-3</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU139"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ANNEX A TO</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LETTER OF CREDIT NO. _________</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SIGHT DRAFT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">___________________</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;"></font><font style="text-decoration:underline;margin-left:36pt;"></font>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(DATE)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pay to ___________________, U.S. _____________________ Dollars</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(U.S. $________________) drawn under ___________________ Irrevocable Letter Of Credit</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No. __________________, by wiring such amount to:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;"></font><font style="text-decoration:underline;margin-left:36pt;"></font>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;"></font><font style="text-decoration:underline;margin-left:36pt;"></font>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;"></font><font style="text-decoration:underline;margin-left:36pt;"></font>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;"></font><font style="text-decoration:underline;margin-left:36pt;"></font>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TO:<font style="margin-left:36pt;">____________________</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">____________________</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:3.85%;">Name:<font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:3.85%;">Title:<font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU140"></a><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">H-4</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;">Annex B-1</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">DRAWING CERTIFICATE</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">_______________________<font style="margin-left:36pt;"></font><font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ISSUER)<font style="margin-left:36pt;">(DATE)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RE:&nbsp;&nbsp;Irrevocable Standby Letter of Credit No. ______ (the &#8220;Letter of Credit&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ladies &amp; Gentlemen:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This drawing under the Letter of Credit is being made pursuant to that certain Agreement of Lease dated _______________, now between ___________________ (&#8220;Landlord&#8221;) and GOODWIN PROCTER LLP (&#8220;Tenant&#8221;), as the same may have been amended or otherwise modified (the &#8220;Lease&#8221;).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The undersigned certifies to ________________ (&#8220;Issuer&#8221;) the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">1.<font style="margin-left:36pt;">Tenant is in default under the Lease and such default has continued beyond any applicable notice and cure period under said Lease or the landlord under the lease is otherwise permitted to draw on the Letter of Credit pursuant to the terms of the Lease.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">2.<font style="margin-left:36pt;">The undersigned is the beneficiary under the Letter of Credit.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:50%;"><font style="text-decoration:underline;"></font><font style="text-decoration:underline;margin-left:36pt;"></font>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;margin-left:234pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:50%;">Name:<font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:50%;">Title:<font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU141"></a><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">H-5</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REQUEST FOR TRANSFER</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DATE: <font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RE:</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">________________________ STANDBY LETTER OF CREDIT NUMBER ______</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GENTLEMEN:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FOR VALUE RECEIVED, THE UNDERSIGNED BENEFICIARY HEREBY IRREVOCABLY TRANSFERS TO:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;"></font><font style="text-decoration:underline;margin-left:36pt;"></font>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(NAME OF TRANSFEREE)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;"></font><font style="text-decoration:underline;margin-left:36pt;"></font>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(STREET ADDRESS)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;"></font><font style="text-decoration:underline;margin-left:36pt;"></font>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(CITY, STATE, COUNTRY)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALL RIGHTS OF THE UNDERSIGNED BENEFICIARY TO DRAW UNDER THE ABOVE LETTER OF CREDIT IN ITS ENTIRETY.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WE FURTHER CERTIFY THAT THIS TRANSFEREE IS THE HOLDER OF THE LANDLORD&#8217;S INTEREST IN THE LEASE REFERENCED IN THE LETTER OF CREDIT.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PLEASE ADVISE THE TRANSFERRED LETTER OF CREDIT THROUGH, (IF APPLICABLE):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;"></font><font style="text-decoration:underline;margin-left:36pt;"></font>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ADVISING BANK)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;"></font><font style="text-decoration:underline;margin-left:36pt;"></font>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(STREET ADDRESS)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;"></font><font style="text-decoration:underline;margin-left:36pt;"></font>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(CITY, STATE, COUNTRY)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BY THIS TRANSFER, ALL RIGHTS OF THE UNDERSIGNED BENEFICIARY IN SUCH LETTER OF CREDIT ARE TRANSFERRED TO THE TRANSFEREE AND THE TRANSFEREE SHALL HAVE THE SOLE RIGHTS AS BENEFICIARY THEREOF, INCLUDING SOLE RIGHTS TO ANY AMENDMENTS WHETHER INCREASES OR EXTENSIONS OR OTHER AMENDMENTS AND WHETHER NOW EXISTING OR HEREAFTER MADE.&nbsp;&nbsp;ALL AMENDMENTS ARE TO BE ADVISED TO THE TRANSFEREE WITHOUT NECESSITY OF ANY CONSENT OF OR NOTICE TO THE UNDERSIGNED BENEFICIARY.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THE ORIGINAL LETTER OF CREDIT IS RETURNED HEREWITH TOGETHER WITH ANY AND ALL AMENDMENTS, AND WE ASK YOU TO ENDORSE THE TRANSFER ON THE REVERSE OF THE LETTER OF CREDIT AND FORWARD IT DIRECTLY TO THE TRANSFEREE WITH YOUR CUSTOMARY NOTICE OF TRANSFER.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:auto;"></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">H-6</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:51.15%;"></td>
<td style="width:51.15%;"></td>
</tr>
<tr>
<td style="width:51.15%;"></td>
<td style="width:51.15%;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:2.9pt;padding-Bottom:2.9pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU142"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VERY TRULY YOURS,</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AUTHENTICATED</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:2.9pt;padding-Bottom:2.9pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURE</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(BANK&#8217;S SEAL REQUIRED)</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:2.9pt;padding-Bottom:2.9pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FOR<font style="text-decoration:underline;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(BENEFICIARY CO&#8217;S NAME)</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:2.9pt;padding-Bottom:2.9pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:2.9pt;padding-Bottom:2.9pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BY<font style="text-decoration:underline;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(AUTHORIZED SIGNATURE)</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:2.9pt;padding-Bottom:2.9pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BY<font style="text-decoration:underline;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(BENEFICIARY&#8217;S BANK)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">H-7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU143"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT I</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant&#8217;s Removable Property</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Tenant&#8217;s personal property and all movable business and trade equipment owned or installed by Tenant or any party claiming by, through or under Tenant, not constituting Laboratory Reusable Installations.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I-1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/91437610.6</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>pti-ex311_7.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
pti-ex311_7.htm
</title>
</head>
<!-- NG Converter v4.0.8.13 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certification</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Meenu Chhabra, certify that:</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. I have reviewed this quarterly report on Form 10-Q for the period ended September 30, 2017 of Proteostasis Therapeutics, Inc.;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b. (Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c. Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d. Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: November 14, 2017</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:39.48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Meenu Chhabra</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:39.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Meenu Chhabra</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:39.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:39.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>pti-ex312_6.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
pti-ex312_6.htm
</title>
</head>
<!-- NG Converter v4.0.8.13 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certification</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Helen M. Boudreau, certify that:</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. I have reviewed this quarterly report on Form 10-Q for the period ended September 30, 2017 of Proteostasis Therapeutics, Inc.;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b. (Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c. Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d. Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: November 14, 2017</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:39.48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Helen M. Boudreau</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:39.48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Helen M. Boudreau</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:39.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:39.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>pti-ex321_8.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
pti-ex321_8.htm
</title>
</head>
<!-- NG Converter v4.0.8.13 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;32.1</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION&#160;1350,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the quarterly report on Form&#160;10-Q of Proteostasis Therapeutics,&#160;Inc. (the &#8220;Company&#8221;) for the period ended September 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;),&#160;I, Meenu Chhabra, President and Chief Executive Officer (Principal Executive Officer) hereby certify, pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section&#160;1350, that to my knowledge:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the Report which this statement accompanies fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934, as amended; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: November 14, 2017</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Meenu Chhabra</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Meenu Chhabra</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the quarterly report on Form 10-Q of Proteostasis Therapeutics, Inc. (the &#8220;Company&#8221;) for the period ended September 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Helen M. Boudreau, Chief Financial Officer (Principal Financial Officer) hereby certify, pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section&#160;1350, that to my knowledge:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the Report which this statement accompanies fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: November 14, 2017</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Helen M. Boudreau</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Helen M. Boudreau</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g201711142133156184463.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201711142133156184463.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $: @8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J)[B".14DFC1VZ
M*S $U+7&3Z5->_$.ZN%MM-DCAMK8E[RT,KCYI#^[;(VG\^U-;CZ-G7+<0/*8
MEFC:0=4# D?A2K/$ZLRRHRH<,0PP/K7E[6[6E[J,'AMTOI[B"\:9_L2QSVDA
MRRCS H))8D -D\#TJO="Q-M<3:-;.E@+"WBNFBB*QK.)0<RKCYMHR7X)(X-)
M U_7W'K4<B2H'C=74]&4Y%-@N(;J!9K>5)8G^ZZ-D'Z&O,=+N_)@$+W4ECIC
MW<ADO].C,4,K[5V+&N#L7J".[#J<U2BU#6K#1M&MTNOL-J+$O%/<3M;AKC>W
M#@1MNP,'9QU-.PEM<]:BN8)WE2*:-VA?9(%8$HV <'T."#^-/WJ0IW#YNG/6
MN7\-++YOB5IE^=[W<2H(5CY$>2N>HS7.Z7#KD=EX.:<VDD"*3#%';R)(I\AL
M!R6(]CP*&K?A^(/:YZ917E$.LZ[)I<\EMJ-])<-ISR7X>/FSNMZA508XZO\
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M>%G_ .ASUNUA6?\ R/&L?]>%G_Z'/3>XS=HHHI %%%% !1110 4444 %%%%
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MKY3UK_D/:E_U]2_^AFM<-&,F[HQQ$I12L=3%\6_$B7]S,(M/W2*@/[ENV?\
M:KJ_ _Q'USQ%XKM]-O4LQ!)&[,8HF#9 R.2QKQI8E65I!NW,,'GBNW^%/_)0
M;/\ ZXR_^@UT3I04&[&$*DG-*Y]#4445YQWGSA\2?^1_U3_>7_T$5QC_ /(1
MA_ZY/_-:[/XD_P#(_P"J?[R_^@BN,?\ Y",/_7)_YK7J1^!?(\V7QOYG0>$_
M^1OTC_K[C_G7U%7R[X3_ .1OTC_K[C_G7U%7+BOB1TX7X6%%%%<ITA69X@M9
M+W0[FU0R*)4*N\<WE,J]R&P?RQ6G6?K=Z=.TF>[\R&)(UR\DTFP(O<YP>?04
MGL-;G,>!;8ES<M(+A4@$4<QU9KME&1E=I1=G0?E7;UP7@>2TDUB>?=IUS?7%
ML'DO+:^:YE=01@.2BA>O KO:N1*"BBBI&%85G_R/&L?]>%G_ .ASUNUA6?\
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M4?\ WYD_^)KI[:XBN[6*Y@??#*@=&QC*D9!KY);[I^E?4_AK_D5]*_Z](O\
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ML=>;B/XC/0H?PT-D_P!6WT-?)EU_Q]S_ /71OYFOK.3_ %;?0U\F77_'W/\
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M.>79_P#"R/,\^7[=_96WRO+^3R_-^]N]<]J\I^,7_(Z1_P#7HG\S7JWFQ_\
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MJWO#USK<FN:I_:5I=16<S>9:M*4*JH)7  .1D;6P>^:K7N*R[$W_  A6@_\
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M_0OV_P#WV_\ \54L'PU\(6LHEM]&2&4<!XII%8?B&JAK,WBG?I/DVUR'&?\
MCVD+*YPN#-E1M_BX.5]\U5TZ?Q%$;!IQK11K]!*DD6XE=G[S<>HCW_=JM6[7
M)T2O8Z3_ (0K0?\ GVN/_ V?_P"+H_X0K0?^?:X_\#9__BZZ"D.=IQUQ4E'*
M3?#/P=<2M+/HL<LC?>>2:1F/U):H_P#A5G@G_H7[?_OM_P#XJLRRT;Q-+IMO
M+?ZAJ2R2:@A\J&Y;<D)8ARYP.,8..W8\U+J4GBA/#-B@@O6D#C?);R$W!(+<
M.H' ^[R"?<8JM;;B23-"/X8>#(I%DCT*%'4Y5EED!!]0=U7O^$*T'_GVN/\
MP-G_ /BZY2:;Q7&VJR.NL*P!^6*,."WFCRQ$/3R\[B.]>D1-OB1\,-R@X88(
M^HI.X[6([2TAL;2.UMU98HQA0SEB/Q))-%3T4@"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#"U[5[O3;J".VCB=3;S3N'!)(C*9 Y]&/Z5DCQLW]KZ3
M1%]FOLNQ\I]PC<D0G(^4$XR<XX(Q79%03D@'\*-BXQM&/I30/86BBBD 5F:Y
M?75C:P&T6,S33I$OF D?-]#6G2$ ]1G% '"W?CR6"RLKM8XA'/<;64Q.Q$:
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M>U,TKQ?%>,3J5E'IJE6=7EN493MD\O&>.=V<537Q_#@'^RI049VD E7]W""
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M +(YQU$_BG3,Z>(A'=2SSI$4C=2;<MC);TQD#'7FJ?\ PE:1SV\,NBE':\>
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M.T>;;/>;)C)B5E6)C$0@7+'/S\D^ISQ7I=%.^MQ'$WVD^*&FTZ3%E>V]JN3
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>BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g201711142133439555643.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201711142133439555643.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,E G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6Z7_ -//_?AO\*W:* ,+_A+=+_Z>?^_#?X4?\);I?_3S_P!^&_PK=HH PO\
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M ("BC[#XB_Z#-O\ ^ HK:\V/_GHG_?0H\V/_ )Z)_P!]"@#%^P^(O^@S;_\
M@**/L/B+_H,V_P#X"BMKS8_^>B?]]"CS8_\ GHG_ 'T* ,7[#XB_Z#-O_P"
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M_P"_3_X4@'?\(GH?_0/7_OMO\:/^$3T/_H'K_P!]M_C3?^$OT'_G_'_?I_\
M"C_A+]!_Y_Q_WZ?_  H =_PB>A_] ]?^^V_QH_X1/0_^@>O_ 'VW^--_X2_0
M?^?\?]^G_P */^$OT'_G_'_?I_\ "@!W_")Z'_T#U_[[;_&C_A$]#_Z!Z_\
M?;?XTW_A+]!_Y_Q_WZ?_  H_X2_0?^?\?]^G_P * '?\(GH?_0/7_OMO\:/^
M$3T/_H'K_P!]M_C3?^$OT'_G_'_?I_\ "C_A+]!_Y_Q_WZ?_  H =_PB>A_]
M ]?^^V_QH_X1/0_^@>O_ 'VW^--_X2_0?^?\?]^G_P */^$OT'_G_'_?I_\
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M_OMO\:/^$3T/_H'K_P!]M_C3?^$OT'_G_'_?I_\ "C_A+]!_Y_Q_WZ?_  H
M=_PB>A_] ]?^^V_QH_X1/0_^@>O_ 'VW^--_X2_0?^?\?]^G_P */^$OT'_G
M_'_?I_\ "@!W_")Z'_T#U_[[;_&L:#PQHQ\87<1L5V"U0@;VZY^M:_\ PE^@
M_P#/^/\ OT_^%8T'BK11XONY3>C8;5%!\M^N?I0!M_\ ")Z'_P! ]?\ OMO\
M:/\ A$]#_P"@>O\ WVW^--_X2_0?^?\ '_?I_P#"C_A+]!_Y_P ?]^G_ ,*
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M&WW-=97(W>NZ;J?B+1(K.Y$KK*Y(V,.-ON*ZZ@ HHHH **** "BBB@ HHHH
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M^N[_ /H-;M<C=V6HV_B+1&O-5-VAE<!/LZI@[>N1774 %%%% !1110 4444
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M_O\ O_C1_P (CH__ #QE_P"_[_XT ;M%87_"(Z/_ ,\9?^_[_P"-'_"(Z/\
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M*1C;M(Q[BK<GB*.:PN;JP\-I*MNF9#*4CVMZ8(S38_$=OYQ@;0XWNV"LL"A
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M"-O_ -]4?\)'HW_01M_^^JYH^+; W,-JF@(URTGERQ$H#&<X]/F_"NP%A9D
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MV0%6!7Y3SSW--JUP2UL1'3)C"5/AAMC-E3_::?+_ +I[4]],GEA"?\(F H
M*Z@@(Q[U@6UKJO\ 9MGI3QW7DV31SB4Y^<-_#GVYJ[;ZKK4!C57F:0K)MMTC
M((.XX9LCIBA[V W(8M0M[.WM(_"V(;=MT:_;TX/Y5#<VEU>WS74WA8/*PPP&
MH)ANW(K+NM7U<"P6RU1O*<YFGN(GX?/W, 57EGU6R>XGC%P'*2 2*#@$OU^E
M+S!'0M;WSJJMX4!"Q>2/]/3[F<XZ5!)IMU)()/\ A%620/OWIJ**<UFV6I^)
M+BSCNGGE#10HQ01'$I+8.<\]*9%K7B$R7C7%V$4.!)$D3%X%S]X<8Z>E/4.A
ML0V-Y!J*W\?A4B=22I_M!, D8)Q2R6=W+<)<2>$E,B2-*K&^3AB,$]*SAX@U
M>V0^:]P\<L!%M(83EV#<$^AQ6GH][>W8U6&XGEG98R58*0JY'W1QUI/1!U((
MK*YMY4N(?#)CVC'RZD@5OKZU$NB2I/',OA-MT;;E_P")BF,]:YXVVL#01I0C
MNO+MBMTLG.7)887/M5R6^\17=GJ7FZ@T+1$$0PQMYB ,.Y&,8]*JP;J_<Z4#
M48[>&+_A%P(X)/,C'V]/E;UZ5!=QW=RDT=QX84?:'#M_Q,(P2PZ$5A7^JZO<
MWUY:127$EJ8L!65MW!&&Z=ZZ#4M+N+_Q1I[@@1PV^YMZ%@3Z>QI";MK_ %_6
MI%#87-K$(X_"@5>!SJ"<X.1^M'V"Y65ICX3 <MN)^WIUSG^=<Y/JVLW<UPD\
MMREM'<HP*QL7B&X@]N>/2M+[7KUU9SL;BX,4<#-%^[P9OFX)_"CI<JVMAE[X
M=U>?7(M3MM%>V*MO=5O(SN.<DY[5U7]JZ\J\^'.G<WT?^%<O+K&IIIUVSW=U
M'?JP58!&0L:<8;@<U3BOM<ECCNKBYNFFELU*P[#L9@^#QCKBBVA-^IVG]J:]
M_P!"W_Y/1_X4?VIKW_0M_P#D]'_A7++J^ORAA%-<"X*L)XC%Q!S\N/7-63J.
ML6UQ!!/=SN$NBFU8R'F7 QSC&!189T']J:]_T+?_ )/1_P"%']J:]_T+?_D]
M'_A6X.@I:0&%_:FO?]"W_P"3T?\ A1_:FO?]"W_Y/1_X5NT4 87]J:]_T+?_
M )/1_P"%']J:]_T+?_D]'_A6[10!A?VIKW_0M_\ D]'_ (4?VIKW_0M_^3T?
M^%;M% &%_:FO?]"W_P"3T?\ A1_:FO?]"W_Y/1_X5NT4 87]J:]_T+?_ )/1
M_P"%']J:]_T+?_D]'_A6[10!A?VIKW_0M_\ D]'_ (4?VIKW_0M_^3T?^%;M
M% &%_:FO?]"W_P"3T?\ A1_:FO?]"W_Y/1_X5NT4 87]J:]_T+?_ )/1_P"%
M']J:]_T+?_D]'_A6[10!A?VIKW_0M_\ D]'_ (4?VIKW_0M_^3T?^%;M% &%
M_:FO?]"W_P"3T?\ A6-!J6M_\)?=L/#^9#:H"GVQ.!GKG%=M6%;_ /(ZWG_7
MFG_H5 &?J8O]26,WOAG.P_*?[01?PJI%;7\5C<6$V@%DN6+L!J$:G;Z<=@*E
M\;_:_M%D8S_HX#$J8RX9_P"$$#UJO+*+_3M3O[P/$L-N+=%3.0^W) QSUXHZ
M#MJA6TR=88$'ADJ8DV1$ZDG3MGUI&LKI]/@T^YT M]G;>"-213N/<UFRW-R\
M^E3INDA2U3RHY(F(9P?FY[$>]7[N>UETFXU&_1]]]/MAP&(11P"<?C39*99%
MG<B]6?\ X1C]^!QG44YXQG'K[TEO:7%C;R1+X;/E22^:PDU-""P^M9\*8U-%
M8W#W2S*8YL-@V^WD_2I[4VE]X;OK>.&2Y<7;+$'5LC<>#S1Z#]2QIVIZS_PD
MVKNF@!F9(,J+U/E^4XY[UM?VIKW_ $+?_D]'_A5;PY:+8:WJEJI)$4-NO)_V
M#734F",+^U->_P"A;_\ )Z/_  H_M37O^A;_ /)Z/_"MVB@#"_M37O\ H6__
M ">C_P */[4U[_H6_P#R>C_PK=HH Y&ZO-3N/$6B+>:3]D02N0_VE9,G;TP*
MZZL+6O\ D.:%_P!=W_\ 0:W: "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#D5AU)_%FNO97T-M&JV^_S(MV?D/-2V5QJFHI(]IX@LY5C;:Q%MT/XU9L5
MW^)/$:[0VY;<;3W_ '9KF[SP[K=Q826\,4D%J)E*VZS#>5'7#>GL:!G2/!KT
M:EI-;LU4#)+0 ?UIJ)KDA8)K=H=N,_Z/QS6 ?"UY+:W=M=6,ER98<0S2W',?
M'W2!_.F'PWJZLI^QEK0!0;07&.0F,Y]CS3$=-]E\0YQ_;-KD]OLX_P :HSWN
MHVMZMG/XBLDN&&0AMJHV?AC4X9X;F1F:XCFB(;S3P@SN%6M2T74)]5G1;99+
M:>=)C-O *A1]W'J:0+8DLKW4M1MY9[3Q!:2Q19WN+4@#'7K4":S=/9F[7Q+9
MFW#;=_V0XS5S0=+O+.*^CD@ECLG7;%;23!R.N<'L#6?%8:U9:=/#;:?(\,IV
M1P2SJS1+W(:A@O,LG4;X7,=N?$MAYLB[E'V?J/KTI]G=ZE?I,UKXALI5A_UA
M%M]VLBZ\+ZG<P36,-JL,$Y1UE,@)BVJ1M]ZU]&TG4$%Q)=6ZP-]C%JJ!P=Y
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M]O\ X4?\)=H7_/\ K_W[?_"@!O\ PB]O_P!!#4__  )-'_"+V_\ T$-3_P#
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MW,!CVZU.(;81F/\ X1"?:4"$9'*@YQU]:ENI%O9X9[GPK<R20_<9B./UYHT
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M1-/!^SG_ $D%ON_-M^7UJ*_TJVOHH(QX7NX5B=6^0CY@O1>O3FK?V>UQ /\
MA$)\0?ZOD<?KS^-/0"E>^,7EN(D2W,+K<%5CW %QC(+>QI;'QU=2QZ?'+HYE
MN;A/,D$ W!5W8S5X0VPG\_\ X1"?S2_F;B03N]>M,6UM%\O;X1N5\MBR%7Q@
MDY]?TI(&:^@ZU_;$MVDEJL#P/M\LGYL>IK:V)_=7\JYJSNFL))7M?#%U$\QW
M2,&&6/YU:_MV_P#^@!>_FM &WL3^ZOY4;$_NK^58G]NW_P#T +W\UH_MV_\
M^@!>_FM &WL3^ZOY4;$_NK^58G]NW_\ T +W\UH_MV__ .@!>_FM &WL3^ZO
MY4;$_NK^58G]NW__ $ +W\UH_MV__P"@!>_FM &WL3^ZOY4;$_NK^58G]NW_
M /T +W\UH_MV_P#^@!>_FM &WL3^ZOY4;$_NK^58G]NW_P#T +W\UH_MV_\
M^@!>_FM &WL3^ZOY4;$_NK^58G]NW_\ T +W\UH_MV__ .@!>_FM &WL3^ZO
MY4;$_NK^58G]NW__ $ +W\UH_MV__P"@!>_FM &WL3^ZOY4;$_NK^58G]NW_
M /T +W\UH_MV_P#^@!>_FM &WL3^ZOY4;$_NK^58G]NW_P#T +W\UH_MV_\
M^@!>_FM &WL3^ZOY4;$_NK^58G]NW_\ T +W\UH_MV__ .@!>_FM &WL3^ZO
MY4;$_NK^58G]NW__ $ +W\UH_MV__P"@!>_FM &WL3^ZOY5AVZ+_ ,)K>?*/
M^/-.W^U2_P!NW_\ T +W\UK&@UJ]'B^[?^P[LL;5!LRN1SUH [38G]U?RHV)
M_=7\JQ/[=O\ _H 7OYK2?V_>A@IT&\W'H-RYH W-B?W5_*C8G]U?RK$_MV__
M .@!>_FM)_;][N*_V#>;AU&Y<T ;FQ/[J_E1L3^ZOY5B?V[?_P#0 O?S6C^W
M;_\ Z %[^:T )IR+_P )9K?RC[D';_9-;FQ/[J_E7%Z?K5Z/$^L.-#NR66'*
M@KE?E-;/]NW_ /T +W\UH V]B?W5_*C8G]U?RK$_MV__ .@!>_FM']NW_P#T
M +W\UH V]B?W5_*C8G]U?RK$_MV__P"@!>_FM']NW_\ T +W\UH 3654:YH>
M !^_?H/]FMZN1N]2N;SQ%HB3:9<6JB5R'D(P?EZ<5UU !1110 4444 %%%%
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M(QN)@(R ?WLG.>F.>:T[+P]H.H6J7-MYSQ/T83O_ (T@.DHK"_X1'2?[D_\
MW_?_ !H_X1'2?[D__?\ ?_&@#=HK"_X1'2?[D_\ W_?_ !H_X1'2?[D__?\
M?_&@#=HK"_X1'2?[D_\ W_?_ !H_X1'2?[D__?\ ?_&@#=HK"_X1'2?[D_\
MW_?_ !H_X1'2?[D__?\ ?_&@#=HK"_X1'2?[D_\ W_?_ !H_X1'2?[D__?\
M?_&@#=HK"_X1'2?[D_\ W_?_ !H_X1'2?[D__?\ ?_&@#=HK"_X1'2?[D_\
MW_?_ !H_X1'2?[D__?\ ?_&@#=HK"_X1'2?[D_\ W_?_ !H_X1'2?[D__?\
M?_&@#=HK"_X1'2?[D_\ W_?_ !H_X1'2?[D__?\ ?_&@#=HK"_X1'2?[D_\
MW_?_ !H_X1'2?[D__?\ ?_&@#=K"M_\ D=;S_KS3_P!"H_X1'2?[D_\ W_?_
M !K&@\+Z6?%]W$4FVBU0C]\WK]: .VHKB=<LM$T5[>(P3233GY5:[9!@=3DF
MF7EEI=M+*(K*YG6&W\^0)<L2,] .<4 =S17 .-#%S8VZ6LQEN8EE(>\*[%/U
M/)J2YLK"*2]:WTVXN(;4A6873+SC)ZGM1L!W=%>?1C1I;J-4TV\-NS"-IOM+
M?*Y&=N,Y_&I#:6+Z1-?6^DW+F&1DDC>]*$!>^2: .@TW_D;-;_W(/_036[7
M>']!T[4-8U&62VN(=T4#",SL2N5/?/-=%_PB.D_W)_\ O^_^- &[16%_PB.D
M_P!R?_O^_P#C1_PB.D_W)_\ O^_^- &[16%_PB.D_P!R?_O^_P#C1_PB.D_W
M)_\ O^_^- !K7_(<T+_KN_\ Z#6[7(W6AV.F>(M$EMED#-*X.Z1F_A]S774
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MD>W;O567A=O([U:6VT!8RIUBW&9HY3M  RG;'I5>'QAIMRB_9_#AD=W(0;%
M8 9SDBMC0=1T_6VD3^QX[9E0. Z(<J?H*-0V,>?3-!EC=4UZ.,L'&5(_B;-6
M-!MM"T-MRZW!*Q5@>BCDYZ5UG]G6/_/E;_\ ?I?\*/[.L?\ GRM_^_2_X4K@
M<;!IV@00M&-<B.Y0,DCC#;JC;3],):1?$T4<OF%T**H5 1@C;_6NV_LZQ_Y\
MK?\ []+_ (4?V=8_\^5O_P!^E_PHN'6YP5QH.ASV9@'B.,9558D @X!'3\:G
M?2M"=&B/B"/R'$89!CJ@QG/N*[;^SK'_ )\K?_OTO^%']G6/_/E;_P#?I?\
M"G=A8XR#3]$26*2?Q!%,8=JQ<*-J YQ[_6MS2]1T32[0VZ:K X+L^2P'4YK7
M_LZQ_P"?*W_[]+_A1_9UC_SY6_\ WZ7_  I7 J_\)%H__02M_P#ONC_A(M'_
M .@E;_\ ?=6O[.L?^?*W_P"_2_X4?V=8_P#/E;_]^E_PH J_\)%H_P#T$K?_
M +[H_P"$BT?_ *"5O_WW5K^SK'_GRM_^_2_X4?V=8_\ /E;_ /?I?\* *O\
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M$7B;6"+^W6,I %._CA36Y_PD6C_]!*W_ .^ZP_#EDDFLZD;VUMC.8;<OB%0
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MA1]EY);N3FI$32DV$>'M<+*[/N-N<DD8.3FJ=UXMN)-02>&8>1%YH!C&0WR
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MZ%0!1U*]LM5\O[5H&ML4^Z5ML'Z=>E5(7M$T^YL9-&UQH[ERS[;;:<= .#T
MJ;QI?7EM<6<<+A("K.^9"FXCHH([U#->OJ%KJ%_]HDM(K:T$:$M@ARN3^/:C
MH.SNAAATORH470-=!@39&3;D\=L\\XI<6,FF6]C/HNNL(&WADMRI+'OP:H3:
MU=-<:6_GB6W6UC? F*M*Q.#C'4^U7KJ[CN+&[U*XO)+<W,WE6@$FW(7@?K3:
M9*9,#IHNQ<_\(_KGF@=3;GDXQGKU]Z2U.FVD$D*:#KK1R2B5E> MEO7K5&*]
MN?[33S-1D-TEPL017^5HMO+8_K4\=Q%=^&KT&_FGEBNF2)HYOFR3@=*0_4ET
M_P 0[?$^L/\ V/JQW+!\HM>1A3U&:V?^$E_Z@FL_^ G_ ->JOANWDM=:U."6
M1I)$AMPS,<DG8:Z>A@C"_P"$E_Z@FL_^ G_UZ/\ A)?^H)K/_@)_]>MVB@#"
M_P"$E_Z@FL_^ G_UZ/\ A)?^H)K/_@)_]>MVB@#D;K5_M_B+1(_[.U"VQ*YW
M7,&Q3\OKFNNK"UK_ )#FA?\ 7=__ $&MV@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH Y$1:G)XLUUK*\@MXU6WWB6/=GY#3;**[U&"9;34]+EA#XD46
M8VY]QWK0L5W^)/$:[0VY8!M/?]V:YN\\/ZW/826\$4MO:+,I$"RC>5'7#>GU
MH&;KZ7JL>'>^TQ=JX#&T48'I]*:NGZG,K1+?Z8RJ02OV,8]O:L<^%[R:UN[:
M[LI;HRPXAFEGYCX^Z0/YU&?#FKJ5/V-FLP%!M!/CD)C.?8\TQ'2?V?KN<?VC
M89X(_P!&';I5&YFO(-32"XUK35O2/E!M<MCZ_P!*J6?AG5(;B&ZE=VN(YHB&
M\TX"#.X8JY>Z/J,FMR!+=6MY;F.?S]PR@7MCUHZAT&V&HWU[YZ6>O6+>0-TJ
MBT*[1Z\XJL]\;JR:ZDUK2Y;<-@N]D2"?Q'-;]AI\RQZA<7D>Z>Z9AL#?P8P!
MFN;BT36+>2&XAM9'MK=SY=G-,&8 C'7IBD!=CCN&N81'JND&<Q^9&1:#(0=P
M>PJ2UN;^^2XDMM<TZ18_]<1;8Q]<]15 :%JD1L[5;$$"UDBDN X&UGSCW(&:
MOZ1I-\%N'O+-4'V1;80[\B3 Z\>M-]0&P->:I#'Y6KZ;<1[L(#9Y (^O2K3:
M3J[,9&O=-)(VEC:#D>E8,_A_7KFU$4<;0PJQ$<9E^95QCDCK[5E^)-.O-("V
MQCF-C+(I55=F_A^;\<T KG706>IS22-#J6F,\9\IRMH,@C^&JFH?:K#5+5[W
M6["*ZV%8 ;8]#UZ=*R)?#&JS")X5N%M&G,@CCD"O@@8)S72ZCX>GU/5;-GFD
M2U2V,<N""7.>AH[ P@@U>[W2PZMI\F&PS"V'452GDGL]26SFU?2X[R50 IL^
M2#T!-47T+4++5;.*$LD5U,Z2JK' C!W _6M#7/#VHWNL2W5M)B#9&/*)&)-I
M]>V*78.Y=72=852BWNFA1U M!BJ=TMWIK6\5QJFEQ%R?)06??O@"LS_A'M;(
MG*0-&VW$W[\_Z3\V>/[O%!\(WTN+C[-Y<BQ2B%#,28MP^49S0!N)I&J/'A+O
M3"C?/C[&,'WQ4PT_7F"@:E8D+P/]&'%<S-X?U73M.:]'F_:51Q*5E+$KL  Q
M]:UOAV!_8LKF.5)&DRY?."<=LTQ=F:#:5KC(4:^L"I&"IM!C'I3/[%U@*%%U
MIVT# 'V,8 ]*Z2BD,YZ+2]=@ $5_81@=-EJ!0VF:\\1B:_L6C/5#:@@_A70T
M4 <ZNE:XB[5OK!5 Q@6@ Q2?V/K(D:07>G;V^\WV,9/XUT=% '/1:9KL (AO
M[&,,<D):@9/X5)]C\2?]!6T_\!ZW:* ,+['XD_Z"MI_X#T?8_$G_ $%;3_P'
MK=HH POL?B3_ *"MI_X#T?8_$G_05M/_  'K=HH POL?B3_H*VG_ (#T?8_$
MG_05M/\ P'K=HH POL?B3_H*VG_@/1]C\2?]!6T_\!ZW:* ,+['XD_Z"MI_X
M#T?8_$G_ $%;3_P'K=HH POL?B3_ *"MI_X#T?8_$G_05M/_  'K=HH POL?
MB3_H*VG_ (#T?8_$G_05M/\ P'K=HH POL?B3_H*VG_@/1]C\2?]!6T_\!ZW
M:* ,+['XD_Z"MI_X#T?8_$G_ $%;3_P'K=HH POL?B3_ *"MI_X#T?8_$G_0
M5M/_  'K=HH POL?B3_H*VG_ (#UC06OB#_A+[L#4K7S/LJ9;R.,9KMJPK?_
M )'6\_Z\T_\ 0J *.IC4K2)&U'5]/"EOD\RTW<^PYJHT-UI\;V\NJV BD!N'
M\RVRN#W.:N>+-'O[^ZM+FR\UFB5EQ')L*D]&^E5K>TOKK2]4N)K4W5T\?V6-
M6PN=HP3S[T=!]4),L\<=M&^JZ6HF7]P%L^<'N,=*BG$MA%]ANM4TX16^.);/
M<%)Z>O-5WT76EDLKQ(98)([5(F"S#$94Y.1_$"*O+!J1T)YHK W%Q?S%YLL%
M9$Z<9]J;1* 2SB^CMQK.E?:63Y +09V^F?Z5&;E[&S-TNL:7';F0J7CLN-P^
M@I(=#U"*Z$2V"BW-PMP'+@E0%QL^M6;&SU;^Q;ZT^P?97FN"5_> C8QY/%(9
M3T8:S>Z_JD]KJUHZND#>8(.&&TXQ6]]C\2?]!6T_\!ZCT2!+7Q'J\$8PL<5N
MH_[X-=#0P,+['XD_Z"MI_P" ]'V/Q)_T%;3_ ,!ZW:* ,+['XD_Z"MI_X#T?
M8_$G_05M/_ >MVB@#D;J#5HO$6B&_O8)X_-?"QQ;2#MKKJPM:_Y#FA?]=W_]
M!K=H **** "BBB@ HHHH **** "BBB@ HHHH **** .0.FQ7GBG7YY+N\A$2
M09%O+MR-A/3O5>R&FW-@][/J6K6MN&VJ\EUG=],#]*T;:\M;;Q3X@2>[@@=U
MM]OFN%_@//-8=WX?L+Y)6GUK3#(TJR+&L@6,X]0#U/M0!=NV\/V4;/-XBU'"
MIO.VX9N/P%"?V&T+3MKVHI"-N&-T><C(XQFHX-+L[:WNK6#6-+CMKJ/#H)!E
M6Q_"<]*A.C6PN5O$U_3A<@!<,ZE,;=IXS3T T4MM$DNX[5/$-\T\F-B"[/.>
MG:JUVEI:ZE]D^U:S(H<1M*MU\JN>@Z=Z+;1M(ME0+K-D2LT<N[S5S\N>.OO5
MBYM+&?5FG77+);6259I(C*NXLO3!STHZAT(+&VCNIKV*:36K=K1=S[KO=GOQ
M@53BN["33Y[OS]<"PE<@7.<@G@YQ706ITV"RO(CK-H9[IF9I1,N1GIW[5@1Z
M-%!I5W:0Z_I:-<!5.'&W [XSU-(>A+=RZ=9W1CEOM9\E,"2?[5\J$C('2K.D
MVUIJDDD?VS6('5!(HDNOO(>C=*K7.CV5\9([C7K#[//M:9%E7)<# (.>E6[&
MTM;>WN1+K]BUP]N+:.1)5&Q!P._6GI81!:/H]Q!=3R:OJMO';R^66DN2-WH1
MQT-3%?#X$)/B.^Q-S'_I1YYQZ5DWF@6=I!$-,UV"5]T>\7%RK#Y3UH;1HC?[
M1K.F^3+$?M$AD7EBV2%&>*- -*$:3(TF_5]3B6/=DO=^AQTQ1=MH=K#$_P#;
MNHR&4C8J71R<G'I5"Z\+Z5<J0=<LB #M5IEP<MGG!J1=!L8U5(-8TJ"-@GFH
MC@C*G/RY.1272X%F^2TL]9CTW[9JKR/%YI8WP4 ?CU_"I8QH;C#>(+]7";V7
M[63M'Y5>FAT6XU>2_EU#3W8VWD)ND0E#GJ#FL4>'-)_LR\M'UJQ<W&S!,J\;
M?7GI0"+S)H"^5N\1WX\T93_2CR,X]*'30(Q(6\1W^(VVO_I1.#Z=*R!HT"7T
M<4.I:3!:FU\J5DD!!);)QDY!K0.DZ?#;P"TUO3UFAD=@7D4J0PP<C/6GH!//
M'H5N563Q#?[F3>H%T3D?E5#3;W1+^T:Z?5]3MX1T:2[//.!QBG)H.GQ 0)KU
MB;5F5Y TB[MP]#G@4]-"TM7@)UNQ98O+R#(O.UB?7WHT LLN@*8 ?$=_F<XB
MQ=$[C^5:W_",0_\ 03U3_P "C_A7$/IIL_%<-Q;WEE<6AE\QB;E55><\C/:O
M1O[8TO\ Z"5G_P!_U_QHTL'6Q0_X1B'_ *">J?\ @4?\*/\ A&(?^@GJG_@4
M?\*O_P!L:7_T$K/_ +_K_C1_;&E_]!*S_P"_Z_XT@*'_  C$/_03U3_P*/\
MA1_PC$/_ $$]4_\  H_X5?\ [8TO_H)6?_?]?\:/[8TO_H)6?_?]?\: *'_"
M,0_]!/5/_ H_X4?\(Q#_ -!/5/\ P*/^%7_[8TO_ *"5G_W_ %_QH_MC2_\
MH)6?_?\ 7_&@"A_PC$/_ $$]4_\  H_X4?\ ",0_]!/5/_ H_P"%7_[8TO\
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M6&UNN.>M5[*&"/2=0A&K6*7-Q^Z1Y)U;$8&!WHZ#TN1L;#S[."._U5Y;F-9
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MS@A8S."T<84_=]JZ:N1N]2N+SQ%HB2Z9<VJB5SOEQ@_+TKKJ "BBB@ HHHH
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M>T?\I: -VBL+'BK^]H_Y2T8\5?WM'_*6@#=HK"QXJ_O:/^4M&/%7][1_REH
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M&M?\)%HG]HFP,7FOC[/OSG;[UUU !1110 4444 %%%% !1110 4444 %%%%
M!1110!S]DN_Q'XC4J6!6 ;0>O[LUR]QI.M?V=+;6,-W:V8F7@1J9BO?'/S"K
M>J21V?B#7+V6^U"!%-M&([,\N2AQQ3X[F"5X0-;U>/?(8Y1+,J&(@9Y!%""Y
M6?1+^XM+NVO8=0N97AQ;S%MH QT8 \&H_P"RM8C('V2]-AA0T*/A\A, ]>@-
M;$T*0ZA':_V_J)5D9GD^TKA,>O%-CCBDN9D_X2'41!'&'\\W"[3G\*=P*MGH
MVMQW$%U,]P9XYH@!YGR^7SNR/RJS?Z7>RZ^X%DSK)<QS+<\815ZCZ^U6/LMI
M\G_%57O[S&W_ $A><_A535'M])NE@N->U@L0&=D<$1J3@%N.!FCJ'0U+'26:
MWU2:X@,4EWN4)& "$ P,>]<W:Z9J5A97+M87%TLX6&-# JO&H&"Q4=\=ZO:=
M-:ZIJ,ME;Z]K'F1@G<S@*P'7!Q34NK1[I83KNLI&[E$N&8"-F'4!L4@"[L9K
MIH+*'2KN)(K<B.X*#ERN!N/;%6-&M-1M8[JZ2P>"1+-85B8 >9(!][Z>]6%M
M+5X7E7Q5>F-/O,+@8'Z4&TM0R+_PE5[ND *#[0O.?PI@8,&A^(-/MI8Y8$DB
MN-DLRV;,&)S\PY[GVJS+IVJRWQ^RVU[#D+]G=W.V-,<JPSUS5RS6"YC4R^(M
M0@D9RHC>Y4DX./2II(+**9X9/%EXLB?>4W R/TH"QC36VNW,)$MI?J(H%CV@
MY\UPW/?H?6F'0M7BU)Y;6TGAEDE20OYA* ;>1R>QKJ8]!DEC62/7]39&&01,
M.?TIW_".S_\ 0=U3_OZ/\*+@<EJ.FZQ)IMK'8V5]#<+(6FD8EF+^HY^Z?6MI
M;+4(/"M[;/:2R7-Q(0%49/..3[5I_P#".S_]!W5/^_H_PH_X1V?_ *#NJ?\
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M^$=G_P"@[JG_ ']'^%'_  CL_P#T'=4_[^C_  HN*QNT5A?\([/_ -!W5/\
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M_P"@UNUR-UI4ECXBT21]2O+D&5QMG?('R_2NNH **** "BBB@ HHHH ****
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M9\GJV>./:JUUI]L^F_86UBPDLK9I)8%1OWC,0< ]NIK8\+7/]JR7275E9$H
MR?Z.J$9_F/>F/<3+X?O[O[#IWVBVN"G^H&-H('IUYI/:PUJ]#F+3P_;76C1_
M:M8L8)O*B @#X4[>SX[_ $J]_86FGYEU;382(XU54<L%*MDX)YKHM0G2QU",
M&PL6MC:/-@0C<649]*9H\K7#SPSV5C-*;5;F'; J@;API_QJM7J*VAS%IX:L
MK<3%]>T]G<Y0Y^[\^ZJ-C E[>ZC#<M:QEV8Q7,\G"\\8QUKI+;6FADMH+G2+
M.>:20K.OE+$T QGICGZTO_";:#Y4C_V(.&VQ?N1B3\=O'TI =+8:SI=KI\$$
MVK6LDD:!6<.!DU9_X2'1_P#H)6W_ '\%8-IJ-M?QZE-%IMM&D-NDL2O  P)4
MGGBJD&IC3T@&HV-G=O=0B2$0P*AW$XVGM^-#O<6B.I_X2'1_^@E;?]_!1_PD
M.C_]!*V_[^"N=/B'3<%%T!&GB!:XCVI^Z4'!.<<_A2C7[%U\V+P[&T#3>2LK
M!%!/<GC@4AG0_P#"0Z/_ -!*V_[^"C_A(='_ .@E;?\ ?P5BZYK.DZ'=6D,V
ME6TBSXR4"97/MCD567Q)I>)#)H"I\N8<HG[WYMOIQSZT ='_ ,)#H_\ T$K;
M_OX*/^$AT?\ Z"5M_P!_!7,3ZD1X7U34/[*M8;JWDV)'Y"N1R!^/6I8-3BMX
MTBN-%2640F:626!( B^XYHZ7#I<Z+_A(='_Z"5M_W\%'_"0Z/_T$K;_OX*Y-
M/%VES6HEA\.K*P#-(BJGRA>IR1S4D_BS1K:V#R:&@G+A5A\M22",YR!Z=J+
M=1_PD.C_ /02MO\ OX*/^$AT?_H)6W_?P5F:3?:=JUY) FC0PHBA@TJ*&;/^
MSC/XUM_V98?\^-M_WZ7_  H K_\ "0Z/_P!!*V_[^"C_ (2'1_\ H)6W_?P5
M8_LRP_Y\;;_OTO\ A1_9EA_SXVW_ 'Z7_"@"O_PD.C_]!*V_[^"C_A(='_Z"
M5M_W\%6/[,L/^?&V_P"_2_X4?V98?\^-M_WZ7_"@"O\ \)#H_P#T$K;_ +^"
MC_A(='_Z"5M_W\%6/[,L/^?&V_[]+_A1_9EA_P ^-M_WZ7_"@"O_ ,)#H_\
MT$K;_OX*/^$AT?\ Z"5M_P!_!5C^S+#_ )\;;_OTO^%']F6'_/C;?]^E_P *
M *__  D.C_\ 02MO^_@H_P"$AT?_ *"5M_W\%6/[,L/^?&V_[]+_ (4?V98?
M\^-M_P!^E_PH K_\)#H__02MO^_@H_X2'1_^@E;?]_!5C^S+#_GQMO\ OTO^
M%']F6'_/C;?]^E_PH K_ /"0Z/\ ]!*V_P"_@H_X2'1_^@E;?]_!5C^S+#_G
MQMO^_2_X4?V98?\ /C;?]^E_PH K_P#"0Z/_ -!*V_[^"C_A(='_ .@E;?\
M?P58_LRP_P"?&V_[]+_A1_9EA_SXVW_?I?\ "@"O_P )#H__ $$K;_OX*/\
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M_P!F6'_/C;?]^E_PK#M].L?^$SO%^QV^T6B''E+CK]* -3_A(='_ .@E;?\
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MIMSR<8SUZ^]%K_9UI!)"FA:\T<DHE820%OF_.J4-]<_VFGF:DYNDN%B$:O\
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M/_[^M1Y_B;_GRT__ +^M6[10!A>?XF_Y\M/_ ._K4>?XF_Y\M/\ ^_K5NT4
M87G^)O\ GRT__OZU'G^)O^?+3_\ OZU;M% &%Y_B;_GRT_\ [^M1Y_B;_GRT
M_P#[^M6[10!A>?XF_P"?+3_^_K4>?XF_Y\M/_P"_K5NT4 87G^)O^?+3_P#O
MZU'G^)O^?+3_ /OZU;M% &%Y_B;_ )\M/_[^M1Y_B;_GRT__ +^M6[10!A>?
MXF_Y\M/_ ._K4>?XF_Y\M/\ ^_K5NT4 87G^)O\ GRT__OZU'G^)O^?+3_\
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M_",Q_P#06U;_ ,"O_K5H?VOIO_01M/\ O^O^-']KZ;_T$;3_ +_K_C0!G_\
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M+_BJ_P#J#?\ D6C_ (JO_J#?^1: -VBL+_BJ_P#J#?\ D6C_ (JO_J#?^1:
M-VBL+_BJ_P#J#?\ D6C_ (JO_J#?^1: -VBL+_BJ_P#J#?\ D6C_ (JO_J#?
M^1: -VBL+_BJ_P#J#?\ D6C_ (JO_J#?^1: -VBL+_BJ_P#J#?\ D6C_ (JO
M_J#?^1: -VBL+_BJ_P#J#?\ D6C_ (JO_J#?^1: -VBL+_BJ_P#J#?\ D6C_
M (JO_J#?^1: -VBL+_BJ_P#J#?\ D6C_ (JO_J#?^1: -VBL+_BJ_P#J#?\
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MQ3N(HV>D:Y'<074SW)FCFB&/,^7R^=V1^5/UG1[R[U6XA^Q2.)YDD2Z3'[M
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M[4V^Y*17ATF[CO5B&FSE//6=9V49$87&T^_M5FRM;J70;ZT32I87DN6V+-&
M K'[P_"F+=6SW:0+KVL$/@>:/N!B,A2<=:5I5_LU[Z'5->GB1V1A&H++CJ2/
M2EZC[&IH-JEEX@U6VC "1Q6ZC'^X:Z.N!T+3I-1UO4YXM8U-%>.!@68!B"IZ
M\5T/_"/W'_0=U+_OX/\ "F[WU!&[16%_PC]Q_P!!W4O^_@_PH_X1^X_Z#NI?
M]_!_A2 W:*PO^$?N/^@[J7_?P?X4?\(_<?\ 0=U+_OX/\* #6O\ D.:%_P!=
MW_\ 0:W:Y&[TN6R\1:)(^I7=R#*XVS,"!\M==0 4444 %%%% !1110 4444
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M3!_SWC_[[%'VF#_GO'_WV*S/^$6T3_H'Q_FW^-'_  BVB?\ 0/C_ #;_ !H
MT_M,'_/>/_OL4?:8/^>\?_?8K,_X1;1/^@?'^;?XT?\ "+:)_P! ^/\ -O\
M&@#3^TP?\]X_^^Q1]I@_Y[Q_]]BLS_A%M$_Z!\?YM_C1_P (MHG_ $#X_P V
M_P : -/[3!_SWC_[[%'VF#_GO'_WV*S/^$6T3_H'Q_FW^-'_  BVB?\ 0/C_
M #;_ !H T_M,'_/>/_OL4?:8/^>\?_?8K,_X1;1/^@?'^;?XT?\ "+:)_P!
M^/\ -O\ &@#3^TP?\]X_^^Q1]I@_Y[Q_]]BLS_A%M$_Z!\?YM_C1_P (MHG_
M $#X_P V_P : -/[3!_SWC_[[%'VF#_GO'_WV*S/^$6T3_H'Q_FW^-'_  BV
MB?\ 0/C_ #;_ !H T_M,'_/>/_OL4?:8/^>\?_?8K,_X1;1/^@?'^;?XT?\
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MHH PO^$F'_0&UC_P%_\ KT?\),/^@-K'_@+_ /7K=HH PO\ A)A_T!M8_P#
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M!(*P A>O^K-<I)!K%KITT&E07%M;B90TPAQ*5YSP.OUH&=3LUO:%_L?2]H!
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M_P!#%+_X#)1_9&L?]#%+_P" R5I?VKIW_/\ VO\ W^7_ !H_M73O^?\ M?\
MO\O^- &;_9&L?]#%+_X#)1_9&L?]#%+_ . R5I?VKIW_ #_VO_?Y?\:/[5T[
M_G_M?^_R_P"- &;_ &1K'_0Q2_\ @,E']D:Q_P!#%+_X#)6E_:NG?\_]K_W^
M7_&C^U=._P"?^U_[_+_C0!F_V1K'_0Q2_P#@,E']D:Q_T,4O_@,E:7]JZ=_S
M_P!K_P!_E_QH_M73O^?^U_[_ "_XT 9O]D:Q_P!#%+_X#)1_9&L?]#%+_P"
MR5I?VKIW_/\ VO\ W^7_ !H_M73O^?\ M?\ O\O^- &;_9&L?]#%+_X#)1_9
M&L?]#%+_ . R5I?VKIW_ #_VO_?Y?\:/[5T[_G_M?^_R_P"- &;_ &1K'_0Q
M2_\ @,E']D:Q_P!#%+_X#)6E_:NG?\_]K_W^7_&C^U=._P"?^U_[_+_C0!F_
MV1K'_0Q2_P#@,E']D:Q_T,4O_@,E:7]JZ=_S_P!K_P!_E_QH_M73O^?^U_[_
M "_XT 9O]D:Q_P!#%+_X#)1_9&L?]#%+_P" R5I?VKIW_/\ VO\ W^7_ !H_
MM73O^?\ M?\ O\O^- &;_9&L?]#%+_X#)1_9&L?]#%+_ . R5I?VKIW_ #_V
MO_?Y?\:/[5T[_G_M?^_R_P"- &;_ &1K'_0Q2_\ @,E']D:Q_P!#%+_X#)6E
M_:NG?\_]K_W^7_&C^U=._P"?^U_[_+_C0!F_V1K'_0Q2_P#@,E']D:Q_T,4O
M_@,E:7]JZ=_S_P!K_P!_E_QH_M73O^?^U_[_ "_XT 9O]D:Q_P!#%+_X#)1_
M9&L?]#%+_P" R5I?VKIW_/\ VO\ W^7_ !H_M73O^?\ M?\ O\O^- &;_9&L
M?]#%+_X#)6-!I6K?\)?=H->D#BU0E_LZ\C/2NK_M73O^?^U_[_+_ (UAP:G8
M?\)G>-]NMMIM$ /FKCK]: +7]D:Q_P!#%+_X#)34T35HQA-?=1G.!:H*U/[5
MT[_G_M?^_P O^-']JZ=_S_VO_?Y?\: ,TZ-K!!!\0R$'J#:I2+HNK(H5/$$B
MJ.@%J@ K3_M73O\ G_M?^_R_XT?VKIW_ #_VO_?Y?\: ,W^R-8_Z&*7_ ,!D
MH_LC6/\ H8I?_ 9*TO[5T[_G_M?^_P O^-']JZ=_S_VO_?Y?\: .4T_2M6/B
M?6%&O2!E6'<WV=?F^4UL_P!D:Q_T,4O_ (#)573M3L!XJUIC?6P4K!@^:N#\
MI]ZW/[5T[_G_ +7_ +_+_C0!F_V1K'_0Q2_^ R4?V1K'_0Q2_P#@,E:7]JZ=
M_P _]K_W^7_&C^U=._Y_[7_O\O\ C0!F_P!D:Q_T,4O_ (#)1_9&L?\ 0Q2_
M^ R5I?VKIW_/_:_]_E_QH_M73O\ G_M?^_R_XT <Y=6-_:^(M$>ZU5[M#*X"
M-"JX.WKQ775S>J7MI<Z]H:P7,,K"9R0D@8_=]JZ2@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH Y:*PM+KQ/X@EN+*&XD18-@= 3_JSQ61%JNC6>GRW&
MK:59)*) BP10_.,]B"*TAJUII_BO7H;D3GS%M\>5&6XV'TJ@\7AR17+MJK3,
MX<3%&+KCI@XZ4 22ZMH)LIKJS\._:HX4W.5@4 'TY[T1ZGH18H^A1F<A2L"P
M#?@KN/Y"C?H.9?WNK;9DV2IL;;)QC)&.OO430^&V(<-JJS#&)E5@^ ,8SCTI
M@6H-3\,W%W%"FCIMD94\TP#:K-T!J[<65E#X@M[$:-8F":-F#[!NR*HQ2^'(
M458X;X*)$D \IOO+T[5)=7^D7>KPZDUQJR2P@A$1&"8/7C%&@M;%K2;*ROXK
MSSM&L4E@E:-55 0?3)K%O+VSTW3[YKG2-+:ZB8K#M4!'.,GD^E7]/O='TY;M
M8[C5Y/M1+.949B">XXXJO"/#B6$EE<#4KR%P<?:8F<KGK@XXI#7F.7R773YH
M]&TR2&[A#[43+ [<_EGBI="%C?Z?=2W>EZ>ES"I8PK 5*\=\U! ="M+F*:VG
MUB$1QB)8T5@@4#'3%6[/4=%LQ<?-J4\EP-LDLT;,Q'IG%#ZV PDUVR;0H9SH
M-@-0,VR2'8,*F?O?E5Y]<\->9+"NDP++"ZA@T((()QQBG^5X6\QG^SWVYHEB
M)\ION@Y';K5=+#PJC.0FID,00I1L+SG X]:>@(FEUO0!;&6'P[YC?*50PJ-Z
MEL9'XTY]>\*1W4UN=(0R1#YL6X/S=U^M/D;PY+"L934%"1^6I6-@0,Y].N:8
MH\/++*P;5=LIR\>QMI/KTZT@Z#I]:\,6UHEQ-HJ(#+Y3H85W(?<?C4BZMX8,
MK*VCHL8W;9# -KE1D@56O8/#-^Y>1=25F<N2D;#.>HZ=.*F8^&G@2%H;\HC,
MRCRFZL,'M3T#J+/J_AJTEMHKG1%BEN.0A@!(4G )QVJ3Q!/HVC75E$FF6#>:
MP:;>B@K'TR/4YJN/["$T$WVC6#-"-HD*L6*_W3QR*L7EQX:U"ZEN+NUNII)(
MQ'EX&.T#TXXH ;_:OA@32H^CHB)NVR& ;7*]0*AEU+2;:^5+CPXL=N8A(6,
MR@)QD^U+M\,_9HX&BU!DCW8S&V?F&#VIXDT$PR1S/JD^^,1%I48G:#D#.*0=
M1T^J^&8/.9M&3RD!V2" 8D(Z@5;TYM$U"_-HNA)$ZH'8R0J,9K-,7AHM)N74
MF1\XC*-M3/4J,<9Q5U-1T5-6&HEM2:54V*K1-L4>PQ3T#H;W]@:1_P! VU_[
M]"C^P-(_Z!MK_P!^A5/_ (2S3O[EW_X#M1_PEFG?W+O_ ,!VI 7/[ TC_H&V
MO_?H4?V!I'_0-M?^_0JG_P )9IW]R[_\!VH_X2S3O[EW_P" [4 7/[ TC_H&
MVO\ WZ%']@:1_P! VU_[]"J?_"6:=_<N_P#P':C_ (2S3O[EW_X#M0!<_L#2
M/^@;:_\ ?H4?V!I'_0-M?^_0JG_PEFG?W+O_ ,!VH_X2S3O[EW_X#M0!<_L#
M2/\ H&VO_?H4?V!I'_0-M?\ OT*I_P#"6:=_<N__  ':C_A+-._N7?\ X#M0
M!<_L#2/^@;:_]^A1_8&D?] VU_[]"J?_  EFG?W+O_P':C_A+-._N7?_ (#M
M0!<_L#2/^@;:_P#?H4?V!I'_ $#;7_OT*I_\)9IW]R[_ / =J/\ A+-._N7?
M_@.U %S^P-(_Z!MK_P!^A1_8&D?] VU_[]"J?_"6:=_<N_\ P':C_A+-._N7
M?_@.U %S^P-(_P"@;:_]^A1_8&D?] VU_P"_0JG_ ,)9IW]R[_\  =J/^$LT
M[^Y=_P#@.U %S^P-(_Z!MK_WZ%']@:1_T#;7_OT*I_\ "6:=_<N__ =J/^$L
MT[^Y=_\ @.U %S^P-(_Z!MK_ -^A1_8&D?\ 0-M?^_0JG_PEFG?W+O\ \!VH
M_P"$LT[^Y=_^ [4 7/[ TC_H&VO_ 'Z%']@:1_T#;7_OT*I_\)9IW]R[_P#
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M1_:>O_\ 0NC_ ,#4_P * -VBL+^T]?\ ^A='_@:G^%']IZ__ -"Z/_ U/\*
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M &M?\AS0O^N[_P#H-;M<C=Z9-9>(M$>34KJZ!E<;9B"!\M==0 4444 %%%%
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MH5E?\(IH?_0/3_OIO\:/^$4T/_H'I_WTW^- &KY\/_/6/_OH4>?#_P ]8_\
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MH/\ S_\ _D%__B:W:* ,+_A,=!_Y_P#_ ,@O_P#$T?\ "8Z#_P __P#Y!?\
M^)K=HH PO^$QT'_G_P#_ ""__P 31_PF.@_\_P#_ .07_P#B:W:* ,+_ (3'
M0?\ G_\ _(+_ /Q-'_"8Z#_S_P#_ )!?_P")K=HH PO^$QT'_G__ /(+_P#Q
M-'_"8Z#_ ,__ /Y!?_XFMVB@#"_X3'0?^?\ _P#(+_\ Q-'_  F.@_\ /_\
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M*]$'B^[E-[^[-JB@^4_7/TKMJPK?_D=;S_KS3_T*@ _X3'0?^?\ _P#(+_\
MQ-'_  F.@_\ /_\ ^07_ /B:I^*]9O=/N+6WM!(%=6DD>/&0J]>M1RZI>7ZW
MES87)2*VM P9EZN1GD?2CI<=C0_X3'0?^?\ _P#(+_\ Q-'_  F.@_\ /_\
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MB3_H'67_ '_-'VKQ)_T#K+_O^:W:* ,+[5XD_P"@=9?]_P T?:O$G_0.LO\
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MAX?T.^TW57FECC6%H@K,6W,S#T[@>U %S^R=:_Z&)_\ P$2C^R=:_P"AB?\
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MQ/\ ^ B5NT4 87]DZU_T,3_^ B4?V3K7_0Q/_P" B5NT4 87]DZU_P!#$_\
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M_P" B4?V3K7_ $,3_P#@(E;M% &%_9.M?]#$_P#X")1_9.M?]#$__@(E;M%
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M#/-85U&D'B*UNK$RRVZ'+&6W/&6R>/\ "NAO+S3[K5GODO;F)98A%+%]AW9
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M.1:G^/\ #M6Y9>)=/M;*&"26ZF:- ID-LR[L>PH%K<G_ .$0T7_GVD_[_O\
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MAL]?I0 FNV.@:*]O$;-GFG)VAKIU  ZDG-,O+#2+>680Z;).L%MY\FRX?OT
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M^,?A3=@ZE$^--8#62#2X9'N%\PB-CPF<=3WK>T/6;C4KR\@N8X8FA;Y8T)+
M>I[?E5*5;^<1"3PA$PB_U>;R/Y?IQ4EM+JEH\CV_A1(VD.7*WL>3^E%T!TM%
M87]K:[NV_P#".C/I]NC_ ,*8^MZS&KL^@*H098F_CX'O2 Z"BL%=7UQT#+X=
M!5AD$7T?/Z4BZQK;$A?#RDCJ!?Q\?I0!OT5A?VIKW_0M_P#D]'_A3)=;UF!"
M\N@*BCJ6OXQ_2@#H**YYM<UA/+W: H\PX3-_'\Q]N*D_M37O^A;_ /)Z/_"@
M#=HKGQK6M&8PCP^OFA=Q3[?'G'KTI_\ :FO?]"W_ .3T?^% &[16%_:FO?\
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M]F&.:8'+?VKXH*R2"2XV0QAXOW?^M^?'/X5L^*I[>?4-,M)!+%,SK*UPJMA
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M1#>?T09W"M;4A>7.O0#[!')90G>LHG4?/CJ1UXK.A;P;/>16T=DY,A50^'V
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MRJ&)0^_S=*EAE\(LL>^Q;YCAG0.4CYP-QSQ0F!4U/0-8O-<OYXRB0S(45EN
M PR,<>M/O/#E\@FAAC2>T.X1PFYQ@E<;L_6M/2[;PGJ]P\%M8.'4$CS ZA@#
M@D<\TNHVGA32KZ"TN[ H\YPC9;;GT^]2V5BNI5UC1+JXT?1K=(A,UM'LE2.X
M"$?+CKW%93^&M<;4(V+1;%@\LLDP"D8Q@CUK4BG\&30O*MC* OW05<&3G'R\
M\\T^RM_#]WHEYJ1TH1K!(\81W8$D=,\\4]=638S+KP[K,VJ22*42,PB,,EP
M", =/6KG_"/W=K=#9$ES8+(C?9OM.,G;@G)]ZBAN?#(L[>:\TQ87=6\R)6=F
M5E.,=:T;W3='2*S%GHP>XNS^[29W3:/4\T:H/(S1X9OY)9Y92H8!V@7[1]TE
M@1^E1>#I6?Q;=&\63ST5E#D\#GO_ $K2*>%[:7R+W33',@Q*R%VC1L9V[L]:
M8DW@Z2W:5=/ER" L95]SYZ%1GD4+0>ZL=OYT7_/1/^^A1YT7_/1/^^A7G$.H
M^&S%&\FARLTA&(XMY89;;D\U?27PE@>9I[EMQ#",.?+ .,MSP*+!<[CSHO\
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M>A_] ]/^^V_QH_X1/0_^@>G_ 'VW^- &MYT7_/1/^^A1YT7_ #T3_OH5D_\
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M /EKML#T%&!Z"G=@<-=2^%+NUB@DU)BL4 A7]TYX'0_=JD]IX6EEMI9-8):
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M?_"C_A,-!_Y_Q_WZ?_"MO ]!1@>@H Q/^$PT'_G_ !_WZ?\ PH_X3#0?^?\
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MQ3HD?B;5W^V@1LD 0^4_93[5M?\ "8:#_P _X_[]/_A6T(T#,P10S=2!R:7
M]!0!B?\ "8:#_P _X_[]/_A1_P )AH/_ #_C_OT_^%;>!Z"C ]!0!B?\)AH/
M_/\ C_OT_P#A1_PF&@_\_P"/^_3_ .%;>!Z"C ]!0!R5WKNFZIXAT2*SN?-=
M97)&QAQM]Q774TQH65BBEEZ$CI3J "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
B**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g201711142133438995641.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201711142133438995641.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,E G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX_M1_>22Q[?,A"$JV<X [>].VMAK4Z7_ (2W2_\ IY_[\-_A1_PENE_]//\
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M(P>OUJDM1K5G1?89':W8^$HF,*LL9^WQG /45+IB7NGRR267AK+L-K'^T4;
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M>C_PJMX)>[DTJXDO(I(IFN'RL@Y_#VKIJ0(PO[4U[_H6_P#R>C_PH_M37O\
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M)"Q#.#\W/8CWJ_=S6TNDW&HWT3F2_GVPX5B(U' )Q^--DIED6EPMZLW_  C
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M$=LSJS! .?F'K3-+\,WNGZSIMPA@%L'>2Y3S!\K\X(]<BA>8-OH=%]A\1?\
M09M__ 44?8?$7_09M_\ P%%;7FQ_\]$_[Z%'FQ_\]$_[Z%(9B_8?$7_09M__
M  %%'V'Q%_T&;?\ \!16UYL?_/1/^^A1YL?_ #T3_OH4 8OV'Q%_T&;?_P !
M11]A\1?]!FW_ / 45M>;'_ST3_OH4>;'_P ]$_[Z% &+]A\1?]!FW_\  44?
M8?$7_09M_P#P%%;7FQ_\]$_[Z%'FQ_\ /1/^^A0!B_8?$7_09M__  %%'V'Q
M%_T&;?\ \!16UYL?_/1/^^A1YL?_ #T3_OH4 8OV'Q%_T&;?_P !11]A\1?]
M!FW_ / 45M>;'_ST3_OH4>;'_P ]$_[Z% &+]A\1?]!FW_\  44?8?$7_09M
M_P#P%%;7FQ_\]$_[Z%'FQ_\ /1/^^A0!B_8?$7_09M__  %%'V'Q%_T&;?\
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M?7I3)=4O(;/[6_B6U^SARA=;3<,CJ.*KPZ/>Q70B6UA%L;A;D.9E)7 QL_\
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M@!W_  B>A_\ 0/7_ +[;_&C_ (1/0_\ H'K_ -]M_C3?^$OT'_G_ !_WZ?\
MPH_X2_0?^?\ '_?I_P#"@!W_  B>A_\ 0/7_ +[;_&C_ (1/0_\ H'K_ -]M
M_C3?^$OT'_G_ !_WZ?\ PH_X2_0?^?\ '_?I_P#"@!W_  B>A_\ 0/7_ +[;
M_&C_ (1/0_\ H'K_ -]M_C3?^$OT'_G_ !_WZ?\ PH_X2_0?^?\ '_?I_P#"
M@!W_  B>A_\ 0/7_ +[;_&C_ (1/0_\ H'K_ -]M_C3?^$OT'_G_ !_WZ?\
MPH_X2_0?^?\ '_?I_P#"@!W_  B>A_\ 0/7_ +[;_&C_ (1/0_\ H'K_ -]M
M_C3?^$OT'_G_ !_WZ?\ PH_X2_0?^?\ '_?I_P#"@!W_  B>A_\ 0/7_ +[;
M_&C_ (1/0_\ H'K_ -]M_C3?^$OT'_G_ !_WZ?\ PH_X2_0?^?\ '_?I_P#"
M@!W_  B>A_\ 0/7_ +[;_&C_ (1/0_\ H'K_ -]M_C3?^$OT'_G_ !_WZ?\
MPH_X2_0?^?\ '_?I_P#"@!W_  B>A_\ 0/7_ +[;_&C_ (1/0_\ H'K_ -]M
M_C3?^$OT'_G_ !_WZ?\ PH_X2_0?^?\ '_?I_P#"@!W_  B>A_\ 0/7_ +[;
M_&C_ (1/0_\ H'K_ -]M_C3?^$OT'_G_ !_WZ?\ PH_X2_0?^?\ '_?I_P#"
M@!W_  B>A_\ 0/7_ +[;_&C_ (1/0_\ H'K_ -]M_C3?^$OT'_G_ !_WZ?\
MPH_X2_0?^?\ '_?I_P#"@!W_  B>A_\ 0/7_ +[;_&C_ (1/0_\ H'K_ -]M
M_C3?^$OT'_G_ !_WZ?\ PH_X2_0?^?\ '_?I_P#"@!W_  B>A_\ 0/7_ +[;
M_&L:#PQHQ\87<1L5V"U0@;VZY^M:_P#PE^@_\_X_[]/_ (5C0>*M%'B^[E-Z
M-AM44'RWZY^E $VL6'AS2'@B;34DFF.$0SE..YR345[9Z#:2R*-&,HBM_/D$
M;L2/0=:A\0WF@:W)#(-2B5XU9#YEN[#:>N/EX/O5:SU#38])U" :HD=Q<?ND
M=XG;$8&!VHZ#TN6VC\->?9P1Z4K2W,:R[6G*[%/U/)]A3KJTT6&6\$.A-<1V
MI =DE8<XR>I[5CS1Z1(EN\FKP2310+$Y^ROD[>1M./E-6EU"R.A1VT6LQ03O
M*9;C? [!\GITINW0E7+,?_"-RW4:)HLC0,P0S;VP'(R%QFI#;:*^E2WUOX>>
M012,DD;3%"N._)JFEQI2WGF?VW&(3()VB%N_^L QQQT]J?;7VGKIUS9W6NQ.
ML\_FDQV[C@G)'2D,DT#0M&U#6=2F;3/+1HH&6-G;*Y4^]=%_PB>A_P#0/7_O
MMO\ &L+3/$^AP^)-6(O0L12 )^[?LI]JV_\ A+]!_P"?\?\ ?I_\*& [_A$]
M#_Z!Z_\ ?;?XT?\ ")Z'_P! ]?\ OMO\:;_PE^@_\_X_[]/_ (4?\)?H/_/^
M/^_3_P"% #O^$3T/_H'K_P!]M_C1_P (GH?_ $#U_P"^V_QIO_"7Z#_S_C_O
MT_\ A1_PE^@_\_X_[]/_ (4 9]YHFG:;XAT26SM5B=IG!(8GC;[FNLKD;O7=
M-U/Q%HD5G<B5UE<D;&'&WW%==0 4444 %%%% !1110 4444 %%%% !1110 4
M444 <)K-]<:?J&OS6KLDADM%W(F]@"AZ"K+W>MKI]G*9]MT7QY#1#=*N>K>G
M%$D[KXKUN+^R9;Y/]&?*$ *0AQUJ6]"ZA>17=UX5NI)XAA'\W! _ T("K:ZM
MJ,TR^9?QI'=1R,/W8_<;3^N:GOM2U2S\%F[DD*W7F!1(L0+%2V =OKBF/:6S
MK.K>$)R+C_6_O!\WZ\?A5F*5H;%;)/"]U]G4A@AD! (^IIBU(M)U756N98+W
MC;:-*F^,*QYX)';Z55OO$&H#1X);::,3R6;R9V@_.#@&KUTWVZ\BN[GPM<O<
M1#"/Y@! ].#4<44,!F,?A&93-Q)\XY[^O'X4GJ@6CN9$GB[4I8]/2%HUFC^2
M]^3^/!P!Z>M)I_B365@B6[?$DDL17>BY*-G/3M6W\F7/_")39=M[?,O+8QG\
MJBMK>"TCV0>$)U7>'QO!Y'3J:=U<:WU.>3QOJ]M#;I<^4\SO(P.S =,X'Y5U
MVC:A(]S=VTUZ]Q,D0DP\(0#(ZJ>XJMB/="Q\(RDPAEC)*_*#U'XTMB1IK2-:
M>%;F(R\.1(#D>G)H;5ANU[F/-KNL66AI=F\6>6ZB=U7RP#&0V!CU%699==2'
M2&?49H'NIQ'(CQ(3CKGBK$5I;00S11^$)Q',")%\P'(/X\?A4UOBUABAA\*W
M(CB??&#(#M;U&31="6UF9TWC"1=<OK6.Y1H8T:*(&/D2*.3GIS70^'M0N+]+
MPSE28G 7C&/ES5%F#6ZV[>$YC$K%PNY>IZFFPA;>^:\A\*W*7##!<2#D=.F<
M4@90GU_5;!;A)G$MYYBLD*H,%"V/E/>J\_B#7;O58;6&*6W+W<D;1*JE@JJ#
MU/%:L<<4+R.GA*<-(P9CO!R1R.])=Q17T@DN?"5P[AS(&\P [CQG(--,%NRM
M:W6N7DVK$W<T,5MN6-Q&A7('YYK3TJ6]E\(QW=SJ0\^1-YF:,#;[ 56ABCM[
MJ2YA\*7*RR J["7[P/J,XJ6>0W.F_P!G3>%KEK08'E;P!Q]#1TL);FSHCW4N
ME1/>X,QSSMQD=CBM#:/0?E7.6=_<Z?;+;VOAN[CB7HOF X_,U/\ VYJ/_0OW
M?_?:T/<%L;FT>@_*C:/0?E6'_;FH_P#0OW?_ 'VM']N:C_T+]W_WVM(9N;1Z
M#\J-H]!^58?]N:C_ -"_=_\ ?:T?VYJ/_0OW?_?:T ;FT>@_*C:/0?E6'_;F
MH_\ 0OW?_?:T?VYJ/_0OW?\ WVM &YM'H/RHVCT'Y5A_VYJ/_0OW?_?:T?VY
MJ/\ T+]W_P!]K0!N;1Z#\J-H]!^58?\ ;FH_]"_=_P#?:T?VYJ/_ $+]W_WV
MM &YM'H/RHVCT'Y5A_VYJ/\ T+]W_P!]K1_;FH_]"_=_]]K0!N;1Z#\J-H]!
M^58?]N:C_P!"_=_]]K1_;FH_]"_=_P#?:T ;FT>@_*C:/0?E6'_;FH_]"_=_
M]]K1_;FH_P#0OW?_ 'VM &YM'H/RHVCT'Y5A_P!N:C_T+]W_ -]K1_;FH_\
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MT,9_\ D_QH W**P_[*US_H8S_P" 2?XT?V5KG_0QG_P"3_&@#<HK#_LK7/\
MH8S_ . 2?XT?V5KG_0QG_P  D_QH W**P_[*US_H8S_X!)_C1_96N?\ 0QG_
M , D_P : -RBL/\ LK7/^AC/_@$G^-']E:Y_T,9_\ D_QH W**P_[*US_H8S
M_P" 2?XT?V5KG_0QG_P"3_&@#<HK#_LK7/\ H8S_ . 2?XT?V5KG_0QG_P
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M>FH<$=<TO4?:Q>\-VGV'6M3MMQ8QPVZDDY/W#73UP>B6^J7^NZI/;^(&VO'
MV\V:?,"IQQVKH/[*US_H8S_X!)_C3>^HEL;E%8?]E:Y_T,9_\ D_QH_LK7/^
MAC/_ (!)_C2&;E%8?]E:Y_T,9_\  )/\:/[*US_H8S_X!)_C0 FM?\AS0O\
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M.C_\\9?^_P"_^- &[16%_P (CH__ #QE_P"_[_XT?\(CH_\ SQE_[_O_ (T
M;M85O_R.MY_UYI_Z%1_PB.C_ //&7_O^_P#C6-!X6TH^+[N(Q2[!:H1^^;KG
MZT 7O%6@7.K7%K/;(':)67!E*;2>C9'I4%KIVHR:7J<C0^?>2I]FC$K;<JHQ
MNR?4\U!KMEH6BO;Q&VD>:<_*K73( !U.2:9>6.E6\LHBT^>=8;?SY EP^>>@
M'.*%L/6Z(I?#.JL]G=-"J316RQ,4G.8BISD8^]FKR6.KG028+9);F\F,ER'<
M(0I[#/M6?(-!%S8VZ6<GF7,2RD/=LNQ3^/)J6YL=/C>]:WTN:XAM2%9A=,O.
M,GJ>U-WZDJQ9B\/ZE%=!%MX5M3.MSGS/F4@8V?\ UZGL],U@Z1>V<MO%;-/<
M%@5E#?(3ST[UDQC1I;F-4TNZ-NSB-I?M+9#D9VXS^M2&SL'TB:^@T>=C#(R2
M1R7A0@+WSFD,W='A2W\2ZQ#&,(D=NH'_   UT%<!X?T#3-0UC499+2:'=% P
MC,[$KE3WSS71?\(CH_\ SQE_[_O_ (TWOJ"-VBL+_A$='_YXR_\ ?]_\:/\
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M=HH PO[4U[_H6_\ R>C_ ,*/[4U[_H6__)Z/_"MVB@#"_M37O^A;_P#)Z/\
MPH_M37O^A;_\GH_\*W:* ,+^U->_Z%O_ ,GH_P#"C^U->_Z%O_R>C_PK=HH
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M;_\ 00U/_P "33O^$NT+_G_7_OV_^%'_  EVA?\ /^O_ '[?_"@!O_"+V_\
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M '[?_"@!O_"+V_\ T$-3_P# DT?\(O;_ /00U/\ \"33O^$NT+_G_7_OV_\
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M&TXX-65O[0Z%';1:Q##/)*9;G?"[!\]NE-VZ$JY.DFGRW4<:3ZRT+$(9OM/
M<C(7%/,4+Z7+?6_]LR+%(R2(;S:5QWYJND^EK>>9_;<(@,HG:(0/_K ,<<=*
M?;7M@-.NK.ZUR%EGG\TF.!QP3DCI2&&@:-!J&LZE-]JU.(-% P4W)W<J>IKH
MO^$7M_\ H(:G_P"!)K&TSQ-H</B35B+U5B*0!/W;=E/M6W_PEVA?\_Z_]^W_
M ,*& W_A%[?_ *"&I_\ @2:/^$7M_P#H(:G_ .!)IW_"7:%_S_K_ -^W_P *
M/^$NT+_G_7_OV_\ A0 W_A%[?_H(:G_X$FC_ (1>W_Z"&I_^!)IW_"7:%_S_
M *_]^W_PH_X2[0O^?]?^_;_X4 9EWHT6G^(M$D2ZO)297&)IBX^[775R5WKF
MFZGXAT2*SN1*ZS.2 C#C;[BNMH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** . \0ZC>Z7>>(+C3R@N3):(I9=W5369J'C?49;J)[!HEMQ;NDG[L$F95R
M?RK>GDSXIUN%](EOXR;9_DQA2$.*>T%JZ;&\'S;2S-CCJWWCU[T(:W*FGZIJ
M\YTFQGG:&:]C:9II8EX &< #CFJ=]XKU>TFNX5A61(K^* 7(4;0IZC%:J6MH
MEJELOA&Z\E&W(N_.T^QSD5*RPO"\3>$K@QR2"1ER.6'0]:=U<70QIO&<YU+5
M((;B';Y+FU7R^4=.N?6F7'BW5(;-P6B%Q#!$TG[L<LS $_B#6Y(L$T,<,GA&
M=HXB2@^7C/6DD2":1WD\(SLSJJ,21R%Z#KVH703N,L]<G?1[[6[FYCC@B,BK
M;E!\I7@<]<YK.TCQ7=W<5A"\T4D[7HBF81XRI&1Q6FT5N\LDK>$;@M(07Y&"
M1[9Q27D%MJ$ADNO"-P[D@EMP!R.G0T!T.OV)_=7\J-B?W5_*L*+6+R&)8X_#
M]Z$484;AP*=_;M__ - "]_-:0S;V)_=7\J-B?W5_*L3^W;__ * %[^:T?V[?
M_P#0 O?S6@#;V)_=7\J-B?W5_*L3^W;_ /Z %[^:T?V[?_\ 0 O?S6@#;V)_
M=7\J-B?W5_*L3^W;_P#Z %[^:T?V[?\ _0 O?S6@#;V)_=7\J-B?W5_*L3^W
M;_\ Z %[^:T?V[?_ /0 O?S6@#;V)_=7\J-B?W5_*L3^W;__ * %[^:T?V[?
M_P#0 O?S6@#;V)_=7\J-B?W5_*L3^W;_ /Z %[^:T?V[?_\ 0 O?S6@#;V)_
M=7\J-B?W5_*L3^W;_P#Z %[^:T?V[?\ _0 O?S6@#;V)_=7\J-B?W5_*L3^W
M;_\ Z %[^:T?V[?_ /0 O?S6@#;V)_=7\J-B?W5_*L3^W;__ * %[^:T?V[?
M_P#0 O?S6@#;V)_=7\J-B?W5_*L3^W;_ /Z %[^:T?V[?_\ 0 O?S6@#;V)_
M=7\J-B?W5_*L3^W;_P#Z %[^:T?V[?\ _0 O?S6@#;V)_=7\J-B?W5_*L3^W
M;_\ Z %[^:T?V[?_ /0 O?S6@#;V)_=7\J-B?W5_*L3^W;__ * %[^:T?V[?
M_P#0 O?S6@#;V)_=7\J-B?W5_*L3^W;_ /Z %[^:T?V[?_\ 0 O?S6@#;V)_
M=7\J-B?W5_*L3^W;_P#Z %[^:T?V[?\ _0 O?S6@#;V)_=7\J-B?W5_*L3^W
M;_\ Z %[^:T?V[?_ /0 O?S6@#;V)_=7\J-B?W5_*L3^W;__ * %[^:T?V[?
M_P#0 O?S6@#;V)_=7\J-B?W5_*L3^W;_ /Z %[^:T?V[?_\ 0 O?S6@#;V)_
M=7\J-B?W5_*L3^W;_P#Z %[^:T?V[?\ _0 O?S6@#;V)_=7\JP[=%_X36\^4
M?\>:=O\ :I?[=O\ _H 7OYK6-!K5Z/%]V_\ 8=V6-J@V97(YZT =IL3^ZOY4
M;$_NK^58G]NW_P#T +W\UI/[?O0P4Z#>;CT&Y<T ;FQ/[J_E1L3^ZOY5B?V[
M?_\ 0 O?S6D_M^]W%?[!O-PZC<N: -S8G]U?RHV)_=7\JQ/[=O\ _H 7OYK1
M_;M__P! "]_-: $TY%_X2S6_E'W(.W^R:W-B?W5_*N+T_6KT>)]8<:'=DLL.
M5!7*_*:V?[=O_P#H 7OYK0!M[$_NK^5&Q/[J_E6)_;M__P! "]_-:/[=O_\
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M[_9MZ%GF\DK]H;Y.<9/-3SV>BVMY>P36=XBVL0EWF=OGR<8 S0]]?ZT%I?\
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M/8.I6D\):R^E_9&+><[0D31J$V 9R"!W'K6_>Z5?WOA_3K2* 6D\,Z[\('
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M_9UC_P ^5O\ ]^E_PH J_P#"1:/_ -!*W_[[H_X2+1_^@E;_ /?=6O[.L?\
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M)K.I&]M;8SF&W+XA4 $H>W:NF_LZQ_Y\K?\ []+_ (4WN"*O_"1:/_T$K?\
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M4CU2QCDNII+>]U+,3'LHSE/I5)-BV5S<MUTBUDM'A\,ZPK6FXPG[+]W=U[T
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M)_\ 7H_X27_J":S_ . G_P!>MVB@#"_X27_J":S_ . G_P!>C_A)?^H)K/\
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M8TO_ *"5G_W_ %_QH_MC2_\ H)6?_?\ 7_&@"A_PC$/_ $$]4_\  H_X4?\
M",0_]!/5/_ H_P"%7_[8TO\ Z"5G_P!_U_QH_MC2_P#H)6?_ '_7_&@"A_PC
M$/\ T$]4_P# H_X4?\(Q#_T$]4_\"C_A5_\ MC2_^@E9_P#?]?\ &C^V-+_Z
M"5G_ -_U_P : *'_  C$/_03U3_P*/\ A1_PC$/_ $$]4_\  H_X5?\ [8TO
M_H)6?_?]?\:/[8TO_H)6?_?]?\: *'_",0_]!/5/_ H_X4?\(Q#_ -!/5/\
MP*/^%7_[8TO_ *"5G_W_ %_QH_MC2_\ H)6?_?\ 7_&@"A_PC$/_ $$]4_\
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M_"J.EZGID7B;6 +^T6/9 %/G+CA3[UN_VQI?_02L_P#O^O\ C0P*'_",0_\
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M!8'YCUQ[5H?V]>_] "^_2FQE[^P])_Z!EG_WX7_"C^P])_Z!EG_WX7_"J/\
M;U[_ - "^_2C^WKW_H 7WZ4@+W]AZ3_T#+/_ +\+_A1_8>D_] RS_P"_"_X5
M1_MZ]_Z %]^E']O7O_0 OOTH O?V'I/_ $#+/_OPO^%']AZ3_P! RS_[\+_A
M5'^WKW_H 7WZ4?V]>_\ 0 OOTH O?V'I/_0,L_\ OPO^%']AZ3_T#+/_ +\+
M_A5'^WKW_H 7WZ4?V]>_] "^_2@"]_8>D_\ 0,L_^_"_X4?V'I/_ $#+/_OP
MO^%4?[>O?^@!??I1_;U[_P! "^_2@"]_8>D_] RS_P"_"_X4?V'I/_0,L_\
MOPO^%4?[>O?^@!??I1_;U[_T +[]* +W]AZ3_P! RS_[\+_A1_8>D_\ 0,L_
M^_"_X51_MZ]_Z %]^E']O7O_ $ +[]* +W]AZ3_T#+/_ +\+_A1_8>D_] RS
M_P"_"_X51_MZ]_Z %]^E']O7O_0 OOTH O?V'I/_ $#+/_OPO^%']AZ3_P!
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M-7(W>I7%YXBT1)=,N;51*YWRXP?EZ5UU !1110 4444 %%%% !1110 4444
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M/_0J,>*O[VC_ )2UC0#Q+_PE]W@Z5YOV5,\28QF@"3QO/=QSV:IL-MAF97+
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M''08[>]8-SX3U>!);>*UE>U%D!'Y9&Y6+@E1[UT5F8;VVNIEUK6D^S+O=9&
M;;C((&.AJB=7T[[$MTNOZTZ-#YP"L,XSC'3KFC6]QQOT%U#0+R^ALH;:VNA;
MW*&"\-Q@.J#D$X]ZU?#FCWG]C7T>J1;)IP80I/\  !A:H->6L5I-<7&M:W L
M,0E99&&=N<<5;6.%X;B5->U=D@B$KD..A&?2CHQ=C!MO#>N/<0//;,OVEQ!=
M9;[L2'Y3^.!6DFD7S6T.GC3I(Y[=W=[L@8D!S@ ]\YIYN[$23I_PD6K%H(TE
M;#CHW3''O0ES;O+M_MG7%B.0DQ(V.1U ..M#V R7\(ZT]BEL2PF;RR)HU"!
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MBVVMS:GJ-M#:V,'E2ESNALED. V!GT'O4[^(HK:]BAGTZR\N/S$NF\E<J_\
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M/[,L/^?&V_[]+_A1_9EA_P ^-M_WZ7_"@"O_ ,)#H_\ T$K;_OX*/^$AT?\
MZ"5M_P!_!5C^S+#_ )\;;_OTO^%']F6'_/C;?]^E_P * *__  D.C_\ 02MO
M^_@H_P"$AT?_ *"5M_W\%6/[,L/^?&V_[]+_ (4?V98?\^-M_P!^E_PH K_\
M)#H__02MO^_@H_X2'1_^@E;?]_!5C^S+#_GQMO\ OTO^%']F6'_/C;?]^E_P
MH K_ /"0Z/\ ]!*V_P"_@H_X2'1_^@E;?]_!5C^S+#_GQMO^_2_X4?V98?\
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M>>WF="1:JP8#H,&E_7Y?\ ?5$VE:SI$'B35@M_;K'Y<"H=XP<*:W?^$AT?\
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M196AP)<CDLU.VHG<G%QK3,Y%GI!:,Y<^;RI]_2JXN;TW41%GH!N"/W>)AO\
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M (T?VOIO_01M/^_Z_P"- &?_ ,(S'_T%M6_\"O\ ZU'_  C,?_06U;_P*_\
MK5H?VOIO_01M/^_Z_P"-']KZ;_T$;3_O^O\ C0!G_P#",Q_]!;5O_ K_ .M1
M_P (S'_T%M6_\"O_ *U:']KZ;_T$;3_O^O\ C1_:^F_]!&T_[_K_ (T 9_\
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MO^%']A:1_P! RT_[\K_A5+_A*]/_ .>5Y_X#M1_PE>G_ //*\_\  =J +O\
M86D?] RT_P"_*_X4?V%I'_0,M/\ ORO^%4O^$KT__GE>?^ [4?\ "5Z?_P \
MKS_P':@"[_86D?\ 0,M/^_*_X4?V%I'_ $#+3_ORO^%4O^$KT_\ YY7G_@.U
M'_"5Z?\ \\KS_P !VH N_P!A:1_T#+3_ +\K_A1_86D?] RT_P"_*_X52_X2
MO3_^>5Y_X#M1_P )7I__ #RO/_ =J +O]A:1_P! RT_[\K_A1_86D?\ 0,M/
M^_*_X52_X2O3_P#GE>?^ [4?\)7I_P#SRO/_  ':@"[_ &%I'_0,M/\ ORO^
M%']A:1_T#+3_ +\K_A5+_A*]/_YY7G_@.U'_  E>G_\ /*\_\!VH N_V%I'_
M $#+3_ORO^%']A:1_P! RT_[\K_A5+_A*]/_ .>5Y_X#M1_PE>G_ //*\_\
M =J +O\ 86D?] RT_P"_*_X4?V%I'_0,M/\ ORO^%4O^$KT__GE>?^ [4?\
M"5Z?_P \KS_P':@"[_86D?\ 0,M/^_*_X4?V%I'_ $#+3_ORO^%4O^$KT_\
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MKH=G!();>.0$D,H()&*DK"'_  E6T8_L7&.,>;1_Q5?_ %!O_(M2(W:*PO\
MBJ_^H-_Y%H_XJO\ Z@W_ )%H W:*PO\ BJ_^H-_Y%H_XJO\ Z@W_ )%H W:*
MPO\ BJ_^H-_Y%H_XJO\ Z@W_ )%H W:*PO\ BJ_^H-_Y%H_XJO\ Z@W_ )%H
M W:*PO\ BJ_^H-_Y%H_XJO\ Z@W_ )%H W:*PO\ BJ_^H-_Y%H_XJO\ Z@W_
M )%H W:*PO\ BJ_^H-_Y%H_XJO\ Z@W_ )%H W:*PO\ BJ_^H-_Y%H_XJO\
MZ@W_ )%H W:*PO\ BJ_^H-_Y%H_XJO\ Z@W_ )%H W:*PO\ BJ_^H-_Y%H_X
MJO\ Z@W_ )%H W:*PO\ BJ_^H-_Y%H_XJO\ Z@W_ )%H W:*PO\ BJ_^H-_Y
M%H_XJO\ Z@W_ )%H W:*PO\ BJ_^H-_Y%H_XJO\ Z@W_ )%H W:*PO\ BJ_^
MH-_Y%H_XJO\ Z@W_ )%H W:*PO\ BJ_^H-_Y%H_XJO\ Z@W_ )%H W:PK?\
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MLW%E99OYK/2+22WM6";I)&&2!EL<_A3=^I*MT+,>AW,=WD7EBML9A<% QR'
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MH5E'&?<"K"7,EE=Z?(^I>?'\JF&&YWG<3U_VA0T[@U9'0_\ "3#_ * VL?\
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MT?\ "3#_ * VL?\ @+_]>MVB@#"_X28?] ;6/_ 7_P"O1_PDP_Z VL?^ O\
M]>MVB@#"_P"$F'_0&UC_ ,!?_KT?\),/^@-K'_@+_P#7K=HH PO^$F'_ $!M
M8_\  7_Z]'_"3#_H#:Q_X"__ %ZW:* ,+_A)A_T!M8_\!?\ Z]'_  DP_P"@
M-K'_ ("__7K=HH PO^$F'_0&UC_P%_\ KT?\),/^@-K'_@+_ /7K=HH PO\
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MP_Z VL?^ O\ ]>C_ (29?^@-K'_@+_\ 7KF+/Q!=07M]+=.7=ED"*LN?+(.
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M$6B/=:J]VAE<!&A5<';UXKKJYO5+VTN=>T-8+F&5A,Y(20,?N^U=)0 4444
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MH_L#2/\ H&VO_?H53_X2S3O[EW_X#M1_PEFG?W+O_P !VH N?V!I'_0-M?\
MOT*/[ TC_H&VO_?H53_X2S3O[EW_ . [4?\ "6:=_<N__ =J +G]@:1_T#;7
M_OT*/[ TC_H&VO\ WZ%4_P#A+-._N7?_ (#M1_PEFG?W+O\ \!VH N?V!I'_
M $#;7_OT*/[ TC_H&VO_ 'Z%4_\ A+-._N7?_@.U'_"6:=_<N_\ P':@"Y_8
M&D?] VU_[]"C^P-(_P"@;:_]^A5/_A+-._N7?_@.U'_"6:=_<N__  ':@"Y_
M8&D?] VU_P"_0H_L#2/^@;:_]^A5/_A+-._N7?\ X#M1_P )9IW]R[_\!VH
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M)4]*Z7^P-(_Z!MK_ -^A7-:?XFT]/$^L/LN=K)  ! W936S_ ,)9IW]R[_\
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MLCRI/4]*KJ\XNHY5\+6@G ^0B]CS^%"V J-J-_;6.FW-KJ,E]<W4Z>9;M(H
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MC_P-3_"@#=HK"_M/7_\ H71_X&I_A1_:>O\ _0NC_P #4_PH W:*PO[3U_\
MZ%T?^!J?X4?VGK__ $+H_P# U/\ "@#=HK"_M/7_ /H71_X&I_A1_:>O_P#0
MNC_P-3_"@#=HK"_M/7_^A='_ (&I_A1_:>O_ /0NC_P-3_"@#=HK"_M/7_\
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MZ'^%']@77_0>U'_OH?X4 ;M%87]@77_0>U'_ +Z'^%']@77_ $'M1_[Z'^%
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MX130_P#H'I_WTW^- &KY\/\ SUC_ .^A1Y\/_/6/_OH5E?\ "*:'_P! ]/\
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M/VJ.1W$@7)P 1C%,\2>*9-/\0Z=80S"%#.BS;HR=X;L#C%.SNEW&G>_D:O\
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M^$QT'_G_ /\ R"__ ,36[12 PO\ A,=!_P"?_P#\@O\ _$T?\)CH/_/_ /\
MD%__ (FMVB@#"_X3'0?^?_\ \@O_ /$T?\)CH/\ S_\ _D%__B:W:* ,+_A,
M=!_Y_P#_ ,@O_P#$T?\ "8Z#_P __P#Y!?\ ^)K=HH PO^$QT'_G_P#_ ""_
M_P 31_PF.@_\_P#_ .07_P#B:W:* ,+_ (3'0?\ G_\ _(+_ /Q-'_"8Z#_S
M_P#_ )!?_P")K=HH PO^$QT'_G__ /(+_P#Q-'_"8Z#_ ,__ /Y!?_XFMVB@
M#"_X3'0?^?\ _P#(+_\ Q-8T'BO1!XONY3>_NS:HH/E/US]*[:L*W_Y'6\_Z
M\T_]"H RM7U3PWJ[1NVJR0N@*[DA?E3U'W:J6MYH46E7MF=7,37+8WQPOE4Q
M@#E?2M3Q7K-[I]Q:V]H) KJTDCQXR%7KUJ.75+R_6\N;"Y*16UH&#,O5R,\C
MZ4=!ZW1DL?#AAA7^VYF:.(1-NA?]X!RH/R]JD%UH;Z-;V1UR2%TD,LC1PN=[
M$]\K4L_B2_6YL%9I! +:.:>2,#DL<=#V^E7)K^]NX+Z^M[XP1B7RK90H.\CT
M'N:;N2K%(7'AL7GV@ZU,?F$C)Y+[3(!C=]WK1;77AZ&SFM9M=GGCFF\YMT+C
MG.<?=Z5+%K.K->J\ERB;+A;5[?;U)'+5.U]J$GAV\GDU%HKB"X=%>-!\W. ,
M&E_7Y#*^G>*M#C\3:N_VW$;) %/E/V4^U;7_  F.@_\ /_\ ^07_ /B:J^&Q
M<C6M3%V^^X\FWWMC&3L-=/3>X(PO^$QT'_G_ /\ R"__ ,31_P )CH/_ #__
M /D%_P#XFMVBD!A?\)CH/_/_ /\ D%__ (FC_A,=!_Y__P#R"_\ \36[10!R
M-UKVF:IXBT2*SN?-=97)'ELO&WW KKJPM:_Y#FA?]=W_ /0:W: "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#B[@W7_"4ZVL5I:309MBQN)=F&V'&*=)
M:7,:>5)HND(I#OM-QC[WWC^-4]?TV35KWQ!:1HSEY;3[O4?*>:S+G3-8OI8[
MVZLYO,CAEME3&?D"X!_X$::U''5V-F&P=]+EMX-(TEK)_P#6;+LE3CU;/]:?
M_9,XELV_L33=\ _T?_2V^4>W-41:J=+O)8],N(K4V:1^0(MI>8=PHJV[H;SP
M[+]@N]Z1LLKB(_("N,'\:.HNA/+'=ZJTX;2])N&.!+MNLD8Z9QTJ7.H?9(O^
M)9I7V>'B,_:?E7MUJ/P[:36LVH001.;,HQ5Y(!&Y<YXX^\/>N8@T'5ETAM)-
MI-]D&;KGN^[[O]:709T#6K7$;6?]DZ,RQK@QK=<J,Y[<CFG)933I!LTC2I!#
MS&1=EL8]\\_C6-9:9=+:ZC$UO<&5IM[1_9PN^/(R _4Y]*T[C3YK_4XIM(BG
MTR 6T@8^0/F/I@]*;"VMBY);7L\,5O)H^E/'DM&GVCUZD4Y_M\TD=PVEZ2S+
MPC_:>FW_  KGX++7O/L;L6#%-/5(\LV&8'[V!WJC#H.KVD5K%':3M!*)Y6'_
M #S<Y_G3L3O&YU4<%U!<%4T?2$FF8R;1<<N3U..^:2TL;FRE,]MHVE)(I*%_
MM))!/4<]/I5:RC?33.UUI4]Q>E$:WD";MN%X&>V#69'8:UI]I*+JPD*SR1W+
M>2=YW _-^.*22O8:U-]-)U"*[CNX]!T])XQA76X88%7+BZUN6":*>PTXQ[<2
M*UQP ?7TK3$UW>16T]F5BB8YD6="&Q].QKEM9\];[Q#;BUN7-W!&(72/<IPO
M/-*W0<5<9!I@N(XUM](TF58273R[UFV^O(-629Y+J?.G:,UQ<1B.7_2_F=!V
M/?%9?V&\M]*L+K3K>9Y\&VF4VXB.UAU('H>].M=)>QU'4H?)FW&+$0%L"&^7
ML_4<]J'H)%UM&DAMHF?1-,2& [T=KM@$_'-7YKK4Y[6.>6QTI[>)@Z2&Z^52
M.AS391#JO@HVT\5W"%14<>1E\CT4]:J7,-W+X&,<]F7*RJ1$D(4L@;N@XZ=J
M8NES1?6=72%97ATI8GX5VNP%;Z&J$=A.Z7 CT72663F;%R3[_A6/J&G2RW]I
M=16<\&G_ &AF6,6PDV#;UV'@9-*VDZI#J5]]CMI1#JC^5*VW;L4#[V.W'%%A
M]C6:"46,=D^E:0+>0Y13=_>/J#G)-6D34H5AVZ3I:+:\1G[1_J\USNGZ7)9:
M7):7FESRS20^7:-LW>6<G'/\/8YJV(;V.QU#39;:YDN7DB8.$)5L8R<T[:BE
MH:4-W=&2-(;/1B\+%D5;L$JQZTQ;>X&K2W TG2?MS?,_^E$M]=O_ -:JTVA-
M'?ZK+!IZH7N(3&Z1@9'?%0QZ?.T$=J+"9=3CE=YKHIPRG/\ %WR,<5)3+UII
MUQ;D&UT;2QYC;P!=%@3Z@9_E2I%-M:V32=&Q$I5HQ<_<!ZY':L[PYHVHZ9KV
MF1-;R_8EA>0,>D;-U4TDGAR]-MJ]ZT85O.E,4<<>)) 2.I[CTIV$MTC1;2KA
M;(6;:'I@@D<,%-RWS-VYZU*D%ZL#0)I.E^6) 67[23\XZ9]ZRM4.JZY+9M8:
M=,(K"-7S/F,F3V'?BJD>DZK%?I=QVDWEWFH;[B/^YCH_T[4):B;LCH[C3=2N
MD=)]"TYP[^8W[\@EO7(IWV'4]FS^PM-V^5Y./-/W/2NJHI#.9CAUF*.W1-&T
M]5M_]2!,?D^E5KC2+^ZNWNI]!T]YG^\QN&Y^HZ5U]% ',-;:N]RMRVB:<9EX
M5_..13K.+6M/B:*TT;3X8V8N528@9/4UTM% &%]J\2?] ZR_[_FC[5XD_P"@
M=9?]_P UNT4 87VKQ)_T#K+_ +_FC[5XD_Z!UE_W_-;M% &%]J\2?] ZR_[_
M )H^U>)/^@=9?]_S6[10!A?:O$G_ $#K+_O^:/M7B3_H'67_ '_-;M% &%]J
M\2?] ZR_[_FC[5XD_P"@=9?]_P UNT4 87VKQ)_T#K+_ +_FC[5XD_Z!UE_W
M_-;M% &%]J\2?] ZR_[_ )H^U>)/^@=9?]_S6[10!A?:O$G_ $#K+_O^:QH+
MGQ!_PE]V186GF?94R/..,9KMJPK?_D=;S_KS3_T*@"AJB:C=1HVIZ5IA1&RI
MEN2H!^M5%M+Z*TFL+C3]/DCN6:9U>Y(R/P["I_&EK?37-E+;J[Q(&^581("_
M\.0>WO54AM1TS5+V\MGE9(1:I%$I/S <X ]Z.@^J'2:=+%#;(=(TJ,(NVW)N
MCQGTR>:9+93_ &*+3KW3M,=;8[@)+HJ03W[<FJ#Q:CYVF74=O,$CM$5(Y;<,
M%8'YLY^[QWJ],5FT::^N;"2YEU"<[=D>_P I!P#BFR4RR+.X6^1AI&E?:O+P
MO^E'<5^G]:CBMI-,MVV:7I$,+R[VWWAVEQ]3UJG#I\B:@J&RN'D$ZR)<,G2$
M+TS_ $JS90BX\.WUI'I<A9KIA$D\/0,?O#- >H[3+S79/$FKR0V5DY9(,XGR
MN-IQ@]ZV_M7B3_H'67_?\U7\/6B6&NZI:Q@!8HK=1C_<-=+28S"^U>)/^@=9
M?]_S1]J\2?\ 0.LO^_YK=HH POM7B3_H'67_ '_-'VKQ)_T#K+_O^:W:* .1
MNYM6D\1:(+^TMX8_-?!CDW'.VNNK"UK_ )#FA?\ 7=__ $&MV@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH X74+A[#Q%KMZVL-I]NOV9&Q ),DH<=:L
M7E[/8W"03^*G$CPF=0+-#E!U--O]);6M7U^S7;@R6I;=Z!#5,^#-491+++%+
M< 2H#G^#&$%->8UOJ6X=1GFLI;K_ (2>9$B 9@]BH8 ]#BK.^\%Q:P?\)0_F
M72EXA]C3D8S47]C:Q)97,TEM +IK1;6.$2\8'\1-22Z;K$KZ,/L<(%JC+,WG
M#(RNWCUH>XE86T.H7KS"'Q'.5A^\YLE"GZ'O51=4=M(_M0>+'-J)/*W?8TSN
MSC&*L>'?#5[I4]QOVQQ-$T>T2%A(Q.=Q!Z5F1>!M02%K<RP_9]A<1@_\ML]?
MRH'H7(M2GE%PP\2W C@X>1K%0N?0'N:FMKB\NG$:>)9UD*%]CV*J<#K5.T\)
M7T,-Y&;2%97F$R3^<2'P00I7M5^\\.W.NW\5UJMK"BQP.@C24\,>AR,4,-+C
M5GNFGM81XI?S+I2T0^QI\P%5HM6,]N)X_%KLA=T_X\TZKUJ&'P=K*F&;[='&
MUJ$6&$*""!URW45 / FHQFU,4D*@)+YZ9X+-G!'YT61/V;FHES=R7:6T?B:9
MW< Y6R4A<C(R>U$=W<2QS2)XJ<K#-Y#_ .AIP_I4EKI.M:7%<6]G%;R"= ?-
M=\%&VXZ=ZSAX/UBRMR(;J*[9_+=D91'\RG/4=?K0K7&O,Z'^R=:_Z&)__ 1*
MHS&^M_MGF>)Y ;-0TP%FGR@C(K<%K/>Q6TMS)/:S1G+102_*?8\<BL#5='U6
M:^UA8+>*2WU")%#M+M*E1CI2'&SW(K2\N[QMJ^)+B-C&90);%5RHZD5'!J=Q
M<RND7B2Y8(NYG^P+M'XTDOA>_DTBQCM;>*RN;=]KCSBX:-AAN:E3PS<V^HW[
M1643)/'MCG\X@K\N,;:'Y"+LD.HQ6'VU_$SB#;NW?9$Z56EFOH-*.I2^(KE(
M <8-BN[GVJ>YTG4-3\)'3;FWCBG3:%42Y#A?<=,U$=!U%?"TEFBH;@S++'"T
MN50 YV[C3%K8JOJDZ1PM_P ))<LTKE%C6P4OD<G(J6"]GN#>*GBIPUD-TZM9
MH"@QFJ^H>&-1O;ZWU&:TAE<3%Y+83%0!MP/F'4T3>#K^6_>:-HH8KF3%RF[)
M:/' ^N:.@WT%&KN\,,R>*9GCE4/N6Q4A1ZMZ5<:2[6":?_A*7,<+!7(LTZGI
M52R\-ZMIMC-90Q6\D=U&8Y&+X\KKT]>#3QX=U2&WN].CBB:VE:-DF,G/RXZC
M\*=E<4KK8BBU>:6ZEMQXCNE>)@K[]/4 $].:G%]<&Z-N/$\V1D!_L2["1U /
MK5JX\/7<MSJ,@9-MQ-$Z<]EZU73P]J9M8]+=(1:02-(DX?YGSD@8[=:DIA87
MD^I?9_LOBMY/M&[R_P#0TYV]:A_M27S[B(^*)E,!(8M8J 2.N#WJ32/"5WIF
MO65VKQBVCA(E0'I(>X^M.?P?(;/4Y#(TEW/+(\"O)^[0,1T'8\4]!+=$UT;V
MR-KY_BAT^U,%B_T1.2:KQW\TLLT2>*W+PSBWD7[&F0YZ"HKOP[KVM21R7,L5
MBMM"$AC7$NYO7/:HO^$-U$75M=J\*S?:_,N!GATZC\0:-!-OH=!_9.M?]#$_
M_@(E']DZU_T,3_\ @(E;M%(9A?V3K7_0Q/\ ^ B4?V3K7_0Q/_X")6[10!A?
MV3K7_0Q/_P" B4?V3K7_ $,3_P#@(E;M% &%_9.M?]#$_P#X")1_9.M?]#$_
M_@(E;M% &%_9.M?]#$__ (")1_9.M?\ 0Q/_ . B5NT4 87]DZU_T,3_ /@(
ME']DZU_T,3_^ B5NT4 87]DZU_T,3_\ @(E']DZU_P!#$_\ X")6[10!A?V3
MK7_0Q/\ ^ B4?V3K7_0Q/_X")6[10!A?V3K7_0Q/_P" B4?V3K7_ $,3_P#@
M(E;M% &%_9.M?]#$_P#X")1_9.M?]#$__@(E;M% &%_9.M?]#$__ (")6-!I
M>K_\)?=H-><.+5"7^RIR,],5VU85O_R.MY_UYI_Z%0!3OUU'31'Y_B28M(<*
MB62,Q_"J]PUWISF-_$4D:B(S/MLD^4>_O5KQ5X?N-7N+6>W57:)67!D*;2>C
M CTJO::;J,FE:F[1>=>2K]FC\UMN548SGW/-'0>ET))->9MT_P"$DFD-RH9%
M2Q4_*>Y]!4<]Q=V$DT#>(9@MOM#>78H0,\]JJS>&-49K.Z:)$FBMEB8I,<Q%
M3G(Q][-7TL-7_L']Q;I)<WDQDN1(^T[3V'X4VNQ*N1B^G-VEL/%,A9P"&%DN
MWD9QGUI'O;M; WJ^([F6!7*$QV"D@CK3XO#^I17018(5M3.MS]_E2!C9_P#7
MJ:STO6#I%[9S0PV[3W!8%9-WR$\_C2&9NB6VI7^N:I/;Z_)M>.!MYM%RP*G'
M':N@_LG6O^AB?_P$2F:/"EOXEUB&,81([=0/^ &N@H8&%_9.M?\ 0Q/_ . B
M4?V3K7_0Q/\ ^ B5NT4 87]DZU_T,3_^ B4?V3K7_0Q/_P" B5NT4 <C=6.H
M6WB+1&N]5:[0RN A@5,';UR*ZZL+6O\ D.:%_P!=W_\ 0:W: "BBB@ HHHH
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M7J?K3OLFA%K60W=_YMO<&?>+8Y?/\)XZ4:"=^AU/_"(:+_S[2?\ ?]_\:/\
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M_O\ XT?\);IG_3S_ -^&_P */^$MTS_IY_[\-_A0 ?\ "(:+_P ^TG_?]_\
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MMV>I>(M$BM_.W+*Y.^(J/N^]==0 4444 %%%% !1110 4444 %%%% !1110
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M^%']J:]_T+?_ )/1_P"% &[16%_:FO?]"W_Y/1_X4?VIKW_0M_\ D]'_ (4
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MJ!65+A;<VXQM92O+8_K4XO)Y_#EY))JLYG@N71)('"ECG"BK86^$PE'A"+S
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MV]CZTFO_ &&UU?7M0NK..X>-K6-?,9@ "A_NU9@L=+:ZTR%]'@9+Q6/FI*^
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M^>B?]]"LG_A$]#_Z!Z?]]M_C1_PB>A_] ]/^^V_QI :WG1?\]$_[Z%'G1?\
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MQ86&Z_EL](MY;>U8(6>5AD@9;O3?F2K#H=(O8KH1+:PBV-PMR',RDK@8V?\
MUZL6-MJ1T:^LVM8K5Y[@E?WZD;&/)XK.B&E37*%="C%J9!"[&5MPD(SC&>E2
MFQLI-&N+V'1;5)()61TEF?&![@]:7]?D/JC9T58+7Q'JT*.@1([=1R.R&NA\
MZ+_GHG_?0KA?#V@:7>ZOJ,EQIB1L8H&\L.V%RI]ZZ3_A$]#_ .@>G_?;?XTW
MN"V-;SHO^>B?]]"CSHO^>B?]]"LG_A$]#_Z!Z?\ ?;?XT?\ ")Z'_P! ]/\
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M[INJ>(=$BL[GS765R1L8<;?<5UU-,:%E8HI9>A(Z4Z@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g201711142133437335635.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201711142133437335635.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,E G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT8/M)./*S\V:U:XA[:W_ .%KPD0Q_P#(/+9VCKNZUV]+HF/K8**** "BBB@
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M-OE,(SM;(R.:V*PK+2+A+NP:XV&&TM0B@'^/&":W:;L(****0!1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"H)'*<8R*6WT?3K6]DO(+.*.YD^_(J\FKM% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 445Q]U\0+6UNY;=K&X8QL5)'?'X4 =A17$_\
M+(L_^@?<?Y_"C_A9%G_T#[C_ #^% ';45Q/_  LBS_Z!]Q_G\*/^%D6?_0/N
M/\_A0!VU%<3_ ,+(L_\ H'W'^?PH_P"%D6?_ $#[C_/X4 =M17$_\+(L_P#H
M'W'^?PH_X619_P#0/N/\_A0!VU%<3_PLBS_Z!]Q_G\*/^%D6?_0/N/\ /X4
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MGDQ?\\T_[Y%'DQ?\\T_[Y%/HH 9Y,7_/-/\ OD4>3%_SS3_OD4^B@!GDQ?\
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MEWE#INF?(P+.%&"IYX]ZU]?U%M-U6SDM[>S^RRVV[RWC RQ(P?H*Z\:/IH
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M67_/I!_W[%6:*0%;^SK+_GT@_P"_8K%T*RM7N]6#VT3!;H@90<#%='6'X?\
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M_/I!_P!^Q1_9UE_SZ0?]^Q5FB@# TV*.'Q5J:1(J+Y4?"C K?K#L?^1MU/\
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MMUGE\MTA<!<8SZ5BP>)-4T^S"2V]M<LY80O(3N.&Q\W_ -:B(F[&'=V:O!+
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M]DT0B.))!]UOPJM+8:9#IN!J,32I(\A,<3%F!&,4,6IVDB^'CI\URD%M-!&
M'\M0>G2I[B/1(;-%NH[:."8A@K@ $]JXC1;^*YT35([B2"SFNF C4Q,H&!U(
MZT:K%%K:VKWU_IQD@3RPBK+L*^OKF@:.[FDT@VD8E:V-NGS(&QM&.XJO;_V'
M>3&T@MX)%V>9E4&W&?\ &N(N-(TR:*XB_MB,PG8;>(HP5<=0<=C6IX;_ ++T
M.=I6O[?#1[2D2-@'/;-,.AU&EW>EW=Q/%8QJ&M#Y;$)@#/.!65<ZAX?BDNA'
M;,98)DWB&/EW/0#UJNMUI8O[JX76'@6:17 @!4\#H>*K:E+87%S/<VNI6Z2E
MXY(PZ-C*^N/6EU0WY'1:=;Z1JEC)+%81JDCD2QO'@AAU!'K5M='TU)(I%LH0
M\0Q&P3[OTKG]#U>STV"1+F_MW,LC2N8U;[Q/;/:M?_A*-'_Y_%_[Y--DHG?1
M;&75#J,L*R7&P("W( 'I3_['T[$H^Q08E.7^0?-57_A*-'_Y_%_[Y-'_  E&
MC_\ /XO_ 'R:0RY'I=A%&42TA53C("C!Q2P:;96LSS06L4<CC#,JX)JE_P )
M1H__ #^+_P!\FC_A*-'_ .?Q?^^30!8;1-+<,&L(#N;<?D')]:A@\.:5;W$L
MZ6<9>3KE<@>PIO\ PE&C_P#/XO\ WR:/^$HT?_G\7_ODT 3C0]+6(Q"P@"$@
ME=@Y(IMWH5A=VSP^2(MRE=\0VL >H!]ZB_X2C1_^?Q?^^31_PE&C_P#/XO\
MWR: +?\ 9=D;"*R:VC>WB "(PR!CI2QZ781)LCM(57=NP$&,^M4_^$HT?_G\
M7_ODT?\ "4:/_P _B_\ ?)H O6VGV=G([VUM'$S_ 'BBX)K,\/\ _'YJ_P#U
M]G^52_\ "4:/_P _B_\ ?)K'T77]-@NM3:2Y"B2Y+)P>1B@#KZ*R/^$HT?\
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M[-%:,NY0,;3]:LGQIJD-EYH>VE=6\H1 ?/P!^\/L:T=)\2ZH_B".POGMVC?
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MDTBI+=WZ/ KLR?O1'(>H)["G8;5CH/\ A*[#_GC>?^ [4?\ "5V'_/&\_P#
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M$MO$Q<(EN,^8.GS?3FK>D>)=3C%E8W,D=Q<7C?N9 O  /S ^X%'*Q=+G0_\
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M '[- &W=Z/IU[#)'-9PD2#:Q" ''UJ1=-L5@2$6<!C3[JF,8'Z5@?\)O;_\
M0.O?^_9H_P"$WM_^@=>_]^S0!T0LK0/O%K"&(QGRQG%0+I%DNHI?+$!,BE4
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MSKI:P['_ )&W4_\ KE'6Y0 4444 %%%% !1110 4444 %%%% !1110 4444
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M?FNXPFT18(V[?K702^/(EM[5H[9V:1@LK[3Y:$C.,]S5Q/'&E$?.+A1DKO\
M*.UF'50>YHV'M8Y6+4O%/VB0O=N(<XE187+QIGA@3QG%;-E-?V_A":2WDN2Y
MN3F5D_>",GE@/7%;5MXGM[N: 1Q2HCS&!_-3:ROC(&*W:&3U/.8;SQ%(;J9+
MJ\,%N4-ON3!F!8 [OPJUXGM;V?Q#%Y4]V@D2/:(\[1AN3]:[RBEV'T/,EO\
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M23UR,&DLO"^G6-W%=QB9[B(G;)))N.",8^F*U?M5O_SWB_[[%'VJW_Y[Q?\
M?8IW=[B):*B^U6__ #WB_P"^Q1]JM_\ GO%_WV*0$M%1?:K?_GO%_P!]BC[5
M;_\ />+_ +[% $M8?A__ (_-7_Z^S_*M?[5;_P#/>+_OL5AZ#<0K=ZL6FC&;
MHD98<\4 =#147VJW_P">\7_?8H^U6_\ SWB_[[% $M%1?:K?_GO%_P!]BC[5
M;_\ />+_ +[% $M%1?:K?_GO%_WV*/M5O_SWB_[[% &;XH_Y%ZZ^@_F*TK;_
M (]8?]P?RK(\37$#>'[H+-&20. P]16E;W5O]EB_?Q?<'\8]* +5%1?:K?\
MY[Q?]]BC[5;_ //>+_OL4 5KC2+.[>5YXR[2J%))Z >GI5Q%V1J@).T8R3S3
M/M5O_P ]XO\ OL4?:K?_ )[Q?]]B@"6BHOM5O_SWB_[[%'VJW_Y[Q?\ ?8H
MR+'_ )&W4_\ KE'6Y6#ISK)XKU-D8,/*CY!S6]0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(0""#T/6EI
M"2%) R0.E '(:AI5O+JDEEIVF6C21QB65IV;!SV&.]9U]>:!8VTF_1\21GRR
MW/EB3^[G-6-<OE-]')<V5W:7!&P/%<A#(N>A]JK?V5!?[F71KV2$MEHUN04W
MC^+'K0@9*U_X7BTV*[DTUCO!^502<C&>_O4<FJ^%X4W2Z-.A+% "IR6';KUY
MJO<Z;96DJ+<Z7>QAR?+C>Z&T=,X'X"M"YTS[9Y9DT"\.R4S+B<?>./\ "JTN
M)WMH6"/#,>C7&I3:<8HX&V.C@[@WIUK.CU;PK-&K1Z3,W!9P%/R '&3S6G+%
M-/97-J^@71CN'\Q_WHR&]15&&S5&DM_['O))C%MDWW"EBI/4U(W?H1W5]X>C
M02PZ2?LXE"-,X(4CN1S2S:IX6MXPTND3*[89$*G+*>C=>E+_ &&IW*VA7[1%
MMPA-R-@/? IK:"7B*-H^I%L!5<W(W*HZ*/:GH)7OJ3/?>$TL3=_V>QC\PQX
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MC'^9J+^V=4_Z 4__ '\6C^V=4_Z 4_\ W\6@"7_A&-&_Y\8_S-'_  C&C?\
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M,WEB^U8_(79MQPN.Q]ZGN+G1[>X2 WFK.[1B3Y&)PI&<G\*EBZF.NA>(EL)
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M:-6(() )![4:[@]3%_MS4/\ H 7G_?2T?VYJ'_0 O/\ OI:W**0&'_;FH?\
M0 O/^^EH_MS4/^@!>?\ ?2UN44 8?]N:A_T +S_OI:/[<U#_ * %Y_WTM;E%
M &'_ &YJ'_0 O/\ OI:/[<U#_H 7G_?2UN44 8?]N:A_T +S_OI:/[<U#_H
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MC)=<FJFO1W$NII):QS&&( W87(\Q<]![UTT15HD9/NE01]*%L#W,;^W-0_Z
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MG_X1O_J*7W_?RG^%M,N=&\.VMA=M&TT0(9H^AYS6S0[7T P_^$;_ .HI??\
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M/^$;_P"HI??]_*/^$KT__GE>?^ [4?\ "5Z?_P \KS_P':@"&ZT(VUL\PO\
M4)-@R563G%5M,L(=51Y;;4M0,"G"R&3ACWQ]*GO?$EE<VKPI]LB+\%A;MT[U
M6TO5M,THR1P"\^SM@K$;=OE/?'UH0&C_ ,(W_P!12^_[^4?\(W_U%+[_ +^4
M?\)7I_\ SRO/_ =J/^$KT_\ YY7G_@.U &9K^A?9]%N)?[0NY-H'RN^0>:OP
M>'=UO&W]IWHRH.!)[51U_P 1V5UHMQ#''<AF P6A('7UJ]!XIL%MXU,5WD*!
MQ;MZ4 2?\(W_ -12^_[^4?\ "-_]12^_[^4?\)7I_P#SRO/_  ':C_A*]/\
M^>5Y_P" [4 '_"-_]12^_P"_E'_"-_\ 44OO^_E'_"5Z?_SRO/\ P':C_A*]
M/_YY7G_@.U !_P (W_U%+[_OY1_PC?\ U%+[_OY1_P )7I__ #RO/_ =J/\
MA*]/_P">5Y_X#M0!6T2U^Q^)-2A\Z27$49W2')KI:YK1+V*_\2:E/"'"&*,8
M=2I_*NEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#EM8O1IVM73W#2K%/9[(2JLP+YZ<=ZY2'7]>M
M86@MII9KJ"0(;4Q$[8\9+%O45Z%>:YI^GW#17EPD. ,%CUSVQ54ZKX=3S4^U
M6Z_:5,KX)&\8ZFA;!H<K8:[JU[?>3!J,TUO&&9Y!!@DA<[?SJA%XGUR>>:":
MZFCLF&[[2+<DH<?=Z>O%=OINI>'+,);6%Q!'YOS* 3\WXFISXHT,(S'480%;
M8>O7\J8+0XKP_J_B'^TM/M))-EO\H\N2-MSKSEL]JLZ_J>JKK>V&28RPRDQ6
MRQ':R[?O9KLO[>TKSV@^W0^8J[R,]OKTJO9^)M,O8KR>.<"WM" \S<+S0]1)
M61QW]LZ_<2M':7LSP)"9/.-O@EP,E,?6FZCKOB:V/E)-M0JCF=XC\I*YVX ]
M:[)/%6CL?FO8D!?8A)/S'\N*ED\2Z-"\B2:A"K1\,"3_ )/X4#1Y_<:SXAN3
M<6]Q<S+]TD0P$>6!CGFM/3-8U);RSAEGFA@8DIBW+><=V,'TXKL[/6M-U"=X
M+2[CEE0991G(J_0M&!P'BG7_ !!I>N?9[**26W $I*Q$_*>-OUS61K.N^(&E
M>T2XN%)^215A.5&,[AQ7JU%): SR^'7O$OFR(EQ\JQX6,PL6Q@8;IBMWQ'?Z
MMI>E:8T%VYD<YF?RLECC(''3FNSHIW$E9GF2>(?%$UW-E_*.P_N/)8L@XPW3
M%7-1U'78DN-//FS&!5E,YBXD#$87CN*]!HH3LRD];GFUWXAUQ;:;R;EUF\W;
M*'MSMMUSUSCFM:]U?6K3P?;:BN9;H':X2,_,#P#CKUP:[.BET$M#R2?4_$NH
MZ:QNC/#)$NQWCB()92-Q'M72>%Y=2BO(Q)<336L\DIVR(1C'0Y]Z[>BG<35S
MS(ZWJNG&Z6%[DK]IE#@PDB-<\,#WIUEXCUJ:*-+RXFB02.BRI;EC-C[HZ>E>
MET4AGD*C6-1\,I97C746QRR*JM\Z9;DGKG-7K;6=?@LHH89)EN(@%6V,)(:(
M#._/K7J%%-O<%HK'">$-<U[5=3DCU"*2*)5,P+1[05;[J_45FCQ#KMQ+&EG>
M2RF2=HY\0<0 -@$'OFO3:BM[:&UB\N"-8TR3M7U-%U<'LT>?P:OXF_M6ZA:<
M,(5<^3Y1W87H<].:KS>(_$\UW!*G^BPS /%%)$Q+YZKP.U>FT4@/,M1O=?>U
M037=P$D59F*0XV8?&/IBE_M[6X;=O*>59U_X]X/()$P[L3VQ7IE% ,Y30[_5
M1]K6]DDFVVRS(3'@AB.0*YFQ\0^(M0U=;-+J5;>0%_-\@Y7C.WD>M>HT4[ZW
M&F>;1:KJM_J&FK>S3QR"X3]PL) =><L376^'_P#C\U?_ *^S_*MRL/P__P ?
MFK_]?9_E0V2E8W****0REJQ0:9-O#G*X 3.<]L5F^&1<QI/%J&\WP(+LW1E_
MAQ6_10 4444 9'BC_D7KKZ#^8K2MO^/6'_<'\JS?%'_(O77T'\Q6E;?\>L/^
MX/Y4 2T444 %%%% !1110!AV/_(VZG_URCK<K#L?^1MU/_KE'6Y0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %(3A2<9P.E+10!PFI1R7NNI?G3[S$;+\OE@YVYK+72[R(3116MR()Q^\#6
MX+9]CV%7?%6JC1_%ZW=M@W(M0H5]Y7)?'0<9Q1<>,=4N-/D-J8!+M."L;GD'
MD].E"6ET#CK8I3Z+YNIBZ73+D?*N6:(EE8# QSBJ'_"-WIG:X:VN#,P R83V
M&,]>M;-WXEEO5D@O"/+AEB:.6-'7)SS5XZ]-IGAJRFLF1Q)=&(F56.%R>?6F
M"?0YY/#(65RVGW;AAD2-&?,W?GC''I6I%;WC:=J-O<V5RTEZRDM'" %VX[?A
M2VOCO5KN]\J/3D\L0E]Q##<1U(K4TGQ/?ZO]J1K)H%2!I4<J0<$?+^-%VD-,
MP-1TF>\O'N([*Z0NX.3#RHQVJK;^&O(NDD&G7)$<HD5S$2[<Y.><?E6I;>*M
M=M+&"*ZCC+L@;[1(C8 .>&QWK3T/7=:O(M4EO(XEDA4/# $(.,9Z]Z>JU[$I
M[6ZF;8PWMAK<^H0V-RJR,2(Q%USUS_\ 6KIO^$AEQ_R"+[_O@5SC^.=4:UGE
M33S'L7S$+QL<J>GXYJM'XVU_[))>/:QD- CQP>6V5))!)/I2Z#\SK?\ A(9?
M^@1??]\"C_A(9?\ H$7W_? K-T+Q%J^J27+SVD<<,%NL@4 [G8@G@_A6(GBK
M6&NI+EL%,H%0!@B<'(/%%M;!T.M_X2&7_H$7W_? H_X2&7_H$7W_ 'P*Y;_A
M+=>WK*BV[));!DC,+#+[L'GVJ&7Q+KUGXA=2=R(C#RF5BLC;A]WC@T6#I<Z_
M_A(9?^@1??\ ? H_X2&7_H$7W_? KF+KQEK4UN5MH(X)HP&F+QL=GSXQ^5*W
MC#5[:#Y+99'7)575B9N?X>./QHLP.F_X2&7_ *!%]_WP*/\ A(9?^@1??]\"
MLBSU_6[_ $;4FD@C@N4M?-@95/!(/!]ZS;;Q3KEA:)!)$+F:.$,P<,7<[<[L
MXZ9XH::#I<ZG_A(9?^@1??\ ? H_X2&7_H$7W_? K/U#7]4L-'L)W2 3W";W
M8JQ5>,A<#G)Z57L/%.M3WB^=I@,+$J(T!#Y SU/%%M;"NK7-C_A(9?\ H$7W
M_? H_P"$AE_Z!%]_WP*Y:XU;7[35KV]8S/$LF([7!VJ-O>IF\9ZLJ+BW@89^
M64(VV;V7T/UHL%SH_P#A(9?^@1??]\"C_A(9?^@1??\ ? K.L]8U>_\ "K:C
M<1BWF>3Y(XU.Y0&QSFN:G\:ZW/=JL:B&."?[YC;:ZX/##%+K8;T.V_X2&7_H
M$7W_ 'P*/^$AE_Z!%]_WP*R-;UC5I=+TYK&WN%NI%\^98AT4=0<^M9TFM>(;
MF*X>WCD$#70"OG#*-O0#'3- '4?\)#+_ - B^_[X%'_"0R_] B^_[X%<R_B?
M4(4@E@E,AAM@MP)4; D+?3DXKN;"[2\M4D5LM@;A@C!IV S/^$AE_P"@1??]
M\"C_ (2&7_H$7W_? K<HI 8?_"0R_P#0(OO^^!1_PD,O_0(OO^^!6Y10!A_\
M)#+_ - B^_[X%9.CZU)#<ZDPTV[?S+@L0J_=XZ&NRK#\/_\ 'YJ__7V?Y4 '
M_"0R_P#0(OO^^!1_PD,O_0(OO^^!6Y10!A_\)#+_ - B^_[X%'_"0R_] B^_
M[X%7]69%TR;S-_*X79USVQ6;X9-R(YTU N;\$%RW0K_#B@!__"0R_P#0(OO^
M^!1_PD,O_0(OO^^!6Y10!R&OZW)<:+<1'3+N,,!\SKP.:OP>()5MXQ_9%Z<*
M!D*/2K/BC_D7KKZ#^8K2MO\ CUA_W!_*@#(_X2&7_H$7W_? H_X2&7_H$7W_
M 'P*W** ,/\ X2&7_H$7W_? H_X2&7_H$7W_ 'P*W** ,/\ X2&7_H$7W_?
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M/RD$'IVJ""ZLIO.*^*KE1')Y1) Y/Y=*J_\ "N[B/2S917\3JQ8'S%. A&%
MQZ4S_A6\ABC1Y[68(>!(K8Y !/!Z\4:!T-F*TCN&F2+Q-<.81^\ V_+]>*SH
M;NTN+N:!/$=T5AP&D(4+R,^E;-AX76ST:^T_S5_TEV8.BXV@@8'Z5D-X%NYY
MIYKBZM"T@ "I$=N N!FACTL+]ML$N5@'BNX&Z/S P VXSCTIEM=VES<^0/$E
MTN5W*S!=K<X]*(O 5TOD[[R!L'YUV$@#<" O_P!>IF\#W'VJ5DO(5AF4HZ^5
MR!NW<'L:-!/;06_>UTV&&6;Q-<[96VQ[0ISSCCBGH+=VC#^)YTD<;@K;<X_*
MJ[>!KYEB0WUN4MP5@!C.<%L_-3O^$&N?)DMOMD/D3$/(VP[PP[*?2D+4N6UI
M%>I*]MXFN)1&,R%0O'Z5 @@80F3Q+<Q-+_JU<*"1Z]*T;'PV;&.95E7]Y:B#
MY5QR,\UB7G@S4-5BA\RXAA$:HNUU)*E3U&/6GU#H6P]GY4D@\6S%8^&P5_PJ
M+S(_[/MK\Z_>B"XE$*.P48)]3Z4YO!$T;6<UO<P":U3 #QY5SDGD?C6@/"YD
MT6QL+F2&06]P)G&SY6Y)QC\:-+@9!O86NKFW&OWSBV4LSKM*G S@'UJQI).K
MK"UOK>H#S(O-^95!4=.?>I+OP0DLDIMIH[:.2X64K&F/D'5?QK2TKPZNF3ZE
M)YQ=;IB44#'EJ1T%&EOZ_K_ABGOH9O\ HI$I_P"$LG/E??Y7C]*15M&DCB7Q
M7*6?E%^7_"L6+PAJ.JRR17<,4,%N-L!D0KYN#GYL<UIP^ %CL98!+#&960DQ
MH0%QUQGFDA+<G+6B[E/BV<;6VD9'7\JK75S86L;.WBBX?#A"%52<G\*;IWP]
M%E?03[[8>0V051BSCU;)ZTT^ ;Q[EIWO+8OC"G8>?FR,_P#UJ>@RY&]NRQ[_
M !3<1LZDA6*YQ2KY+Q[X/$UU*@<(Q3;\I/3/%4V\ 7)M9K7[;#Y5QM,K%#N4
MC.-I].:T&\+RV\/E0LC"1(HVPN,;#R:-"5?J.FLHH)/+F\33HY?;M;;RV,XZ
M5CW.MV5G<20MXDO2R#=\@4@C.,]*O^)/ SZYJBWD5\+?;&,+MS^\'&[\N*KO
M\/Y!<N\5U#LDX8,ASC(/'Y41MU+5NI9\^#*G_A*KGRBN[S,KCKC%:%MIDUY
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MB=%A<P8\U2<%C3XM;U^+6[>WEFF>-9S'L\D@R#/7/3I7HU%"8GJ<5JUQJ_\
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MRR'J^/6O1Z*+AT.9\'7/F6,T<D\LTAE9U:5"I9<]>:Z:BBD(**** "L/P_\
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MF9@0!UR.U4Q+X4,K1B_O"Z@$@3,3ST_E2:-/)9ZQJ6H3Z7>@W+XCC"Y"K_\
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M\_\  AJ/^$4T_P#YZ7G_ ($-1_PD9_Z!=]_W[H_X2,_] N^_[]T '_"*:?\
M\]+S_P "&H_X133_ /GI>?\ @0U-/B= 2#IUX-O)RG2E'B3(R-,OL?\ 7.@!
M?^$4T_\ YZ7G_@0U'_"*:?\ \]+S_P "&H_X2,_] N^_[]T?\)&?^@7??]^Z
M *VB645AXDU*"$N4$49R[%C^==+7-:)=?;/$FI3>3)%F*,;9!@UTM !1110
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M>R!(TVR, 64E1D U,VN;+"2X?7+[>I^6-54[AQSGL.:L0ZM"Q"3>);R.0G!
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MXBC/F.!DUTM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!GSV 'R>Q--)[AS6:(MFD1P-%;WNHQ;UV2'[,#N7CCVZ4]!H207<1EU!A<J
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M_/)/^^16)H$49O-6S&AQ='&5'I2 K_\ "<Z9_P \;O\ []&C_A.=,_YXW?\
MWZ-='Y$/_/)/^^11Y$/_ #R3_OD4 <K>>,--N[5X +V+?P66$YQ5?3O$FCZ8
M\HMTO! ^"(O).%/<CZUTVJQVR:9,74)\O!1><]L5F^&5DDCG&H(/MP(WJ5&
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M&P02.HRQ[8&,U7/@,%5C;4G\B/<8DV#Y2<<Y[]*6'P,/[26^N-2,LQF64XC
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M3$CDX'DK@ GG/K70?\)$_P#T";[_ +XI=!]3;P/2C ]*Q/\ A(G_ .@3??\
M?%'_  D3_P#0)OO^^* -O ]!1@>@K$_X2)_^@3??]\4?\)$__0)OO^^* -O
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M F^_[XK)T?6FAN=28:==OYEP6PJ_=XZ&@#LJ*P_^$B?_ *!-]_WQ1_PD3_\
M0)OO^^* -RBL/_A(G_Z!-]_WQ1_PD3_] F^_[XH W**P_P#A(G_Z!-]_WQ1_
MPD3_ /0)OO\ OB@"7Q1_R+UU]!_,5I6W_'K#_N#^5<KK^N/<:+<1'3;N/<!\
MSIP.:OP>(76WC']E7IPH&0GM0!T%%8?_  D3_P#0)OO^^*/^$B?_ *!-]_WQ
M0!N45A_\)$__ $";[_OBC_A(G_Z!-]_WQ0!N45A_\)$__0)OO^^*/^$B?_H$
MWW_?% !8_P#(VZG_ -<HZW*YK1+HWGB34IC!)#F*,;)!@UTM !1110 4444
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M\2/=P7%Y-=#_ $E8VA(^0QD')(_*JY17TN= /%,!<H+&\+CJOE\BE_X2:/\
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MWW_?JMRB@##_ .$EC_Z!]]_WZH_X26/_ *!]]_WZK<HH P_^$EC_ .@???\
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M8M_^?V^_[_FC_A*;3_GTOO\ P'-'_"4VG_/I??\ @.: #_A&+?\ Y_;[_O\
MFC_A&+?_ )_;[_O^:/\ A*;3_GTOO_ <T?\ "4VG_/I??^ YH /^$8M_^?V^
M_P"_YH_X1BW_ .?V^_[_ )H_X2FT_P"?2^_\!S1_PE-I_P ^E]_X#F@ _P"$
M8M_^?V^_[_FC_A&+?_G]OO\ O^:/^$IM/^?2^_\  <T?\)3:?\^E]_X#F@ _
MX1BW_P"?V^_[_FLG1]!AGN=24W5VOEW!4;92,\=ZUO\ A*;3_GTOO_ <UDZ/
MK]O;W.I,UO=MYMP6&V$G''>@#6_X1BW_ .?V^_[_ )H_X1BW_P"?V^_[_FC_
M (2FT_Y]+[_P'-'_  E-I_SZ7W_@.: (;KP]#;6TDRW-_)L&=HG.2*JZ5IMG
MJ\3SV]UJ'V<'"R&<_,>_'M5B\\0VUU:O"L.H1;^"RVYSBJ^FZI8:6TJV]O?B
M!\$1?9SA3W(^M &A_P (Q;_\_M]_W_-'_",6_P#S^WW_ '_-'_"4VG_/I??^
M YH_X2FT_P"?2^_\!S0!F:_X?AMM%N)EN[MBH'#RDCK5^#PS;M;QM]LO1E0>
M)CZ50U_Q#;7.BW$*6UVK,!R\) Z^M7X/$]JMO&IM;WA0.(#Z4 2?\(Q;_P#/
M[??]_P T?\(Q;_\ /[??]_S1_P )3:?\^E]_X#FC_A*;3_GTOO\ P'- !_PC
M%O\ \_M]_P!_S1_PC%O_ ,_M]_W_ #1_PE-I_P ^E]_X#FC_ (2FT_Y]+[_P
M'- !_P (Q;_\_M]_W_-'_",6_P#S^WW_ '_-'_"4VG_/I??^ YH_X2FT_P"?
M2^_\!S0!6T2S6Q\2:E DDD@$49W2-N/YUTM<UHEXE]XDU*>-)$4Q1C$B[3^5
M=+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% '%:]!J%YXG>&UMYI@ML"I6Y\I8VSU([UF7?B'7%LY+
M?[5$L^&C9%CR\6W^,GT-=?=>)-*L=5FL[J40RQ0B5W9>,$],U$GB3PW-.H2\
MM6EF &=O)ST!./YT): <-K'C/55A%O%<(\3IM,BIM96&#GUYJS=^*]9BU!G@
M N-D>Q) -L;9/WCGCBNM.O>&$,F9[0&-@C?N^<GH.G-0KXO\----"9H1'&H)
M<Q_*=W;I57T'>R*H\1ZDGA(7MP8$NFF\H.F'7Z\<?TK'MO&.O7%K+<@0XM0"
M\8CR93NQP>U=T;K2_LUO&6@\B<9B7:-K #/ JE'K_ATRF".ZM0VS>5"X&!^%
M+J+H8_A_6+[4-8EDGNTD'V8OY*+CRCGH?>J@\4:W''!Y\D"BZ7<)?*X@&XCG
MUKKM+OM*U)))]->"09P[1K@Y]ZNM;PLNUH8RN,8*C&*0CA+3Q3K<\[.3";>&
M9(CB+_7 G&X'L*L>)/%&HZ5J5TEH\,GV>-'2TV9>8GJ :[,00J,") !V"BH1
MIUH+Y[SR$-PX +D9.!1V*//I_%&KRM:'[9&(R4FE>.+B//6,^]5F\8ZI<:K!
M"]U%'%O$BS!.,'(P0/ZUZ<+6W"LHMX@&.2-@Y/K2"RM!TM81](Q3NB7JK'FK
M>+=>CGE:")-TSKEY6"HH"]L^M;GB'Q-J^E:587,$$337<>T*!N"R=>OIC-=@
MUM;NNUX(F7K@H#3FBC<*&C5@O0$=*&P2L><7/C?5S80W,/EQLZ[Q&T>"RYQU
M/]*@M?%GB"%88HV@FYW.\K!-V3]T#KQ[5Z6UI;-MW6\1V_=R@X^E'V2VRI^S
MQ94Y!V#@TNH'-#6=4B\)W.JRF-Y\_NU$>!&,XR?7'6L2^\::C:-"(;JVNMA7
MS"D>T."<9&?Z5Z)Y:;"FQ=AZKCBH38VC  VT. ,#]V.![4Q]+'GO_":ZKY4#
M"\M&6>0*T@BX@^8C!]:2/QKXA?4/(2VMWBB?;YC,$^T#U4'G\J[@:!I@M([4
M6D?DHXD"XZL#GGUJ]]EM\H?(BRGW#L'R_3TH;0/R./T+6;V\UB::YNTD46I<
MPQICRB">#ZFL=/%6KW^IQ0?:HXX/-1Q(J#[I."I_^O7I*6\,;,R0QJS?>*J
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MX39?^@1??]\5U=% '*?\)LO_ $"+[_OBC_A-E_Z!%]_WQ75T4 <I_P )LO\
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MKIZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
ML;4/$"V%^UN;.61$56EE4C" ]*D;Q+HR1O))J$**C;6+$C!H U:*I6VKV%ZT
MBVERDS1C<RISQ5:RU^UNH+J64&W6U;$GF$<?E0!K45B6WB:SO[V>VL ;EHHA
M)E#@'/;GO5S2=2;4[5IFM7MRKE-KD'I]* +]%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@! H484 ?04M%% !1110 4444 )@#H
M.M+110 4A4,,, 1[BEHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
1BB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g201711142133439835644.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201711142133439835644.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,E G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'R3^%7?[4U[_ *%O_P GH_\ "MVB@#"_M37O^A;_ /)Z/_"C^U->_P"A;_\
M)Z/_  K=HH PO[4U[_H6_P#R>C_PH_M37O\ H6__ ">C_P *W:* ,+^U->_Z
M%O\ \GH_\*/[4U[_ *%O_P GH_\ "MVB@#"_M37O^A;_ /)Z/_"C^U->_P"A
M;_\ )Z/_  K=HH PO[4U[_H6_P#R>C_PH_M37O\ H6__ ">C_P *W:* ,+^U
M->_Z%O\ \GH_\*/[4U[_ *%O_P GH_\ "MVB@#"_M37O^A;_ /)Z/_"C^U->
M_P"A;_\ )Z/_  K=HH PO[4U[_H6_P#R>C_PH_M37O\ H6__ ">C_P *W:*
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MYI/V1!*Y#_:5DR=O3 KKJPM:_P"0YH7_ %W?_P!!K=H **** "BBB@ HHHH
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M &'Q%_T&;?\ \!14&BK!:^(]6A1T")%;J.?1#70^;'_ST3_OH4,#%^P^(O\
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M^% #O^$3T/\ Z!Z_]]M_C1_PB>A_] ]?^^V_QIO_  E^@_\ /^/^_3_X4?\
M"7Z#_P _X_[]/_A0 [_A$]#_ .@>O_?;?XT?\(GH?_0/7_OMO\:;_P )?H/_
M #_C_OT_^%'_  E^@_\ /^/^_3_X4 ._X1/0_P#H'K_WVW^-'_")Z'_T#U_[
M[;_&F_\ "7Z#_P _X_[]/_A1_P )?H/_ #_C_OT_^% #O^$3T/\ Z!Z_]]M_
MC1_PB>A_] ]?^^V_QIO_  E^@_\ /^/^_3_X4?\ "7Z#_P _X_[]/_A0 [_A
M$]#_ .@>O_?;?XT?\(GH?_0/7_OMO\:;_P )?H/_ #_C_OT_^%'_  E^@_\
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M^% #O^$3T/\ Z!Z_]]M_C1_PB>A_] ]?^^V_QIO_  E^@_\ /^/^_3_X4?\
M"7Z#_P _X_[]/_A0 [_A$]#_ .@>O_?;?XT?\(GH?_0/7_OMO\:;_P )?H/_
M #_C_OT_^%'_  E^@_\ /^/^_3_X4 ._X1/0_P#H'K_WVW^-'_")Z'_T#U_[
M[;_&F_\ "7Z#_P _X_[]/_A1_P )?H/_ #_C_OT_^% #O^$3T/\ Z!Z_]]M_
MC1_PB>A_] ]?^^V_QIO_  E^@_\ /^/^_3_X4?\ "7Z#_P _X_[]/_A0 [_A
M$]#_ .@>O_?;?XT?\(GH?_0/7_OMO\:;_P )?H/_ #_C_OT_^%'_  E^@_\
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M7Z#_ ,_X_P"_3_X4 ._X1/0_^@>O_?;?XT?\(GH?_0/7_OMO\:;_ ,)?H/\
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MO_OM:/[<U'_H7[O_ +[6@#<VCT'Y4;1Z#\JP_P"W-1_Z%^[_ .^UH_MS4?\
MH7[O_OM: -S:/0?E1M'H/RK#_MS4?^A?N_\ OM:/[<U'_H7[O_OM: -S:/0?
ME1M'H/RK#_MS4?\ H7[O_OM:/[<U'_H7[O\ [[6@#<VCT'Y5AVX'_":WG _X
M\T_]"H_MS4?^A?N_^^UK&@UF_'B^[?\ L.Z+&U0%-ZY'/6@"[XKUB[T^XM;>
MT5P'5I)'C4$A5Z]:CEU.[OEO+G3YPD5M:!@S+P7(SR/I4M_.^IA!>^%[F8(<
MKN<<56CB9;"XLYO#=Y-#<2%Y%:0#.>W!Z4=!Z7*T_B.^6YL$8NL(MHYKB2-
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MZUUAL]0!VGQ3"".QM8O\:JV>DSVS3F#Q%%"TDI,F;.,;G[]Z70"A=Z[KMO\
M9H_M \YH$D5?(_U[,>5]L54E\5^)?L]XL< $MF1%*S18&YC]X>P%=,;#4_-V
M'Q/'YBC.TVD>0/SH>PU- ?,\3QJ"1G=:1C.?QI <S+XC\2B,E9X6\N!)"T<.
MX2$O@_I1-XH\2">"V3RXP)'#7$L>%?!X6MN^^VZ:\<4WB,[Y!\J1V",<>N!V
MJS]BU!P0?$\7 W$&TCR/<C/%,#F;G7_$TL<Z),4,BSJAC@Y0H,@@]ZU/#NLZ
MG-JME:W5V]Q%):AB1#CYL<[CVK3-EJ(C$A\4PA"<!OLL6"?KFD%EJ"98>*85
MP<$_98N/;K0F#U.EHKF42_D:4)XNB)B.)/\ 1H_E^O-1:BVHZ7!'-<>)7*R-
MM398HQ)_ T@.KHKF+=;^ZB22'Q9&P==P'V6/./IFGR6^J13+$_B@!B,\VD?'
MZT =)17.&VU-8Q(WBR(1DX#&VCP3]<U,-+UM@"/$A(/0BS3_ !H W:*P_P"R
MM<_Z&,_^ 2?XT?V5KG_0QG_P"3_&@#<HK#_LK7/^AC/_ (!)_C1_96N?]#&?
M_ )/\: -RBL/^RM<_P"AC/\ X!)_C1_96N?]#&?_  "3_&@#<HK#_LK7/^AC
M/_@$G^-']E:Y_P!#&?\ P"3_ !H W**P_P"RM<_Z&,_^ 2?XT?V5KG_0QG_P
M"3_&@#<HK#_LK7/^AC/_ (!)_C1_96N?]#&?_ )/\: -RBL/^RM<_P"AC/\
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M&S6_]R#_ -!-;M<'HEOJE_KNJ3V_B!MKQP-O-FGS J<<=JZ#^RM<_P"AC/\
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MH_\ SQE_[_O_ (T?\(CH_P#SQE_[_O\ XT@-VBL+_A$='_YXR_\ ?]_\:/\
MA$='_P">,O\ W_?_ !H W:*PO^$1T?\ YXR_]_W_ ,:/^$1T?_GC+_W_ '_Q
MH W:*PO^$1T?_GC+_P!_W_QH_P"$1T?_ )XR_P#?]_\ &@#=HK"_X1'1_P#G
MC+_W_?\ QH_X1'1_^>,O_?\ ?_&@#=HK"_X1'1_^>,O_ '_?_&C_ (1'1_\
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M_P#T&MVN1NM#L-,\1:)+:QNKM*X.Z1F_A]S774 %%%% !1110 4444 %%%%
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MM_\ OJK?]GV7_/I;_P#?H?X4?V?9?\^EO_WZ'^% %3_A(]&_Z"-O_P!]4?\
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M #Z6_P#WZ'^%']GV7_/I;_\ ?H?X4@*G_"1Z-_T$;?\ [ZH_X2/1O^@C;_\
M?56_[/LO^?2W_P"_0_PH_L^R_P"?2W_[]#_"@#G[_5K"^\0:'':W<4SB9R0A
MSQMKJ:YW5;6WAU[0VB@BC)F?E$ _AKHJ "BBB@ HHHH **** "BBB@ HHHH
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M1_:FO?\ 0M_^3T?^%;M% &%_:FO?]"W_ .3T?^%']J:]_P!"W_Y/1_X5NT4
M87]J:]_T+?\ Y/1_X4?VIKW_ $+?_D]'_A6[10!A?VIKW_0M_P#D]'_A1_:F
MO?\ 0M_^3T?^%;M% &%_:FO?]"W_ .3T?^%']J:]_P!"W_Y/1_X5NT4 87]J
M:]_T+?\ Y/1_X4?VIKW_ $+?_D]'_A6[10!A?VIKW_0M_P#D]'_A1_:FO?\
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M>C_PH_M37O\ H6__ ">C_P *W:* .1NKS4[CQ%HBWFD_9$$KD/\ :5DR=O3
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M'[X>$3IZ^?%.9@X\V0,4&>QH>UPZEFTN-5OD1[;7[.17!((MO2K!BUT2B/\
MMNTW$9 ^S=JYWQ#X=N[%(GLQ-<1'F;#D-([,,]*9_P (KK,J1KL:*W9V/D^>
M?W:DC"Y[]Z>X'3_9O$  )UFTP>A^SC_&G?8O$?\ T%[;_P !JX36;*[T[4[.
MQN(IWLS,[1JC,V%W# !]:]5BP(4 ! VC -%M+AUL8OV+Q'_T%[;_ ,!J/L7B
M/_H+VW_@-6[12 POL7B/_H+VW_@-1]B\1_\ 07MO_ :MVB@#"^Q>(_\ H+VW
M_@-1]B\1_P#07MO_  &K=HH POL7B/\ Z"]M_P" U'V+Q'_T%[;_ ,!JW:*
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M-;M% &-;^&K2WO8;LW%Y-)"28Q-,6 )XZ5LT44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
/!1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g201711142133436845633.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201711142133436845633.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,E G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT8/M)./*S\V:U:XA[:W_ .%KPD0Q_P#(/+9VCKNZUV]+HF/K8**** "BBB@
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M-OE,(SM;(R.:V*PK+2+A+NP:XV&&TM0B@'^/&":W:;L(****0!1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"H)'*<8R*6WT?3K6]DO(+.*.YD^_(J\FKM% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 445Q]U\0+6UNY;=K&X8QL5)'?'X4 =A17$_\
M+(L_^@?<?Y_"C_A9%G_T#[C_ #^% ';45Q/_  LBS_Z!]Q_G\*/^%D6?_0/N
M/\_A0!VU%<3_ ,+(L_\ H'W'^?PH_P"%D6?_ $#[C_/X4 =M17$_\+(L_P#H
M'W'^?PH_X619_P#0/N/\_A0!VU%<3_PLBS_Z!]Q_G\*/^%D6?_0/N/\ /X4
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M+7_OQ0!L^3%_SS3_ +Y%'DQ?\\T_[Y%8WV/Q%_T%+7_OQ1]C\1?]!2U_[\4
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MB@#9\F+_ )YI_P!\BCR8O^>:?]\BL;['XB_Z"EK_ -^*/L?B+_H*6O\ WXH
M33U5?%FIA0 /*CZ"MVN:T1+J/Q)J2WDR33>5'ET7:/RKI: "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H)
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MKEM*O%U/Q%;JUG91VCQ2$0H,OP<?-Z&L^3Q5Y9EB_L&Q:<R%8E4$@#.,M_\
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M_G_@_P"^Z/[<TO\ Y_X/^^Z?_9&G?\^4'_? H_LC3O\ GR@_[X% #/[<TO\
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M '6T5RZZAJCG":OI+'.W /?TZU+!-KEUN^SZAILNPX;8I.#0!T=%8?E>)?\
MGYL?^_9H\KQ+_P _-C_W[- &Y6'X?_X_-7_Z^S_*CRO$O_/S8_\ ?LUDZ/'K
MAN=2\B>T#"X/F;D/+8[4 =E16'Y7B7_GYL?^_9H\KQ+_ ,_-C_W[- &Y17/7
M+^(K6W>:2XLRB#)VQ$G%0V=WKE^7^S7EDZIC+B,[2?0&@#IZ*P_*\2_\_-C_
M -^S1Y7B7_GYL?\ OV: )?%'_(O77T'\Q6E;?\>L/^X/Y5RNOQZ\-%N#<W%H
MT6!N"(0>M7X(O$?V>/;<V6W:,9C/I0!T%%8?E>)?^?FQ_P"_9H\KQ+_S\V/_
M '[- &Y16'Y7B7_GYL?^_9H\KQ+_ ,_-C_W[- &Y16'Y7B7_ )^;'_OV:/*\
M2_\ /S8_]^S0 6/_ "-NI_\ 7*.MRN:T07:^)-2%Z\;S>5'DQC Q72T %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,T?4M,@N_P"S($,BY*XZ5<_X1[2/^@?!_P!\T;: U<X23PDWV&:W34=-D,X
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MT7_H'0_D:/\ A&M%_P"@=#^1JK%K6JS)OCT<LN<9$HI_]JZQ_P! 5O\ OZ*
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M#CFK\&J:P+>,#1F("C!\T<\4 6_^$:T7_H'0_D:/^$:T7_H'0_D:@_M76/\
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M_P"1MU/_ *Y1UN5S6B6<=AXDU*")Y&411G,C;C^==+0 4444 %%%% !1110
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M [G&[&!GVYKGSX_U'RW'V&U$HDP 7.%3U/O]*=+\0YH[B,I:P26[J1\CG<&
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M (]8?]P?RK-\4?\ (O77T'\Q6E;?\>L/^X/Y4 2T444 %%%% !1110!AV/\
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MY_X#M1_PE>G_ //.\_\  =JW** ,/_A*]/\ ^>=Y_P" [4?\)7I__/.\_P#
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MH R/^$KT_P#YYWG_ (#M1_PE>G_\\[S_ ,!VK<HH P_^$KT__GG>?^ [4?\
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MA_V%??\ 0?OOR6C^PK[_ *#]]^2T ;E%8?\ 85]_T'[[\EH_L*^_Z#]]^2T
M;E%8?]A7W_0?OOR6C^PK[_H/WWY+0!N45A_V%??]!^^_):/["OO^@_??DM &
M?KOV9M:9=7:9;,0@V^PL%\SO]WO7-'7M=2&XM([QQ-&JK#;F'<[J<\D^H%7M
M9NKZPUV/2UU6XD9HQ)NE=5ZG&!Q4=A=633RS2ZW>6]RS[)6V@@8X&3VH2T!W
MW(+#6]5MX4C:[:.,K\UTT!8LP'"X]S5G_A(_$,=L;Z=BJ;S&8!!G;Q]ZK)O[
M$+SXCOOOA5'E#YR3@;>.:6^FDLK^.VEUF]".JMN8+W]L4"M8B\,ZSJFJ:^BW
MCM(D08+($*A@1W[5'?:HC>%M:LOM+_;!</A"&R%W#T[8]*MW=[8Z<%,WBBZ3
M(!&%7H:=?;;*2W:37;LP7$9D$H53D=NW.:=QG/7<5J(;&**YL_+,V92GG;.G
M\7.:M :3]MD6XFW;+/\ T8P-*%\S/\.>_P!:T7O=/BC1I/$5Z@=MI#1 ;3[\
M<4ZWE2[UN+3K;6;V3<K-YNQ0HQZ<<T;@7M1U/4K#1M*W3FW:10)YFBWD''0C
MWK ;Q-XGDOYD1XD4OL">5EE7C#?C6K)=6P6<MXCOV6$X;$8()]N.:A34;"1H
MRGB6^(D4-O$8P >F3CBEN[A8Q+]M:^T7UE)J$\LC2O\ /Y."JX&,8[&K^GZO
MJ6FQVUIYIMX(T8KF!G,S XV^W'-7EO[%UF<>);[=$0&7RQN.>F!WJJ^K1)J4
M-JVM:@5D)Q((P0N!WXXII[(;WN9-SXCUR]O$1KN1;=763*P8ZY&TU?7Q-KL=
MIF-L3J=@M?(/"8_UF?Z5N20PQ6LUP?$5V8XGV,0BG+>@XYJA8W;ZEX@73K/5
MK]U$!EDE9%&WG&W&.M-/I8G9W9;2ZUBXT'5X+BY8SI;JT<JQ;2"RY( K%M=:
MUO3]/C@AF9ID7;]G: DA=N?,)[\]JN3WE['->P17^HF6"6.)%?:HD+=/PJI#
MJM_+-(/MEX%MV6.Z;<G[LDX&..:-WH-I\ITVL:>;[P<6ORUQ=+")%=<H0QQT
M"FN>O-2UC1;N&QTJ..&U6%65'!8R$CDY.36K>S16%[]CN?$E^L@ +?("J@],
MGM67=:Q'^Y%CK6H7<LEPL  0 #/?..E39MZ=1;+4=/XBUZTA$<UR=\T:.LHM
M^$)[567Q#XEO=&:Z\TQMA8S&L'))R"<_A6KJ#R6-X8)M:O/+3'F.0N%SSCI[
M4U+^R>V,J^([_:",+Y0RV>A QS3Z%)JY%J$%YJ7ACP] LQGEDD42M(&4'CG=
MMYJ*\2_TK6;*UA8PPQ%#((%8JY/;+&K=I=).UPK:_>QB DC*KRH[]/>JD^L1
MB_BMXM<OI%<$F4J O'H<<T7UO\Q6NO0O7]Q#=ZA-)K<5U;1B(?98]Q^]W/R]
MZSSX@UF/3IK"1Y$NR%$1\HEMA4\Y]>E6UU&RF7=_PDE^W=08AEN<?+QS5EWA
M&F1:D?$-^T$K;$(C!8GTQBET#=W-KPQ<F?0K5)+EI[A(AYC,N#GWK9KA/[2L
M8VC'_"37R^8,@^6 !['WJE)X@3SY4BUK4W2.,/O* !L^E-O6X6L>D45Y[::S
M'<6XEDU_48]V-L>P%^1GI4YU:Q#LI\4WVU>"^P;<XSC/K19@=W17%VLK7KVI
MM]?OVAN"RJY4###G%4%U<KJE[:3ZUJ48MW\L-L!+GN<>@I >AT5R6GK_ &I/
M)%:>([^0QCYF"#;^=:/]A7W_ $'[[\EH W*P_#__ !^:O_U]G^5']A7W_0?O
MOR6LG1M(NY;G4@FL7<12X*L5 ^<XZF@#LJ*P_P"PK[_H/WWY+1_85]_T'[[\
MEH W**YR[TC4+>UDF36[Z0H,[1MYJKI,%WJ\+W$&MWXMP<(YV_,>] '6T5A_
MV%??]!^^_):/["OO^@_??DM $OBC_D7KKZ#^8K2MO^/6'_<'\JY77]'NX-%N
M)'UF[F4 91P,'FK\&AWIMXR->O0"H. %XXH Z"BL/^PK[_H/WWY+1_85]_T'
M[[\EH HZ^;C^TU-J9O(4#[:$SRF>WO\ 2NGB*F)"GW"HV_2L7^P;W_H/7O/L
MM+_85[_T'KW\EHZ!U-RBL/\ L*^_Z#]]^2T?V%??]!^^_): "Q_Y&W4_^N4=
M;E<UHEO):^)-2BEN9+AA%&?,DZFNEH **** "BBB@ HHHH **** "BBB@ HH
MHH *XGQGX<U'7KZ#R(-]O$!D^8H).<\9Y4^XKMJ* /,H_!NJ+>SSMIZNLBNJ
MH9T^7>,$YQS5>+P/KL<OVCRRUR"-LAECP%"[<;>G3O7JM%%P/*I/ VMEY&BA
M,?F!@W[V,\,,$42^ ;^6RA@.FJ6BE\P.UPISQ@@CO7JM% 6*NFPM;Z;;PM$(
MF2,*44Y"X[9JU110 4444 %%%% !1110 4444 9W]E0'6WU%FW2M"(MA ( !
MSFL)O =H#=+]NF6VNWWW,6T?/SD<]JK>(I+S3=?N=3AGN0L5JK+'N_=R8/*_
M6L:#4M=GDFVW=])=E@PMRN8UC89(/N*$]- .F@\%6ZSVLSW\LHM75K<;0 J@
MYV^_7K5_4/#UMJ.K17DL[!X\'RQCD#/^-<B^HZY DOF2:DLP0*D<,0*!,?>S
MV-7O"<FK3:K)-?B=]D+*DD@.6&>.O4T]Q/:Q</@"S%O&D=T_FH['S)8UD.UN
MV#^AK2U+PQ;:E#;1M-)']F3;&5 X/8UQJ7_B6YU+R4FOTAFE4.2O,?S'('&
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M:W** .:T2YDNO$FI2RVTENQBC'ER=172UAV/_(VZG_URCK<H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBD.0I(&3C@4 9&I>(+?3+ITF1C'%%YDK*,D9.  /4U5?QKH\:J7:=<MM8-%@
MQ_[WI6%XA@U2[GGS#!:-<HL8+3J"2K9!&:HR^%-0NWDD>WDD>3_7-YRG>?7V
M-"V!G66?BZTU#6X].MK>Y971F\\QX3Y3ZU'J7C2PLH+HQ1S32P@[ (SMD8=0
M#WQ6;8Z9JMA<6TL.G-F!67!F'SAO6JCZ#J$\DF;%VAW,R1"<8C9NI%#!>9U=
MOJ\DEW8VTL&Q[F RMS]WVJCJ/C73[)IX5$C3PD?*RX#<@''KUJA?VFOW=S;7
M%O:M:RVZ&,,DBG(_&L9_"FH74LDDD$DCDG+"9<@DYZT^HGL=I+XBMSIDEY;H
MS&.41O&XVLI)QR*AOO%5MIVJM97$,I.Q2GE)N9B>V*QQ8ZE#I=S;3:>6\]M\
MD[S@'/8_A6==Z)KC21WLFY)XVW-<O*H^4#@>E [,Z:3QMHL:A_,F:,@$NL1*
MJ3V)[&E/C/24\@RF>)9L;6DBVC!Z$_6N2F\*:E+;I%9VS1VSD-*@F#"0^N?Q
MJS?^&-0U"6-I;!_+1$3R_-!!V]#[4:"6YLR^/]+@OVAE$J0B+>DC+@R'./ES
MU%7K3QAH]]>PVMM,\CRJ""J949Z GUKDI?"6HSRI++9N[1*$@WNK",9ST/6K
M4/A_4H;ZWN5T]OW('RB15R1]/Y4:#?D=-<^*M-M+Z2UF,RM&VUG\H[ V,XSZ
MU"GC32)(BZM.6$GE^4(\OG&>GIBN<OM"UB^NKN2ZMW6WN)!)Y*S  -C .:KP
M>'+^TG'EQ-'>LV]&$RAN!@X'TI+;4'Y'46/C*PNH[QF# VS$,J+N(';/H3Z4
M[_A-=',"S!YF4@E]L>?+&<?-Z5S7_"+7ZK.8K&6.2<YE<3#+G.03ZU"WA/5T
MM)8;6W>)IN)3YBX<9SC':@#JH_&FE70N%LI?.D@7>R]-R]R/I7012+-"DJ'*
MNH8'V->?VGAW4[&"XBM]-4"6,Q@;E&T'KR!DUN6U[K.GVJ02:?&5484O.!P!
M3T Z>BN>AUG5KF/S(--AE3INCN P_2I/[3UO=M_LB/=UQYPS2 W:*P_[1US_
M * Z?]_A1_:.N?\ 0'3_ +_"@#<HK!_M36LD?V3'D#)'GCBE75-:=0RZ3&RG
MH1."* -VBL(ZEK8!)TA !U)F%"ZIK3J&728V4]")P0: -VBL/^T=<_Z Z?\
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M9T#KHK%6&0?-%</=>&-;:RAA:SGDN$D#1.LF%C7GC'KS5UM"URUL$N5>:.X
M83,TIP$VCC^=-I%\J.M_M76/^@(__?T5DZ/J&I1W.I&+2FD+7!+CS -IQTI_
M@67SX[^2..>.V\Q1$LS%NW.,^]:?A_\ X_-7_P"OL_RH:L2']JZQ_P! 1_\
MOZ*/[5UC_H"/_P!_16Y12 P)-9U6*-I)-&9449),HXIL6O:E.S+%I)<J 3MF
M!QGI6U=K(]I*D2*[LI #]/QK-T#2IM'2:W=EDC8[UD_BR>H/L.U #/[5UC_H
M"/\ ]_11_:NL?] 1_P#OZ*W** .0U_4=3ET6X2;26BC(&7\P''-7X-4U<6\8
M&BN0%&#YHYXJSXH_Y%ZZ^@_F*TK;_CUA_P!P?RH R/[5UC_H"/\ ]_11_:NL
M?] 1_P#OZ*W** ,/^U=8_P"@(_\ W]%']JZQ_P! 1_\ OZ*W** ,/^U=8_Z
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M17D<;0&/'-9_A_3)]'ADLWVO"#O27/))Z@T(&,^U^(_^@7:?^!%'VOQ'_P!
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MH.'0@Y.,XQ4]OXJBGT&75!:2#RVVF$,"23TYK"F\,76J7LUTSVCR;_W@21@
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MR8W  \9Z4 =%16'M\2_W['\C1M\2_P!^Q_(T 2^*/^1>NOH/YBM*V_X]8?\
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M.ND&]!@WFVB23[V-VXXK*C\<W#>1$VGH)[H VZB7(()Q\Q[=*<;VT!K0J_\
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MTCPS=KX@MK^:S,$$/W8VF+E3CEOQ-1W_ (6OEU2]N8+0RPSS.VQ)BO)'RO\
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MK&IZ<5O^%] U33Q?_;&F+2Q%3YD@(=^>17;44V[A<\WM_#^OVDUG<0VS*+<
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MQ%_WV*/M5O\ \_$7_?8H R=_B7_GE8_]]&C?XE_YY6/_ 'T:UOM5O_S\1?\
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MK?\ Y^(O^^Q0!@:(;L^)-2^VB,3>5'D1GC%=+6#ISK)XKU-D8,OE1\@YK>H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "D(!!!Z'K2T4 >=ZUIN?%HL+*U*P>0)7\J .<ENY)X%07&I:9:V
MSS-X?1T1F&?-P6"\$XKOY5L;:\:[D,:7#1[2Q;YBHYZ5EG2O#>IVD<[1V[P@
ME@V_&-W7//>A;!IU.674M,E.Z+PXK1,K-&QEQG:,GZ<57M_$6@7.]T\/2>1C
M]W(2<,W''MUKK@OANVF^QJD2M&C_ "C. I7YOTJ2WT3PZ8VDB@@"21_,-W 4
M^V>*>@'/6@L4T_4+J^TB(20SB*.%&SR>@SG]:@>^TQ)Y8#X=3S;=2UP/.X0#
MT]:Z^'2M#M["2SC2 6\WS.IDSN]\YK.N/#GAZ!HM0D"_9HEV!0V5))ZDYYHZ
MDZI',+KVB2S,(/#CO$S!(I"2 Q_I4OV_3/M7DC0E,XD,+0[^ ^<?>KJY=.\-
MVT_GO' 'DD"\/D!NW&<"K$FE:+#*MVUO%N>3>) <Y8]Z2'T9QPU32&1G7P\I
M6)Q'/^]^XQ/0>M7-.;2]3T[4)4T6.&>WC+HCOG<,'&:T+SPII-]J4-RMW#'#
M&VYH4"_.W7ELUK6>FZ)8QS_9E@1)_ED/F9S[=?THZ%:7."L=2LH='%U?Z)'+
MY>!-(CXP[<@ >GO6_=PZ99Z%#J$NB1":8C9#YOK[UM?\(_H$\@<6UNY4;,!\
MCCVSUJQ>V.DWUM'9W0A>./#(A?!&._6AB6YP#:OIEU:175IHB);K*J3N[Y()
MZ@#/ZTR?5[&TOVCF\/JPE16MXHVR3W))^E=K%X;\-AXS%;6Q*<J%?(X]L\TG
M_".^&MCGR;<!VY;S>X]#FCJ)>9ROVNPO9K'['HJ10R74<,S2-R,YR,9_6K>K
M7>BZ7+<M_8:RV]LXCDD$F#O(X 'I701:=X;FO%FC6W\ZUD"@[\;7'3OUJ[=>
M'M*OKHW-Q9I)*PP2<X/X4]"M#FKB/3[?1[*\.@1F:[=52$2],C()-9L>J:3+
M-;6Z^'5^T72EH$,N V.N3VKT!].M)(H(GA4I 08Q_=P,"J<WAK1YXT22R0A!
MM7!(*C.>#1H(X#4]5L&L?/T_1HT6.0).[MDJ><@#//3K5:VU*""ZFN;_ $Y&
MM B^5#&HRQ(!Y.<]Z]$F\)Z'/L\S3XR$&%'(%2_\(YI&TK]BCP5V_AC%&EAO
MR.%DU*PN-/E-KX>$=TBEG$K8"@=QZUI:H^DZ7)9Q-HR2>=$'>7=@)FND?PKH
MTD"0O9*40Y&6.?Q.>:GO-!TR_>%KFU60PC"9)X'I2$CA+*^L!I\;W>AQ--)&
M7B*R8$GS$?A67<ZH;B^M9-/T6W2T* RH[<D[MIYKTR;PWI$\$<,EDACC7:@&
M1M&<\?C3%\+:*D)B6QC"$8QD^N?YT[J]P6BLSF]+ET:_6]\W1%A:V0R!2^2X
M%9TFL:3#-%')X;;E!))L8ML5NE=U:>']+LC.;>T5#.NV0Y)R/2B7P_I<TL,C
MVB%H5"IR1P.@/K0".+BU+1VU"UMI= 5$N@&BD\W/RDXY':H1J>DM>21Q:()1
MNP%WX P"2<_A75OX*T:347NF@^5X]ABR<9SG(]*NV_AS2+5U>&RC5AT/X8HT
ML-V.(M=6TJ\39%X;*SR,!"'?"O[YI+\1P^'=-O4TZ!9)[C;.>NU1G( S[5VO
M_"+Z/Y,D/V)=DC;B-QZ^W/'X5971M/6TAM1;)Y$+;HT/132)U.*CN]-DN;:U
M'AY//N2IB'F\%3SDGM]*ZT>&-'P,V$8..1DT^U\.Z59RK+!9HDBMN5LDD&M2
M@9D?\(QHW_/C'^9K(T70=,GNM366T1A'<E4!)X&*ZZL/P_\ \?FK_P#7V?Y4
M 2_\(QHW_/C'^9H_X1C1O^?&/\S6O10!@7_AS2HK&:2*UAC=%W!FR1_.L[P[
MI>G:M:R7,]A#'\VT0\Y3'<\]ZZN>WBNHC%,@="<D&DBM((9WFCC59' #$=\=
M* ,[_A&-&_Y\8_S-'_",:-_SXQ_F:UZ* .5\0>']+MM$N)H;-$D4## GCFK\
M'AK1VMXF-C&24!/)]*D\4?\ (O77T'\Q6E;?\>L/^X/Y4 9O_",:-_SXQ_F:
M/^$8T;_GQC_,UKT4 9'_  C&C?\ /C'^9H_X1C1O^?&/\S6O10!D?\(QHW_/
MC'^9H_X1C1O^?&/\S6O10!SFC6D%CXFU*"VC$<8BC(45T=8=C_R-NI_]<HZW
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ H)P,GH**",C!Z&@#S[Q-:#4=;6YM+NU^X$WO/PN.OR_X5E7O
MAY#' +>^@$2(OFPQ7(3S&]<UO^);"*'4%D55CMDCW,L!4.&]2#]X5D66J3DS
M*-/TVX"AY0SH5(11TQZFA;6![D::*\<L>S4+4(058M<;B%( /)ZU//IW[V98
MIK%T$HD$C7&#*@_Y9D=A4\NO6KWD-K::5II>1%?S)6P@^7)!/KZ5!8:RD37@
MOK#3FV+))&5_V>BT[,$MVBNNA"6/49'OK6%YU'D1QW'^K&>5![9]:U(+.&/P
MC/IR7D*3R2!U26Y\S;@CO5"7Q%LL&NQHVF;<L5C(8L0HR:T]/O+-_#U[JKV-
ML2''EI(H 7(&!G\:'= ]=SGTT>Z^TB9IK$@.K/&UR-KD$G/'3-;UQ;+)X72P
M34;59_-:3;YW" Y^4'VK,_X2F-8U:31-/ CD*S,<@<>GI^--_P"$LC\K8N@V
M37$C?NE520%_VO\ ZU'05E<;?Z+##H\_V>ZM1,L4>-LW)8#YOSHM-*2]2WED
MGM+2+RP#")\_-M^^?>KEOK<MW*HCT#3XU)1"),[@S GMVXK./B$;-1N/[/L]
MJJ@$0'S(2""5'<9'>GKJ#C?4MIILRPM);7EE:7$4:I&!/N$C \N?3(JK>^'?
M-NY"NI1R;P"LAO-JKQRNWJ:6V\1^7&L,>B0W4N\EW=>-HQT]#S6[HVIVVHZC
M<6UQH]G"%1GB4#+''KV_*AW3&M#,N-"A^RLEIJ%K!(905=9L%5VX('U-5]/\
M/0QRAI[N'8$<;);SS/F*X#>@YJU<:_) ]NH\/64GFJ9?D4\)NQC/K2GQ'"DU
MNTFC:<L%PQ 7/SQ@''S4E=BE9+4H2:&R?ZN:S9_-WB07(&<@#)'?%>A66LVB
MVJ)<7=NLB *2L@(; ZUQESK<)U$PV>E63LSB)-Y.SEB,\4EKK)2%I)=&L'AA
M=4E(R7);/W?R[T7T#J=[_;6F?\_T'_?8H_MK3/\ G^@_[[%<MIMU'J(NXVTW
M34=;<S1&/G'7 ;WK T2_N(8TAFL;2ZG<-*[R9("@$X48I!<](_MK3/\ G^@_
M[[%']M:9_P _T'_?8KC-'U^RNXII-0T.&W3&Z(I$3G/0&JR:_O6W5=&TMY+H
MCR]A)"#)'S>_%.P-VW.\_MK3/^?Z#_OL4?VUIG_/]!_WV*X,>(HU6W$FC:=O
MNSB+:3B,YQ^\]*R[G5IVUMY6L[1+>T!5HH2=LC ]<XY%'*Q]#U#^VM,_Y_H/
M^^Q1_;6F?\_T'_?8KATUH[HH9-&TQ)YXUEC8D[%4]F/K4^H7BKX?TS4X=/L4
M,LO[Y-N00,\ _A0U8%J['8_VUIG_ #_0?]]BC^VM,_Y_H/\ OL5R=E>P7MO=
MK+IMBD@M#<Q/!R%'HV>]9'_"1K;6D,0T:SNKF1%9)$&5P>N[WHL*YZ'_ &UI
MG_/]!_WV*/[:TS_G^@_[[%<GJ.HQ6FAV%]'HEH);AL2+*.$ Z]*SSXCA$+7*
MZ/IKPES&BJ27W8SD^U*P-I*YWG]M:9_S_0?]]BC^VM,_Y_H/^^Q7"-KIBOX+
M9]&TR0R'81&#D,5R.M0W'BN!KD)8>'K>:+&2Y7KCA@/?-.P7/0?[:TS_ )_H
M/^^Q1_;6F?\ /]!_WV*XS3KQ=4\06*'3[*"TD\P&$#,F0/XA79_V-IO_ #XP
M?]\"AJP7U#^VM,_Y_H/^^Q6-H>J6,5UJADNXE#W)926ZC%;/]C:;_P ^,'_?
M K&T/3+&6[U4/:1,$N2%!7H,4AFS_;6F?\_T'_?8H_MK3/\ G^@_[[%']C:;
M_P ^,'_? H_L;3?^?&#_ +X% !_;6F?\_P!!_P!]BC^VM,_Y_H/^^Q2'1],
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ML]EH=I;R7LMO:K$@R\FT8 KS@?:A;"R>]A>/S#*9O/()R,;<8SQZUHV+V_\
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MZ+I0NH;!+F1W6-$6,')-<@/&MVMRX.BYF?"I!Y0.TCJ:[&>?1(=+DMYYHKB
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MT&WA:[U8&&,XNB!E1QQ705A^'_\ C\U?_K[/\J -?[+;_P#/"+_O@4?9;?\
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MC;J?_7*.MR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^N4=;E8=C_R-NI_]<HZW* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M \GVJSXH_P"1>NOH/YBM*V_X]8?]P?RH R/[/UW_ *"\?_?FC^S]=_Z"\?\
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M6.\MV@EW;&ZA3C-1VVGV]I/)+ I0R ;E!^7COCUK-_L*^_Z#][^2T?V%??\
M0?O?R6@#<HK#_L*^_P"@_>_DM']A7W_0?O?R6@"7Q1_R+UU]!_,5I6W_ !ZP
M_P"X/Y5RNOZ1>0:+<2/K-W,H RC@8/-7X-#OC;QD:]>@%0< +QQ0!T%%8?\
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M"WP\9K<()+6(LK"18U;;STP2<U=/A>XL?#$UE:QVQN))EDVQJ=@P??DUV-%
M' WG@._O4;?>VP,S%Y$"$*C9'W<?3O23^ +R588C=6;PP!MF^([F)_O&N_HI
MW'=G.0>&9$T6SL)KA',$PE)V\?05AGX=$7,DD<UNGSEDE"L7.3GGG'Y5W]%%
M];B:NK' )\/[SSWFDO+8NP4<(W."3D^^#VHM?A[+9R">"2S6>,_NR48AQWWY
M/\J[^BE<#E[CPM-/X>LM/^T1":WF$A?9\IZY ';K4^@Z!<:9=--<30OMB$*"
M%"N5!SEO>NAHIW%8****0PK#\/\ _'YJ_P#U]G^5;E8?A_\ X_-7_P"OL_RH
M W**** "BBB@ HHHH R/%'_(O77T'\Q6E;?\>L/^X/Y5F^*/^1>NOH/YBM*V
M_P"/6'_<'\J ):*** ,;4M$?4KM;EKC8\&#;8'W&]3ZUKIN\M=Y!?'S$=,TZ
MB@ HHHH P['_ )&W4_\ KE'6Y6'8_P#(VZG_ -<HZW* "BBB@ HHHH ****
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MXI<[F(DZF@#H**P_^$;'_03OO^_E'_"-C_H)WW_?R@#<HK#_ .$;'_03OO\
MOY1_PC8_Z"=]_P!_* -RBL/_ (1L?]!.^_[^4?\ "-C_ *"=]_W\H E\4?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK&U#Q MA?M;FSED1%
M5I95(P@/2I&\2Z,D;R2:A"BHVUBQ(P: -6BJ5IJUA?.Z6MU'*R#+!3VJ*TUR
MSNK2XNMQB@@<H[R#'3O0!I45B6WB:SO[V>VL ;EHHA)E#@'/;GO5S2=2;4[5
MIFM7MRKE-KD'I]* +]%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g201711142133437095634.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201711142133437095634.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,E G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT8/M)./*S\V:U:XA[:W_ .%KPD0Q_P#(/+9VCKNZUV]+HF/K8**** "BBB@
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M-OE,(SM;(R.:V*PK+2+A+NP:XV&&TM0B@'^/&":W:;L(****0!1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DJ)+$T<JAHV&
M&!Z$5@V^C>%7:6WM[>Q<X^>-6!Q^&:M>*'N$\+ZDUKGSQ VW;UZ5YGJD5K#H
M'AJ72'6/4)582O%]]EV'=N_^O2&=X]EX.\F-7CTWRU=E3+# ;OBMPV-C<V4<
M!@BDM5PR)CY1CH17A]O926O]DSB<.4TN><*\8(+9[BNNT3Q#J=\6EDU.*S2T
M$:+;,@Q-E<_KVJK?U^!-]3T6>QM;F2*2>!)'A),989VYX.*RH8/#5M-/:0BP
M26;Y98@RY;V(KF_!>OZ]JVK;[XQ_9)D<A#(NY"&P,*.<?6JWANUEEU_Q%*;&
MTDA6Z?\ ?N/WBG;VI?Y#.VLM'T58HGL[2VV1OOC:, @-TR#4\>D:?%?->I:1
M+<MUD YKR71->U*WT9K:UO19QV=M)<KE1^^;>?EYK0C\::W<+_:1G$12YB@^
MP;1E@PY/K3MJ+H>GW5C;7H07$*R>6VY"P^Z?45F_\(]HEKI\,5Q:P-!;$LKS
M8^7)R3FN&L]4\577A]=3343,'NI%DB4*KJBDCY<]376QW^GZQX,BN;R=7@F4
M#?<#:"^< ,/K2V0^MBS'I&@/87,K+;SVL\IFD=B"N?K4DMOI&NZ/+IMM/ ]N
M%"X@8'R_3ITKG? !M/[$O[&Z,)D%W*)(LCRV_P!P?W<4WP4MG%8ZUJP6*VAO
M;N180H"_*HP,4/\ 0/\ ,Z/3]/T7[47A%K/?1J$EE7!?ICFI;>RT.WGGLX(K
M1)IAF6)2-S?45YIX"E2V\2VTMPT<4<EM*8W#<O\ .>9/>GRQSV/C:(J(9&DU
M0R&Z64%@A7[A'4 55M4N_P#F)Z)^1Z8]GI,5_!))%;)= ;8B<!L#L*KW&FZ!
MJNI,\T-K<7J !OFRX'O@US'BVTMCXO\ #>I0?/-+,ZAP^00$.,=JP_#6%U[0
M)8L?;)9[D7>#\Q7_ &J25QRT1Z./#6BK,THTRW$C @MM]1@U$WA31O(\F*QB
MA0NKL(QC.TY ^E;5%("I?:78ZDB)>VL4ZH<J'7.*8=&TTW45T;*'SXAA'V\J
M*O44 4YM*L+A)$FM(G65MS@C[Q]:?+I]I-9_8Y+:-K?&/+*\8JS10!GQZ%I<
M5K]F2QA6'<'V;>-PZ&G?V/IQ8L;.')D\TG;_ !_WOK5ZB@#-70-)1IF73[<&
M<8D^3[U3V^F65I9M:6]M'';MG=&HX.>M6Z* (!96RV?V,0(+?;M\O'RX]*K0
M:'I=L(Q#8PH(G\Q,+]UO6M"B@""2TMYKF*XDA1IH<^6Y'*YZXJ*?2K"YDEDG
MM(I'E01R,RY+*.QJY10!G?V!I)L?L7]GP?9@V[R]O&?6I(=)T^W8-#9PHPC\
MO*K_  ^GTJ[10!A7GA/3+FV^S10);Q/*LDHC'^L .<'VK< "J !@ 8%+10 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (0&!
M! (/!!K-@\.Z/:SR30:? DD@(9@O4'K6G10!G?V#I6$'V&'"1F)1MZ(>H^E)
M_P (]I'VF*Y_L^#SH0!&^W[H'2M*B@"C:Z-IMC=275K9Q13R_?=1R:F@L+6V
M,QA@1//;=)@?>/J:L44 94GAK194B1]-MV6$Y0;?N\YJ1M!TI[Y;UK" W*])
M-O(K1HH SGT'2I+,6;6,1MPQ<(!@ GJ:F;2[%]/^P-:Q&TQM\K;\N*MT4 9$
M/AK2[:YAF@M4C$*,B(HX ;K3Y/#^GO#:0+ L<%K)YD<:CY<UJ44 8D_A/1I5
MD"V441E<,[(,%L'-3S^'=+GDFF-G$L\J;&E5?FQTK4HH HQZ18QQ6<?V=&^Q
M_P"H)'*<8R*6WT?3K6]DO(+.*.YD^_(J\FKM% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 445RMSXWAMKF2$V,C&-BN1(O- '545R'_">P
M?\^$G_?U:/\ A/8/^?"3_OZM '7T5R'_  GL'_/A)_W]6C_A/8/^?"3_ +^K
M0!U]%<A_PGL'_/A)_P!_5H_X3V#_ )\)/^_JT =?17(?\)[!_P ^$G_?U:/^
M$]@_Y\)/^_JT =?17(?\)[!_SX2?]_5H_P"$]@_Y\)/^_JT =?17(?\ ">P?
M\^$G_?U:/^$]@_Y\)/\ OZM '7T5R'_">P?\^$G_ ']6C_A/8/\ GPD_[^K0
M!5\17;CQ5- ^JS6D<6G^=$B2A TF[T[_ $K'T?4M3U+6I&O;\Q;/+_=O=B+&
M1V7O6U-XOTVYE66?15ED7[K.4)'T)IDGBK299O.DT*-Y?[[>66_/%"!ZF#!X
MBUJTU75('GEN9#&[P212!XP >Z]5(%:>MWAMM&M_[.UF[NY9KB$2)',"PW=0
M&[9]*OIXPTZ*1Y(]'5'?[S*4!;ZTB>+M,B7;'HJH-V["E!SZ_6A!U.7N-=U>
M NB7UU&H%P!%*^9$VKQN/UZ5?$.N_P#")WNH37FH6\2V:RPE[@%S)@9.0.GM
M6TWC#3G<NVC*S'JQ*9-2'QQ:-%Y3:8QCQC877&/3%.^E@ZF%<ZEJ>FW5O;P7
MUU)%)8Q22O(^XIN(W-4&M:IJEKK=G8:-JLT]JTJ,9BX?+=TS[^E=%_PFEB3D
MZ3SMVYW)T]/I3(_%^FQ*%CT5456W *4&#Z_6B^H+8N>!]6N-735Y9Y7<)>LB
M*_\   !Q^==77&1^-[.'=Y6EE-QW-M=1D^IJ3_A/8/\ GPD_[^K2 Z^BN0_X
M3V#_ )\)/^_JT?\ ">P?\^$G_?U: .OHKD/^$]@_Y\)/^_JT?\)[!_SX2?\
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MT<5U=3(QX$\F[;].!B@"Q_9UE_SZ0?\ ?L4?V=9?\^D'_?L59HI 5O[.LO\
MGT@_[]BC^SK+_GT@_P"_8JS10!6_LZR_Y](/^_8H_LZR_P"?2#_OV*LT4 5O
M[.LO^?2#_OV*/[.LO^?2#_OV*LT4 5O[.LO^?2#_ +]BC^SK+_GT@_[]BK-%
M 'G?B:^_L3Q2)=D7]GBVV-#Y8P)&.%;IZUD:!KUQ9V%T]];Q7D\4BJ0ZC)W>
M@QVKU"XCL))0ERMNTC8PLF,G'3K4832D9W46@*G#$;>#[TXNRLQG#6.NM!J-
MRE]'ISQ,SF,A -N%R!^-,D\2W7V/[1%I.GLKR"-,IC!QG)/I7<RV^C;0TL5F
M0PW+D+\V.X]:6 :3?VJQQ);212#?Y>!S[XH)ZG.3ZH%TK391I]A!/=YW-*H\
MM,#U]ZJ:%<R7LVIZG<6T)AB@#1VRH, @'V[XKLY8].D3[+,MLRH,^4VWY1]*
MCFN=,M;*68S01P[2&=&';TI/J,\]F\2NE_#YD.G>6L7FD0J"IR. WTJ>#Q)+
M=1-''!H\=TDVS9(H =<9R*Z;3M*\/Z9+L7][)>(9=UQALK^7 K1&F:'(H<6E
MBR@9#!%XILE)[G"VWBNYF+;]&L$1SM1R!A.<9;VK1L]0,'ABXO98+*XN/MC1
M+)M'EJ,X!SZ"NN-II42.YAM$60?.2% 8>]&-*CM3;?Z(L!&3'E0I'KBBY74X
MR7Q-#!#=![/37FB\O9Y8!$FX')'MQ5,:W>0W#SW,.F*LMNCPP^7@ DUZ"NF:
M:X1UM+9@%PC! <#VI\NF6,P ELX'P-HW1@X'I0P/.['Q)-?O%Y&FV2S2D(0Z
MY13SD@?A3+KQI]CF@BET>S))W2E4X5#P"/\ @7%>D1Z?9Q8\NUA3'3:@&*&T
M^R<Y:UA)QCE!TZXH \NU7Q7-Q;I9V47F@@/$@W1L,'!S]:WY]372?"=MJ<EE
M;W!9RCET&<G.WMZUUYTK3VD,C65N7)R6,8R:F:UMW@\EH(VBSG85&/RHZ6'=
M'ED_B:ZO]-$]O8VMK*%96.S@.,9XQS6SX:O)Y;N.&]@LYX9Y)%1U0;AM _2N
MW^P6>TK]EAVG.1L'?K3H[.VA"B*"--OW=J@8IW1.MK'GRZ[,DUV(]/LF@MI/
MG\Q<L06QQQ3[#Q0DE\(;RPT^-&EV[@H^5>>I]:[[[%:_-_H\7S?>^0<U'_96
MGD.#96^'.YAY8Y/J:0SS&'Q8_E7MRMK9,V[,<3H-H4 Y ^N*>/$]Y'YKII]C
M,9G#1JR@")=N<&O2CI.G,H4V-N5!R!Y8I6TK3W&&LK<@XX,8[=*&T.33=SA=
M.U>35=8T\/:V5M$\S1O;JH,AP.I]JCU[77@FFAAMK")!<& *%'FC&/FQZ&O0
M%T^S6<3K:PB8# <(,_G6>_AC3I=9.J3+)+.>BR$%%^@Q1=71+3LSB&\7,LKQ
MQZ=IT@:,F)BH&"#@[JLV?B@3W]G'+I^GK"^!*P7G<3CCVKN_[)T[+'[#;Y;[
MW[L<T'2K [?]#@!1=JD(,J/:BZ&8OB*5-/M[4V%E92//)LS(@V@8SVKEKGQ5
M=6X@C&C6#2W""1&"@*@[Y)KTB.RMXX(X1&K)']T,,XILFG64J;)+2%UQC#("
M*0'G"^(;F+[3++;:<KOM\J%D'R\9-;G@B[CU^UO+NXM81^]PJ;!A..@KJ9-+
MT^7_ %EE V,#F,'ITJ:"UM[52MO#'$I.2$4"FFK,.A'_ &=9?\^D'_?L4?V=
M9?\ /I!_W[%6:*0%;^SK+_GT@_[]BL70K*U>[U8/;1,%NB!E!P,5T=8?A_\
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M+FK=CXUO05CDTM)88HL-*>'9@N<_2I*>]CK?^$ITK_GL_P#W[-'_  E.E?\
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MZU-I)6 EN"R_(>1BNM\F+_GFG_?(K#T".,WFKY13BZ../:@";_A*=*_Y[/\
M]^S1_P )3I7_ #V?_OV:UO)B_P">:?\ ?(H\F+_GFG_?(H R?^$ITK_GL_\
MW[-'_"4Z5_SV?_OV:MZFL46G3/N6$JN0X4<&L[PW<2W\$TMZ%6Y#8:#;@(.Q
M_'K0!-_PE.E?\]G_ ._9H_X2G2O^>S_]^S6MY,7_ #S3_OD4>3%_SS3_ +Y%
M '+>(/$.G76B7$,4K%V P"A'>K\'B?2EMXU,SY" ']V?2G^)XHQX?NB$4' Z
M#W%:5O%']EA_=I]P?PCTH SO^$ITK_GL_P#W[-'_  E.E?\ /9_^_9K6\F+_
M )YI_P!\BCR8O^>:?]\B@#)_X2G2O^>S_P#?LT?\)3I7_/9_^_9K6\F+_GFG
M_?(H\F+_ )YI_P!\B@#)_P"$ITK_ )[/_P!^S1_PE.E?\]G_ ._9K6\F+_GF
MG_?(H\F+_GFG_?(H Y[1;R&^\2ZE/;L6C,48!(Q725A6"A?%FIA0 /*CX K=
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "D.=IQUQQ2T4 <E<Z9?7VJ%)KG3)+J-=PWVY+*N>*0:%>LDD8
MGT@J[?.HM^I]ZMZA;:K%KLUS9V0GBGMA#O\ /"&,YZX/6N?3POKD3PW$4$:/
M;LC-&+C_ (^2&)+$]N#WH7F!MQZ3JD>PQW6E#R@0I%O]W/6HH=)OK=O,BN](
M1MQ^80]SUJ@GA?7':-3,D,4V]K@"3)#<[,?G5/3/ ^HQ7T$ETK&%"WF"2YW[
MSMP&P.G-,$;T&G:E:0SO!>Z5'&03*4@X]\U4M+.?4HH[N"\TB164A&-O@E?\
M*D\/>'=0L;34K>ZB18IT944R[RQ.><^E8TG@K5ULS:01Q*Q52MP)L>6 ,%,>
M_K2ZAT-K5(;Y--!O[_3'M5("K]G+#/8 "H;32YM0M(Y(9M):),A0UJ1M_ UK
M7.CM'X=M;.&RCG>(*6C\W8=P')#>N:P9M!\1M'+M1&^T*5VO.,PC<#R?XJ?4
M%T+_ /8MV/-'VG1_G_UG[CK]::]I=RH-,>^TEHU3S!$8/E"YQFN7FT'5GLHI
MET['EW)$G[T[K@;NA'85=G\$ZU*\DJXCC?)%M'/@A=V=FZA+2X[(W#HEUY<<
M1N=&VIRBF#IFGMHU\R^6USI!#CH8.HK(T_P/>Q.7N%S\\97=.6*J =PS567P
M-K3SDM([@KB,K=;5B SQCJ<T6$S<^PW-DT0%]H\9=O+3$'4D=/RJB_AVZBUV
MWU%M7LC/O$<,8C^4-CT'>FS^#+]#;O;P0OY7EL4:7JX!!-&C^%M9M]8BNKB)
M(X5E21E\X-R,Y(%"W)?P[$SSRRZJ;8W>GR722$$BR8[6/7FM!-(U#[09$NM(
M\W&PD0<X]*JC0K^'6[Z<::\HGF+QSI>!0H(QRE9$>@ZU;ZY"8;%0]NH=CY_R
MS_,<G/8\T(<G8W8M,O(&DBCNM)CP,-_H^ 0>U"Z'=1R%A<:,K]2?(YK F\.Z
MS#J-F;BR6Z$K/F(3?*/E[FKEAX'U"$QF[*2OO<NWF'E2ORC\#1;2XS8ETG49
M3(LMWI+&09<&#EA55M)E%Q#&;G1C+(-L8%OUQ6,? ^MO*QDDD=R@ D^U84#^
M[MZULV?A6YLO$4%XMO&UO&XVCS.4^7!(_&A"N[%JZTG4+F-(;J\TETA^ZKP_
M<_7BJEUX8N;E(8GNM+3RF#IMBP1C^E1:UX1OKUKF>(%GDNC(42;873' R>!6
M7+X5U:S6"W,)E:1L"Y,Y9HQ@_*?;WI)]1O38VKC0+GRS:M<:5'YP/*V^#^=3
M6NB7MM$D,%WI( 7C$/)'>LF?POX@OYE>:..)1$D143YS@8)_&FWO@?4WU.9[
M:1UC/,4@N-JHN/N;>M"!&E+;3W"7327ND2+;8,S&WR%P..?I4MM:7E_:*\-[
MI+PR?O #;XS[XI-+\.W4>EZQ!/90V_VP*(XA+O'"X))K)D\&ZN(&M88XE.[<
M+D38)3&/+Q_6GUL"U.@_XG%J+>!=4TY%D^6(+"<'%*UQK*3Q0G6=.WR@E/W7
M7'6H]5\/W;Z7I\%A'&'ME.Y2V 25QUKG+;P?KD<ZR/:0M&"^(GN,[=RXXQ[T
MNHGL=A]F\2?]!&Q_[\FE^S>)/^@A9?\ ?DUIZ=!):Z=;P3/ODC0*S>IJS0QK
M8P_LWB3_ *"%E_WY-'V;Q)_T$++_ +\FMRB@##^S>)/^@A9?]^363H\&N-<Z
MEY%[:JPN")"T1.6QU%=E6'X?_P"/S5_^OL_RH /LWB3_ *"%E_WY-'V;Q)_T
M$++_ +\FMRB@# DL?$,J;9+ZP9<YP8#0MAX@61I%O; .PP6$!R:V+R66&TDE
MA17=%W!6.,U2T35CK-N]TD6RWSM3/WB1US^- %?[-XD_Z"%E_P!^31]F\2?]
M!"R_[\FMRB@#D=?@UY=%N#<WMH\0 W*D1!/-7H+;Q']GCVZA9!=HP#"?2K/B
MC_D7KKZ#^8K2MO\ CUA_W!_*@#(^S>)/^@A9?]^31]F\2?\ 00LO^_)K<HH
MP_LWB3_H(67_ 'Y-'V;Q)_T$++_OR:W** ,/[-XD_P"@A9?]^31]F\2?]!"R
M_P"_)K<HH YK1$NT\2:DM[+'+-Y4>6C7 Q]*Z6L.Q_Y&W4_^N4=;E !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 444AR5(!P<=: .5UOQ'>:;K/V2T@CE9P@ E<A1G))X^E4!XVU)YK: 65
MFDERN]#)*0H'?/Y4FKJUKJI2>[O)YU02,\5H'$:] 2<TDOAZPU 0M)K4#>2N
M]054;5]Z%L'4EC\:ZA<+NBLK95:58%,DAQO/<G^[Q2KX\=0\4MDOVE2Q5$8D
M.J_>(JG?C3+2!K>;78FC==Y2.)6! ..WI5^/2;=$AE37;95 ,<3;$Z'J!3Z
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M!?*PLA!X/UKT+ QC QZ4!5'10/PHOK<3//[SQ)JS3QV=LQ2?[0T<A\@G:N<
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M+[_OW69/K.K3>']-GM9!'<W$P221H,\8/.VLO_A)=?1;=9[B.-+A0S7'V?B
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MUV316P+.%C]/2J%EXMT75&>*6(P^9A1O3[V1G&:L:3X4CTN"\B^UO*+E=GW
MH4?0=ZK_ /"%1FQ^SO?REO.67S @!X& *741,GB[1;B_M-/@)FDED,8&S[A
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M_,5I6W_'K#_N#^59OBC_ )%ZZ^@_F*TK;_CUA_W!_*@"6BBB@ HHHH ****
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M /0:*\^FU70H'0-J6JE'3>L@)VGC./K5RY.FV>FQ7]U?:K!#(I9=Y(. ,]*
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M 6/_ "-NI_\ 7*.MRN:T2T%EXDU*$2R2 11G=(V372T %%%% !1110 4444
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MXH#(CQPD"0[L8Y'I0D.VESJK;Q)86T?EA+]ES\H-N>!Z"I_^$JL?^?>^_P#
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M]!_,5I6W_'K#_N#^5 &1_P )58_\^]]_X#M1_P )58_\^]]_X#M6Y10!A_\
M"56/_/O??^ [4?\ "56/_/O??^ [5N44 8?_  E5C_S[WW_@.U'_  E5C_S[
MWW_@.U;E% '-:)>1W_B34IXED53%&,2+M/Y5TM8=C_R-NI_]<HZW* "BBB@
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MV_X]8?\ <'\J ,C_ (1U_P#H+7W_ 'W1_P (Z_\ T%K[_ONMRB@##_X1U_\
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MT!8](HKSR^UJUL]R#6=5>88Q'L )_P#U5-#J-LRIYNO:BK,3NVKD(,X^;TH
M[VBN ;6-.6,NWB'4PO\ #E/O\X^7UI^L7+Z98V-U'JVHS)=R!%/ "@]S0&YW
ME%<(NH6;;1_;VJ>8[!53R_F;/0@>GO1J\&N6-]:0VU]<2Q7+;%=Y0I!QDY&*
M N=W17GPUG31(\+^)+XS(=I1,-D],#UJ675-/ABBED\1:DJ2'&2H^4YQSZ4
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M ,]"?8UH:3$FM1/)9Z]J#*C8.X 46"YUM%8?]@7/_0;OOS%']@7/_0;OOS%
M&Y16'_8%S_T&[[\Q1_8%S_T&[[\Q0!N5A^'_ /C\U?\ Z^S_ "H_L"Y_Z#=]
M^8K)T;1YYKG4E75;N/R[@J2I'S<=30!V5%8?]@7/_0;OOS%']@7/_0;OOS%
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M@C4[8M)%,C74[(GF0J<(O\1;/J/2MO6?#UY<WUE!9) MM':M \DJYV@\<>]
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M+RRRX7"$=:HW?PZOKMH@]_;E8MN&*-N(  (].U:-WX&DGOIKB.ZBC5Q\J;.
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M@C=QC<1G [U4TC2?['62WADS:$[D0CE3W_ T("M_8=__ -!^]_[Y6C^P[_\
MZ#][_P!\K6Y10!R&OZ1>0:+<2/K-U,H RC 8/-7X-$OC;QD:]> %1P O'%6?
M%'_(O77T'\Q6E;?\>L/^X/Y4 9']AW__ $'[W_OE:/[#O_\ H/WO_?*UN44
M8?\ 8=__ -!^]_[Y6C^P[_\ Z#][_P!\K6Y10!A_V'?_ /0?O?\ OE:/[#O_
M /H/WO\ WRM;E% '-:);R6OB34HI;F2X811GS),9-=+6'8_\C;J?_7*.MR@
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MH_L;4_\ H/7'_?M: -RBL/\ L;4_^@]<?]^UH_L;4_\ H/7'_?M: -RBL/\
ML;4_^@]<?]^UH_L;4_\ H/7'_?M: -RBL/\ L;4_^@]<?]^UH_L;4_\ H/7'
M_?M: -RL/P__ ,?FK_\ 7V?Y4?V-J?\ T'KC_OVM9.C:7?RW.I"/5YXREP0Q
M"#YSCK0!V5%8?]C:G_T'KC_OVM']C:G_ -!ZX_[]K0!N45SMUIFJ6UM),NM7
M4FP9VJBY(JKI<=]J\3S6^MW7D X60HOS'OQ[4 =916'_ &-J?_0>N/\ OVM'
M]C:G_P!!ZX_[]K0!+XH_Y%ZZ^@_F*TK;_CUA_P!P?RKE=?TJ_AT6XDDUB>9
M!E&0 'FK\&C:D;>,C7;@ J,#8O'% '045A_V-J?_ $'KC_OVM']C:G_T'KC_
M +]K0!N45A_V-J?_ $'KC_OVM']C:G_T'KC_ +]K0!N45A_V-J?_ $'KC_OV
MM']C:G_T'KC_ +]K0 6/_(VZG_URCK<KFM$@FMO$FI1SW+7#B*,^8PP372T
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M_P"@^O\ WP:/[$\3?]!]?^^#0!U5%<K_ &)XF_Z#Z_\ ?!H_L3Q-_P!!]?\
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M%%% !1110 4444 %%%% !1110 4444 %(2 "3T%+10!QMQ+H5QXE?4KJXBD
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M-@NM3:2X"B2Y+)\IY&*ZK[/!_P \8_\ OD5B:##$UWJV8D.+HXRHXXH L?\
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M?]\FM/[/!_SQC_[Y%'V>#_GC'_WR* ,S_A*-(_Y^Q_WR:/\ A*-(_P"?L?\
M?)K.URZ>RU.&& QB*; F.P'R!G[WX]*Z-+>#8N(HVXZ[1S1TN!F_\)1I'_/V
M/^^31_PE&D?\_8_[Y-:?V>#_ )XQ_P#?(H^SP?\ /&/_ +Y% &#HUY!?>)=2
MGMWWQF*, XKHZPM/54\5ZF%4*/*CX Q6[0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(<[3CKCBEHZ#)H
MX;6=:U'3]16WN6BE>,>:&2V+",'C).:<]I,L+W?F:2PF&XXBY?OTS1XBTF/5
M-7>YCGTUT>$1$S2D-&<]1@_SK/?PW*ZQ6_\ :]@;>$N48O\ ,2P Y_*A;#TN
M.EN(XK9+^272QM)1%,!W]<<#-:=LUVXMXXKW25:,$Q1E/F3UXS6+-X4)MI8$
MU+37$Q!9Y&^:/!S\M2KX6@AL'4ZC:>=YOF>8A&[;@C JM+$)R+ZZ=)+:W#Q2
M:/-&/GE$<>?ZU+&EP@"K>Z-&4"OM*8*^A/-8^E-(FD:PTMO'$98!!%&@"LY
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MW-]9N(UX9' Y]/I3T$/\GQ+_ ,_=C_W[-'D^)?\ G[L?^_9K2_M*Q_Y_(/\
MOX*/[2L?^?R#_OX*0S-\GQ+_ ,_=C_W[-'D^)?\ G[L?^_9K2_M*Q_Y_(/\
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M"J.*Z*L.Q_Y&W4_^N4=;E !1110 4444 %%%% !1110 4444 %%%% !1110
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M"K1QX.?E)%12ZUJ#W\%P9(I6(7,"PX$1R>#ZGBA(>YWW_"4:3_S\'_O@T?\
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M:R=&U_3K>ZU-I)R!+<%E^4\C%=7Y$/\ SR3_ +Y%8F@11F\U;,:'%T<94>E
M$W_"4:3_ ,_!_P"^#1_PE&D_\_!_[X-:OD0_\\D_[Y%'D0_\\D_[Y% &5_PE
M&D_\_!_[X-'_  E&D_\ /P?^^#5G58[9-,F+J$^7@HO.>V*S?#*R21SC4$'V
MX$;U*C 7^''X4("S_P )1I/_ #\'_O@T?\)1I/\ S\'_ +X-:OD0_P#/)/\
MOD4>1#_SR3_OD4 <QX@\0Z;<Z)<0Q3EG8# VGUJ_!XGTI;>-3<'(0 _(?2E\
M30Q+X?NB(T!P.0H]16G;P1?98OW2?<'\(]* ,[_A*-)_Y^#_ -\&C_A*-)_Y
M^#_WP:U?(A_YY)_WR*/(A_YY)_WR* ,K_A*-)_Y^#_WP:/\ A*-)_P"?@_\
M?!K5\B'_ )Y)_P!\BCR(?^>2?]\B@#*_X2C2?^?@_P#?!H_X2C2?^?@_]\&M
M7R(?^>2?]\BCR(?^>2?]\B@# T:\@OO$NI3V[[HS%& <8KHZPM/55\6:F%4
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M^C?\_P GY&D!F?V/XI_Z#L7_ '[-9FE:9X@DN+\6^K1QLD^)"4/S-CK73?\
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MC V'@8I_B#Q!I=SHEQ##=HTC 8 !YYJ_!XFT=;>)3>H"$ /!]* *']C^*?\
MH.Q?]^S1_8_BG_H.Q?\ ?LUI_P#"3Z-_S_)^1H_X2?1O^?Y/R- &9_8_BG_H
M.Q?]^S1_8_BG_H.Q?]^S6G_PD^C?\_R?D:/^$GT;_G^3\C0!F?V/XI_Z#L7_
M '[-']C^*?\ H.Q?]^S6G_PD^C?\_P GY&C_ (2?1O\ G^3\C0!F^'8+RWU_
M48[ZX%Q.(T)D QD5U-<YHUW!?>)M2GMI!)&8HP&%='0 4444 %%%% !1110
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MMNO^?2DNK^?PV\<4]YIMH7 5!Y3G(]. :>E@U.R^RV__ #PB_P"^!1]EM_\
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M1?\ ? H^RV__ #PB_P"^!7/RWFM0.Z2WNG(R+N8%3P*L*OB1E#">Q((R/D-
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MAVJ36L+2/M;*D@XP#4NCW&FZE>01RZ%:Q17!=8F5LG*C)R*;38[6.V^WV?\
MS]P?]_!1]OL_^?N#_OX*\TTN MKT7VFP4V<UW) "47;QTQCFN_\ ^$;T;_H'
M0?\ ?-38.MBY]OL_^?N#_OX*Q=!N[9+O5BUQ$H:Z)&7'/%7O^$;T;_H'0?\
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MS&ARJ[> :BL=&T[399)+.T2)Y/O$9/\ /I4?_"0Z1_T$(/\ OJC_ (2'2/\
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M/^@A!_WU1_PD.D?]!"#_ +ZH OS017$?ES('0G.T]*1+:&.9YDC59' #,!U
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)]*HRZZD/F.=*TMT@*K(J-EG)[IZB@+G9_VYI?\ S_P?]]T?VYI?_/\ P?\
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M7(0:Y \T=M)H]EY\\@C@V#*N0<,<^@'-=E_9&G?\^4'_ 'P*=@&?VYI?_/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%8VH>(%L+]K<V<LB(JM+*I&$!Z5(WB71DC>234(45&VL6)
M&#0!JT51MM7L+UI%M+E)VC7<RISQ4%IKL,T=R]S$]I]GY<2GH.QH U:*Q+;Q
M-9W][/;6 -RT40DRAP#GMSWJYI.I-J=JTS6KVY5RFUR#T^E %^BBB@ HHHH
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MBB@ HHHH **** $P!T'6EHHH *0J&&& (]Q2T4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g201711142133436175632.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201711142133436175632.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &3 F\# 2(  A$! Q$!_\0
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M2 ./;F@#2HJI932S>8TARH( X]N?YU;H **** "BBB@ HHHH **** "BBB@
MHHHH ***9,66"1D.&"DCZT /HJC8W4D[2"1@< %>,=<U=R/44 +1110 450U
MJ>XMM)N)[5@LL:[@2,US.E>)-0N-5MH;B9&BD?:0$ ZCC]: .UHHHH **HZQ
M-<6VDW$]LP66--P)&:Y?2O$FHW&J6L,\R-%(^U@(P.HX_7% ';4444 %%%5+
MZX> 1B,@%B<\=L4 6Z*JVD[-;-+,X #'D\  5-'<0RMMCE1R.<*<T 24444
M%%027EM"^R2>-&'8M3H;F"X)$,J/MZ[3G% $M%9,NHR12LS./*60@X7L#_\
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M2G5_^?A/^_0H_P"$IU?_ )^$_P"_0H ]!HKS[_A*=7_Y^$_[]"C_ (2G5_\
MGX3_ +]"@#T&BO/O^$IU?_GX3_OT*/\ A*=7_P"?A/\ OT* /0:*\^_X2G5_
M^?A/^_0H_P"$IU?_ )^$_P"_0H ]!HKE?#NLZAJ6IM%<2JT2QEB @'.0!6O<
MWTT<\JHPVIQT[XS0!IT51NKB:!( &&]@=W'7BI[.1Y;5)'.6.>WO0!/1110
M4444 %%%% !1110 4444 %4]2?%NJ#^-@/PZG^57*R]2?=<(G]U<_B?_ -5
M$5J UY'G&U 7/X?_ *ZB#%QYC8RQ+'\>:EB^2UNI.[ 1K^/7^=5V0R+Y:<,_
MRCVS0!%;^*K"V9[>6.5=C$&15W _E6G;^(=*N<!+R,$]F.#7&76@:K!([-9N
MX+$[H\-W]!S69+&T;;9HV0CLZX_G0!ZLDL<@S&ZL/8YI]<5X+C;[=<NK,(UC
M *@\$D\<?@:[6@ HHHH **** "BBB@ HHHH **** "@\C%%% ')ZC;7-Q:LE
MJ&\]1D*IP3@\@?K62=)UX%?W$_S=,../KSQ75Q_N]4_[:D?F/_KUK9&<9YH
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M9U7[S ?4TB312,0DBL1U .<4 1P6=M:LYMX(XMYRVQ0,U/110 4444 %%%%
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M$$Z_ZR!6_P!QR/YYJ];Z]!+(D;AXRQ RZY _$5S=6M-C\W4K=3T#AC^'/]*
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M/MY%*N%+,I&"#_DUIZ8N(9&_O/\ RXH I7GSWDH'=E7]!_C6U6+]^_\ K/\
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MM 'I=%(6 ZD#ZFA65AE6!'J#0 M%%5#J=B"0;J+(_P!J@"W16/J/B&UL(XI
M#.DA*@QGH169)XTB,;".VE5\?*2,@&@#JZ*X+_A+M4(Z0#\*%\7:F'4L(64'
MD8QF@#O:*Y.35M0A\5K:%S]G>15"LO\ "?>NLH ***J:G>G3]/EN@F_RQG;Z
MT )J.I0Z9;B><-L+8^49JMIOB"RU.=H8F99 ,A7&-WTK+NIYO$OAR1[>W(FC
ME ,>1SC!X_.J&B^'=035[>YN(3!'"2^6(.[VX/% '4ZF.(3_ +1'Z5SNH7NE
M6DD(GTY;BY,8W$CM_*NCU/\ U41_Z:?T-9EQX>M]6MX)S(\,RC:67D$9/44
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M;(/Z4 >=5U.CIY6EQMC[P+_F3_0"K4UAI\Y);38%)[QL5_E3XXECA$2C"@8
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M;)0IC)7:7+]EQVK9L4\C3X5<@';EB?4\G^= %FBH#=PC[I+G_8&:C-U(?NQ
M>[-_A0!;HJ@9)FZRX]D&*845N6RQ_P!HYH NM<PH<&1<^@.349O$_A21OPQ_
M.H ,< 8^@ICRQQC+R*OU;% %@W4IZ1JO^\V:899S_P M /\ =7_&J3:E:*<"
M7>?1%)I/MSO_ *JSG?W(VB@"V=S?>DD/_ L?RI/+3.2H/UYJKYFH/]V"&/\
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M"0/Z4 =V=4N\</%_W[_^O2#6+H=4A;_@)']:X%O$B_\ /*?\;W_ZU,/B)/\
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MAL[:V_U4*J?[W4_G3IIHK>)I9Y4BC'5W8 ?F: .2\5_:OL<5M+=DM,P+1QC
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MK6$@+S%(28@0H7J2#@G/H?<4_:4]_P!3"I3E3UD8,'AU[QV2V^TRLN<^6-Q
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MT?VMI_\ S]Q?G0!:\M/3]31Y:^GZFJO]K:?_ ,_<7YU:1UD171@R,,A@>#0
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MG7,=_?RSVJ"<LBJT<;@JF.^?>NASC:Z9FKMV:);G4K2WU2.WMXHY&N T)6+
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M8FNI1M&_RWA6 ?*<_>Z9-7AK6ER:C_9]O!&7:$R"01D \?SK3*:<(F1KNS"
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MU L]M+:S1MT99#_A6W)HMZ)=#9$5EM HF 8?+CJ?>@#IJ*** "BBB@ K$O\
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M6:W2-V$3 AP>Y'I]*CJ"++75P^>!M0?@,G^= '4OXCL=6$5OJUEM3=D2QO\
M</KV.*T(M#T[3[E;V&28E5)1'7()(P"#CWKC:T-.U+4[?_1K5A.&0JL,AXX4
MD8.>.0* ,/5Y8KOQ)+''Y8:)MC.@=7'08.?E/ (R.:D^Q6^,&/=_O$FEN4N%
MUIHKE)4\D9C62;S" 03CV(+<@<>G2IZ (UAB482)!Z86N[B3RX(X^RJ!C\*X
MJ-D26-I,[ P+8&>,UUB:O82'BX5<]F!% %RJ&KO*MA((?.\PA0IA(#YW#[N[
MC. :N)-%+_JY4?\ W6!K%\2J\]DMLGE@R2;@9(&E7"C)R%!(^N* ,%[B2[NI
M9I!)N+G_ %B@-QQR%XS]*6H+9 D*J  %7@#TJ>@"YH]NEQK%JCX W;B2VWH,
M]:["156=U1E*\$;6W8_&N5T&)9-5#,5'EQ,<MG )P.P^M=1'AR TFP$X!"9'
M7 [T -1P9$+1%D#<@]Z8CL\!D?[\A+-^)_PJS?0?9(PPD+LP;C '05 #Y8B!
M[$"@"1OO'C'M24=>:* "BBB@#GO$TF8X8?[\R CV7+'^0K&J]KTGF:G;Q]E1
MY/S(4?UJC0!<TJ/S-4MQV#;C^'-==VKF_#\>Z^D?^Y'_ #-=)0!'.RI$<]3T
MKC;U_,U6Z/9"L8_ 9/ZM77W1^55[G_/]*XE',IEE/625W_\ 'CC],4 /KK_"
M\OVC0[BT)^:%V4?1AD?J37(5O>$9VCU>6'JLT)/T*D8_]"- &9JO_(0_[9+_
M #:JE:OB*W,&HH2,!MRCZ9R/ZUE4 ,E4O'M!P6(&?J17JQ^\?K7ET<7G3PQ9
MQOE1<^GS"O3-DW.9AGU\O_Z])C1)14>R7'^OY]=@HV2XQYYSZ[!2&245!")F
MA5GF)8CG"@54U:YFT[2I[I96=HQG!4?X4 :5,D("@$'YB%X.,9KAQXMU-D!$
M"C(SG>,_RK6T/69]5>X@ND:-XH_-5T<<]O3K3L*Y.(E%JT2'"E<#VR!_C6+'
MX/U..% C6[J!P=Y!_E6O>DQV,Y3.57 QUX ']*YJ#Q!JD<*8OF.%'! /:F([
MK0+&73M)2WG"B4,S-M.1R:?J.HFRGLXE"LT\RQD$\@$XS5BUE>73H9I,;WB#
M-CIDC-<!9SRW/B&U,LKN%NAL#'./FH ]'HHHH **** ,>] ^V2'OQ_*JLI=8
MR4C\P_W=V,U-=O*=4G1HP(E52KY^\>XQ[<?G38+>ZN&;9Y6Q3C<<C\/>@"C=
M6%K<2J\MHLS' +D#('N>M1G1K!8Y0MN%$BX<JQS@'.!G..0.E:LEK=0HSR)%
MM7DD28_F*C59FC$@MY"I&05PV?R- &7I^EP6M[#>PR2.L9)". 1G!'7@\5?>
M:68R2 1LKDGY7YIDM];0-LGE$3'M("O\Z= ;58P+<Q*C'<-F #GO0!I/J$>(
MT"D*&&>1T'U]\51DN$:5V.X!W)!VGUIP.>AHH SM4NKB&V$ME)&70[G0X)*^
MPKCXR\ER\SC!89ZCJ3FO0&Q@EN<#/3-5%73KW:XC@D+#C* $C\1F@#D:*ZU=
M)TOSFWVF<KT20@CWQFF/X?TEB=KWL7Y,!^AH Y6BNB;PQ ?]5JJ9["6(C^M5
MV\+7^W,4]G,?1)<?S% &+16E+X?U:%<M8NW^XRM_(U2EM;JW&9K6>,>KQ,/Z
M4 144W>O=@/J:=0 5J:'#=&Y>:#RPH 1VD&>^<#'>LNNFT!-NF;O[\C'^0_I
M0!HD?OLYXP./QKB=?LYK?44GVG;-/E&'3W!KMB/WN<_P@8_&N6\2R_Z9;Q]=
MJ,?H2Q_PH HT4W9Z,P_&C:W9S^(% #J*;^\_V#^8HW/W3/T- #JTM,TL7\<C
MM*R!&"C SGBLO?ZHWY5MZ!?JN+/R7W.[-OSQT].O:@"P/#L'>XE_[Y%+_P (
M[;=YYOT_PK8HH R1X?L^[S'_ ($/\*>-!L!U64_60UIT4 9XT.PX_=-_W\:N
M6=(X[FX$(Q&9F*\Y[X_I7:SRB&WEE8X"(6)^@KAHAB% >NT9H ?5FQ+QO<SH
MC.8;=V 49.3@# _.JU2,S0Z/>3*B.QEB15=U49!W<[N#U'!ZT 5K+2[J-//\
MJXD61=Q:13O7/.&&3M^@XJ6NFM0MIH#,%*%(CD$C(('3CCKZ5S(X 'I0 U_X
M1ZL*=6GHEI%=74GG1JZ(G1AW)_\ UUKOHM@__+$I_N.10!E>'XP=0=\?=C/Z
MD4WQ/]A4$7;77GW$)2$1$[-P8D$^A&XD$_S K;M-.AL&D>%G)<8PY!QBN7\2
MZ@!K"Z:DSJ71#, 2 P4Y!Z<]>Q'7OB@"N@(&#U'%.I%^[GUYI: -OPVH,EV_
M=0B?S/\ A6_C/!&?K6)X::,V=QM93(9CN7/(   _E6TQPI/H* (Y%PB@)M+E
M<9_ND_\ UC3G5G=0,;0=S$_CBG7 /VM4!X3Y3^"X_F:5<_.>Q(% !112.RQC
M+' )Q0 M(QPC'T%()$;HPIMP?W#8[\4 <??MYFKW!_N*D8_(L?\ T*H:0OYD
M]Q+VDF<CZ9P/T I: .@\.IB">3U8+^0_^O6U6?HD>S2XS_?);]?_ *U:% &=
MJMPT%K/)C'E1LRY[_+_C7)PJ4@C0]54 _7%;_B*0M8RJ"!YC)&/H6'],UAT
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MT&VM;FPU6*]N9%9H-K[!\NSL_NP/^>:5@N0'Q%KB'S&O(SL^;;L.#CMUK?\
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MAF6-2L%XC#).)$(/)SU&?Y5T5% '*2:+J,?(A20?],Y ?T.*IS0S6V#<0R1
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M\AVC(.3BNTLM<L;V!95E$>6V[9."#7-7&C6=U*\L$KQL[;B%=77/Z']:;+H
MDT^& 7(62-V9M\9VMGITSCB@#MU=6&58$>H-+7!Z9IFIVNJVPCF_=>8-YCF#
M#;W^4\]/:N\H **** "N>UWPY)JETMS#<*CA=NQQQ^8KH:XF\\47]KJEQ''Y
M;0HV KCD?C0!?TS29M)L+L7.SS9W5%*-GY?\DU5UPXTN8^N$'XG_ .M6U<W!
MN;>T<H4+IYI4GID?_7-1MI=OJ6FLMR613)O#J<$8X_I0!P]K%Y][;PC^.55_
M,UZG7,67AJT@OX+J'4/,6)]VP@<_B*Z>@ HHJGJWF?V5<^4K,_EG 7K0!PFI
MVNH1ZG<RF&Z4&0D,@;&/8CBNA\'2W,L%V)Y97564*).QP<_TKE(]2U"W Q>W
M"''1F_QKT/1IYKG1[6:=@TKQ@L<=: +U8EV?.NIL?Q,(Q_+^>:VG8(C,>BC)
MK%M!ON8B_09D8^G^2: *GB71KW4)+=[15=(E*["V"/SI?"FF7-D]W)=0M$[;
M44-CD#)/3ZUSEUJUZ-2N9(+N5%,AP >*[S29IKC2;6:X(,KQAF(&,YH N444
M4 %<5XS<&_M4!Z(217:USFI:=I>M77F"_$<Z#80K _F#0!4\%(-]Z^#N 10?
MSK;U-LS1)Z M_3_&DT32/[(MY8_-$ID?=NVXXP !45\^;N0]D4#],_UH JW]
MZNG:+O>!9EGD*E&/4=/Z5SB2Z)*ZJ]I=V^3C<DNX#\\UJ^+"T6GV$&,+U)/K
MBL71;)-0U6&VD9@K9;*D=N?2@"G(BQSRHI)56*@GT'%-KII_!EUYCM#=Q,"Q
M(#J0>3[9KGKNW>TN)+>1X_,0X.UN/UH T['Q)>Z?;1VT<<3QQJ,;N#SS_6NH
MT'6GUA)O,@\MHB,X.0<__JK$ATK0)YUD&IY0XW1;@,\8Z]:Z/2=-LM/BD-D[
M.DK9)+[NE $6I2#[3@GB-,D?7_\ 57GMRJ2W4KE1G=C(XKN[P-<3SHA :1O+
M4G\O\:Y.?0]4M]QDLY&&22R88?I0!32YNHL>7=3KCMO)'ZUW>DVOVS2;6XG(
M\UURQ"@9YX_2O/\ [PPO4\#ZUZI:PBWM(81_RS0+^0H JMI@S\LG'IS_ (U$
MVFR= <J?4@_IBM6B@#&^QSI\H3"C@848_0_TIC0R*0&49[=1_,5N5GQZWITL
MK1B[C#J<%6.#F@"CM;.-I)'8$'^1IDJ;XRL@=0>^"/UK='DS#(V./7@TGV:$
M$D1A2>NWB@#!01@ *1QZ'FI.<Y)))]3FM<V<1SRQSV8[OYU%_9L>."N?4H!_
M+% &;CD'C(]1D?E3C(YX,<1^FY?Y&KATXXXQGV<C^>:B:PF R"WT^5O\* ("
MZG_EBR_[C@_S%&Z(MUD4?[4>?Y&GM:S*,]O=&_IFF-'(O4)_W\ _GB@!?W9.
M$EB_X&2O\Q2K%*Q.U X'='4Y_6F[)1_RQDQ[+G^51E4W89 &/]Y<']: )2K*
M2&BE7'JAQ3 Z'HPXH7<GW'=?]UR*?Y\^,><Q'HP#?S% #3[5*UJDVF7(?^,;
M00.5.,#'XFH]YQ@Q0,/]S;_(T;T$1C$+H"V[,<YSG.>] &-_PA%U$JI%>PNB
MJ NZ,J>/H35:3PIJL?W8XI/]V3_'%=.+MPH"W-PI]7C5_P"6*D^WR@#$]NY[
M^8C1_P"- '$2Z+J<.=]C-QW5=W\JJI:,;R".6!E9I4'SQD'[P]17HXOI20%@
MCE_ZY3J?YXIYO=IP]K<CZ1[OY9H SI>9I#_M'^=,IS)+EF%O,<G/W#3=D^,_
M99_IL_\ KT <]XIMF\W3;KG8&D0\<9P>].\) -K3+G[UNX_5:ZF-I$2$-9SL
M 6+#:O<<=35H7 4@K9R@^VP?UH X'_A'M4AEDA6SD<*[8<8P022,?G6OH^FW
M6GK/]JB,;2E2H)!R!GT^M=2;IA_RP;_OM/\ &J=XSSNA6,# YS(O^- %6I;>
M,2S>6P!5U93D9X(J$K,#C9%CU\]:DMY)8K@.4@P!_P _"\T <];>$-2M9HT7
MR6BBE!#;\94-D<8]*Z34@6OH3GA XQZYVU9_M%LG*08[?Z0/\*H32/-=^8=F
MT*1\C%N21[#L/UH JW^DS:M;)' Z*R2%OGZ'A1_C45CH%UI4QGGEA967;A"<
MY_$>U:UK<"$_?1>N0^><D<C%3W-S#/"%\Y0V<GY6Q_*@"C>Z4VKZ4L*2B-TE
MW L,BJVF:!-I-ZDTL\<@<A %4COG^E;%K=6\$6QI<G.>$;_"G27,$\D2H[9#
M@_</- %ZBBB@ HHHH *HZII<6K6ZP322(H;=\A&35ZB@#GHO"%G"^Y+FYS@@
M_,._X4]/#"1_<U*^'_ U_P *WJ* ,ZUTHV\R2->33;#D!POICL*T:** "BBB
M@!&&Y2,XR,9KGCX/LVE,C7%PQ+;B&*D'VP1TKHJ* *LEC'))N+,,*% '0 5)
M]F7[']F#$*5VY[U-10!S:^#+).5NKH'U#@?TJS%X<\G_ %>J7Z_]M ?YBMNB
M@"E#8SQ==0N)/]X+_A5VBB@!CQ)(,.BM_O#-$<?EJ%!^4< !0 *?10 R6,2Q
M-&20&&"15;^SXPL@#N-Z;"?05<HH YH>"[ #'VBY([\CG]*Z..-8HDC081 %
M4>@%.HH **** $(R".F:YQ_!EC)(TC3W&YF+$Y7_  KI** (X(A!!'$&9@BA
M<L<DX'>J\FG1R,[%WRYR>E7** &O''*NV1%=?1AD5!'I]G#.)XK6&.4#&]$
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ML8Q:Q.\4A)Q*R#YUZ8X)'0GH?2G>'?$[:[</;R6AMIH;>.6:-FR59B< >JD
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M3@5)10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
A10 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g201711142133435995631.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201711142133435995631.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &2 G # 2(  A$! Q$!_\0
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M%<C_ ,)=J_\ T*.H_P#?Q*/^$NU?_H4=1_[^)0!UU%<C_P )=J__ $*.H_\
M?Q*/^$NU?_H4=1_[^)0!UU%<C_PEVK_]"CJ/_?Q*/^$NU?\ Z%'4?^_B4 ==
M17(_\)=J_P#T*.H_]_$H_P"$NU?_ *%'4?\ OXE '745R/\ PEVK_P#0HZC_
M -_$H_X2[5_^A1U'_OXE '745R/_  EVK_\ 0HZC_P!_$H_X2[5_^A1U'_OX
ME '745R/_"7:O_T*.H_]_$H_X2[5_P#H4=1_[^)0!UU%<C_PEVK_ /0HZC_W
M\2C_ (2[5_\ H4=1_P"_B4 ==17(_P#"7:O_ -"CJ/\ W\2C_A+M7_Z%'4?^
M_B4 ==17(_\ "7:O_P!"CJ/_ '\2C_A+M7_Z%'4?^_B4 ==17(_\)=J__0HZ
MC_W\2@^+]6 S_P (CJ/'_31* .NHK(\.Z]'XATYKI('MV21HWB<@E2/I6O0
M4444 %%%% !1110 4444 %%%% !1110 4444 %8]_P :_IQVYR& /I6Q63?0
MB36[%]A+("<YZ4=0Z&M1110 4444 %%%% !1110 4444 %%1SR>3;R2XSL4M
MCUP*X[2?'<FI2.K:>8]D+R$;N<KS^5 ':T5PO_"P=^FF>"VCDG!QL#'%6M-\
M77NHW\,"V< 1G97(D)*X7- '845PTOC;4A;37$&FPRI%N^59"6)!JK'\0]0N
M+DQ0Z7$.&(+R=@N: /0Z*K:=<2W6G6]Q,BI)+&KLJG(&1FK- !1110 4444
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MH>K/M_XJ"X7;_=0<US$#07&L62Z0$BN<OA_LY 7COP.*ZFV@\2_:@UQ>69@
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M4RSH**YV7P;87)S<7-])@8&;AA@?A6KIFFQ:5:_9X7E= <YD<L?SH NT444
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M5.*+C+?:]O#2VT<^[M\O%%HH>/3U'"LLL#!NIZXI;8^:EFK<"6UEA*'J=N:
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M/E_\>%GOR,YFX([TXE1V'2Z%J+I&$UZ[4A]SG .[V]A3FT;4W15;6YLA<9"
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MI]V5 P_$5/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% %#6I9(=%NY(G9)%C)5EZ@U@P6,[V\;MJ^IY9 3^_\ ;Z5N:\YC
MT&^<*K$1'AAD5YU%IDK0HWGPC*@X$'_V5)JXFFSI)6O-,U"S>&\O[O>S P/+
MN#\=.E:/]OZGY>[_ (1Z\W9&5R.E<II@_LK7+.>9XGC^;=B$Y'';DUUK>+K
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M%^'&@,,K)>D>UR:7_A6VA?W[[_P(-=<B+&NU%"CT%.H X_\ X5MH/]^^_P#
M@T?\*VT'^_??^!!KL** ./\ ^%;:%_?OO_ @TC?#?0%&6DO0/>Y-=C2,BNI5
M@"#V- '&1?#WP],,I+>GV^TFI/\ A6VA?W[[_P "#7506L5L"(U R>M34 <<
MWPVT+8</?9QQ_I!JI8>!M&OUD\X7*-$VW]W,1GW-=Y6-I?[K4KR+WS0!D?\
M"MM!_OWW_@0:/^%;:%_?OO\ P(-=A10!Q_\ PK;0O[]]_P"!!JSIW@/1M,U&
M&^@^U&>$Y0O,6%=/10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M1W"&6VEC4D,R%01VR*^<['^T[S[7#+K%\GDW#+M$A]37TA7S_+$UIXSUVV*X
M03EAQZUW8*S;3&FTG8A_LZ]_Z#>H_P#?XT?V=>@Y_MO4?^_QK2HKT.6/8GGD
M49;34)B"^MW_  ,<28_E4?\ 9U[_ -!O4?\ O\:TJ*.6/8.>1F_V=>_]!O4?
M^_QH_LZ]_P"@WJ/_ '^-:5%'+'L'/(S?[.O?^@WJ/_?XT?V=>_\ 0;U'_O\
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MQ^AKJP;M4MY#74RZ***]4R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA\0-C[+*VW9^7=(N,>]/7PAX]\M=UE!O[XD7%>Z44?7)]E^/^8:=CPE?"'Q
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M,47Q!U3SI43]W$!N8#/%9WV^S_Y^H?\ OX*]*#O%,F2UT+%%5_M]G_S]0_\
M?P4?;[/_ )^H?^_@JB;,L457^WV?_/U#_P!_!1]OL_\ GZA_[^"@+,L457^W
MV?\ S]0_]_!1]OL_^?J'_OX* LRQ15?[?9_\_4/_ '\%'V^S_P"?J'_OX* L
MRGJL^I?:]/L=*6-KJ\E,2"3H3C-:;^#_ !ZT0 LH-QX;,BX]ZCTC[/?^._#H
M2=&\JX:3Y&!Z+7O-<>)KRIR21HDDEH<3\,M$U?0-!N+/5XECD,Y=-KAL@UVU
M%%>=.;G)R?4&[NX4445(@HHHH **** "BBB@ HHHH *S;T+_ &I9G)R">W%:
M59-__P AJQR#M.>AHZ@:U%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!EWGAO1=0G>>\TRVGE<89Y
M$!)J(^$_#[!0='LL*01^Y':MFBK]I/N/F9CCPIX?#EQH]EN/!/DBD'A/P^$9
M1HUEM;.1Y([ULT4>TGW8<S[F,?"?A\JBG1K+"$%?W0XQ2_\ "*: 9 _]CV6X
M# /DBMBBCVD^[#F?<QAX3\/A64:-98<DM^Y'.:#X2\/&,(=&LMHQ@>4*V:*/
M:3[L.9]S'/A3P^SJYT>RW+T/DBA?"GA]=V-'LOF.3^Y%;%%'M)]V',^YE6GA
MG1+&:.:UTNUADC.5=(P"/QK5HHJ7)O<3;84444@"BBB@ HHHH **** "BBB@
M HHHH *H7<3/?VKA@ A.0>IJ_69?8_M.SX!Y/UH N7-W#:*IE) 8X&!5;^V;
M/^^W_?-5O$'^JA_WC6'L?.-K9/;% '2_VS9_WV_[YH_MFS_OM_WS7-;7_N=.
MO%!$F!\N,],K0!TO]LV?]]O^^:/[9L_[[?\ ?-<T-PR'BR?88IRB.218]QC=
MC@!QP3]: .ECU:TED"*[;CTXJ;[;#_>/Y5S<$+P:BD<@PP-:% &I]MA_O'\J
M/ML/]X_E6713$:GVV'^\?RH^VP_WC^59=% &I]MA_O'\J/ML/]X_E6710!J?
M;8?[Q_*C[;#_ 'C^59=% &I]MA_O'\J/ML/]X_E6710!J?;8?[Q_*C[;#_>/
MY5ET4 :GVV'^\?RH^VP_WC^59=% &I]MA_O'\J/ML/\ >/Y5ET4 :GVV'^\?
MRH^VP_WC^59=% &I]MA_O'\J/ML/]X_E6710!J?;8?[Q_*C[;#_>/Y5ET4 :
MGVV'^\?RH^VP_P!X_E6710!J?;8?[Q_*C[;#_>/Y5ET4 :GVV'^\?RH^VP_W
MC^59=% &I]MA_O'\J/ML/]X_E6710!J?;8?[Q_*C[;#_ 'C^59=% &I]MA_O
M'\J/ML/]X_E6710!JK=Q,< G\J3[;#_>/Y50@_UA_P!TU%0,U/ML/]X_E1]M
MA_O'\JRZ*!&I]MA_O'\J/ML/]X_E6710!J?;8?[Q_*C[;#_>/Y5ET4 :GVV'
M^\?RH^VP_P!X_E6710!J?;8?[Q_*C[;#_>/Y5ET4 ;4<BR)N7I3JYO4->?2$
MMXX[8S-*"< ],50B\;SS'$>FECTX:N.ICJ%.?))Z^C,Y5H1=F=G17*VOBZ::
M_@MI; Q>:VT,6I-5\7S:=>74"6!F$&<[<YP .:UHXBG63<'L5"<9['5T5RC^
M+Y@(RFG._F0F92,XP.N?>C_A,A]C686C%W@\U$P<DYQMK8LZNBN.'C*]DF\N
M#2FF&TL'7.T@=:B'CB]CVFZT:2%6*@').0>] ';45R">,;N2[G@&EN!&C.CG
M.' Q_C75P.TD$;NNUF4$CTH P+CQOHEK<R02S2"2-MK 1GK4?_"?Z!_SWE_[
M]FO+M>_Y#U]_UV:J2032KNCB=E!QE5)KQ99A64FDD?30RC#N"DVSU[_A/] _
MY[R_]^S1_P )_H'_ #WE_P"_9KR,6MPQ($$A*G!PIXH^R7//[B7CK\AXI?VA
M7[(?]D8;N_O/7/\ A/\ 0/\ GO+_ -^S1_PG^@?\]Y?^_9KR$02L%*QL=V=N
M!UQ1Y,N ?+?D9'RGFC^T*W9#_L?#=W]YZ]_PG^@?\]Y?^_9H_P"$_P! _P">
M\O\ W[->1BTN3TMY3W^X:/L=R" ;>7)Z?(>:/[0K]D+^R,+W?WGKG_"?Z!_S
MWE_[]FC_ (3_ $#_ )[R_P#?LUY']CN<9^SR_P#?!J)E*L58$$=0:7]HUET0
MUD^&>S?WGOFF:G;:M9K=VC%HF) )&.E7*Y;X??\ (J1?]='_ )UU->Q1FYTU
M)]3YW$4U3JR@MDPJA=L1?VJ@#!)R<<U?K"U2_NH-9MH8K421G'S%22<GG![8
MK0Q)M=.%MSUP]9[W@EE&$(P"#SS5[7^(H3_M&L3S&!R,#Z"@"V+C[Q*$JRX'
M/\Z:LK@QC[P3.>:K>8W/O1YK=L#/H* +@N"LF0G &WYCUJNB_:]:@4+@%]Y'
MH!4?FMC''%+;3O;7C7( +E=JY[4 :5S()-< '\)Q5/6)9H;:-H+B.%O,&6<X
M!'I1:NTFH(['+,V35NYM8+N,)<1+(H.0&'>@#'DOKD1Q,]Y;J<D-AL#V^M5Y
M+RZ!$C:C$J-C WC'7FMEM)L'^]:QG'J*<VF63J%:VC( P 1VIB,T333B&"VU
M%7D)8N0W..U0W']HVL^V74456!*!F /3_&MJ"PM+5MT$"(<8RHI;BQM;MU>>
M!)&484L.E &3%>NB9%_'+)E<JSC'O44-QJ$5R?M6HVVT(P*JW?M6L=)L",&U
MCQ]*1M'T]V+-:1ECU)')H RGN;QN$U&%.!R7!P:CDN[Q!\^JP CK@^H_QK:&
MD:>N[%I%\W7CK2KI5@A)6UC!/7B@#,MTU>6W5TO$D!0?.#P3WQ5RRAU-+L-<
MSJ\)'*]P:T(HHX(Q'$@1!T I] !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5EZI%<,0R7:P1$@$DD'.:U*CF@CN(]DJ!ESG!H P
MK=I+>=9)-6CE7@$,<9]:U]/>1[8F659&W'YAZ=J8=)L21FV0XZ<5:CC2)=L:
MA5]!0!8@_P!8?]TU$>!FI8/]8?\ =-14 5&U2R6-G:=0JYSGVI8-1M+F41PS
M!V*[@!Z5.T,3?>B0\8Y44+%&ARB*IQC@8H ?1110 4444 %%%% !1110!CZY
M(8KVQD! *QR$9K-TQH)(GGC(!D.&CS@@X[5T>H>'UUJ*!S.8_+R.!UJ@/ :#
MI>L/H*\/$8;$.NYQC=>ODCDG3J<]TM#-L0OVO3@4:-EN?NNV2>.M=A+B>>X9
MG,<<1VG8.2?>LFR\&K:7T-R;MG,3;L$=:W;FRF:4RVL_DNWW\C(-=>7TJE.,
MO:*QK0C**?,BA//&/L:K<%8VW!G5>3BB*5F79$0R/($BE91T[U?CTY4:%MQ8
MQ[B<]R:0Z:FV1 [!&;>H'\#>U>@;D3QR6,D6)"\<AV$,.A]J'<G1#,0ID"]2
M/>I8+&42B2ZN/.9?N<8 J,Z9(7\O[0?LA.?*Q_7TH K/*OGS!KDQE$4JH'7(
MK5MF=[:-I!ABO(I([5$GDEP"7QU'3%0/9SL?^/C"YX&V@#Q77O\ D/7W_79J
M=8:PUC:/;B-BKN')#D=.U,UP8UR]'I*:SZ^8<G&;:/N80C.E%2[(W5\1*BW"
MBT_U[;G_ 'ISGVH7Q(Z,Y%O_ *P?.#(>>,5A44_;U.XOJU+L:=MJ@M7M94CR
M\#,V,X'-:'_"2&YN(@MA"'QL +'&#U'M7.4=*(UIQTOH$L/3D[M:G8OJ-^D1
M"QPH I"8EY7M^-":G>_Z/')#"7A&%8S\D]*X_<W]X_G1N/J?SK3ZR[_U_D9?
M4XVZ?U\SKDO;I'1!'$7']^X/.37,7I9KZ=F #%R2 <_K4&YLYW'\Z2LZE7G5
MC6E15-W/8/A]_P BI%_UT?\ G74URWP^_P"14B_ZZ/\ SKJ:]_#?P8^A\AC?
M]XGZL****W.8BFMX;@ 2QAP.F:B_LVS_ .?=*M44 5?[-L_^?=*/[-L_^?=*
MM44 5?[-L_\ GW2C^S;/_GW2K5% %9=/M$8,L"AAT(I?L</]T_G5BB@"O]CA
M_NG\Z/L</]T_G5BB@"O]CA_NG\Z/L</]T_G5BB@"O]CA_NG\Z/L</]T_G5BB
M@"O]CA_NG\Z/L</]T_G5BB@"O]CA_NG\Z/L</]T_G5BB@"O]CA_NG\Z/L</]
MT_G5BB@"O]CA_NG\Z/L</]T_G5BB@"O]CA_NG\Z/L</]T_G5BB@"O]CA_NG\
MZ/L</]T_G5BB@"O]CA_NG\Z/L</]T_G5BB@"O]CA_NG\Z/L</]T_G5BB@"O]
MCA_NG\Z/L</]T_G5BB@"O]CA_NG\Z/L</]T_G5BB@"O]CA_NG\Z/L</]T_G5
MBB@"O]CA_NG\Z/L</]T_G5BB@"O]CA_NG\Z/L</]T_G5BB@"O]CA_NG\Z/L<
M/]T_G5BB@"!;6)3D _G2?8X?[I_.K%% %?['#_=/YT?8X?[I_.K%% %?['#_
M '3^='V.'^Z?SJQ10!7^QP_W3^='V.'^Z?SJQ10!7^QP_P!T_G1]CA_NG\ZL
M44 5_L</]T_G1]CA_NG\ZL44 -CC6-=J]*=110 4444 %%%% !1110 4444
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40 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g201711142133437865637.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201711142133437865637.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,E G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT8/M)./*S\V:U:XA[:W_ .%KPD0Q_P#(/+9VCKNZUV]+HF/K8**** "BBB@
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M-OE,(SM;(R.:V*PK+2+A+NP:XV&&TM0B@'^/&":W:;L(****0!1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"H)'*<8R*6WT?3K6]DO(+.*.YD^_(J\FKM% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 445Q]U\0+6UNY;=K&X8QL5)'?'X4 =A17$_\
M+(L_^@?<?Y_"C_A9%G_T#[C_ #^% ';45Q/_  LBS_Z!]Q_G\*/^%D6?_0/N
M/\_A0!VU%<3_ ,+(L_\ H'W'^?PH_P"%D6?_ $#[C_/X4 =M17$_\+(L_P#H
M'W'^?PH_X619_P#0/N/\_A0!VU%<3_PLBS_Z!]Q_G\*/^%D6?_0/N/\ /X4
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MGDQ?\\T_[Y%'DQ?\\T_[Y%/HH 9Y,7_/-/\ OD4>3%_SS3_OD4^B@!GDQ?\
M/-/^^11Y,7_/-/\ OD4^B@#@M?LY9O$SVUI;W)"VP=%MBJJ&)ZMD<U FKWL2
MQ13V>EHS.Z>9(F "@R<^Y[5WY:W24NS1K(<*22 ?85DW>I:$'-M<B%OGSM*
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M?\^D'_?L59HH P--BCA\5:FD2*B^5'PHP*WZP['_ )&W4_\ KE'6Y0 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME8XP215MO#&HWGA;3;(M;Q31!O-CD!V\YZ8[BGT"R-NSN=#M6DM[86\(D8#
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M*[#_ )XWG_@.U;E% &'_ ,)78?\ /&\_\!VH_P"$KL/^>-Y_X#M6Y10!A_\
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M1MU/_KE'6Y0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2JWFD?*,^OI0][D['->'?$WB#5-?6UN86CMF).XQ8P%X;GW-/O/$&O1^)+J
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M5T5%#=PL8&C^%H-'BGBCGWI)'Y:@1*NU?PZGW-5_^$*M/L36PNI0&</NP,Y
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M4.W0 _X1:T_Y^[[_ ,"#1_PBUI_S]WW_ ($&MRBD!SEYX;AAM))8;F\9T7<
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M_,5I6W_'K#_N#^59OBC_ )%ZZ^@_F*TK;_CUA_W!_*@"6BBB@ HHHH ****
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M (&I_A60L6KIX,6,R7<MQYF6& LQCST ]:S98]>9F\F/4EF('V8NXVJG</\
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M;!%&?F;)KI*P['_D;=3_ .N4=;E !1110 4444 %%%% !1110 4444 %%%%
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M'607.^=5?!VYR<D5B7'A_P 0"6,0QW "2$WA\XXN8\\*O/'% *QU?_"%Z44
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MC+R*^UAD8.?J*BE\)Z5=>5*OG(ZQJB2Q288*!QS]*Q+#0+EM&UFW:PEA^TQ
M)')(268#GGW--T32-5MM2M6DMYXRC?-*TI*B+& F/7-"WL'0ZB\T"RO;2"W<
MRH(.(WC?#C\:K-X2TE\EHY2Q !;S#D@=B?2N:U32O$-QXDFN+..:)<LHD$GR
MLI''TYIL>CZJ#;E=/O5C4$*ANCE9/[_T]J2[@]-#HO\ A"M)W.Q^T%F.0?-.
M4]A[5-_PBFF+:R0)$Q#D-AG)R0,"N4'A[69WBC:&YC7</M;&<_OSGJ.>F*=_
MPC&K>5:1_P"D;6)6X_?'E0WRCKZ4[:!?J;^B^%#8QWRWMRUQ]K41E0Q^5!T
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$Z&&2XW%BP."3[4VX\(:K#;1V]I;HT!B19(Q/CYPN"1FBP^AL^=XQQG;I_\
MWV*A.H>*A/'#OTWS),[%#C)QUK)LO#7B6*P6RG12"0S2_:>1P1BK.@>%M3L=
M5M+JZM8_+A9@ 9MS*".N>]%M;"3=B[-J/BJ">."5M.660X12XR34IG\8+]X:
M>.<<N*R=8\*ZQ=ZG)-#;QNXG:9;DSX)7C"8[5)+H&N7%R+JXLXY%:8L;8W.
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MDEGL09.U":BM+W7+XR?9KBQD5,9<(=ISZ&@#IJ*P]GB7_GK8_P#?)HV>)?\
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MWFBY8W&0P(^7C-%O,2>A/%8W%_');Q6NE2I$3&ZKNPI/45;GTO5KI0)[/39
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M_P"?B+_OL4@,G/B7^[8_F:,^)?[MC^9K6^UVW_/Q%_WV*/M=M_S\1?\ ?8H
MR<^)?[MC^9K)T8ZY]IU+R%M-WV@^9N)^]CM76?:[;_GXB_[[%8F@W,"W>K%I
MHQFZ)&7'/% $N?$O]VQ_,T9\2_W;'\S6M]KMO^?B+_OL4?:[;_GXB_[[% &3
MGQ+_ ';'\S1GQ+_=L?S-:WVNV_Y^(O\ OL4?:[;_ )^(O^^Q0!DY\2_W;'\S
M1GQ+_=L?S-:WVNV_Y^(O^^Q1]KMO^?B+_OL4 <MKYU[^Q;C[2MIY6!NV$YZU
M?@/B/[/'M6RV[1C)/I3_ !-<P/X?NE6>-B0. X]16E;W=L+:+_2(ON#^,>E
M&=GQ+_=L?S-&?$O]VQ_,UK?:[;_GXB_[[%'VNV_Y^(O^^Q0!S5P=2#W N$TO
M<R#SMQ.2O:KD?_"1+$HC2QV #;R>E5=;MFU#48KF)[?%IAE!D'[X_P!T^U="
ME[;M&I::)21RN\<4= ZF7GQ+_=L?S-&?$O\ =L?S-:WVNV_Y^(O^^Q1]KMO^
M?B+_ +[% &!HGVO_ (234OMHC$WE1Y\OIBNEK!TYTD\5ZFR,K+Y4?*G(K>H
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MUK6HH YS1[2WL?$VI06T2QQB*,A171UAV/\ R-NI_P#7*.MR@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,9XIL,VNW$CI%>Z>[)C=M0\9Z4 =%16'Y7B7_GYL?^^#1Y7B7_GYL?\ O@T
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MI;#=F*OVF"WN=-C2R99)'=+QIUXST)'7-8/]CW_VJ&;,'V6./9-:?;1^_?\
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M*MD KS^-*S9-[(RM*T[45N;JTD>/[3'Y9BN6N^(AR<#GGTJRFC:K]IDD=H3
MQ5I8/MH E()SSGCBM#4=4L-/6,2:%9,V!YPB?=LSP.G]:Z30M(TR^TB&XFL(
M&D?.3M]Z=WN4SD9=)\FX;4+QX%2-9"I%UN,7'RXYYYKK?"=T%T5+B_NX?M5P
M?,<&0<>E:?\ PCNC_P#0/@_[YH_X1W1_^@?!_P!\TKB>KN6O[0LO^?N#_OX*
M/[0LO^?N#_OX*J_\([H__0/@_P"^:/\ A'='_P"@?!_WS2 M?VA9?\_<'_?P
M5BZ%>6J7>K%KF)0UT2,N.1BM#_A'='_Z!\'_ 'S6/HFB:9-=:HLEE$PCN2J
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M,#@]/ZUIP016T*Q01A(UZ*.@K/\ ^$CT?_H(P?\ ?5'_  D>C_\ 01@_[ZI
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M2VA5@!@A #U%:-O869MHB;6#[@_Y9CTJKXH_Y%ZZ^@_F*TK;_CUA_P!P?RH
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M4%@$'!IV ;_;NE?\_P#!_P!]4?V[I7_/_!_WU4O]E:?_ ,^<'_? H_LK3_\
MGS@_[X%("+^W=*_Y_P"#_OJC^W=*_P"?^#_OJI?[*T__ )\X/^^!1_96G_\
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M;*;0AA&< #(XX[U)?PZM B->)HP#$!=RKR<=JRH-!G02P_;+&,2!0LXN/F3
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MDZ9:1V>^5"!]]BH'4=JAN-8B<K%%HUC#()T $F<LF<&D-JQZ5_:5C_S^0?\
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M@TUQ'YT9#$J$]_>FZ]=6-QHD']DVUK!>N0908SE!@]#C!H>@+5V/0O[2L?\
MG\@_[^"C^TK'_G\@_P"_@KSBTUNQATM+JXT:VEAC(AD;I(TF.H'I5ZUOH+C6
MK;2_["L/.F'F;PQ*A,9_.G9WL.S.Y_M*Q_Y_(/\ OX*/[2L?^?R#_OX*X/5;
MRSTK4[^%=,M)MC+Y<;#&!MR<8ZTWP[J%EJ,\?G:7:F&XN#&F/OIQD9'I0E<E
MR2.^_M*Q_P"?R#_OX*/[2L?^?R#_ +^"N#U*^TBU\3FT6VMQ;HIB9?*/WR,@
MYZ>U9TMS/]BTYFT6& 2I*QF)5O,P..!TI)75RK:V/3?[2L?^?R#_ +^"C^TK
M'_G\@_[^"N$U:XM=.N86MM,MKI6MD8H!P&)ZFNETC3](U32X;P:=; R#D*,@
M&G8E.YK?VE8_\_D'_?P5BZ%?6B7>JE[F)0UT2N7'(Q6E_P (_I'_ $#X/^^:
MQ]$T;3IKK5%DLXF$=R54%>@QTI#.@_M*Q_Y_(/\ OX*/[2L?^?R#_OX*K_\
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MJ6+;"6!X-,OOA_<3WK2H\9A,A*Q!RJH#CD>_%,2.CG3PO9L;J06(:,!"0P.
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MV=#NV[>AQCZ4X>'-'$ @_L^$Q#.%()Z\&C0KJ8T'C)O,F@GM5$L,#2DJ^5;
MSUK'L/'E^\B-<VR9G;;!&K<9)&,FNO?PQHKPK$VG0F-"6 YZF@>&-%&_&G0_
M.NUN#T_I1= K6,)_&URCS(=.4FV/^D$2<#D#CUZUK>'6W7.K,.]UG]*MQZ!I
M44!A2QB$97:1CJ,YYJIX> %WJX'071Q^5'01NT444@"BBB@ HHHH R/%'_(O
M77T'\Q6E;?\ 'K#_ +@_E6;XH_Y%ZZ^@_F*TK;_CUA_W!_*@"6BBB@ HHHH
M**** ,.Q_P"1MU/_ *Y1UN5AV/\ R-NI_P#7*.MR@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0D $GH.:
M6B@#SGQ%]CU#6C?0X9D1%*/$?WFULE2<=#3?#+6>EZC>WMWC=,!Y2I$Q\KU
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MW0QWBI=21I&/OH!C'X5HVOB*\N_#=Y>7-I'#-"Z@>4W# T6ZA+0VO^$ITO\
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ME8C\B'_GDG_?(K$T"*,W>K9C0XNCC*^U;]8?A_\ X_-7_P"OL_RI#-CR(?\
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MUAV/_(VZG_URCK<H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "D)PI)[#-+10!R>J:O;7EW9NL5XOV:8NW^
MCMSQCBN171[87,[M%,0[[@YMW+,-V2&[5ZU10M'<35U8\BU+2VNYIA#YB0.^
M] ;5P8^<\8JQ+I\)>RECCD\RW8,VZT;#G=GFO5:*$[;%7//M6NA>:J+RWBE
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M?^ YK<HH P_^$JLO^?:^_P# <T?\)59?\^U]_P" YK<HH P_^$JLO^?:^_\
M <T?\)59?\^U]_X#FMRB@##_ .$JLO\ GVOO_ <T?\)59?\ /M??^ YK<HH
MP_\ A*K+_GVOO_ <T?\ "567_/M??^ YK<HH P_^$JLO^?:^_P# <T?\)59?
M\^U]_P" YK<HH P_^$JLO^?:^_\  <T?\)59?\^U]_X#FMRB@##_ .$JLO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH888 CW%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
*4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g201711142133439275642.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201711142133439275642.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,E G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH*N>(-5DTO0VO+=3)(2JIA<\GOBCI<?4A_X2W2_^GG_OPW^%'_"6Z7_T\_\
M?AO\*GT#4&O],\R69I)48K(7B\L@CL17,3>-;I[C5H;26W9HXRUH,9Y4X.ZA
MZ M3H/\ A+=+_P"GG_OPW^%'_"6Z7_T\_P#?AO\ "N97Q?JU[,EI%)%;3F2&
M&0^6&V,V=W!KI].O;V]L;V"2X2.ZMG,?VE8P5/OMZ4VK*X=A/^$MTO\ Z>?^
M_#?X4?\ "6Z7_P!//_?AO\*RSK.JVW@[4-3ENDEDC<B"7R0/ER!G:.M2:)KV
MI7.J06MV5:%XV=93%L,@'?':BP6TN:'_  ENE_\ 3S_WX;_"C_A+=+_Z>?\
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M0!A?\);I?_3S_P!^&_PH_P"$MTO_ *>?^_#?X5NT4 87_"6Z7_T\_P#?AO\
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M855>O%,FUB]NOM4VG31F.VM!)N=>&<C/3Z4=+CL7/^$MTO\ Z>?^_#?X4?\
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MH Y2ZMM5A\1:(U]?Q7$9E?"I"$P=OK775@ZPZ-KFAA64_OGZ'_9K>H ****
M"BBB@ HHHH **** "BBB@ HHHH **** ."U8:7;Z[KU_J%D+DH;:- 9-G5#W
MSBK4=GH+7-C ^B,KW:LRLLI91@9QD'FJ.N2V$FMZ[975Y';R.UK(GF1-(IPI
MZ@ TZ75+22[TZ==:M(Q9ALHEHX!)&...*$'4L"UT<M=1?\(Y+Y]O@^7YI^93
MWSGBG7=OX<M= CU7^R=RR,$$9F*X)..23BJ U&,6MW'_ ,)%;^=<."9?LLF<
M>AX]*M7^I:1?>'X=/;5+82Q.KY-LY0X[;<4= ZDD4'AUX;MWT@*UK )G F+
M@C/!!Q5:V.A7=K;O#H'F37',<,=SN)4#))(.!4#W-BTUPRZW:I'=0"&5%M'
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MQV\BK<MWHE_*)M4U2WN91 \0S:-@9[C*T= ZD]Y#X?MK"RNHM%,XNQE568C
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M/^$3T/\ Z!Z_]]M_C3?^$OT'_G_'_?I_\*/^$OT'_G_'_?I_\* '?\(GH?\
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M?]^G_P *& [_ (1/0_\ H'K_ -]M_C1_PB>A_P#0/7_OMO\ &F_\)?H/_/\
MC_OT_P#A1_PE^@_\_P"/^_3_ .% #O\ A$]#_P"@>O\ WVW^-'_")Z'_ - ]
M?^^V_P :;_PE^@_\_P"/^_3_ .%'_"7Z#_S_ (_[]/\ X4 9]YHFG:;XAT26
MSM5B=IG!(8GC;[FNLKD;O7=-U/Q%HD5G<B5UE<D;&'&WW%==0 4444 %%%%
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MH/RHVCT'Y5A_VYJ/_0OW?_?:T?VYJ/\ T+]W_P!]K0!N;1Z#\J-H]!^58?\
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M/\: -RBL/^RM<_Z&,_\ @$G^-']E:Y_T,9_\ D_QH W*PK?_ )'6\_Z\T_\
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MCH__ #QE_P"_[_XT ;M%87_"(Z/_ ,\9?^_[_P"-'_"(Z/\ \\9?^_[_ .-
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MM+6K@VOA>VO;:T@^TS-&IV6RN?FZX7O3=^H%&2&QDGGD_P"$H@47,(AF58%
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M?9?\^EO_ -^A_A0!4_X2/1O^@C;_ /?5'_"1Z-_T$;?_ +ZJW_9]E_SZ6_\
MWZ'^%']GV7_/I;_]^A_A0!4_X2/1O^@C;_\ ?5'_  D>C?\ 01M_^^JM_P!G
MV7_/I;_]^A_A1_9]E_SZ6_\ WZ'^% %3_A(]&_Z"-O\ ]]4?\)'HW_01M_\
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MZ3>ZEXQ9X=J11P(WG,6RI!_A[46"QK_VOKFW=_PCHV^OV^/_  H_M?7 <?\
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M[8>'\R&U0%/MB<#/7.*[:L*W_P"1UO/^O-/_ $*@#/U,7^I+&;WPSG8?E/\
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M_:FO?]"W_P"3T?\ A6[10!A?VIKW_0M_^3T?^%']J:]_T+?_ )/1_P"%;M%
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MIMW9#39,-=+.KK<*"PST'H:&,M-JUXBPLWB2S FY3-H<G\.WXU5_X2<GS?\
MBJK+]TVU_P#0VX/ITK0L[+4;+4/M*Z<9DN(UC833!FBQZGO56^\.:E<_;1$1
M$TU_'.CJ1E5 Y-.R!%A=0OW@\Y?$ECY>SS-WV?\ A]:1=1OVMXK@>([(13/Y
M<;&VQN;TYK.'A;5 BDQHSPD-RW^N(;//IFK&L:/KGB"5&$$%A'$A958AR7[=
M.A]Z0&K#'KEPTBQ:W:.8FVN!;?=/I2W$6NVL+33ZU:1QKU8VW IGAZ+5+6ZN
MX[VRV+,_F>>L@(S@#IUJ?5=,O7T&[MXYGO)W;<@?"]\XH$9MYJE]872VUSXC
MLXYF3>$^R$_+Z\476IWME!'/<^);&..5=Z,;;.X>HQ40T[4;GQ%#?7&F3I$U
ML(75+E0%P>=P[BL^?PIJSV-[')'YGDLL=FJ2;28]VXG/8]J8XZO4V;6[U.\&
M;?Q!9OB/S#_HN,+Z\TD%]J-S9S7</B*R:WASYC_9N%Q4=O9ZE;ZD)?[*DD@E
ML_(<2W +*<YY/>I]+TR]CTW4;:[LR+60;8;?S06QCD;O3TH8EOJ.T^76-4MA
M<66NVLL). PM2/YTU;C57U V":_:-=*,F,6O3\>E/\/B]TTI97,$^R9F,2O)
MO\E .C-6?%IVIZ1KEQ?[)FMA(\C[9,B4'HH7L<]Z.H^A9U*^U'2-GV_Q!:P;
M^A-H2/TJ\MOX@>(2KK-J8RNX-]F[58U>UN=3MK6W1-D$LBM<9/(4<XIE]+>:
MAH5Y%IT!BGYAC,G ]-WTQ2Z!U,H:G>&.WD'B;3]EQ(8HCY'#N.H'O4<NM7,$
MJQR>)[$.S%0/LI/(ZUFCP5J9DAM)VBEM8W,JRH-NQMN 0/K2Z5H>OZ<,SV$=
MQ),DJ2$2C W'@G/6G9 ^AM7MUJ>G0QRW?B&RBCD^XQMLY_*F7U_J.FI"]WXB
MLXEF_P!6?LI.[\J;K'A^\DT:QMK82-<Q1&$RHX 4$8.<]14]WIU_9+I!M;3[
M9]EB\J0;PO;&>:3 K2:M>17,=NWB2R\V1-ZJ+4G*^O%.&IWK:<NH#Q-8&T=]
MBR_9^"V<8_.L^T\-ZE8:DCM;RRJUL4W13A51B2<$=P,U77P;JJP?8PD?V, 3
M+'NZ39Y_#O3ZBN;#:E?+>?9#XDL1-_=^S?UZ5++=:G!;1W$GB"S$4GW&^S9W
M?2J3:'JC6#Z1]D3RS.9OM8D'Y8ZYJS8Z?JCPZ7#/8^1]BFRS&4-N&#R,4@>A
M%9:W<ZC_ ,>GB>QDY*Y^RD<CKUI/[;N/*FD/BBP"0?ZQFML!><=Z8?#.H2:9
M;VQ"HZS3,QW= W2H=2\/:GK5K%%-81P"WA$./,!\WD9_# IK<JRN:J3ZK)YV
MSQ!9-Y*AY,6_W5(R#^506FIWM\J-;>)+&0.XC7_1L98]!S4>B^'=1L/[<BFV
MF.= EJP;DJ%QSZ4P^&[W3;33[F"-[Z]BGC>96<+\J@C /3BC2_W$N]B])-JL
M5VUK)X@LEG2/S6C-OR%]:9:7FI7QA%KXBL93,I>/;;_> ZFLR70?$%YJ+ZNZ
MPQR2.R?9B06$97&-U3^'_"]_I'B&WF*(+%+8C ;E')Y&/2DO,9M?8O$?_07M
MO_ :C[%XC_Z"]M_X#5NT4 87V+Q'_P!!>V_\!J/L7B/_ *"]M_X#5NT4 87V
M+Q'_ -!>V_\  :C[%XC_ .@O;?\ @-6[10!A?8O$?_07MO\ P&H^Q>(_^@O;
M?^ U;M% &%]B\1_]!>V_\!J/L7B/_H+VW_@-6[10!A?8O$?_ $%[;_P&H^Q>
M(_\ H+VW_@-6[10!A?8O$?\ T%[;_P !J/L7B/\ Z"]M_P" U;M% &%]B\1_
M]!>V_P# :L:"TU__ (2^[ U2W\S[*F6^S\$9KMJPK?\ Y'6\_P"O-/\ T*@"
MK?2ZOIL:O>:]:1*QPN;7))^@JNTE_II,9UJSA4H9V/V7  ]34WBS1[_4+JTN
M+(2,T2LN$EV%2>C>]5;>TOKK2]4N);7[5=.GV:-6PN[:,$\^]"V';5$TUWJ"
MK DOB"RQ=#]V/LN=X/T[5')>7NF%[:37;.!8 H(^R<+GH.*SWT361)97BP20
M21VJ1-MF&(RIR<C^($5>6WU,Z$\T-C]HN;^8O-E@K(AXXS[4VB5<F_M"_P#M
MB6G_  DECY[KN5?L_4?7I3)M5O(+/[6_B2S^S[RGF+:EAD=1Q4$.AZC%=");
M%1;&X6Y#F0$J ,;/K5FQLM6.BWUH;$6KSW!*_O 1L8\GBD,I:,NL7NO:I/:Z
MQ;.KQP-Y@M^&&TXQ6]]B\1_]!>V_\!JCT6!+7Q'J\$8PL<5NH_[X-=#0P,+[
M%XC_ .@O;?\ @-1]B\1_]!>V_P# :MVB@#"^Q>(_^@O;?^ U'V+Q'_T%[;_P
M&K=HH Y&ZM]5B\1:(;Z^AGC\U\*D.T@[:ZZL+6O^0YH7_7=__0:W: "BBB@
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MX2[0O^?]?^_;_P"% #?^$7M_^@AJ?_@2:/\ A%[?_H(:G_X$FG?\)=H7_/\
MK_W[?_"C_A+M"_Y_U_[]O_A0 W_A%[?_ *"&I_\ @2:/^$7M_P#H(:G_ .!)
MIW_"7:%_S_K_ -^W_P */^$NT+_G_7_OV_\ A0 W_A%[?_H(:G_X$FC_ (1>
MW_Z"&I_^!)IW_"7:%_S_ *_]^W_PH_X2[0O^?]?^_;_X4 -_X1>W_P"@AJ?_
M ($FC_A%[?\ Z"&I_P#@2:=_PEVA?\_Z_P#?M_\ "C_A+M"_Y_U_[]O_ (4
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M_P#"@!O_  B]O_T$-3_\"31_PB]O_P!!#4__  )-._X2[0O^?]?^_;_X4?\
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M^ZOY5B?V[?\ _0 O?S6C^W;_ /Z %[^:T ;>Q/[J_E1L3^ZOY5B?V[?_ /0
MO?S6C^W;_P#Z %[^:T )K*J-<T/  _?OT'^S6]7(W>I7-YXBT1)M,N+51*Y#
MR$8/R].*ZZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X'7XI[B^UZ&
MW^^\UHO)(&-IZXYQ46ISZA9ZG9P6UK.T6F*K2FW+>62QY!SR1BK]Q=7UGXFU
MV>"?3X;=1;[VNPW78<8Q5Q;[6W$)%WHG^D\19$G[SZ4(1FPW]H]YXC3^T+CR
MS$CJQ9LK\O../6JQO+*[TC18_MLJWS ;)2S ( >2?4]N:VA/K&9\7&@_N?\
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M16%M\4_\]-(_[YDHV^*?^>FD?]\R4 ;M%86WQ3_STTC_ +YDHV^*?^>FD?\
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M+_A)?^H)K/\ X"?_ %Z/^$E_Z@FL_P#@)_\ 7K=HH PO^$E_Z@FL_P#@)_\
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MGY?7-==6%K7_ "'-"_Z[O_Z#6[0 4444 %%%% !1110 4444 %%%% !1110
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ML:7_ -!*S_[_ *_XT?VQI?\ T$K/_O\ K_C0!0_X1B'_ *">J?\ @4?\*/\
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M/;VIT;2O/O<-;GR1M53G[W%:]JWV0YB\.ZC_ *KR<,P/RU0&EP"-E&A:QNW
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MZ]_Z %]^E']O7O\ T +[]* +W]AZ3_T#+/\ [\+_ (4?V'I/_0,L_P#OPO\
MA5'^WKW_ * %]^E']O7O_0 OOTH O?V'I/\ T#+/_OPO^%']AZ3_ - RS_[\
M+_A5'^WKW_H 7WZ4?V]>_P#0 OOTH O?V'I/_0,L_P#OPO\ A1_8>D_] RS_
M ._"_P"%4?[>O?\ H 7WZ4?V]>_] "^_2@"]_8>D_P#0,L_^_"_X4?V'I/\
MT#+/_OPO^%4?[>O?^@!??I1_;U[_ - "^_2@"]_8>D_] RS_ ._"_P"%']AZ
M3_T#+/\ [\+_ (51_MZ]_P"@!??I1_;U[_T +[]* +W]AZ3_ - RS_[\+_A1
M_8>D_P#0,L_^_"_X51_MZ]_Z %]^E']O7O\ T +[]* +W]AZ3_T#+/\ [\+_
M (4?V'I/_0,L_P#OPO\ A5'^WKW_ * %]^E']O7O_0 OOTH O?V'I/\ T#+/
M_OPO^%']AZ3_ - RS_[\+_A5'^WKW_H 7WZ4?V]>_P#0 OOTH O?V'I/_0,L
M_P#OPO\ A1_8>D_] RS_ ._"_P"%4?[>O?\ H 7WZ4?V]>_] "^_2@"]_8>D
M_P#0,L_^_"_X5B0:-I9\97:'3K3:+1"%\E<9S]*N_P!O7O\ T +[]*QH-:NQ
MXONW_L2]+&U0;.,CGK0!)XEETW1YK:"'2K+?,"S.UL&"J.IP!3;G[([7$EAI
M>G2QVUJ)6)A7#,1D=O2IM4=M7,9N-"U1&3(#1.%)!Z@^QJG;Q31:==6#Z3J2
M?:F))A948)C 4>P%'0>ER*;4M/6ZL(/[*L(Q+ DTSFV#*-W;@<59N$BD74+F
MRTW3/L]NXC3S(%^8@<XX]>*@;3E\F%!HVL,T,?EJ7E!W@= WJ!2BVDDTNWL)
M-+U9&A;S"UO($)8]S3=B5<2*YBEND?\ L/35MQ,MNZ&$;]Y&<].E3%%ET*YO
M$TS289K>9T8/ "I Z8P.M M5%X+K^Q=8,G#$&48+ 8WD?WO>BUMOLUM+;G1]
M:GCEE\YA-*&^;_"D,?X=TNSN-8U)[S3+)93%;L46$;5)4].*Z7^P])_Z!EG_
M -^%_P *YC3]:NU\3ZPPT.])*P J,97"FMG^WKW_ * %]^E# O?V'I/_ $#+
M/_OPO^%']AZ3_P! RS_[\+_A5'^WKW_H 7WZ4?V]>_\ 0 OOTH O?V'I/_0,
ML_\ OPO^%']AZ3_T#+/_ +\+_A5'^WKW_H 7WZ4?V]>_] "^_2@"MJ6G6-IK
M^AO;6<$+&9P6CC"G[OM735R-WJ5Q>>(M$273+FU42N=\N,'Y>E==0 4444 %
M%%% !1110 4444 %%%% !1110 4444 <]9_\C%XD^8I\L'S#J/W9YKE!K%_I
M.GSPZ8PED,ZJ]X[%DYSSANA]:WU_M?\ X2W73IQL1&%M]_VG=G.P],=JEM9M
M;O4D%M)H,JJV'"B0C/O0/H8TFMZW=V5XK:G'9W,4.8XXH _F<9W FHE\0ZK#
M+Y7VQ51PNZ]:WSSLSC'3D\5TIA\2+\Q70Q@8R5DX%-5?$4FY%_L-MN,C;)3$
M9-GKVORW$,TS1K!YT43P^3RP;.6SVJOX@GN5UBY:%YQJ,<JBU12<%,'/'3%=
M'Y?BC_J"_P#?,E59;S6XKU();C05N6'RJWF;J0+0H>&F\P7BPSRB)[4&9Y"Q
M"RD'/6LE %T&YLS-#^[?*70>79*V/SS^E=);7NM3I,;:XT%UCSYFP2<?6JJZ
MS?-"Q6]\.^6A^;B3 -# YZ:[U Q>9&UT-40(+=&)Y3:<G'0\UM:#-<>1?-I[
MRN#9!V+DG$^.>O>M1;C76G1%FT$RLFY /,R5]?I3;>\UN59C;W&A%8B?,*"3
M"_6FWN'8R4U&+3]/MVT^\DCN)R!>3RJT@C;')*GC.:B_M_Q-.D<D<T40"H"#
M;YW[F(W>W'-=#''XBEB#H-#:.0;LA9,-[T_R_$_IHO\ WS)1?4#FKCQ3K44D
M,)NXDF$;':;?)F8/C'MD4V[\4:Q=6 MX9_L]X$E,Q6#)3;TZUT)L/$#78NC%
MHAF"[ Y63@=:E\GQ-DG;HF3U.V3FA/N.YSB>)/$']H>3'- T,<0P9$ :7Y<[
M@/KVK1U>/4[WPG9K-.LMU/,A8["B@'L=O.*TO(\2Y!V:)D< [9.*KWE_KFGB
M,7ESH4(<X0/Y@R?:DQ(P[F[U+3;QH8H@3:RKM2+=M;Y">IZC-;/AR\O]>T6[
M&KM#(&& (C@CCH<5<5?$S@.IT5@W(.).:$B\3Q@A!HJYZX604=+,25CG-'%[
MI]K:164CPK+YTD[.AD9MO0#<>*AT_P 3>(M1<0)<(FZ8@3-;@D+MSC'3-=.O
M_"2EV16T7<O4 2<4Y8?$R_=71!]%DH!:'-R>*=:\HL)D$K6^Y(E@W8?."6[C
MZ4EUK?B*V6X2XGCN$!9 %M]N?ER#Q72>1XESG9HF3WVR4IB\3GJ-%/\ P&2G
MH,Y/^T=>6^!?7)(81-#F+[*" C+SSZ9I8O$6KZC<W-O([M DZ&-A'L8#=@@X
MKJ?*\2.3QH;8X/RR&E$/B8$D+H@)ZX63FB^H+0QO$NIWR:_ ;2WNGAL KRM'
M]P[NH;UXK-M/%>O:C).]O>Q(ID")&;<$KEL9'<C%=:8_%!!S_8WS=>).:SK'
MP]JVFW,EQ:6NB1RR?>8"4T1=MP?D9C>)?$D-]J"'R)%M@RK$R@.V.CX]ZBC\
M0>*)K)'6ZM=PC>0LD(?=C& ?0UU'D^)BY?;HFX\$[9,TBP>)5&%71 /0+)2
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M/7"Z3-XAN?$.K36\ND/O2 EAYFTC:<8K=QXJ_O:/^4M-[@C=HK"QXJ_O:/\
ME+1CQ5_>T?\ *6D!NT5A8\5?WM'_ "EHQXJ_O:/^4M !K7_(<T+_ *[O_P"@
MUNUR-T-:_P"$BT3^T38&+S7Q]GWYSM]ZZZ@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH Y^R7?XC\1J5+ K -H/7]V:Y>XTG6O[.EMK&&[M;,3+P(U,Q
M7OCGYA6S]@:Z\5:]-_:-W:+&D&X0/@'Y"<FH['[/>VCW7]OZO!"K8WS2!0WN
M.*!ZV,]]$O[BTN[:]AU"YE>'%O,6V@#'1@#P:C_LK6(R!]DO3884-"CX?(3
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M:)J%JDFRSO6G-V)2H8F.0$#J<\ <UZ*F?+7(P<<BN62UMV$.?$^H(THRBM.
M3^E36VFQ7A86WB:_E*?>V3@X_2CR#S.EHK"_X1V?_H.ZI_W]'^%'_".S_P#0
M=U3_ +^C_"D!NT5A?\([/_T'=4_[^C_"C_A'9_\ H.ZI_P!_1_A0!NT5A?\
M".S_ /0=U3_OZ/\ "C_A'9_^@[JG_?T?X4 ;M%87_".S_P#0=U3_ +^C_"C_
M (1V?_H.ZI_W]'^% &[16%_PCL__ $'=4_[^C_"C_A'9_P#H.ZI_W]'^% &[
M16%_PCL__0=U3_OZ/\*/^$=G_P"@[JG_ ']'^% &[16%_P ([/\ ]!W5/^_H
M_P */^$=G_Z#NJ?]_1_A0!NT5A?\([/_ -!W5/\ OZ/\*/\ A'9_^@[JG_?T
M?X4 ;M%87_".S_\ 0=U3_OZ/\*/^$=G_ .@[JG_?T?X4 ;M%87_".S_]!W5/
M^_H_PH_X1V?_ *#NJ?\ ?T?X4 ;M%87_  CL_P#T'=4_[^C_  H_X1V?_H.Z
MI_W]'^% &[16%_PCL_\ T'=4_P"_H_PH_P"$=G_Z#NJ?]_1_A0!NUA6__(ZW
MG_7FG_H5'_".S_\ 0=U3_OZ/\*QH-!F/B^[C_MK4@1:H=WFC)YZ=* +/B_3;
M^[NK.>T%PPC5@!!C(<]"<]JK1PW-[IFJ7=S:O<SF+[+'&BYR0.2!]:LZI;KI
M1B6;6]8>24X2..0%C^E07:1V$C(^L:QM2'SY-C@[1],=:.@^J,Y].U82Z?=I
M;7<)CM$C"X&V,J?FWCTQ5XI<OH<ET=.ENI]0F)?8@8Q)T''TISM#YEK$FM:S
M*]T@D55<953W-)<[;.6YC&J:W(EM@.T3@@$C/IVIM]R58@ATB[CO%B&FS%//
M6=9V R(PN-I]_:K-E:WDF@WUHNE2PO+<ML$R  *Q^\/PJ);FU>[2!=<UHJ^!
MYH;Y Q&0I..M.:13IKWT.IZ_/$CLCB,@LN.I(]*7J/L:FA6R6?B#5K:,82.*
MW4?]\&NCK@="TU]1UK4YXM8U5%>.!@6<!CE3UXKH?^$=G_Z#NJ?]_1_A3=[Z
M@C=HK"_X1V?_ *#NJ?\ ?T?X4?\ ".S_ /0=U3_OZ/\ "D!NT5A?\([/_P!!
MW5/^_H_PH_X1V?\ Z#NJ?]_1_A0 :U_R'-"_Z[O_ .@UNUR-UI4ECXBT21]2
MO+D&5QMG?('R_2NNH **** "BBB@ HHHH **** "BBB@ HHHH **** .6BU&
MSL_%&OQW-U#"[K;[1(V,_(:YR\TJUOH)!+K&F &99%MTD81''KW!/M5[6YVM
M-6UR:&&W:=I;2)7FB#[05/K52X\00Z?>);WMC#+)!<-$_D0(!* N<GCBA 21
M6%C#;W5JFHZ08+F/!+,6:-L=%)[5"=-MQ<+=+K&DF0 +Y+$^61MVDX]>XJU-
MXFTEM3A>'3@UN(Y"%6%")2H!].V:6+Q'IIU"3.FQ.TD4?E6RK&068\?-CK3U
M$-M=,TJV,;_VQ8M*DT4@?=R N<C]:EU6WLM0O+A%UNQ6QN9%DD!;YP0,8';%
M*?%VC!F']A*3$ 9_D3]W\VT]N>:=XAU-;"^D6SL++RK:%)I%>!29 S 8'''6
MC<:NB32C9VRS_;M7TZ8F 6\:HV 5'][WK.ATZQ@L[E5U+26EN"%:.21FC51T
MQWS6]I$D=UJNIV]U866RV"M&$@&<$9YXK&@\0VB3QW5[:01V<PD,:+9@@!,Y
MRWKQTI B5B%N;(1:WIGD6]LT)=G.\DCJ.W%.T".STN*\2;6-/Q-%Y86)SC./
MO'/>F0^,=(N+>*2'P\&>4G8OEJ 0!G.2/2G+XR\/R7*0Q:.LF8A(Y$*_)D9P
M>/;K3?6X&9+X?TP6?D1:Y9.,*6664X9AVSU J&YTRVM5A%M>Z8T+/%O1'+-'
MMSG:3VYK<G\5Z/;6-E=3Z)'&EV05!5,A2< GBJ]QK!'@DZM%86GVDW)B7;;*
MW&[' [G%%V@78HW&D0W</E3Z]II2./RXE5B-PW;OF_\ K5-%IEC&8TCU'2+>
M,0F.38[.6SV^;M3K+Q=806-I]NTJ&>YN)' $5NJD(#C)7'!]JNS>+=%A8G^P
MU,)+JDGEI\Q7KQCCK18!NEK:V6J6MRVIZ3&D40CD\ECNDQTZ\"EELM&:UU'9
MJEBMU=3&19=_;(.T^U0WWB?28[Z(+IRJD3D.BQ(?,^3=Z58E\5Z/#<6D$FA+
MYL\8E9%B5BBGH>!S1O\ U\PM_7X$>C6FF66M?VG=:IIK.48>7$?E0D_PYI][
M:Z3>:N;N35K%HS(S[&;/5=HIJ^+M)+'/A]0FPR!BJ<H&VD]/6D/C+02]WY6C
M"6.W&0ZPKAB",CIQUI,=RH-*L(XBT>LZ:TZF,KO/RMLSPWL<U)#I>EB*Y,VK
M:<TD\+(,'Y4).>/:IO\ A*+5]1M;6'PW"?,=TFR$RFU<\<<\5T&AS:=K=D;E
M=+MH@&*[2J,?QP.#[4W=[DG,'2M+1I'MM8T^%RP*LI''R;:J6.BVEI:J#J^E
M-,)_-P6)7!7!Z\Y[UZ-_9EA_SXVW_?I?\*/[,L/^?&V_[]+_ (4KC//ETFT2
M&.#^V]-:,JH=V/SJ1G[OMS6QH::1H]S'(NJV.U;?RF"-C<V<YKJ?[,L/^?&V
M_P"_2_X4?V98?\^-M_WZ7_"G<5BO_P )#H__ $$K;_OX*/\ A(='_P"@E;?]
M_!5C^S+#_GQMO^_2_P"%']F6'_/C;?\ ?I?\*0RO_P )#H__ $$K;_OX*/\
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M0!A?\)+_ -036?\ P$_^O1_PDO\ U!-9_P# 3_Z];M% &%_PDO\ U!-9_P#
M3_Z]'_"2_P#4$UG_ ,!/_KUNT4 87_"2_P#4$UG_ ,!/_KT?\)+_ -036?\
MP$_^O6[10!A?\)+_ -036?\ P$_^O1_PDO\ U!-9_P# 3_Z];M% &%_PDO\
MU!-9_P# 3_Z]'_"2_P#4$UG_ ,!/_KUNT4 87_"2_P#4$UG_ ,!/_KT?\)+_
M -036?\ P$_^O6[10!A?\)+_ -036?\ P$_^O1_PDO\ U!-9_P# 3_Z];M%
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M_B;_ )\M/_[^M1Y_B;_GRT__ +^M6[10!A>?XF_Y\M/_ ._K4>?XF_Y\M/\
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M1ZBJZZ!:6=BGV/4M(CN(PZD+)E9 PQSD]:70#9-EI?D^:OB#467(4$7?4D9
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M [?WCD]:2![&A_PC,?\ T%M6_P# K_ZU'_",Q_\ 06U;_P "O_K5H?VOIO\
MT$;3_O\ K_C1_:^F_P#01M/^_P"O^- &:?"L#.KG4]4++T)N>1^E._X1F/\
MZ"VK?^!7_P!:M#^U]-_Z"-I_W_7_ !H_M?3?^@C:?]_U_P : ,__ (1F/_H+
M:M_X%?\ UJ/^$9C_ .@MJW_@5_\ 6K0_M?3?^@C:?]_U_P :/[7TW_H(VG_?
M]?\ &@#/_P"$9C_Z"VK?^!7_ -:C_A&8_P#H+:M_X%?_ %JT/[7TW_H(VG_?
M]?\ &C^U]-_Z"-I_W_7_ !H S_\ A&8_^@MJW_@5_P#6H_X1F/\ Z"VK?^!7
M_P!:M#^U]-_Z"-I_W_7_ !H_M?3?^@C:?]_U_P : ,__ (1F/_H+:M_X%?\
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M(_Z!EI_WY7_"J7_"5Z?_ ,\KS_P':C_A*]/_ .>5Y_X#M0!=_L+2/^@9:?\
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M6D=*UI3O-IX?!5=F2LGW?2F?V9JTJ-"+3P\RJ02NV3CTIB(;3Q?J%S<PLUE
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M *@W_D6C_BJ_^H-_Y%H W:*PO^*K_P"H-_Y%H_XJO_J#?^1: -VBL+_BJ_\
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MY;?>^;(!]*C.D^(5U&W1Y[Z.SBD81^4@D.-W&XD],5U7_"/W'_0=U+_OX/\
M"C_A'[C_ *#NI?\ ?P?X47%8Y6Y\.ZO+ISJXNY&F20RJ93U#94#TXK:T*UNX
M->=C;78MC"!NN,@(0/NCGFM#_A'[C_H.ZE_W\'^%'_"/W'_0=U+_ +^#_"BX
MWJ;M%87_  C]Q_T'=2_[^#_"C_A'[C_H.ZE_W\'^%(#=HK"_X1^X_P"@[J7_
M '\'^%'_  C]Q_T'=2_[^#_"@#=HK"_X1^X_Z#NI?]_!_A1_PC]Q_P!!W4O^
M_@_PH W:*PO^$?N/^@[J7_?P?X4?\(_<?]!W4O\ OX/\* -VBL+_ (1^X_Z#
MNI?]_!_A1_PC]Q_T'=2_[^#_  H W:*PO^$?N/\ H.ZE_P!_!_A1_P (_<?]
M!W4O^_@_PH W:*PO^$?N/^@[J7_?P?X4?\(_<?\ 0=U+_OX/\* -VBL+_A'[
MC_H.ZE_W\'^%'_"/W'_0=U+_ +^#_"@#=HK"_P"$?N/^@[J7_?P?X4?\(_<?
M]!W4O^_@_P * -VBL+_A'[C_ *#NI?\ ?P?X4?\ "/W'_0=U+_OX/\* -VBL
M+_A'[C_H.ZE_W\'^%'_"/W'_ $'=2_[^#_"@#=K"M_\ D=;S_KS3_P!"H_X1
M^X_Z#NI?]_!_A6-!H5P?%]W'_;6H BU0[MXR>>G2@"SXPTZ_N[JSGM%N'6-6
M&V#!(<]"0>U58X;B^TS5+NZM'N9O*%K''&F22!R0/3-6M3MQI1B6;7-6>24X
M2.)@6-07:II\C(^LZMM2'SY"C E1],=:.EAWU1FOI^K"73[M+:[B,=HD84J-
ML;*?FW@]L5>9;B31);IM-ENY]0F);9'N,2=!Q]*D=HO,M8DUO6)7ND$BJA!*
MJ>[>E-N2+.6XC_M769$ML!VA(;!(STQVIM]R4BO#I-W'>K$--G*>>LZSLHR(
MPN-I]_:K-E:W4N@WUHFE2PO)<ML6:, !6/WA^%,6ZMGNT@77M8(? \T?<#$9
M"DXZTK2K_9KWT.J:]/$CLC"-067'4D>E+U'V-30;5++Q!JMM& $CBMU&/]PU
MT=<#H6G2:CK>ISQ:QJ:*\<# LP#$%3UXKH?^$?N/^@[J7_?P?X4W>^H(W:*P
MO^$?N/\ H.ZE_P!_!_A1_P (_<?]!W4O^_@_PI ;M%87_"/W'_0=U+_OX/\
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M_P"@?'^;?XT?\(MHG_0/C_-O\: -/[3!_P ]X_\ OL4?:8/^>\?_ 'V*S/\
MA%M$_P"@?'^;?XT?\(MHG_0/C_-O\: -/[3!_P ]X_\ OL4?:8/^>\?_ 'V*
MS/\ A%M$_P"@?'^;?XT?\(MHG_0/C_-O\: -/[3!_P ]X_\ OL4?:8/^>\?_
M 'V*S/\ A%M$_P"@?'^;?XT?\(MHG_0/C_-O\: -/[3!_P ]X_\ OL4?:8/^
M>\?_ 'V*S/\ A%M$_P"@?'^;?XT?\(MHG_0/C_-O\: -/[3!_P ]X_\ OL4?
M:8/^>\?_ 'V*S/\ A%M$_P"@?'^;?XT?\(MHG_0/C_-O\: -/[3!_P ]X_\
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M%(#"_P"$F'_0&UC_ ,!?_KT?\),/^@-K'_@+_P#7K=HH PO^$F'_ $!M8_\
M 7_Z]'_"3#_H#:Q_X"__ %ZW:* ,+_A)A_T!M8_\!?\ Z]'_  DP_P"@-K'_
M ("__7K=HH PO^$F'_0&UC_P%_\ KT?\),/^@-K'_@+_ /7K=HH PO\ A)A_
MT!M8_P# 7_Z]'_"3#_H#:Q_X"_\ UZW:* ,+_A)A_P! ;6/_  %_^O1_PDP_
MZ VL?^ O_P!>MVB@#"_X28?] ;6/_ 7_ .O1_P ),/\ H#:Q_P" O_UZW:*
M,+_A)A_T!M8_\!?_ *]'_"3#_H#:Q_X"_P#UZW:* ,+_ (28?] ;6/\ P%_^
MO1_PDP_Z VL?^ O_ ->MVB@#"_X28?\ 0&UC_P !?_KT?\),/^@-K'_@+_\
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MVN[5GTV9+B+"2SW2N\1Q]W)ZBHCHY$RSBXTMT 4&U:X78?DVY_ \TQ'4"QU
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MT,4O_@,E']D:Q_T,4O\ X#)6E_:NG?\ /_:_]_E_QH_M73O^?^U_[_+_ (T
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MZL;^U\1:(]UJKW:&5P$:%5P=O7BNNKF]4O;2YU[0U@N896$SDA) Q^[[5TE
M!1110 4444 %%%% !1110 4444 %%%% !1110!RT5A:77B?Q!+<64-Q(BP;
MZ G_ %9XK(BU71K/3Y;C5M*LDE$@18(H?G&>Q!%:0U:TT_Q7KT-R)SYBV^/*
MC+<;#Z50>+PY(KEVU5IF<.)BC%UQTP<=* ))=6T$V4UU9^'?M4<*;G*P* #Z
M<]Z(]3T(L4?0HS.0I6!8!OP5W'\A1OT',O[W5MLR;)4V-MDXQDC'7WJ)H?#;
M$.&U59AC$RJP? &,9QZ4P+4&I^&;B[BA31TVR,J>:8!M5FZ TV\:T@U9HXM&
MT]K.*9()"T8W[FZ$=L4L4OAR%%6.&^"B1) /*;[R].U+<7.@7&IB^8:B)-P<
MHL;!&8=&(QU%&EPZ%O3+?3;BWOI;[2;&'[+(RG:@(VCO7.#Q!I)T[49QI&F>
M=$^+:/Y?G&,Y:MO3KW1=.%T!)JEPMRQ:1;B-G'/X56\KP@%NE_LR7%S]\?93
MQQCCCBD->90?6+%+07_]BZ<UG&J"7:@+;F7/';%:NE?9+G[0EWH^GJXMA<Q>
M7'QM(R <]ZJK;^%D*!8+\0JH4P^4VQL# )&.N*N:?=Z#IL<R1#47\U/++2QL
MQ"=E'' %-VUL(SM/U33C81W-]HEM(TS[8H[>U(/KWZU-=Z[X9A=8XM'CD9HP
M^1"N%R,\CK4ML^A6RPJ9M6F6$DQ+*K,$R,8''2L5]/L!K9N(;FZ2R9!&T?D/
MN*^G3]:-!&U!K'AEV(ETB-$7AIC -FX#.!4'_"2^$/L37/\ 92<2; GV<9;C
M.1QZ5,!X9%N(##?F,2&3!B;KC'I4?E^'_LR0^;JW[M]\;[&W1]L XZ4:#'MJ
MWAV2&2:#18_)C=4:1[<8R>P]Z5=9\,>1)*^BI'M4,BO H,@)QD?C3VE\//:2
MVSIJ#)+*)7)B;)8?A6;KEMH]_8)%9->0S(BQJSPN05!SCIZ]Z0%S5[S3H/#M
MIJ=EH=J&N)UC"309(!SS@5+I>H^'[R**.;2;=;IF52BPC!+>E1K<:;<:%::?
M?W&H-);L'6:"%D8,.F#BFP?V%;:Q97L27>VUC=1N@<L[-W)[T]+@]B\8+674
MKI8-(TX6=FVV=I(_F/&3BJS:OX<4JIT']Y(P$2?9URX/0CVJ6YN]"N;U[D_V
MDGFC$L<<;!)/]X8YJ"V'ARUFCF U.1XV!C,B,=H'0#CI2!^0QM;\/J\K?\(\
M#;QPB4R"%>YQC'KFISJOAF+4/L5SHT<$OEF3YX5Z 9Q]:B9/#;#;MU)5*[64
M1MAANW<\>M$R>&KC4Y+^6/46D<$,GEMLY&"<8IZ ]]!TFJ:-%<6ZR^&3'#-&
M9/-:%<!1WQ4BZEX?,L<']@8N)'"K$8%S@C(/TQ4+#P_)#%%++J\JQ JN]6/R
MG^'ITJ2TD\/6<\4X_M.6:-MRR2QLQZ8 Z= *%:X=#I1H.D$ _P!F6H]O*%+_
M &!I'_0-M?\ OT*I_P#"6:=_<N__  ':C_A+-._N7?\ X#M2 N?V!I'_ $#;
M7_OT*/[ TC_H&VO_ 'Z%4_\ A+-._N7?_@.U'_"6:=_<N_\ P':@"Y_8&D?]
M VU_[]"C^P-(_P"@;:_]^A5/_A+-._N7?_@.U'_"6:=_<N__  ':@"Y_8&D?
M] VU_P"_0H_L#2/^@;:_]^A5/_A+-._N7?\ X#M1_P )9IW]R[_\!VH N?V!
MI'_0-M?^_0H_L#2/^@;:_P#?H53_ .$LT[^Y=_\ @.U'_"6:=_<N_P#P':@"
MY_8&D?\ 0-M?^_0H_L#2/^@;:_\ ?H53_P"$LT[^Y=_^ [4?\)9IW]R[_P#
M=J +G]@:1_T#;7_OT*/[ TC_ *!MK_WZ%4_^$LT[^Y=_^ [4?\)9IW]R[_\
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M4?\ "6:=_<N__ =J +G]@:1_T#;7_OT*Q(-$TH^,;M#I]ML%HA"^6,9S5_\
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M?^!J?X4?VGK_ /T+H_\  U/\* -VBL+^T]?_ .A='_@:G^%']IZ__P!"Z/\
MP-3_  H W:*PO[3U_P#Z%T?^!J?X4?VGK_\ T+H_\#4_PH W:*PO[3U__H71
M_P"!J?X4?VGK_P#T+H_\#4_PH W:*PO[3U__ *%T?^!J?X4?VGK_ /T+H_\
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M[Z'^% !K7_(<T+_KN_\ Z#6[7(W>F367B+1'DU*ZN@97&V8@@?+774 %%%%
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M?\(IH?\ T#T_[Z;_ !H U?/A_P">L?\ WT*//A_YZQ_]]"LK_A%-#_Z!Z?\
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M_/\ _P#D%_\ XFMVB@#"_P"$QT'_ )__ /R"_P#\31_PF.@_\_\ _P"07_\
MB:W:* ,+_A,=!_Y__P#R"_\ \31_PF.@_P#/_P#^07_^)K=HH PO^$QT'_G_
M /\ R"__ ,31_P )CH/_ #__ /D%_P#XFMVB@#"_X3'0?^?_ /\ (+__ !-'
M_"8Z#_S_ /\ Y!?_ .)K=HH PO\ A,=!_P"?_P#\@O\ _$T?\)CH/_/_ /\
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M_P"@=9?]_P T?:O$G_0.LO\ O^:W:* ,+[5XD_Z!UE_W_-'VKQ)_T#K+_O\
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M3K7_ $,3_P#@(E']DZU_T,3_ /@(E;M% &%_9.M?]#$__@(E']DZU_T,3_\
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M2V. 6QC</3Z5";?3!.MTFIWR7:@ 2_8R1C;M(QTY%/01I1P>#Y;N*U0NTDA
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MPH /^$0T7_GVD_[_ +_XT?\ "(:+_P ^TG_?]_\ &C_A+=,_Z>?^_#?X4?\
M"6Z9_P!//_?AO\* #_A$-%_Y]I/^_P"_^-'_  B&B_\ /M)_W_?_ !H_X2W3
M/^GG_OPW^%'_  ENF?\ 3S_WX;_"@ _X1#1?^?:3_O\ O_C1_P (AHO_ #[2
M?]_W_P :/^$MTS_IY_[\-_A1_P );IG_ $\_]^&_PH /^$0T7_GVD_[_ +_X
MT?\ "(:+_P ^TG_?]_\ &C_A+=,_Z>?^_#?X4?\ "6Z9_P!//_?AO\* #_A$
M-%_Y]I/^_P"_^-'_  B&B_\ /M)_W_?_ !H_X2W3/^GG_OPW^%'_  ENF?\
M3S_WX;_"@ _X1#1?^?:3_O\ O_C1_P (AHO_ #[2?]_W_P :/^$MTS_IY_[\
M-_A1_P );IG_ $\_]^&_PH /^$0T7_GVD_[_ +_XT?\ "(:+_P ^TG_?]_\
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M_"C^U->_Z%O_ ,GH_P#"@#=HK"_M37O^A;_\GH_\*/[4U[_H6_\ R>C_ ,*
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M_P !13>^H(W:*POL/B+_ *#,'_@**/L/B+_H,P?^ HI ;M%87V'Q%_T&8/\
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MB_YZ)_WT*/.B_P">B?\ ?0K)_P"$3T/_ *!Z?]]M_C1_PB>A_P#0/3_OMO\
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M#_S_ (_[]/\ X4?\)AH/_/\ C_OT_P#A6W@>@HP/04 8G_"8:#_S_C_OT_\
MA1_PF&@_\_X_[]/_ (5MX'H*,#T% &)_PF&@_P#/^/\ OT_^%'_"8:#_ ,_X
M_P"_3_X5MX'H*,#T% &)_P )AH/_ #_C_OT_^%'_  F&@_\ /^/^_3_X5MX'
MH*,#T% &)_PF&@_\_P"/^_3_ .%'_"8:#_S_ (_[]/\ X5MX'H*,#T% &)_P
MF&@_\_X_[]/_ (4?\)AH/_/^/^_3_P"%;>!Z"C ]!0!B?\)AH/\ S_C_ +]/
M_A1_PF&@_P#/^/\ OT_^%;>!Z"C ]!0!B?\ "8:#_P _X_[]/_A1_P )AH/_
M #_C_OT_^%;>!Z"C ]!0!B?\)AH/_/\ C_OT_P#A1_PF&@_\_P"/^_3_ .%;
M>!Z"C ]!0!B?\)AH/_/^/^_3_P"%'_"8:#_S_C_OT_\ A6W@>@HP/04 8G_"
M8:#_ ,_X_P"_3_X4?\)AH/\ S_C_ +]/_A6W@>@HP/04 8G_  F&@_\ /^/^
M_3_X4?\ "8:#_P _X_[]/_A6W@>@HP/04 8G_"8:#_S_ (_[]/\ X4?\)AH/
M_/\ C_OT_P#A6W@>@HP/04 8G_"8:#_S_C_OT_\ A6-!XJT4>+[N8WH\LVJ*
M#Y;]<_2NTP/04GEH'+[%W$8+8YH Q?\ A,-!_P"?\?\ ?I_\*/\ A,-!_P"?
M\?\ ?I_\*V\#T%&!Z"@#$_X3#0?^?\?]^G_PH_X3#0?^?\?]^G_PK;P/048'
MH* ,3_A,-!_Y_P ?]^G_ ,*/^$PT'_G_ !_WZ?\ PK;P/048'H* .+T_Q5HJ
M^)]8E:] 1UAVGRWYPISVK9_X3#0?^?\ '_?I_P#"MH1H&9@BAFZD#DTN!Z"@
M#$_X3#0?^?\ '_?I_P#"C_A,-!_Y_P ?]^G_ ,*V\#T%&!Z"@#$_X3#0?^?\
M?]^G_P */^$PT'_G_'_?I_\ "MO ]!1@>@H Y*[UW3=4\0Z)%9W/FNLKDC8P
MXV^XKKJ:8T+*Q12R]"1TIU !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
>1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g201711142133438435639.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201711142133438435639.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,E G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT8/M)./*S\V:U:XA[:W_ .%KPD0Q_P#(/+9VCKNZUV]+HF/K8**** "BBB@
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M-OE,(SM;(R.:V*PK+2+A+NP:XV&&TM0B@'^/&":W:;L(****0!1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"H)'*<8R*6WT?3K6]DO(+.*.YD^_(J\FKM% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 445Q]U\0+6UNY;=K&X8QL5)'?'X4 =A17$_\
M+(L_^@?<?Y_"C_A9%G_T#[C_ #^% ';45Q/_  LBS_Z!]Q_G\*/^%D6?_0/N
M/\_A0!VU%<3_ ,+(L_\ H'W'^?PH_P"%D6?_ $#[C_/X4 =M17$_\+(L_P#H
M'W'^?PH_X619_P#0/N/\_A0!VU%<3_PLBS_Z!]Q_G\*/^%D6?_0/N/\ /X4
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MGDQ?\\T_[Y%'DQ?\\T_[Y%/HH 9Y,7_/-/\ OD4>3%_SS3_OD4^B@!GDQ?\
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M%6:* *W]G67_ #Z0?]^Q1_9UE_SZ0?\ ?L59HH K?V=9?\^D'_?L4?V=9?\
M/I!_W[%6:* ,#Q+8VD>@73);0JP P0@!ZBM&WT^R-M$3:09*#_EF/2JWBC_D
M7KKZ#^8K2MO^/6'_ '!_*@"/^SK+_GT@_P"_8H_LZR_Y](/^_8JS10!Q^O*E
MKJ<<=LD8A< 7)$8/DKG[PXKI4T^P,:E;:!ACAM@YJP88FW9C4[QALCK]:<JA
M5"J  !@ 4= ZE?\ LZR_Y](/^_8H_LZR_P"?2#_OV*LT4 8&FQ1P^*M32)%1
M?*CX48%;]8=C_P C;J?_ %RCK<H **** "BBB@ HHHH **** "BBB@ HHHH
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M[WF*0F.52@M"6VP$_P 8/K70^&]:OM3DU!IA L*6HDB3JX)SS52U\87Z6]I
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M&F"Z?8,MK_KF5CA_F ^3\^];OAY(WN=58QKS<\9'3BETN(G_ .$ITK_GL_\
MW[-'_"4Z5_SV?_OV:UO)B_YYI_WR*/)B_P">:?\ ?(H R?\ A*=*_P">S_\
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M%_SS3_OD4 <]HMY#?>)=2GMV+1F*, D8KI*PK!0OBS4PH 'E1\ 5NT %%%%
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M_P!\FC_A*-'_ .?Q?^^30!:DT?3IEC62RA98QA 4Z"E;2K!XA$UI"4 P%*C
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M%_[Y-'_"4:/_ ,_B_P#?)H UZ*R/^$HT?_G\7_ODT?\ "4:/_P _B_\ ?)H
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M%% !1110 4444 %%%(<E2 <''6@#A]8TNYU'QJ(84A\B.U5V5V91G=U&WO\
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M 'P*/LT'_/&/_O@5D?V3J_\ T')/^_8H_LG5_P#H.2?]^A0!K_9H/^>,?_?
MH^S0?\\8_P#O@5D?V3J__0<D_P"_0H_LG5_^@Y)_WZ% &O\ 9H/^>,?_ 'P*
MQ-!@B:[U;,2'%T0,J..*D_LG5_\ H.2?]^A63H^G:E)<ZD(]5>,I<$,1&#N.
M.M '6_9H/^>,?_? H^S0?\\8_P#O@5D?V3J__0<D_P"_0H_LG5_^@Y)_WZ%
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MUS+)-=>(;9I'V@[5P, 8I+I<;V9-/J<*WYM/[6M9&E&9F^SKCCU)'-74O83
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M"*2:)JD841ZE"H4Y 6W48IA\/Z@;C[0;ZV,__/3[*N[\^M:'_"1Z-_T$8/\
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MBU,1E;@ASY8.XXZUO?\ "1Z-_P!!&#_OJL?1-;TR"ZU1I;V)1)<ED)/48ZT
M:']FZW_T&5_[\BC^S=;_ .@RO_?D58_X2/1O^@C!_P!]4?\ "1Z-_P!!&#_O
MJ@"C=6FN6UL\W]J[P@R56$9Q5?3FU75$>2VUC="IP)/)&&/?'TJ]>Z[I=S:O
M#%JT$3.,%L]!WJKI5]HND^9%!JL/V5L%(R?NGO\ G0@+7]FZW_T&5_[\BC^S
M=;_Z#*_]^15C_A(]&_Z",'_?5'_"1Z-_T$8/^^J ,37[#5H]%N'FU02Q@#*>
M4!GFK\&G:T;>,C6% *C \D<<57\0Z[I=QH=S%#?0O(P&%!Y/-:$'B+1UMXE.
MH0 A "-WM0!'_9NM_P#097_OR*/[-UO_ *#*_P#?D58_X2/1O^@C!_WU1_PD
M>C?]!&#_ +ZH K_V;K?_ $&5_P"_(H_LW6_^@RO_ 'Y%6/\ A(]&_P"@C!_W
MU1_PD>C?]!&#_OJ@"O\ V;K?_097_OR*/[-UO_H,K_WY%6/^$CT;_H(P?]]4
M?\)'HW_01@_[ZH SM$BN(?$FI)=3B>7RH\N%Q72USND74%YXFU*:VE66,Q1@
M,IXKHJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHI#G:<'!QQ0!R]U/96OB*[AG-K'&+0.B.%7+9[9[US
M!\2R&P0I;6*;G$.UU!D.0?F'M6OJYGCU-8+J>"XN NY<6'F%5SQS44GAE[G4
MXK^76[7S(0"L+(H5/3Y>U"V&FD9<VK:A&MI!*EBA!1WD\L#>I4G!]ZG@\2W$
M5G%<2:;9/#)O10$^8$ <DXZ<UT,FGWC$I+JNF$J 2K0+P!T-,DTV\GA-NNLZ
M>NY3CRXE# 'J10"M<K6VI"YT75I9(+"22TP%>W48.<=Z70M2EO[Z*.YL;(03
M;U39&-PV^M-TK09M'LGBM]<LFBF;+O*JMO/N>E:*V6IQ2A%U>P60<A1"H(S3
MTN2S"O;1-%U#5+N,W%U]F16C@D<%,MZ\=*A@\17\T?.F::K1HTCG:&# >F*W
MKY-1M(FDN=5M"LA\MO\ 1P=Q]#5*RE::66VM]6TY/) #C[,JJ-W;_P"M25[
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M'_?L4@(?[>TK_G_@_P"^J/[>TK_G_@_[ZJ;^R[#_ )\X/^_8H_LNP_Y\X/\
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M1?2?^?<_]]FF?:_$?_0,M/\ O_1]K\1_] RT_P"_](8__A%])_Y]S_WV:/\
MA%])_P"?<_\ ?9IGVOQ'_P! RT_[_P!'VOQ'_P! RT_[_P! #_\ A%])_P"?
M<_\ ?9K)T;0-.N+K4UDA)$=R57YCP,5I_:_$?_0,M/\ O_63H]QK:W.I&"PM
MG8W!,@:;&UL=!0!L_P#"+Z3_ ,^Y_P"^S1_PB^D_\^Y_[[-,^U^(_P#H&6G_
M '_H^U^(_P#H&6G_ '_H ?\ \(OI/_/N?^^S1_PB^D_\^Y_[[-1/?>(8T+/I
MUDJCJ3<4BZAK[NR+I]DS+U N.E $W_"+Z3_S[G_OLT?\(OI/_/N?^^S3/M?B
M/_H&6G_?^C[7XC_Z!EI_W_H H>(/#VFVVB7$T4!5U P=Y]:OP>&-*:WC8VYR
M4!/SGTK-U^YUUM%N%N+"V2(@;F6;)'-7H+KQ%]GCVZ;:%=@P?/\ :@"?_A%]
M)_Y]S_WV:/\ A%])_P"?<_\ ?9IGVOQ'_P! RT_[_P!'VOQ'_P! RT_[_P!
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M5O)YS<2J'6-#,XV!O?;S7I7P^FO)/#S)?7'GS),V&))PIZ#D5U=%.X!1112
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MOK^='F)_?7\ZQ_\ A%=+_N2_]_6H_P"$5TO^Y+_W]:@"YJ;AM.F1(Q.SKM"
MCO6=X;M9M,BFM+K#N#N%QNSY@/;\.E-N_#6GP6LDL4,CN@SM,S#-4]&TO2]9
MMWNH[>9+?.U"TK9)'7CZT(&=7YB?WU_.CS$_OK^=8_\ PBNE_P!R7_OZU'_"
M*Z7_ ')?^_K4 +XG=#X>N@&4\#O[BM*VD3[+#\Z_<'?VKF=?\.Z?:Z+<31)(
M'4#&9">]7X/"^F-;QL4ER4!/[UO2@#<\Q/[Z_G1YB?WU_.L?_A%=+_N2_P#?
MUJ/^$5TO^Y+_ -_6H V/,3^^OYT>8G]]?SK'_P"$5TO^Y+_W]:C_ (172_[D
MO_?UJ -CS$_OK^='F)_?7\ZQ_P#A%=+_ +DO_?UJ/^$5TO\ N2_]_6H 98$'
MQ9J9!!_=1]*W:YO1;.&P\2:E! &""*,C<V3724 %%%% !1110 4444 %%%%
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MI,NDW<F^X+$+CY>.AIOA:UU%=?N+R_CNU,T/R^8?E'S'CZXK8\/_ /'YJ_\
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M%B1M1,D8&23CMBM/2-;L];@::S9RBG!W+BLVQ\'VUF\<GVAF=%905C5.",=
M*?I/AQ]%N UM=LZ.V90R@ C'& *-"=1NI^,=.TXW,9$K2P<'*$*6],^M*GC/
M2FA#'SQ(/O0^4=Z\9SCT]ZJ3^#CJ%Y>O>WDGV::82QPH!@$=ZGN/!UO)>27<
M-Y-!<2*$9U /RXP127F-$B>-M$?>?M#K&F?WK(0A(Z@'UJ>V\5Z3=Z7/J,5Q
MF" XDXY4U0_X033?[/6R,DAA5V< X/)__55RV\,PV^D7%AYY/G?>=8E7'X 8
MINW0.H+XNTAK-[DS.D:+O.]"#C.*I_\ ">:4[6[1"9H96(:0I@( ,Y^E5?\
MA!U%U9)YS-;PL\DCDX+L>VWH!4R^ K/:P>[F8LW/R@ C&,8Z?C1H!.GCS0I(
MB\<TDF&VE43<W3.>.V*>WCC1$95,LN]R J^6<D$9S]*9:^"[6W7!N&8C(&V-
M4P",8XJ.[\#6ES(KBZE0A%0C:#D*,?@?>C0#H;K4+:RL&O;B0);JNXL?2L1/
M'.AR6XFCGDD'.Y43<4 ZDXZ"KKZ+]KT>;3;V3S(6.U#C)"CIGUK'N/! %A(M
MI>M'=,C(76-5#*>Q I=1JW4OS>+],6PCNHI2RRYV;E(SC&?YTT^--'V,S-.
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MLN22%&<CFKNF:AX2U754L+;3LLX.U]IVY'44K#.U^UVW_/Q%_P!]BC[7;?\
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M*!AAGCFM"#PUHS6\3&PB)* GKZ4 :GVNV_Y^(O\ OL4?:[;_ )^(O^^Q6?\
M\(QHO_0/B_6C_A&-%_Z!\7ZT :'VNV_Y^(O^^Q1]KMO^?B+_ +[%9_\ PC&B
M_P#0/B_6C_A&-%_Z!\7ZT :'VNV_Y^(O^^Q1]KMO^?B+_OL5G_\ ",:+_P!
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MWB9HV=Q\[ 9Z=JQ+C3?LUN!-IFG*N\#<;L[B3V)Z_A6E9_VC]B>"VTO3U@N
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MT =!17-W&KZW:V\L\UIIZQQ#+M]H^Z*2WUC6KJ!)H;33V1UW _:,<>M '2$
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M'%-Y4>5C;<,?6NEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP&L>#=0N=9NKVS2)1+,)#^\P9% Y!],U%_PBNL^8\GV6/RI<B*V^T<6I)'S
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M6/\ WP:R='37#<ZEY$UH&%P?,W*>6QVKLJP_#_\ Q^:O_P!?9_E2 /*\2_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQC^+OGVK;3=Y:[P V.0/6G44 %%%% &'8_\ (VZG_P!<HZW*P['_ )&W4_\
MKE'6Y0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZS;"08S^XX&>F37.6.D7UCXAL[)K7SVCN!*UUS\B8^[GT%:FM>'[_4KZ]AA
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M10 4444 %%%% !1110 4444 %8TOBG2X)GB=YMR'!Q"Q_I6S10!A?\)=I/\
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MUAM.OM.L+>VN K6J[2TMM)WZD8'6LBYT^*6![==0B,3;N6M9 V3WX'6O7J*
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MX?\ PH_X2[2?^>D__?A_\*W:* ,+_A+M)_YZ3_\ ?A_\*/\ A+M)_P">D_\
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MH3W/O6FVE:W+93E?MHF,D<B":?<?EZC\:8'=T5YR-,\5K,R(]W'YLC.[I/P
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MHH *0J&&& (]Q2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
..4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g201711142133438185638.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201711142133438185638.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,E G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT8/M)./*S\V:U:XA[:W_ .%KPD0Q_P#(/+9VCKNZUV]+HF/K8**** "BBB@
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M-OE,(SM;(R.:V*PK+2+A+NP:XV&&TM0B@'^/&":W:;L(****0!1110 4444
M%%%% !1110 4444 ,E6-H768*8R/F#=,>]8^EQ>'))I%TR.Q,@&'$0&<5H:I
M%#/I=U%/(8XGC*NX/W1CK7E)UFX\+++I]LEI=2_9LVVHVR_,L>['[P>M"W'T
M/5(]'TV*"2&.R@6*0Y=0@PWUH72-.41!;* "(YCP@^4^U<%=ZM>VZZ=8Q>(V
MEANK@K->8&Z'"YVYZ<FL.+Q3K5Y<7*2ZS);+:V;2Q$8'GLK8!/KFF(]871M,
M02!;"W D.7Q&/F^M%Q+IFE$SW#P6QG8(7;"[SV'O7FVF^*?$FHZW S.D"(\*
MM%)*JJZL.?EZDU+\2GEU;6[?28;2>Z%M;/<LL(R5?^$FD] 6IVLMGX9LYG$L
M%C%(R[G#* 2#W/UJ]!HVF0;&@L;=-IW*50#!]:\7UC4_[6B2\/\ K&TV ./1
MA( :Z*/Q1K$=U'=+>-)(;MK<Z=@8"!>#CK^-.U@_K\#T:71=,G7;+86[C<6P
M8QU/4T'3-+A*L;2W0H 0=@&-O3\J\\A\1W2>'?[1N/$4GVFZ49ME0%HF+8P/
M[OIS6+#K&J:C?:=+=ZA,AMYKF+/F [@JY 8C@TM@/1-;T#^VK-7TE[%4E+,_
MFP[E<D8W<<YK7T'24T/0[33(VWK;QA=V.M>5V?BG6)-(24ZBULUK9)-$B@ 7
M#EB"/?\ "K4/B'7Y;BZOWU.5$BU*. 6NT;0K 9!JK:V_KL#[O^NIZ5?/I%U=
M1Z=?&VDG8;T@DP6(]0*9;)HNIR"6V6TN'M6\L,@!,9';VKR[XAS-IWQ"M];0
MMNL[$$@=PQQ6-X>O[G0-*U.WM[N:"ZGO3(!&0"QV;N6/05*VO_6]@>_]=CW6
MZM+2_3R;J&*91SM< XJO]@TF9&T[[-;,L6&,.P87/?%>/PZ[JQ_M?4QJDT5W
M)9VY4!AC)."0*V-0U;5=*DUH#5I&FM;6WEB=U&Z1C_"?K3:MN"=STJ31=,EM
MH[>2PMVAC.40H,*?456O[+0+&R0WUO9PVR-A3(H"@GTK-\*ZO>7/@R/4YC+?
MW;@NT28W Y^X/I6?X_G%SX8TR:Y@, ?4("\<N,K\W0T-.]O0$[J_J=&^H:";
M"*Z>XM/LL+CRW)&U&[8]#4DEQHVKV+RR26MU:Q\LS8*KCU]*\D\2A1J.J_V;
M"DUG]OM=L:D"-I,\@=J==WTO]FZZZ6XM[S4;F.R&FQ'+)SR??(I;K^O+_,>S
M/5&N= 31HY&DLQIK$;#QY9/;%1S:QX<0&XFN[,"9?++L1\X]*\I\V:+0/[#6
MU\F6TU>+R8+H8PK=,@=J[+QS8[?"5G]KM+1+@7L(80+\H^;MFG;\7_E_F2G_
M %]YU4>CZ%?P13)8VLT87$;! 1M]![5+)H6E2S"9]/MVD  #E!GCI5Z&-(H5
M2-%10.%48 I] R+[+ +@7'DIYP7:'QSCTS4M%%( HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"H)'*<8R*6WT?3K6]DO(+.*.YD^_(J\FKM% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 445Q]U\0+6UNY;=K&X8QL5)'?'X4 =A17$_\
M+(L_^@?<?Y_"C_A9%G_T#[C_ #^% ';45Q/_  LBS_Z!]Q_G\*/^%D6?_0/N
M/\_A0!VU%<3_ ,+(L_\ H'W'^?PH_P"%D6?_ $#[C_/X4 =M17$_\+(L_P#H
M'W'^?PH_X619_P#0/N/\_A0!VU%<3_PLBS_Z!]Q_G\*/^%D6?_0/N/\ /X4
M=M17$_\ "R+/_H'W'^?PH_X619_] ^X_S^% ';45Q/\ PLBS_P"@?<?Y_"C_
M (6/9_\ 0/N/\_A0 SQ%=N/%4T#ZK-:1Q:?YT2)*$#2;O3O]*Q]'U+4]2UJ1
MKV_,6SR_W;W8BQD=E[UM3>+]-N9%EGT599%^ZSE"1^)IDGBK299O.DT*-Y?[
M[>66_/%"!ZF#!XBUJTU75('GEN9#&[P212!XP >Z]5(%:>MWAMM&M_[.UF[N
MY9KB$2)',"PW=0&[9]*OIXPTZ*1Y(]'5'?[S*4!;ZTB>+M,B7;'HJH-V["E!
MSZ_6A!U.7N-=U> NB7UU&H%P!%*^9$VKQN/UZ5?$.N_\(G>ZA->:A;Q+9K+"
M7N 7,F!DY Z>U;3>,-.=R[:,K,>K$IDU(?'%HT7E-IC&/&-A=<8],4[Z6#J8
M5SJ6IZ;=6]O!?74D4EC%)*\C[BFXC<U0:UJFJ6NMV=AHVJS3VK2HQF+A\MW3
M/OZ5T7_":6).3I/.W;G<G3T^E,C\7Z;$H6/1515;< I08/K]:+Z@MBYX'U:X
MU=-7EGE=PEZR(K_P  <?G75UQD?C>SAW>5I93<=S;749/J:D_P"$]@_Y\)/^
M_JT@.OHKD/\ A/8/^?"3_OZM'_">P?\ /A)_W]6@#KZ*Y#_A/8/^?"3_ +^K
M1_PGL'_/A)_W]6@#KZ*Y#_A/8/\ GPD_[^K1_P )[!_SX2?]_5H Z^BN0_X3
MV#_GPD_[^K1_PGL'_/A)_P!_5H Z^BN0_P"$]@_Y\)/^_JT?\)[!_P ^$G_?
MU: .OHKD/^$]@_Y\)/\ OZM'_">P?\^$G_?U: .OHKD/^$]@_P"?"3_OZM'_
M  GL'_/A)_W]6@#KZ*Y#_A/8/^?"3_OZM'_">P?\^$G_ ']6@#KZ*Y#_ (3V
M#_GPD_[^K1_PGL'_ #X2?]_5H Z^BN0_X3V#_GPD_P"_JT?\)[!_SX2?]_5H
M Z^BN0_X3V#_ )\)/^_JT?\ ">P?\^$G_?U: .OHKD/^$]@_Y\)/^_JT?\)[
M!_SX2?\ ?U: .:O/&^L6NKWUL)5E*W"K"D:@@INQC/8_6FP^,=<N]?:UEG-K
M&)I%\OY 5 (P"3U_"M[_ (2[3/,:3^Q4WL<LV4R3[FFR>*M)F??+H43MG.6\
MLG/KTH6R!ZD%GXRF;2]+DFU"V\Z6]:&?+*"$!(&1GBIKKQ)=W6NR0V^IPVNG
M;F5+D@,I91R,].333XDT0YSX=@.3D_+'S^E2?\)9I0A6$:''Y2G<$^3:#ZXI
MW&_(SY_%>J)!-=1WT3S).81:!!DJ!]_U]_2L,^-O$*RV\,EX8S*\882*BMAL
M\KGC;77?\)?IIE\W^QE\S&W?E,X],TR7Q5I,^/.T*.3:,#?Y9P/Q%"9)UVER
M/+IL#R2^8[+DOD'/Y<5<KC8_'%I#&(XM,9$7HJR* /PI_P#PGL'_ #X2?]_5
MI,:.BU?S_P"RKEK><P2JA99 H.,>QKSR/Q#K:7UE!+JA99;43,=L:<YZ<]OI
M70'QY;L"#I\A!Z@RK5:3Q7I4S*TNAQN4&%+>6=OTHZ@<@/B3K\1-E< ?;)8V
M%N5CSYA+X4@=\#M4UW\0=?M[%)!R8X#'<GRL-'+NP&(]*ZK_ (2W2R\;G1$W
MQ_<;*97Z>E*?%^FL7SHRG?\ ?R4^;Z^M#&WKH6O"=QJESJ%\M]J37$<(0*IC
M"_>7/:NMKC4\<6D9)33&4MU*NHS3_P#A/8/^?"3_ +^K3;N(Z^BL70O$<.N2
M3QQV[Q-#@G<00<_2MJD 4444 %%%% !1110 4444 %%%% !1110 4PQ1DY,:
M_P#?-/HH 9Y,7_/-/^^11Y,7_/-/^^13Z* &>3%_SS3_ +Y%'DQ?\\T_[Y%/
MHH 9Y,7_ #S3_OD4>3%_SS3_ +Y%/HH 9Y,7_/-/^^11Y,7_ #S3_OD4^B@!
MGDQ?\\T_[Y%'DQ?\\T_[Y%/HH 9Y,7_/-/\ OD4>3%_SS3_OD4^B@!GDQ?\
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M_P J -/^SK+_ )](/^_8H_LZR_Y](/\ OV*LT4 5O[.LO^?2#_OV*/[.LO\
MGT@_[]BK-% %;^SK+_GT@_[]BC^SK+_GT@_[]BK-% &!XEL;2/0+IDMH58 8
M(0 ]16C;Z?9&VB)M(,E!_P LQZ56\4?\B]=?0?S%:5M_QZP_[@_E0!'_ &=9
M?\^D'_?L4?V=9?\ /I!_W[%6:* *ALM.!(-O;#;R<HO%*-/L2,BT@Q_US%8.
MO6MS<ZFDUM#(8H #<*#CSUS]W\.M=-&0T2,H(! (!'2CH'4@_LZR_P"?2#_O
MV*/[.LO^?2#_ +]BK-% &!IL4</BK4TB147RH^%&!6_6'8_\C;J?_7*.MR@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *0D $GH.:6B@#SCQ"]OJ'B**ZAD&P (SMN^7!Y^7'\JPY;=[O\
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M?]^36Y10!SS:;KSERUYIY\P8?-N>14BVGB-%"K?V(4#  @-;M% &']F\2?\
M00LO^_)H^S>)/^@A9?\ ?DUN44 <UHB7:>)-26]ECEF\J/+1K@8^E=+6'8_\
MC;J?_7*.MR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCMP 1G!S[U0^U6=LD=HNNVTR2S>3M-N& /7G(Z5OZ'X472)VF$D>7B,;+&I
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MUAV/_(VZG_URCK<H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+ JN.!TQ5<:/:"$*+^,%6^4"W?"#U'?/MTJY;^-=6@CBB>QMKF0%FD<<<;B
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ML %\6:F  !Y4?2MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%;J.7D<MK=]!I'V!(]*LY%EA#R22#&.G3%95KKACLII)M,TV4VX,DAY!=2<
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M2UU"WFFO+.!;@-M:#9C8.Q_'K73RQ1S)LD0.N<X(I%AB25I5C4.P + <D"A
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M._X2?1O^?^/\C1_PD^C?\_\ '^1K1^R6W_/O%_WP*/LEM_S[Q?\ ? H SO\
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M:/V2V_Y]XO\ O@4?9+;_ )]XO^^!0!G?\)/HW_/_ !_D:/\ A)]&_P"?^/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBD()4@'!(ZT <OKFN7=AK20)<16\"Q!P'B+F8Y^Z,=,5RO\
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M@P0M=ZMF*,XNB!E1QQ0!9_X2?1_^?U/R-'_"3Z/_ ,_J?D:TOLUO_P \(O\
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MV:W_ .>$7_? H P=&O(+[Q+J4]M()(S%& PKHZP=/14\5ZFJ*%'E1\ 8K>H
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M=:!&-_9GBO\ Z"\'_?%9FE6'B*2XOQ;ZE"C+/B4E/O-CK7>UA^'_ /C\U?\
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MW5KKMM;/-_:@<(,E5A&<57TY]6U17DMM75H5.!)Y(PQ[X^E '545A_V=KO\
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M$(O[QV4<<^F:F\5:AJUKXE'V>\9+>.!2L2L0"Q.,GUJK:^-=4ATL2RFUG>$
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MQI]D'9Q:0AFZML&34$&BV5OJ1OXXR)O+\M1GY47.3M';-8__  G%A_S[7?\
MWZ-'_"<6'_/M=_\ ?HT =!+86DXQ+;0OEMWS(#SZ_6I4ABB0K'&JJ>H48%<U
M_P )Q8?\^UW_ -^C1_PG%A_S[7?_ 'Z- '2K%&D?EJBA,8V@<5$EA9QD%+6%
M2,8P@'2N?_X3BP_Y]KO_ +]&C_A.+#_GVN_^_1H WFTRP=G9K. L_P!\F,?-
M]:<EC:1@!+:)0,8P@&,5S_\ PG%A_P ^UW_WZ-'_  G%A_S[7?\ WZ- &_-I
MUE<S+-/:0R2KT=T!(_&F#2=.!.+&V&>O[H5A_P#"<6'_ #[7?_?HT?\ "<6'
M_/M=_P#?HT =&;:!H! T,9B'1"HP/PJ/^S[/:5^RPX))(V#OUK _X3BP_P"?
M:[_[]&C_ (3BP_Y]KO\ []&@#HH[6WBV>7!&FS.W:H&,^E1R:;8RN[R6D#-(
M,.6C!+?6L'_A.+#_ )]KO_OT:/\ A.+#_GVN_P#OT: -:/0=,AO6NTLXA*5"
M_<&!CT':IO[*T\;\6-O\_P![]V.?K6'_ ,)Q8?\ /M=_]^C1_P )Q8?\^UW_
M -^C0!N2Z79RP&+R$C&.&C4 KVR#V-+::;:6=@EE%$# @P%;G/N:PO\ A.+#
M_GVN_P#OT:/^$XL/^?:[_P"_1H W_P"S[,2.XM8=[_>;8,GZU.\:2+M=%9<Y
MP1FN9_X3BP_Y]KO_ +]&C_A.+#_GVN_^_1H Z;RT,@D*+O P&QSBL7P__P ?
MFK_]?9_E5/\ X3BP_P"?:[_[]&LS2?%EG:7&H.\%R1-.77;&3@8[T =W17+_
M /"<6'_/M=_]^C1_PG%A_P ^UW_WZ- '445R_P#PG%A_S[7?_?HT?\)Q8?\
M/M=_]^C0!U%%<O\ \)Q8?\^UW_WZ-'_"<6'_ #[7?_?HT :/BC_D7KKZ#^8K
M2MO^/6'_ '!_*N,UOQ=97ND3V\=O<JS@8+1D#K5V'QM8)!&IMKO*J!_JCZ4
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MSYWW_?@TG_"4VN<?9+[/IY!KC(]:\1W%VR1S72K*H# QG,3;AG'&!Q6SH/\
M:2^*;G[9<74@6%DB\P?*V#_.D*YM?\)3:[MOV2]SZ>0:#XIM5&6M+T#U,!KB
M;R\U_P#M&2XMIKDW*Q%9O,C;9"-_\..O%,N+S7KFP\F]N[E_F0V_DPL!,-W.
M[/--(<M#N1XIM6&1:7I'J(#1_P )3:YQ]DON?^F!KEK35-8@"B=[V-EB8Q0Q
M09$G)R3Z5EIJ'B*6[$ZSW<AB4F#<APS$=&X[4GHP>]CO3XIM0,FSO@/^N!H_
MX2JT./\ 1;WGI^Y/-<7_ &AK\FE3)>7T[6[JX$L$+[MVW[O(SC-;WV35)?\
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M$,M@_I^-6;GP ;O5$O)=1)\N4NJ^6,X)S@U8N/!3//<2P7YC-P2)08P<J3G
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M97)SFM.74[BVT+6M4MIF1&N08)70D;<@9 -9_P#PD>M;W3[2P@56-O<?9O\
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MTN[6U#[VMV88<XZUI61OK+2[NU72)C'/\C2*RKM[ <=ZZ+5H;[^V8X;1QO\
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MN7%I)/\ V]:VX?RV@" 1\9?':A[ F9VCZKJ]C9)':Z---;@'9\X(ZDGD?6M
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M4444@"L/P_\ \?FK_P#7V?Y5N5A^'_\ C\U?_K[/\J -RBBB@ HHHH ****
M,CQ1_P B]=?0?S%:5M_QZP_[@_E6;XH_Y%ZZ^@_F*TK;_CUA_P!P?RH EHHH
MH **** "BBB@##L?^1MU/_KE'6Y6'8_\C;J?_7*.MR@ HHHH **** "BBB@
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MWAS3[C2H9;.==^#N6?\ OY['Z4 'G^)?^?.Q_P"_IH\_Q+_SYV/_ ']-;E%
M'(:_-KS:+<"YM;18L#<4D)/6K\$_B/[/'ML[(KM&,RGTJSXH_P"1>NOH/YBM
M*V_X]8?]P?RH R//\2_\^=C_ -_31Y_B7_GSL?\ OZ:W** ,/S_$O_/G8_\
M?TT>?XE_Y\['_OZ:W** ,/S_ !+_ ,^=C_W]-'G^)?\ GSL?^_IK<HH YK1&
MNV\2:D;V.-)O*CRL9R,5TM8=C_R-NI_]<HZW* "BBB@ HHHH **** "BBB@
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M +YH F_M2P_Y_(/^^Q1_:EA_S^0?]]BH?[!TK_GP@_[YH_L'2O\ GP@_[YH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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9%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g201711142133437595636.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201711142133437595636.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,E G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT8/M)./*S\V:U:XA[:W_ .%KPD0Q_P#(/+9VCKNZUV]+HF/K8**** "BBB@
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M-OE,(SM;(R.:V*PK+2+A+NP:XV&&TM0B@'^/&":W:;L(****0!1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"H)'*<8R*6WT?3K6]DO(+.*.YD^_(J\FKM% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 445Q]U\0+6UNY;=K&X8QL5)'?'X4 =A17$_\
M+(L_^@?<?Y_"C_A9%G_T#[C_ #^% ';45Q/_  LBS_Z!]Q_G\*/^%D6?_0/N
M/\_A0!VU%<3_ ,+(L_\ H'W'^?PH_P"%D6?_ $#[C_/X4 =M17$_\+(L_P#H
M'W'^?PH_X619_P#0/N/\_A0!VU%<3_PLBS_Z!]Q_G\*/^%D6?_0/N/\ /X4
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MGDQ?\\T_[Y%'DQ?\\T_[Y%/HH 9Y,7_/-/\ OD4>3%_SS3_OD4^B@!GDQ?\
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M]^Q6/<7OB&V@::6WL@B]3O/%1VVIZ[=LZP0V#[,9(D..?>@#<_LZR_Y](/\
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M:!]2D==S9+>#P_8)"TI3#YRH'7.*[>UTK2KFUAG6PM\2(&&%]17*M;:Q</\
M86L-*=D_>>4&''O6E'-XN"!8X-/VJ, *XXHN@>YN_P!AZ7_SX0?]\4?V'I?_
M #X0?]\5STVH^*K=-\HTY%R%R9!U/2I/M7B_G]UI_'7]X.*0&[_8>E_\^$'_
M 'Q1_8>E_P#/A!_WQ6&+CQ@WW8; ]^'%1_;_ !8)?*V6&_&<;QTH Z#^P]+_
M .?"#_OBC^P]+_Y\(/\ OBL/[3XPR!Y5AST_>#FD%SXO)P(K D] )!0!N_V'
MI?\ SX0?]\4?V'I?_/A!_P!\5B^;XS_Y][+_ +[H\WQG_P ^]E_WW0!M?V'I
M?_/A!_WQ1_8>E_\ /A!_WQ6+YOC/_GWLO^^Z/-\9_P#/O9?]]T ;7]AZ7_SX
M0?\ ?%']AZ7_ ,^$'_?%8OF^,_\ GWLO^^Z/-\9_\^]E_P!]T ;7]AZ7_P ^
M$'_?%8^AZ382W6J"2TB8)<E5!7H,4WS?&?\ S[V7_?=9FE2>)Q<:A]EAM2YG
M_>[FZ-CM0!UO]AZ7_P ^$'_?%']AZ7_SX0?]\5B^;XS_ .?>R_[[H\WQG_S[
MV7_?= &AJ6CZ9%I\T@MX(2JY#[.AK.\-V=IJ-O--=V4"SAMI@V8V#L?QZU#=
MS>*EMV:ZM[#R1R=S<5';W/B:6YE:W@TYI0 '*MV[4(#I?[#TO_GP@_[XH_L/
M2_\ GP@_[XK%\WQG_P ^]E_WW1YOC/\ Y][+_ON@";Q'I&GPZ%<R16<*. ,,
M%Y'-:%OHFF&VB)L8"2@S\GM7,ZU)XI.DSB\AM!!@;BC<]:NPR^,?(CV6]EMV
MC&6[8H W?[#TO_GP@_[XH_L/2_\ GP@_[XK%\WQG_P ^]E_WW1YOC/\ Y][+
M_ON@#:_L/2_^?"#_ +XH_L/2_P#GP@_[XK%\WQG_ ,^]E_WW1YOC/_GWLO\
MON@#:_L/2_\ GP@_[XH_L/2_^?"#_OBL7S?&?_/O9?\ ?='F^,_^?>R_[[H
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M-Z ';USG\:ZV]/A^QN3;RZ7'YV RH ,L#Z?2LF+7/#\TS6T?A_?=;@%A7!+
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M_A'-&_Z!UO\ ]\TM2O=MJ6O[2L?^?R#_ +^"E_M&R_Y^X/\ OX*J?\(YH_\
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MY?"FDS2K(\+[U3RU(<C QBHX_!VDQ!?+6=6!RSK*0S^S'N*V/MMK_P _,/\
MW\%'VVU_Y^8?^_@H SK7PUI]E=-<0><LC'J9"<#T'M4?A_\ X_-7_P"OL_RK
M5^VVO_/S#_W\%8F@W5NMWJQ:>(9NB1EQSQ0!T5%0?;;7_GYA_P"_@H^VVO\
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MU!K,Z,@E48/"_>!.1^7-02>++=KA(X]#@0*X,N=IS'C.1[T =O\ V]I7_/\
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M'_O\:W** .:T1KM_$FI&]CCCF\J/*QMD8KI:P['_ )&W4_\ KE'6Y0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%(<[3CKCB@#E=:\72:'J\\,UF9+9(D*,CC<SL< 8JK;_$$7+8BT:Y(
M5E60F11M9N@QWJIK\1_M3;J-_9+<-'@ 1/D+G@G'3ZU-8Z'.XD%K=Z?)M*%V
MVL>1RN30MM0+/_">H/.=M+F6&WQ]HD\Q3Y>3CIW_  J&#XC074ZPV^E7+M+(
M$B.X /[Y/3I4/_"&7(OY+LW-B2YRR$'82.>13H= F@OT"7FG>>#YR*0Q QW
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M2,H87MC@C(_=&@#=HK#\CQ+_ ,_EC_WZ-'D>)?\ G\L?^_1H +'_ )&W4_\
MKE'6Y7-:(MVOB34A>R1O-Y4>6C&!BNEH **** "BBB@ HHHH **** "BBB@
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MCJ$5U&(U^R8:$$_ZQNX;VK>0L8U+KM8CD9S@TZBCI8 HHHH P['_ )&W4_\
MKE'6Y6'8_P#(VZG_ -<HZW* "BBB@ HHHH **** "BBB@ HHHH **** "N7O
M]8OK+4'M9-1TV%]AF6.3.[RQWKJ*\N^(?A'5]=\0&\T^S=FCL_*AF64+ARV2
M"#VQ0!UGVS6A:"Z-[IH@*AA(<XP>AJ<'Q$RAA/8%2,@X->6W/A3QG>2*)=(7
MR5@\HHMR 'QC!/Y5+>>&_&UV([<:6T=JCLV%O.2& X_#%.VH'H]U=ZW8VSW%
MS>:=%"G+.P.!5>]UG4M.\O[7J.FQ>:,H"K$D>O':N"U;PQXPO;]C;Z0(;3RO
M*$8N1\PXQG/?BM_6+/Q+/<_:;'0W\Q[06SA[E5VX[@TN@'51OX@EC5X[G3V5
MAD$ \BGA?$A&1-8G_@)KS%O#GCB6YC,NG,8D@,3&.["-)D<9_&N\\$C7;'3H
MK#5=,:(J3^]$P8 =AZFG81I[/$O_ #UL?^^31L\2_P#/6Q_[Y-;E%(9A[/$O
M_/6Q_P"^31L\2_\ /6Q_[Y-;E% &'L\2_P#/6Q_[Y-&SQ+_SUL?^^36Y10!A
M[/$O_/6Q_P"^31L\2_\ /6Q_[Y-;E(2 "3P!UH \_O8)F\4/]M>PDOA;B14>
M,D;1Z>I]J41Q16;71;18T8><0PPV!WQFK&M'2]1OKJ==6MHY3 (XFSRC@_RK
MEI]$BN/*635M-;9U?)Y&,$'BA;!=W.L^QS7MM'.6T9XF"E6/3@<=_2FHLFG6
M4R13:,L,B%W1#NW@=>,\U@_8XFMA:'5--6 $M\I/4KC'TJ/5])M+V6(6VIZ=
M%'$$VD':1A<$<"GI<(ZO4W@;G2;2UN+>"QS*-\"0PLTC9'8?2FQPM?G[=*FE
M1RRDHWVA"CD]",'O4]Q>626NG/::K:&YM(?**NQ"L,8//:N=O;!;R ))K=G*
M6R?WLA)B.<\''-#W Z*/1)9<6\2:,YA;=L7)*GWYS^=7(9]2MX9#%?:2D:M\
MY#\*??GBL308[+3-6GN)-4LA'(A!VL26)]:Q7T.T<./[5L1&)-PA60@2>Y.*
M 1W0O=8,JQ#4-*,C<JF[D_09I@U'6?-D1KS35V$*68X!)[#FN9MM,TNVL+M8
MM5LEO&6/[/,26,94>IYQ41TZRBO1<)J>G3C"9CF)VD[<%OKFBR&=BEQKDDS0
MI>Z8TJC+(IR1^%5H-7U.X5FCU'2\+(8CDX^8=JP= M-,TK73>S:I:N!N/F"4
MY;/;&.@JO+967VRXDCO],:.5G #Y^4,<[NGWA2$;VJ:_K.DW,=O,89)'0R?N
M82P50<9/-6_[1UDV8NA=Z>8R 1P<\]L>M8.NQZ=?W5I(EY87"Q6IMSYTK*0<
M_>&*S[S3XI;3[#'K5B8#(DI=V.[(&,4T/2Z.D/B#45LVNGO;!$#;<,I#$^P[
MU9AU/5Y@F+[349SA4<X8_AFN1.F6J6[1C4]-F,BA"9"?W>"#E?>E_LC3A:7H
M?5K(S2;/*D&=R8.3BA>9+.TAN-<N&98;W3)&7[P0Y(J;9XE_YZV/_?)KC?">
MLVMOJ5Q(3:P1HJQ;V!0R8/+>YKN?^$FT7_H)0?G2&0;/$O\ SUL?^^31L\2_
M\];'_ODU/_PDVB_]!*#\Z/\ A)M%_P"@E!^= $&SQ+_SUL?^^31L\2_\];'_
M +Y-3_\ "3:+_P!!*#\Z/^$FT7_H)0?G0!!L\2_\];'_ +Y-&SQ+_P ];'_O
MDU/_ ,)-HO\ T$H/SH_X2;1?^@E!^= $&SQ+_P ];'_ODT;/$O\ SUL?^^34
M_P#PDVB_]!*#\Z/^$FT7_H)0?G0!!L\2_P#/6Q_[Y-&SQ+_SUL?^^34__"3:
M+_T$H/SH_P"$FT7_ *"4'YT 0;/$O_/6Q_[Y-&SQ+_SUL?\ ODU/_P )-HO_
M $$H/SH_X2;1?^@E!^= $&SQ+_SUL?\ ODT;/$O_ #UL?^^34_\ PDVB_P#0
M2@_.C_A)M%_Z"4'YT 0;/$O_ #UL?^^363HZZX;G4O(DM WV@^9N4_>QVK=_
MX2;1?^@E!^=8^BZ[I<%UJ;2WT2"2Y+(2?O#'6@#1V>)?^>MC_P!\FC9XE_YZ
MV/\ WR:G_P"$FT7_ *"4'YT?\)-HO_02@_.@"G<R^(K6W::22SV(,G:A.*BM
M+W7+XR?9KBQD5,9<(=ISZ&K%]XATN:SDBM]3MED<;<L> .]4M$U#2-&CDM4U
M2V:USNCY^8$]<T("_L\2_P#/6Q_[Y-&SQ+_SUL?^^34__"3:+_T$H/SH_P"$
MFT7_ *"4'YT 8NOKKPT6X^TR6ABP-P13GK5^!/$?V>/;+9;=HQE3Z56\0Z_I
M5SH=Q%#?0O(P&%!Y/-:$'B31EMXE.HP A ",^U #-GB7_GK8_P#?)HV>)?\
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M,=KODRG*,3PWTK%N-;LH;"(1:+:2R2)M$W;?C/->FW4.FF5_M0M_,G3RV$C
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MSIUNCAMOD;>4QW/UZUU<T$5S'Y<R!T)SM/2D2VACF>9(U61P S =0.E &?\
M\(UHO_0.@_[YH_X1K1?^@=!_WS6K10!RWB'0=*MM#N)8;&%)% PP'(YK0@\.
M:,UO$QTZ DH"3CVIWBC_ )%ZZ^@_F*TK;_CUA_W!_*@#/_X1K1?^@=!_WS1_
MPC6B_P#0.@_[YK5HH RO^$:T7_H'0?\ ?-'_  C6B_\ 0.@_[YK5HH RO^$:
MT7_H'0?]\T?\(UHO_0.@_P"^:U:* .=T>T@LO$VI0VT2Q1B*,A5'%=%6'8_\
MC;J?_7*.MR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M ;F)S\P]JNZUK+6\E]%;6-@OEEHD5D_> [2=^/2FVUH"=SKO^$@TC_H(0?\
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M;:V\LM^[D51@>^:F']BZ@[7H-K.T(^:7@[138=3D+#QAJ^I7$-M%HUG'+/\
M,C2Y"XQG!QSFI9?&6[9-%8QE(LI*HX_> <CZ"NDMY/#UM']IMWLXU#?ZQ2.I
MIL][X=M8YF>2T&S=*ZC!//4T70K,YRY\8WUO+! FEV<\K#=(T+93;GH#V/UJ
M_P"(O$[:-/;I#96SAD6257^\ 3CC%6K&Z\+7P\N%+4>2VY590.V<BM"0:%J;
M)-)]DG*@A6)!P!UH&<JGC*]*6SOIUBJWFX0')PN#C+^WTJ[:ZS>Q^&/MC0VM
MQ=M<F(9^Y]['4<XK;SH$BFWS9L(D)*9'RJ:LV4.F36*I9I ]J&RHC *@T"=S
MBKGQO?6D,+2:1:N]P62,1Y.&4X)/M4!\9:I%,\\FFVVUH5"6X!)WEL;OI7H$
MFEV$L>R2TB9>>"OKUIAT;360(;*$J%V ;>WI2&SG]!UV_P!9O/)DTZTMUCBW
MRDY))[;?_KUE6?BG4$6=)H+"1H'=G+$@LF[ 51_>KN[>RM;0?Z/!''QM^48X
MJ%M'TUY!(UE"6#;P=O?UI@<]KWB9](N;398V[6\D8DD:3AAGL,=ZR;;QMJ5[
M<QPPZ+:I]HE"0O+D #)'S?EVKO+C3K.ZECDGMHY'C^XS+G%,CTG3XI3+'9PK
M(6W;@O.?6A6ZB=[:''7?C.>")XHM+@ENXG\F8 ':K_X8K2_MR\ET>PN(M.MD
MN[J0QE)?NK[\<UT$FF6,JRK):Q,)CF3*_>/O4BV=LD<<:P($BY10.%^E+H/J
M>?\ _"=WTKQK;:'#)A?WF>[9(^4^G%7=!\:?VYK7V%-.A12<J_<J!\Q_ \5U
MO]D:<)(Y/L<.^/[AV]*?!IME:R"2"UBC< @,J@$ \FGH#\CA+GQA<:3<7JR6
MT%T@OWMXU_B3I@D?W146I^++M)EA,,*2Q-\[VQRCCKQFN^.E:>99)#9PEY,[
MVV#+9ZYI$T?3HT5%LH0J\J-G2A/N#U=T</;>-M2NKF*%-&M4\]PL3R9  ]_>
MMC0?$4FHW-Y!>V=K$T"&11'SP#CG-=!'I&GPRF6.SA5RVXL%YSZT^#3K.V>1
MX+:*-I?OE5^]1H#.$B\;WMQJ7V&'3K!I)"#&Y)V[3GK[\5,WB>\O9+98H+2W
M03QQRC/SL2>=H]*["+1=,@E$L5C D@Z,$YIQTG3S,DQLX?,3[K;>10+74Y/Q
M#XS.@ZP+)M.A=0VYW_NQD<-^?%96I^.-05?)@L[&-I5.U^3L88)S^!KT2XTV
MRNI#)/:Q2.5VEF4$XZXJ)M$TMY6D:Q@+MU8IUI+S*NKG#GQS?KY^-'MVCC&U
M7/ + @9/L<UWUK$S6T;7,4 F(RPC7Y?PS40T;359F%E &88)V=15[I3NK"&>
M3%_SR3_OD5AZ!%&;S5\QJ<71QQ[5OUA^'_\ C\U?_K[/\J0&SY,7_/)/^^11
MY,7_ #R3_OD4^B@"CJ211:=,X9(2JY#[1P:S?#=Q)?P32WJHMP&PT&W 0=C^
M/6MV2*.9-DB!EZX(H6&-)&D5%#L,%@.2*$ >3%_SR3_OD4>3%_SR3_OD4^B@
M#%\311CP_=$1H#@=%]Q6E;PQ?98OW2?<'\(]*H>*/^1>NOH/YBM*V_X]8?\
M<'\J '>3%_SR3_OD4>3%_P \D_[Y%/HH 9Y,7_/)/^^11Y,7_/)/^^13Z* &
M>3%_SR3_ +Y%'DQ?\\D_[Y%/HH PM/55\6:F%  \J/@"MVL.Q_Y&W4_^N4=;
ME !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4A( )/04M% '!>((]*U>>^;^TH(WFC2-6*$E"IR36%#HEE;0
M2+#J=D)"R\LKGS%!R=WO]*ZWQ)HMK-JNFR[95,LVV18VP" ,U@)XBU@2W$26
M=DD:MLC#;6=/FQR,9_.B/9 Y6W,X:#9?9?*;5K)N5;&QP"0<@$]<<U:AT?28
M=.NH1?61DFVE04<JI';/7%3:AXKU"Q9HO*M'EMY,2#R0/,&<9'_UJ+S6-6DD
ML59K:**>96++ /D4/C!/O35WMU"WX%J=+&?PW;Z:VK0>;$Y8ML;;@@\#\Z56
MTRPTJ_C@O87:6R6%41",L%QG\:N>(];ETR_:.+[)%'&J$+)$"9MQP<?2L*;Q
MAJ/VJ2*&.R*/RCM&J[ #@C![_6C5KU%HBO)I-G?6\$]QJ%DDRHJFW"NL> N,
MG'\56O[(TE;'R%U.U#>86W>6W0KC%;UWJMU)HVESV<5NDUUN\QG@X& 3T_"L
M>\\3:Q;+#&MG9O)/&L@D**BQYZ@D\4/=C2LD5[C2=.N; 1-JMI%/YPD+QQMC
M  &/IQ3FLXOM#WD>K6$=Q(IC:-8W$87;MR/>HV\0ZU#+))Y5F9)ECPA"A(^#
MDAB,5TGAC4;[5!=SW\%I'';H/W<48;)QG.>]/6S"]K(Y5]"LI'D7^V+5$=>2
MB.&<X'!]N.U=-X9O--T*T-N;RT".Q=Q$'X/MFL6/Q5J=SK*6$$=GLG(*2F '
M:,D$8_QI\FN7M\T$<AMK8I+&IC$6&FR>2/:A)OYBE[JU.U_X2?1_^?U/R-'_
M  D^C_\ /ZGY&N:UG7+BTU2^@A%HRP%%6V\H;W##).?:L<^)[W[$Y5+23;*(
M?LRQ?.!C[V?:DE<+G>_\)/H__/ZGY&C_ (2?1_\ G]3\C7&Q^(M3BM(IY(+5
MDG5U4>1_JMN/F/K6I!K,S>'[RY'V.>2&<1+.D0V ?WB/:AIH+F]_PD^C_P#/
MZGY&C_A)]'_Y_4_(UP":Y?VIN#$]K.^[ F9 %QN[ \59LM8U.[U':DMN/M!5
M0C6P^08.2!2Z!<[;_A)]'_Y_4_(T?\)/H_\ S^I^1KS^U\07UK#<2QK!),,;
M;9HLE^O(_*I]3\0W-V;9K9[>.)8@\NV(8+%"2N?K3L5;6QW/_"3Z/_S^I^1H
M_P"$GT?_ )_4_(UPS^*M0ATY9HX+3S/EC%LT.6' ^?/IS6Y)<WTGA_6%D\A;
MJUQLF2$#@@'I[4-65PMJEW-W_A)]'_Y_4_(T?\)/H_\ S^I^1KFM&URYN;^W
MAE6UE5I/):)80'  _P!9GT--U/3HM-\07UU;PRRF&T\](B_RE]V*+"6IT_\
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M*V-!@A:[U;,49Q=$#*CCBD!9_P"$GT?_ )_4_(T?\)/H_P#S^I^1K2^S6_\
MSPB_[X%'V:W_ .>$7_? H S?^$GT?_G]3\C1_P )/H__ #^I^1K2^S6__/"+
M_O@4?9K?_GA%_P!\"@#-_P"$GT?_ )_4_(T?\)/H_P#S^I^1K2^S6_\ SPB_
M[X%'V:W_ .>$7_? H YKQ!X@TNYT2XAANE:1@,#!]:OP>)M(6WC4WB@A #P?
M2D\36\*^'[HK#&" .0H]16E;VT'V6+]Q']P?P#TH I?\)/H__/ZGY&C_ (2?
M1_\ G]3\C6E]FM_^>$7_ 'P*/LUO_P \(O\ O@4 9O\ PD^C_P#/ZGY&C_A)
M]'_Y_4_(UDZ]F+4XQ;+B# ^V;4'[M,\$>]=-';VIC4I#$5(&#M'(HZ7 S_\
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MME4QC)/;![4/382WU%M6^V6+W5OXDB>V@X9O) "?GTJF^H6$D"L_B>W:-_E
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ML8C52\B-$#]<\<U=3P$Z016PU'_1XRS!3&-VXC!.:==>"=FEQQPS-++!O9
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M^1GLNFZ:DDBZ_ 3*#<;! &SQU''%,M9[&60:DVN11.P"H6A!/KTQQ6S'X*:
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M<CZ5M7MM;VC6[//>7%S+ )I"BIE$]22*8VKK0)?%VM6EL\L_V4A)6A)"D#.
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M9F+9W-(20/3Z5T-% &%#X2TR+_GO)A2J^9*3M4C&![8JW'H5C%#+$L;;)81
MPW?P 8Q6E10!S;>!M&9%&V<%1M#"4[MN,;<^E.'@G1@1F.9E5=JHTA(7W'O7
M144 <\_@W2Y(@CM=$]&<S'<P]"?2KE]X>L-0\DRB53$GE@QOM+)_=/J*U:*
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ME1&L.)3SC.X]:T=,T'5X);:ZF$XN$NDSF4X$6#NXZ4[(IHZ+^U=8_P"@(_\
MW]%']JZQ_P! 1_\ OZ*YG5='U]O$-U=QW5PB<F-E V!,="<_TK-T:PO-8U%V
MM4NH[6)",R2L5\W;P?SJ5JA-V.X_M76/^@(__?T4?VKK'_0$?_OZ*XE/#OB!
M;%Q(]_(?,!=.%#'U&#G%:^A:9KEOXCBN+J*;84Q(SR94#' 'K^--('H;_P#:
MNL?] 1_^_HK)T?4-2CN=2,6E-(6N"7'F ;3CI795A^'_ /C\U?\ Z^S_ "I
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M +_&@#<HKF'US5XYW@>+3%E0;F4W!R!4B:KKDL22);:<R2'",+@X8^U '1D
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M6I;,I;07RS1%DF>1_D*C&% ]:1;+Q#>V>[3OMT.'873N=WF+GH@/>O50JKT
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M-2:\A2*;RH\JC;ACZUTM8&F2QS>*M3>)U=3%'RIR*WZ "BBB@ HHHH ****
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MLCO$Q9A[FM6W\1Z9:Q^6BWQ7.1NA8XIZ6 T/^$?TC_H'P?\ ?-'_  C^D?\
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M?TC_ *!\'_?-'_"/Z1_T#X/^^:J_\)7IW_/.[_\  =J/^$KT[_GG=_\ @.U
M%K_A'](_Z!\'_?-'_"/Z1_T#X/\ OFJO_"5Z=_SSN_\ P':C_A*]._YYW?\
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MHHH **** "BBB@ HHHH **** "BBB@ HHI"0 2>@H HW&I:99WHCGN(8KEP
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MWDQ?\\T_[Y%'DQ?\\T_[Y%/HH 9Y,7_/-/\ OD4>3%_SS3_OD4^B@!GDQ?\
M/-/^^11Y,7_/-/\ OD4^B@#"T]0OBS4PH 'E1\ 5NUAV/_(VZG_URCK<H **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "D)"J2>@&:6B@#B[[5O#<NIW$]U=?O)8?("/;D[?<9%<])I^E%XWM
M?$%Q$T+AXV^QEBAQCTKH-?\ L"^(YSJ$4C[K0"WVHQ^?/;'>L!;[Q'9*J/)/
M&1(1M6,YDZ8&>E$=@M>X^[M]-O;58KG7Y2H0QL19$ @]^G7WJPL.BIIL5M;:
MO.CHCQ-+]E)W*W48Q5)#KAL;N-;F^_=YD,;)U8N./IBK=EJ>LV4*F,WAAC;-
MPKPGY!N[>O%4'FC8M]=TD:5)IEY=NT.P11D0,#MQC/3K61+!H]W*)+O5[B5D
M 6,BT93@$=>.>E4I;_7)M7FO(FNY"\H%O$\9"E03BM.VO]=O+B""*\N_+D(^
MT2&+!B?'*CVI:_$.44E8BNK70KLRQOJER+=G:6.,6S91SWSCGITJGY-H=7>;
M^VY72:,K</\ 93D\8P!CCBMN]U?4(M#T=KJ[GMI)I72:1(\N0,XXK&76=:2Y
MVWUQ<VC2C*M'%EG(!Q^?%/5 XWW-K4-5L+M+2*SUB6W@MP%:,VC.'QTSD5-I
MVN6%M>W5U)>.#.XW*+=N548';BL6RO/$TD-U+(]Q!)&S2;%C^^<CK^%:6AZW
M?W/B."UN;N7SG60SVQ3"QX^[@T).X.-D;W_"7Z,/^6\O_?A_\*0>,M$/2YD.
M?^F+?X5Q]_K'BL:M<6<23F!2UOO\O@M]X/\ 3'%06-OJ[WW-W>QS9\S[IPHV
M=OQJ>EQ,[C_A+]'_ .>TO_?A_P#"C_A+]'_Y[2_]^'_PK,O-8U*TT[2;B3S1
MYD3B?;&2=^WY<CZUS:Z_X@FCF^S7=T]ZLNQH/*^5$QRWU%/E!Z';CQAHQ) G
MDXZ_N7_PI/\ A,-%Y_TB3CK^Y?\ PKE+S4=4TMI!<WUS#!C=]HV99GVY"_3-
M5#_;DFDS7"75X!=2,'55[;0=PI"N=O\ \)AHV<>?)D]/W+_X4?\ "7Z/_P ]
MI?\ OP_^%9&JQWT@T^:RN;E&BL6?>HY9@. :P_[=\4B>66:1EQ'DVZ0L6 P/
MF]*8TKJYV9\7Z,!DSR@?]<7_ ,*/^$OT8C(GE_[\/_A7#MJ^N7.G7,%U<W:P
M8<12QQ$F4XX4\5M^$-0U=]0>VO'FEC6$8#(5"8 P.>]%A7-L^,]#5@K73ACT
M!B;/\J<?&&C#K<2#_MB_^%>;:E>_:+]Y[NZGBN!+C"@G R<_3'%=JUO-++HU
MY.]Q+F!A*$)(QCT]:72XWH[&C_PFN@[=WVMMN<9\IL?RIW_"8:+MW?:)-OKY
M+_X5QCQP1W4C%)Y-':3=_JV&UL?=QUZ]ZKO<Z]):SV#3791XMJQI&047L>?Y
MBC<%O8[P>,-&896>0@]Q"_\ A1_PE^C_ //:7_OP_P#A6)KMQJ6DV6D16,TR
MHL8#JJ$ESQQG_&LBW\1:S):&>*XNYB=XN%\KB#!^4BG8$=E_PE^C_P#/>7_O
MP_\ A0/&&C$9$\I'M"_^%<;::YKL@"7EQ=I&H<1/' 6,S9X!SVQ4\%]XDBL5
MNHWGW+,L8MS'A=I!R318:5SJ_P#A+]'_ .>TO_?A_P#"@^,-&49,\@'J87_P
MK#T#5K[4%U:.*_FG>&%64NF"DF,D#\:P?[7\5ZC:7L<T5Q&NSS4_=8X) "_7
MJ:+:V!+4[D>,=%/2XD/_ &Q?_"E'C#1F&1/(1[0O_A7#:6FLVL=S=0W5ZTD*
MH"CJ3O.[D'\*T]+NM?'V>5Y9U1;A(S#Y?RE23DFGR@T=-_PE^C_\]I?^_#_X
M5E:-X@M(;G4G$5S*DMP75HX2>,5V58?A_P#X_-7_ .OL_P JD0?\)1:?\^M]
M_P" YH_X2BT_Y];[_P !S6Y10!A_\)1:?\^M]_X#FC_A*+3_ )];[_P'-:&J
MND>FSL\C1X7ADZY[8K-\,SW,T4XU!G^W!AO0] O\./PH0#O^$HM/^?6^_P#
M<T?\)1:?\^M]_P" YK<HH Y'7_$-M<Z+<0I;W:LP&"\) Z^M7H/$]JMO&IM;
MWA .(#Z59\4?\B]=?0?S%:5M_P >L/\ N#^5 &1_PE%I_P ^M]_X#FC_ (2B
MT_Y];[_P'-;E% &'_P )1:?\^M]_X#FC_A*+3_GUOO\ P'-;E% &'_PE%I_S
MZWW_ (#FC_A*+3_GUOO_  '-;E% '-:)>)?>)-2GC21%,:#$B[3^5=+6'8_\
MC;J?_7*.MR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[XH Z*\T^TU!46[@64(<J&[&K"JJ*%4 *!@ =JY7_A-T'72;[_OBE_X39/\
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M\1;[02?FR>V*[V^\3VNF:G-:W:NL<<:N9%4D#/KZ"HK[Q?86]O#)"WF-, R
M@C(.1_2G'1#.*GOM5N]11_M%R\K;4E7R2!"<G('^-.TFYU+1X8H&FN8(';<\
M_DL[,W88]ZZP^-[$26JF.0++_K)-IV)QG&>YJ];^*]+N"ZAY4=(S(R21E6"C
MG.*+DVN<)JFN:W>M=P1W%RL1&2%A(:/:P]O2K"Z[K4,<PBDF5E8FU00$_:#G
MG/IQ79Z7XEMM4MKRY6*:."V;[S)]X8SD547QWHKDJK7!=<[D$62H'<^@H78+
M7U*_AV]UF3!O9'F:6V,H5H]NU\GBN>O+O5]6CAMC=7+*TR&Y582OE'=]W/<8
MKL$\5VESJ]O86J22B4D&;;A.!G@]ZKR>(K^TU>YM[VVM8K2WC\UYO,.=A.!Q
MZT=;@M$9GB?6=5TK5HXK25Q L'$:Q$[CCKGIQ699ZWKNH36L5O>S2VTT>Z:;
MR,;'QR@KIO\ A.-!N8"H>68."K1K'N(&.<X[8IS>,-"TXK:AWC1$&S;&=I]A
MZT+:S&]CE9[_ ,0'2+IEEFVIMC6$1$9!4Y.>O6F'4_$"6&GRB*7[= LBNI4[
M5&T8/OQ78VWBZTO-6M;&W@N"TV_<S1XV%?6JEQXZL;9KF%\"YANO($6#\PR.
M<XQ0D[^O_#!'1F?X6U'7M1U>.*\O"UJD1DWI$5$AW8P2:IZEKVJM=WD5K<23
MLERT;6XA.U(QCYLUTY\9Z7OG15N7D@7<Z)%D[>FX#TJ >+M L<966 7'SDM$
M1DD=_>AZ@<M_;^L7%H3#/+=')\U/)($)!XQZU9?6M>M5MS=7DR6\Z!Y9O(YA
MY(P!6^OBO3;9+>"QM9L32JN#$55=W<GUI^KZUIC7-QIVIVTDD:,H14!)<D9Z
M"AO0E(H3Z[??\(;:WB7#^=-)L,ZQYP,GDCM638Z[XFFLUO"\K.DRQ>3Y) <'
M//\ *N@D\8:1816<-E&S0/(L98)A(P<]3Z\=*M6_C;0[H2&.Z.$."2/R_.BV
MI6VYSVE7-[>-K4LEQ<32&QZ-&5V/@Y4?2J4VI^)--L;>VBN',9BC9KB6(_N\
MKTX%>F12"6))%!"L,C(P:?0V-NYY?=^*/$<,MN(R[SA5#Q" X?(^\.*U-)N+
MJZM=<E-S<7!-LNUFC*8;'( ]C7>44F38\OC\0ZY'>10PRRJD:[7BDB/ 50<Y
M]^:GC\2:Y=-]I,DL*S /9P"'/F G&TGMBO1+BWBNH'@G0/$XPRGN*=%$D,2Q
M1($1!A5'0"G<+'FUSKFJ:@=.B::YA,3@W>R$C#!\8/'I6CK]YJ%AXFD>&ZG2
MWE@C!(C+!%S\S#WKNZ*0)'&76K:J/!HNTF=)_-VB8Q'+)GKCM68OB?5FLY(9
M!/\ :',?E P'YD(.XUZ-10-GG>AG49/"^NK+<W(NCED!0@H,<;:I6^N^) _E
MQW!*I!A4:%BQ&W[W3&<UZC13;NQ6TL><:AK>NV-N8#=3&0@,DWD]3MSMX'K5
M=]4\1WNC^<]Q.GVA71D6'!3"YR*]/HI#6A3TIM^D6C>8TA,*Y9A@GCO6?X?_
M ./S5_\ K[/\JW*P_#__ !^:O_U]G^5-N[N)*RL;E%%%(84444 %%%% &1XH
M_P"1>NOH/YBM*V_X]8?]P?RK-\4?\B]=?0?S%:5M_P >L/\ N#^5 $M%%% '
M*Z^MP^IJ]JLWD1@&\"9^=,]![UT\15HD9/NE01]*?11T#J%%%% &'8_\C;J?
M_7*.MRL.Q_Y&W4_^N4=;E !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4A.%)QG Z4M% 'G^NS6-UJ4CWB7L
M'G((WA+JHD4'W-4X]'MI50_9]4FCCP(P%4A0"2!^M;VHZ%/J7C0W)(2!+50&
M>!9 QW=.>E<];V_B&VDNH(OML+&8_9!&,1D$_,6IQV&66T>%MD9L]5^S+DB'
M8,;B,9S2/I/F.9FAU<W#(8GE\M<LA&-M.T67Q;-XCCBOOM*V3/\ ,QX "?\
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MSIV7V^M#:;9>5;+';:G&UJFV%A"/E.<@^],%YCK76[>909]?U& M*8EW*/7
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M(=2F:%=Q54'/.*/[5TETD1O$MY^[P[)L4\^P]<U#<:1:7$\C^3J:1M'L5%@
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M9<%L+'G;QT- &M_8-[_T'K[]*/[!O?\ H/7WZ4?\)(O_ $#;[_OU1_PDB_\
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MY'%9E]<V]_.TTUCJ._ $1$?^J([CWK23Q'MC56T^^9@,%O*ZT= ZCO[!O?\
MH/7WZ4?V#>_]!Z^_2C_A)%_Z!M]_WZH_X21?^@;??]^J *VB6TEKXDU**2YD
MN&$49\R3J:Z6N:T2[^V^)-2F$4D68HQMD&#72T %%%% !1110 4444 %%%%
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MC;*UO_JN<$8[_C77/XOT$E?,N 6ZA6C.1[X[5+JMWH<$5NU\(BKD21X3.?\
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M", Y!^M=!12&<FW@:$^;&M]*()SF>/8/GYR.>U.M_!4<5W:327\DJV9Q;H4
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ML)@>G%;=% !6'X?_ ./S5_\ K[/\JW*P_#__ !^:O_U]G^5 &Y1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKF;[*8P(EDD#8;N30M1O0ZZBBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** $"A1A0!]!2T44 %%%% !1110 F .@ZTM%% !2%0PPP!'N*
M6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g201711142133438715640.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201711142133438715640.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,E G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#T ]7_ / ;_P"O6[10!A?\)(__ $ ]7_\  ;_Z]'_"2/\ ] /5_P#P&_\
MKUNT4 87_"2/_P! /5__  &_^O1_PDC_ /0#U?\ \!O_ *];M% &%_PDC_\
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ME+;6EQI]Q=37#EHO,7Y_*&/O8Z&K+>-]2+/Y>GVX'VI[= [G.5&233L!N_\
M"2/_ - /5_\ P&_^O1_PDC_] /5__ ;_ .O7+77C>YNHK='M1%)(8Y8_+D/0
MDC!_&M.RUC7=4\%2WJFV6_,C*@C;;P&QWZ&BSM<%J:W_  DC_P#0#U?_ ,!O
M_KT?\)(__0#U?_P&_P#KUSMMXZN6ELK*SL;B[D9"TS2KRN&QCCC\:W_">JZA
MJ]C<37ZP*R3M&@BSP >^>]%@&1^+HY;F:V31]6,T(4R+]F^[GD=ZF_X21_\
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M&CH+J6'N="6VCG76]8D22+SEV3DDKG'3'7-.:32HYX89=1U^-Y%#8>0C8"<
MMQQS6-=^&HC-/Y&IZ:]N]NJ)$URJX;<"PSGH:NSZ1#<S1W":C96IB@5%MTO
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M_P# H_X5H?VQIG_01M/^_P"O^-']L:9_T$;3_O\ K_C0!G_\(Q%_T%-5_P#
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M_",1?]!35?\ P*/^%4=(U#3+?Q)JR+?6JQK';JI\Y<'"GWK>_MC3/^@C:?\
M?]?\:'Y 9_\ PC$7_04U7_P*/^%'_",1?]!35?\ P*/^%:']L:9_T$;3_O\
MK_C1_;&F?]!&T_[_ *_XT 9__",1?]!35?\ P*/^%'_",1?]!35?_ H_X5H?
MVQIG_01M/^_Z_P"-']L:9_T$;3_O^O\ C0!SUUHZ:?XBT21;R]F)E<;9YMX'
MR^E==7-:G?6=UKVAI;W4$K"9R1'(&/W?:NEH **** "BBB@ HHHH **** "B
MBB@ HHHH **** ..G.F6_B'7KK4;6*?:;9$#QAF)*' &:;<ZIX>LKB."ZT)(
MI70.5:W7Y06V\\54U?[!/K^M6UU?):SJ]K-"6!(RJ'KCM3;O^S=3NWN;[6K4
MR/9FW(C1@ 2<@CBA#+]SJ?AFVOFM3I,#$%EWK N"57<>U;5EINBWUE#=1:7:
MA)5#*# N<'\*XP6&D_8;&)M>@:: 2^9(4;]X77&>E=!H.N6.G:7%:7FJVDC1
M*%5HE8 @>N1UIZ"-K^PM)_Z!EG_WY7_"C^PM)_Z!EG_WY7_"H/\ A*-$_P"@
MA%^1_P */^$HT3_H(1?D?\*0$_\ 86D_] RS_P"_*_X4?V%I/_0,L_\ ORO^
M%0?\)1HG_00B_(_X4?\ "4:)_P!!"+\C_A0!/_86D_\ 0,L_^_*_X4?V%I/_
M $#+/_ORO^%0?\)1HG_00B_(_P"%'_"4:)_T$(OR/^% $_\ 86D_] RS_P"_
M*_X4?V%I/_0,L_\ ORO^%0?\)1HG_00B_(_X4?\ "4:)_P!!"+\C_A0!/_86
MD_\ 0,L_^_*_X4?V%I/_ $#+/_ORO^%0?\)1HG_00B_(_P"%'_"4:)_T$(OR
M/^% $_\ 86D_] RS_P"_*_X4?V%I/_0,L_\ ORO^%0?\)1HG_00B_(_X4?\
M"4:)_P!!"+\C_A0!/_86D_\ 0,L_^_*_X4?V%I/_ $#+/_ORO^%0?\)1HG_0
M0B_(_P"%'_"4:)_T$(OR/^% $_\ 86D_] RS_P"_*_X4?V%I/_0,L_\ ORO^
M%0?\)1HG_00B_(_X4?\ "4:)_P!!"+\C_A0!/_86D_\ 0,L_^_*_X4?V%I/_
M $#+/_ORO^%0?\)1HG_00B_(_P"%'_"4:)_T$(OR/^% $_\ 86D_] RS_P"_
M*_X4?V%I/_0,L_\ ORO^%0?\)1HG_00B_(_X4?\ "4:)_P!!"+\C_A0!/_86
MD_\ 0,L_^_*_X4?V%I/_ $#+/_ORO^%0?\)1HG_00B_(_P"%'_"4:)_T$(OR
M/^% $_\ 86D_] RS_P"_*_X4?V%I/_0,L_\ ORO^%0?\)1HG_00B_(_X4?\
M"4:)_P!!"+\C_A0!/_86D_\ 0,L_^_*_X4?V%I/_ $#+/_ORO^%0?\)1HG_0
M0B_(_P"%'_"4:)_T$(OR/^% $_\ 86D_] RS_P"_*_X4?V%I/_0,L_\ ORO^
M%0?\)1HG_00B_(_X4?\ "4:)_P!!"+\C_A0!/_86D_\ 0,L_^_*_X4?V%I/_
M $#+/_ORO^%0?\)1HG_00B_(_P"%'_"4:)_T$(OR/^% $_\ 86D_] RS_P"_
M*_X4?V%I/_0,L_\ ORO^%0?\)1HG_00B_(_X4?\ "4:)_P!!"+\C_A0!/_86
MD_\ 0,L_^_*_X4?V%I/_ $#+/_ORO^%0?\)1HG_00B_(_P"%'_"4:)_T$(OR
M/^% $_\ 86D_] RS_P"_*_X4?V%I/_0,L_\ ORO^%0?\)1HG_00B_(_X4?\
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MW_D6@#=HK"_XJOTT;_R+1_Q5?IHW_D6@#=HK"_XJOTT;_P BT?\ %5^FC?\
MD6@#=HK"_P"*K]-&_P#(M'_%5^FC?^1: -VBL+_BJ_31O_(M'_%5^FC?^1:
M-VBL+_BJ_31O_(M'_%5^FC?^1: -VBL+_BJ_31O_ "+1_P 57Z:-_P"1: -V
MBL+_ (JOTT;_ ,BT?\57Z:-_Y%H W:*PO^*K]-&_\BT?\57Z:-_Y%H W:*PO
M^*K]-&_\BT?\57Z:-_Y%H W:*PO^*K]-&_\ (M'_ !5?IHW_ )%H W:*PO\
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M8?$7_09@_P# 44?8?$7_ $&8/_ 44 ;E%8?V'Q%_T&8/_ 44?8?$7_09@_\
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M_P!!F#_P%%'V'Q%_T&8/_ 44 ;E%8?V'Q%_T&8/_  %%'V'Q%_T&8/\ P%%
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M26 YP/K5W4=,TS3/+$UYJKR2G"1Q3EF/X57NK+1].=DDN]355B\Y]LQ^4>X
MZT=+#OJ94EGJOFZ==I9W:".T1 DD((C93\V_/3CO5Z02RZ)+>2:9->3:A,3^
MZBWF).@./I5A[71]UM&MWJ\S7*!U5)2<*>[>@IES;:38RSPFXU=EM\!S#*6
MR,_H*;?<E%2'2[E+Y4_LRY;$ZRI<,G2(+]TGKGVJQ96TTWA^^M%T:>-WN6\M
M;B$ !6/WAG/:G :$UVENNHZJ=X&)!,VP$C(4GU]J5H])_LYKZ*?6YX5<HWE.
MQ((ZDCTI>H^UC1T"TCL=?U6UB "116Z@#_<-=)7!:'HUEJ.MZG-%=ZD(FC@9
M=TY5N5/6N@_X1:U_Y_=1_P# DTW>^H(W:*PO^$6M?^?W4?\ P)-'_"+6O_/[
MJ/\ X$FD!NT5A?\ "+6O_/[J/_@2:/\ A%K7_G]U'_P)- !K7_(<T+_KN_\
MZ#6[7(W6C0Z=XBT26.XNI"97&)IBP^[774 %%%% !1110 4444 %%%% !111
M0 4444 %%%% '":JB7>NZY9'4H+'S'M6=I)%4E0AS@'K51-,^QY2WUW39D*/
M#F6=00C'.>#U%;+II\>O^([R^LX;@0I;D;XPQ^X>!FF2:GH M+:>+0X)O.C,
MI1;=,QH."3Q0AF,_ARTCGWP>)[5T\DJ5DF3EL@CG/3BM016]QHVHPW6KZ<ES
M>L"?+N%PN,=#FI%U;PY))/Y6DVCPPKDN(H\D^FW&:GCN=%;2KJ]?08$>V.'@
M:!-V>W:A[!K<R;W1--N&ABM_$%K! D3;F^T([O(>,DDT6VFV\>I07\VNV+RQ
MNA,9N5V, ,9QGK5NXUC0[6W4S^'[>.X,BQ^0\4:XW=#DC&*FM=2\.SWUU9R:
M/:PRV\ F8M A4CV('-/S)\B*TM[*"2)FUC3SLO7N#B=?NGMUJJVF64EJD#ZS
MIX GFD)$Z]'&!WJQ;:UH5];+-9^'HYCM+R(+= 44=SQ5^.Z\/2VES<QZ5:M'
M BN?]'3D'\*-BKW=_P"OZU,:ZM!J5FL%WJVE)Y$(ABV7"_-R.3SZ"IM*TW3]
M/U#5"VM6!L[J'RHD$ZYCSU[]*DDU?28;JXBE\,1*D"+(\GE1XVMC!Z>]63?:
M'Y_&A0&U\SRC<BW3:'].E&MA=##N=.EN+=[9M<TXVZ0")8_M8V28Z$C/%3W&
MEV5[:0(VH:7:O#"Z(L=T&"L>AR36AIFL^&M4>%(=(MU>6=H=K6Z9!7OTZ&EN
M=4T&TOKBWFT* 1PN8_-\A,,P&<8Q0[]0:U]#$TK2(M/N9'FO](F:6V6(S?:@
M&0A2#@9P>M.CT**&%;6/Q'9B&0)YTC7"LZ[?X5R>E=-J4N@:99VMS+I-LRW#
M*JA;=,C/<\=*HS:SX9AN[RV?2+??:L@/^CIA]W<<=J+MATL4M*A?1]6AFCUC
M3+F!(FA+27*A@I;<#P:;XATFSU:YO[F#6M.CFF\ORF,Z\ ## \]#6UILVBZE
M!<SIH=ND,()#M GS8Z]N*AO;_0K2PL;H:+:.+QML:F.-,?4D8H;8T^QGV=K'
M;VL.EMJVEFP2593(+A=YQSC&?6H]2TZUN;2XC74M,E,FH+="-[D %1V)!K3;
M4?#Z63SMHMN'2;R3$($)W8SZ=*33-0T/4OLY&AVD:W$A2,^7&W09YP.*+O\
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M+Y5TH+[O?--CLK"TU.^D@FT9X9QA&DNAD#&-I&<5V/\ 8NE?] RR_P# =?\
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M>!?ERI]JZ3^Q=*_Z!EE_X#K_ (4WN"#^VM*_Z"=E_P!_U_QH_MK2O^@G9?\
M?]?\:/[%TK_H&67_ (#K_A1_8NE?] RR_P# =?\ "D ?VUI7_03LO^_Z_P"-
M']M:5_T$[+_O^O\ C1_8NE?] RR_\!U_PH_L72O^@99?^ Z_X4 9&I:A97>O
MZ&EM>6\S"9R5CE5C]WV-=+7-:EI]E::_H;VUG;PL9G!:.)5/W?85TM !1110
M 4444 %%%% !1110 4444 %%%% !1110!P&L-8S^(=9L;W46LU=[9VV [F4(
M>A XJHMOI5J2+/Q"-C!XSYT;L?+8Y(SCKFMRXOX],U7Q+>.(RR"W">8< L4.
M!FH%\47%W96[V=O:&;R&FGW<J IP0,4(>IB'3- W%$UB!(D):-E@8/N./O''
M(XZ5J+=Z8=(OH)M:A:[NR&,@B?:".G&/:K.F>*6U2^=(X(8XRK")'0@NP&?O
M=*T!JTY\)OJ?V> 72@@+CY<YQ0]A7UL<S=C3KQ8[B?6;.6\61'^>W<QD*, 8
MQ3KN'1;V=9WUJ**0R*9!#"P!3'*].AJ[J'B74=/5+62VM6O&EC7>D99=K#/3
MKFI8_%<MOJ=W:W]K L<4 >*15P7?'*X-,1GP'3=/>5]/UR",SAEEWPN?E/3'
M'44!M-@6XMK;6K=;.>)48-"^X$=^E7-,\1ZIJ\#B&SLXKB!#),) <$=@/>KU
MOXC-SIE]=K:1+Y$2NJD=2>N:3\P72QFW<FB7+7A_MA%^T01Q?ZIN-I!ST]J8
MLVEJQMO[<A_L\S>>8_)??N],XZ5/<Z]J]K=WNZ*P:"WA24 (=QW$#'ZU;_MV
M\93?+:VWV!;CR"I'SYZ9]*IWMJ/H8UG;:#9ZCIMXFM(#:%_,41-B3))';MFK
M<G_",O+J=S]OB-U>,2LK1N=G'IBG:-XPFU"[M+6XL8(I9YW7CO&,X8?E3KOQ
M3=6^L7UM';6TL=NY38$.Y0!G<3TQ2E?J-[LH7"Z;JBPKJ?B !8(3'&+573D]
MSD<U#<6.BW%NH.O(+A9UE$OE-R ,%3QWQ72Z[XB32;&QE6*V,MQAF5R!A>Y%
M9ESXSEM[Z[A^Q0&(.BVS_P!_.,@^_-'42%LKS2H+R]N)M8@/GPF(+%"ZC_>8
M8ZU1,EJUE8P2ZQITOV*0M&)+9V4C'<8ZUT6E:O<70OOM=O;Q2PH72';A@!TS
MZCW%84?C&_DTI[A;:UD8N@5XXF*C)QMQU)'M0'0?(=#EUIM0;6(U1H2K0K$V
MWS,8W=/2J]M):6EK9I!J^G1R6LN]&2V<!@1CYL#K5JY\87=A>7$%Q90&-+=6
M2785_>$9VD'I3SXAU:&:]>:&Q:"VMXY]J(=QW=J+.P6U)-/U'38-9?4;G6+9
MF*%=L,+KN]VXYJF\UA<S7IN]:M6AN)UE"I"^1M['BKZ>*Y+V_-E962)(Y18S
M/&5P2,DD>E6;+79WU:/3;FVM_.5W21D'!P,@BBPKV1D:2NA:9>PW)UM96CD<
MC=&V=IZ+T[5N1:YX<M!</9WD<<TV69F60@MZ]*I)XDO&N82]K;16SAAYCJ<.
MP)X![&KGAC5Y]5TZ:]OHH8XUR1MB*X SW/7I1N@LDSG(FMDMUSK]J+@-)\RP
M/C:_7C'6NHL?$6@V-C!:IJ*E8D"Y*-SC\*PV\:3OI-S<6UG:RW"7"K'&K [H
MV/!X[\5+#XIO-3OA;:=!:+NE"*TJD\;<G..^>*$G8'IN;_\ PEFA_P#003_O
MAO\ "C_A+-#_ .@@G_?#?X5F7_B)[?PW'?K%;13&?R9#(N44@X)X[5#:Z_J&
MI0+]DMK19$@,\K.#M89(^7ZXI#N;/_"6:'_T$$_[X;_"C_A+-#_Z""?]\-_A
M60OB&\O()[JSM;98;5$:99!\S$C)"U-X;URXUO4;I9+>)+>-BJ 1'/\ WUTI
MV%=&C_PEFA_]!!/^^&_PH_X2S0_^@@G_ 'PW^%:_E1_\\T_[Y%'E1_\ /-/^
M^12&9'_"6:'_ -!!/^^&_P */^$LT/\ Z""?]\-_A6OY4?\ SS3_ +Y%'E1_
M\\T_[Y% &1_PEFA_]!!/^^&_PH_X2S0_^@@G_?#?X5K^5'_SS3_OD4>5'_SS
M3_OD4 9'_"6:'_T$$_[X;_"C_A+-#_Z""?\ ?#?X5K^5'_SS3_OD4>5'_P \
MT_[Y% &1_P )9H?_ $$$_P"^&_PH_P"$LT/_ *""?]\-_A6OY4?_ #S3_OD4
M>5'_ ,\T_P"^10!D?\)9H?\ T$$_[X;_  H_X2S0_P#H()_WPW^%:_E1_P#/
M-/\ OD4>5'_SS3_OD4 9'_"6:'_T$$_[X;_"C_A+-#_Z""?]\-_A6OY4?_/-
M/^^11Y4?_/-/^^10!D?\)9H?_003_OAO\*/^$LT/_H()_P!\-_A6OY4?_/-/
M^^11Y4?_ #S3_OD4 9'_  EFA_\ 003_ +X;_"C_ (2S0_\ H()_WPW^%:_E
M1_\ /-/^^11Y4?\ SS3_ +Y% &1_PEFA_P#003_OAO\ "C_A+-#_ .@@G_?#
M?X5K^5'_ ,\T_P"^11Y4?_/-/^^10!D?\)9H?_003_OAO\*QH/$^C#QA=RF^
M78;5 #L;KGZ5V'E1_P#/-/\ OD5AV\4?_":7@V+_ ,>B=O\ :H Q?$5SH>MR
M0RKJ=NKQJR'S868;3UQQUJM97UA'I.H0C5(DN;C]TCRH[8C P.U;OB77!H\U
MM!##'OF!9G:,L%4=3@4RYU>=VN7L(K>6.VM1*Q(X9B,C]*.@];HYJ6'2Y$MI
M)-7M'FB@6)R(&R=O(VG'!JTE]:G0H[:+6+>&>24RW/F1N=^>W K0F\4LEU80
M>3#'YL"33.T991N[<=/QJU<:I>.NH7-DEK]GMW$:>8OWB!SC'OQ3=^I*MT,=
M)=-6\W_VW;B RB=HQ"_^L QQQTIUM>60TVZL[K7+=EGG\TF*%Q\I.2.E7XO$
M-Y+=(_V*W6W$RV[H1\^\C.?I4QU34)="N;Q([*&:WF=&#J2I Z8QWI?U^7_
M'N5-,\2:)#XDU8B]18BD 3Y&[*?:MO\ X2S0_P#H()_WPW^%4/#GF3ZUJ<MW
M#$LSPV[.JC@$H:Z;RH_^>:?]\BF]P1D?\)9H?_003_OAO\*/^$LT/_H()_WP
MW^%:_E1_\\T_[Y%'E1_\\T_[Y%(#(_X2S0_^@@G_ 'PW^%'_  EFA_\ 003_
M +X;_"M?RH_^>:?]\BCRH_\ GFG_ 'R* .6O-;T[4O$.B16=TLKK,Y("D<;?
M<5UE8.LHBZYH955'[]^@_P!FMZ@ HHHH **** "BBB@ HHHH **** "BBB@
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M!K_C1_9OB#_H/I_X!K_C6Q]JM_\ GO%_WV*/M5O_ ,]XO^^Q0!C_ -F^(/\
MH/I_X!K_ (T?V;X@_P"@^G_@&O\ C6Q]JM_^>\7_ 'V*/M5O_P ]XO\ OL4
M8_\ 9OB#_H/I_P" :_XT?V;X@_Z#Z?\ @&O^-;'VJW_Y[Q?]]BC[5;_\]XO^
M^Q0!C_V;X@_Z#Z?^ :_XT?V;X@_Z#Z?^ :_XUL?:K?\ Y[Q?]]BC[5;_ //>
M+_OL4 8_]F^(/^@^G_@&O^-']F^(/^@^G_@&O^-;'VJW_P">\7_?8H^U6_\
MSWB_[[% &/\ V;X@_P"@^G_@&O\ C1_9OB#_ *#Z?^ :_P"-;'VJW_Y[Q?\
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M/^@^G_@&O^-;'VJW_P">\7_?8H^U6_\ SWB_[[% &/\ V;X@_P"@^G_@&O\
MC1_9OB#_ *#Z?^ :_P"-;'VJW_Y[Q?\ ?8H^U6__ #WB_P"^Q0!RUW::G!XB
MT1KW4UNHS*X""W5,';UR*ZZN?U>:*37=#"2HQ\Y^%8'^&N@H **** "BBB@
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MB^B?] ^+\S_C1_PB^B?] ^+\S_C4/_"2_P#4$UG_ ,!/_KT?\)+_ -036?\
MP$_^O0!-_P (OHG_ $#XOS/^-'_"+Z)_T#XOS/\ C4/_  DO_4$UG_P$_P#K
MT?\ "2_]036?_ 3_ .O0!-_PB^B?] ^+\S_C1_PB^B?] ^+\S_C4/_"2_P#4
M$UG_ ,!/_KT?\)+_ -036?\ P$_^O0!-_P (OHG_ $#XOS/^-'_"+Z)_T#XO
MS/\ C4/_  DO_4$UG_P$_P#KT?\ "2_]036?_ 3_ .O0!-_PB^B?] ^+\S_C
M1_PB^B?] ^+\S_C4/_"2_P#4$UG_ ,!/_KT?\)+_ -036?\ P$_^O0!-_P (
MOHG_ $#XOS/^-'_"+Z)_T#XOS/\ C4/_  DO_4$UG_P$_P#KT?\ "2_]036?
M_ 3_ .O0!-_PB^B?] ^+\S_C1_PB^B?] ^+\S_C4/_"2_P#4$UG_ ,!/_KT?
M\)+_ -036?\ P$_^O0!-_P (OHG_ $#XOS/^-'_"+Z)_T#XOS/\ C4/_  DO
M_4$UG_P$_P#KT?\ "2_]036?_ 3_ .O0!-_PB^B?] ^+\S_C1_PB^B?] ^+\
MS_C4/_"2_P#4$UG_ ,!/_KT?\)+_ -036?\ P$_^O0!-_P (OHG_ $#XOS/^
M-'_"+Z)_T#XOS/\ C4/_  DO_4$UG_P$_P#KT?\ "2_]036?_ 3_ .O0!-_P
MB^B?] ^+\S_C1_PB^B?] ^+\S_C4/_"2_P#4$UG_ ,!/_KT?\)+_ -036?\
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M3?\ /CI__?UJ/M'B;_GQT_\ [^M0!NT5A?:/$W_/CI__ ']:C[1XF_Y\=/\
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M7?F>3MNCN78>_'>A*XWH>AT5A?\ ",1_]!;5O_ K_P"M1_PC$?\ T%M6_P#
MK_ZU &[16%_PC$?_ $%M6_\  K_ZU'_",1_]!;5O_ K_ .M0!NT5A?\ ",1_
M]!;5O_ K_P"M1_PC$?\ T%M6_P# K_ZU &[16%_PC$?_ $%M6_\  K_ZU'_"
M,1_]!;5O_ K_ .M0!NT5A?\ ",1_]!;5O_ K_P"M1_PC$?\ T%M6_P# K_ZU
M &[16%_PC$?_ $%M6_\  K_ZU'_",1_]!;5O_ K_ .M0!NT5A?\ ",1_]!;5
MO_ K_P"M1_PC$?\ T%M6_P# K_ZU &[16%_PC$?_ $%M6_\  K_ZU'_",1_]
M!;5O_ K_ .M0!NT5A?\ ",1_]!;5O_ K_P"M1_PC$?\ T%M6_P# K_ZU &[1
M6%_PC$?_ $%M6_\  K_ZU'_",1_]!;5O_ K_ .M0!NT5A?\ ",1_]!;5O_ K
M_P"M1_PC$?\ T%M6_P# K_ZU &[16%_PC$?_ $%M6_\  K_ZU'_",1_]!;5O
M_ K_ .M0!NT5A?\ ",1_]!;5O_ K_P"M1_PC$?\ T%M6_P# K_ZU &[16%_P
MC$?_ $%M6_\  K_ZU'_",1_]!;5O_ K_ .M0!NT5A?\ ",1_]!;5O_ K_P"M
M1_PC$?\ T%M6_P# K_ZU &[16%_PC$?_ $%M6_\  K_ZU'_",1_]!;5O_ K_
M .M0!NT5A?\ ",1_]!;5O_ K_P"M1_PC$?\ T%M6_P# K_ZU &[6%;_\CK>?
M]>:?^A4?\(Q'_P!!;5O_  *_^M6-!X=0^+[N/^U-4XM4.[[3SU]<4 :'BGP[
M-K,]M- $9HE9,.Y7;G^(8[BH+/2]2.E:D2@>\F7[/&9CC**,9_'K6;XEB.CS
M6T$.J:MOE!9G,Y8*HZG %,N+6XD:YDT_5M1ECMK42L3='#,1D=O2A;#UNB:;
MPIJ3FSN76(3PVZQ,4D;*%3G*^N?>KR:9K']@[((XC<74QDNA,V#@]ORK FG=
M;JPA.J:I&)($FFD,Y91N[<#BK5Q8WLBZA=66L7XM[=Q&GF7)^8@<XX]>*;OU
M)5NAJ1>'=1CNL*+=;4SK<X!.58#&T>WO4UKI&KMI5Y9W @B-Q<%]T;$_(3R/
MK7/1+?2W2/\ ;]06W$RV[H;H[]Y&<].E3&QU&70KJ\76+R&:WF=&#7)92!T
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M[!TC_H&6G_?E:/[!TC_H&6G_ 'Y6@"7^UM-_Z"%I_P!_E_QH_M;3?^@A:?\
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M[!TC_H&6G_?E:/[!TC_H&6G_ 'Y6@"7^UM-_Z"%I_P!_E_QH_M;3?^@A:?\
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MH_M^[_Z .H?]\C_&MVB@#"_M^[_Z .H?]\C_ !H_M^[_ .@#J'_?(_QK=HH
MPO[?N_\ H ZA_P!\C_&C^W[O_H ZA_WR/\:W:* ,+^W[O_H ZA_WR/\ &C^W
M[O\ Z .H?]\C_&MVB@#"_M^[_P"@#J'_ 'R/\:/[?N_^@#J'_?(_QK=HH PO
M[?N_^@#J'_?(_P :/[?N_P#H ZA_WR/\:W:* ,+^W[O_ * .H?\ ?(_QH_M^
M[_Z .H?]\C_&MVB@#"_M^[_Z .H?]\C_ !H_M^[_ .@#J'_?(_QK=HH PO[?
MN_\ H ZA_P!\C_&C^W[O_H ZA_WR/\:W:* ,+^W[O_H ZA_WR/\ &C^W[O\
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M +-,9#+.1&'$A)Z'--VZ$JYB1ZSKDMU&J:I(;=F$;3?8X_E<C.W&<_C4AO\
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M"@]0..*26X\'2S/-O=)7C6,ND<BG:.G:GH&MRWI/A[3;[3(;C[1<3%ARZS,
M3].U7?\ A$]-_OW7_@0U06?B3P[86J6UO<,L:=!Y+_X5/_PF&B?\_;?]^7_P
MH8T'_")Z;_?NO_ AJ/\ A$]-_OW7_@0U'_"8:)_S]M_WY?\ PH_X3#1/^?MO
M^_+_ .%( _X1/3?[]U_X$-1_PB>F_P!^Z_\  AJ/^$PT3_G[;_OR_P#A1_PF
M&B?\_;?]^7_PH /^$3TW^_=?^!#4?\(GIO\ ?NO_  (:C_A,-$_Y^V_[\O\
MX4?\)AHG_/VW_?E_\* #_A$]-_OW7_@0U'_")Z;_ '[K_P "&H_X3#1/^?MO
M^_+_ .%'_"8:)_S]M_WY?_"@ _X1/3?[]U_X$-1_PB>F_P!^Z_\  AJ/^$PT
M3_G[;_OR_P#A1_PF&B?\_;?]^7_PH /^$3TW^_=?^!#4?\(GIO\ ?NO_  (:
MC_A,-$_Y^V_[\O\ X4?\)AHG_/VW_?E_\* #_A$]-_OW7_@0U'_")Z;_ '[K
M_P "&H_X3#1/^?MO^_+_ .%'_"8:)_S]M_WY?_"@ _X1/3?[]U_X$-1_PB>F
M_P!^Z_\  AJ/^$PT3_G[;_OR_P#A1_PF&B?\_;?]^7_PH /^$3TW^_=?^!#4
M?\(GIO\ ?NO_  (:C_A,-$_Y^V_[\O\ X4?\)AHG_/VW_?E_\* #_A$]-_OW
M7_@0U'_")Z;_ '[K_P "&H_X3#1/^?MO^_+_ .%'_"8:)_S]M_WY?_"@ _X1
M/3?[]U_X$-1_PB>F_P!^Z_\  AJ/^$PT3_G[;_OR_P#A1_PF&B?\_;?]^7_P
MH /^$3TW^_=?^!#4?\(GIO\ ?NO_  (:C_A,-$_Y^V_[\O\ X4?\)AHG_/VW
M_?E_\* #_A$]-_OW7_@0U8T'AC3SXONXMUSM%JA'[]L]:V?^$PT3_G[;_OR_
M^%8T'BK1QXONY3=-L-JB@^4_7/TH I^*+&UTJ>VM[<WP,@9WD1FD*JO7C-,G
MTR*Y^U3:=<3&.VM!(6>9L,Y&>GTK8U/6O"NI",WMRWR'Y3Y;K^'3I52+4O"L
M5C<6$NH.RW+%V C=3M]!QT HZ#TN8TX@6ZL(F>]CC:W2:>5"SCYN,'GY1[U;
MGT<7$>H7EG>31012>7$'E9MY YQSW-7&N/!JPP(+F0&)-D199#QVSQS2&^\(
MOIT&GW&H2-]G;?E5=3N/<\4W8E7,R*SDDNU=GD2)9UMG@,S9W$9W9S^E3G1W
MDT"ZNC?2V]Q;S.F59F# =!@FM(7W@\7BS_:'\X#C*R<\8W8QU]Z2WU#P=96\
MD2W<ABDE\UA()""P^HI#*OAWPU!+JVH+>O<&810%BLS#DJ:Z/_A$]-_OW7_@
M0U8NG>*]%'B;5Y?M1\MT@VD1/SA3[5M?\)AHG_/VW_?E_P#"A[@@_P"$3TW^
M_=?^!#4?\(GIO]^Z_P# AJ/^$PT3_G[;_OR_^%'_  F&B?\ /VW_ 'Y?_"@
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M0%SM**XL>/9?.MXCH<RR7#NB*UPG5>N?2E'CN<RV<?\ 8,X:\SY.9UYQZ^E
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M8D4F0-@G&.M5KL+FT.YM]2TBVMHH(]2M-D:!%S<+T ^M2_VSI?\ T$K/_O\
MK_C3?[#TG_H&6?\ WX7_  H_L/2?^@99_P#?A?\ "I&._MG2_P#H)6?_ '_7
M_&C^V=+_ .@E9_\ ?]?\:;_8>D_] RS_ ._"_P"%']AZ3_T#+/\ [\+_ (4
M._MG2_\ H)6?_?\ 7_&C^V=+_P"@E9_]_P!?\:;_ &'I/_0,L_\ OPO^%']A
MZ3_T#+/_ +\+_A0 [^V=+_Z"5G_W_7_&C^V=+_Z"5G_W_7_&F_V'I/\ T#+/
M_OPO^%']AZ3_ - RS_[\+_A0 [^V=+_Z"5G_ -_U_P :/[9TO_H)6?\ W_7_
M !IO]AZ3_P! RS_[\+_A1_8>D_\ 0,L_^_"_X4 ._MG2_P#H)6?_ '_7_&C^
MV=+_ .@E9_\ ?]?\:;_8>D_] RS_ ._"_P"%']AZ3_T#+/\ [\+_ (4 ._MG
M2_\ H)6?_?\ 7_&C^V=+_P"@E9_]_P!?\:;_ &'I/_0,L_\ OPO^%']AZ3_T
M#+/_ +\+_A0 [^V=+_Z"5G_W_7_&C^V=+_Z"5G_W_7_&F_V'I/\ T#+/_OPO
M^%']AZ3_ - RS_[\+_A0 [^V=+_Z"5G_ -_U_P :/[9TO_H)6?\ W_7_ !IO
M]AZ3_P! RS_[\+_A1_8>D_\ 0,L_^_"_X4 ._MG2_P#H)6?_ '_7_&C^V=+_
M .@E9_\ ?]?\:;_8>D_] RS_ ._"_P"%']AZ3_T#+/\ [\+_ (4 ._MG2_\
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M - RS_[\+_A0 [^V=+_Z"5G_ -_U_P :/[9TO_H)6?\ W_7_ !IO]AZ3_P!
MRS_[\+_A1_8>D_\ 0,L_^_"_X4 ._MG2_P#H)6?_ '_7_&C^V=+_ .@E9_\
M?]?\:;_8>D_] RS_ ._"_P"%']AZ3_T#+/\ [\+_ (4 ._MG2_\ H)6?_?\
M7_&C^V=+_P"@E9_]_P!?\:;_ &'I/_0,L_\ OPO^%']AZ3_T#+/_ +\+_A0
M[^V=+_Z"5G_W_7_&C^V=+_Z"5G_W_7_&F_V'I/\ T#+/_OPO^%']AZ3_ - R
MS_[\+_A0 [^V=+_Z"5G_ -_U_P :PX-6TW_A,KQ_[0M-IM$ /G+CK]:VO[#T
MG_H&6?\ WX7_  K$@T;3#XRNT.G6FT6B$+Y*XZ_2@";68M'U=XW.LVT,B*4+
M+,ARIZCDU4M+33X=*O;3^V[2%[EMOF),C%8P, <GTKH/[#TG_H&6?_?A?\*/
M[#TG_H&6?_?A?\* N<R^CZ2880?$$#O'"(FS+&/- Y4'GC\*D%C8-HMO9_\
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M  &:MVBD!A?\)59?\^U]_P" S4?\)59?\^U]_P" S5NT4 87_"567_/M??\
M@,U'_"567_/M??\ @,U;M% &%_PE5E_S[7W_ (#-1_PE5E_S[7W_ (#-6[10
M!A?\)59?\^U]_P" S4?\)59?\^U]_P" S5NT4 87_"567_/M??\ @,U'_"56
M7_/M??\ @,U;M% &%_PE5E_S[7W_ (#-1_PE5E_S[7W_ (#-6[10!A?\)59?
M\^U]_P" S4?\)59?\^U]_P" S5NT4 87_"567_/M??\ @,U'_"567_/M??\
M@,U;M% &%_PE5E_S[7W_ (#-1_PE5E_S[7W_ (#-6[10!A?\)59?\^U]_P"
MS4?\)59?\^U]_P" S5NT4 87_"567_/M??\ @,U'_"567_/M??\ @,U;M% &
M%_PE5E_S[7W_ (#-1_PE5E_S[7W_ (#-6[10!A?\)59?\^U]_P" S4?\)59?
M\^U]_P" S5NT4 87_"567_/M??\ @,U'_"567_/M??\ @,U;M% &%_PE5E_S
M[7W_ (#-1_PE5E_S[7W_ (#-6[10!A?\)59?\^U]_P" S4?\)59?\^U]_P"
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M^?:^_P# 9J/^$JLO^?:^_P# 9JW:* ,+_A*K+_GVOO\ P&:C_A*K+_GVOO\
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M_*2MVB@#"QXJ_O:/^4E&/%7][1_RDK=HH PL>*O[VC_E)1CQ5_>T?\I*W:*
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M0S(T&Z\1W^M:E=1#34:6.!F619!@;3BNAQXJ_O:/^4E-TF-8O%&LQH,*L=N
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M2'1_^@E;?]_!2 J_\(EI?I<?]_V_QH_X1+2_2X_[_M_C5K_A(='_ .@E;?\
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M7'_?]O\ &C_A$M+]+C_O^W^-6O\ A(='_P"@E;?]_!1_PD.C_P#02MO^_@H
MQ+K0[+3?$6B2VXEW-*X.^4M_#[UUU<OJ&J6%[X@T..UNXIG$SDA&R<;:ZB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH X'6[6&XU37S(\$;!K;#2CJ-
MA^7/;-02O8"?198DCC:2*4>1(JG.%X/3GFKM]JS:7XCUYY--2ZMB+?>SRJH!
MV' P0<U8_P"$A9[BV4^'H#-*NZ#-S'G:/3CBA#.<@CM/LEZXD14:R\R9RJ_)
M-NZ#CCCM6MKEE#>^%='%E#;-)//"K/M # ]<D#-2_P#"70M#<_\ $AMVCC;]
M\/M"'GZ8YJ>?Q7)8Z9#=R:%''9LP$3"Y3&3TP .M.X)Z_><Z]H-,\0AYK)$@
M@D57F&&CQMR4VD9Y]:JR/+<Z1J<)LYK:6ZVS6\DMN%*@MC"GTKJ(_&?VN\6S
M718WGDP1&URG/IU'6I)O%[1VMQ<3:-"(;1O+E8W<>(SZ'BA>8GY'*7D\UY/;
MRK;K$MM'+;R*(@-\BKR>E1S?:+-Y)3$'AN)X(U_=#Y&P/;H:["Y\5/:R11W&
MAPHTR&6,&[C^9<<GI3%\7^9YBKHT#>4R!Q]KC^4M]WM3O_7S)DKF9HWV$ZU:
MBYL1)>3NZRX*@1X/ *8Z8[TBV+V^MZIJ?V&,6MK*^XMM(<8X4)CCGO6M#XH>
M756MXM B:]'!VW*9_P"^L?UIT?BV6?4)=.31$:Y4_/%]J3K^6":DMG'CS9;$
MV<NE7#323K,L<D:Q.RL.0#Z UK6VAV=W/X>EFCR\H82A1@?+T!XZBM67QIY=
ML;R31XS$DAB\P72'##MP*C?QW'#/;Q'1T$DPW0@7"G=GTP*:):*NKZ-+<>*K
MD65G&J00HWFY4*@P<C;CDFJFH7EI-X<L;&R@%Q?RY,GV6%7D4+SR*W9_&,MK
MJ'V.?1E2Z902INDR1VR<4IU][&T_M'_A'8(86X\X7,8SGWQ4K8?4Y/4IY#YV
MJ06X6%;-$EA\D?*QXW8QU!K9\.V]FFN(DR0W3W$6X%5'[O '#+CCV-:4GBIX
M9Y+:30X5D6+SG0W<?W/7ITHLO%$ES?/%9Z#$UR%!;9<H#CZXJD#V+GABRMI]
M+D:>T@=A/(,M$O3/':MK^S+#_GQMO^_2_P"%<_:^*+RXF^SVNAJTF"VQ+M.@
M.">GK5W^UM<_Z%QO_ Q*&-[FG_9EA_SXVW_?I?\ "C^S+#_GQMO^_2_X5F?V
MMKG_ $+C?^!B4?VMKG_0N-_X&)2$:?\ 9EA_SXVW_?I?\*/[,L/^?&V_[]+_
M (5F?VMKG_0N-_X&)1_:VN?]"XW_ (&)0!I_V98?\^-M_P!^E_PH_LRP_P"?
M&V_[]+_A69_:VN?]"XW_ (&)1_:VN?\ 0N-_X&)0!I_V98?\^-M_WZ7_  H_
MLRP_Y\;;_OTO^%9G]K:Y_P!"XW_@8E']K:Y_T+C?^!B4 :?]F6'_ #XVW_?I
M?\*/[,L/^?&V_P"_2_X5F?VMKG_0N-_X&)1_:VN?]"XW_@8E &G_ &98?\^-
MM_WZ7_"C^S+#_GQMO^_2_P"%9G]K:Y_T+C?^!B4?VMKG_0N-_P"!B4 :?]F6
M'_/C;?\ ?I?\*/[,L/\ GQMO^_2_X5F?VMKG_0N-_P"!B4?VMKG_ $+C?^!B
M4 :?]F6'_/C;?]^E_P */[,L/^?&V_[]+_A69_:VN?\ 0N-_X&)1_:VN?]"X
MW_@8E &G_9EA_P ^-M_WZ7_"C^S+#_GQMO\ OTO^%9G]K:Y_T+C?^!B4?VMK
MG_0N-_X&)0!I_P!F6'_/C;?]^E_PH_LRP_Y\;;_OTO\ A69_:VN?]"XW_@8E
M']K:Y_T+C?\ @8E &G_9EA_SXVW_ 'Z7_"C^S+#_ )\;;_OTO^%9G]K:Y_T+
MC?\ @8E']K:Y_P!"XW_@8E &G_9EA_SXVW_?I?\ "C^S+#_GQMO^_2_X5F?V
MMKG_ $+C?^!B4?VMKG_0N-_X&)0!I_V98?\ /C;?]^E_PH_LRP_Y\;;_ +]+
M_A69_:VN?]"XW_@8E']K:Y_T+C?^!B4 :?\ 9EA_SXVW_?I?\*/[,L/^?&V_
M[]+_ (5F?VMKG_0N-_X&)1_:VN?]"XW_ (&)0!I_V98?\^-M_P!^E_PH_LRP
M_P"?&V_[]+_A69_:VN?]"XW_ (&)1_:VN?\ 0N-_X&)0!I_V98?\^-M_WZ7_
M  K#M]/LO^$SO%^QV^T6B''E+CK]*L_VMKG_ $+C?^!B5C0:GK'_  E]VPT!
MBYM4!3[4G SUS0!%XUA2WGLXXK.T6W*L[[EV;R.B@@=:AF@LM0M-0OVABM(K
M:U$:'8H(<KD\XZ]JUM2\17=G&C:AX?4*6^0/<HW/L,54?76TZ-[>7PXJQ2 W
M#^9=(5P>YR*%L/JC"FFB:XTM_L]I-;K:QN%QM:1\X.,#DCWJ_=V^E7%A=ZE<
MI% ;F;R[50JKPO _7FM";Q%L2VC?P]"!.O[@+<)T/<8'%13>(UT^,V5SX<01
M6V.)+A&"YZ=NM-DHRX8+?^TT\QHC=I.L0547:T6WEL8Z>]3QVFE7GAJ]!"7$
ML5TR1,F-V2>.@K3'BD?;H[8:%!]H9/D N8_N^F<?I49\6QV=D;I= A2W,A4O
M'.F-P^@I>H_0G\.:-:VNL:E;2VT,C1PVX)>,'G8<]JZ;^S+#_GQMO^_2_P"%
M<=HVNZE>:]JEW:Z(94EC@(Q=(,#:<=JWO[6US_H7&_\  Q*;W!&G_9EA_P ^
M-M_WZ7_"C^S+#_GQMO\ OTO^%9G]K:Y_T+C?^!B4?VMKG_0N-_X&)2 T_P"S
M+#_GQMO^_2_X4?V98?\ /C;?]^E_PK,_M;7/^A<;_P #$H_M;7/^A<;_ ,#$
MH AU6TMK?7M#:&WAC8S."40 _=]JZ.N1NKW4;GQ%HBW>E&T02N0YG5\G;TP*
MZZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XV]M)+S6/$$<5K]H<-;
M,JB380=AY!IL^FZU)+I0>Q61XDD6:<2*,;A@<=\4ES<7=IXFUVXBU"VL[=1;
MAS-&6R=AZ5<%WJK2P1C7=/WSJ6C7R>6 [T(9FPZ7KEHIFCTV-Y8K86J)YH^?
MYLE_;BM&]T&:_P!!TRS6%[?R;E))5$HW*!G)!'>H/[9O/+GD_P"$BT_; <2$
M6YX_Q_"I;C4-2M-/COY]>L%M9" DGV<D,3T Q3OU!;E.[\-:I%JDEY:N9HTE
M5HX)''S87 ;/J#5+_A#]9^PW-M.\%PEXBF50-N&#9/UXK5@U>]N+Q+2+Q!8-
M<.,JGV9@3^=/DU+4(;>XN)/$.FK#;-LF<P\(?0TEH)ZF-)X0UB9EDF$;O#YD
M,7S](]N%I+GP9JA(FMTC65YHA*-_WD4#)^H(K<N+[4[62*.?7].1I4,D8,/W
ME')(IJZG?N9 OB'328BJN/)^Z6Z?G3NQ-)[D>EZ7KECJ-I;[0ME"SF1]P(D!
M.0<=0:<_AN]%QJ5\LC-<-(SVD>X!5)&-U21W^IS7YL8]=L&N1U06Y_GTI(M0
MU*;47T^/7K!KJ/AH_LYR/Z4MRKF1'X/UR +;K=QB-F20RQ@*48#!X[YK:L=$
MO8#H@>-1]C+B4ANN>_XU#+JU[#:-=/XAT[R%D,1<0$X8=1Q44FO7,4T,+^(K
M 23@&("V8[P?3 IDM%R_\-2ZCKMY=32L+9HD"1J1AV /6LJ71M?U/3[/26M8
M[*"#<9)G<2!_3"BM"?4M1MKY;*;7[!+AEW!#;GI_*II;C5X+(7LNN:>EL<8D
M,/%2MAWU,&^\):S=VLLVV+[>END4;;N' X(/L16QHFDZC8ZM&1:K;VPC/G'S
M PD;& 0.H/K3I+[4HKAX)-?TY94B\YD,/(3^]]*+:^U.\NFMK?7K"295W%5@
M/2J0":!H5]8:W]IG11%Y4BY#9Y+Y'Z5UE<F=1U$$Y\0:=P,G]R?7'\^*O_9?
M$A&?[3L_^_%#;>XY-MW9NT5A?9/$G_03L_\ OQ1]D\2?]!.S_P"_%(1NT5A?
M9/$G_03L_P#OQ1]D\2?]!.S_ ._% &[16%]D\2?]!.S_ ._%'V3Q)_T$[/\
M[\4 ;M%87V3Q)_T$[/\ [\4?9/$G_03L_P#OQ0!NT5A?9/$G_03L_P#OQ1]D
M\2?]!.S_ ._% &[16%]D\2?]!.S_ ._%'V3Q)_T$[/\ [\4 ;M%87V3Q)_T$
M[/\ [\4?9/$G_03L_P#OQ0!NT5A?9/$G_03L_P#OQ1]D\2?]!.S_ ._% &[1
M6%]D\2?]!.S_ ._%'V3Q)_T$[/\ [\4 ;M%87V3Q)_T$[/\ [\4?9/$G_03L
M_P#OQ0!NT5A?9/$G_03L_P#OQ1]D\2?]!.S_ ._% &[16%]D\2?]!.S_ ._%
M'V3Q)_T$[/\ [\4 ;M%87V3Q)_T$[/\ [\4?9/$G_03L_P#OQ0!NT5A?9/$G
M_03L_P#OQ1]D\2?]!.S_ ._% &[16%]D\2?]!.S_ ._%'V3Q)_T$[/\ [\4
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M@CP%CBMU'_?!KH<CUK@?#WAW2;[5]1DGTWRB8H&$?G/\N5/?-='_ ,(?H/\
MSX?^17_^*IO<%L;>1ZT9'K6)_P (?H/_ #X?^17_ /BJ/^$/T'_GP_\ (K__
M !5(#;R/6C(]:Q/^$/T'_GP_\BO_ /%4?\(?H/\ SX?^17_^*H 36O\ D.:%
M_P!=W_\ 0:W:Y&[T+3=,\1:)+9VWE.TK@G>QXV^YKKJ "BBB@ HHHH ****
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MLT/_ *""?]\-_A1_PEFA_P#003_OAO\ "M;R8O\ GDG_ 'R*/)B_YY)_WR*
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M\D4_QH_LO7O^AD_\D4_QK=HH PO[+U[_ *&3_P D4_QH_LO7O^AD_P#)%/\
M&MVB@#"_LO7O^AD_\D4_QH_LO7O^AD_\D4_QK=HH PO[+U[_ *&3_P D4_QH
M_LO7O^AD_P#)%/\ &MVB@#"_LO7O^AD_\D4_QH_LO7O^AD_\D4_QK=HH PO[
M+U[_ *&3_P D4_QH_LO7O^AD_P#)%/\ &MVB@#"_LO7O^AD_\D4_QH_LO7O^
MAD_\D4_QK=HH PO[+U[_ *&3_P D4_QH_LO7O^AD_P#)%/\ &MVB@#"_LO7O
M^AD_\D4_QH_LO7O^AD_\D4_QK=HH PO[+U[_ *&3_P D4_QH_LO7O^AD_P#)
M%/\ &MVB@#"_LO7O^AD_\D4_QH_LO7O^AD_\D4_QK=HH PO[+U[_ *&3_P D
M4_QH_LO7O^AD_P#)%/\ &MVB@#"_LO7O^AD_\D4_QK&@TW6_^$ONU&OXD%JA
M+_8TY&>F,UVU85O_ ,CK>?\ 7FG_ *%0!2U&/4;%(S>>)!\S81?[/1B3["JD
MD%QI8>!_$2I&RFXDSIZ$8/<\U=\5Z%=ZI<VMQ:IYC1*R[?-\O:3T;/?'I5:U
ML-0FTO4Y7M_M-Y(GV:-9&"Y"C&[)]3S1T'U0V47 6VC/B1&^T+F)4TU#\I[\
M=!44PFTY7LY/$($=L "/[-1@N>:@E\.ZN7LKLVXBEBMEB8K<?ZHJ<YX^]FKR
M6>K'06:"S6>XO9B]P&D",JGL,^U-DJXP3S?;8[<>*8_-9?E(TZ/&,9QG^E-:
MXFM[%KQ/$@-N'*EH],0_,.O2G0Z!J45T(UM(EM3.MSGS067 QL_^O5BST[6&
MT>]LY+2.U:>X+ B8-\A//3O2&9^B0:K?Z[JD]MXBRKQP-YGV)/F!4XXSQ6__
M &7KW_0R?^2*?XU'HT*6_B75X8QA4CMU'_?!KH:'Y 87]EZ]_P!#)_Y(I_C1
M_9>O?]#)_P"2*?XUNT4 87]EZ]_T,G_DBG^-']EZ]_T,G_DBG^-;M% '(W5G
MJ=OXBT1KS5OM:&5P$^S+'@[>N1775A:U_P AS0O^N[_^@UNT %%%% !1110
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M=Z5%,MGX;9$ED,C_ .F(1N/6KG]MZMG']@-G_K[2D!J?V7I__/A:_P#?E?\
M"C^R]/\ ^?"U_P"_*_X5F?VSK&<?\(\^3V^UI2_VQK'_ $+S_P#@6E &E_9>
MG_\ /A:_]^5_PH_LO3_^?"U_[\K_ (5F_P!L:P 2?#S\=?\ 2TI/[:U?&?\
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MK7_0NR?^!24?VOK7_0NR?^!24 :7]EZ?_P ^%K_WY7_"C^R]/_Y\+7_ORO\
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M?7I4CD[E'P>B+H.H8E#W123>H1U=3SC)/7\*RO[!U2/2;%_(5_/<'[-YC[>
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M$)PPVG&*WOLWB7_H(V7_ 'X--[Z@C=HK"^S>)?\ H(V7_?@T?9O$O_01LO\
MOP:0&[16%]F\2_\ 01LO^_!H^S>)?^@C9?\ ?@T &M?\AS0O^N[_ /H-;M<C
M=PZO'XBT0W]U;RQ^:^!'&5.=M==0 4444 %%%% !1110 4444 %%%% !1110
M 4444 <3J6F3:MJ^NVT)<$RVC$HVT@!3G!J:\\)37NI7 >YF^QFW1%#$$R,/
M4]:HZN8;77M=OI[J_B5#;($M9Q&&)0]<TC7%M'<1QR7FNA2JL\@O RINZ=!S
M0@ZD/_"/ZQ]IL[K["!]@54,6\?O\,3G_ /75ZUT[4HI+.UGTMFMQ-]H>1''#
M9R ?84QFLQ#.XU#7B\4_V=8_M.&=O;BGVPL[JXLH5U+70UT6 )N>%*]0>.M5
M=L&7KO0+BYU_4;[?,JO;JD2I)A7.#]X5E0^&-5CO(9V^:%'0F#(Y(7&[/MZ5
M)>FUL]8?3CJ&M.\:"1V^V@8&.P(R:B2YLWO(X?MVO"-RJB8W7RAB,@=*D;OU
M-'PUI=[9Z)=V4]O<I*R.%,LH923G&T=AS5$^#K];&Q:.[87P($DI4?( .!CO
M4FDBVU:TN+J/4-:2*$,<F]!)QGL!QTJBNH6S1IBX\0&=R-D/VH9(/?I0]P>_
MWEVVTC4]/A9!IPG\^U\@_./D//)]CG-23>'+Y5N$1 ^=-6!6#8)<'I5=I;1H
M4DMK[7K@&/S9 ES_ *M??BJ[WT"W$L8G\0&..#S_ #?M8P4['I3?6X1TV_K8
MT+;3M0MDTZZ%A<S-;!D:"XF#,<CJ#TQ5JXTB]N+^_N!;+&L]BL2*".&SG%9L
M4D$MK!)'=ZX\TY/EPI>AB0.IR!BHA<(+Z:VD?Q%'Y,7FNS78P%_*AB+2Z+J4
M5K<Z;]B$BW4HE^T[A\@XX]>,52TSPCJ>GZEI<J1KY(G:6Z7=T(SAA]15EY+0
M.2E]KSVZ,%EG6Z^5&/8\5'I][I>I-&L.JZX&>Y-OM:YP01WZ=#33=] >VI;U
M'PM=7=W?7*R3AI+M)$B$N$91C)(J.7PW=VMIJ3P6QED>[5X8]_\ RS!S@>G>
MM&^TFWL'MEDU;62;B41+BZZ$_A63<S6MMJ%U:_;M;?[+_K'%Z./PQFDG96_K
MH#5UJ)?>&]8U"]CO(0+,O)([)PVT%, 'ZTP>'=?EN8[[9#$;<K''"3EBF,-@
M^AIVHW=A8RI&NI:W,7V $7@4989 R16II^G0:@9E75-91H<;P;O/49ZXH"]S
M..B:M-9QVK6>W['!*BMO'[TMTQZ4^YTC5-26&9K$PF&W1#%(X.\J0<?C2))9
MO/-']OU_:BLR/]ISYNWKCBG?Z-+;6SVU[KT\UPGF+"MU\P7.,GBB[W_KJ)I-
MW-C4;>\U70)8UL!;3-(A$989P"#DD5S,GA'5(KV.:WB7RY;B22==WL=K5TT'
MAY9H$D_M764W#.UKKD?I5&XL[6V>]1M5UHFTB\U\774>W%)A97N1VV@WFD6V
MF3Q137LD /F022@X)_NYK/G\*:O,_G1D0^89)'A&"/F(.SVZ=:FT^:SO3%OU
M'6H%EC,B,;T," ,GD#K5>#4+*XGEC2]UP"*/S'+7H!QC/3&33U3#="+X3U47
M5V8X5C@OIG-RN[JN!M_PJ0>&]>,MM,@@C6Q2-88VY9L'+8/:K=ZMK9Q6[C4-
M=E\Z/S=J77*)ZGBG:>EGJ>H/:VNJZPZI]Z3[8,9],8S1K<;=]22XT*_G&HXB
M"FXO$E7G^$#DU ^BZE<V=OIS6(B%JS/YX88DSG 'US59KNRCN)HY;[7D2-VC
M60W7#E>N./>M"_M[+3Y[&&75M:+7;84BZX7W/%)+06B9!X=\-:AI'B"V<QJ+
M!+4XPWW'/5<>E=Q7G_V[2Q->1'5==#VLXA8&YZY[CCD5HZ-8PZS \T6HZW'&
M&PI>Z^][]*>X))'7T5A?\(RG_08U?_P*_P#K4?\ ",I_T&-7_P# K_ZU(9NT
M5A?\(RG_ $&-7_\  K_ZU'_",I_T&-7_ / K_P"M0!NT5A?\(RG_ $&-7_\
M K_ZU'_",I_T&-7_ / K_P"M0!NT5A?\(RG_ $&-7_\  K_ZU'_",I_T&-7_
M / K_P"M0!NT5A?\(RG_ $&-7_\  K_ZU'_",I_T&-7_ / K_P"M0!NT5A?\
M(RG_ $&-7_\  K_ZU'_",I_T&-7_ / K_P"M0!NT5A?\(RG_ $&-7_\  K_Z
MU'_",I_T&-7_ / K_P"M0!NT5A?\(RG_ $&-7_\  K_ZU'_",I_T&-7_ / K
M_P"M0!NT5A?\(RG_ $&-7_\  K_ZU'_",I_T&-7_ / K_P"M0!NUA6__ ".M
MY_UYI_Z%1_PC*?\ 08U?_P "O_K5C0>'5/B^[C_M75>+5#N^T\GGUQ0!<\6:
M3?WUU:7-EYQ,2LH$4@4JQZ'GM56"UO;O3-4N9K4W5T\?V6-" ,[1@D9]Z?J]
MK:Z0T,<FK:P\LQPB"\"Y_$BH[R""RE=/[0UMQ%!Y\FRZR5'8=*.EAWU12?1]
M962QO$AG@>.U2)@LHQ&5/.X=P15Y8=1;0GGCL#<W%_,6EY 9$Z#&?:HF-EY]
MG!'J>LO)=1B0+]L *J?7(I;J*.WENUCO-<GCMB [1W70XR>W:F_,E6$AT2_B
MNA"MABW-PMP)"PRH"XV?6K5C9ZH=$OK0:>;5YK@[<L,;&/)X]JI)+8R74<::
MCKS1.0IF%S\H<C(7IUIY6-M+DOH+G7Y5BD9'3[4 5QU/(I#[&OHENEKXCU:"
M,86.*W4?]\&NBK@=!TA-0UG4IAJ.KQ!HX& :YPW*GKQ70_\ ",I_T&-7_P#
MK_ZU-[Z@C=HK"_X1E/\ H,:O_P"!7_UJ/^$93_H,:O\ ^!7_ -:D!NT5A?\
M",I_T&-7_P# K_ZU'_",I_T&-7_\"O\ ZU !K7_(<T+_ *[O_P"@UNUR-UI"
MZ?XBT207U]<9E<;;B;>!\OIBNNH **** "BBB@ HHHH **** "BBB@ HHHH
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M !H_X2"Z_P"@#J/_ 'P/\:W:* ,+_A(+K_H ZC_WP/\ &C_A(+K_ * .H_\
M? _QK=HH PO^$@NO^@#J/_? _P :/^$@NO\ H ZC_P!\#_&MVB@#"_X2"Z_Z
M .H_]\#_ !H_X2"Z_P"@#J/_ 'P/\:W:* ,+_A(+K_H ZC_WP/\ &C_A(+K_
M * .H_\ ? _QK=HH PO^$@NO^@#J/_? _P :/^$@NO\ H ZC_P!\#_&MVB@#
M"_X2"Z_Z .H_]\#_ !H_X2"Z_P"@#J/_ 'P/\:W:* ,+_A(+K_H ZC_WP/\
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M* #\M==6%K7_ "'-"_Z[O_Z#6[0 4444 %%%% !1110 4444 %%%% !1110
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MB@#"_P"*K_Z@W_D6C_BJ_P#J#?\ D6MVB@#"_P"*K_Z@W_D6C_BJ_P#J#?\
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MQV<&M2ZA-K^G3&=564%$R<#'!SQ2T'I8S=0NM&LX(9(H;Z?S8ED_X_"@7<<
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M_P">EW_X$-1_PB>G?\]+O_P(:KG]O:1_T$K7_OZ*/[>TC_H)6O\ W]% %/\
MX1/3O^>EW_X$-1_PB>G?\]+O_P "&JY_;VD?]!*U_P"_HH_M[2/^@E:_]_10
M!3_X1/3O^>EW_P"!#4?\(GIW_/2[_P# AJN?V]I'_02M?^_HH_M[2/\ H)6O
M_?T4 4_^$3T[_GI=_P#@0U'_  B>G?\ /2[_ / AJN?V]I'_ $$K7_OZ*/[>
MTC_H)6O_ ']% %/_ (1/3O\ GI=_^!#5C0>&+ ^+[N+S+K:+5"/W[9ZUTO\
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M4=2L;S7]#2VNX9G$SDJC@G[M=/0 4444 %%%% !1110 4444 %%%% !1110
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M@?:?]^5_PH_LG3?^@?:?]^5_PK._X29/^@1J_P#X"_\ UZ/^$F3_ *!&K_\
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MM?\ (<T+_KN__H-;M<Y_9>MSZOI]S>7=I)#;.S%8T*GD8KHZ "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
$B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>21
<FILENAME>pti-20170930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFS ActiveDisclosure(SM) XBRL Instance Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2017-11-14T21:33:05.9314603+00:00 -->
<!-- Version            : 2.5.0.9 -->
<!-- Package ID         : C898DE00A4E7409BAA35AC9210F2845E-0001445283-001709 -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<xbrl xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.xbrl.org/2003/instance" xmlns:pti="http://www.proteostasis.com/20170930" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="pti-20170930.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <unit id="U_shares">
    <measure>shares</measure>
  </unit>
  <unit id="U_iso4217USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="U_iso4217USD_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="U_pure">
    <measure>pure</measure>
  </unit>
  <unit id="U_utrsqft">
    <measure>utr:sqft</measure>
  </unit>
  <context id="C_0001445283_20170101_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="C_0001445283_20171109">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
    </entity>
    <period>
      <instant>2017-11-09</instant>
    </period>
  </context>
  <context id="C_0001445283_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
    </entity>
    <period>
      <instant>2017-09-30</instant>
    </period>
  </context>
  <context id="C_0001445283_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001445283_20170701_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
    </entity>
    <period>
      <startDate>2017-07-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="C_0001445283_20160701_20160930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
    </entity>
    <period>
      <startDate>2016-07-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="C_0001445283_20160101_20160930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="C_0001445283_us-gaapPlanNameAxis_ptiEmployeeStockPurchasePlanMember_20170101_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pti:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="C_0001445283_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20160101_20160930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="C_0001445283_us-gaapSubsidiarySaleOfStockAxis_ptiFollowOnPublicOfferingMember_20160101_20160930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pti:FollowOnPublicOfferingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="C_0001445283_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="C_0001445283_20160930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaapCertificatesOfDepositMember_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-09-30</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaapCertificatesOfDepositMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-09-30</instant>
    </period>
  </context>
  <context id="C_0001445283_20160201_20160229">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
    </entity>
    <period>
      <startDate>2016-02-01</startDate>
      <endDate>2016-02-29</endDate>
    </period>
  </context>
  <context id="C_0001445283_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20170101_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="C_0001445283_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-09-30</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSTreasurySecuritiesMember_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-09-30</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSTreasurySecuritiesMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-09-30</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-09-30</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-09-30</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-09-30</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-09-30</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-09-30</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-09-30</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-09-30</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-09-30</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-09-30</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001445283_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001445283_us-gaapPlanNameAxis_ptiTwoThousandSixteenStockOptionAndIncentivePlanMember_20160203">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pti:TwoThousandSixteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-02-03</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapPlanNameAxis_ptiTwoThousandSixteenStockOptionAndIncentivePlanMember_20160202_20160203">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pti:TwoThousandSixteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-02-02</startDate>
      <endDate>2016-02-03</endDate>
    </period>
  </context>
  <context id="C_0001445283_us-gaapPlanNameAxis_ptiTwoThousandSixteenStockOptionAndIncentivePlanAndTwoThousandEightPlanMember_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pti:TwoThousandSixteenStockOptionAndIncentivePlanAndTwoThousandEightPlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-09-30</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapPlanNameAxis_ptiTwoThousandSixteenStockOptionAndIncentivePlanMember_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pti:TwoThousandSixteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-09-30</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapPlanNameAxis_ptiTwoThousandSixteenEmployeeStockPurchasePlanMember_20160203">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pti:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-02-03</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapPlanNameAxis_ptiTwoThousandSixteenEmployeeStockPurchasePlanMember_20160202_20160203">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pti:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-02-02</startDate>
      <endDate>2016-02-03</endDate>
    </period>
  </context>
  <context id="C_0001445283_us-gaapPlanNameAxis_ptiTwoThousandSixteenEmployeeStockPurchasePlanMember_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pti:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-09-30</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapPlanNameAxis_ptiTwoThousandSixteenEmployeeStockPurchasePlanMember_20170101_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pti:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="C_0001445283_us-gaapPlanNameAxis_ptiTwoThousandSixteenEmployeeStockPurchasePlanMember_us-gaapRangeAxis_us-gaapMaximumMember_20170701_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pti:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-07-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="C_0001445283_us-gaapPlanNameAxis_ptiTwoThousandSixteenEmployeeStockPurchasePlanMember_us-gaapRangeAxis_us-gaapMaximumMember_20170101_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pti:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="C_0001445283_us-gaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ptiPriorToTwoThousandThirteenMember_us-gaapTitleOfIndividualAxis_ptiNonEmployeesMember_20170101_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">pti:NonEmployeesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">pti:PriorToTwoThousandThirteenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="C_0001445283_us-gaapTitleOfIndividualAxis_ptiNonEmployeesMember_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">pti:NonEmployeesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-09-30</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapTitleOfIndividualAxis_ptiNonEmployeesMember_20170101_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">pti:NonEmployeesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="C_0001445283_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20170701_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-07-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="C_0001445283_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20160701_20160930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-07-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="C_0001445283_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20170101_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="C_0001445283_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20160101_20160930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="C_0001445283_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20170701_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-07-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="C_0001445283_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20160701_20160930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-07-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="C_0001445283_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20170101_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="C_0001445283_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20160101_20160930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="C_0001445283_us-gaapTypeOfArrangementAxis_ptiAstellasCollaborationAgreementMember_20170701_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pti:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-07-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="C_0001445283_us-gaapTypeOfArrangementAxis_ptiAstellasCollaborationAgreementMember_20160701_20160930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pti:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-07-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="C_0001445283_us-gaapTypeOfArrangementAxis_ptiAstellasCollaborationAgreementMember_20170101_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pti:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="C_0001445283_us-gaapTypeOfArrangementAxis_ptiAstellasCollaborationAgreementMember_20160101_20160930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pti:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="C_0001445283_us-gaapTypeOfArrangementAxis_ptiAstellasCollaborationAgreementMember_20150101_20150131">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pti:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-01-31</endDate>
    </period>
  </context>
  <context id="C_0001445283_us-gaapTypeOfArrangementAxis_ptiAstellasCollaborationAgreementMember_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pti:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-09-30</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapTypeOfArrangementAxis_ptiAstellasCollaborationAgreementMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pti:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapTypeOfArrangementAxis_ptiBiogenLicenseAgreementsMember_20160701_20160930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pti:BiogenLicenseAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-07-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="C_0001445283_us-gaapTypeOfArrangementAxis_ptiBiogenLicenseAgreementsMember_20160101_20160930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pti:BiogenLicenseAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="C_0001445283_us-gaapTypeOfArrangementAxis_ptiBiogenLicenseAgreementsMember_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pti:BiogenLicenseAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-09-30</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapTypeOfArrangementAxis_ptiBiogenLicenseAgreementsMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pti:BiogenLicenseAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20170101_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="C_0001445283_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20160101_20160930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="C_0001445283_us-gaapStatementClassOfStockAxis_ptiWarrantsToPurchaseConvertiblePreferredStockMember_20160101_20160930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pti:WarrantsToPurchaseConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="C_0001445283_us-gaapCounterpartyNameAxis_ptiIceBoxLLCMember_20170919">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pti:IceBoxLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-09-19</instant>
    </period>
  </context>
  <context id="C_0001445283_us-gaapCounterpartyNameAxis_ptiIceBoxLLCMember_20170918_20170919">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pti:IceBoxLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-09-18</startDate>
      <endDate>2017-09-19</endDate>
    </period>
  </context>
  <context id="C_0001445283_us-gaapCounterpartyNameAxis_ptiIceBoxLLCMember_20170101_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001445283</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pti:IceBoxLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <dei:DocumentType id="F_000000" contextRef="C_0001445283_20170101_20170930">10-Q</dei:DocumentType>
  <dei:AmendmentFlag id="F_000001" contextRef="C_0001445283_20170101_20170930">false</dei:AmendmentFlag>
  <dei:DocumentPeriodEndDate id="F_000002" contextRef="C_0001445283_20170101_20170930">2017-09-30</dei:DocumentPeriodEndDate>
  <dei:DocumentFiscalYearFocus id="F_000003" contextRef="C_0001445283_20170101_20170930">2017</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus id="F_000004" contextRef="C_0001445283_20170101_20170930">Q3</dei:DocumentFiscalPeriodFocus>
  <dei:TradingSymbol id="F_000005" contextRef="C_0001445283_20170101_20170930">PTI</dei:TradingSymbol>
  <dei:EntityRegistrantName id="F_000006" contextRef="C_0001445283_20170101_20170930">PROTEOSTASIS THERAPEUTICS, INC.</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="F_000007" contextRef="C_0001445283_20170101_20170930">0001445283</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate id="F_000008" contextRef="C_0001445283_20170101_20170930">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityFilerCategory id="F_000009" contextRef="C_0001445283_20170101_20170930">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityCommonStockSharesOutstanding id="F_000010" contextRef="C_0001445283_20171109" decimals="INF" unitRef="U_shares">25216088</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000011" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">18192000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000012" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">18613000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:ShortTermInvestments id="F_000013" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">25034000</us-gaap:ShortTermInvestments>
  <us-gaap:ShortTermInvestments id="F_000014" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">66897000</us-gaap:ShortTermInvestments>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue id="F_000015" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">294000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableNetCurrent id="F_000016" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">1079000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="F_000017" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">668000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000018" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">1838000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000019" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">4059000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000020" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">46437000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000021" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">90237000</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000022" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">12582000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000023" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">541000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:OtherAssetsNoncurrent id="F_000024" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">41000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent id="F_000025" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">68000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent id="F_000026" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">1656000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent id="F_000027" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">294000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:Assets id="F_000028" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">60716000</us-gaap:Assets>
  <us-gaap:Assets id="F_000029" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">91140000</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent id="F_000030" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">2535000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="F_000031" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">2021000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="F_000032" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">5855000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="F_000033" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">4328000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:DeferredRevenueCurrent id="F_000034" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">1754000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent id="F_000035" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">2204000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRentCreditCurrent id="F_000036" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">139000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:DeferredRentCreditCurrent id="F_000037" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">201000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:OtherLiabilitiesCurrent id="F_000038" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">756000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000039" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">11039000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000040" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">8754000</us-gaap:LiabilitiesCurrent>
  <us-gaap:DeferredRevenueNoncurrent id="F_000041" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">752000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent id="F_000042" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">87000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent id="F_000043" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent id="F_000044" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">91000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent id="F_000045" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">11355000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:Liabilities id="F_000046" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">22397000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="F_000047" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">9684000</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies id="F_000048" xsi:nil="true" contextRef="C_0001445283_20170930" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsAndContingencies id="F_000049" xsi:nil="true" contextRef="C_0001445283_20161231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:PreferredStockValue id="F_000050" xsi:nil="true" contextRef="C_0001445283_20170930" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:PreferredStockValue id="F_000051" xsi:nil="true" contextRef="C_0001445283_20161231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommonStockValue id="F_000052" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">26000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue id="F_000053" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">26000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapital id="F_000054" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">241758000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital id="F_000055" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">238902000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="F_000056" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">-7000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="F_000057" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">-22000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000058" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">-203458000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000059" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">-157450000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="F_000060" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">38319000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000061" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">81456000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000062" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">60716000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000063" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">91140000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000064" contextRef="C_0001445283_20170930" decimals="INF" unitRef="U_iso4217USD_shares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000065" contextRef="C_0001445283_20161231" decimals="INF" unitRef="U_iso4217USD_shares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized id="F_000066" contextRef="C_0001445283_20170930" decimals="INF" unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized id="F_000067" contextRef="C_0001445283_20161231" decimals="INF" unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued id="F_000068" contextRef="C_0001445283_20170930" decimals="INF" unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued id="F_000069" contextRef="C_0001445283_20161231" decimals="INF" unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="F_000070" contextRef="C_0001445283_20170930" decimals="INF" unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding id="F_000071" contextRef="C_0001445283_20161231" decimals="INF" unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000072" contextRef="C_0001445283_20170930" decimals="INF" unitRef="U_iso4217USD_shares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000073" contextRef="C_0001445283_20161231" decimals="INF" unitRef="U_iso4217USD_shares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="F_000074" contextRef="C_0001445283_20170930" decimals="INF" unitRef="U_shares">125000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000075" contextRef="C_0001445283_20161231" decimals="INF" unitRef="U_shares">125000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="F_000076" contextRef="C_0001445283_20170930" decimals="INF" unitRef="U_shares">25112724</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000077" contextRef="C_0001445283_20161231" decimals="INF" unitRef="U_shares">25000734</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="F_000078" contextRef="C_0001445283_20170930" decimals="INF" unitRef="U_shares">25112724</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000079" contextRef="C_0001445283_20161231" decimals="INF" unitRef="U_shares">25000734</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:Revenues id="F_000080" contextRef="C_0001445283_20170701_20170930" decimals="-3" unitRef="U_iso4217USD">1551000</us-gaap:Revenues>
  <us-gaap:Revenues id="F_000081" contextRef="C_0001445283_20160701_20160930" decimals="-3" unitRef="U_iso4217USD">1715000</us-gaap:Revenues>
  <us-gaap:Revenues id="F_000082" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">3719000</us-gaap:Revenues>
  <us-gaap:Revenues id="F_000083" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">4324000</us-gaap:Revenues>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000084" contextRef="C_0001445283_20170701_20170930" decimals="-3" unitRef="U_iso4217USD">12894000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000085" contextRef="C_0001445283_20160701_20160930" decimals="-3" unitRef="U_iso4217USD">9218000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000086" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">41372000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000087" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">23498000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000088" contextRef="C_0001445283_20170701_20170930" decimals="-3" unitRef="U_iso4217USD">2741000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000089" contextRef="C_0001445283_20160701_20160930" decimals="-3" unitRef="U_iso4217USD">3266000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000090" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">8813000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000091" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">8682000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses id="F_000092" contextRef="C_0001445283_20170701_20170930" decimals="-3" unitRef="U_iso4217USD">15635000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000093" contextRef="C_0001445283_20160701_20160930" decimals="-3" unitRef="U_iso4217USD">12484000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000094" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">50185000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000095" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">32180000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="F_000096" contextRef="C_0001445283_20170701_20170930" decimals="-3" unitRef="U_iso4217USD">-14084000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000097" contextRef="C_0001445283_20160701_20160930" decimals="-3" unitRef="U_iso4217USD">-10769000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000098" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">-46466000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000099" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">-27856000</us-gaap:OperatingIncomeLoss>
  <us-gaap:InvestmentIncomeInterest id="F_000100" contextRef="C_0001445283_20170701_20170930" decimals="-3" unitRef="U_iso4217USD">155000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest id="F_000101" contextRef="C_0001445283_20160701_20160930" decimals="-3" unitRef="U_iso4217USD">36000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest id="F_000102" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">515000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest id="F_000103" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">56000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000104" contextRef="C_0001445283_20170701_20170930" decimals="-3" unitRef="U_iso4217USD">-25000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000105" contextRef="C_0001445283_20160701_20160930" decimals="-3" unitRef="U_iso4217USD">-38000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000106" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">-57000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000107" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">-15000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss id="F_000108" contextRef="C_0001445283_20170701_20170930" decimals="-3" unitRef="U_iso4217USD">-13954000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000109" contextRef="C_0001445283_20160701_20160930" decimals="-3" unitRef="U_iso4217USD">-10771000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000110" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">-46008000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000111" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">-27815000</us-gaap:NetIncomeLoss>
  <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment id="F_000112" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">1378000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000113" contextRef="C_0001445283_20170701_20170930" decimals="-3" unitRef="U_iso4217USD">-13954000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000114" contextRef="C_0001445283_20160701_20160930" decimals="-3" unitRef="U_iso4217USD">-10771000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000115" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">-46008000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000116" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">-29193000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000117" contextRef="C_0001445283_20170701_20170930" decimals="2" unitRef="U_iso4217USD_shares">-0.56</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000118" contextRef="C_0001445283_20160701_20160930" decimals="2" unitRef="U_iso4217USD_shares">-0.54</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000119" contextRef="C_0001445283_20170101_20170930" decimals="2" unitRef="U_iso4217USD_shares">-1.84</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000120" contextRef="C_0001445283_20160101_20160930" decimals="2" unitRef="U_iso4217USD_shares">-1.75</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000121" contextRef="C_0001445283_20170701_20170930" decimals="0" unitRef="U_shares">25093344</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000122" contextRef="C_0001445283_20160701_20160930" decimals="0" unitRef="U_shares">20073685</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000123" contextRef="C_0001445283_20170101_20170930" decimals="0" unitRef="U_shares">25051536</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000124" contextRef="C_0001445283_20160101_20160930" decimals="0" unitRef="U_shares">16672368</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="F_000125" contextRef="C_0001445283_20170701_20170930" decimals="-3" unitRef="U_iso4217USD">20000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="F_000126" contextRef="C_0001445283_20160701_20160930" decimals="-3" unitRef="U_iso4217USD">-9000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="F_000127" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">15000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="F_000128" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">-9000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000129" contextRef="C_0001445283_20170701_20170930" decimals="-3" unitRef="U_iso4217USD">-13934000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000130" contextRef="C_0001445283_20160701_20160930" decimals="-3" unitRef="U_iso4217USD">-10780000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000131" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">-45993000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000132" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">-27824000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000133" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">187000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000134" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">248000</us-gaap:DepreciationDepletionAndAmortization>
  <pti:PremiumOnShortTermInvestments id="F_000135" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">140000</pti:PremiumOnShortTermInvestments>
  <pti:PremiumOnShortTermInvestments id="F_000136" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">124000</pti:PremiumOnShortTermInvestments>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments id="F_000137" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">-182000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments id="F_000138" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">-2000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <pti:NoncashRentExpenseIncome id="F_000139" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">-149000</pti:NoncashRentExpenseIncome>
  <pti:NoncashRentExpenseIncome id="F_000140" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">-134000</pti:NoncashRentExpenseIncome>
  <us-gaap:ShareBasedCompensation id="F_000141" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">2228000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000142" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">1245000</us-gaap:ShareBasedCompensation>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims id="F_000143" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">555000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims id="F_000144" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">130000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <pti:ChangeInFairValueOfDerivativeLiability id="F_000145" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">-88000</pti:ChangeInFairValueOfDerivativeLiability>
  <pti:ChangeInFairValueOfDerivativeLiability id="F_000146" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">140000</pti:ChangeInFairValueOfDerivativeLiability>
  <us-gaap:FairValueAdjustmentOfWarrants id="F_000147" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">-82000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:GainLossOnDispositionOfAssets id="F_000148" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">13000</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="F_000149" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">411000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="F_000150" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">-473000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInPrepaidExpensesOther id="F_000151" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">-2221000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
  <us-gaap:IncreaseDecreaseInPrepaidExpensesOther id="F_000152" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">2200000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="F_000153" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">-27000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="F_000154" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">-63000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000155" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">514000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000156" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">390000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="F_000157" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">1527000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="F_000158" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">1849000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="F_000159" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">-1202000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="F_000160" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">-1992000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="F_000161" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">-40557000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="F_000162" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">-27820000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:IncreaseDecreaseInRestrictedCash id="F_000163" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">1656000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecurities id="F_000164" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">23727000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecurities id="F_000165" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">56299000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
  <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities id="F_000166" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">65563000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000167" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">117000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000168" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">32000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="F_000169" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">13000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="F_000170" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">40063000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="F_000171" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">-56318000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="F_000172" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">46500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000173" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">70265000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromStockOptionsExercised id="F_000174" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">30000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="F_000175" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">144000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000176" contextRef="C_0001445283_us-gaapPlanNameAxis_ptiEmployeeStockPurchasePlanMember_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">43000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000177" contextRef="C_0001445283_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">2515000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000178" contextRef="C_0001445283_us-gaapSubsidiarySaleOfStockAxis_ptiFollowOnPublicOfferingMember_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">272000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="F_000179" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">73000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="F_000180" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">114122000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="F_000181" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">-421000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="F_000182" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">29984000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000183" contextRef="C_0001445283_20151231" decimals="-3" unitRef="U_iso4217USD">13844000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000184" contextRef="C_0001445283_20160930" decimals="-3" unitRef="U_iso4217USD">43828000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:ConversionOfStockAmountConverted1 id="F_000185" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">112292000</us-gaap:ConversionOfStockAmountConverted1>
  <pti:StockIssuedForPaymentOfAccruedDividends id="F_000186" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">3000</pti:StockIssuedForPaymentOfAccruedDividends>
  <pti:StockIssuedForPaymentOfAccruedBonus id="F_000187" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">62000</pti:StockIssuedForPaymentOfAccruedBonus>
  <pti:ConversionOfPreferredStockWarrantsIntoCommonStockWarrants id="F_000188" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">28000</pti:ConversionOfPreferredStockWarrantsIntoCommonStockWarrants>
  <pti:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense id="F_000189" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">524000</pti:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid id="F_000190" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">12111000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:NatureOfOperations id="F_000191" contextRef="C_0001445283_20170101_20170930">&lt;div&gt;

&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Nature of the Business&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Proteostasis Therapeutics, Inc. (the &amp;#8220;Company&amp;#8221;) was incorporated in Delaware on December 13, 2006. The Company is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis (&amp;#8220;CF&amp;#8221;) and other diseases caused by dysfunctional protein processing.&amp;nbsp;&amp;nbsp;The Company focuses on identifying therapies that restore protein function.&amp;nbsp;&amp;nbsp;CF is a disease caused by defects in the cystic fibrosis transmembrane conductance regulator (&amp;#8220;CFTR&amp;#8221;) protein and insufficient CFTR protein function. The Company&amp;#8217;s lead product candidates, PTI-428, PTI-801 and PTI-808&amp;nbsp;&amp;nbsp;are in early clinical development, with plans for double and triple combinations, and the Company&amp;#8217;s other drug candidates are in the preclinical development and discovery phases.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2016, the Company adopted the provisions of Financial Statement Account Standards Board (FASB) Accounting Standard Codification (ASC) Topic 205-40, &lt;font style="font-style:italic;"&gt;Presentation of Financial Statements &amp;#8211; Going Concern&lt;/font&gt; (ASC 205-40), which requires management to assess the Company&amp;#8217;s ability to continue as a going concern for twelve months after the date of the financial statements are issued. This standard &lt;font style="color:#000000;"&gt;requires management to 1) identify and disclose if there are initial conditions indicating substantial doubt about the Company&amp;#8217;s ability to continue as a going concern within twelve months of the issuance date of the financial statements, 2) disclose the principal conditions that gave rise to substantial doubt, 3) disclose management&amp;#8217;s evaluation of the significance of those conditions in relation to the Company&amp;#8217;s ability to meet its obligations and 4) disclose management&amp;#8217;s plans that are intended to mitigate the adverse conditions.&amp;#160;&amp;#160;In accordance with the accounting standard, when considering management&amp;#8217;s plans to mitigate the conditions giving rise to substantial doubt, management can only consider those plans which are probable to be successfully implemented&lt;/font&gt;. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has incurred losses from operations since its inception. As of September&amp;#160;30, 2017, the Company had an accumulated deficit of $203.5 million. During the three and nine months ended September&amp;#160;30, 2017, the Company incurred losses of $14.0 million and $46.0 million and during the nine months ended September 30, 2017 the Company used $40.6 million of cash in operations. The Company expects to continue to generate operating losses in the foreseeable future. The Company currently expects that its cash, cash equivalents and short-term investments of $43.2 million will be sufficient to fund its operating expenses and capital requirements, based upon its current operating plan, through the second quarter of 2018. &lt;font style="color:#000000;"&gt;As of September 30, 2017, management has further assessed this risk and, in accordance with the requirements of ASC 205-40, determined that there are initial conditions indicating that there is substantial doubt about the Company&amp;#8217;s ability to continue as a going concern within twelve months of the issuance date of these condensed financial statements.&amp;#160;&amp;#160;These indicators are the Company&amp;#8217;s accumulated deficit and the forecasted cash expenditures. &lt;/font&gt;Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all, nor is it considered probable under the accounting standards. &lt;font style="color:#000000;"&gt;As such, under the requirements of ASC 205-40, management may not consider the potential for future capital raises in its assessment of the Company&amp;#8217;s ability to meet its obligations for the next twelve months. If the Company is unable to obtain funding, the Company would be forced to delay, reduce or eliminate its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The ability to reduce spending at a level that mitigates the factors described above, is not considered probable, as defined in the accounting standards; as such, under the requirements of ASC 205-40, the full extent to which management may extend the Company&amp;#8217;s funds through these actions may not be considered in management&amp;#8217;s assessment of the Company&amp;#8217;s ability to continue as a going concern for the next twelve months.&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thus, in accordance with the requirements of ASC 205-40, management has concluded that substantial doubt exists about the Company&amp;#8217;s ability to continue as a going concern for twelve months from the date these condensed financial statements are issued.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The condensed financial statements have been prepared&amp;#160;assuming that the Company will continue as a going concern, which contemplates continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business&lt;font style="color:#000000;"&gt;.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="F_000192" contextRef="C_0001445283_20170101_20170930">&lt;div&gt;

&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Summary of Significant Accounting Policies &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Unaudited Interim Financial Information&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The condensed balance sheet at December&amp;#160;31, 2016 was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;). The accompanying condensed financial statements as of September&amp;#160;30, 2017 and for the three and nine months ended September&amp;#160;30, 2017 are unaudited. The accompanying unaudited interim financial statements have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the Company&amp;#8217;s&amp;#160;audited financial statements and the notes thereto for the year ended December&amp;#160;31, 2016 included in the Company&amp;#8217;s&amp;#160;Annual Report on Form 10-K filed with the SEC on March&amp;#160;30, 2017. In the opinion of management, all adjustments, consisting only of normal recurring adjustments as necessary, for the fair statement of the Company&amp;#8217;s condensed financial position as of September&amp;#160;30, 2017 and condensed results of its operations and cash flows for the three and nine months ended September&amp;#160;30, 2017 have been made. The results of operations for the three and nine months ended September&amp;#160;30, 2017 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2017. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, the accrual for research and development expenses and the valuation of common stock and the derivative liability. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Restricted Cash&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September&amp;#160;30, 2017 and December&amp;#160;31, 2016, restricted cash consisted of a certificate of deposit in the amount of $0.3 million collateralizing a letter of credit issued as a security deposit in connection with the Company&amp;#8217;s lease of its corporate facilities at 200 Technology Square, Cambridge, MA.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 19, 2017, the Company entered into a lease agreement for a new corporate headquarters at 80 Guest Street, Brighton, MA (see Note 11). As of September 30, 2017, restricted cash, net of current portion, consisted of a money market account in the amount of $1.7 million collateralizing a letter of credit issued as a security deposit for this lease agreement.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash Equivalents&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. As of September&amp;#160;30, 2017 and December&amp;#160;31, 2016, the Company&amp;#8217;s cash equivalents consisted of money market funds.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Short-term Investments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments represent holdings of available-for-sale marketable securities in accordance with the Company&amp;#8217;s investment policy and cash management strategy. Short-term investments mature within one-year from the balance sheet date. Investments in marketable securities are recorded at fair value, with any unrealized gains and losses, net of taxes, reported as a component of stockholders&amp;#8217; equity until realized or until a determination is made that an other-than-temporary decline in market value has occurred. The cost of marketable securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investments are reflected as a component of other expense, net.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&amp;#8212;Quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&amp;#8212;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&amp;#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s derivative liability, short-term investments and cash equivalents are carried at fair value determined according to the fair value hierarchy described above (see Note 4). The carrying value of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate their fair value due to the short-term nature of these assets and liabilities.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss per Share&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, upon the closing of the IPO, all of the outstanding shares of the Company&amp;#8217;s redeemable convertible preferred stock automatically converted into 9,699,600 shares of the Company&amp;#8217;s common stock. Prior to this conversion, the Company followed the two-class method when computing net loss per share as the Company had issued shares that met the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company&amp;#8217;s redeemable convertible preferred stock contractually entitled the holders of such shares to participate in dividends, but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, the two-class method did not apply for periods in which the Company reported a net loss or a net loss attributable to common stockholders resulting from dividends or accretion related to its redeemable convertible preferred stock.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net income (loss) per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares, including potential dilutive common shares assuming the dilutive effect of outstanding stock options and unvested restricted common shares, as determined using the treasury stock method. For periods in which the Company has reported net losses, diluted net loss per common share attributable to common stockholders is the same as basic net loss per common share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. For any period in which the Company has reported net income, basic net income per common share attributable to common stockholders is adjusted for certain amounts to calculate diluted net loss per common share attributable to common stockholders, since dilutive common shares are assumed to have been issued if their effect is dilutive and not to have been issued if their effect is anti-dilutive.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2014, the &lt;font style="color:#000000;"&gt;FASB issued ASU No.&amp;#160;2014-09,&amp;#160;&lt;/font&gt;&lt;font style="font-style:italic;color:#000000;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;&lt;font style="color:#000000;"&gt;&amp;#160;(&amp;#8220;ASU 2014-09&amp;#8221;), which supersedes existing revenue recognition guidance under GAAP. The standard&amp;#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The standard defines a five-step process to achieve this principle, and will require companies to use more judgment and make more estimates than under the current guidance. The Company expects that these judgments and estimates will include identifying performance obligations in the customer contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. In August 2015, the FASB issued ASU 2015-14,&amp;#160;&lt;/font&gt;&lt;font style="font-style:italic;color:#000000;"&gt;Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date&lt;/font&gt;&lt;font style="color:#000000;"&gt;, which delays the effective date of ASU 2014-09 such that the standard is effective for public entities for annual periods beginning after December&amp;#160;15, 2017 and for interim periods within those fiscal years. Early adoption of the standard is permitted for annual periods beginning after December&amp;#160;15, 2016. In April 2016, the FASB issued ASU 2016-10,&amp;#160;&lt;/font&gt;&lt;font style="font-style:italic;color:#000000;"&gt;Identifying Performance Obligations and Licensing&lt;/font&gt;&lt;font style="color:#000000;"&gt;. The new standard clarifies two aspects of ASU 2014-09, &lt;/font&gt;&lt;font style="font-style:italic;color:#000000;"&gt;Revenue from Contracts with Customers&amp;#160;(Topic 606)&lt;/font&gt;&lt;font style="color:#000000;"&gt;: identifying performance obligations and the licensing implementation guidance. These new standards will become effective for the Company on January&amp;#160;1, 2018. The Company only has one contract (see Note 8) within the scope of Topic 606 and intends to use the modified retrospective method for adoption. Since the inception of the contract the Company has recognized $8.1 million in revenue. The Company is still assessing the impact that the adoption of these new standards will have on its financial statements and related disclosures.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued ASU No.&amp;#160;2016-02, &lt;font style="font-style:italic;"&gt;Leases &lt;/font&gt;(&amp;#8220;ASU 2016-02&amp;#8221;)&lt;font style="font-style:italic;"&gt;.&lt;/font&gt; This guidance will require that lease arrangements longer than 12 months result in an entity recognizing an asset and liability equal to the present value of the lease payments in the statement of financial position. This guidance is effective for annual periods beginning after December&amp;#160;15, 2018, and interim periods therein. This standard requires a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU 2016-02 will have on its financial statements and related disclosures.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2016, the FASB issued ASU No.&amp;#160;2016-09,&amp;#160;&lt;font style="font-style:italic;"&gt;Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting &lt;/font&gt;(&amp;#8220;ASU 2016-09&amp;#8221;)&lt;font style="font-style:italic;"&gt;.&lt;/font&gt; The new standard involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The new standard was adopted by the Company on January&amp;#160;1, 2017 on a modified retrospective basis. &lt;font style="color:#000000;"&gt;As a result, the Company has made an accounting policy election to account for forfeitures as they occur. The adoption of ASU 2016&amp;#8209;09 also requires excess tax benefits and tax deficiencies be recorded in the income statement as opposed to additional paid&amp;#8209;in capital when the awards vest or are settled. This had no material impact on the condensed financial statements as of and for the three and nine months ended September&amp;#160;30, 2017&lt;/font&gt;.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2016, the FASB issued ASU 2016-15, &lt;font style="font-style:italic;"&gt;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments&lt;/font&gt;. The new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs, settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactions. The new standard also clarifies that an entity should determine each separately identifiable source or use within the cash receipts and cash payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. The new standard will be effective for the Company on January 1, 2018. The Company is currently evaluating the impact that the adoption of this standard will have on its statements of cash flows&lt;font style="color:#000000;"&gt;.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2017, the FASB issued ASU 2017-09, &lt;font style="font-style:italic;"&gt;Compensation &amp;#8211; Stock Compensation (Topic 719): Scope of Modification Accounting&lt;/font&gt;. The new standard provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The new standard will be effective for the Company on January 1, 2018; however, early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company&amp;#8217;s financial position or results of operations.&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock id="F_000193" contextRef="C_0001445283_20170101_20170930">&lt;div&gt;

&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Short Term Investments&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&amp;#8217;s short term investments as of September&amp;#160;30, 2017 and December&amp;#160;31, 2016 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.28%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&amp;#160;30, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Unrealized Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Unrealized Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S government-sponsored enterprise securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,519&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,516&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,522&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,518&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,041&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,034&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.28%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Unrealized Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Unrealized Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S government-sponsored enterprise securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,384&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,364&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,535&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,533&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66,919&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66,897&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company did not have any realized gains or losses on its short-term investments for the three and nine months ended September&amp;#160;30, 2017 and &lt;font style="letter-spacing:-0.1pt;"&gt;2016&lt;/font&gt;. There were no other-than-temporary impairments recognized for the three and nine months ended September&amp;#160;30, 2017 and &lt;font style="letter-spacing:-0.1pt;"&gt;2016&lt;/font&gt;.&lt;/p&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock id="F_000194" contextRef="C_0001445283_20170101_20170930">&lt;div&gt;

&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Fair Value of Financial Assets and Liabilities&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables present information about the Company&amp;#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.28%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements as of September&amp;#160;30, 2017 Using:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,370&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,370&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government-sponsored enterprise securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,516&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,516&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,518&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,518&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,370&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,034&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,404&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derivative liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.28%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements as of December&amp;#160;31, 2016 Using:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,440&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,440&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government-sponsored enterprise securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,365&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,365&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,532&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,532&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,440&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66,897&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;82,337&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derivative liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the periods ended September&amp;#160;30, 2017 and December&amp;#160;31, 2016, there were no transfers between Level 1, Level 2 and Level 3.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Derivative Liability&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The derivative liability relates to a cash settlement option associated with the change of control provision in our Cystic Fibrosis Foundation Therapeutics, Inc. (&amp;#8220;CFFT&amp;#8221;) agreement, which meets the definition of a derivative. The fair value of the derivative liability is based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of the derivative instrument was determined using the Monte-Carlo simulation analysis. In determining the fair value of the derivative liability, the inputs impacting fair value include the fair value of the Company&amp;#8217;s common stock, expected term of the derivative instrument, expected volatility of the common stock price, risk-free interest rate, expected sales-based milestone payments, discount rate, probability of a change of control event, and the probability that the counterparty would elect to accept the alternative cash payment in lieu of its right to the future sales-based milestone payments.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September&amp;#160;30, 2017 and December&amp;#160;31, 2016, the Company determined the per share common stock price available based on the closing price of its common stock on the NASDAQ Global Market as of September 29, 2017 and December 30, 2016, respectively. The Company determined the expected term of the instrument to be 2.25 years and 2.50 years as of September&amp;#160;30, 2017 and December&amp;#160;31, 2016, respectively. The Company estimated its expected stock volatility to be 80.0% and 81.1% as of September&amp;#160;30, 2017 and December&amp;#160;31, 2016, respectively, based on the historical volatility of publicly traded peer companies for terms matching the expected term of the instrument for each respective period. The risk-free interest rate was determined to be 1.51% and 1.33% as of September&amp;#160;30, 2017 and December&amp;#160;31, 2016, respectively, by reference to the U.S. Treasury yield curve for terms matching the expected term of the instrument for each respective period.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Changes in the values of the derivative liability are summarized below (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derivative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value at December 31, 2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(88&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value at September&amp;#160;30, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock id="F_000195" contextRef="C_0001445283_20170101_20170930">&lt;div&gt;

&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Prepaids and Other Current Assets&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaids and other current assets consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.04%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.56%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.44%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.28%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.28%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid clinical, manufacturing and scientific expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,197&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,390&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid insurance expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;218&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;104&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;423&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,565&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.04%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.56%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,838&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.28%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.44%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,059&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.28%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
  <pti:AccruedExpensesDisclosureTextBlock id="F_000196" contextRef="C_0001445283_20170101_20170930">&lt;div&gt;

&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Accrued Expenses&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued payroll and related expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,293&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,813&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,086&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,612&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional fees&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;399&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;383&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;520&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,855&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,328&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/div&gt;</pti:AccruedExpensesDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="F_000197" contextRef="C_0001445283_20170101_20170930">&lt;div&gt;

&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;2016 Stock Option and Incentive Plan&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On February&amp;#160;3, 2016, the Company&amp;#8217;s stockholders approved the 2016 Stock Option and Incentive Plan (the &amp;#8220;2016 Plan&amp;#8221;), which became effective on February&amp;#160;9, 2016. The 2016 Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock units, restricted stock awards and other stock-based awards. The number of shares initially reserved for issuance under the 2016 Plan is 1,581,839 shares. The number of shares of common stock that may be issued under the 2016 Plan will automatically increase on each January&amp;#160;1, beginning on January&amp;#160;1, 2017, by the lesser of 3% of the shares of the Company&amp;#8217;s common stock outstanding on the immediately preceding December&amp;#160;31 or an amount determined by the Company&amp;#8217;s board of directors or the compensation committee of the board of directors. The shares of common stock underlying any awards that are forfeited, canceled, repurchased or are otherwise terminated by the Company under the 2016 Plan and the 2008 Plan will be added back to the shares of common stock available for issuance under the 2016 Plan.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September&amp;#160;30, 2017, the total number of shares reserved under the 2016 Plan and 2008 Plan was 3,577,930 and the Company had 631,077 shares available for future issuance under the 2016 Plan.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;2016 Employee Stock Purchase Plan&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On February&amp;#160;3, 2016, the Company&amp;#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the &amp;#8220;2016 ESPP&amp;#8221;), which became effective in connection with the completion of the Company&amp;#8217;s initial public offering. A total of 138,757 shares of common stock were reserved for issuance under this plan. In addition, the number of shares of common stock that may be issued under the 2016 ESPP will automatically increase on each January&amp;#160;1, beginning on January&amp;#160;1, 2017 and ending on January&amp;#160;1, 2026, by the least of (i)&amp;#160;138,757 shares of common stock, (ii)&amp;#160;1% of the Company&amp;#8217;s shares of common stock outstanding on the immediately preceding December&amp;#160;31 and (iii)&amp;#160;an amount determined by the Company&amp;#8217;s board of directors or the compensation committee of the board of directors.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the nine months ended September 30, 2017, 10,829 shares of common stock were issued pursuant to the 2016 ESPP. As of September&amp;#160;30, 2017, the total number of shares reserved under the 2016 ESPP was 266,685 shares. The Company recognized less than $0.1 million of stock-based compensation during each of the three and nine month periods ended September&amp;#160;30, 2017. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock Option Grants and Shares to Non-employees&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to 2013, the Company issued options to purchase 203,964 shares of common stock to non-employees, primarily members of the Company&amp;#8217;s scientific advisory board, that vest upon the achievement of specified development and clinical milestones. As of September&amp;#160;30, 2017, options for the purchase of 83,250 shares held by non-employees remained unvested, pending achievement of the specified milestones, and had an aggregate fair value of $0.1 million. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense, including shares issued to a non-employee for consulting services, was classified in the statements of operations as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended September&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nine Months Ended September&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;412&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;119&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,070&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;351&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;636&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;451&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,713&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,048&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;570&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,783&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,375&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock id="F_000198" contextRef="C_0001445283_20170101_20170930">&lt;div&gt;

&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Collaboration Agreement&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Astellas&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Collaborative Research, Development, Commercialization and License Agreement (as further amended, the &amp;#8220;Astellas Agreement&amp;#8221;) with Astellas Pharma Inc. (&amp;#8220;Astellas&amp;#8221;), entered into in November 2014, the Company &lt;font style="letter-spacing:-0.1pt;"&gt;recognized revenue of $1.6 million and $1.0&amp;#160;million for the three months ended September&amp;#160;30, 2017 and 2016, respectively, and $3.7 million and $2.2 million for the nine months ended September&amp;#160;30, 2017 and 2016, respectively. The Company recognizes revenue from all upfront payments, research funding payments, non-substantive milestone payments and reimbursements of third-party costs under this arrangement, together as a single unit, over the &lt;/font&gt;three and a half year research term of the agreement, which commenced in January 2015, with a cumulative catch-up for the elapsed portion of the &lt;font style="letter-spacing:-0.1pt;"&gt;services being recognized at the time any non-substantive milestone payment or other consideration is earned. Amounts recorded as deferred revenue under the Astellas Agreement totaled $1.8 million and $3.0 million as of September&amp;#160;30, 2017 and December&amp;#160;31, 2016, respectively.&lt;/font&gt; &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Biogen&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the now-terminated collaboration agreement between the Company and Biogen New Ventures, formerly Biogen Idec New Ventures Inc. (&amp;#8220;Biogen&amp;#8221;), the Company recognized revenue of $0.7 million and $2.1 million for the three and nine months ended September&amp;#160;30, 2016. The Company did not have any deferred revenue under the Biogen agreement as of September&amp;#160;30, 2017 and December 31, 2016 and will not recognize any additional revenue under this terminated agreement in the future.&lt;/p&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock id="F_000199" contextRef="C_0001445283_20170101_20170930">&lt;div&gt;

&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Income Taxes&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company did not record a federal or state income tax benefit for its losses for the three and nine months ended September&amp;#160;30, 2017 and 2016 due to the conclusion that a full valuation allowance is required against the Company&amp;#8217;s deferred tax assets. &amp;#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:EarningsPerShareTextBlock id="F_000200" contextRef="C_0001445283_20170101_20170930">&lt;div&gt;

&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Net Loss per Share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended September&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nine Months Ended September&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,954&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,771&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(46,008&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27,815&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accruing dividends on preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,378&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; stockholders-basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,954&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,771&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(46,008&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(29,193&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average number of common shares&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; outstanding&amp;#8212;basic&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,093,344&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,073,685&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,051,536&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,672,368&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share attributable to common&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; stockholders&amp;#8212;basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.56&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.54&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.84&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.75&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s potential dilutive securities, which include stock options and a warrant to purchase common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="color:#000000;"&gt; Company has reported a net loss for all periods presented. Therefore, diluted net loss per common share is the same as basic net loss per common share. The following potentially dilutive securities outstanding, prior to the use of the treasury stock method or if-converted method, have been excluded from the computation of diluted weighted-average shares outstanding, because such securities had an antidilutive impact due to the losses reported&lt;/font&gt;:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.54%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,946,853&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,731,823&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrant for the purchase of convertible preferred stock&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,946,853&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,746,623&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="color:#000000;"&gt; warrant for the purchase of common stock was exercised in February 2016. The Company issued 4,349 shares in a net issuance transaction.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:LeasesOfLesseeDisclosureTextBlock id="F_000201" contextRef="C_0001445283_20170101_20170930">&lt;div&gt;

&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Build-to-Suit Lease&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 19, 2017, the Company entered into a lease agreement for its new headquarters, consisting of approximately 30,000 square feet of laboratory and office space located in Brighton, Massachusetts. The lease commencement date will be on the earlier of (i) the first date on which tenant commenced occupancy for the conduct of business in the premises, or (ii)&amp;#160;April 15, 2018, subject to extension for certain delays.&amp;#160;The lease will extend for a lease term from the commencement date and then for ten years starting with the first day of the month following the month in which the commencement date falls, unless terminated earlier.&amp;#160;The Company is entitled to one seven-year option to extend. Annual rent under the lease, exclusive of operating expenses and real estate taxes, will be approximately $1.7 million in the first year, with annual increases of 2.75% each year thereafter. Total expected rental payments through the initial lease term are approximately $18.8 million. The Company will be entitled to an improvement allowance of approximately $4.8 million for certain permitted costs related to the design and construction of Company improvements to the premises. &lt;font style="color:#000000;"&gt;The lease contains customary provisions allowing the landlord to terminate the lease if the Company fails to remedy a breach of any of its obligations within specified time periods, or upon bankruptcy or insolvency of the Company&lt;/font&gt;.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is not the legal owner of the leased space. However, in accordance with ASC 840, &lt;font style="font-style:italic;"&gt;Leases&lt;/font&gt;, because of the Company&amp;#8217;s expected level of direct financial and operational involvement in the substantial tenant improvements required, the Company is deemed to be the owner of the leased space, including the building shell, during the construction period. As a result, the Company capitalized approximately $12.1 million as a build-to-suit asset within property, plant and equipment, net and recognized a corresponding build-to-suit facility lease obligation within other liabilities and other non-current liabilities on its balance sheets equal to the estimated replacement cost of its leased portion of the building at the inception of the lease.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additionally, construction costs incurred as part of the build-out and tenant improvements will also be capitalized within property, plant and equipment, net. Rental payments made under the lease will be allocated to interest expense and the build-to-suit facility lease obligation, based on the implicit rate of the build-to-suit facility lease obligation. The build-to-suit facility lease obligation was approximately $12.1 million as of September 30, 2017&lt;font style="color:#000000;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:LeasesOfLesseeDisclosureTextBlock>
  <pti:UnauditedInterimFinancialInformationPolicyTextBlock id="F_000202" contextRef="C_0001445283_20170101_20170930">&lt;div&gt;

&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Unaudited Interim Financial Information&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The condensed balance sheet at December&amp;#160;31, 2016 was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;). The accompanying condensed financial statements as of September&amp;#160;30, 2017 and for the three and nine months ended September&amp;#160;30, 2017 are unaudited. The accompanying unaudited interim financial statements have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the Company&amp;#8217;s&amp;#160;audited financial statements and the notes thereto for the year ended December&amp;#160;31, 2016 included in the Company&amp;#8217;s&amp;#160;Annual Report on Form 10-K filed with the SEC on March&amp;#160;30, 2017. In the opinion of management, all adjustments, consisting only of normal recurring adjustments as necessary, for the fair statement of the Company&amp;#8217;s condensed financial position as of September&amp;#160;30, 2017 and condensed results of its operations and cash flows for the three and nine months ended September&amp;#160;30, 2017 have been made. The results of operations for the three and nine months ended September&amp;#160;30, 2017 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2017. &lt;/p&gt;&lt;/div&gt;</pti:UnauditedInterimFinancialInformationPolicyTextBlock>
  <us-gaap:UseOfEstimates id="F_000203" contextRef="C_0001445283_20170101_20170930">&lt;div&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, the accrual for research and development expenses and the valuation of common stock and the derivative liability. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.&lt;/p&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy id="F_000204" contextRef="C_0001445283_20170101_20170930">&lt;div&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Restricted Cash&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;As of September&amp;#160;30, 2017 and December&amp;#160;31, 2016, restricted cash consisted of a certificate of deposit in the amount of $0.3 million collateralizing a letter of credit issued as a security deposit in connection with the Company&amp;#8217;s lease of its corporate facilities at 200 Technology Square, Cambridge, MA.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 19, 2017, the Company entered into a lease agreement for a new corporate headquarters at 80 Guest Street, Brighton, MA (see Note 11). As of September 30, 2017, restricted cash, net of current portion, consisted of a money market account in the amount of $1.7 million collateralizing a letter of credit issued as a security deposit for this lease agreement.&lt;/p&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock id="F_000205" contextRef="C_0001445283_20170101_20170930">&lt;div&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash Equivalents&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. As of September&amp;#160;30, 2017 and December&amp;#160;31, 2016, the Company&amp;#8217;s cash equivalents consisted of money market funds.&lt;/p&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:InvestmentPolicyTextBlock id="F_000206" contextRef="C_0001445283_20170101_20170930">&lt;div&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Short-term Investments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Short-term investments represent holdings of available-for-sale marketable securities in accordance with the Company&amp;#8217;s investment policy and cash management strategy. Short-term investments mature within one-year from the balance sheet date. Investments in marketable securities are recorded at fair value, with any unrealized gains and losses, net of taxes, reported as a component of stockholders&amp;#8217; equity until realized or until a determination is made that an other-than-temporary decline in market value has occurred. The cost of marketable securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investments are reflected as a component of other expense, net.&lt;/p&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock id="F_000207" contextRef="C_0001445283_20170101_20170930">&lt;div&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&amp;#8212;Quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&amp;#8212;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&amp;#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s derivative liability, short-term investments and cash equivalents are carried at fair value determined according to the fair value hierarchy described above (see Note 4). The carrying value of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate their fair value due to the short-term nature of these assets and liabilities.&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock id="F_000208" contextRef="C_0001445283_20170101_20170930">&lt;div&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss per Share&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;In February 2016, upon the closing of the IPO, all of the outstanding shares of the Company&amp;#8217;s redeemable convertible preferred stock automatically converted into 9,699,600 shares of the Company&amp;#8217;s common stock. Prior to this conversion, the Company followed the two-class method when computing net loss per share as the Company had issued shares that met the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company&amp;#8217;s redeemable convertible preferred stock contractually entitled the holders of such shares to participate in dividends, but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, the two-class method did not apply for periods in which the Company reported a net loss or a net loss attributable to common stockholders resulting from dividends or accretion related to its redeemable convertible preferred stock.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net income (loss) per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares, including potential dilutive common shares assuming the dilutive effect of outstanding stock options and unvested restricted common shares, as determined using the treasury stock method. For periods in which the Company has reported net losses, diluted net loss per common share attributable to common stockholders is the same as basic net loss per common share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. For any period in which the Company has reported net income, basic net income per common share attributable to common stockholders is adjusted for certain amounts to calculate diluted net loss per common share attributable to common stockholders, since dilutive common shares are assumed to have been issued if their effect is dilutive and not to have been issued if their effect is anti-dilutive.&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="F_000209" contextRef="C_0001445283_20170101_20170930">&lt;div&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;In May 2014, the &lt;font style="color:#000000;"&gt;FASB issued ASU No.&amp;#160;2014-09,&amp;#160;&lt;/font&gt;&lt;font style="font-style:italic;color:#000000;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;&lt;font style="color:#000000;"&gt;&amp;#160;(&amp;#8220;ASU 2014-09&amp;#8221;), which supersedes existing revenue recognition guidance under GAAP. The standard&amp;#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The standard defines a five-step process to achieve this principle, and will require companies to use more judgment and make more estimates than under the current guidance. The Company expects that these judgments and estimates will include identifying performance obligations in the customer contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. In August 2015, the FASB issued ASU 2015-14,&amp;#160;&lt;/font&gt;&lt;font style="font-style:italic;color:#000000;"&gt;Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date&lt;/font&gt;&lt;font style="color:#000000;"&gt;, which delays the effective date of ASU 2014-09 such that the standard is effective for public entities for annual periods beginning after December&amp;#160;15, 2017 and for interim periods within those fiscal years. Early adoption of the standard is permitted for annual periods beginning after December&amp;#160;15, 2016. In April 2016, the FASB issued ASU 2016-10,&amp;#160;&lt;/font&gt;&lt;font style="font-style:italic;color:#000000;"&gt;Identifying Performance Obligations and Licensing&lt;/font&gt;&lt;font style="color:#000000;"&gt;. The new standard clarifies two aspects of ASU 2014-09, &lt;/font&gt;&lt;font style="font-style:italic;color:#000000;"&gt;Revenue from Contracts with Customers&amp;#160;(Topic 606)&lt;/font&gt;&lt;font style="color:#000000;"&gt;: identifying performance obligations and the licensing implementation guidance. These new standards will become effective for the Company on January&amp;#160;1, 2018. The Company only has one contract (see Note 8) within the scope of Topic 606 and intends to use the modified retrospective method for adoption. Since the inception of the contract the Company has recognized $8.1 million in revenue. The Company is still assessing the impact that the adoption of these new standards will have on its financial statements and related disclosures.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued ASU No.&amp;#160;2016-02, &lt;font style="font-style:italic;"&gt;Leases &lt;/font&gt;(&amp;#8220;ASU 2016-02&amp;#8221;)&lt;font style="font-style:italic;"&gt;.&lt;/font&gt; This guidance will require that lease arrangements longer than 12 months result in an entity recognizing an asset and liability equal to the present value of the lease payments in the statement of financial position. This guidance is effective for annual periods beginning after December&amp;#160;15, 2018, and interim periods therein. This standard requires a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU 2016-02 will have on its financial statements and related disclosures.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2016, the FASB issued ASU No.&amp;#160;2016-09,&amp;#160;&lt;font style="font-style:italic;"&gt;Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting &lt;/font&gt;(&amp;#8220;ASU 2016-09&amp;#8221;)&lt;font style="font-style:italic;"&gt;.&lt;/font&gt; The new standard involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The new standard was adopted by the Company on January&amp;#160;1, 2017 on a modified retrospective basis. &lt;font style="color:#000000;"&gt;As a result, the Company has made an accounting policy election to account for forfeitures as they occur. The adoption of ASU 2016&amp;#8209;09 also requires excess tax benefits and tax deficiencies be recorded in the income statement as opposed to additional paid&amp;#8209;in capital when the awards vest or are settled. This had no material impact on the condensed financial statements as of and for the three and nine months ended September&amp;#160;30, 2017&lt;/font&gt;.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2016, the FASB issued ASU 2016-15, &lt;font style="font-style:italic;"&gt;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments&lt;/font&gt;. The new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs, settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactions. The new standard also clarifies that an entity should determine each separately identifiable source or use within the cash receipts and cash payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. The new standard will be effective for the Company on January 1, 2018. The Company is currently evaluating the impact that the adoption of this standard will have on its statements of cash flows&lt;font style="color:#000000;"&gt;.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2017, the FASB issued ASU 2017-09, &lt;font style="font-style:italic;"&gt;Compensation &amp;#8211; Stock Compensation (Topic 719): Scope of Modification Accounting&lt;/font&gt;. The new standard provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The new standard will be effective for the Company on January 1, 2018; however, early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company&amp;#8217;s financial position or results of operations.&lt;/p&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:DerivativesPolicyTextBlock id="F_000210" contextRef="C_0001445283_20170101_20170930">&lt;div&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Derivative Liability&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The derivative liability relates to a cash settlement option associated with the change of control provision in our Cystic Fibrosis Foundation Therapeutics, Inc. (&amp;#8220;CFFT&amp;#8221;) agreement, which meets the definition of a derivative. The fair value of the derivative liability is based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of the derivative instrument was determined using the Monte-Carlo simulation analysis. In determining the fair value of the derivative liability, the inputs impacting fair value include the fair value of the Company&amp;#8217;s common stock, expected term of the derivative instrument, expected volatility of the common stock price, risk-free interest rate, expected sales-based milestone payments, discount rate, probability of a change of control event, and the probability that the counterparty would elect to accept the alternative cash payment in lieu of its right to the future sales-based milestone payments.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September&amp;#160;30, 2017 and December&amp;#160;31, 2016, the Company determined the per share common stock price available based on the closing price of its common stock on the NASDAQ Global Market as of September 29, 2017 and December 30, 2016, respectively. The Company determined the expected term of the instrument to be 2.25 years and 2.50 years as of September&amp;#160;30, 2017 and December&amp;#160;31, 2016, respectively. The Company estimated its expected stock volatility to be 80.0% and 81.1% as of September&amp;#160;30, 2017 and December&amp;#160;31, 2016, respectively, based on the historical volatility of publicly traded peer companies for terms matching the expected term of the instrument for each respective period. The risk-free interest rate was determined to be 1.51% and 1.33% as of September&amp;#160;30, 2017 and December&amp;#160;31, 2016, respectively, by reference to the U.S. Treasury yield curve for terms matching the expected term of the instrument for each respective period.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Changes in the values of the derivative liability are summarized below (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derivative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value at December 31, 2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(88&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value at September&amp;#160;30, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
  <us-gaap:AvailableForSaleSecuritiesTextBlock id="F_000211" contextRef="C_0001445283_20170101_20170930">&lt;div&gt;

&lt;p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following table summarizes the Company&amp;#8217;s short term investments as of September&amp;#160;30, 2017 and December&amp;#160;31, 2016 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.28%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&amp;#160;30, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Unrealized Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Unrealized Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S government-sponsored enterprise securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,519&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,516&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,522&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,518&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,041&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,034&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.28%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Unrealized Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Unrealized Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S government-sponsored enterprise securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,384&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,364&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,535&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,533&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66,919&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66,897&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock id="F_000212" contextRef="C_0001445283_20170101_20170930">&lt;div&gt;

&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following tables present information about the Company&amp;#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.28%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements as of September&amp;#160;30, 2017 Using:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,370&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,370&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government-sponsored enterprise securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,516&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,516&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,518&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,518&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,370&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,034&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,404&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derivative liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.28%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements as of December&amp;#160;31, 2016 Using:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,440&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,440&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government-sponsored enterprise securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,365&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,365&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,532&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,532&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,440&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66,897&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;82,337&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derivative liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock id="F_000213" contextRef="C_0001445283_20170101_20170930">&lt;div&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Changes in the values of the derivative liability are summarized below (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derivative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value at December 31, 2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(88&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value at September&amp;#160;30, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
  <pti:ScheduleOfPrepaidsAndOtherCurrentAssetsTableTextBlock id="F_000214" contextRef="C_0001445283_20170101_20170930">&lt;div&gt;

&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Prepaids and other current assets consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.04%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.56%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.44%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.28%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.28%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid clinical, manufacturing and scientific expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,197&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,390&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid insurance expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;218&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;104&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;423&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,565&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.04%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.56%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,838&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.28%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.44%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,059&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.28%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</pti:ScheduleOfPrepaidsAndOtherCurrentAssetsTableTextBlock>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock id="F_000215" contextRef="C_0001445283_20170101_20170930">&lt;div&gt;

&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued payroll and related expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,293&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,813&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,086&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,612&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional fees&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;399&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;383&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;520&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,855&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,328&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="F_000216" contextRef="C_0001445283_20170101_20170930">&lt;div&gt;

&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Stock-based compensation expense, including shares issued to a non-employee for consulting services, was classified in the statements of operations as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended September&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nine Months Ended September&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;412&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;119&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,070&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;351&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;636&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;451&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,713&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,048&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;570&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,783&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,375&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock id="F_000217" contextRef="C_0001445283_20170101_20170930">&lt;div&gt;

&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended September&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nine Months Ended September&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,954&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,771&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(46,008&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27,815&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accruing dividends on preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,378&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; stockholders-basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,954&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,771&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(46,008&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(29,193&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average number of common shares&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; outstanding&amp;#8212;basic&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,093,344&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,073,685&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,051,536&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,672,368&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share attributable to common&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; stockholders&amp;#8212;basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.56&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.54&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.84&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.75&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="F_000218" contextRef="C_0001445283_20170101_20170930">&lt;div&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following potentially dilutive securities outstanding, prior to the use of the treasury stock method or if-converted method, have been excluded from the computation of diluted weighted-average shares outstanding, because such securities had an antidilutive impact due to the losses reported&lt;font style="color:#000000;"&gt;:&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.54%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,946,853&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,731,823&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrant for the purchase of convertible preferred stock&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,946,853&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,746,623&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:CashCashEquivalentsAndShortTermInvestments id="F_000219" contextRef="C_0001445283_20170930" decimals="-5" unitRef="U_iso4217USD">43200000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue id="F_000220" contextRef="C_0001445283_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaapCertificatesOfDepositMember_20170930" decimals="-5" unitRef="U_iso4217USD">300000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue id="F_000221" contextRef="C_0001445283_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaapCertificatesOfDepositMember_20161231" decimals="-5" unitRef="U_iso4217USD">300000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent id="F_000222" contextRef="C_0001445283_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20170930" decimals="-5" unitRef="U_iso4217USD">1700000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000223" contextRef="C_0001445283_20160201_20160229" decimals="INF" unitRef="U_shares">9699600</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:Revenues id="F_000224" contextRef="C_0001445283_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20170101_20170930" decimals="-5" unitRef="U_iso4217USD">8100000</us-gaap:Revenues>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost id="F_000225" contextRef="C_0001445283_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20170930" decimals="-3" unitRef="U_iso4217USD">12519000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost id="F_000226" contextRef="C_0001445283_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSTreasurySecuritiesMember_20170930" decimals="-3" unitRef="U_iso4217USD">12522000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost id="F_000227" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">25041000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost id="F_000228" contextRef="C_0001445283_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20161231" decimals="-3" unitRef="U_iso4217USD">53384000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost id="F_000229" contextRef="C_0001445283_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSTreasurySecuritiesMember_20161231" decimals="-3" unitRef="U_iso4217USD">13535000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost id="F_000230" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">66919000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000231" contextRef="C_0001445283_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20170930" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000232" contextRef="C_0001445283_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSTreasurySecuritiesMember_20170930" decimals="-3" unitRef="U_iso4217USD">4000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000233" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">7000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000234" contextRef="C_0001445283_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20161231" decimals="-3" unitRef="U_iso4217USD">20000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000235" contextRef="C_0001445283_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSTreasurySecuritiesMember_20161231" decimals="-3" unitRef="U_iso4217USD">2000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000236" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">22000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecurities id="F_000237" contextRef="C_0001445283_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20170930" decimals="-3" unitRef="U_iso4217USD">12516000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities id="F_000238" contextRef="C_0001445283_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSTreasurySecuritiesMember_20170930" decimals="-3" unitRef="U_iso4217USD">12518000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities id="F_000239" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">25034000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities id="F_000240" contextRef="C_0001445283_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20161231" decimals="-3" unitRef="U_iso4217USD">53364000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities id="F_000241" contextRef="C_0001445283_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSTreasurySecuritiesMember_20161231" decimals="-3" unitRef="U_iso4217USD">13533000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities id="F_000242" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">66897000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet id="F_000243" contextRef="C_0001445283_20170701_20170930" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet id="F_000244" contextRef="C_0001445283_20170101_20170930" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet id="F_000245" contextRef="C_0001445283_20160701_20160930" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet id="F_000246" contextRef="C_0001445283_20160101_20160930" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet>
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities id="F_000247" contextRef="C_0001445283_20170701_20170930" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities id="F_000248" contextRef="C_0001445283_20170101_20170930" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities id="F_000249" contextRef="C_0001445283_20160701_20160930" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities id="F_000250" contextRef="C_0001445283_20160101_20160930" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000251" contextRef="C_0001445283_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20170930" decimals="-3" unitRef="U_iso4217USD">14370000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000252" contextRef="C_0001445283_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20170930" decimals="-3" unitRef="U_iso4217USD">14370000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent id="F_000253" contextRef="C_0001445283_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20170930" decimals="-3" unitRef="U_iso4217USD">12516000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent id="F_000254" contextRef="C_0001445283_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20170930" decimals="-3" unitRef="U_iso4217USD">12516000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent id="F_000255" contextRef="C_0001445283_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20170930" decimals="-3" unitRef="U_iso4217USD">12518000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent id="F_000256" contextRef="C_0001445283_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20170930" decimals="-3" unitRef="U_iso4217USD">12518000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AssetsFairValueDisclosure id="F_000257" contextRef="C_0001445283_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20170930" decimals="-3" unitRef="U_iso4217USD">14370000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000258" contextRef="C_0001445283_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20170930" decimals="-3" unitRef="U_iso4217USD">25034000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000259" contextRef="C_0001445283_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20170930" decimals="-3" unitRef="U_iso4217USD">39404000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:DerivativeLiabilitiesNoncurrent id="F_000260" contextRef="C_0001445283_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20170930" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent id="F_000261" contextRef="C_0001445283_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20170930" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:LiabilitiesFairValueDisclosure id="F_000262" contextRef="C_0001445283_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20170930" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure id="F_000263" contextRef="C_0001445283_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20170930" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000264" contextRef="C_0001445283_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231" decimals="-3" unitRef="U_iso4217USD">15440000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000265" contextRef="C_0001445283_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231" decimals="-3" unitRef="U_iso4217USD">15440000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent id="F_000266" contextRef="C_0001445283_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231" decimals="-3" unitRef="U_iso4217USD">53365000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent id="F_000267" contextRef="C_0001445283_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231" decimals="-3" unitRef="U_iso4217USD">53365000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent id="F_000268" contextRef="C_0001445283_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231" decimals="-3" unitRef="U_iso4217USD">13532000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent id="F_000269" contextRef="C_0001445283_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231" decimals="-3" unitRef="U_iso4217USD">13532000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AssetsFairValueDisclosure id="F_000270" contextRef="C_0001445283_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231" decimals="-3" unitRef="U_iso4217USD">15440000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000271" contextRef="C_0001445283_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231" decimals="-3" unitRef="U_iso4217USD">66897000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000272" contextRef="C_0001445283_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231" decimals="-3" unitRef="U_iso4217USD">82337000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:DerivativeLiabilitiesNoncurrent id="F_000273" contextRef="C_0001445283_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231" decimals="-3" unitRef="U_iso4217USD">91000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent id="F_000274" contextRef="C_0001445283_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231" decimals="-3" unitRef="U_iso4217USD">91000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:LiabilitiesFairValueDisclosure id="F_000275" contextRef="C_0001445283_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231" decimals="-3" unitRef="U_iso4217USD">91000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure id="F_000276" contextRef="C_0001445283_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231" decimals="-3" unitRef="U_iso4217USD">91000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount id="F_000277" contextRef="C_0001445283_20170930" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
  <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount id="F_000278" contextRef="C_0001445283_20161231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
  <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount id="F_000279" contextRef="C_0001445283_20170930" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
  <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount id="F_000280" contextRef="C_0001445283_20161231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
  <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount id="F_000281" contextRef="C_0001445283_20170930" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
  <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount id="F_000282" contextRef="C_0001445283_20161231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
  <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount id="F_000283" contextRef="C_0001445283_20170930" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
  <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount id="F_000284" contextRef="C_0001445283_20161231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
  <us-gaap:FairValueOptionMethodologyAndAssumptions id="F_000285" contextRef="C_0001445283_20170101_20170930">Monte-Carlo simulation analysis</us-gaap:FairValueOptionMethodologyAndAssumptions>
  <us-gaap:FairValueAssumptionsExpectedTerm id="F_000286" contextRef="C_0001445283_20170101_20170930">P2Y3M</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedTerm id="F_000287" contextRef="C_0001445283_20160101_20161231">P2Y6M</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate id="F_000288" contextRef="C_0001445283_20170101_20170930" decimals="3" unitRef="U_pure">0.800</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate id="F_000289" contextRef="C_0001445283_20160101_20161231" decimals="3" unitRef="U_pure">0.811</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate id="F_000290" contextRef="C_0001445283_20170101_20170930" decimals="4" unitRef="U_pure">0.0151</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate id="F_000291" contextRef="C_0001445283_20160101_20161231" decimals="4" unitRef="U_pure">0.0133</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss id="F_000292" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">-88000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
  <pti:PrepaidClinicalManufacturingAndScientificExpensesCurrent id="F_000293" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">1197000</pti:PrepaidClinicalManufacturingAndScientificExpensesCurrent>
  <pti:PrepaidClinicalManufacturingAndScientificExpensesCurrent id="F_000294" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">1390000</pti:PrepaidClinicalManufacturingAndScientificExpensesCurrent>
  <us-gaap:PrepaidInsurance id="F_000295" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">218000</us-gaap:PrepaidInsurance>
  <us-gaap:PrepaidInsurance id="F_000296" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">104000</us-gaap:PrepaidInsurance>
  <pti:OtherPrepaidExpensesAndOtherCurrentAssets id="F_000297" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">423000</pti:OtherPrepaidExpensesAndOtherCurrentAssets>
  <pti:OtherPrepaidExpensesAndOtherCurrentAssets id="F_000298" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">2565000</pti:OtherPrepaidExpensesAndOtherCurrentAssets>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000299" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">1293000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000300" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">1813000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <pti:AccruedResearchAndDevelopmentExpenses id="F_000301" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">4086000</pti:AccruedResearchAndDevelopmentExpenses>
  <pti:AccruedResearchAndDevelopmentExpenses id="F_000302" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">1612000</pti:AccruedResearchAndDevelopmentExpenses>
  <us-gaap:AccruedProfessionalFeesCurrent id="F_000303" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">399000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="F_000304" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">383000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="F_000305" contextRef="C_0001445283_20170930" decimals="-3" unitRef="U_iso4217USD">77000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="F_000306" contextRef="C_0001445283_20161231" decimals="-3" unitRef="U_iso4217USD">520000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000307" contextRef="C_0001445283_us-gaapPlanNameAxis_ptiTwoThousandSixteenStockOptionAndIncentivePlanMember_20160203" decimals="INF" unitRef="U_shares">1581839</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum id="F_000308" contextRef="C_0001445283_us-gaapPlanNameAxis_ptiTwoThousandSixteenStockOptionAndIncentivePlanMember_20160202_20160203" decimals="INF" unitRef="U_pure">0.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000309" contextRef="C_0001445283_us-gaapPlanNameAxis_ptiTwoThousandSixteenStockOptionAndIncentivePlanAndTwoThousandEightPlanMember_20170930" decimals="INF" unitRef="U_shares">3577930</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000310" contextRef="C_0001445283_us-gaapPlanNameAxis_ptiTwoThousandSixteenStockOptionAndIncentivePlanMember_20170930" decimals="INF" unitRef="U_shares">631077</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000311" contextRef="C_0001445283_us-gaapPlanNameAxis_ptiTwoThousandSixteenEmployeeStockPurchasePlanMember_20160203" decimals="INF" unitRef="U_shares">138757</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum id="F_000312" contextRef="C_0001445283_us-gaapPlanNameAxis_ptiTwoThousandSixteenEmployeeStockPurchasePlanMember_20160202_20160203" decimals="INF" unitRef="U_pure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="F_000313" contextRef="C_0001445283_us-gaapPlanNameAxis_ptiTwoThousandSixteenEmployeeStockPurchasePlanMember_20170930" decimals="INF" unitRef="U_shares">138757</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans id="F_000314" contextRef="C_0001445283_us-gaapPlanNameAxis_ptiTwoThousandSixteenEmployeeStockPurchasePlanMember_20170101_20170930" decimals="INF" unitRef="U_shares">10829</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000315" contextRef="C_0001445283_us-gaapPlanNameAxis_ptiTwoThousandSixteenEmployeeStockPurchasePlanMember_20170930" decimals="INF" unitRef="U_shares">266685</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000316" contextRef="C_0001445283_us-gaapPlanNameAxis_ptiTwoThousandSixteenEmployeeStockPurchasePlanMember_us-gaapRangeAxis_us-gaapMaximumMember_20170701_20170930" decimals="INF" unitRef="U_iso4217USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000317" contextRef="C_0001445283_us-gaapPlanNameAxis_ptiTwoThousandSixteenEmployeeStockPurchasePlanMember_us-gaapRangeAxis_us-gaapMaximumMember_20170101_20170930" decimals="INF" unitRef="U_iso4217USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross id="F_000318" contextRef="C_0001445283_us-gaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ptiPriorToTwoThousandThirteenMember_us-gaapTitleOfIndividualAxis_ptiNonEmployeesMember_20170101_20170930" decimals="INF" unitRef="U_shares">203964</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares id="F_000319" contextRef="C_0001445283_us-gaapTitleOfIndividualAxis_ptiNonEmployeesMember_20170930" decimals="INF" unitRef="U_shares">83250</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 id="F_000320" contextRef="C_0001445283_us-gaapTitleOfIndividualAxis_ptiNonEmployeesMember_20170101_20170930" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000321" contextRef="C_0001445283_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20170701_20170930" decimals="-3" unitRef="U_iso4217USD">412000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000322" contextRef="C_0001445283_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20160701_20160930" decimals="-3" unitRef="U_iso4217USD">119000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000323" contextRef="C_0001445283_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">1070000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000324" contextRef="C_0001445283_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">351000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000325" contextRef="C_0001445283_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20170701_20170930" decimals="-3" unitRef="U_iso4217USD">636000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000326" contextRef="C_0001445283_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20160701_20160930" decimals="-3" unitRef="U_iso4217USD">451000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000327" contextRef="C_0001445283_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">1713000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000328" contextRef="C_0001445283_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">1024000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000329" contextRef="C_0001445283_20170701_20170930" decimals="-3" unitRef="U_iso4217USD">1048000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000330" contextRef="C_0001445283_20160701_20160930" decimals="-3" unitRef="U_iso4217USD">570000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000331" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">2783000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000332" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">1375000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:Revenues id="F_000333" contextRef="C_0001445283_us-gaapTypeOfArrangementAxis_ptiAstellasCollaborationAgreementMember_20170701_20170930" decimals="-5" unitRef="U_iso4217USD">1600000</us-gaap:Revenues>
  <us-gaap:Revenues id="F_000334" contextRef="C_0001445283_us-gaapTypeOfArrangementAxis_ptiAstellasCollaborationAgreementMember_20160701_20160930" decimals="-5" unitRef="U_iso4217USD">1000000</us-gaap:Revenues>
  <us-gaap:Revenues id="F_000335" contextRef="C_0001445283_us-gaapTypeOfArrangementAxis_ptiAstellasCollaborationAgreementMember_20170101_20170930" decimals="-5" unitRef="U_iso4217USD">3700000</us-gaap:Revenues>
  <us-gaap:Revenues id="F_000336" contextRef="C_0001445283_us-gaapTypeOfArrangementAxis_ptiAstellasCollaborationAgreementMember_20160101_20160930" decimals="-5" unitRef="U_iso4217USD">2200000</us-gaap:Revenues>
  <pti:ResearchAndDevelopmentCollaborationAgreementInitialTerm id="F_000337" contextRef="C_0001445283_us-gaapTypeOfArrangementAxis_ptiAstellasCollaborationAgreementMember_20150101_20150131">P3Y6M</pti:ResearchAndDevelopmentCollaborationAgreementInitialTerm>
  <us-gaap:DeferredRevenue id="F_000338" contextRef="C_0001445283_us-gaapTypeOfArrangementAxis_ptiAstellasCollaborationAgreementMember_20170930" decimals="-5" unitRef="U_iso4217USD">1800000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue id="F_000339" contextRef="C_0001445283_us-gaapTypeOfArrangementAxis_ptiAstellasCollaborationAgreementMember_20161231" decimals="-5" unitRef="U_iso4217USD">3000000</us-gaap:DeferredRevenue>
  <us-gaap:Revenues id="F_000340" contextRef="C_0001445283_us-gaapTypeOfArrangementAxis_ptiBiogenLicenseAgreementsMember_20160701_20160930" decimals="-5" unitRef="U_iso4217USD">700000</us-gaap:Revenues>
  <us-gaap:Revenues id="F_000341" contextRef="C_0001445283_us-gaapTypeOfArrangementAxis_ptiBiogenLicenseAgreementsMember_20160101_20160930" decimals="-5" unitRef="U_iso4217USD">2100000</us-gaap:Revenues>
  <us-gaap:DeferredRevenue id="F_000342" contextRef="C_0001445283_us-gaapTypeOfArrangementAxis_ptiBiogenLicenseAgreementsMember_20170930" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue id="F_000343" contextRef="C_0001445283_us-gaapTypeOfArrangementAxis_ptiBiogenLicenseAgreementsMember_20161231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:DeferredRevenue>
  <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations id="F_000344" contextRef="C_0001445283_20170701_20170930" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
  <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations id="F_000345" contextRef="C_0001445283_20170101_20170930" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
  <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations id="F_000346" contextRef="C_0001445283_20160701_20160930" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
  <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations id="F_000347" contextRef="C_0001445283_20160101_20160930" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
  <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations id="F_000348" contextRef="C_0001445283_20170701_20170930" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
  <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations id="F_000349" contextRef="C_0001445283_20170101_20170930" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
  <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations id="F_000350" contextRef="C_0001445283_20160701_20160930" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
  <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations id="F_000351" contextRef="C_0001445283_20160101_20160930" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted id="F_000352" contextRef="C_0001445283_20170701_20170930" decimals="-3" unitRef="U_iso4217USD">-13954000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted id="F_000353" contextRef="C_0001445283_20160701_20160930" decimals="-3" unitRef="U_iso4217USD">-10771000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted id="F_000354" contextRef="C_0001445283_20170101_20170930" decimals="-3" unitRef="U_iso4217USD">-46008000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted id="F_000355" contextRef="C_0001445283_20160101_20160930" decimals="-3" unitRef="U_iso4217USD">-29193000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="F_000356" contextRef="C_0001445283_20170701_20170930" decimals="0" unitRef="U_shares">25093344</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="F_000357" contextRef="C_0001445283_20160701_20160930" decimals="0" unitRef="U_shares">20073685</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="F_000358" contextRef="C_0001445283_20170101_20170930" decimals="0" unitRef="U_shares">25051536</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="F_000359" contextRef="C_0001445283_20160101_20160930" decimals="0" unitRef="U_shares">16672368</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000360" contextRef="C_0001445283_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20170101_20170930" decimals="INF" unitRef="U_shares">2946853</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000361" contextRef="C_0001445283_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20160101_20160930" decimals="INF" unitRef="U_shares">1731823</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000362" contextRef="C_0001445283_us-gaapStatementClassOfStockAxis_ptiWarrantsToPurchaseConvertiblePreferredStockMember_20160101_20160930" decimals="INF" unitRef="U_shares">14800</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000363" contextRef="C_0001445283_20170101_20170930" decimals="INF" unitRef="U_shares">2946853</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000364" contextRef="C_0001445283_20160101_20160930" decimals="INF" unitRef="U_shares">1746623</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000365" contextRef="C_0001445283_20170101_20170930" decimals="INF" unitRef="U_shares">4349</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:AreaOfRealEstateProperty id="F_000366" contextRef="C_0001445283_us-gaapCounterpartyNameAxis_ptiIceBoxLLCMember_20170919" decimals="INF" unitRef="U_utrsqft">30000</us-gaap:AreaOfRealEstateProperty>
  <us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract id="F_000367" contextRef="C_0001445283_us-gaapCounterpartyNameAxis_ptiIceBoxLLCMember_20170918_20170919">P10Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent id="F_000368" contextRef="C_0001445283_us-gaapCounterpartyNameAxis_ptiIceBoxLLCMember_20170919" decimals="-5" unitRef="U_iso4217USD">1700000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm id="F_000369" contextRef="C_0001445283_us-gaapCounterpartyNameAxis_ptiIceBoxLLCMember_20170918_20170919">P7Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm>
  <us-gaap:DescriptionOfLesseeLeasingArrangementsOperatingLeases id="F_000370" contextRef="C_0001445283_us-gaapCounterpartyNameAxis_ptiIceBoxLLCMember_20170101_20170930">The lease will extend for a lease term from the commencement date and then for ten years starting with the first day of the month following the month in which the commencement date falls, unless terminated earlier. The Company is entitled to one seven-year option to extend.</us-gaap:DescriptionOfLesseeLeasingArrangementsOperatingLeases>
  <pti:AnnualIncreaseInLeasePayments id="F_000371" contextRef="C_0001445283_us-gaapCounterpartyNameAxis_ptiIceBoxLLCMember_20170918_20170919" decimals="4" unitRef="U_pure">0.0275</pti:AnnualIncreaseInLeasePayments>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue id="F_000372" contextRef="C_0001445283_us-gaapCounterpartyNameAxis_ptiIceBoxLLCMember_20170919" decimals="-5" unitRef="U_iso4217USD">18800000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <pti:ImprovementAllowanceReceivable id="F_000373" contextRef="C_0001445283_us-gaapCounterpartyNameAxis_ptiIceBoxLLCMember_20170919" decimals="-5" unitRef="U_iso4217USD">4800000</pti:ImprovementAllowanceReceivable>
  <pti:BuildToSuitAssetCapitalized id="F_000374" contextRef="C_0001445283_20170930" decimals="-5" unitRef="U_iso4217USD">12100000</pti:BuildToSuitAssetCapitalized>
  <pti:BuildToSuitFacilityLeaseObligation id="F_000375" contextRef="C_0001445283_20170930" decimals="-5" unitRef="U_iso4217USD">12100000</pti:BuildToSuitFacilityLeaseObligation>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>22
<FILENAME>pti-20170930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFS ActiveDisclosure(SM) XBRL Schema Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2017-11-14T21:33:05.9314603+00:00 -->
<!-- Version            : 2.5.0.9 -->
<!-- Package ID         : C898DE00A4E7409BAA35AC9210F2845E-0001445283-001709 -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:pti="http://www.proteostasis.com/20170930" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.proteostasis.com/20170930" xmlns="http://www.w3.org/2001/XMLSchema">
  <import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <import schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" namespace="http://fasb.org/us-gaap/2017-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2014-01-31" />
  <import schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" namespace="http://fasb.org/us-types/2017-01-31" />
  <import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <import schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" namespace="http://xbrl.sec.gov/country/2017-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2017-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2017-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" namespace="http://xbrl.sec.gov/invest/2013-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2011-01-31" />
  <annotation>
    <appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.proteostasis.com/20170930/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pti-20170930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pti-20170930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pti-20170930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pti-20170930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/StatementCondensedBalanceSheets" id="Role_StatementCondensedBalanceSheets">
        <link:definition>100010 - Statement - Condensed Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/StatementCondensedBalanceSheetsParenthetical" id="Role_StatementCondensedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Condensed Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/StatementCondensedStatementsOfOperations" id="Role_StatementCondensedStatementsOfOperations">
        <link:definition>100030 - Statement - Condensed Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/StatementCondensedStatementsOfComprehensiveLoss" id="Role_StatementCondensedStatementsOfComprehensiveLoss">
        <link:definition>100040 - Statement - Condensed Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/StatementCondensedStatementsOfCashFlows" id="Role_StatementCondensedStatementsOfCashFlows">
        <link:definition>100050 - Statement - Condensed Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNatureOfBusiness" id="Role_DisclosureNatureOfBusiness">
        <link:definition>100060 - Disclosure - Nature of the Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100070 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureShortTermInvestments" id="Role_DisclosureShortTermInvestments">
        <link:definition>100080 - Disclosure - Short Term Investments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilities" id="Role_DisclosureFairValueOfFinancialAssetsAndLiabilities">
        <link:definition>100090 - Disclosure - Fair Value of Financial Assets and Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosurePrepaidsAndOtherCurrentAssets" id="Role_DisclosurePrepaidsAndOtherCurrentAssets">
        <link:definition>100100 - Disclosure - Prepaids and Other Current Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureAccruedExpenses" id="Role_DisclosureAccruedExpenses">
        <link:definition>100110 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100120 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureCollaborationAgreement" id="Role_DisclosureCollaborationAgreement">
        <link:definition>100130 - Disclosure - Collaboration Agreement</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100140 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100150 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureBuildToSuitLease" id="Role_DisclosureBuildToSuitLease">
        <link:definition>100160 - Disclosure - Build-to-Suit Lease</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100170 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureShortTermInvestmentsTables" id="Role_DisclosureShortTermInvestmentsTables">
        <link:definition>100180 - Disclosure - Short Term Investments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables" id="Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables">
        <link:definition>100190 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosurePrepaidsAndOtherCurrentAssetsTables" id="Role_DisclosurePrepaidsAndOtherCurrentAssetsTables">
        <link:definition>100200 - Disclosure - Prepaids and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureAccruedExpensesTables" id="Role_DisclosureAccruedExpensesTables">
        <link:definition>100210 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100220 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100230 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail" id="Role_DisclosureNatureOfBusinessAdditionalInformationDetail">
        <link:definition>100240 - Disclosure - Nature of the Business - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>100250 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetail" id="Role_DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetail">
        <link:definition>100260 - Disclosure - Short Term Investments - Summary of Short Term Investments (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureShortTermInvestmentsAdditionalInformationDetail" id="Role_DisclosureShortTermInvestmentsAdditionalInformationDetail">
        <link:definition>100270 - Disclosure - Short Term Investments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" id="Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
        <link:definition>100280 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail" id="Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail">
        <link:definition>100290 - Disclosure - Fair Value of Financial Assets and Liabilities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfChangesInValuesOfDerivativeLiabilityDetail" id="Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfChangesInValuesOfDerivativeLiabilityDetail">
        <link:definition>100300 - Disclosure - Fair Value of Financial Assets and Liabilities - Summary of Changes in Values of Derivative Liability (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosurePrepaidsAndOtherCurrentAssetsScheduleOfPrepaidsAndOtherCurrentAssetsDetail" id="Role_DisclosurePrepaidsAndOtherCurrentAssetsScheduleOfPrepaidsAndOtherCurrentAssetsDetail">
        <link:definition>100310 - Disclosure - Prepaids and Other Current Assets - Schedule of Prepaids and Other Current Assets (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" id="Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail">
        <link:definition>100320 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetail">
        <link:definition>100330 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseIncludingSharesIssuedToNonEmployeeForConsultingServicesDetail" id="Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseIncludingSharesIssuedToNonEmployeeForConsultingServicesDetail">
        <link:definition>100340 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense, Including Shares Issued to Non-Employee for Consulting Services (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetail" id="Role_DisclosureCollaborationAgreementAdditionalInformationDetail">
        <link:definition>100350 - Disclosure - Collaboration Agreement - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>100360 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetail" id="Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetail">
        <link:definition>100370 - Disclosure - Net Loss per Share - Schedule of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOutstandingDetail" id="Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOutstandingDetail">
        <link:definition>100380 - Disclosure - Net Loss per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Weighted-average Shares Outstanding (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail" id="Role_DisclosureNetLossPerShareAdditionalInformationDetail">
        <link:definition>100390 - Disclosure - Net Loss per Share - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureBuildToSuitLeaseAdditionalInformationDetail" id="Role_DisclosureBuildToSuitLeaseAdditionalInformationDetail">
        <link:definition>100400 - Disclosure - Build-to-Suit Lease - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </appinfo>
  </annotation>
  <element id="pti_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="pti_PremiumOnShortTermInvestments" name="PremiumOnShortTermInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="pti_NoncashRentExpenseIncome" name="NoncashRentExpenseIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="pti_ChangeInFairValueOfDerivativeLiability" name="ChangeInFairValueOfDerivativeLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="pti_StockIssuedForPaymentOfAccruedDividends" name="StockIssuedForPaymentOfAccruedDividends" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="pti_StockIssuedForPaymentOfAccruedBonus" name="StockIssuedForPaymentOfAccruedBonus" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="pti_ConversionOfPreferredStockWarrantsIntoCommonStockWarrants" name="ConversionOfPreferredStockWarrantsIntoCommonStockWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="pti_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense" name="DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="pti_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="pti_FollowOnPublicOfferingMember" name="FollowOnPublicOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="pti_AccruedExpensesDisclosureTextBlock" name="AccruedExpensesDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="pti_UnauditedInterimFinancialInformationPolicyTextBlock" name="UnauditedInterimFinancialInformationPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="pti_ScheduleOfPrepaidsAndOtherCurrentAssetsTableTextBlock" name="ScheduleOfPrepaidsAndOtherCurrentAssetsTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="pti_SignificantAccountingPoliciesLineItems" name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="pti_SignificantAccountingPoliciesTable" name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="pti_PrepaidClinicalManufacturingAndScientificExpensesCurrent" name="PrepaidClinicalManufacturingAndScientificExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="pti_OtherPrepaidExpensesAndOtherCurrentAssets" name="OtherPrepaidExpensesAndOtherCurrentAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="pti_AccruedResearchAndDevelopmentExpenses" name="AccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="pti_TwoThousandSixteenStockOptionAndIncentivePlanMember" name="TwoThousandSixteenStockOptionAndIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="pti_TwoThousandSixteenStockOptionAndIncentivePlanAndTwoThousandEightPlanMember" name="TwoThousandSixteenStockOptionAndIncentivePlanAndTwoThousandEightPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="pti_TwoThousandSixteenEmployeeStockPurchasePlanMember" name="TwoThousandSixteenEmployeeStockPurchasePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="pti_NonEmployeesMember" name="NonEmployeesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="pti_PriorToTwoThousandThirteenMember" name="PriorToTwoThousandThirteenMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="pti_ResearchAndDevelopmentCollaborationAgreementInitialTerm" name="ResearchAndDevelopmentCollaborationAgreementInitialTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="pti_VariableInterestsAndEquityMethodInvestmentsDisclosureAbstract" name="VariableInterestsAndEquityMethodInvestmentsDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="pti_AstellasCollaborationAgreementMember" name="AstellasCollaborationAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="pti_BiogenLicenseAgreementsMember" name="BiogenLicenseAgreementsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="pti_WarrantsToPurchaseConvertiblePreferredStockMember" name="WarrantsToPurchaseConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="pti_AnnualIncreaseInLeasePayments" name="AnnualIncreaseInLeasePayments" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="pti_ImprovementAllowanceReceivable" name="ImprovementAllowanceReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="pti_IceBoxLLCMember" name="IceBoxLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="pti_BuildToSuitAssetCapitalized" name="BuildToSuitAssetCapitalized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="pti_BuildToSuitFacilityLeaseObligation" name="BuildToSuitFacilityLeaseObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>23
<FILENAME>pti-20170930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFS ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2017-11-14T21:33:05.9314603+00:00 -->
<!-- Version            : 2.5.0.9 -->
<!-- Package ID         : C898DE00A4E7409BAA35AC9210F2845E-0001445283-001709 -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="pti-20170930.xsd#TemplateLink" roleURI="http://www.proteostasis.com/20170930/role/TemplateLink" />
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/StatementCondensedBalanceSheets" xlink:href="pti-20170930.xsd#Role_StatementCondensedBalanceSheets" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/StatementCondensedBalanceSheets">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10070.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10080.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="10180.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10190.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10200.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10210.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="10220.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10230.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="10240.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="10250.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10260.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10270.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/StatementCondensedStatementsOfOperations" xlink:href="pti-20170930.xsd#Role_StatementCondensedStatementsOfOperations" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/StatementCondensedStatementsOfOperations">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterest" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10080.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10090.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/StatementCondensedStatementsOfComprehensiveLoss" xlink:href="pti-20170930.xsd#Role_StatementCondensedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/StatementCondensedStatementsOfComprehensiveLoss">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10020.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/StatementCondensedStatementsOfCashFlows" xlink:href="pti-20170930.xsd#Role_StatementCondensedStatementsOfCashFlows" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/StatementCondensedStatementsOfCashFlows">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <loc xlink:href="pti-20170930.xsd#pti_ChangeInFairValueOfDerivativeLiability" xlink:type="locator" xlink:label="pti_ChangeInFairValueOfDerivativeLiability" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <loc xlink:href="pti-20170930.xsd#pti_NoncashRentExpenseIncome" xlink:type="locator" xlink:label="pti_NoncashRentExpenseIncome" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <loc xlink:href="pti-20170930.xsd#pti_PremiumOnShortTermInvestments" xlink:type="locator" xlink:label="pti_PremiumOnShortTermInvestments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="10120.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10130.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="10140.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" order="10150.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10160.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="pti_PremiumOnShortTermInvestments" order="10170.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10180.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="pti_NoncashRentExpenseIncome" order="10190.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" order="10200.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="10210.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="pti_ChangeInFairValueOfDerivativeLiability" order="10220.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10230.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="10240.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10250.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="10260.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="10270.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10280.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10290.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="10300.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetail" xlink:href="pti-20170930.xsd#Role_DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecurities" order="10030.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="pti-20170930.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosurePrepaidsAndOtherCurrentAssetsScheduleOfPrepaidsAndOtherCurrentAssetsDetail" xlink:href="pti-20170930.xsd#Role_DisclosurePrepaidsAndOtherCurrentAssetsScheduleOfPrepaidsAndOtherCurrentAssetsDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosurePrepaidsAndOtherCurrentAssetsScheduleOfPrepaidsAndOtherCurrentAssetsDetail">
    <loc xlink:href="pti-20170930.xsd#pti_OtherPrepaidExpensesAndOtherCurrentAssets" xlink:type="locator" xlink:label="pti_OtherPrepaidExpensesAndOtherCurrentAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidInsurance" xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" />
    <loc xlink:href="pti-20170930.xsd#pti_PrepaidClinicalManufacturingAndScientificExpensesCurrent" xlink:type="locator" xlink:label="pti_PrepaidClinicalManufacturingAndScientificExpensesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="pti_PrepaidClinicalManufacturingAndScientificExpensesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="pti_OtherPrepaidExpensesAndOtherCurrentAssets" order="10030.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" xlink:href="pti-20170930.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <loc xlink:href="pti-20170930.xsd#pti_AccruedResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="pti_AccruedResearchAndDevelopmentExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="pti_AccruedResearchAndDevelopmentExpenses" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetail" xlink:href="pti-20170930.xsd#Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>24
<FILENAME>pti-20170930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFS ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2017-11-14T21:33:05.9314603+00:00 -->
<!-- Version            : 2.5.0.9 -->
<!-- Package ID         : C898DE00A4E7409BAA35AC9210F2845E-0001445283-001709 -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <roleRef xlink:type="simple" xlink:href="pti-20170930.xsd#TemplateLink" roleURI="http://www.proteostasis.com/20170930/role/TemplateLink" />
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/StatementCondensedStatementsOfCashFlows" xlink:href="pti-20170930.xsd#Role_StatementCondensedStatementsOfCashFlows" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/StatementCondensedStatementsOfCashFlows">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <loc xlink:href="pti-20170930.xsd#pti_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense" xlink:type="locator" xlink:label="pti_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense" />
    <loc xlink:href="pti-20170930.xsd#pti_ConversionOfPreferredStockWarrantsIntoCommonStockWarrants" xlink:type="locator" xlink:label="pti_ConversionOfPreferredStockWarrantsIntoCommonStockWarrants" />
    <loc xlink:href="pti-20170930.xsd#pti_StockIssuedForPaymentOfAccruedBonus" xlink:type="locator" xlink:label="pti_StockIssuedForPaymentOfAccruedBonus" />
    <loc xlink:href="pti-20170930.xsd#pti_StockIssuedForPaymentOfAccruedDividends" xlink:type="locator" xlink:label="pti_StockIssuedForPaymentOfAccruedDividends" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <loc xlink:href="pti-20170930.xsd#pti_ChangeInFairValueOfDerivativeLiability" xlink:type="locator" xlink:label="pti_ChangeInFairValueOfDerivativeLiability" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <loc xlink:href="pti-20170930.xsd#pti_NoncashRentExpenseIncome" xlink:type="locator" xlink:label="pti_NoncashRentExpenseIncome" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <loc xlink:href="pti-20170930.xsd#pti_PremiumOnShortTermInvestments" xlink:type="locator" xlink:label="pti_PremiumOnShortTermInvestments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <loc xlink:href="pti-20170930.xsd#pti_FollowOnPublicOfferingMember" xlink:type="locator" xlink:label="pti_FollowOnPublicOfferingMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <loc xlink:href="pti-20170930.xsd#pti_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="pti_EmployeeStockPurchasePlanMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10310.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" order="10340.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pti_EmployeeStockPurchasePlanMember" order="10390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10400.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10430.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pti_FollowOnPublicOfferingMember" order="10470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="10500.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10580.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10620.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10700.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="pti_PremiumOnShortTermInvestments" order="10740.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10780.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="pti_NoncashRentExpenseIncome" order="10820.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10860.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="10900.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="pti_ChangeInFairValueOfDerivativeLiability" order="10940.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10980.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="11020.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="11060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="11140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="11180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="11220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="11300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="11340.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="11380.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="11420.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="11500.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" order="11540.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="11580.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11620.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="11660.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="11700.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" order="11740.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11820.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11860.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11900.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11980.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="12060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="12100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="12140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="12220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="12300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="pti_StockIssuedForPaymentOfAccruedDividends" order="12340.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="pti_StockIssuedForPaymentOfAccruedBonus" order="12380.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="pti_ConversionOfPreferredStockWarrantsIntoCommonStockWarrants" order="12420.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="pti_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense" order="12460.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="12500.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="pti-20170930.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:type="locator" xlink:label="us-gaap_CertificatesOfDepositMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" />
    <loc xlink:href="pti-20170930.xsd#pti_SignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="pti_SignificantAccountingPoliciesTable" />
    <loc xlink:href="pti-20170930.xsd#pti_SignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="pti_SignificantAccountingPoliciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pti_SignificantAccountingPoliciesLineItems" xlink:to="pti_SignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pti_SignificantAccountingPoliciesTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CertificatesOfDepositMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pti_SignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_2" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pti_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pti_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="10240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pti_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pti_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_Revenues" order="10360.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetail" xlink:href="pti-20170930.xsd#Role_DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10040.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" order="10570.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="pti-20170930.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="10370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="10480.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10680.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10780.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10980.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="11080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="11280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="11380.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="pti-20170930.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <loc xlink:href="pti-20170930.xsd#pti_PriorToTwoThousandThirteenMember" xlink:type="locator" xlink:label="pti_PriorToTwoThousandThirteenMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:type="locator" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" />
    <loc xlink:href="pti-20170930.xsd#pti_NonEmployeesMember" xlink:type="locator" xlink:label="pti_NonEmployeesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="pti-20170930.xsd#pti_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="pti_TwoThousandSixteenEmployeeStockPurchasePlanMember" />
    <loc xlink:href="pti-20170930.xsd#pti_TwoThousandSixteenStockOptionAndIncentivePlanAndTwoThousandEightPlanMember" xlink:type="locator" xlink:label="pti_TwoThousandSixteenStockOptionAndIncentivePlanAndTwoThousandEightPlanMember" />
    <loc xlink:href="pti-20170930.xsd#pti_TwoThousandSixteenStockOptionAndIncentivePlanMember" xlink:type="locator" xlink:label="pti_TwoThousandSixteenStockOptionAndIncentivePlanMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pti_TwoThousandSixteenStockOptionAndIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pti_TwoThousandSixteenStockOptionAndIncentivePlanAndTwoThousandEightPlanMember" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pti_TwoThousandSixteenEmployeeStockPurchasePlanMember" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="10340.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_2" order="10350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10430.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="10440.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2" order="10450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="10470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="pti_NonEmployeesMember" order="10490.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" order="10540.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="us-gaap_AdjustmentsForErrorCorrectionDomain_2" order="10550.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="us-gaap_AdjustmentsForErrorCorrectionDomain" order="10570.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:to="pti_PriorToTwoThousandThirteenMember" order="10590.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10620.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="10660.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10930.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="10990.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" order="11260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="11300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="11340.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseIncludingSharesIssuedToNonEmployeeForConsultingServicesDetail" xlink:href="pti-20170930.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseIncludingSharesIssuedToNonEmployeeForConsultingServicesDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseIncludingSharesIssuedToNonEmployeeForConsultingServicesDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetail" xlink:href="pti-20170930.xsd#Role_DisclosureCollaborationAgreementAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <loc xlink:href="pti-20170930.xsd#pti_ResearchAndDevelopmentCollaborationAgreementInitialTerm" xlink:type="locator" xlink:label="pti_ResearchAndDevelopmentCollaborationAgreementInitialTerm" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <loc xlink:href="pti-20170930.xsd#pti_BiogenLicenseAgreementsMember" xlink:type="locator" xlink:label="pti_BiogenLicenseAgreementsMember" />
    <loc xlink:href="pti-20170930.xsd#pti_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="pti_AstellasCollaborationAgreementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pti_AstellasCollaborationAgreementMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pti_BiogenLicenseAgreementsMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pti_ResearchAndDevelopmentCollaborationAgreementInitialTerm" order="10300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="10400.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOutstandingDetail" xlink:href="pti-20170930.xsd#Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOutstandingDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOutstandingDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <loc xlink:href="pti-20170930.xsd#pti_WarrantsToPurchaseConvertiblePreferredStockMember" xlink:type="locator" xlink:label="pti_WarrantsToPurchaseConvertiblePreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pti_WarrantsToPurchaseConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10180.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureBuildToSuitLeaseAdditionalInformationDetail" xlink:href="pti-20170930.xsd#Role_DisclosureBuildToSuitLeaseAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureBuildToSuitLeaseAdditionalInformationDetail">
    <loc xlink:href="pti-20170930.xsd#pti_BuildToSuitFacilityLeaseObligation" xlink:type="locator" xlink:label="pti_BuildToSuitFacilityLeaseObligation" />
    <loc xlink:href="pti-20170930.xsd#pti_BuildToSuitAssetCapitalized" xlink:type="locator" xlink:label="pti_BuildToSuitAssetCapitalized" />
    <loc xlink:href="pti-20170930.xsd#pti_ImprovementAllowanceReceivable" xlink:type="locator" xlink:label="pti_ImprovementAllowanceReceivable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <loc xlink:href="pti-20170930.xsd#pti_AnnualIncreaseInLeasePayments" xlink:type="locator" xlink:label="pti_AnnualIncreaseInLeasePayments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases" xlink:type="locator" xlink:label="us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <loc xlink:href="pti-20170930.xsd#pti_IceBoxLLCMember" xlink:type="locator" xlink:label="pti_IceBoxLLCMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pti_IceBoxLLCMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" order="10140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" order="10180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pti_AnnualIncreaseInLeasePayments" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="10240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pti_ImprovementAllowanceReceivable" order="10260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pti_BuildToSuitAssetCapitalized" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pti_BuildToSuitFacilityLeaseObligation" order="10360.00" priority="2" use="optional" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>25
<FILENAME>pti-20170930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFS ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2017-11-14T21:33:05.9324600+00:00 -->
<!-- Version            : 2.5.0.9 -->
<!-- Package ID         : C898DE00A4E7409BAA35AC9210F2845E-0001445283-001709 -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <loc xlink:href="pti-20170930.xsd#pti_DocumentAndEntityInformationAbstract" xlink:type="locator" xlink:label="pti_DocumentAndEntityInformationAbstract" />
    <label xml:lang="en-US" xlink:label="pti_DocumentAndEntityInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Document And Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_DocumentAndEntityInformationAbstract" xlink:to="pti_DocumentAndEntityInformationAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="pti_DocumentAndEntityInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Abstract]</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</label>
    <label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investments</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents At Carrying Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaids and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liabilities Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value; 5,000,000 shares authorized as of September 30, 2017 and December 31, 2016, respectively; no shares issued and outstanding as of September 30, 2017 and December 31, 2016</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; 125,000,000 shares authorized as of September 30, 2017 and December 31, 2016, respectively; 25,112,724 and 25,000,734 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Interest</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expense, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accruing dividends on preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Accretion To Redemption Value Adjustment</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders&#8212;basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding&#8212;basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Income And Comprehensive Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</label>
    <loc xlink:href="pti-20170930.xsd#pti_PremiumOnShortTermInvestments" xlink:type="locator" xlink:label="pti_PremiumOnShortTermInvestments" />
    <label xml:lang="en-US" xlink:label="pti_PremiumOnShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Premium on short term investments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_PremiumOnShortTermInvestments" xlink:to="pti_PremiumOnShortTermInvestments_lbl" />
    <loc xlink:href="pti-20170930.xsd#pti_NoncashRentExpenseIncome" xlink:type="locator" xlink:label="pti_NoncashRentExpenseIncome" />
    <label xml:lang="en-US" xlink:label="pti_NoncashRentExpenseIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash rent expense (income).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_NoncashRentExpenseIncome" xlink:to="pti_NoncashRentExpenseIncome_lbl" />
    <loc xlink:href="pti-20170930.xsd#pti_ChangeInFairValueOfDerivativeLiability" xlink:type="locator" xlink:label="pti_ChangeInFairValueOfDerivativeLiability" />
    <label xml:lang="en-US" xlink:label="pti_ChangeInFairValueOfDerivativeLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Change In Fair Value Of Derivative Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_ChangeInFairValueOfDerivativeLiability" xlink:to="pti_ChangeInFairValueOfDerivativeLiability_lbl" />
    <loc xlink:href="pti-20170930.xsd#pti_StockIssuedForPaymentOfAccruedDividends" xlink:type="locator" xlink:label="pti_StockIssuedForPaymentOfAccruedDividends" />
    <label xml:lang="en-US" xlink:label="pti_StockIssuedForPaymentOfAccruedDividends_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued for payment of accrued dividends.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_StockIssuedForPaymentOfAccruedDividends" xlink:to="pti_StockIssuedForPaymentOfAccruedDividends_lbl" />
    <loc xlink:href="pti-20170930.xsd#pti_StockIssuedForPaymentOfAccruedBonus" xlink:type="locator" xlink:label="pti_StockIssuedForPaymentOfAccruedBonus" />
    <label xml:lang="en-US" xlink:label="pti_StockIssuedForPaymentOfAccruedBonus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued for payment of accrued bonus.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_StockIssuedForPaymentOfAccruedBonus" xlink:to="pti_StockIssuedForPaymentOfAccruedBonus_lbl" />
    <loc xlink:href="pti-20170930.xsd#pti_ConversionOfPreferredStockWarrantsIntoCommonStockWarrants" xlink:type="locator" xlink:label="pti_ConversionOfPreferredStockWarrantsIntoCommonStockWarrants" />
    <label xml:lang="en-US" xlink:label="pti_ConversionOfPreferredStockWarrantsIntoCommonStockWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of preferred stock warrants into common stock warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_ConversionOfPreferredStockWarrantsIntoCommonStockWarrants" xlink:to="pti_ConversionOfPreferredStockWarrantsIntoCommonStockWarrants_lbl" />
    <loc xlink:href="pti-20170930.xsd#pti_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense" xlink:type="locator" xlink:label="pti_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense" />
    <label xml:lang="en-US" xlink:label="pti_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred offering costs included in accounts payable and accrued expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense" xlink:to="pti_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</label>
    <loc xlink:href="pti-20170930.xsd#pti_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="pti_EmployeeStockPurchasePlanMember" />
    <label xml:lang="en-US" xlink:label="pti_EmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_EmployeeStockPurchasePlanMember" xlink:to="pti_EmployeeStockPurchasePlanMember_lbl" />
    <label xml:lang="en-US" xlink:label="pti_EmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan [Member]</label>
    <label xml:lang="en-US" xlink:label="pti_EmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</label>
    <loc xlink:href="pti-20170930.xsd#pti_FollowOnPublicOfferingMember" xlink:type="locator" xlink:label="pti_FollowOnPublicOfferingMember" />
    <label xml:lang="en-US" xlink:label="pti_FollowOnPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Follow on public offering.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_FollowOnPublicOfferingMember" xlink:to="pti_FollowOnPublicOfferingMember_lbl" />
    <label xml:lang="en-US" xlink:label="pti_FollowOnPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Follow-on Public Offering [Member]</label>
    <label xml:lang="en-US" xlink:label="pti_FollowOnPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Follow On Public Offering [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</label>
    <label xml:lang="en-US" xlink:label="pti_PremiumOnShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Premium on short-term investments</label>
    <label xml:lang="en-US" xlink:label="pti_PremiumOnShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Premium On Short Term Investments</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of premium on short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Amortization Of Discounts And Premiums Investments</label>
    <label xml:lang="en-US" xlink:label="pti_NoncashRentExpenseIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash rent expense</label>
    <label xml:lang="en-US" xlink:label="pti_NoncashRentExpenseIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Rent Expense Income</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <label xml:lang="en-US" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issued for consulting services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Stock And Warrants For Services Or Claims</label>
    <label xml:lang="en-US" xlink:label="pti_ChangeInFairValueOfDerivativeLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of derivative liability</label>
    <label xml:lang="en-US" xlink:label="pti_ChangeInFairValueOfDerivativeLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Derivative Liability</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of preferred stock warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment Of Warrants</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" />
    <label xml:lang="en-US" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain on disposal of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss On Disposition Of Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaids and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Expenses Other</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Operating Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Deferred Revenue</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities Continuing Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Restricted Cash</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Available For Sale Securities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds received from maturities of short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds received from disposal of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Of Property Plant And Equipment</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities Continuing Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities Continuing Operations [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock upon completion of initial public offering, net of commissions and underwriting discounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments of public offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities Continuing Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Period Increase Decrease</label>
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of period</label>
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash investing and financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Stock Amount Converted1</label>
    <label xml:lang="en-US" xlink:label="pti_StockIssuedForPaymentOfAccruedDividends_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock to settle accrued Series A preferred stock dividends</label>
    <label xml:lang="en-US" xlink:label="pti_StockIssuedForPaymentOfAccruedDividends_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued For Payment Of Accrued Dividends</label>
    <label xml:lang="en-US" xlink:label="pti_StockIssuedForPaymentOfAccruedBonus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for partial payment of accrued bonus</label>
    <label xml:lang="en-US" xlink:label="pti_StockIssuedForPaymentOfAccruedBonus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued For Payment Of Accrued Bonus</label>
    <label xml:lang="en-US" xlink:label="pti_ConversionOfPreferredStockWarrantsIntoCommonStockWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock warrants into common stock warrants</label>
    <label xml:lang="en-US" xlink:label="pti_ConversionOfPreferredStockWarrantsIntoCommonStockWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Preferred Stock Warrants Into Common Stock Warrants</label>
    <label xml:lang="en-US" xlink:label="pti_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs included in accounts payable and accrued expenses</label>
    <label xml:lang="en-US" xlink:label="pti_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs Included In Accounts Payable And Accrued Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts capitalized under build-to-suit lease transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of the Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Short Term Investments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Short Term Investments [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Assets and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaids and Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Text Block]</label>
    <loc xlink:href="pti-20170930.xsd#pti_AccruedExpensesDisclosureTextBlock" xlink:type="locator" xlink:label="pti_AccruedExpensesDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="pti_AccruedExpensesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Expenses Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_AccruedExpensesDisclosureTextBlock" xlink:to="pti_AccruedExpensesDisclosureTextBlock_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_TextBlockAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Text Block [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="pti_AccruedExpensesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</label>
    <label xml:lang="en-US" xlink:label="pti_AccruedExpensesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Build-to-Suit Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases Of Lessee Disclosure [Text Block]</label>
    <loc xlink:href="pti-20170930.xsd#pti_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:type="locator" xlink:label="pti_UnauditedInterimFinancialInformationPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="pti_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unaudited Interim Financial Information Policy [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:to="pti_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="pti_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unaudited Interim Financial Information</label>
    <label xml:lang="en-US" xlink:label="pti_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unaudited Interim Financial Information Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Policy Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derivatives Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Short Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Changes in Values of Derivative Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Input Reconciliation Table [Text Block]</label>
    <loc xlink:href="pti-20170930.xsd#pti_ScheduleOfPrepaidsAndOtherCurrentAssetsTableTextBlock" xlink:type="locator" xlink:label="pti_ScheduleOfPrepaidsAndOtherCurrentAssetsTableTextBlock" />
    <label xml:lang="en-US" xlink:label="pti_ScheduleOfPrepaidsAndOtherCurrentAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of Prepaids and other current assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_ScheduleOfPrepaidsAndOtherCurrentAssetsTableTextBlock" xlink:to="pti_ScheduleOfPrepaidsAndOtherCurrentAssetsTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="pti_ScheduleOfPrepaidsAndOtherCurrentAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Prepaids and Other Current Assets</label>
    <label xml:lang="en-US" xlink:label="pti_ScheduleOfPrepaidsAndOtherCurrentAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Prepaids And Other Current Assets Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-Based Compensation Expense, Including Shares Issued to Non-Employee for Consulting Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Basic and Diluted Net Loss per Share Attributable to Common Stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Antidilutive Securities Excluded from Computation of Diluted Weighted-average Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</label>
    <label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Short Term Investments</label>
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Cash in operations</label>
    <loc xlink:href="pti-20170930.xsd#pti_SignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="pti_SignificantAccountingPoliciesLineItems" />
    <label xml:lang="en-US" xlink:label="pti_SignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_SignificantAccountingPoliciesLineItems" xlink:to="pti_SignificantAccountingPoliciesLineItems_lbl" />
    <loc xlink:href="pti-20170930.xsd#pti_SignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="pti_SignificantAccountingPoliciesTable" />
    <label xml:lang="en-US" xlink:label="pti_SignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_SignificantAccountingPoliciesTable" xlink:to="pti_SignificantAccountingPoliciesTable_lbl" />
    <label xml:lang="en-US" xlink:label="pti_SignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies [Table]</label>
    <label xml:lang="en-US" xlink:label="pti_SignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:type="locator" xlink:label="us-gaap_CertificatesOfDepositMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Certificate of Deposit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Certificates Of Deposit [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments for New Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For New Accounting Pronouncements [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Type of Adoption</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Adoption [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2014-09 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201409Member" xlink:to="us-gaap_AccountingStandardsUpdate201409Member_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201409 [Member]</label>
    <label xml:lang="en-US" xlink:label="pti_SignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies [Line Items]</label>
    <label xml:lang="en-US" xlink:label="pti_SignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of common shares issued on conversion of convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</label>
    <label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue recognized</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Debt And Equity Securities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Major Types of Debt and Equity Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Major Types Of Debt And Equity Securities [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Major Types of Debt and Equity Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Major Types Of Debt And Equity Securities [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S Government-Sponsored Enterprise Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Government Sponsored Enterprises Debt Securities [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury Securities [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Available-for-sale Securities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Amortized Cost</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecurities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized gains (losses) on short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Gross Realized Gain Loss Net</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other-than-temporary impairments recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Than Temporary Impairment Losses Investments Availableforsale Securities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurement Frequency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Asset Class [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Fair Value Disclosure</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Fair Value Disclosure [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Fair Value Disclosure</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfer of assets from level 1 to level 2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level1 To Level2 Transfers Amount</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfer of assets from level 2 to level 1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level2 To Level1 Transfers Amount</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfer of liabilities from level 1 to level 2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Level1 To Level2 Transfers Amount</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfer of liabilities from level 2 to level 1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Level2 To Level1 Transfers Amount</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOptionMethodologyAndAssumptions" xlink:type="locator" xlink:label="us-gaap_FairValueOptionMethodologyAndAssumptions" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueOptionMethodologyAndAssumptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value determination model</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionMethodologyAndAssumptions" xlink:to="us-gaap_FairValueOptionMethodologyAndAssumptions_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueOptionMethodologyAndAssumptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Option Methodology And Assumptions</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assumptions Expected Term</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assumptions Expected Volatility Rate</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assumptions Risk Free Interest Rate</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments Financial Assets Balance Sheet Groupings [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Assets, Liabilities and Stockholders&apos; Equity Measured on Recurring Basis [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring Basis [Abstract]</label>
    <label xml:lang="en-US" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Derivative Liability, Fair value, Beginning Balance</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Derivative Liability, Change in fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss</label>
    <label xml:lang="en-US" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Derivative Liability, Fair value, Ending Balance</label>
    <loc xlink:href="pti-20170930.xsd#pti_PrepaidClinicalManufacturingAndScientificExpensesCurrent" xlink:type="locator" xlink:label="pti_PrepaidClinicalManufacturingAndScientificExpensesCurrent" />
    <label xml:lang="en-US" xlink:label="pti_PrepaidClinicalManufacturingAndScientificExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid clinical, manufacturing and scientific expenses, current.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_PrepaidClinicalManufacturingAndScientificExpensesCurrent" xlink:to="pti_PrepaidClinicalManufacturingAndScientificExpensesCurrent_lbl" />
    <loc xlink:href="pti-20170930.xsd#pti_OtherPrepaidExpensesAndOtherCurrentAssets" xlink:type="locator" xlink:label="pti_OtherPrepaidExpensesAndOtherCurrentAssets" />
    <label xml:lang="en-US" xlink:label="pti_OtherPrepaidExpensesAndOtherCurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other prepaid expenses and other current assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_OtherPrepaidExpensesAndOtherCurrentAssets" xlink:to="pti_OtherPrepaidExpensesAndOtherCurrentAssets_lbl" />
    <label xml:lang="en-US" xlink:label="pti_PrepaidClinicalManufacturingAndScientificExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid clinical, manufacturing and scientific expenses</label>
    <label xml:lang="en-US" xlink:label="pti_PrepaidClinicalManufacturingAndScientificExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Clinical Manufacturing And Scientific Expenses Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidInsurance" xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid insurance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</label>
    <label xml:lang="en-US" xlink:label="pti_OtherPrepaidExpensesAndOtherCurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other prepaid expenses and other current assets</label>
    <label xml:lang="en-US" xlink:label="pti_OtherPrepaidExpensesAndOtherCurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Prepaid Expenses And Other Current Assets</label>
    <label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Prepaids and other current assets</label>
    <loc xlink:href="pti-20170930.xsd#pti_AccruedResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="pti_AccruedResearchAndDevelopmentExpenses" />
    <label xml:lang="en-US" xlink:label="pti_AccruedResearchAndDevelopmentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_AccruedResearchAndDevelopmentExpenses" xlink:to="pti_AccruedResearchAndDevelopmentExpenses_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued payroll and related expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</label>
    <label xml:lang="en-US" xlink:label="pti_AccruedResearchAndDevelopmentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expenses</label>
    <label xml:lang="en-US" xlink:label="pti_AccruedResearchAndDevelopmentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</label>
    <label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <loc xlink:href="pti-20170930.xsd#pti_TwoThousandSixteenStockOptionAndIncentivePlanMember" xlink:type="locator" xlink:label="pti_TwoThousandSixteenStockOptionAndIncentivePlanMember" />
    <label xml:lang="en-US" xlink:label="pti_TwoThousandSixteenStockOptionAndIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand sixteen stock option and incentive plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_TwoThousandSixteenStockOptionAndIncentivePlanMember" xlink:to="pti_TwoThousandSixteenStockOptionAndIncentivePlanMember_lbl" />
    <label xml:lang="en-US" xlink:label="pti_TwoThousandSixteenStockOptionAndIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2016 Plan [Member]</label>
    <label xml:lang="en-US" xlink:label="pti_TwoThousandSixteenStockOptionAndIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Sixteen Stock Option And Incentive Plan [Member]</label>
    <loc xlink:href="pti-20170930.xsd#pti_TwoThousandSixteenStockOptionAndIncentivePlanAndTwoThousandEightPlanMember" xlink:type="locator" xlink:label="pti_TwoThousandSixteenStockOptionAndIncentivePlanAndTwoThousandEightPlanMember" />
    <label xml:lang="en-US" xlink:label="pti_TwoThousandSixteenStockOptionAndIncentivePlanAndTwoThousandEightPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand sixteen stock option and incentive plan and two thousand eight plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_TwoThousandSixteenStockOptionAndIncentivePlanAndTwoThousandEightPlanMember" xlink:to="pti_TwoThousandSixteenStockOptionAndIncentivePlanAndTwoThousandEightPlanMember_lbl" />
    <label xml:lang="en-US" xlink:label="pti_TwoThousandSixteenStockOptionAndIncentivePlanAndTwoThousandEightPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2016 Plan and 2008 Plan [Member]</label>
    <label xml:lang="en-US" xlink:label="pti_TwoThousandSixteenStockOptionAndIncentivePlanAndTwoThousandEightPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Sixteen Stock Option And Incentive Plan And Two Thousand Eight Plan [Member]</label>
    <loc xlink:href="pti-20170930.xsd#pti_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="pti_TwoThousandSixteenEmployeeStockPurchasePlanMember" />
    <label xml:lang="en-US" xlink:label="pti_TwoThousandSixteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand sixteen employee stock purchase plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:to="pti_TwoThousandSixteenEmployeeStockPurchasePlanMember_lbl" />
    <label xml:lang="en-US" xlink:label="pti_TwoThousandSixteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2016 ESPP [Member]</label>
    <label xml:lang="en-US" xlink:label="pti_TwoThousandSixteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Sixteen Employee Stock Purchase Plan [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Relationship to Entity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</label>
    <loc xlink:href="pti-20170930.xsd#pti_NonEmployeesMember" xlink:type="locator" xlink:label="pti_NonEmployeesMember" />
    <label xml:lang="en-US" xlink:label="pti_NonEmployeesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non employees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_NonEmployeesMember" xlink:to="pti_NonEmployeesMember_lbl" />
    <label xml:lang="en-US" xlink:label="pti_NonEmployeesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-Employees [Member]</label>
    <label xml:lang="en-US" xlink:label="pti_NonEmployeesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Employees [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:type="locator" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments for Error Corrections</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Error Corrections And Prior Period Adjustments Restatement By Restatement Period And Amount [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments for Error Correction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:to="us-gaap_AdjustmentsForErrorCorrectionDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For Error Correction [Domain]</label>
    <loc xlink:href="pti-20170930.xsd#pti_PriorToTwoThousandThirteenMember" xlink:type="locator" xlink:label="pti_PriorToTwoThousandThirteenMember" />
    <label xml:lang="en-US" xlink:label="pti_PriorToTwoThousandThirteenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prior to two thousand thirteen.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_PriorToTwoThousandThirteenMember" xlink:to="pti_PriorToTwoThousandThirteenMember_lbl" />
    <label xml:lang="en-US" xlink:label="pti_PriorToTwoThousandThirteenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prior to 2013 [Member]</label>
    <label xml:lang="en-US" xlink:label="pti_PriorToTwoThousandThirteenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prior To Two Thousand Thirteen [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for issuance, percentage of number of shares of common stock outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock available for issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Employee Stock Purchase Plans</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option issued to purchase common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Share Based Compensation Gross</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options unvested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</label>
    <label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Stock-based compensation expense</label>
    <loc xlink:href="pti-20170930.xsd#pti_ResearchAndDevelopmentCollaborationAgreementInitialTerm" xlink:type="locator" xlink:label="pti_ResearchAndDevelopmentCollaborationAgreementInitialTerm" />
    <label xml:lang="en-US" xlink:label="pti_ResearchAndDevelopmentCollaborationAgreementInitialTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development collaboration agreement initial term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_ResearchAndDevelopmentCollaborationAgreementInitialTerm" xlink:to="pti_ResearchAndDevelopmentCollaborationAgreementInitialTerm_lbl" />
    <loc xlink:href="pti-20170930.xsd#pti_VariableInterestsAndEquityMethodInvestmentsDisclosureAbstract" xlink:type="locator" xlink:label="pti_VariableInterestsAndEquityMethodInvestmentsDisclosureAbstract" />
    <label xml:lang="en-US" xlink:label="pti_VariableInterestsAndEquityMethodInvestmentsDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Variable Interests And Equity Method Investments Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_VariableInterestsAndEquityMethodInvestmentsDisclosureAbstract" xlink:to="pti_VariableInterestsAndEquityMethodInvestmentsDisclosureAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="pti_VariableInterestsAndEquityMethodInvestmentsDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Interests And Equity Method Investments Disclosure [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Type of Arrangement and Non-arrangement Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Arrangements and Non-arrangement Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</label>
    <loc xlink:href="pti-20170930.xsd#pti_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="pti_AstellasCollaborationAgreementMember" />
    <label xml:lang="en-US" xlink:label="pti_AstellasCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Astellas Collaboration Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_AstellasCollaborationAgreementMember" xlink:to="pti_AstellasCollaborationAgreementMember_lbl" />
    <label xml:lang="en-US" xlink:label="pti_AstellasCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Astellas Collaboration Agreement [Member]</label>
    <label xml:lang="en-US" xlink:label="pti_AstellasCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Astellas Collaboration Agreement [Member]</label>
    <loc xlink:href="pti-20170930.xsd#pti_BiogenLicenseAgreementsMember" xlink:type="locator" xlink:label="pti_BiogenLicenseAgreementsMember" />
    <label xml:lang="en-US" xlink:label="pti_BiogenLicenseAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Biogen License Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_BiogenLicenseAgreementsMember" xlink:to="pti_BiogenLicenseAgreementsMember_lbl" />
    <label xml:lang="en-US" xlink:label="pti_BiogenLicenseAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Biogen License Agreements [Member]</label>
    <label xml:lang="en-US" xlink:label="pti_BiogenLicenseAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Biogen License Agreements [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</label>
    <label xml:lang="en-US" xlink:label="pti_ResearchAndDevelopmentCollaborationAgreementInitialTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial research term</label>
    <label xml:lang="en-US" xlink:label="pti_ResearchAndDevelopmentCollaborationAgreementInitialTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Collaboration Agreement Initial Term</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="locator" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal income tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Federal Income Tax Expense Benefit Continuing Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="locator" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Income Tax Expense Benefit Continuing Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common stockholders-basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Diluted</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Outstanding [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average number of common shares outstanding&#8212;basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Outstanding Basic</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</label>
    <loc xlink:href="pti-20170930.xsd#pti_WarrantsToPurchaseConvertiblePreferredStockMember" xlink:type="locator" xlink:label="pti_WarrantsToPurchaseConvertiblePreferredStockMember" />
    <label xml:lang="en-US" xlink:label="pti_WarrantsToPurchaseConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants To Purchase Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_WarrantsToPurchaseConvertiblePreferredStockMember" xlink:to="pti_WarrantsToPurchaseConvertiblePreferredStockMember_lbl" />
    <label xml:lang="en-US" xlink:label="pti_WarrantsToPurchaseConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to Purchase Convertible Preferred Stock [Member]</label>
    <label xml:lang="en-US" xlink:label="pti_WarrantsToPurchaseConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants To Purchase Convertible Preferred Stock [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to Purchase Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potentially dilutive securities excluded from computation of diluted weighted-average shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued in net issuance transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</label>
    <loc xlink:href="pti-20170930.xsd#pti_AnnualIncreaseInLeasePayments" xlink:type="locator" xlink:label="pti_AnnualIncreaseInLeasePayments" />
    <label xml:lang="en-US" xlink:label="pti_AnnualIncreaseInLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual increase in lease payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_AnnualIncreaseInLeasePayments" xlink:to="pti_AnnualIncreaseInLeasePayments_lbl" />
    <loc xlink:href="pti-20170930.xsd#pti_ImprovementAllowanceReceivable" xlink:type="locator" xlink:label="pti_ImprovementAllowanceReceivable" />
    <label xml:lang="en-US" xlink:label="pti_ImprovementAllowanceReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Improvement allowance receivable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_ImprovementAllowanceReceivable" xlink:to="pti_ImprovementAllowanceReceivable_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</label>
    <loc xlink:href="pti-20170930.xsd#pti_IceBoxLLCMember" xlink:type="locator" xlink:label="pti_IceBoxLLCMember" />
    <label xml:lang="en-US" xlink:label="pti_IceBoxLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Ice Box, LLC.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_IceBoxLLCMember" xlink:to="pti_IceBoxLLCMember_lbl" />
    <label xml:lang="en-US" xlink:label="pti_IceBoxLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ice Box, LLC [Member]</label>
    <label xml:lang="en-US" xlink:label="pti_IceBoxLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ice Box L L C [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <label xml:lang="en-US" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, area of property leased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Real Estate Property</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leasing Arrangements Operating Leases Term Of Contract</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, annual rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" />
    <label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, renewal term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leasing Arrangements Operating Leases Renewal Term</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases" xlink:type="locator" xlink:label="us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases" />
    <label xml:lang="en-US" xlink:label="us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease term description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases" xlink:to="us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Lessee Leasing Arrangements Operating Leases</label>
    <label xml:lang="en-US" xlink:label="pti_AnnualIncreaseInLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual increase lease payment</label>
    <label xml:lang="en-US" xlink:label="pti_AnnualIncreaseInLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual Increase In Lease Payments</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total expected rental payments through expiration of lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due</label>
    <label xml:lang="en-US" xlink:label="pti_ImprovementAllowanceReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Improvement allowance receivable</label>
    <label xml:lang="en-US" xlink:label="pti_ImprovementAllowanceReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Improvement Allowance Receivable</label>
    <loc xlink:href="pti-20170930.xsd#pti_BuildToSuitAssetCapitalized" xlink:type="locator" xlink:label="pti_BuildToSuitAssetCapitalized" />
    <label xml:lang="en-US" xlink:label="pti_BuildToSuitAssetCapitalized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Build-to-suit asset capitalized.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_BuildToSuitAssetCapitalized" xlink:to="pti_BuildToSuitAssetCapitalized_lbl" />
    <label xml:lang="en-US" xlink:label="pti_BuildToSuitAssetCapitalized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Build-to-suit asset capitalized</label>
    <label xml:lang="en-US" xlink:label="pti_BuildToSuitAssetCapitalized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Build To Suit Asset Capitalized</label>
    <loc xlink:href="pti-20170930.xsd#pti_BuildToSuitFacilityLeaseObligation" xlink:type="locator" xlink:label="pti_BuildToSuitFacilityLeaseObligation" />
    <label xml:lang="en-US" xlink:label="pti_BuildToSuitFacilityLeaseObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Build-to-suit facility lease obligation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pti_BuildToSuitFacilityLeaseObligation" xlink:to="pti_BuildToSuitFacilityLeaseObligation_lbl" />
    <label xml:lang="en-US" xlink:label="pti_BuildToSuitFacilityLeaseObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Build-to-suit facility lease obligation</label>
    <label xml:lang="en-US" xlink:label="pti_BuildToSuitFacilityLeaseObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Build To Suit Facility Lease Obligation</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>26
<FILENAME>pti-20170930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFS ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2017-11-14T21:33:05.9324600+00:00 -->
<!-- Version            : 2.5.0.9 -->
<!-- Package ID         : C898DE00A4E7409BAA35AC9210F2845E-0001445283-001709 -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef roleURI="http://www.proteostasis.com/20170930/role/TemplateLink" xlink:href="pti-20170930.xsd#TemplateLink" xlink:type="simple" />
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="pti-20170930.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DocumentDocumentAndEntityInformation">
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <loc xlink:href="pti-20170930.xsd#pti_DocumentAndEntityInformationAbstract" xlink:type="locator" xlink:label="pti_DocumentAndEntityInformationAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pti_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pti_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pti_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pti_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pti_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pti_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pti_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pti_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pti_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pti_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pti_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/StatementCondensedBalanceSheets" xlink:href="pti-20170930.xsd#Role_StatementCondensedBalanceSheets" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/StatementCondensedBalanceSheets">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRentCreditCurrent" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/StatementCondensedBalanceSheetsParenthetical" xlink:href="pti-20170930.xsd#Role_StatementCondensedBalanceSheetsParenthetical" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/StatementCondensedBalanceSheetsParenthetical">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/StatementCondensedStatementsOfOperations" xlink:href="pti-20170930.xsd#Role_StatementCondensedStatementsOfOperations" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/StatementCondensedStatementsOfOperations">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/StatementCondensedStatementsOfComprehensiveLoss" xlink:href="pti-20170930.xsd#Role_StatementCondensedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/StatementCondensedStatementsOfComprehensiveLoss">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/StatementCondensedStatementsOfCashFlows" xlink:href="pti-20170930.xsd#Role_StatementCondensedStatementsOfCashFlows" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/StatementCondensedStatementsOfCashFlows">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <loc xlink:href="pti-20170930.xsd#pti_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense" xlink:type="locator" xlink:label="pti_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense" />
    <loc xlink:href="pti-20170930.xsd#pti_ConversionOfPreferredStockWarrantsIntoCommonStockWarrants" xlink:type="locator" xlink:label="pti_ConversionOfPreferredStockWarrantsIntoCommonStockWarrants" />
    <loc xlink:href="pti-20170930.xsd#pti_StockIssuedForPaymentOfAccruedBonus" xlink:type="locator" xlink:label="pti_StockIssuedForPaymentOfAccruedBonus" />
    <loc xlink:href="pti-20170930.xsd#pti_StockIssuedForPaymentOfAccruedDividends" xlink:type="locator" xlink:label="pti_StockIssuedForPaymentOfAccruedDividends" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <loc xlink:href="pti-20170930.xsd#pti_ChangeInFairValueOfDerivativeLiability" xlink:type="locator" xlink:label="pti_ChangeInFairValueOfDerivativeLiability" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <loc xlink:href="pti-20170930.xsd#pti_NoncashRentExpenseIncome" xlink:type="locator" xlink:label="pti_NoncashRentExpenseIncome" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <loc xlink:href="pti-20170930.xsd#pti_PremiumOnShortTermInvestments" xlink:type="locator" xlink:label="pti_PremiumOnShortTermInvestments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="pti-20170930.xsd#pti_FollowOnPublicOfferingMember" xlink:type="locator" xlink:label="pti_FollowOnPublicOfferingMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <loc xlink:href="pti-20170930.xsd#pti_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="pti_EmployeeStockPurchasePlanMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pti_EmployeeStockPurchasePlanMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10330.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pti_FollowOnPublicOfferingMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="pti_PremiumOnShortTermInvestments" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="pti_NoncashRentExpenseIncome" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="pti_ChangeInFairValueOfDerivativeLiability" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="12090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="12130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_li0l2" order="12170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="12210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="12290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="pti_StockIssuedForPaymentOfAccruedDividends" order="12330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="pti_StockIssuedForPaymentOfAccruedBonus" order="12370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="pti_ConversionOfPreferredStockWarrantsIntoCommonStockWarrants" order="12410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="pti_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense" order="12450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="12490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNatureOfBusiness" xlink:href="pti-20170930.xsd#Role_DisclosureNatureOfBusiness" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNatureOfBusiness">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="pti-20170930.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureShortTermInvestments" xlink:href="pti-20170930.xsd#Role_DisclosureShortTermInvestments" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureShortTermInvestments">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilities" xlink:href="pti-20170930.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilities" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilities">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosurePrepaidsAndOtherCurrentAssets" xlink:href="pti-20170930.xsd#Role_DisclosurePrepaidsAndOtherCurrentAssets" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosurePrepaidsAndOtherCurrentAssets">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureAccruedExpenses" xlink:href="pti-20170930.xsd#Role_DisclosureAccruedExpenses" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureAccruedExpenses">
    <loc xlink:href="pti-20170930.xsd#pti_AccruedExpensesDisclosureTextBlock" xlink:type="locator" xlink:label="pti_AccruedExpensesDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="pti_AccruedExpensesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="pti-20170930.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureStockBasedCompensation">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureCollaborationAgreement" xlink:href="pti-20170930.xsd#Role_DisclosureCollaborationAgreement" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureCollaborationAgreement">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureIncomeTaxes" xlink:href="pti-20170930.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureIncomeTaxes">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNetLossPerShare" xlink:href="pti-20170930.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNetLossPerShare">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureBuildToSuitLease" xlink:href="pti-20170930.xsd#Role_DisclosureBuildToSuitLease" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureBuildToSuitLease">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="pti-20170930.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <loc xlink:href="pti-20170930.xsd#pti_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:type="locator" xlink:label="pti_UnauditedInterimFinancialInformationPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pti_UnauditedInterimFinancialInformationPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureShortTermInvestmentsTables" xlink:href="pti-20170930.xsd#Role_DisclosureShortTermInvestmentsTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureShortTermInvestmentsTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables" xlink:href="pti-20170930.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosurePrepaidsAndOtherCurrentAssetsTables" xlink:href="pti-20170930.xsd#Role_DisclosurePrepaidsAndOtherCurrentAssetsTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosurePrepaidsAndOtherCurrentAssetsTables">
    <loc xlink:href="pti-20170930.xsd#pti_ScheduleOfPrepaidsAndOtherCurrentAssetsTableTextBlock" xlink:type="locator" xlink:label="pti_ScheduleOfPrepaidsAndOtherCurrentAssetsTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="pti_ScheduleOfPrepaidsAndOtherCurrentAssetsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureAccruedExpensesTables" xlink:href="pti-20170930.xsd#Role_DisclosureAccruedExpensesTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureAccruedExpensesTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="pti-20170930.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureStockBasedCompensationTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="pti-20170930.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNetLossPerShareTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail" xlink:href="pti-20170930.xsd#Role_DisclosureNatureOfBusinessAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="pti-20170930.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="pti-20170930.xsd#pti_SignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="pti_SignificantAccountingPoliciesLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:type="locator" xlink:label="us-gaap_CertificatesOfDepositMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" />
    <loc xlink:href="pti-20170930.xsd#pti_SignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="pti_SignificantAccountingPoliciesTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pti_SignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pti_SignificantAccountingPoliciesTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CertificatesOfDepositMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pti_SignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pti_SignificantAccountingPoliciesTable" xlink:to="pti_SignificantAccountingPoliciesLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pti_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pti_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pti_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pti_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_Revenues" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetail" xlink:href="pti-20170930.xsd#Role_DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureShortTermInvestmentsAdditionalInformationDetail" xlink:href="pti-20170930.xsd#Role_DisclosureShortTermInvestmentsAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureShortTermInvestmentsAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="pti-20170930.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10070.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10070.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail" xlink:href="pti-20170930.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOptionMethodologyAndAssumptions" xlink:type="locator" xlink:label="us-gaap_FairValueOptionMethodologyAndAssumptions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueOptionMethodologyAndAssumptions" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfChangesInValuesOfDerivativeLiabilityDetail" xlink:href="pti-20170930.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfChangesInValuesOfDerivativeLiabilityDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfChangesInValuesOfDerivativeLiabilityDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_li0l2" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosurePrepaidsAndOtherCurrentAssetsScheduleOfPrepaidsAndOtherCurrentAssetsDetail" xlink:href="pti-20170930.xsd#Role_DisclosurePrepaidsAndOtherCurrentAssetsScheduleOfPrepaidsAndOtherCurrentAssetsDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosurePrepaidsAndOtherCurrentAssetsScheduleOfPrepaidsAndOtherCurrentAssetsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:href="pti-20170930.xsd#pti_OtherPrepaidExpensesAndOtherCurrentAssets" xlink:type="locator" xlink:label="pti_OtherPrepaidExpensesAndOtherCurrentAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidInsurance" xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" />
    <loc xlink:href="pti-20170930.xsd#pti_PrepaidClinicalManufacturingAndScientificExpensesCurrent" xlink:type="locator" xlink:label="pti_PrepaidClinicalManufacturingAndScientificExpensesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="pti_PrepaidClinicalManufacturingAndScientificExpensesCurrent" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidInsurance" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="pti_OtherPrepaidExpensesAndOtherCurrentAssets" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" xlink:href="pti-20170930.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <loc xlink:href="pti-20170930.xsd#pti_AccruedResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="pti_AccruedResearchAndDevelopmentExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="pti_AccruedResearchAndDevelopmentExpenses" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="pti-20170930.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <loc xlink:href="pti-20170930.xsd#pti_PriorToTwoThousandThirteenMember" xlink:type="locator" xlink:label="pti_PriorToTwoThousandThirteenMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:type="locator" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" />
    <loc xlink:href="pti-20170930.xsd#pti_NonEmployeesMember" xlink:type="locator" xlink:label="pti_NonEmployeesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="pti-20170930.xsd#pti_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="pti_TwoThousandSixteenEmployeeStockPurchasePlanMember" />
    <loc xlink:href="pti-20170930.xsd#pti_TwoThousandSixteenStockOptionAndIncentivePlanAndTwoThousandEightPlanMember" xlink:type="locator" xlink:label="pti_TwoThousandSixteenStockOptionAndIncentivePlanAndTwoThousandEightPlanMember" />
    <loc xlink:href="pti-20170930.xsd#pti_TwoThousandSixteenStockOptionAndIncentivePlanMember" xlink:type="locator" xlink:label="pti_TwoThousandSixteenStockOptionAndIncentivePlanMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pti_TwoThousandSixteenStockOptionAndIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pti_TwoThousandSixteenStockOptionAndIncentivePlanAndTwoThousandEightPlanMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pti_TwoThousandSixteenEmployeeStockPurchasePlanMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="pti_NonEmployeesMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="us-gaap_AdjustmentsForErrorCorrectionDomain" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:to="pti_PriorToTwoThousandThirteenMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseIncludingSharesIssuedToNonEmployeeForConsultingServicesDetail" xlink:href="pti-20170930.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseIncludingSharesIssuedToNonEmployeeForConsultingServicesDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseIncludingSharesIssuedToNonEmployeeForConsultingServicesDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetail" xlink:href="pti-20170930.xsd#Role_DisclosureCollaborationAgreementAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <loc xlink:href="pti-20170930.xsd#pti_ResearchAndDevelopmentCollaborationAgreementInitialTerm" xlink:type="locator" xlink:label="pti_ResearchAndDevelopmentCollaborationAgreementInitialTerm" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <loc xlink:href="pti-20170930.xsd#pti_BiogenLicenseAgreementsMember" xlink:type="locator" xlink:label="pti_BiogenLicenseAgreementsMember" />
    <loc xlink:href="pti-20170930.xsd#pti_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="pti_AstellasCollaborationAgreementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:href="pti-20170930.xsd#pti_VariableInterestsAndEquityMethodInvestmentsDisclosureAbstract" xlink:type="locator" xlink:label="pti_VariableInterestsAndEquityMethodInvestmentsDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pti_VariableInterestsAndEquityMethodInvestmentsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pti_AstellasCollaborationAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pti_BiogenLicenseAgreementsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pti_ResearchAndDevelopmentCollaborationAgreementInitialTerm" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="pti-20170930.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="locator" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="locator" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetail" xlink:href="pti-20170930.xsd#Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAbstract" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOutstandingDetail" xlink:href="pti-20170930.xsd#Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOutstandingDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOutstandingDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <loc xlink:href="pti-20170930.xsd#pti_WarrantsToPurchaseConvertiblePreferredStockMember" xlink:type="locator" xlink:label="pti_WarrantsToPurchaseConvertiblePreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pti_WarrantsToPurchaseConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail" xlink:href="pti-20170930.xsd#Role_DisclosureNetLossPerShareAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureBuildToSuitLeaseAdditionalInformationDetail" xlink:href="pti-20170930.xsd#Role_DisclosureBuildToSuitLeaseAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.proteostasis.com/20170930/taxonomy/role/DisclosureBuildToSuitLeaseAdditionalInformationDetail">
    <loc xlink:href="pti-20170930.xsd#pti_BuildToSuitFacilityLeaseObligation" xlink:type="locator" xlink:label="pti_BuildToSuitFacilityLeaseObligation" />
    <loc xlink:href="pti-20170930.xsd#pti_BuildToSuitAssetCapitalized" xlink:type="locator" xlink:label="pti_BuildToSuitAssetCapitalized" />
    <loc xlink:href="pti-20170930.xsd#pti_ImprovementAllowanceReceivable" xlink:type="locator" xlink:label="pti_ImprovementAllowanceReceivable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <loc xlink:href="pti-20170930.xsd#pti_AnnualIncreaseInLeasePayments" xlink:type="locator" xlink:label="pti_AnnualIncreaseInLeasePayments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases" xlink:type="locator" xlink:label="us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <loc xlink:href="pti-20170930.xsd#pti_IceBoxLLCMember" xlink:type="locator" xlink:label="pti_IceBoxLLCMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pti_IceBoxLLCMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pti_AnnualIncreaseInLeasePayments" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pti_ImprovementAllowanceReceivable" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pti_BuildToSuitAssetCapitalized" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pti_BuildToSuitFacilityLeaseObligation" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803182784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Nov. 09, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pti_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PTI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROTEOSTASIS THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001445283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,216,088<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pti_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document And Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pti_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803750656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 18,192<span></span>
</td>
<td class="nump">$ 18,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">25,034<span></span>
</td>
<td class="nump">66,897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">1,079<span></span>
</td>
<td class="nump">668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaids and other current assets</a></td>
<td class="nump">1,838<span></span>
</td>
<td class="nump">4,059<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">46,437<span></span>
</td>
<td class="nump">90,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">12,582<span></span>
</td>
<td class="nump">541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash, net of current portion</a></td>
<td class="nump">1,656<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">60,716<span></span>
</td>
<td class="nump">91,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,535<span></span>
</td>
<td class="nump">2,021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">5,855<span></span>
</td>
<td class="nump">4,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">1,754<span></span>
</td>
<td class="nump">2,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="nump">756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,039<span></span>
</td>
<td class="nump">8,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities, net of current portion</a></td>
<td class="nump">11,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">22,397<span></span>
</td>
<td class="nump">9,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000,000 shares authorized as of September 30, 2017 and December 31, 2016, respectively; no shares issued and outstanding as of September 30, 2017 and December 31, 2016</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 125,000,000 shares authorized as of September 30, 2017 and December 31, 2016, respectively; 25,112,724 and 25,000,734 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">241,758<span></span>
</td>
<td class="nump">238,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(203,458)<span></span>
</td>
<td class="num">(157,450)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">38,319<span></span>
</td>
<td class="nump">81,456<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 60,716<span></span>
</td>
<td class="nump">$ 91,140<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803234160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">25,112,724<span></span>
</td>
<td class="nump">25,000,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">25,112,724<span></span>
</td>
<td class="nump">25,000,734<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803940720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 1,551<span></span>
</td>
<td class="nump">$ 1,715<span></span>
</td>
<td class="nump">$ 3,719<span></span>
</td>
<td class="nump">$ 4,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">12,894<span></span>
</td>
<td class="nump">9,218<span></span>
</td>
<td class="nump">41,372<span></span>
</td>
<td class="nump">23,498<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,741<span></span>
</td>
<td class="nump">3,266<span></span>
</td>
<td class="nump">8,813<span></span>
</td>
<td class="nump">8,682<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">15,635<span></span>
</td>
<td class="nump">12,484<span></span>
</td>
<td class="nump">50,185<span></span>
</td>
<td class="nump">32,180<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(14,084)<span></span>
</td>
<td class="num">(10,769)<span></span>
</td>
<td class="num">(46,466)<span></span>
</td>
<td class="num">(27,856)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">515<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(13,954)<span></span>
</td>
<td class="num">(10,771)<span></span>
</td>
<td class="num">(46,008)<span></span>
</td>
<td class="num">(27,815)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accruing dividends on preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,378)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (13,954)<span></span>
</td>
<td class="num">$ (10,771)<span></span>
</td>
<td class="num">$ (46,008)<span></span>
</td>
<td class="num">$ (29,193)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders&#8212;basic and diluted</a></td>
<td class="num">$ (0.56)<span></span>
</td>
<td class="num">$ (0.54)<span></span>
</td>
<td class="num">$ (1.84)<span></span>
</td>
<td class="num">$ (1.75)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding&#8212;basic and diluted</a></td>
<td class="nump">25,093,344<span></span>
</td>
<td class="nump">20,073,685<span></span>
</td>
<td class="nump">25,051,536<span></span>
</td>
<td class="nump">16,672,368<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6791911808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement Of Income And Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (13,954)<span></span>
</td>
<td class="num">$ (10,771)<span></span>
</td>
<td class="num">$ (46,008)<span></span>
</td>
<td class="num">$ (27,815)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">20<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (13,934)<span></span>
</td>
<td class="num">$ (10,780)<span></span>
</td>
<td class="num">$ (45,993)<span></span>
</td>
<td class="num">$ (27,824)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e557-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809430176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (46,008)<span></span>
</td>
<td class="num">$ (27,815)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pti_PremiumOnShortTermInvestments', window );">Premium on short-term investments</a></td>
<td class="num">(140)<span></span>
</td>
<td class="num">(124)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premium on short-term investments</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pti_NoncashRentExpenseIncome', window );">Non-cash rent expense</a></td>
<td class="num">(149)<span></span>
</td>
<td class="num">(134)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,228<span></span>
</td>
<td class="nump">1,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Stock issued for consulting services</a></td>
<td class="nump">555<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pti_ChangeInFairValueOfDerivativeLiability', window );">Change in fair value of derivative liability</a></td>
<td class="num">(88)<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of preferred stock warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Gain on disposal of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(411)<span></span>
</td>
<td class="nump">473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Prepaids and other current assets</a></td>
<td class="nump">2,221<span></span>
</td>
<td class="num">(2,200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">514<span></span>
</td>
<td class="nump">390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">1,527<span></span>
</td>
<td class="nump">1,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(1,202)<span></span>
</td>
<td class="num">(1,992)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(40,557)<span></span>
</td>
<td class="num">(27,820)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Change in restricted cash</a></td>
<td class="num">(1,656)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities', window );">Purchases of short-term investments</a></td>
<td class="num">(23,727)<span></span>
</td>
<td class="num">(56,299)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds received from maturities of short-term investments</a></td>
<td class="nump">65,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(117)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds received from disposal of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">40,063<span></span>
</td>
<td class="num">(56,318)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock upon completion of initial public offering, net of commissions and underwriting discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">114,122<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(421)<span></span>
</td>
<td class="nump">29,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">18,613<span></span>
</td>
<td class="nump">13,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">18,192<span></span>
</td>
<td class="nump">43,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of convertible preferred stock into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pti_StockIssuedForPaymentOfAccruedDividends', window );">Issuance of common stock to settle accrued Series A preferred stock dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pti_StockIssuedForPaymentOfAccruedBonus', window );">Issuance of common stock for partial payment of accrued bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pti_ConversionOfPreferredStockWarrantsIntoCommonStockWarrants', window );">Conversion of preferred stock warrants into common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pti_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense', window );">Deferred offering costs included in accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Amounts capitalized under build-to-suit lease transaction</a></td>
<td class="nump">12,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of public offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,515)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pti_FollowOnPublicOfferingMember', window );">Follow-on Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of public offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (272)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pti_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pti_ChangeInFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Of Derivative Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pti_ChangeInFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pti_ConversionOfPreferredStockWarrantsIntoCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of preferred stock warrants into common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pti_ConversionOfPreferredStockWarrantsIntoCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pti_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs included in accounts payable and accrued expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pti_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pti_NoncashRentExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash rent expense (income).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pti_NoncashRentExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pti_PremiumOnShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premium on short term investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pti_PremiumOnShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pti_StockIssuedForPaymentOfAccruedBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued for payment of accrued bonus.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pti_StockIssuedForPaymentOfAccruedBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pti_StockIssuedForPaymentOfAccruedDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued for payment of accrued dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pti_StockIssuedForPaymentOfAccruedDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with maturities (principal being due), prepayments and calls (requests of early payments) on securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pti_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pti_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pti_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pti_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6601866384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of the Business</a></td>
<td class="text"><div>

<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Nature of the Business</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proteostasis Therapeutics, Inc. (the &#8220;Company&#8221;) was incorporated in Delaware on December 13, 2006. The Company is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis (&#8220;CF&#8221;) and other diseases caused by dysfunctional protein processing.&nbsp;&nbsp;The Company focuses on identifying therapies that restore protein function.&nbsp;&nbsp;CF is a disease caused by defects in the cystic fibrosis transmembrane conductance regulator (&#8220;CFTR&#8221;) protein and insufficient CFTR protein function. The Company&#8217;s lead product candidates, PTI-428, PTI-801 and PTI-808&nbsp;&nbsp;are in early clinical development, with plans for double and triple combinations, and the Company&#8217;s other drug candidates are in the preclinical development and discovery phases.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2016, the Company adopted the provisions of Financial Statement Account Standards Board (FASB) Accounting Standard Codification (ASC) Topic 205-40, <font style="font-style:italic;">Presentation of Financial Statements &#8211; Going Concern</font> (ASC 205-40), which requires management to assess the Company&#8217;s ability to continue as a going concern for twelve months after the date of the financial statements are issued. This standard <font style="color:#000000;">requires management to 1) identify and disclose if there are initial conditions indicating substantial doubt about the Company&#8217;s ability to continue as a going concern within twelve months of the issuance date of the financial statements, 2) disclose the principal conditions that gave rise to substantial doubt, 3) disclose management&#8217;s evaluation of the significance of those conditions in relation to the Company&#8217;s ability to meet its obligations and 4) disclose management&#8217;s plans that are intended to mitigate the adverse conditions.&#160;&#160;In accordance with the accounting standard, when considering management&#8217;s plans to mitigate the conditions giving rise to substantial doubt, management can only consider those plans which are probable to be successfully implemented</font>. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred losses from operations since its inception. As of September&#160;30, 2017, the Company had an accumulated deficit of $203.5 million. During the three and nine months ended September&#160;30, 2017, the Company incurred losses of $14.0 million and $46.0 million and during the nine months ended September 30, 2017 the Company used $40.6 million of cash in operations. The Company expects to continue to generate operating losses in the foreseeable future. The Company currently expects that its cash, cash equivalents and short-term investments of $43.2 million will be sufficient to fund its operating expenses and capital requirements, based upon its current operating plan, through the second quarter of 2018. <font style="color:#000000;">As of September 30, 2017, management has further assessed this risk and, in accordance with the requirements of ASC 205-40, determined that there are initial conditions indicating that there is substantial doubt about the Company&#8217;s ability to continue as a going concern within twelve months of the issuance date of these condensed financial statements.&#160;&#160;These indicators are the Company&#8217;s accumulated deficit and the forecasted cash expenditures. </font>Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all, nor is it considered probable under the accounting standards. <font style="color:#000000;">As such, under the requirements of ASC 205-40, management may not consider the potential for future capital raises in its assessment of the Company&#8217;s ability to meet its obligations for the next twelve months. If the Company is unable to obtain funding, the Company would be forced to delay, reduce or eliminate its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability to reduce spending at a level that mitigates the factors described above, is not considered probable, as defined in the accounting standards; as such, under the requirements of ASC 205-40, the full extent to which management may extend the Company&#8217;s funds through these actions may not be considered in management&#8217;s assessment of the Company&#8217;s ability to continue as a going concern for the next twelve months.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thus, in accordance with the requirements of ASC 205-40, management has concluded that substantial doubt exists about the Company&#8217;s ability to continue as a going concern for twelve months from the date these condensed financial statements are issued.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed financial statements have been prepared&#160;assuming that the Company will continue as a going concern, which contemplates continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business<font style="color:#000000;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6635140464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div>

<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Summary of Significant Accounting Policies </p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Unaudited Interim Financial Information</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed balance sheet at December&#160;31, 2016 was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying condensed financial statements as of September&#160;30, 2017 and for the three and nine months ended September&#160;30, 2017 are unaudited. The accompanying unaudited interim financial statements have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the Company&#8217;s&#160;audited financial statements and the notes thereto for the year ended December&#160;31, 2016 included in the Company&#8217;s&#160;Annual Report on Form 10-K filed with the SEC on March&#160;30, 2017. In the opinion of management, all adjustments, consisting only of normal recurring adjustments as necessary, for the fair statement of the Company&#8217;s condensed financial position as of September&#160;30, 2017 and condensed results of its operations and cash flows for the three and nine months ended September&#160;30, 2017 have been made. The results of operations for the three and nine months ended September&#160;30, 2017 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2017. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, the accrual for research and development expenses and the valuation of common stock and the derivative liability. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restricted Cash</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September&#160;30, 2017 and December&#160;31, 2016, restricted cash consisted of a certificate of deposit in the amount of $0.3 million collateralizing a letter of credit issued as a security deposit in connection with the Company&#8217;s lease of its corporate facilities at 200 Technology Square, Cambridge, MA.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 19, 2017, the Company entered into a lease agreement for a new corporate headquarters at 80 Guest Street, Brighton, MA (see Note 11). As of September 30, 2017, restricted cash, net of current portion, consisted of a money market account in the amount of $1.7 million collateralizing a letter of credit issued as a security deposit for this lease agreement.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash Equivalents</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. As of September&#160;30, 2017 and December&#160;31, 2016, the Company&#8217;s cash equivalents consisted of money market funds.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Short-term Investments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments represent holdings of available-for-sale marketable securities in accordance with the Company&#8217;s investment policy and cash management strategy. Short-term investments mature within one-year from the balance sheet date. Investments in marketable securities are recorded at fair value, with any unrealized gains and losses, net of taxes, reported as a component of stockholders&#8217; equity until realized or until a determination is made that an other-than-temporary decline in market value has occurred. The cost of marketable securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investments are reflected as a component of other expense, net.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value Measurements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2&#8212;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s derivative liability, short-term investments and cash equivalents are carried at fair value determined according to the fair value hierarchy described above (see Note 4). The carrying value of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate their fair value due to the short-term nature of these assets and liabilities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss per Share</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, upon the closing of the IPO, all of the outstanding shares of the Company&#8217;s redeemable convertible preferred stock automatically converted into 9,699,600 shares of the Company&#8217;s common stock. Prior to this conversion, the Company followed the two-class method when computing net loss per share as the Company had issued shares that met the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company&#8217;s redeemable convertible preferred stock contractually entitled the holders of such shares to participate in dividends, but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, the two-class method did not apply for periods in which the Company reported a net loss or a net loss attributable to common stockholders resulting from dividends or accretion related to its redeemable convertible preferred stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net income (loss) per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares, including potential dilutive common shares assuming the dilutive effect of outstanding stock options and unvested restricted common shares, as determined using the treasury stock method. For periods in which the Company has reported net losses, diluted net loss per common share attributable to common stockholders is the same as basic net loss per common share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. For any period in which the Company has reported net income, basic net income per common share attributable to common stockholders is adjusted for certain amounts to calculate diluted net loss per common share attributable to common stockholders, since dilutive common shares are assumed to have been issued if their effect is dilutive and not to have been issued if their effect is anti-dilutive.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the <font style="color:#000000;">FASB issued ASU No.&#160;2014-09,&#160;</font><font style="font-style:italic;color:#000000;">Revenue from Contracts with Customers (Topic 606)</font><font style="color:#000000;">&#160;(&#8220;ASU 2014-09&#8221;), which supersedes existing revenue recognition guidance under GAAP. The standard&#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The standard defines a five-step process to achieve this principle, and will require companies to use more judgment and make more estimates than under the current guidance. The Company expects that these judgments and estimates will include identifying performance obligations in the customer contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. In August 2015, the FASB issued ASU 2015-14,&#160;</font><font style="font-style:italic;color:#000000;">Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date</font><font style="color:#000000;">, which delays the effective date of ASU 2014-09 such that the standard is effective for public entities for annual periods beginning after December&#160;15, 2017 and for interim periods within those fiscal years. Early adoption of the standard is permitted for annual periods beginning after December&#160;15, 2016. In April 2016, the FASB issued ASU 2016-10,&#160;</font><font style="font-style:italic;color:#000000;">Identifying Performance Obligations and Licensing</font><font style="color:#000000;">. The new standard clarifies two aspects of ASU 2014-09, </font><font style="font-style:italic;color:#000000;">Revenue from Contracts with Customers&#160;(Topic 606)</font><font style="color:#000000;">: identifying performance obligations and the licensing implementation guidance. These new standards will become effective for the Company on January&#160;1, 2018. The Company only has one contract (see Note 8) within the scope of Topic 606 and intends to use the modified retrospective method for adoption. Since the inception of the contract the Company has recognized $8.1 million in revenue. The Company is still assessing the impact that the adoption of these new standards will have on its financial statements and related disclosures.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU No.&#160;2016-02, <font style="font-style:italic;">Leases </font>(&#8220;ASU 2016-02&#8221;)<font style="font-style:italic;">.</font> This guidance will require that lease arrangements longer than 12 months result in an entity recognizing an asset and liability equal to the present value of the lease payments in the statement of financial position. This guidance is effective for annual periods beginning after December&#160;15, 2018, and interim periods therein. This standard requires a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU 2016-02 will have on its financial statements and related disclosures.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016, the FASB issued ASU No.&#160;2016-09,&#160;<font style="font-style:italic;">Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting </font>(&#8220;ASU 2016-09&#8221;)<font style="font-style:italic;">.</font> The new standard involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The new standard was adopted by the Company on January&#160;1, 2017 on a modified retrospective basis. <font style="color:#000000;">As a result, the Company has made an accounting policy election to account for forfeitures as they occur. The adoption of ASU 2016&#8209;09 also requires excess tax benefits and tax deficiencies be recorded in the income statement as opposed to additional paid&#8209;in capital when the awards vest or are settled. This had no material impact on the condensed financial statements as of and for the three and nine months ended September&#160;30, 2017</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2016, the FASB issued ASU 2016-15, <font style="font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</font>. The new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs, settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactions. The new standard also clarifies that an entity should determine each separately identifiable source or use within the cash receipts and cash payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. The new standard will be effective for the Company on January 1, 2018. The Company is currently evaluating the impact that the adoption of this standard will have on its statements of cash flows<font style="color:#000000;">.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2017, the FASB issued ASU 2017-09, <font style="font-style:italic;">Compensation &#8211; Stock Compensation (Topic 719): Scope of Modification Accounting</font>. The new standard provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The new standard will be effective for the Company on January 1, 2018; however, early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company&#8217;s financial position or results of operations.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6799890832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short Term Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash Cash Equivalents And Short Term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock', window );">Short Term Investments</a></td>
<td class="text"><div>

<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Short Term Investments</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s short term investments as of September&#160;30, 2017 and December&#160;31, 2016 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30, 2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Gains</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S government-sponsored enterprise securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,519</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,516</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,522</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,518</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,041</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,034</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Gains</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S government-sponsored enterprise securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,384</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,364</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,535</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,533</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,919</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,897</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not have any realized gains or losses on its short-term investments for the three and nine months ended September&#160;30, 2017 and <font style="letter-spacing:-0.1pt;">2016</font>. There were no other-than-temporary impairments recognized for the three and nine months ended September&#160;30, 2017 and <font style="letter-spacing:-0.1pt;">2016</font>.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -URI http://asc.fasb.org/topic&amp;trid=2122426<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6791506368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Assets and Liabilities</a></td>
<td class="text"><div>

<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fair Value of Financial Assets and Liabilities</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of September&#160;30, 2017 Using:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,370</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,370</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government-sponsored enterprise securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,516</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,516</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,518</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,518</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,370</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,034</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,404</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liability</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of December&#160;31, 2016 Using:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,440</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,440</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government-sponsored enterprise securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,365</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,365</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,532</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,532</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,440</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,897</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,337</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liability</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the periods ended September&#160;30, 2017 and December&#160;31, 2016, there were no transfers between Level 1, Level 2 and Level 3.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Derivative Liability</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The derivative liability relates to a cash settlement option associated with the change of control provision in our Cystic Fibrosis Foundation Therapeutics, Inc. (&#8220;CFFT&#8221;) agreement, which meets the definition of a derivative. The fair value of the derivative liability is based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of the derivative instrument was determined using the Monte-Carlo simulation analysis. In determining the fair value of the derivative liability, the inputs impacting fair value include the fair value of the Company&#8217;s common stock, expected term of the derivative instrument, expected volatility of the common stock price, risk-free interest rate, expected sales-based milestone payments, discount rate, probability of a change of control event, and the probability that the counterparty would elect to accept the alternative cash payment in lieu of its right to the future sales-based milestone payments.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September&#160;30, 2017 and December&#160;31, 2016, the Company determined the per share common stock price available based on the closing price of its common stock on the NASDAQ Global Market as of September 29, 2017 and December 30, 2016, respectively. The Company determined the expected term of the instrument to be 2.25 years and 2.50 years as of September&#160;30, 2017 and December&#160;31, 2016, respectively. The Company estimated its expected stock volatility to be 80.0% and 81.1% as of September&#160;30, 2017 and December&#160;31, 2016, respectively, based on the historical volatility of publicly traded peer companies for terms matching the expected term of the instrument for each respective period. The risk-free interest rate was determined to be 1.51% and 1.33% as of September&#160;30, 2017 and December&#160;31, 2016, respectively, by reference to the U.S. Treasury yield curve for terms matching the expected term of the instrument for each respective period.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in the values of the derivative liability are summarized below (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Derivative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liability</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value at December 31, 2016</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(88</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value at September&#160;30, 2017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6631309360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaids and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense And Other Assets Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Prepaids and Other Current Assets</a></td>
<td class="text"><div>

<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Prepaids and Other Current Assets</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaids and other current assets consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid clinical, manufacturing and scientific expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,197</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,390</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">218</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other prepaid expenses and other current assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">423</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,565</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,838</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.28%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,059</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.28%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6632615536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pti_AccruedExpensesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div>

<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Accrued Expenses</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued payroll and related expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,293</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,813</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,086</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,612</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional fees</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">399</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">383</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">520</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,855</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,328</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pti_AccruedExpensesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Expenses Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pti_AccruedExpensesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6799872992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div>

<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stock-Based Compensation</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2016 Stock Option and Incentive Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February&#160;3, 2016, the Company&#8217;s stockholders approved the 2016 Stock Option and Incentive Plan (the &#8220;2016 Plan&#8221;), which became effective on February&#160;9, 2016. The 2016 Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock units, restricted stock awards and other stock-based awards. The number of shares initially reserved for issuance under the 2016 Plan is 1,581,839 shares. The number of shares of common stock that may be issued under the 2016 Plan will automatically increase on each January&#160;1, beginning on January&#160;1, 2017, by the lesser of 3% of the shares of the Company&#8217;s common stock outstanding on the immediately preceding December&#160;31 or an amount determined by the Company&#8217;s board of directors or the compensation committee of the board of directors. The shares of common stock underlying any awards that are forfeited, canceled, repurchased or are otherwise terminated by the Company under the 2016 Plan and the 2008 Plan will be added back to the shares of common stock available for issuance under the 2016 Plan.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September&#160;30, 2017, the total number of shares reserved under the 2016 Plan and 2008 Plan was 3,577,930 and the Company had 631,077 shares available for future issuance under the 2016 Plan.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2016 Employee Stock Purchase Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February&#160;3, 2016, the Company&#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the &#8220;2016 ESPP&#8221;), which became effective in connection with the completion of the Company&#8217;s initial public offering. A total of 138,757 shares of common stock were reserved for issuance under this plan. In addition, the number of shares of common stock that may be issued under the 2016 ESPP will automatically increase on each January&#160;1, beginning on January&#160;1, 2017 and ending on January&#160;1, 2026, by the least of (i)&#160;138,757 shares of common stock, (ii)&#160;1% of the Company&#8217;s shares of common stock outstanding on the immediately preceding December&#160;31 and (iii)&#160;an amount determined by the Company&#8217;s board of directors or the compensation committee of the board of directors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the nine months ended September 30, 2017, 10,829 shares of common stock were issued pursuant to the 2016 ESPP. As of September&#160;30, 2017, the total number of shares reserved under the 2016 ESPP was 266,685 shares. The Company recognized less than $0.1 million of stock-based compensation during each of the three and nine month periods ended September&#160;30, 2017. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock Option Grants and Shares to Non-employees</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to 2013, the Company issued options to purchase 203,964 shares of common stock to non-employees, primarily members of the Company&#8217;s scientific advisory board, that vest upon the achievement of specified development and clinical milestones. As of September&#160;30, 2017, options for the purchase of 83,250 shares held by non-employees remained unvested, pending achievement of the specified milestones, and had an aggregate fair value of $0.1 million. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense, including shares issued to a non-employee for consulting services, was classified in the statements of operations as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended September&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">412</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,070</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">351</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">636</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">451</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,713</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,024</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,048</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">570</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,783</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,375</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6636049744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreement<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreement</a></td>
<td class="text"><div>

<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Collaboration Agreement</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Astellas</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Collaborative Research, Development, Commercialization and License Agreement (as further amended, the &#8220;Astellas Agreement&#8221;) with Astellas Pharma Inc. (&#8220;Astellas&#8221;), entered into in November 2014, the Company <font style="letter-spacing:-0.1pt;">recognized revenue of $1.6 million and $1.0&#160;million for the three months ended September&#160;30, 2017 and 2016, respectively, and $3.7 million and $2.2 million for the nine months ended September&#160;30, 2017 and 2016, respectively. The Company recognizes revenue from all upfront payments, research funding payments, non-substantive milestone payments and reimbursements of third-party costs under this arrangement, together as a single unit, over the </font>three and a half year research term of the agreement, which commenced in January 2015, with a cumulative catch-up for the elapsed portion of the <font style="letter-spacing:-0.1pt;">services being recognized at the time any non-substantive milestone payment or other consideration is earned. Amounts recorded as deferred revenue under the Astellas Agreement totaled $1.8 million and $3.0 million as of September&#160;30, 2017 and December&#160;31, 2016, respectively.</font> </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Biogen</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the now-terminated collaboration agreement between the Company and Biogen New Ventures, formerly Biogen Idec New Ventures Inc. (&#8220;Biogen&#8221;), the Company recognized revenue of $0.7 million and $2.1 million for the three and nine months ended September&#160;30, 2016. The Company did not have any deferred revenue under the Biogen agreement as of September&#160;30, 2017 and December 31, 2016 and will not recognize any additional revenue under this terminated agreement in the future.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6638661552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div>

<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Income Taxes</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not record a federal or state income tax benefit for its losses for the three and nine months ended September&#160;30, 2017 and 2016 due to the conclusion that a full valuation allowance is required against the Company&#8217;s deferred tax assets. &#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;;font-size:9pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6799891808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><div>

<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Net Loss per Share</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended September&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,954</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,771</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,008</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,815</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruing dividends on preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,378</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stockholders-basic and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,954</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,771</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,008</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,193</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of common shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; outstanding&#8212;basic</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,093,344</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,073,685</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,051,536</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,672,368</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stockholders&#8212;basic and diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.56</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.54</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.84</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.75</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s potential dilutive securities, which include stock options and a warrant to purchase common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="color:#000000;"> Company has reported a net loss for all periods presented. Therefore, diluted net loss per common share is the same as basic net loss per common share. The following potentially dilutive securities outstanding, prior to the use of the treasury stock method or if-converted method, have been excluded from the computation of diluted weighted-average shares outstanding, because such securities had an antidilutive impact due to the losses reported</font>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,946,853</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,731,823</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant for the purchase of convertible preferred stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,800</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,946,853</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,746,623</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="color:#000000;"> warrant for the purchase of common stock was exercised in February 2016. The Company issued 4,349 shares in a net issuance transaction.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6799771600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Build-to-Suit Lease<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">Build-to-Suit Lease</a></td>
<td class="text"><div>

<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Build-to-Suit Lease</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 19, 2017, the Company entered into a lease agreement for its new headquarters, consisting of approximately 30,000 square feet of laboratory and office space located in Brighton, Massachusetts. The lease commencement date will be on the earlier of (i) the first date on which tenant commenced occupancy for the conduct of business in the premises, or (ii)&#160;April 15, 2018, subject to extension for certain delays.&#160;The lease will extend for a lease term from the commencement date and then for ten years starting with the first day of the month following the month in which the commencement date falls, unless terminated earlier.&#160;The Company is entitled to one seven-year option to extend. Annual rent under the lease, exclusive of operating expenses and real estate taxes, will be approximately $1.7 million in the first year, with annual increases of 2.75% each year thereafter. Total expected rental payments through the initial lease term are approximately $18.8 million. The Company will be entitled to an improvement allowance of approximately $4.8 million for certain permitted costs related to the design and construction of Company improvements to the premises. <font style="color:#000000;">The lease contains customary provisions allowing the landlord to terminate the lease if the Company fails to remedy a breach of any of its obligations within specified time periods, or upon bankruptcy or insolvency of the Company</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is not the legal owner of the leased space. However, in accordance with ASC 840, <font style="font-style:italic;">Leases</font>, because of the Company&#8217;s expected level of direct financial and operational involvement in the substantial tenant improvements required, the Company is deemed to be the owner of the leased space, including the building shell, during the construction period. As a result, the Company capitalized approximately $12.1 million as a build-to-suit asset within property, plant and equipment, net and recognized a corresponding build-to-suit facility lease obligation within other liabilities and other non-current liabilities on its balance sheets equal to the estimated replacement cost of its leased portion of the building at the inception of the lease.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, construction costs incurred as part of the build-out and tenant improvements will also be capitalized within property, plant and equipment, net. Rental payments made under the lease will be allocated to interest expense and the build-to-suit facility lease obligation, based on the implicit rate of the build-to-suit facility lease obligation. The build-to-suit facility lease obligation was approximately $12.1 million as of September 30, 2017<font style="color:#000000;">.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6798201696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pti_UnauditedInterimFinancialInformationPolicyTextBlock', window );">Unaudited Interim Financial Information</a></td>
<td class="text"><div>

<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Unaudited Interim Financial Information</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The condensed balance sheet at December&#160;31, 2016 was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying condensed financial statements as of September&#160;30, 2017 and for the three and nine months ended September&#160;30, 2017 are unaudited. The accompanying unaudited interim financial statements have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the Company&#8217;s&#160;audited financial statements and the notes thereto for the year ended December&#160;31, 2016 included in the Company&#8217;s&#160;Annual Report on Form 10-K filed with the SEC on March&#160;30, 2017. In the opinion of management, all adjustments, consisting only of normal recurring adjustments as necessary, for the fair statement of the Company&#8217;s condensed financial position as of September&#160;30, 2017 and condensed results of its operations and cash flows for the three and nine months ended September&#160;30, 2017 have been made. The results of operations for the three and nine months ended September&#160;30, 2017 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2017. </p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div>

<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, the accrual for research and development expenses and the valuation of common stock and the derivative liability. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div>

<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restricted Cash</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">As of September&#160;30, 2017 and December&#160;31, 2016, restricted cash consisted of a certificate of deposit in the amount of $0.3 million collateralizing a letter of credit issued as a security deposit in connection with the Company&#8217;s lease of its corporate facilities at 200 Technology Square, Cambridge, MA.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 19, 2017, the Company entered into a lease agreement for a new corporate headquarters at 80 Guest Street, Brighton, MA (see Note 11). As of September 30, 2017, restricted cash, net of current portion, consisted of a money market account in the amount of $1.7 million collateralizing a letter of credit issued as a security deposit for this lease agreement.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><div>

<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash Equivalents</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. As of September&#160;30, 2017 and December&#160;31, 2016, the Company&#8217;s cash equivalents consisted of money market funds.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><div>

<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Short-term Investments</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Short-term investments represent holdings of available-for-sale marketable securities in accordance with the Company&#8217;s investment policy and cash management strategy. Short-term investments mature within one-year from the balance sheet date. Investments in marketable securities are recorded at fair value, with any unrealized gains and losses, net of taxes, reported as a component of stockholders&#8217; equity until realized or until a determination is made that an other-than-temporary decline in market value has occurred. The cost of marketable securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investments are reflected as a component of other expense, net.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div>

<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value Measurements</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2&#8212;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s derivative liability, short-term investments and cash equivalents are carried at fair value determined according to the fair value hierarchy described above (see Note 4). The carrying value of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate their fair value due to the short-term nature of these assets and liabilities.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><div>

<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss per Share</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">In February 2016, upon the closing of the IPO, all of the outstanding shares of the Company&#8217;s redeemable convertible preferred stock automatically converted into 9,699,600 shares of the Company&#8217;s common stock. Prior to this conversion, the Company followed the two-class method when computing net loss per share as the Company had issued shares that met the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company&#8217;s redeemable convertible preferred stock contractually entitled the holders of such shares to participate in dividends, but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, the two-class method did not apply for periods in which the Company reported a net loss or a net loss attributable to common stockholders resulting from dividends or accretion related to its redeemable convertible preferred stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net income (loss) per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares, including potential dilutive common shares assuming the dilutive effect of outstanding stock options and unvested restricted common shares, as determined using the treasury stock method. For periods in which the Company has reported net losses, diluted net loss per common share attributable to common stockholders is the same as basic net loss per common share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. For any period in which the Company has reported net income, basic net income per common share attributable to common stockholders is adjusted for certain amounts to calculate diluted net loss per common share attributable to common stockholders, since dilutive common shares are assumed to have been issued if their effect is dilutive and not to have been issued if their effect is anti-dilutive.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><div>

<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">In May 2014, the <font style="color:#000000;">FASB issued ASU No.&#160;2014-09,&#160;</font><font style="font-style:italic;color:#000000;">Revenue from Contracts with Customers (Topic 606)</font><font style="color:#000000;">&#160;(&#8220;ASU 2014-09&#8221;), which supersedes existing revenue recognition guidance under GAAP. The standard&#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The standard defines a five-step process to achieve this principle, and will require companies to use more judgment and make more estimates than under the current guidance. The Company expects that these judgments and estimates will include identifying performance obligations in the customer contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. In August 2015, the FASB issued ASU 2015-14,&#160;</font><font style="font-style:italic;color:#000000;">Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date</font><font style="color:#000000;">, which delays the effective date of ASU 2014-09 such that the standard is effective for public entities for annual periods beginning after December&#160;15, 2017 and for interim periods within those fiscal years. Early adoption of the standard is permitted for annual periods beginning after December&#160;15, 2016. In April 2016, the FASB issued ASU 2016-10,&#160;</font><font style="font-style:italic;color:#000000;">Identifying Performance Obligations and Licensing</font><font style="color:#000000;">. The new standard clarifies two aspects of ASU 2014-09, </font><font style="font-style:italic;color:#000000;">Revenue from Contracts with Customers&#160;(Topic 606)</font><font style="color:#000000;">: identifying performance obligations and the licensing implementation guidance. These new standards will become effective for the Company on January&#160;1, 2018. The Company only has one contract (see Note 8) within the scope of Topic 606 and intends to use the modified retrospective method for adoption. Since the inception of the contract the Company has recognized $8.1 million in revenue. The Company is still assessing the impact that the adoption of these new standards will have on its financial statements and related disclosures.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU No.&#160;2016-02, <font style="font-style:italic;">Leases </font>(&#8220;ASU 2016-02&#8221;)<font style="font-style:italic;">.</font> This guidance will require that lease arrangements longer than 12 months result in an entity recognizing an asset and liability equal to the present value of the lease payments in the statement of financial position. This guidance is effective for annual periods beginning after December&#160;15, 2018, and interim periods therein. This standard requires a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU 2016-02 will have on its financial statements and related disclosures.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016, the FASB issued ASU No.&#160;2016-09,&#160;<font style="font-style:italic;">Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting </font>(&#8220;ASU 2016-09&#8221;)<font style="font-style:italic;">.</font> The new standard involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The new standard was adopted by the Company on January&#160;1, 2017 on a modified retrospective basis. <font style="color:#000000;">As a result, the Company has made an accounting policy election to account for forfeitures as they occur. The adoption of ASU 2016&#8209;09 also requires excess tax benefits and tax deficiencies be recorded in the income statement as opposed to additional paid&#8209;in capital when the awards vest or are settled. This had no material impact on the condensed financial statements as of and for the three and nine months ended September&#160;30, 2017</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2016, the FASB issued ASU 2016-15, <font style="font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</font>. The new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs, settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactions. The new standard also clarifies that an entity should determine each separately identifiable source or use within the cash receipts and cash payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. The new standard will be effective for the Company on January 1, 2018. The Company is currently evaluating the impact that the adoption of this standard will have on its statements of cash flows<font style="color:#000000;">.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2017, the FASB issued ASU 2017-09, <font style="font-style:italic;">Compensation &#8211; Stock Compensation (Topic 719): Scope of Modification Accounting</font>. The new standard provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The new standard will be effective for the Company on January 1, 2018; however, early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company&#8217;s financial position or results of operations.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Liability</a></td>
<td class="text"><div>

<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Derivative Liability</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The derivative liability relates to a cash settlement option associated with the change of control provision in our Cystic Fibrosis Foundation Therapeutics, Inc. (&#8220;CFFT&#8221;) agreement, which meets the definition of a derivative. The fair value of the derivative liability is based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of the derivative instrument was determined using the Monte-Carlo simulation analysis. In determining the fair value of the derivative liability, the inputs impacting fair value include the fair value of the Company&#8217;s common stock, expected term of the derivative instrument, expected volatility of the common stock price, risk-free interest rate, expected sales-based milestone payments, discount rate, probability of a change of control event, and the probability that the counterparty would elect to accept the alternative cash payment in lieu of its right to the future sales-based milestone payments.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September&#160;30, 2017 and December&#160;31, 2016, the Company determined the per share common stock price available based on the closing price of its common stock on the NASDAQ Global Market as of September 29, 2017 and December 30, 2016, respectively. The Company determined the expected term of the instrument to be 2.25 years and 2.50 years as of September&#160;30, 2017 and December&#160;31, 2016, respectively. The Company estimated its expected stock volatility to be 80.0% and 81.1% as of September&#160;30, 2017 and December&#160;31, 2016, respectively, based on the historical volatility of publicly traded peer companies for terms matching the expected term of the instrument for each respective period. The risk-free interest rate was determined to be 1.51% and 1.33% as of September&#160;30, 2017 and December&#160;31, 2016, respectively, by reference to the U.S. Treasury yield curve for terms matching the expected term of the instrument for each respective period.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in the values of the derivative liability are summarized below (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Derivative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liability</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value at December 31, 2016</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(88</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value at September&#160;30, 2017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pti_UnauditedInterimFinancialInformationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unaudited Interim Financial Information Policy [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pti_UnauditedInterimFinancialInformationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=d3e41620-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5579240-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5579245-113959<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=d3e41675-113959<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=d3e41638-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2,12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.M)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877573&amp;loc=d3e87990-122713<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=75025870&amp;loc=d3e40691-111596<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6636735056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short Term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash Cash Equivalents And Short Term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Summary of Short Term Investments</a></td>
<td class="text"><div>

<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following table summarizes the Company&#8217;s short term investments as of September&#160;30, 2017 and December&#160;31, 2016 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30, 2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Gains</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S government-sponsored enterprise securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,519</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,516</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,522</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,518</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,041</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,034</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Gains</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S government-sponsored enterprise securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,384</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,364</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,535</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,533</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,919</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,897</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62557-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6650076992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div>

<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of September&#160;30, 2017 Using:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,370</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,370</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government-sponsored enterprise securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,516</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,516</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,518</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,518</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,370</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,034</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,404</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liability</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of December&#160;31, 2016 Using:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,440</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,440</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government-sponsored enterprise securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,365</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,365</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,532</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,532</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,440</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,897</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,337</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liability</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock', window );">Summary of Changes in Values of Derivative Liability</a></td>
<td class="text"><div>

<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Changes in the values of the derivative liability are summarized below (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Derivative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liability</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value at December 31, 2016</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(88</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value at September&#160;30, 2017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6799822048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaids and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense And Other Assets Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pti_ScheduleOfPrepaidsAndOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaids and Other Current Assets</a></td>
<td class="text"><div>

<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Prepaids and other current assets consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid clinical, manufacturing and scientific expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,197</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,390</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">218</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other prepaid expenses and other current assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">423</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,565</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,838</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.28%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,059</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.28%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pti_ScheduleOfPrepaidsAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Prepaids and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pti_ScheduleOfPrepaidsAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6617558560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div>

<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Accrued expenses consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued payroll and related expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,293</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,813</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,086</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,612</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional fees</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">399</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">383</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">520</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,855</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,328</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6600224896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Expense, Including Shares Issued to Non-Employee for Consulting Services</a></td>
<td class="text"><div>

<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Stock-based compensation expense, including shares issued to a non-employee for consulting services, was classified in the statements of operations as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended September&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">412</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,070</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">351</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">636</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">451</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,713</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,024</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,048</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">570</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,783</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,375</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803480096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><div>

<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended September&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,954</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,771</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,008</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,815</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruing dividends on preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,378</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stockholders-basic and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,954</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,771</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,008</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,193</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of common shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; outstanding&#8212;basic</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,093,344</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,073,685</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,051,536</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,672,368</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stockholders&#8212;basic and diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.56</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.54</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.84</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.75</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Diluted Weighted-average Shares Outstanding</a></td>
<td class="text"><div>

<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following potentially dilutive securities outstanding, prior to the use of the treasury stock method or if-converted method, have been excluded from the computation of diluted weighted-average shares outstanding, because such securities had an antidilutive impact due to the losses reported<font style="color:#000000;">:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,946,853</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,731,823</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant for the purchase of convertible preferred stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,800</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,946,853</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,746,623</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803283264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (203,458)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (203,458)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (157,450)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">43,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (13,954)<span></span>
</td>
<td class="num">$ (10,771)<span></span>
</td>
<td class="num">(46,008)<span></span>
</td>
<td class="num">$ (27,815)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Cash in operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,557<span></span>
</td>
<td class="nump">$ 27,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803435424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 29, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pti_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of common shares issued on conversion of convertible preferred stock</a></td>
<td class="nump">9,699,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,551<span></span>
</td>
<td class="nump">$ 1,715<span></span>
</td>
<td class="nump">3,719<span></span>
</td>
<td class="nump">$ 4,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">ASU 2014-09 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pti_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificate of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pti_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pti_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pti_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pti_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6797266224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short Term Investments - Summary of Short Term Investments (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">$ 25,041<span></span>
</td>
<td class="nump">$ 66,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">25,034<span></span>
</td>
<td class="nump">66,897<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S Government-Sponsored Enterprise Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">12,519<span></span>
</td>
<td class="nump">53,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">12,516<span></span>
</td>
<td class="nump">53,364<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">12,522<span></span>
</td>
<td class="nump">13,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">$ 12,518<span></span>
</td>
<td class="nump">$ 13,533<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6638627184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short Term Investments - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet', window );">Realized gains (losses) on short-term investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities', window );">Other-than-temporary impairments recognized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the difference between the gross realized gains and losses realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities. Additionally, this item would include any losses recognized for other than temporary impairments (OTTI) of the subject investments in debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803357488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">39,404<span></span>
</td>
<td class="nump">82,337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">14,370<span></span>
</td>
<td class="nump">15,440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | U.S Government-Sponsored Enterprise Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">12,516<span></span>
</td>
<td class="nump">53,365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | U.S. Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">12,518<span></span>
</td>
<td class="nump">13,532<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">14,370<span></span>
</td>
<td class="nump">15,440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">14,370<span></span>
</td>
<td class="nump">15,440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">25,034<span></span>
</td>
<td class="nump">66,897<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | U.S Government-Sponsored Enterprise Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">12,516<span></span>
</td>
<td class="nump">53,365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | U.S. Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">12,518<span></span>
</td>
<td class="nump">13,532<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt securities classified as available-for-sale, expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6798842256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Transfer of assets from level 1 to level 2</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Transfer of assets from level 2 to level 1</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount', window );">Transfer of liabilities from level 1 to level 2</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount', window );">Transfer of liabilities from level 2 to level 1</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionMethodologyAndAssumptions', window );">Fair value determination model</a></td>
<td class="text">Monte-Carlo simulation analysis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term</a></td>
<td class="text">2 years 3 months<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">81.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.51%<span></span>
</td>
<td class="nump">1.33%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionMethodologyAndAssumptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the annual disclosure of the methods and significant assumptions used to estimate the fair value of items for which the fair value option has been elected. This disclosure would not reflect the disclosure of the methodology and assumptions for items otherwise required to be reported at fair value and, therefore, for which the fair value option has not been elected or is not applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14210-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionMethodologyAndAssumptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6649789952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities - Summary of Changes in Values of Derivative Liability (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract', window );"><strong>Fair Value, Assets, Liabilities and Stockholders' Equity Measured on Recurring Basis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative Liability, Fair value, Beginning Balance</a></td>
<td class="nump">$ 91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Derivative Liability, Change in fair value</a></td>
<td class="num">(88)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative Liability, Fair value, Ending Balance</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) recognized in the income statement for a financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6806762688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaids and Other Current Assets - Schedule of Prepaids and Other Current Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense And Other Assets Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pti_PrepaidClinicalManufacturingAndScientificExpensesCurrent', window );">Prepaid clinical, manufacturing and scientific expenses</a></td>
<td class="nump">$ 1,197<span></span>
</td>
<td class="nump">$ 1,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance expenses</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pti_OtherPrepaidExpensesAndOtherCurrentAssets', window );">Other prepaid expenses and other current assets</a></td>
<td class="nump">423<span></span>
</td>
<td class="nump">2,565<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaids and other current assets</a></td>
<td class="nump">$ 1,838<span></span>
</td>
<td class="nump">$ 4,059<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pti_OtherPrepaidExpensesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pti_OtherPrepaidExpensesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pti_PrepaidClinicalManufacturingAndScientificExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid clinical, manufacturing and scientific expenses, current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pti_PrepaidClinicalManufacturingAndScientificExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6620624128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and related expenses</a></td>
<td class="nump">$ 1,293<span></span>
</td>
<td class="nump">$ 1,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pti_AccruedResearchAndDevelopmentExpenses', window );">Accrued research and development expenses</a></td>
<td class="nump">4,086<span></span>
</td>
<td class="nump">1,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">399<span></span>
</td>
<td class="nump">383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">520<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 5,855<span></span>
</td>
<td class="nump">$ 4,328<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pti_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pti_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809915760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 03, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,048,000<span></span>
</td>
<td class="nump">$ 570,000<span></span>
</td>
<td class="nump">$ 2,783,000<span></span>
</td>
<td class="nump">$ 1,375,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=pti_NonEmployeesMember', window );">Non-Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of options unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=pti_NonEmployeesMember', window );">Non-Employees [Member] | Prior to 2013 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Option issued to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pti_TwoThousandSixteenStockOptionAndIncentivePlanMember', window );">2016 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="nump">1,581,839<span></span>
</td>
<td class="nump">631,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">631,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Common stock reserved for issuance, percentage of number of shares of common stock outstanding</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pti_TwoThousandSixteenStockOptionAndIncentivePlanAndTwoThousandEightPlanMember', window );">2016 Plan and 2008 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,577,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,577,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pti_TwoThousandSixteenEmployeeStockPurchasePlanMember', window );">2016 ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="nump">138,757<span></span>
</td>
<td class="nump">266,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Common stock reserved for issuance, percentage of number of shares of common stock outstanding</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pti_TwoThousandSixteenEmployeeStockPurchasePlanMember', window );">2016 ESPP [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP). Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=pti_NonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=pti_NonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=pti_PriorToTwoThousandThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=pti_PriorToTwoThousandThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pti_TwoThousandSixteenStockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pti_TwoThousandSixteenStockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pti_TwoThousandSixteenStockOptionAndIncentivePlanAndTwoThousandEightPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pti_TwoThousandSixteenStockOptionAndIncentivePlanAndTwoThousandEightPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pti_TwoThousandSixteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pti_TwoThousandSixteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6810207088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-Based Compensation Expense, Including Shares Issued to Non-Employee for Consulting Services (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Stock-based compensation expense</a></td>
<td class="nump">$ 1,048<span></span>
</td>
<td class="nump">$ 570<span></span>
</td>
<td class="nump">$ 2,783<span></span>
</td>
<td class="nump">$ 1,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Stock-based compensation expense</a></td>
<td class="nump">412<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="nump">1,070<span></span>
</td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Stock-based compensation expense</a></td>
<td class="nump">$ 636<span></span>
</td>
<td class="nump">$ 451<span></span>
</td>
<td class="nump">$ 1,713<span></span>
</td>
<td class="nump">$ 1,024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6798654304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreement - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,551,000<span></span>
</td>
<td class="nump">$ 1,715,000<span></span>
</td>
<td class="nump">$ 3,719,000<span></span>
</td>
<td class="nump">$ 4,324,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pti_AstellasCollaborationAgreementMember', window );">Astellas Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">3,700,000<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pti_ResearchAndDevelopmentCollaborationAgreementInitialTerm', window );">Initial research term</a></td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pti_BiogenLicenseAgreementsMember', window );">Biogen License Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pti_ResearchAndDevelopmentCollaborationAgreementInitialTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development collaboration agreement initial term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pti_ResearchAndDevelopmentCollaborationAgreementInitialTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pti_AstellasCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pti_AstellasCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pti_BiogenLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pti_BiogenLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6618345200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations', window );">Federal income tax benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations', window );">State income tax benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of state and local current and deferred income tax expense (benefit) attributable to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)-(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6798943104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (13,954)<span></span>
</td>
<td class="num">$ (10,771)<span></span>
</td>
<td class="num">$ (46,008)<span></span>
</td>
<td class="num">$ (27,815)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accruing dividends on preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,378)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common stockholders-basic and diluted</a></td>
<td class="num">$ (13,954)<span></span>
</td>
<td class="num">$ (10,771)<span></span>
</td>
<td class="num">$ (46,008)<span></span>
</td>
<td class="num">$ (29,193)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding&#8212;basic</a></td>
<td class="nump">25,093,344<span></span>
</td>
<td class="nump">20,073,685<span></span>
</td>
<td class="nump">25,051,536<span></span>
</td>
<td class="nump">16,672,368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders&#8212;basic and diluted</a></td>
<td class="num">$ (0.56)<span></span>
</td>
<td class="num">$ (0.54)<span></span>
</td>
<td class="num">$ (1.84)<span></span>
</td>
<td class="num">$ (1.75)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6632059472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Weighted-average Shares Outstanding (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computation of diluted weighted-average shares outstanding</a></td>
<td class="nump">2,946,853<span></span>
</td>
<td class="nump">1,746,623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computation of diluted weighted-average shares outstanding</a></td>
<td class="nump">2,946,853<span></span>
</td>
<td class="nump">1,731,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pti_WarrantsToPurchaseConvertiblePreferredStockMember', window );">Warrants to Purchase Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computation of diluted weighted-average shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pti_WarrantsToPurchaseConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pti_WarrantsToPurchaseConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6618387984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2017 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in net issuance transaction</a></td>
<td class="nump">4,349<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6798885072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Build-to-Suit Lease - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 19, 2017 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pti_BuildToSuitAssetCapitalized', window );">Build-to-suit asset capitalized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pti_BuildToSuitFacilityLeaseObligation', window );">Build-to-suit facility lease obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=pti_IceBoxLLCMember', window );">Ice Box, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Operating lease, area of property leased | ft&#178;</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Operating lease, term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Operating lease, annual rent</a></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases', window );">Operating lease term description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The lease will extend for a lease term from the commencement date and then for ten years starting with the first day of the month following the month in which the commencement date falls, unless terminated earlier. The Company is entitled to one seven-year option to extend.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pti_AnnualIncreaseInLeasePayments', window );">Annual increase lease payment</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total expected rental payments through expiration of lease</a></td>
<td class="nump">$ 18.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pti_ImprovementAllowanceReceivable', window );">Improvement allowance receivable</a></td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pti_AnnualIncreaseInLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual increase in lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pti_AnnualIncreaseInLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pti_BuildToSuitAssetCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Build-to-suit asset capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pti_BuildToSuitAssetCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pti_BuildToSuitFacilityLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Build-to-suit facility lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pti_BuildToSuitFacilityLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pti_ImprovementAllowanceReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Improvement allowance receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pti_ImprovementAllowanceReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A general description of the nature of the existing leasing arrangements of a lessee for all operating leases including, but not limited to: (1) rental escalation clauses; (2) renewal or purchase options; (3) guarantees or indemnities, if any, (4)  restrictions imposed by lease arrangements; (5) unusual provisions or conditions; (6) contingent rentals, if any; and (7) lease expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 1)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84164451&amp;loc=d3e36991-112694<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=pti_IceBoxLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=pti_IceBoxLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>68
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M#[^KL O&[NT_-KX(R@Y^W87\ E!+ P04    " "WBFY+F5R<(Q &  "<)P
M$P   'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03
M<VEVV[29A.U.'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS
M[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#
MW(*+"$MX%,O67.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S
M^!7+5(UEHP$35T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4
MPL3 :F<_5FO'T=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:
MX./Q>#BVR]*+<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;
M:)P*C5M/TVMWW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ
M$A6UY4#3( !8<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&
M<IV0!0X -\313%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD
M,WJ=?3K.:Y1_::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z
M'&="?,_V]I&E)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S
M(M>41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(
MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU
M+,76>)7 \:V</!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/
M:;,CIW0FS>@S&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:
MK<(1*T(^8ADV&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1
MDEXW0CYBSHN0$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*
MY \FIS_I,C0'HYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_
MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R
MS<C'5*^3*=@YG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;
M)0G+5--E-XH2GD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R
M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ
MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR
MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2
M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE
ML<%5'<]56_*POFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_
M13.V$I<8O./FQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7G
MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5
M' 86%S+D4.Z2D 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2
M)1(4BK ,!2$7<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%
MV^)4S;L:OB9@2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODR
MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\
MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS
MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!
M4$L#!!0    ( +>*;DMW<AG*90(  !4(   8    >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL?5;;CML@$/T5RQ^P&'R)$SF6DE15*[52M%6WSR0AL;78N$#B
M[=\7L-?U NY+N)TS9P;/,"EZQE]%18@,WAK:BFU82=EM !#GBC18/+&.M.KD
MRGB#I5KR&Q =)_AB2 T%*(HRT."Z#<O"[!UY6;"[I'5+CCP0]Z;!_,^>4-9O
M0QB^;SS7MTKJ#5 6';Z1'T3^[(Y<K<!DY5(WI!4U:P-.KMMP!S<'F&B"0;S4
MI!>S>:!#.3'VJA=?+]LPTAX12LY2F\!J>) #H51;4G[\'HV&DZ8FSN?OUC^;
MX%4P)RS(@=%?]456VS /@PNYXCN5SZS_0L: TC 8H_]&'H0JN/9$:9P9%>8W
M.-^%9,UH1;G2X+=AK%LS]L-)$H\T/P&-!#018O1?0CP2XHDPW"88/#.A?L(2
MEP5G?<"'K]5AG11P$ZO+/.M-<W?F3$4KU.ZCC KPT&9&Q'Y H!D"3@B@;$\"
MR">P1PX=?10XN(C8+Q![(X@-/9[1$S\]\=(30T]F]-2Z !>1^052KT#JT%>6
M@(O(_0*95R!SZ&M+P$7 R*^P\BJL7#ZT) 9(:B#M\)DCN/*+Y%Z1W!6Q,F4_
M0+(Y9"%5UEZ)M2N16!(>2.J7@)&_H"+70F:7E >S<%=PH6RA:R&W5:#S36"2
MI"A?N#/H+> =1*Z4G6 >#%K(,.BO8AB[%NP<\V'0@HJ_V*%;RRBVGJ,1\R&5
M4P2S*+>K$LP>V8;PF^E'(CBS>VN:X6QWZGD[\ZJ#?_"A87['_%:W(C@QJ9YZ
M\R!?&9-$.10]*5<JU:.G!257J:<K->=#HQH6DG5C$P;3/X'R+U!+ P04
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M(3O)12<Y=T(*;9OS3E*C2=&67%4HU($2*$0O!?>BB9>"CPK:G#X:7&4-R$Y
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MVOMD;G.;KQ:-N0;-L![.>;?LZ+UTY=IU@WUU^F\NGZT;?5[%Z2)Z[OR,R'I
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M\Q^,L=H)< 4.@Y.[:-Y>2GVPW:-RS\UPVQI>K#F/-\GH=IU=_0902P,$%
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MXPV>[31FD^%-/_\@MGSC\B=02P,$%     @ MXIN2WN'YI"T 0  T@,  !@
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MH_,O&_M?(3KP4C97?H0:_\%F0T+EPO'&G\TX9J/AL)M^$)N_<?X;4$L#!!0
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MV/_&& ^82G*#(]3A!UL,"8T/QUL\VVG,)L.;?OY!;/G&Y1]02P,$%     @
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M&<]V'+/1\*:;?A";OW'^%U!+ P04    " "WBFY+LDKQFB8"   $!P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6QUE=N.FS 0AE\%\0!K#N&0")"2
MK:I6:J5HJVZO'3(): VFMA.V;U_;L)22X28^\,__S4 \SGHNWF0%H)SWAK4R
M=RNENATALJR@H?*)=]#J)Q<N&JKT4ER)[ 30LPUJ& D\+R8-K5NWR.S>4109
MORE6MW 4CKPU#15_#L!XG[N^^['Q4E\K939(D77T"C] _>R.0J_(Y'*N&VAE
MS5M'P"5W]_[NX <FP"I>:^CE;.Z84DZ<OYG%UW/N>B8C8% J8T'U<(=G8,PX
MZ3Q^CZ;NQ#2!\_F'^V=;O"[F1"4\<_:K/JLJ=U/7.<.%WIAZX?T7& N*7&>L
M_AO<@6FYR40S2LZD_77*FU2\&5UT*@U]'\:ZM6,_/(DV8Q@>$(P!P1206@X9
M0#;S3U31(A.\=\3P\CMJOK&_"_2[*<VF?17VF4Y>ZMU[X<=A1N[&:-0<!DTP
MUTP*HMTG1( A#L%#>("'AVB&H0T/Y_0PP@TVJ,'&&FS^*W&S*!'3K$ B%!(A
M!O$"@FD2'!*CD!@Q2!<03+/%(0D*21X-$F\!P30K_XD4A:2(0;" 8)H0AVQ1
MR!8Q6'YX3+/RX7T//T'>HT64+(\0(DKB%<[*2?41BP<.)DI7..AQW?L!8K%=
M<A!1ZBTX9-:$&A!7VWZE4_);:WO_;'=J\7O;X<D_^7 _?*?B6K?2.7&E6Z%M
M6!?.%>A<O"=]KBI])4T+!A=EIHF>BZ$O#PO%N_'.(=/%5_P%4$L#!!0    (
M +>*;DNVDVY7M0$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM
M;&U3VV[<(!#]%<0'A#7>I*N5;2F;J&JE5EJE:OO,VF,;!8P+>)W^?0?L==W4
M+\ ,YYRY,&2CL:^N!?#D3:O.Y;3UOC\RYLH6M'!WIH<.;VICM?!HVH:YWH*H
M(DDKQG>[!Z:%[&B11=_9%ID9O)(=G"UQ@];"_CZ!,F-.$WISO,BF]<'!BJP7
M#7P#_[T_6[38HE))#9V3IB,6ZIP^)L?3/N CX(>$T:W.)%1R,>8U&)^KG.Y"
M0J"@]$%!X':%)U J"&$:OV9-NH0,Q/7YIOXQUHZU7(2#)Z-^RLJW.3U04D$M
M!N5?S/@)YGKN*9F+_P)74 @/F6",TB@75U(.SAL]JV J6KQ-N^SB/DXW#S?:
M-H'/!+X0#I' ID Q\V?A19%9,Q([];X7X8F3(\?>E,$96Q'O,'F'WFN1')*,
M78/0C#E-&+[&+ B&ZDL(OA7BQ/^C\VUZNIEA&NGI.GIZV!;8;PKLH\#^GQ+Y
MNQ*W,.F[(&S54PVVB=/D2&F&+D[RRKL,["./;_(7/DW[5V$;V3ER,1Y?-O:_
M-L8#IK*[PQ%J\8,MAH+:A^,'/-MIS";#FW[^06SYQL4?4$L#!!0    ( +>*
M;DOX#KS*Q0$  #<$   9    >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;'54
MVV[;, S]%4$?4"6*W02!;:!I46S !@0=MCTK-GU!=?$D.>[^?I+LNEZFO5@B
M=7@.*8K.1J5?30M@T9O@TN2XM;8_$F+*%@0S=ZH'Z4YJI06SSM0-,;T&5H4@
MP0G=;.Z)8)W$119\9UUD:K"\DW#6R Q",/W[!%R-.=[B=\=+U[36.TB1]:R!
M;V"_]V?M++*P5)T :3HED88ZQP_;XRGU^ #XT<%H5GOD*[DH]>J-SU6.-SXA
MX%!:S\#<<H5'X-P3N31^S9QXD?2!Z_T[^W.HW=5R808>%?_95;;-\0&C"FHV
M</NBQD\PUY-B-!?_!:[ '=QGXC1*Q4WXHG(P5HF9Q:4BV-NT=C*LXW2RW\]A
M\0 Z!] EX!!TR"04,G]BEA695B/2T]WWS+=X>Z3N;DKO#%<1SESRQGFOQ?:0
M9.3JB6;,:<+0-69!$,>^2-"8Q(G^$T[CX;MHAKL0OENK)__13Z($22!(_BHQ
MO2DQAKF/BZ11D31"L+\1B6$.-R)DU3@!N@E/UJ!2#3*,R\J[3,4##8W_@$\C
M]97III,&791USR<TN5;*@DME<^=R:=T4+P:'VOKMWNWU])8GPZI^'E.R_"N*
M/U!+ P04    " "WBFY+H;?E[[8!  #2 P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6QM4]MNG# 0_17+'Q"S+$DW*T#*IHI:J956J9H^>V$ *[Y0
MVRSIWW=L"$4I+[9G?,Z9B\?Y:.RKZP \>5-2NX)VWO='QES5@>+NQO2@\:8Q
M5G&/IFV9ZRWP.I*49&F2W#'%A:9E'GUG6^9F\%)H.%OB!J6X_7,":<:"[NB[
MXUFTG0\.5N8];^$'^)_]V:+%%I5:*-!.&$TL- 5]V!U/6<!'P(N T:W.)%1R
M,>8U&%_K@B8A(9!0^:# <;O"(T@9A#"-W[,F74(&XOK\KOX4:\=:+MS!HY&_
M1.V[@AXHJ:'A@_3/9OP"<SVWE,S%?X,K2(2'3#!&9:2+*ZD&YXV:53 5Q=^F
M7>BXC]/-;3K3M@GI3$@7PB'&85.@F/EG[GF96S,2._6^Y^&)=\<4>U,%9VQ%
MO,/D'7JOY>YPG[-K$)HQIPF3KC$+@J'Z$B+="G%*_Z.GV_3]9H;[2-^OHV?9
MMD"V*9!%@6PM<)]\*'$+\[%(MNJI MO&:7*D,H..D[SR+@/[$!^1_8-/T_Z=
MVU9H1R[&X\O&_C?&>,!4DAL<H0X_V&)(:'PX?L*SG<9L,KSIYQ_$EF]<_@50
M2P,$%     @ MXIN2PW18!>V 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H
M965T,C(N>&UL;5/;;MP@$/T5Q >$7=9MDI5M*9NJ:J566J5J^\S:8QN%BPMX
MG?Y]!^RX;NH78(9SSEP8\M&Z9]\!!/*BE?$%[4+HCXSYJ@,M_(WMP>!-8YT6
M 4W7,M\[$'4B:<7X;O>>:2$-+?/D.[LRMT-0TL#9$3]H+=SO$R@[%G1/7QU/
MLNU"=+ R[T4+WR!\[\\.+;:HU%*#\=(:XJ IZ,/^>,HB/@%^2!C]ZDQB)1=K
MGZ/QN2[H+B8$"JH0%01N5W@$I:(0IO%KUJ1+R$A<GU_5/Z;:L9:+\/!HU4]9
MAZZ@=Y34T(A!A2<[?H*YGG>4S,5_@2LHA,=,,$9EE4\KJ08?K)Y5,!4M7J9=
MFK2/TPV_GVG;!#X3^$*X2W'8%"AE_D$$4>;.CL1-O>]%?.+]D6-OJNA,K4AW
MF+Q'[[7<W_.<7:/0C#E-&+[&+ B&ZDL(OA7BQ/^C\VWZ83/#0Z(?UM&SVVV!
M;%,@2P+9/R4>WI2XA<G>!&&KGFIP;9HF3RH[F#3)*^\RL \\O<E?^#3M7X5K
MI?'D8@.^;.I_8VT 3&5W@R/4X0=;# 5-B,=;/+MIS"8CV'[^06SYQN4?4$L#
M!!0    ( +>*;DN+Y87)LP$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(S+GAM;&U3;6^;,!#^*Y9_0$U(TFX1(#6=JDW:I*C3ML\.'&#5]E';A.[?
MSS:$L8PO^.YXGN=>?,X&-*^V!7#D74EM<]HZUQT8LV4+BML[[$#[/S4:Q9UW
M3<-L9X!7D:0D2Y/DGBDN-"VR&#N9(L/>2:'A9(CME>+F]Q$D#CG=T&O@132M
M"P%69!UOX#NX']W)>(_-*I50H*U 30S4.7W<'(Z[@(^ GP(&N[!)Z.2,^!J<
M+U5.DU 02"A=4.#^N, 32!F$?!EODR:=4P;BTKZJ/\?>?2]G;N$)Y2]1N3:G
M'RBIH.:]="\X?(:IGSTE4_-?X0+2PT,E/D>)TL8O*7OK4$TJOA3%W\=3Z'@.
MD_Z5MDY()T)Z0V!CHECY)^YXD1D<B!EGW_%PQ9M#ZF=3AF <1?SGB[<^>BDV
M'_<9NP2A"7,<,>D2,R.85Y]3I&LICNE_]'2=OEVM<!OIVV7V?;(NL%L5V$6!
MW3\MWM^TN(9YN$G"%C-58)JX39:4V.NXR8OHO+"/:;R3O_!QV[]QTPAMR1F=
MO]DX_QK1@2\EN?,KU/H'-CL2:A?,!V^;<<U&QV$WO2 V/^/B#U!+ P04
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MD;GK-6,2E*#WH%(UZO6;%P1JJ:<[->?C&S N).NGYPW-;VS^#U!+ P04
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M_$(POQ#(+X()&$C KJ\P!PDX$$%L5;C#L(M4(TJ87;@IU" 8 08CW& BVXT
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M)(0C4;S_) :B%+?YL,'HR.4R%6O:7VG]AI-67]?>\)\A_P=02P,$%     @
MMXIN2QX\9)'& @  K H  !D   !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL
MC9;M;ML@%(9OQ?(%U( _B*,D4O.Y29M4M=KVFR8DL6H;#TC2W?W IJYM:)(_
ML<'/^W+.@0"3"^-OXDBI]-Z+O!13_RAE-0X"L3W2@H@'5M%2?=DS7A"IFOP0
MB(I3LJM%11X@ )*@(%GISR9UWQ.?3=A)YEE)G[@G3D5!^+\YS=EEZD/_H^,Y
M.QRE[@AFDXH<Z N5OZHGKEI!Z[++"EJ*C)4>I_NI_PC'&QAJ04W\SNA%=-X]
MG<HK8V^Z\7TW]8&.B.9T*[4%48\S7= \UTXJCK_&U&_'U,+N^X?[NDY>)?-*
M!%VP_$^VD\>I/_*]'=V34RZ?V>4;-0G%OF>R_T'/-%>XCD2-L66YJ'^][4E(
M5A@7%4I!WIMG5M;/B_'_D+D%R A0*X#XJB T@O!3$%\51$80?0JBJX+8".)[
M1TB,(+EW!&P$>" (FNK6T[4DDLPFG%T\WJRXBNB%#<=8+8BM[JSGO_ZF9DRH
MWO,,I<DD.&LCP\P;!G49@/O,PF8PZ",K&X$M$:@@VTB1*](YLJ-(AU$XF#ZQ
MM D,!W'>-%G?-MDX3&)WMJ%S7L):'_:R';D-(J=!5!M$W1C#0;4:!-=(V4Q(
M'$, !A.W=' 8QA:WLKD0P]3BUC87A2CJ<KW\8F=^L94?2E.W0>(T2.ZO,'8:
MX-L5;I"X6[D$ +O"#@XXN)7-A=C!K6T.H3[7RV_DS&]DY1<.!YJ[F"_^U:ES
MD-0RB 9C+%*[."-7<>[D-JF]3,&5XD#@WCB!(W7TA<47>R^\?PE"YZ;X"-'-
M1;@T3#=AYZ)Q< A>*XQ[YX+A[2DU3'<HZ[2XB6RN(DVH0><<+"@_U-<>X6W9
MJ92Z\IW>]FKUB/0Y.NA?P/$2.OI7<+QN+DZ?]LT][B?AAZP4WBN3ZO2NS]@]
M8Y*JR,&#6J5'=75L&SG=2_V*U3MO[D]-0[+*W V#]H(Z^P]02P,$%     @
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M;.U]67/;2)+P\_)7('K=^TD1(,U#!V7W=(0LRU[M^M!8\DQL3.P#2!0E3(,
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MSL#?+N37"U:K+/U&FAHN%]9J[XN#+NCB-(!*[$C37+1PP8&'(>\?5,8;E9]
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M7B9"D3F-J5F9%'26@R$.M20KVAL]M$KN0'>5,G?Q-8&>I<9JJH"0!C,TXRT
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M$*#G#1QD@(:3PM3QLK_0%A(.]LK0YZ_*.I F+]5X8!2L]<;P4L)0X$J<TG1
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M_0XXD+O1QKY>LCAM-_M.7/>RV19%"P^'T^Y-TON7-]?7K6^,7--4=FK"KKN
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M0F1Z[,2NCKI7SMZ8IGRL>?]EGA<__W]02P,$%     @ MXIN2V+3V_9' @
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MF+4:*"(\VI\AI35_VQ8<']SQ#U!+ P04    " "WBFY+ 98&QV(#   D&P
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M+=8,UX<_EF'J;X2Y^H-E]P-02P,$%     @ MXIN2^&/R5:K 0  MQD  !,
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M<F5L<R\N<F5L<U!+ 0(4 Q0    ( +>*;DMF\PM@@@   +$    0
M      "  >D   !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ MXIN2QV0
MX1'N    *P(  !$              ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ MXIN2YE<G",0!@  G"<  !,              ( !M@(
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "WBFY+=W(9RF4"   5
M"   &               @ 'W"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ MXIN2V<*2TKW P  _Q(  !@              ( !D@L
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( +>*;DMATUF6
M/ (  +('   8              "  ;\/  !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6Q02P$"% ,4    " "WBFY+3B/U]HL#  #:#@  &
M@ $Q$@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ MXIN
M2\?.4OIB @  ?0<  !@              ( !\A4  'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;%!+ 0(4 Q0    ( +>*;DO.QHN8"P4  /H9   8
M      "  8H8  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M" "WBFY+_I[NZ;0!  #2 P  &               @ '+'0  >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&UL4$L! A0#%     @ MXIN2WN'YI"T 0  T@,  !@
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M970Q,BYX;6Q02P$"% ,4    " "WBFY+ZR[A-+0!  #2 P  &0
M    @ %)*0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (
M +>*;DO!QEWCM $  -(#   9              "  30K  !X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L! A0#%     @ MXIN2P?V$-"T 0  T@,  !D
M             ( !'RT  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"
M% ,4    " "WBFY+#7J2Y;,!  #2 P  &0              @ $*+P  >&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( +>*;DLF..,1L@$
M -(#   9              "  ?0P  !X;"]W;W)K<VAE971S+W-H965T,3<N
M>&UL4$L! A0#%     @ MXIN2[)*\9HF @  ! <  !D              ( !
MW3(  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "WBFY+
MMI-N5[4!  #2 P  &0              @ $Z-0  >&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;%!+ 0(4 Q0    ( +>*;DOX#KS*Q0$  #<$   9
M      "  28W  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%
M  @ MXIN2Z&WY>^V 0  T@,  !D              ( !(CD  'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " "WBFY+#=%@%[8!  #2 P
M&0              @ $/.P  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M 0(4 Q0    ( +>*;DN+Y87)LP$  -(#   9              "  ?P\  !X
M;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ MXIN2S!]M*'#
M 0  -P0  !D              ( !YCX  'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"% ,4    " "WBFY+CZ ZWF\"  "]!P  &0
M@ '@0   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( +>*
M;DNMA*4TV@(  #,+   9              "  89#  !X;"]W;W)K<VAE971S
M+W-H965T,C8N>&UL4$L! A0#%     @ MXIN2^IH)?I\ @  10D  !D
M         ( !ET8  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
M    " "WBFY+/4,Z$1@"  !-!@  &0              @ %*20  >&PO=V]R
M:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( +>*;DN0,W2Y5P,  ' 0
M   9              "  9E+  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL
M4$L! A0#%     @ MXIN2QLO+@Y+ @   @@  !D              ( !)T\
M 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " "WBFY+;^0
MD-X!  ";!   &0              @ &I40  >&PO=V]R:W-H965T<R]S:&5E
M=#,Q+GAM;%!+ 0(4 Q0    ( +>*;DN4F>18^ $  &\%   9
M  "  ;Y3  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @
MMXIN2^JQ"+</ @  ^04  !D              ( ![54  'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6Q02P$"% ,4    " "WBFY+694VKAL#   +#@  &0
M            @ $S6   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4
M Q0    ( +>*;DMH2=)=<@(  #\(   9              "  85;  !X;"]W
M;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ MXIN2QX\9)'& @
MK H  !D              ( !+EX  'AL+W=O<FMS:&5E=',O<VAE970S-BYX
M;6Q02P$"% ,4    " "WBFY+@P>]LQD"  !-!@  &0              @ $K
M80  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( +>*;DNU
MM!:BH@(  .8(   9              "  7MC  !X;"]W;W)K<VAE971S+W-H
M965T,S@N>&UL4$L! A0#%     @ MXIN2Q=MCG4E @  :@8  !D
M     ( !5&8  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
M" "WBFY+$!S:/L !  #5 P  &0              @ &P:   >&PO=V]R:W-H
M965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( +>*;DN9*. E1P(  -@'   9
M              "  :=J  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L!
M A0#%     @ MXIN2X9/MXWT,   (0@! !0              ( !)6T  'AL
M+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#%     @ MXIN2V+3V_9' @  ?0L
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;72YX;6Q02P4&     #( ,@"0#0  "J@

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>80</ContextCount>
  <ElementCount>177</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>28</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/StatementCondensedBalanceSheets</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/StatementCondensedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Condensed Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/StatementCondensedStatementsOfOperations</Role>
      <ShortName>Condensed Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Condensed Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/StatementCondensedStatementsOfComprehensiveLoss</Role>
      <ShortName>Condensed Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Condensed Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/StatementCondensedStatementsOfCashFlows</Role>
      <ShortName>Condensed Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Disclosure - Nature of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNatureOfBusiness</Role>
      <ShortName>Nature of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Short Term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureShortTermInvestments</Role>
      <ShortName>Short Term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Fair Value of Financial Assets and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilities</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Prepaids and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosurePrepaidsAndOtherCurrentAssets</Role>
      <ShortName>Prepaids and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Collaboration Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureCollaborationAgreement</Role>
      <ShortName>Collaboration Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Build-to-Suit Lease</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureBuildToSuitLease</Role>
      <ShortName>Build-to-Suit Lease</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Short Term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureShortTermInvestmentsTables</Role>
      <ShortName>Short Term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureShortTermInvestments</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilities</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Prepaids and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosurePrepaidsAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaids and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.proteostasis.com/20170930/taxonomy/role/DisclosurePrepaidsAndOtherCurrentAssets</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureAccruedExpenses</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNetLossPerShare</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Nature of the Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail</Role>
      <ShortName>Nature of the Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Short Term Investments - Summary of Short Term Investments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetail</Role>
      <ShortName>Short Term Investments - Summary of Short Term Investments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Short Term Investments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureShortTermInvestmentsAdditionalInformationDetail</Role>
      <ShortName>Short Term Investments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Fair Value of Financial Assets and Liabilities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Fair Value of Financial Assets and Liabilities - Summary of Changes in Values of Derivative Liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfChangesInValuesOfDerivativeLiabilityDetail</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities - Summary of Changes in Values of Derivative Liability (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Prepaids and Other Current Assets - Schedule of Prepaids and Other Current Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosurePrepaidsAndOtherCurrentAssetsScheduleOfPrepaidsAndOtherCurrentAssetsDetail</Role>
      <ShortName>Prepaids and Other Current Assets - Schedule of Prepaids and Other Current Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense, Including Shares Issued to Non-Employee for Consulting Services (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseIncludingSharesIssuedToNonEmployeeForConsultingServicesDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-Based Compensation Expense, Including Shares Issued to Non-Employee for Consulting Services (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Collaboration Agreement - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetail</Role>
      <ShortName>Collaboration Agreement - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Net Loss per Share - Schedule of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetail</Role>
      <ShortName>Net Loss per Share - Schedule of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Net Loss per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Weighted-average Shares Outstanding (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOutstandingDetail</Role>
      <ShortName>Net Loss per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Weighted-average Shares Outstanding (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Net Loss per Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail</Role>
      <ShortName>Net Loss per Share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="pti-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Build-to-Suit Lease - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proteostasis.com/20170930/taxonomy/role/DisclosureBuildToSuitLeaseAdditionalInformationDetail</Role>
      <ShortName>Build-to-Suit Lease - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>pti-20170930.xml</File>
    <File>pti-20170930.xsd</File>
    <File>pti-20170930_cal.xml</File>
    <File>pti-20170930_def.xml</File>
    <File>pti-20170930_lab.xml</File>
    <File>pti-20170930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>74
<FILENAME>0001564590-17-023831-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-17-023831-xbrl.zip
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M="8ZA^27SG")C'/OWT',0Y)'R]A%3,'PJ_WF@.1Q-4?52]Y>%'&U=&N'[K9
MVFC-8;V7:-TU_+(-NH-Y7]XRTI3F+MT#TLM5K[W*DY>E*HM66B[I <?D!E=K
M_&2YK %D7K@ 1E%^N;@'')+KS$F[4H:=!3[@(-UP/@YM(?%\/"@7]H#C<H;1
MF<LXEHNPU/55V0Y(/.UV9VZT4WGG1L(<D%Z&_<'2 #0WWNY/)HX<B<4N"[S?
M\1ZX9\W)!JSR(W1>>X[[RT4$N=-&>BL7COV8N%[X&AY7F(=_ZC3]X.$5Q"7C
MU?_]_=,MSM2;EW+!B 7O>[63W,.MY$Y4?$RYBRNIY@>Q>RW=]+Q&7D,W_2I3
M90O"'K#KTRYF1O-OW5RF W9SMI+IV@;N='S/=+^:COW1NS&G3F2J\^R] W9N
MVEWHWLSUP<H%V%K*0W9P.H-AJ[V#E)853V(7)Y<%'^'BW("/<0'0(Y=%73[Y
M8?B91U]&=^8/5?H#$M#EW.#T=D(=K$4'9+'+=OMP3?K&(]/QN)TNEE8>!DDE
M+K-26W' 7M1EN]7ISAG_>F'V$?Z @W>71N^JVVOM);P(06/?M7D0XGAHI"[F
MZ!]P6*\SZ!C%'N'BJ[<1[8 =KH'1G>M,KQ--R=@@P5DMZ &);7' >)T@NXM]
M0.Y;'&3>3NQBFO/5#+X$8KV\+:@SW5BA"K\M.\ZO]\FESY;^M)HM7)FYG4S[
MMF-;_CQ%.^2BI^LX&ON!\R]NJ_)ORZ#+UEV)(#<W*[Y"A%W%W98>GTW<CV$8
M%T7=E@.7B;I&2/GB703<EN>.+&#YPL"K;0EN1RF7+@G<0M1M">_0HBI=E@U"
MU]6VM+=]Z-I H+U:L"T#/F\+5L2QJWWI+Q77:"]$LA42["3JO@QW%%$7HMG5
MH8BLW3.,]E6[NT+*LHBV@82'XBZAQZO.WA(NB6*'XJT-%+E))%LIZZ$H; .5
M+I4UF?11QTT':TFK4$=UP]'[7J\XV9"^>+TXZXBI6!YHTPEWH[>C.-MM^MFP
M\WHUUW?=7)QU+%+<IKSQFHGYY4WEXJPX]T"5<2U?[&)0[<'B&JSEXNPH^3KZ
MV,7VAFUC?D#H\()OMW%IT_60G:OVT25?1S2[&'2[TQWNK/,U1;=5V=>RSPZ&
MWKZ:6X>Z1IZ=A5]'1[O8>J?=[S^'\,/M-IEN.&XWF-L1="SAUS+<#B8_Z,\M
M"-]*^"]3W"\'V4+RJTHYP[4,N%-^T)];EKD@PA82KB7%75*&=G=N7GT?";?;
M.KOADLR6,3B<#M=2WPY&V9'4MX.$^0R/*N-:EMO!$B^-;FL9T+D46XFYEM)V
M,,=+ WJ-PX.*N=V^W@W%[/:[<Q2PKYAK>6H'P[QL7PWF%SRN$S/?QRBO^(@5
M'N";7%9C?>V#W;I2!4&7R;&]M,?H:77Z1Q+V&/VPGG$LU1ZCF];;1;5B\ORS
M[_E%\U[(2HSUU1UV":[MDB5\2Z795?)C]-HN.R7[K0XN^3&Z;9>]JV>0_!C=
MMDMC=VOYS*,R^C#65Z_8*6?H#.=6?1?>OZ%HQ^B!89YP9>PKVMH*%SOF!CC:
MN*]HQ^@]83XP9WPK1+OCDZD?F,%,KB[ '48<%X[=^=^X#;_A9S'K<FW_3RQ#
MM-J =2OF=VF T;DJ:G8'&5?H__K1=%S<BW;G*V/-R1J+MV;H6&H#UZZQ/X++
MK9?P8,U;MR+_&&[[C,W;KN3285S_&9NWAG)W#!]#8]@Y7/,6BKSB)3ATB65>
MU7DZ8UUMCN6^UEXWN7S9:O;Z>8/6R+1S ];P\W)OVJ@!W>,W8+L*55LUP&@.
MCM^ =84\EGO$)@VXZNW8@/_FSL,8OKU^A.3O@7^.L2[BEY&X49G>7-&NM>6N
MEKE&<9N%,NTZ['2Z"B"[B7CH9JY-)Y8YT))FXMQR?]#3K9G;U3[<!$WH_7?Z
MNC5S;7*QS!G+FVGT^U=M@/.PS5RV(O^[%W#3Q14Q_P'<!D_YS70\), OGE*9
M/'!"^.D=_.D]R&J0BWL+C'6E4W:;6YL;C#Y2,YY?66N3FEU2TF%-E;5=1<U-
M!VEKJJRUZ=DNZ?(I+*OD!67M79O-[=AWG2O>N$*:7<1>5S!GYS[IW/3=H<7>
MKH;SIGW-WG"N,W9HL8\Q@H-#4.T=C>0=A^LL1QP1 I]=,=*#,_\3/XB<?XGO
M5?EWSJ565DF<K]ZP7J;]6K%SJK1R\^I@QU9@<?>O 9\X\03BT\K*J\:Z2CV[
M 9!LBEHKR [R'F/0Q$BL?4-Y4T2RD4P5@B^C=TXHBV8!.,G3PB6-.0;_7QJ#
MA?VK.XAYZ*8>A;T/UU"$'JMXF.'X6[X<3T8ZM1D[#[&L7O<QS.QOF1!;B;FV
MJM!N<V*=[H9BIHBD8RO<1@*!J^8CY[KJ0COIL]V>*[Q6+L:VHAYELJ3=[6TM
M*NY2P"H4Z6%*GIV>HO3!#VYY\.A8//P2W+BF,U%]<'W%H5T6+LRO"=E&N .U
MZQCT*Q9@[M<N]).;,9[Q^-'[8#J!F.2">+10[&BF-N8HDQZ#0>:YFTFT3PN.
M0M%*2K%-"U+XLFOS2<8OHQ1!5?BCK":88^25PLRMY<TZFD!C4S]T)*?-ETXU
MNL?@U_E%R*MDF5^8!%0,4>P=E__]Z"V65U>E/P:M=HWB+.8F,NW5BMY16+=[
MU3EX,XJEUT,Q[*$VY"B=8:#E=8"4R;5O6XY!VZ)"S.&;(B[*5G\N^/BZJDT[
MPG*UIB5E4NW;DF,P]F5_G:/LTI*Y"LAJ(X[!U#VCNZ&W)P+M(?\Q>%K41CVP
M_'-%D]4F'&< ?:U++ JU7S..0MZ#[O#@S9BKV*JVX3@]X_9<9;2U(NW>@G4U
MH7;L- ^'>[4 #Z&!CO;7P']T;&Z_G7V'OB&$LBR*69#URA*_HAIE#-\E/_J>
M:F3KZDKM.,+=ZLTM\MU/X&,U_FCCY*VC-7[14(IG/:C-.\HP^OR9&>L$FBL
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M@5KZ=W,R??-O ^CSO,$%QJ8WR[XQWKQD3R9$(<_R ZS8(O8#>^P==\TG/$'
MQ\^6Z$$SH]-@P-/])KZ))8]B\&*36:[C.9;I@B+-!X@TCC\=FR"F):2![ZWD
M:EN6O\71S1!:X;*)[W(KAN@4*=*SR&<1).L1LV8A?,%&SGW@8QM?J(WY4&B'
MZ=G,%RO!;"?$1#]DEAGCX-<]O'<6CF+/D@>LL2FJ#9HYQ0&;$'?P-<6CO/MP
M^B;_I#9SY%LQ/E*L#P?XG1&FLXG4.!,6C4%<K(#F@]K2%Z3O+'W\S0>IO$1<
M55H@40N3%$^8^;P2A'E, !3X+T?.L&-+G%$([W_ X['\8$Y1=]\*JDK%0Y4Y
M7AB/\"PMG#O!*Q>%5_%.GV-<O0F9RTT;+\?W@_C A#98$!C?U[N/T/<<R ^#
MEB'>)#\/RE0A#JOP&#<#=Y8;DYW72FX XT1C-G6AY8 %8.S'R&GXW"APIB[J
M87(/'79!JPWYPQ*Q$RL)X@=%:);(@#?AKJL2(<1#;=Q: @G=C$UQ%#%LYL%G
M:3 QVI6()M<A!M;,WSL&^KO1;ZB*9*;M3S%*2#WYCTXH\ABX,1DN 9V)HS^$
MQI)\#[_Q;#. ?M!;'_[#7GRXOGW[,OT9/2F] EYD.V"/<B_&B^O;FY?L#B*&
M!;+T+KNM!BNE7=ELS,D<*XV-/ 01Y'/*Q0NSV&@8;]AO/LH!Z;K% Z_ ID*,
MY/TOP13'CC4&7Q,SF"$#<"#HB>9"W#)#,(IPJ>VE:^?A2DN.)8$18Q1X$&^W
MY-N%B4=/W'WD$"&]: Q7C"+ !!^+YIHRX"AK5)@W2EBRZ$&AZT+ "%/=SJL.
M$CH_>/UO8AJH)=6VI%G&RRSN96[@^MBW$(+ &Z7_B,DB$9.<),&%3Y98",/"
M^!XE$5>@_X)#W?MQM*^N,#*@XQ;4E>C'289GURH-3/UEWBAIW,"*SK38&A'E
M'TQX3^#@=?YBHQJLHSPIUV*A:1QRL#@S37Q=""F9L'N45GR'MQ<4"2;GRGN0
M']<K;<)YQ!PP"/\>$KZDPX'@==<+*".M:*X$-H*.#KH]/!8$>D!UH@BFC9U;
M55#)=?\&/<@W^:>/0#;@ZX$MFB=BN;@[]__41M&]N(?/"\'@Q#SH:A'G!%(T
M]N \XNTKD%)L'!0/Y([TD[PY04"^1;J\*:G]7G2GX(GW %ML80HQBEVXU9D
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M9#_)O'\Z$XL_*IMT\8KW/RQ10@N?-H&L5TRNSJT.N7U_4U@F@)I9)7.3W?!
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M]J6C&<H8FQQ=%3;@+^VXSF_I4R;8NLG25BNID9I;D)"G3+!&.F,6)@,BR4[
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M12)2"<6:0=$(.8.7Q!FUQU88(D^8&S.2R/PA>H?@XUP6<4@W*UAY[=$G0:5
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M@59:U@S#JHV,[U\OC  \[63N_@C6/4/IMO4HC"+3$2KZ5@7O.]!R6H*'V(T
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M$8[*85. ._KRD&,/ 29I-149U9VF5$XBM.K$75025N=:V,1=I\> HAY%O;-
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MG";\+9XCJ\N/8@_93_D);/,RC._#",P2C0Y$YV$$!IM=(^0)N#.YCX.0RZ]
MY]'8">Q+R :C&1 Z) XL3NS8@5OR= "@]A^XM$+X@87P?J#IV'/@)[ )J:%"
M6)?XB'(6;&RZ(S8#Z?-&@&U,I 1P46JW#09,"S]:Z!V>)0R/_:?IQ68P0VWV
M&M*:36;%D]B5'F:9D36^C*<94%P0O\VF?B \*WG+%@8:\N 17#%D]QP5K=BK
M&4GC@_C"$,*UFF<@E"\4!PE3Z(!RI;N#?D$1'K>;['KBQX@'OB9 NP(5VWS$
M@T!QD#B++XON#N! N.;"8P9%0^XT6_D7 O)U1ON.6_,_&XTR4RZ@S38(Y,9@
MFTA^(F)ZZX"A>S6D)<A;+]'I' ]["<PJ9">9!X+%1T^<>X70CF8A]2)D_R=<
M!QT#B#LH 0_<6?KK1YM;A4L6>2;1;X%EHK*86.2&UF*$-A8B=!YRMHG5_6)0
MMAVXW8\@9CU*%U_ABDFS<^UMYV(L]2SQ[1.T1KPY4X%X/79U$"/371  8HB"
M:"Z%(^$;Q8A!<UU_<HLN8+'O"-CZ$WYG_EC361Q29Y$ZB[O*,CR/SJ+T)0;.
MQ,-GZR'J1E9E85@F19#QC;@M"J1!K(=L*^(0Y83*(O,'D);'1TXDB,"!3 J"
M40BR[\<+>0[/; BZT '"9T$DL]PX1-J)QI -@F QQ&TPO3BA4M?UGTQ(7C'%
M"_A?L1.(X&PZ7ABI5)=RH''U1LGWL#DF2!^%39:+M"8?V6QH=G$0X'))OK7?
M .4J7B@RR'O(@"$TAU]Y($8L2^BCW6H1?1!][#PMTSH/_OC,(_8)HAZ;0F8H
M?.EL6>2M&3J6/(+/<6/,C#U0CILJ)T3E0#\^"IS[6$8 ".TXX@#!&[KNUI]C
MP(X'(7N";-XR72MV97Z-A(+!/60O1(;MQR&\!;I!_(<%+)(^&5ZLO$?V[5^^
MWCF"EPW:GG:Y0ADCJ::S=5A-W$X>J[IQE!UN$&2/O<MV_S*VRKSXX8Z5U<%*
M=-C7?J"B$4?!:($M=#Y45CWDN7_20Y[;K6:WOUE)@K-#\D[T<WZ7W9OW*[HW
M6KCE<U9GUP8B"HTU1(M"H_9(?L:!GPI%1NUJMVB#Y&$*MYQIQZ!2*!(/5@RM
MC ?;)^7!P4YKVXDGL:TXCJZ%1U+OX/08%*/B3HY$89/"YAD@C;/$6K@LA<W3
M8[#TZ-5Z^P!%NW-!6J<DD09**A45USK<V3D3A<US05JG))'"YG''EX]4&'RI
M7R;CS?6OJ/$YGN 6*I!G1U<Z.A1+T_^:(5&/TC5G699&?^@VK$]#M6>J >=S
M#DL1,L16542"V*JRT!%;U0I.8BM=D2&VT@4)8JO*0D=L52LXB:UT18;82A<D
MB*TJ"QVQ5:W@)+8ZX+3BT:?[SV=:,2D1<>+Y>4HE=%FT1 'L0$=9'!T0F2 0
M_V-K7QB=QK#7U16J<_6=E[H"0K2B"Q+GZAI$*Q4 Z871:EQ=&;I"=:Z^0[1"
MM$*N0;1259!>=/N-5FN@*U3GZCM$*T0KY!I$*U4%Z47[JC$P=CV,E7SG^6GE
M9/OI#E6LK69075M6$(.JF.T\.B"B'3+?8],@/:1"E$D_\0SS@0JWU0RY2BP
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M/7XT9@N3ZJ6"ERY1*,S3,T<V+C0GO+F!R1F5L3EL 5Z0-J(8WL15J5F"G82
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M=:%H#:E#4XKC>%8@V!Q?W(9D_!_0;%"5:$2$Y?C,$:@$[-B/\/4@D(6ZP6;
MWU-SAHK$2GR!'S](%3N>(RI0*HB+PHES0@Z:@U3*8I*3MDI5K^EAZ;K ?Y3
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MVRT,G\T=:0PD%04[!J<82WJZL2%R[*4M=\.M9(0JCB-WN*'T['S@+S V0/)
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MMNOT6=HY0?(,1#N-J=XA+6DJE+Q1["WM,,FW@<IY;RG:RCYZGO1*(?PJCFS
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M03J"%1GBFCJA17I4XL%:78KUNJ-V;X >HH_\S\\&'_>?+#3FD3L+L)Y.DUN
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ML[#<1SX*VS7"!0/[$?&?O+GX:;:E+MC@6FT$T9)/C8]T9CPPQ_MNO!;?]Z+
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M(UA(D<A*DI5LI)5$4]A-5K*8PW^F>K:="J<V ,T_2OF\@C!Q  '<5>1/%U;
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M'YL"8]TQ##[D?_S]QX/O_/;_ 5!+ P04    " "WBFY+>JOFOGH-  "<A0
M$    '!T:2TR,#$W,#DS,"YX<V3M7=USXC@2?[^J^Q]T/,W6+0%"LC-));M%
M2')%569()>S'VY:P!:C62*PLDW!__;5DR]CX0S8A,TR=\S!C[.Y6MW[M[E;+
MF*M?7I<>6A/A4\ZN6[V3;@L1YG"7LOEU*_#;V'<H;?WR\S__<?6O=AO=WC^C
M@2/IFMQ2W_&X'PCRX?GS#^B/FZ<'].PLR!*C6^X$2\(D:J.%E*O+3N?EY>7$
MG?D./W'XLC.C##.'8J_M$[&F#O$[J-TV0PP%P1*T0;=8$J3_+M%IM_>QW>NU
M>V>3T]YEOW_9/3^YZ/?.?NKV_]WM7G:["0&_A=:@Q!\(.#D_Z9Y<),@>L?,7
MGA,TNDV0#3]=?+J]ZW8'9W<?S[H7-X-!_WPPO#CM=>]//YV=W[6[W6[O[.S\
M]%,?#GL?NTF)0[[:"#I?2/3!^4&K#%/!&/$\LD'WQN@?T</#\ 0-/ \]*6(?
M/1$U#\0]B63YX30",LR_9" A6%ZW$C/Y.A7>"1?SCBM%1VY6I -$;: B@CHM
MPV=G2C, V.JT'W/-L#_5'.9*1Z/0[;7[/</DRY6(&?00/G%.YGS=45<40R_-
MP#!U_'P.?2EG#,K6Q)?Y/.$UQ=1/,RDJ=X=)V7+:[9YWPHL)P^<8KW+M5A=R
M5'()S=<'+BCRLZPR-!\-T*</5O@2G(,8>H<'3(I-_A#1Q1RM/,K^*AE%79YB
M/Q[E-4/_TM?4O8N+BXZ^&BL4" %AH4BCZ&J.2BN9MGLEN"0<K/6IKV/!J;Z)
M^EW#0%Z=1?XHZDJ>!U*GP &ID_(_+*6@TT"2>RZ6MV2& P_\(V!_!]BC,TI<
MB'P>47$K19"X++&8$_D%+XF_P@ZI95C>/ ,JO<X?GQ_"L-F"6Q^A*[I<<2%1
M& ,>N*-C80FJZE/;.%!;G6KW3L'@DU<?5&:YRA9Y7^<-*ACOVDN%K6ONI8*Y
MH]78YT6CYH> 2N-IUMRPT"&>],V9]M8[BY0HC2W5==D--^J@O8T[I5-0%*H.
M-1,Z5=2<BFQZJ>\'NWE-.<.%<L3>3Y4<,9L7WZ(#9U_>JD8RI]=WC62:,!\J
MH&)--7MHDDP/\:?:NN0EF?K*Q%E$']55(I.#ZBN0J%BBX_:V>JFD1$[-4U^-
M;;$5'M:=B6RQ5E\'DZ'507N;JBN-OYO=]QC=%*CZJ/;XN^5MI !FC$L]JOZL
MSJQ6E,UX]!%.J&1W*;A')G";(^I>MR9DN?)@M?.@2RYUZ=>G4;7RHJ.H.VD!
M]:K!6#&CFDM@@4:U"5WU!\NXQ(K.#(746%>=78Y=88%/W#'[61^O!"QT6#@[
M">Z(I(S3P9X3>'LP;C4KYHO.&D1V@#+S]$1F2-?$EU@XBK:\<NX 8BLB)(6\
MEBB\M8"%(+/K%I3&;8/BGV#@"<!F*#+RT]AIS'?F)-+12)!4*A'#+9$&S/\1
M82\>1N69ZY8/-XU'WG,1T?DF<PK8UYW3M+OD3^EM3&.=T6]CMX>G=>T&%N(5
MF_R@+A^IM1!4ZEJ[&X?RC7Y,4-6V/0[O]8*YQ*^<\>4FU--$7?/_@+EW#+3;
MC""?B*76K*43R!.0_UF)O"S:]W+"?7R(F8M"<2@AKUX"V#N,[Y\YWIX #@+E
M,^BN>PM#SES"8/P;[*E%]_."$.DG4+11V@#L*0!C(4AU)2,Y*!*$0DD-= >!
M[A'#LD0NB*0P1=5Q3+/90#VM"BKZD!+\0P/ROB#'9_SQ; SY2-M6?J,6L-C
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MG^[1VVF0/E23IP3;?$H;FO:&3P/>@3L_92FXC,$&9?4N4 /IH5:M)5CF4]I
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M@-T.XB-0I/AU\[\I".)!^[P==!!C,YAW_D#>%,OPDH;63'4PHBQXQ&Q\Y[^
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MD$4ZUB&=MDB05.^&XT?L0TL>#)NV.R8^ 6,21BT6PTEFOS$32G_*.(8G2]C
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MSI,!ND"K?^M+ET=7LY W*.2,W%+"-8%SOOP1\-TC8V*QU<5F7<0^FS*;3QS
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M+PT.N@?P5,J?:7C@MO-K]."6V2VP]A0"7=_=R_R<YA=YUILHTF*&):H4Y>Y
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M'U^2*"4ED10I,>MV%HO.2J<B0O&+" ;)8/!/__YE@\ SS/($IW_^YN3U\3<
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MN-TV@T\PS4DTNTI7> .O<9Y_A,5R?1]],?(#4]*V!<,F7+R4;Y<"E U49!$
M(MQG+NFV0AB/U/'AH(GV@>2KR WN@+,'E#]K8K1< R+"1(>=BRA)87P192E)
M4'))U'.X3E:)X2'G86J61V.'"/MUOY@SF?< LS92V%QQ0:,BW*AD!TI^0(;H
M7 W11&M]X];XG*TJ^=J>R3M7]L):V--;T'.ZD.=[ 6_JK<5%&H\S[V%:8W?-
ME&0GV)EDL_0P74$;0/5N9H]& P9K?]^3[?W,Y43-]<2;*%MF["J)F"TRW,",
MW61BOQK>3='!\F<7\0G6S*LUNW!6H ?!ZUR4[M=C\$!U+%T3IF"9 <Z6+YK1
MFV#YW3PS.!>_$VA1+>?:.]4^)0<8M8E.X$1[*]SA.%,G6)U.I-9?L,!T.(VX
MN&K1"<EDCG+%=B/&.DE)Q1D.G.!TSL$W94)SC!8X TXAZRQ((/J=X4H)P62.
M8'CIH38I9TAXO?:PRR_PO%<>F@(VX"'C+CV<%)Q^7YGZQD-IU]7%Y$6+W-CM
MX>FF+<UR@R#F+": J3?J/<Q6)@-'M9T__SQE[ZI4NTE*+YFQN/B?GC2=):BY
MB0Y :F=Q."OQ#H;*.>:9C^R]JOEDI).$&]W[FH8HG6#^.<@0('W&/WKVX57Y
M/48_X;QC[$WK>G3<:-_K=$-I_X',-70O5]?77*" ]/C$U/,+7N92W:YM<SRF
MDX25]CNH.56\J.VI;TP/XV[T(2RPII8\WX N>I<8G2>LG[$L:N&/^[@E8?;>
ME'OZQ%TO'H#N4$-MTYSB6VYA%M&3@^)2M-PF2O40L3O@WD7/0\^!DE75-'C6
MHWO#<&!M-86H>M36>LEFZF-[MS"'!!=ZZ\@Y\3>$V3520AJSZ-M+R/9BE&Z:
M7FZS8>Q8N4]<,YSY^AH-?+"1SD+% K5@6+"S416OTD<F\8M?8$I<$Q$1%O$F
M21/JD_0XEH5G#)*RPF. JGOO$ R9<T0-EG/ZARY.V%!SX6*"FG!0)VERF]1/
M]L;)4?F2J\':5TTHWLN2@DJ2M)(CETF1YV1H6@NN#P-9V;#\^#CMUI3<VS$[
M:T3-J+1EG(9APPKMJZRXK9NP-+UGR=()KXF6VIYASMKA<,Y7*1G"R3=F:VU=
M-"P7V]3DW&<H)660,$;S+K,-X(!U%12@SJL5SI)):>8EF^D:17[$*6XZLT6"
M/D3)OCEA)U%?32-%6C+[G=R:X+0[1 [H*U@@D(R!S*OTC"E3\H^PL$ME6@]:
M:;M!PWWZ0D])SWW\7:U?W*N#4'2):C5.G9K<P\T69U'V(OJ@K589I.GG/;Z%
M,?D;_<P*MQ;Q/W9\7#$Q7BOR5K!8<!H)WGL.7@H?:7F;< 5VXQP-,7'RG,0P
MC7. 4[!MEOK.Z2=C ,<.U'T@X#8]L^)?MO&K) #W&-0RB!K'6HKIAY;%<Y0@
M>K?G/9;*&<3YR],H3U;6@X\.Z?$A=9B+OP$,1$61)0^[@EV.6F#:XJ4JFA$B
M!#/(&2#=-0SJZOIP4%4/I:!B3_U5KKXI#R8S$2;QUK)=1EE^S3C3_9L$[0JS
M2LQ!4E:X#5!U/TFJO(_DY[PP3<</V6G_MW]\H-+QO4$NWYS^J8LM-M1VN#@*
M?ZMZP%3E_=RC^&ZA&A@OWO4K3!Z?"+/%,YGK/<*/.]K"<;EF(DD5=B.<SI:#
M%89VS-R[:"D'B+@@E4/NE9&&Z)8CC0*[P>/@# "UL!<R "X$[8O&/5V28R:O
MK\HAEVL^ZK/N]GLMY>Q:P!N2MFQD9,3%<9>CLAB6("J2)MZT7]$5+XQZ65N\
M\4B-A[)@I,J>IEO>'VC6>,.O05I(*=P]OHDRRR)S9RSMUZG'<_>UL[#?@G3>
M E''YM'>B7 %Q.&;0F-O0Z=_*1"B 5DV.AOFTDU=X=JES$]I!B-$CT/^!YGF
MD8SBERA)Z:LLTSNXVF6\B5F6Y.1/Y^2?Z2.9<20XMFE<[$\&I_8U5ASWL:>6
M"#P26<"W-/!\1Q>ZDVKW>?X;XGU:ET9@<@/;5VA)PZ%+LB\A**"2\I"V3$$M
M+!#2 BXNX/).W;99H6J;>-1+QO9 8Q=%]XOH9T&U0]?!!!MH*DS](Y7JA1=I
M.\&V2)AE'[]_=\SLFGQ!.^YLDMV&1(8GDCC<PVQ35Q9IU2]H$#'2Z2 ]-QJ-
M\6I'R;$B3-8,B'($;*V+\ 1D'-S(P]SK.8Q<'R"LK;C.LZ-*\Z"7K4;YTVU]
MVH1;G:YE=#]O;!1=I+S8@V#&;H\OZ[K M[RT\;O9;&$0#:RC*C,+.'LBJ)#G
M+Z,D8]O>R_7^O=A:K:I-J!E;AQYA+[;"6=.;7BAS41M (K+B2N]9NE5;H(C-
ME6IF56Q3EK<'N<393?3"E^A860V,S\NB&EVSTB9G;%>:E+T8%N\;(2XU6^,,
M;#E[>IM9Q 6HZX]F"TJF4&(+Q;HTKE.<[AP9EB#EV*@8U=D,ZH%R#]28FM!I
M&9*D3,-Q#Y/,*<N)WI;K9EO*7Z,LBT@^=946<I%+^;7V4&C/P'QTM.7E9\"L
MI*&&URJ:!)\%:Y)]MRI"JC_-9I[CC0([ <3,E,\%_>6:_#=)'\]P3NFOT"Z&
M\55*/ 7O"&GB.G2QF!Z@Y;YC<)K#"1MCLQ[)T8MQES(1T^9"$1/.F35SL<@'
M&FN98#3^LO5Y=JQ;!& QVYC-QEU9"W:(D>>&1](F\1F9-UTB_-FJ!4T_G;$5
M WLD_94'4%: \0JO$J ;(?6V?X?:IC*I>VK65D8DGAQG-HR(^ZTAJ;,:XQ"&
M<31UK3('21W!Z'7/ 3M4ZJ=?/WGGC]$&+KXD1L?5FL_9-7N72'AHNT^H TI^
MUN;Z*NWB/A4$HDG44B(9!@CM:4WR'&^B)+4QRO+)4<KD1+YRPVSI6&&:LAJ"
MT>>^>7+J0P:JG!Y=;+8(OT#(N^<349ZB'%+2'R M@-6=_@R2,9[>#%#T,GTI
M>8H9]U9P!5O"=K8IB2Y"V$!O8:(A!XH*"G'+0@D%L_J_<:[*O"N4ET$CWL-/
M4KY[R),XB;*7NPC!Y9H)9)KY]!"Q2RF[Z'G(V@D#NN1V-_?IY&$@L+:"0E1Z
MF=)77 !3_5*H?LIL2GH_.E(NU_=9E.9D&DS"O7F&I4/-#I!!PE^S.^ACA,U5
M%C0>2(*B<@^6TM&:IIJG;H;GJ)/7S5(_^5,\9-<WJGS>1W.NI$@B1,;>!Y2L
M0+D6VYM%3-:M:T_7N%,G(>A56.P5N %+W?1%.>^XQ CAS\N4@U)B8C;IZ*=A
MG./VD?,RW> ,6>\4;IKEKLEL<PTM5+"NN@)$0(X+G-L14;])9 CB-9#\!K1:
M7/<-_"[W7R<IO"(?S:84BJ?'+4]7A+PN_5,N@+$)8_U_7_FJ/8"6;H)2]/Y>
M0(^.?749HCMF-QFF%5CQZ<NGG.[35EU5%R0=>V:',LYP2KZ@7;"653=;FUU3
M5QQM3^TZ8.[A&B^Z [MF.[!RPV 2UZ)*HEG/@#JV$^P'DH.W"1$0Z"$/9A*E
M4.#T!5"Q:-EQW?&XE@S4HH%:MJF/?]8=TG)1D\XB&>WG1DTL0;!Q:OX>:^K=
M)LSXE\7*V'R+Y3XT21+3GDU9*2=M>\L;/-&Z/6JLNYS7.P47O":S2SPUT%^Q
M#:)]\RN/Z3!Q>8_&TAC;K>%H0SBC #IQJ#R'6^))"8O3Y#-B;2=I.=R&'NC_
M%Y\O&X0[/7I6YJ)#VGW8D;GR@DF)W9S!Q @Y;*/&P%%""H JCOR.G &H9CX3
MJFSQVSX2>M0^$AK@B[3*(\0;T*/T[% K90:NNM_ 3PY8]M"5C6"Y/D]R7OE+
M[$,(FAL>/1[+P6ZLM&+FI0>U)( X2&%NL)-E7..L +L!X' 0;^4\51_J!NCT
MD&DI!8NSI1Q]3JX9IOP>MVYT-L/IT=YAZR"E1I7 3-Y;Z5Y$D6M.L]@LVKQ"
MULF.<#=.#KLHV*V%*HGY6'C&J]^.'B@CUA"MY-1G,I,M0?=#@O6T%9SZR^7H
MLM,OY.TB2R;3[,7G^2XB )1%.FE<GH6[Q-D=S)Z3%<R7V1F*$K-=%T/"=GO/
M)CP\N8Q\X)>8<KY#;*J;"^ZS[OU;88M'Z?=0<"SK# 3GNCJ&#O0E=T#8@Y(_
M6&: 2V Y>D[91*.QV<$[:"0I6-,.&L^L@P;):..Z@P;JZZ 1V*NAQEM9]07Q
M$DFK=Z^7T)9KDV/KFH2L/*R7YG0FUW$:O=_^I@J7>@!B(Z6&"E99WU&[3LV+
M>E');9H+R:L&BF2^M<5YPJ> BSR'9IXS0,CNXNL^FCX6'EB31I)WQXP=O9F9
M^@W=Y"E>V,HL_.<NV:KN19K26?0PPT9Z# Z?UK7D<O=,B1GU%\YNHGMP5QDD
MDX5SR/\K[0V=1=NDB)#-_JT)5<M[6W49^!J.\M9F*8.,>50Y_,R]<6H!+;;7
M\$' 6.;I@BTH^38W%@7KJ7<5]Y51-MRXA2M(TE##Y@1Z]!SAMD_:TU6.? $U
MJ]B$Y6$]B/7Z5I?Z0D5'PY\JK&X[L9K(C6XRN(V2LDM-SKI<CW,D-45'8*F(
M>]HTI7SXH(7YW16[C"WL1\H$9%[7ZD6QU[FZ%1HN8AH.)KB6NQHDD:1\Y\H:
M*>^ZK,AXLJ5+T56:H2#NP\=X1_T0W:D7L/X\L%-WX8*CD_\QJ*3RLCDG8:U6
M:V[2OHJ8XZQ"T/50O=KJO1>6!W5AI)7H-706,AY:*=Z-&I_IG(5V(;RNY]VC
M_66/GCN(6J2]>(W<G#*P<:<'K"''46HN<& &W(<!)3&=R8/*QI^W\!FFNY'#
MS1XQ1Q"UZ/JH6A;;21GG$);C=&'4ZS5*G86,1Y^_5/C<JO$)\(REB2>-Y33#
M^3GW-U;1HR"#YY$.]RRERFM=0'"PV*,:=@=G)N>,"+R,=\I3U\8<75J)(7/_
MIZZ34J!0#BXZMI/AB&$%R<';A$X$J00+[M3U?EIU2R3-DE4!8_HZXU+Q-BU'
MF5^3K(]UT[KD*ZMXL;P@K)R\ ZO>E%REO!!QT4C(:W[,]:;I.,TO#<KO\6+U
MSUV2P<5SE""Z^D2K>R,$ZYMH37S'B*Q=;V5]#EYV^T0KUYQ6@(5WYLP&5CQ"
MN8%#V#H<*OC2@_&",ZA8\[)RVI.QYCZ-)V9X!6&<7Q(@/T2%8,UV);FXBY3$
M(83RY=J1C[IA: >]"]X>&M0+L41!##TY0G/A325AH-[NU'2P%Y@.W4Q0RT*H
M2*"6"4A"L6,J3"Q6?3I_9&G'V1M1L4S;D!=$V(NR:'G4$-]#U<WPT,G ^P ?
M7HFW!:9]X_N :L/&;WAT+SFSQOL%\\^++A2]#^Z\O[0;'S0A.SH"#W"8;#@.
M^_"%#=0=0ZZ6P@\#5N7P6;8^G]T]QRW 3;?V/,OZHL==J6VYN/CP KX56U3?
M*9>>#W?EV?V*\VPKS2&N,,\9'RZ3-$I74^Y1&7-T:26&S/WO4:U+@0+?H[*U
MD^&(807)P=N$3@2I! MNCTK.O<H6%^*6DN:= ;8S@0&BHQ/&7OH>9P%\7[IL
M"D*2_Q6[)%ZT*]AMR4?:'$DT7R1_3\3=+ZT+-EZQ=KWB>4*/&0&=/^S2&&:?
MZ<H,,9"X;"\6RF1"SU8ZIA(:F!V"72BG$56?F(Z[?F;SZN7ZC%DH:UXSUIM;
MQ)RAU: [E_>&YF-JY 9\2Z')D%'J]R4R+><<U7?$^5\EHUR76S9"7WR!V2HA
M [OUVIB:V/BE$Q5=WSX$!2.V%\6&/KQ53H5F6_7JA:YKK:M;E2'#I%[78J@(
MAJ#B..EFCVC75OKS&<[-3I#VTQFU(: BZ64+I]P)H.O$S120##YY&!4:O3@I
MMFRZE1<:)AW;,E4SOVJH.5-A$> ZSG3K-[/,T2=:YU4MVASNFHW[M9K9UFA"
M7)N9)"I0.5DA2?Y$MYV>(T0#U0T9*'#<K@HUB0%F=*T0-V'AQ[^3LI+UVUCP
MH1LXW.WIF@K[ &O9YG1U*Z#Q&&T?"*A(6E_GQ4OD@\0;<.9@KVS9HB5M_ULN
M2 3+LA<2!5CG2S>OMV72WQ515L@["2KS!%$!'N!CDJ8T$-'$D3U[2.]YD<8Z
M;PEIFZ*N]_,69R\1_EQ>M%5M.J:Q8HBBUSL@G.\R:+-_-IZ7M>N.8>NA#_IN
MNT7L0M4(L35MSI!"GY:W3T@;[L0H@MM5<V8WV#50!VPC<LBGTM07RM5;[\08
ME*E:+=/4>V<D27PFQLVZR/)V]!NZ1\._)C/_$Z,8,4S,#N ANAYVQBN6?&6=
M<4IHT7&[JW>2TBLJ UEZUX<3&ZLW9.C0'FKU%0>,(:@Y6G;]KY9S8'R),['Z
MLER+)BGG"9V4I;&',Q1771NTQ.YR6!3$)B/1J>6.Y!XDG"SVC#0NQ3N$EQ=@
MUHM:Y#5HJ;]@R\X B!<^]_I>ISC=30DHO55E2W)JML4N7I;\ID3W@8H3^HL:
M@'<ZXGWDN')3&CMC6C;SOR)Q6=KB\WC]0V.HZ+CT(=\?)ZH_':8*E"&WDD,$
MW^IN&2I*8_^S\](%S;<OF^V4-0ELS9M,I]$NIDMTK5YS]*Y2;G6B&ZG'[DS-
M+1&ZGL-DHHLX4:MA(+][5J,?VJ$H!+5T40K#MR1 *8ZJ.1^_W%7HXD)]#9NG
M631KI\Y8QDE!DG"J-MII.#[=%1]Q\5^PN(D2H[UR?9J6,QX]\AZ:]VTX:"LN
M0?(O**J\P,,N0?%1@8_R75( Q%:UR$0FS>FD=]Y;E8T1QK:J/@ TJWDJOT1
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M\S7A1/Y-_D4^/)"?_^7_ 5!+ P04    " "WBFY+!B!1M*@H  "2V@( %
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MR,:,"*4?/YQ^.$ACPB->4').0/\-31&Y@[R[#*!:[AGK"7EO(/:;[PN@C:/
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MY%E%UX7;&657M\. IM==T>0A9/6'\:_IIK?A>OLC8#Q_"ZU!RV2%EQ5XQ'Z
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M# 2S]4'!@PBL[5.A]5XHO2K7+P4KNP-N/[PWH=BA5C-5AA)<:[7A@%@KZ=L
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M;JULP(*>?V6A94D\P:MR?I>T\%:4^.1Y\+#2!K)REZ"D PG"NA-; B>.\VI
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M,S N>&UL4$L! A0#%     @ MXIN2WJKYKYZ#0  G(4  !
M ( !7+8  '!T:2TR,#$W,#DS,"YX<V102P$"% ,4    " "WBFY+UKCP.-\,
M  !_LP  %               @ $$Q   <'1I+3(P,3<P.3,P7V-A;"YX;6Q0
M2P$"% ,4    " "WBFY+AO*E2F@7  !+9@$ %               @ $5T0
M<'1I+3(P,3<P.3,P7V1E9BYX;6Q02P$"% ,4    " "WBFY+R+WJ^^%%  "'
M[P, %               @ &OZ   <'1I+3(P,3<P.3,P7VQA8BYX;6Q02P$"
M% ,4    " "WBFY+!B!1M*@H  "2V@( %               @ '"+@$ <'1I
G+3(P,3<P.3,P7W!R92YX;6Q02P4&      8 !@"$ 0  G%<!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
